{"title": "PDF", "author": "PDF", "url": "digibug.ugr.es/bitstream/handle/10481/5541/18748284.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Universidad \u00a0de\u00a0Granada\u00a0\nFacultad\u00a0de\u00a0Medicina\u00a0\nDepartamento\u00a0 de\u00a0Anatom\u00eda\u00a0 y\u00a0Embriolog\u00eda \u00a0Humana\u00a0\n\u00a0\n\u00a0\n\u00a0\nIMPACTO \u00a0DEL\u00a0TRATAMIENTO\u00a0 CON\u00a0MEGADOSIS\u00a0 DE\u00a0\nCORTICOIDES \u00a0EN\u00a0LESI\u00d3N\u00a0MEDULAR\u00a0 AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0\nPOLIVALENTE \u00a0\n\u00a0\nMIRIAM\u00a0AOMAR\u00a0MILL\u00c1N\u00a0\nTesis\u00a0 Doctoral\u00a02010\u00a0\n\u00a0\nDirectores:\u00a0\n\u00a0Dr.\u00a0D.\u00a0Manuel\u00a0Corti\u00f1as\u00a0S\u00e1enz\u00a0\nProf.\u00a0Dr.\u00a0D.\u00a0Indalecio\u00a0S\u00e1nchez\u2010Montesinos \u00a0Garc\u00edaEditor: Editorial de la Universidad de Granada\nAutor: Miriam Aomar Mill\u00e1nD.L.: \nGR 3107-2010\nISBN: 978-84-693-3295-5\u00a0\n\u00a0\n\u00a0\nD.\u00a0MANUEL\u00a0CORTI\u00d1AS \u00a0S\u00c1ENZ,\u00a0Doctor\u00a0en\u00a0Medicina \u00a0y\u00a0Cirug\u00eda\u00a0y\u00a0Facultativo\u00a0 Especialista \u00a0\nde\u00a0\u00c1rea\u00a0 del\u00a0Servicio\u00a0de\u00a0Anestesiolog\u00eda \u00a0del\u00a0Complejo \u00a0Hospitalario \u00a0Torrec\u00e1rdenas \u00a0de\u00a0\nAlmer\u00eda\u00a0y\u00a0D.\u00a0INDALECIO \u00a0S\u00c1NCHEZ \u2010MONTESINOS \u00a0GARC\u00cdA,\u00a0Catedr\u00e1tico \u00a0de\u00a0Anatom\u00eda \u00a0y\u00a0\nEmbriolog\u00eda \u00a0Humana\u00a0de\u00a0la\u00a0Facultad\u00a0 de\u00a0Medicina \u00a0de\u00a0Granada\u00a0\n\u00a0\nCERTIFICAN \u00a0\nQue\u00a0la\u00a0Licenciada \u00a0en\u00a0Medicina \u00a0y\u00a0Cirug\u00eda\u00a0D\u00f1a.\u00a0Miriam\u00a0Aomar\u00a0Mill\u00e1n\u00a0ha\u00a0realizado\u00a0en\u00a0el\u00a0\nDepartamento \u00a0de\u00a0Anatom\u00eda \u00a0y\u00a0Embriolog\u00eda \u00a0Humana\u00a0y\u00a0bajo\u00a0nuestra\u00a0direcci\u00f3n, \u00a0el\u00a0trabajo\u00a0\ncuya\u00a0memoria\u00a0presenta\u00a0para\u00a0optar\u00a0al\u00a0grado\u00a0de\u00a0Doctor\u00a0en\u00a0Medicina, \u00a0con\u00a0 el\u00a0t\u00edtulo:\u00a0\n\u201cImpacto \u00a0del\u00a0tratamiento \u00a0con\u00a0Megadosis\u00a0 de\u00a0Corticoides\u00a0 en\u00a0Lesi\u00f3n\u00a0Medular\u00a0Aguda\u00a0\nTraum\u00e1tica \u00a0en\u00a0una\u00a0Unidad\u00a0de\u00a0Cr\u00edticos\u00a0Polivalente\u201d ,\u00a0dando\u00a0nuestra\u00a0conformidad \u00a0para\u00a0\nque\u00a0sea\u00a0presentada,\u00a0 le\u00edda\u00a0y\u00a0defendida \u00a0ante\u00a0el\u00a0tribunal\u00a0que\u00a0le\u00a0sea\u00a0asignado\u00a0 para\u00a0su\u00a0\njuicio\u00a0cr\u00edtico\u00a0y\u00a0calificaci\u00f3n.\u00a0\n\u00a0\u00a0\u00a0\u00a0\nDr.D.\u00a0Manuel\u00a0Corti\u00f1as\u00a0S\u00e1enz\u00a0\u00a0 \u00a0 Prof.\u00a0Dr.\u00a0D.\u00a0Indalecio\u00a0S\u00e1nchez\u2010 Montesinos \u00a0Garc\u00eda\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\nA\u00a0MI\u00a0MADRE\u00a0\nA\u00a0mi\u00a0T\u00eda\u00a0Paqui,\u00a0a\u00a0mi\u00a0padre\u00a0y\u00a0muy\u00a0especialmente \u00a0a\u00a0mis\u00a0hermanos \u00a0\nA\u00a0\u00a0Javi\u00a0por\u00a0hacer\u00a0siempre\u00a0que\u00a0todo\u00a0sea\u00a0mucho\u00a0m\u00e1s\u00a0 f\u00e1cil\u00a0Esta\u00a0Tesis\u00a0est\u00e1\u00a0dedicada\u00a0a\u00a0mi\u00a0madre,\u00a0porque\u00a0estoy\u00a0segura\u00a0que\u00a0nunca\u00a0ha\u00a0dejado\u00a0\nde\u00a0acompa\u00f1arme, \u00a0guiarme\u00a0y\u00a0quererme. \u00a0\n\u00a0\nAsimismo \u00a0quiero\u00a0expresar\u00a0 mi\u00a0agradecimiento \u00a0a\u00a0todas\u00a0 aquellas\u00a0personas\u00a0que\u00a0han\u00a0\nhecho\u00a0posible\u00a0de\u00a0forma\u00a0directa\u00a0 o\u00a0indirecta\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0este\u00a0proyecto,\u00a0 y\u00a0muy\u00a0\nespecialmente:\u00a0\u00a0\nAl\u00a0Dr.\u00a0Manuel\u00a0Corti\u00f1as\u00a0S\u00e1enz,\u00a0 director\u00a0de\u00a0esta\u00a0tesis,\u00a0magn\u00edfico \u00a0anestesi\u00f3logo\u00a0 e\u00a0\ninmejorable \u00a0persona;\u00a0por\u00a0su\u00a0dedicaci\u00f3n, \u00a0su\u00a0tiempo,\u00a0 su\u00a0esfuerzo,\u00a0sus\u00a0buenas\u00a0\npalabras\u00a0y\u00a0consejos\u00a0\u00a0y\u00a0\u00a0porque\u00a0sin\u00a0su\u00a0ayuda\u00a0este\u00a0sue\u00f1o\u00a0nunca\u00a0se\u00a0habr\u00eda\u00a0hecho\u00a0\nrealidad.\u00a0\n\u00a0Al\u00a0Prof.\u00a0Dr.\u00a0Indalecio\u00a0S\u00e1nchez\u2010Montesinos, \u00a0Decano\u00a0de\u00a0la\u00a0Facultad\u00a0 de\u00a0Medicina \u00a0de\u00a0\nla\u00a0Universidad\u00a0 de\u00a0Granada\u00a0y\u00a0director\u00a0de\u00a0esta\u00a0tesis,\u00a0por\u00a0su\u00a0gran\u00a0calidad\u00a0 humana,\u00a0\nsu\u00a0cari\u00f1o,\u00a0 apoyo\u00a0y\u00a0ayuda\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0los\u00a0a\u00f1os.\u00a0\n\u00a0\nAl\u00a0personal\u00a0 de\u00a0la\u00a0Unidad\u00a0 de\u00a0Reanimaci\u00f3n\u00a0 del\u00a0Complejo \u00a0Hospitalario \u00a0Universitario \u00a0\nde\u00a0Albacete,\u00a0 tanto\u00a0facultativo \u00a0como\u00a0de\u00a0enfermer\u00eda \u00a0y\u00a0auxiliar\u00a0de\u00a0enfermer\u00eda, \u00a0por\u00a0\nsu\u00a0colaboraci\u00f3n \u00a0en\u00a0el\u00a0manejo\u00a0de\u00a0los\u00a0pacientes \u00a0y\u00a0en\u00a0la\u00a0recogida\u00a0de\u00a0datos.\u00a0\nEspecialmente, \u00a0al\u00a0Dr.\u00a0Ram\u00f3n\u00a0Peyr\u00f3,\u00a0como\u00a0Jefe\u00a0de\u00a0Secci\u00f3n\u00a0 de\u00a0la\u00a0Unidad,\u00a0por\u00a0su\u00a0\n\u00e1nimo\u00a0y\u00a0constancia \u00a0en\u00a0el\u00a0trabajo\u00a0diario,\u00a0y\u00a0por\u00a0\u201cense\u00f1arnos\u201d \u00a0a\u00a0querer\u00a0y\u00a0defender\u00a0\nla\u00a0medicina\u00a0cr\u00edtica\u00a0en\u00a0el\u00a0\u00e1mbito\u00a0de\u00a0nuestra\u00a0especialidad. \u00a0\u00a0\n\u00a0\nA\u00a0todos\u00a0y\u00a0cada\u00a0uno\u00a0de\u00a0los\u00a0componentes\u00a0 del\u00a0Servicio\u00a0de\u00a0Medicina \u00a0Preventiva \u00a0del\u00a0\nHospital\u00a0General\u00a0 Universitario \u00a0de\u00a0Albacete. \u00a0Su\u00a0colaboraci\u00f3n \u00a0diaria\u00a0ha\u00a0sido\u00a0\nfundamental \u00a0para\u00a0la\u00a0elaboraci\u00f3n \u00a0de\u00a0este\u00a0trabajo.\u00a0\u00a0\n\u00a0\nA\u00a0los\u00a0compa\u00f1eros \u00a0del\u00a0Servicio\u00a0de\u00a0Anestesiolog\u00eda \u2010Reanimaci\u00f3n \u00a0del\u00a0Complejo \u00a0\nHospitalario \u00a0Torrec\u00e1rdenas \u00a0de\u00a0Almer\u00eda,\u00a0donde\u00a0realic\u00e9\u00a0mi\u00a0 formaci\u00f3n \u00a0de\u00a0\nespecialista, \u00a0y\u00a0muy\u00a0especialmente \u00a0a\u00a0aquellas\u00a0que\u00a0no\u00a0solamente \u00a0han\u00a0 sido\u00a0 mis\u00a0\nmaestras\u00a0sino\u00a0mis\u00a0grandes\u00a0amigas,\u00a0la\u00a0Dra.\u00a0Marisa\u00a0Gallo,\u00a0Dra.\u00a0Eva\u00a0Mar\u00eda\u00a0Garc\u00eda\u00a0\nFuentes\u00a0y\u00a0por\u00a0supuesto\u00a0al\u00a0Dr.\u00a0Benito\u00a0Gonz\u00e1lez\u00a0y\u00a0la\u00a0Dra.\u00a0Irene\u00a0Jim\u00e9nez.\u00a0\u00a0\nA\u00a0la\u00a0Dra.\u00a0Francisca \u00a0L\u00f3pez,\u00a0tutora\u00a0 de\u00a0residentes \u00a0del\u00a0 Complejo \u00a0Hospitalario \u00a0\nTorrec\u00e1rdenas, \u00a0porque\u00a0sin\u00a0su\u00a0ayuda\u00a0en\u00a0la\u00a0elaboraci\u00f3n \u00a0de\u00a0la\u00a0Suficiencia \u00a0\nInvestigadora \u00a0no\u00a0habr\u00eda\u00a0podido\u00a0acceder\u00a0a\u00a0emprender \u00a0este\u00a0trabajo.\u00a0\n\u00a0\nA\u00a0Pablo\u00a0Garrido,\u00a0matem\u00e1tico \u00a0y\u00a0estad\u00edstico \u00a0de\u00a0la\u00a0Fundaci\u00f3n \u00a0\u00a0para\u00a0la\u00a0Investigaci\u00f3n \u00a0\nBiosanitaria \u00a0de\u00a0Andaluc\u00eda \u00a0Oriental\u00a0 Alejandro \u00a0Otero\u00a0(FIBAO),\u00a0por\u00a0su\u00a0amabilidad, \u00a0\nexplicaciones, \u00a0desarrollo \u00a0de\u00a0los\u00a0modelos\u00a0estad\u00edsticos \u00a0y\u00a0paciencia \u00a0en\u00a0el\u00a0desarrollo \u00a0\nde\u00a0este\u00a0estudio.\u00a0\n\u00a0\nA\u00a0Sara,\u00a0por\u00a0ser\u00a0mi\u00a0luz.\u00a0\n\u00a0\nA\u00a0mis\u00a0compa\u00f1eras \u00a0pero\u00a0principalmente \u00a0amigas,\u00a0Susana,\u00a0Marta,\u00a0Elisa,\u00a0 Gabriela;\u00a0\npor\u00a0animarme \u00a0y\u00a0hacerme\u00a0re\u00edr\u00a0un\u00a0d\u00eda\u00a0tras\u00a0otro,\u00a0ayud\u00e1ndome \u00a0con\u00a0ello\u00a0a\u00a0superar\u00a0 las\u00a0\ndificultades \u00a0y\u00a0el\u00a0cansancio. \u00a0\n\u00a0\nA\u00a0la\u00a0Dra.\u00a0Loli\u00a0Cabello,\u00a0por\u00a0sus\u00a0palabras\u00a0afectuosas, \u00a0por\u00a0no\u00a0dudar\u00a0en\u00a0ning\u00fan\u00a0\nmomento \u00a0de\u00a0este\u00a0trabajo,\u00a0y\u00a0por\u00a0estar\u00a0 ah\u00ed\u00a0siempre.\u00a0\n\u00a0\nA\u00a0Pablo,\u00a0porque\u00a0con\u00a0 su\u00a0nacimiento \u00a0inund\u00f3\u00a0de\u00a0alegr\u00eda\u00a0 los\u00a0malos\u00a0momentos \u00a0que\u00a0\nnos\u00a0toco\u00a0vivir\u00a0mientras\u00a0se\u00a0desarrollaba \u00a0esta\u00a0tesis.\u00a0\n\u00a0\nA\u00a0mi\u00a0T\u00edo\u00a0Juan\u00a0Jos\u00e9\u00a0porque\u00a0desde\u00a0donde\u00a0est\u00e1\u00a0podr\u00e1\u00a0disfrutar\u00a0conmigo\u00a0este\u00a0\nmomento.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u201cVivir\u00a0no\u00a0es\u00a0s\u00f3lo\u00a0existir,\u00a0\nsino\u00a0existir\u00a0y\u00a0crear,\u00a0\u00a0\nsaber\u00a0gozar\u00a0y\u00a0sufrir\u00a0\ny\u00a0no\u00a0dormir\u00a0sin\u00a0so\u00f1ar.\u00a0\nDescansar, \u00a0es\u00a0empezar\u00a0a\u00a0morir\u201d\u00a0\n\u00a0\n\u00a0\n\u00a0\nGregorio\u00a0Mara\u00f1\u00f3n\u00a0 (1887\u20101960)\u00a0\u00cdNDICE\u00a0DE\u00a0CONTENIDOS \u00a0\n \n P\u00e1gina \n \nI.- INTRODUCCI\u00d3N \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...\u2026. \n 1 \n1.1. HISTORIA DE LA LESI\u00d3N ME DULAR \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026 \u2026\u2026............ \n 2 \n1.2. DEFINICI\u00d3N, EPIDEMIOLOG\u00cdA E IMPORTANCIA SOCIOECON\u00d3MICA\u2026\u2026 \n 4 \n1.3. ANATOM\u00cdA DESCRIPTIVA DE LA COLUMNA VERTEBRAL \u2026\u2026\u2026\u2026......... \n 6 \n1.4. BIOMEC\u00c1NICA Y CLASIFICACI\u00d3N DE LAS FRACTURAS CERVICODORSOLUMBARES \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \n  \n10 \n1.5. EVALUACI\u00d3N CL\u00cdNICA Y T\u00c9CNICAS DE IMAGEN EN LA LESI\u00d3N MEDULAR AGUDA TRAUM\u00c1TICA \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.......... \n  \n16 \n1.6. FISIOPATOLOG\u00cdA DE LA LESI\u00d3N MEDULAR AGUDA \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \n 21 \n1.7. TRATAMIENTO M\u00c9DICO  DE LA LESI\u00d3N MEDULAR AGUDA \u2026\u2026\u2026\u2026..\u2026 \n 24 \n1.8. TRATAMIENTO QUIR\u00daRGICO DE LA  LESI\u00d3N MEDULAR AGUDA \u2026\u2026\u2026. \n 38 \n1.9. COMPLICACIONES DE LA LESI\u00d3N MEDULAR AGUDA \u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026 \n 41 \n \n \nII.- JUSTIFICACI\u00d3N DEL ESTUDIO E HIP\u00d3TESIS \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. 49 \n2.1. JUSTIFICACI\u00d3N DEL ESTUDIO \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... \n 50 \n2.2. HIP\u00d3TESIS Y OBJETIVOS \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \n 53 \n \n \nIII.- MATERIAL Y M\u00c9TODOS \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. 54 \n3.1. \u00c1MBITO DE ESTUDIO  \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. \n 55 \n3.2. CARACTER\u00cdSTICAS DEL COMPLEJO HOSPITALARIO DE ALBACETE \u2026.. \n 55 \n3.3. SELECCI\u00d3N DE LA COHORTE Y CARAC TER\u00cdSTICAS DE LA UNIDAD DE \nREANIMACI\u00d3N \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... \n  \n56 \n3.4. VARIABLES RECOGIDAS. DEFINICI\u00d3N Y MEDIDA \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... \n 58 \n3.5. M\u00c9TODOS DE AN\u00c1LISIS \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. \n 69 \n3.6. ANEXOS \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... \n 74 \n  \n  \n IV.- RESULTADOS \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... 88 \n4.1. AN\u00c1LISIS DESCRIPTIVO \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. \n 89 \n4.2. AN\u00c1LISIS UNIVARIANTE \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \n 109 \n4.3. AN\u00c1LISIS DE SUPERVIVENCIA DE KAPLAN-MEYER \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... \n 116 \n4.4. AN\u00c1LISIS MULTIVARIANTE. RE GRESI\u00d3N DE COX \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... \n 121 \n \n \nV.- DISCUSI\u00d3N\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. 124 \n5.1. SOBRE LA COHORTE \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \n 127 \n5.2. LESI\u00d3N MEDULAR AGUDA TRAUM\u00c1TICA \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \n 129 \n5.3. UTILIZACI\u00d3N DE MEGADOSIS DE CORTICOIDES \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \n 137 \n5.4. INTERVENCI\u00d3N QUIR\u00daRGICA \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \n 142 \n5.5. USO DE DISPOSITIVOS M\u00c9DICOS Y COMPLICACIONES INFECCIOSAS ... \n 155 \n5.6. ANTIMICROBIANOS EMPLEADOS EN UNIDAD DE REANIMACI\u00d3N \u2026\u2026.. \n 150 \n5.7. OTRAS COMPLICACIONES \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. \n 151 \n5.8. MORTALIDAD Y LESI\u00d3N MEDULAR AGUDA TRAUM\u00c1TICA \u2026\u2026\u2026\u2026\u2026.. \n 154 \n \n5.9. PROTOCOLO NASCIS II Y LESI\u00d3N MEDULAR AGUDA TRAUM\u00c1TICA \u2026.. \n 159 \n5.10. INTERVENCI\u00d3N QUIR\u00daRGICA Y LESI\u00d3N MEDULAR AGUDA TRAUM\u00c1TICA \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \n  \n165 \n \n \nVI.- CONCLUSIONES\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... 171 \n  \nVII.- BIBLIOGRAFIA\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... 174 \n\u00a0\u00a0\nABREVIATURAS\n\u00a0\n\u2022 ACO:\u00a0 Anticoagulantes\u00a0 Orales.\u00a0\n\u2022 APACHE:\u00a0 Clasificaci\u00f3n \u00a0de\u00a0la\u00a0Acute\u00a0Physiology \u00a0and\u00a0Chronic\u00a0Health\u00a0\nEvaluation.\u00a0\n\u2022 ASA:\u00a0\u00a0 American \u00a0Society\u00a0of\u00a0Anaesthesiology. \u00a0\n\u2022 ASIA:\u00a0 American \u00a0Spinal\u00a0Injury\u00a0Association.\u00a0\n\u2022 ATLS:\u00a0 Advanced \u00a0Trauma\u00a0 Life\u00a0Support.\u00a0\n\u2022 BN:\u00a0 Bacteriemia\u00a0 Nosocomial. \u00a0\n\u2022 CHUA:\u00a0 Complejo \u00a0Hospitalario \u00a0Universitario \u00a0de\u00a0Albacete. \u00a0\n\u2022 CTC:\u00a0\u00a0 Corticoides. \u00a0\n\u2022 CV:\u00a0 Columna\u00a0Vertebral. \u00a0\n\u2022 CVC:\u00a0\u00a0 Cat\u00e9ter\u00a0 Venoso\u00a0 Central.\u00a0\n\u2022 DASIA:\u00a0 Grados\u00a0de\u00a0mejor\u00eda\u00a0 en\u00a0la\u00a0Escala\u00a0ASIA.\u00a0\n\u2022 DI:\u00a0\u00a0 Densidad\u00a0 de\u00a0Incidencia. \u00a0\n\u2022 EE.UU.:\u00a0 Estados\u00a0 Unidos.\u00a0\n\u2022 FIM:\u00a0 Functional \u00a0Independence \u00a0Measure\u00a0.\u00a0\n\u2022 FMO:\u00a0\u00a0 Fracaso\u00a0Multiorg\u00e1nico. \u00a0\n\u2022 FRA:\u00a0 Fallo\u00a0Renal\u00a0Agudo.\u00a0\n\u2022 HBPM:\u00a0 Heparinas \u00a0de\u00a0Bajo\u00a0Peso\u00a0Molecular. \u00a0\n\u2022 HDA:\u00a0 Hemorragia \u00a0Digestiva\u00a0Alta.\u00a0\n\u2022 HFVVC:\u00a0 Hemofiltraci\u00f3n \u00a0veno\u00a0\u2013\u00a0venosa\u00a0Continua.\u00a0\n\u2022 HFVVI:\u00a0 Hemofiltraci\u00f3n \u00a0veno\u00a0\u2013\u00a0venosa\u00a0Intermitente. \u00a0\n\u2022 HGA:\u00a0 Hospital\u00a0General\u00a0de\u00a0Albacete. \u00a0\n\u2022 HNPS:\u00a0 Hospital\u00a0Nuestra\u00a0 Se\u00f1ora\u00a0del\u00a0Perpetuo \u00a0Socorro.\u00a0\n\u2022 HTA:\u00a0 Hipertensi\u00f3n \u00a0Arterial.\u00a0\n\u2022 IA:\u00a0 Incidencia \u00a0Acumulada. \u00a0\n\u2022 IC:\u00a0\u00a0 Intervalo\u00a0de\u00a0Confianza. \u00a0\n\u2022 IHQ:\u00a0\u00a0 Infecci\u00f3n\u00a0de\u00a0la\u00a0Herida\u00a0Quir\u00fargica. \u00a0\n\u2022 IN:\u00a0 Infecci\u00f3n\u00a0Nosocomial. \u00a0\n\u2022 IQ:\u00a0\u00a0 Intervenci\u00f3n \u00a0Quir\u00fargica. \u00a0\n\u2022 IQ:\u00a0\u00a0 Infecci\u00f3n\u00a0Quir\u00fargica. \u00a0\n\u2022 IRA:\u00a0\u00a0 Insuficiencia \u00a0Respiratoria \u00a0Aguda.\u00a0\n\u2022 ISS:\u00a0\u00a0 Injury\u00a0Severity\u00a0Score.\u00a0\n\u2022 ITRI:\u00a0 Infecci\u00f3n\u00a0del\u00a0Tracto\u00a0Respiratorio \u00a0Inferior.\u00a0\n\u2022 ITU:\u00a0\u00a0 Infecci\u00f3n\u00a0del\u00a0Tracto\u00a0Urinario.\u00a0\n\u2022 Ji2\u00a0:\u00a0 Chi\u2010cuadrado. \u00a0\n\u2022 LI:\u00a0 Lesiones\u00a0Inadvertidas. \u00a0\n\u2022 LM:\u00a0 Lesi\u00f3n\u00a0Medula.\u00a0\n\u2022 LMA:\u00a0 Lesi\u00f3n\u00a0Medular\u00a0Aguda.\u00a0\n\u2022 LMAT:\u00a0 Lesi\u00f3n\u00a0Medular\u00a0Aguda\u00a0Traum\u00e1tica. \u00a0\n\u2022 LMT:\u00a0\u00a0 Lesi\u00f3n\u00a0Medular\u00a0Traum\u00e1tica. \u00a0\u2022 LP:\u00a0\u00a0 Lesi\u00f3n\u00a0Primaria.\u00a0\n\u2022 LS:\u00a0\u00a0 Lesi\u00f3n\u00a0Secundaria. \u00a0\n\u2022 ME:\u00a0 M\u00e9dula\u00a0Espinal.\u00a0\n\u2022 MP:\u00a0 Metilprednisolona. \u00a0\n\u2022 NACIS:\u00a0 National\u00a0Acute\u00a0Spinal\u00a0Cord\u00a0Injury\u00a0Study.\u00a0\n\u2022 NAV:\u00a0 Neumonia \u00a0Asociada\u00a0a\u00a0Ventilaci\u00f3n \u00a0Mec\u00e1nica. \u00a0\n\u2022 NE:\u00a0 Nutrici\u00f3n\u00a0 Enteral.\u00a0\n\u2022 NEXUS:\u00a0 National\u00a0Emergency\u00a0 X\u2010Radiography \u00a0Utilization \u00a0Study.\u00a0\n\u2022 NMDA:\u00a0 N\u2010metil\u2010 D\u2010aspartato. \u00a0\n\u2022 NN:\u00a0 Neumon\u00eda \u00a0Nosocomial. \u00a0\n\u2022 NNP:\u00a0 Neumon\u00eda \u00a0Nosocomial \u00a0precoz.\u00a0\n\u2022 NNT:\u00a0 Neumon\u00eda \u00a0Nosocomial \u00a0Tard\u00eda.\u00a0\n\u2022 NP:\u00a0 Nutrici\u00f3n\u00a0 Parenteral. \u00a0\n\u2022 NR:\u00a0 Nervios\u00a0Raqu\u00eddeos.\u00a0\n\u2022 QIF:\u00a0 Quadriplegia \u00a0Index\u00a0of\u00a0Function. \u00a0\n\u2022 RNM:\u00a0 Resonancia \u00a0Nuclear\u00a0 Magn\u00e9tica. \u00a0\n\u2022 RR:\u00a0 Riesgo\u00a0Relativo.\u00a0\n\u2022 RTS:\u00a0 Revised\u00a0Trauma\u00a0 Score.\u00a0\n\u2022 SCIM:\u00a0 Spinal\u00a0Cord\u00a0Independence \u00a0Measure. \u00a0\n\u2022 SCIWORA:\u00a0 Spinal\u00a0Cord\u00a0Injury\u00a0Without\u00a0Radiographic \u00a0Abnormality. \u00a0\n\u2022 SDRA:\u00a0\u00a0 S\u00edndrome \u00a0de\u00a0Distress\u00a0 Respiratorio \u00a0del\u00a0Adulto.\u00a0\n\u2022 SESCAM:\u00a0 Servicio\u00a0Sanitario\u00a0 de\u00a0Castilla\u00a0la\u00a0Mancha.\u00a0\n\u2022 SN:\u00a0 Sistema\u00a0 Nervioso. \u00a0\n\u2022 SNC:\u00a0 Sistema\u00a0 Nervioso\u00a0Central.\u00a0\n\u2022 TA:\u00a0 Trauma\u00a0 abdominal.\u00a0\n\u2022 TAC:\u00a0 Tomograf\u00eda \u00a0Axial\u00a0 Computerizada. \u00a0\n\u2022 TCE:\u00a0 Trauma\u00a0 Cr\u00e1neo\u00a0Encef\u00e1lico. \u00a0\n\u2022 TE:\u00a0\u00a0 Trauma\u00a0 Esquel\u00e9tico.\u00a0\n\u2022 TEP:\u00a0\u00a0 Tromboembolismo \u00a0pulmonar. \u00a0\n\u2022 TMX:\u00a0 Trauma\u00a0 Maxilofacial. \u00a0\n\u2022 TRISS:\u00a0\u00a0 Trauma\u00a0 Related\u00a0Injury\u00a0Severity\u00a0Score.\u00a0\n\u2022 TSV:\u00a0\u00a0 Taquicardia \u00a0Supra\u00a0Ventricular. \u00a0\n\u2022 TT:\u00a0 Trauma\u00a0 Tor\u00e1cico.\u00a0\n\u2022 TV:\u00a0\u00a0 Trauma\u00a0 Vascular.\u00a0\n\u2022 TVP:\u00a0\u00a0 Trombosis \u00a0Venosa\u00a0Profunda. \u00a0\n\u2022 UC:\u00a0\u00a0 Unidades \u00a0de\u00a0Cuidados\u00a0Cr\u00edticos.\u00a0\n\u2022 UPP:\u00a0 \u00dalceras\u00a0por\u00a0presi\u00f3n.\u00a0\n\u2022 UR:\u00a0\u00a0 Unidad\u00a0 de\u00a0Reanimaci\u00f3n.\u00a0\n\u2022 VIH:\u00a0\u00a0 Virus\u00a0 de\u00a0la\u00a0Inmunodeficiencia \u00a0Humana.\u00a0\n\u2022 VM:\u00a0\u00a0 Ventilaci\u00f3n \u00a0Mec\u00e1nica. \u00a0\n\u2022 VMI:\u00a0\u00a0 Ventilaci\u00f3n \u00a0Mec\u00e1nica \u00a0Invasiva.\u00a0\n\u2022 VMNI:\u00a0 Ventilaci\u00f3n \u00a0Mec\u00e1nica \u00a0No\u00a0Invasiva.\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N\u00a0\n\u00a0 1\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0 21.1. HISTORIA \u00a0DE\u00a0LA\u00a0LESI\u00d3N\u00a0MEDULAR\u00a0\n\u00a0\nLa\u00a0lesi\u00f3n\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0espinal\u00a0(ME)\u00a0es\u00a0una\u00a0de\u00a0las\u00a0principales \u00a0causas\u00a0de\u00a0\nmortalidad\u00a0 entre\u00a0los\u00a0menores\u00a0de\u00a045\u00a0a\u00f1os.\u00a0Diferentes \u00a0tipos\u00a0 de\u00a0fractura\u00a0en\u00a0la\u00a0\ncolumna\u00a0vertebral\u00a0(CV)\u00a0o\u00a0en\u00a0el\u00a0tubo\u00a0neural\u00a0 pueden\u00a0dar\u00a0lugar\u00a0a\u00a0esta\u00a0patolog\u00eda. \u00a0Las\u00a0\nlesiones\u00a0neurol\u00f3gicas, \u00a0en\u00a0especial\u00a0las\u00a0de\u00a0etiolog\u00eda\u00a0traum\u00e1tica,\u00a0 ejemplifican \u00a0la\u00a0\nincapacidad \u00a0de\u00a0la\u00a0ciencia\u00a0m\u00e9dica\u00a0actual\u00a0 de\u00a0restaurar \u00a0las\u00a0funciones\u00a0 neurol\u00f3gicas\u00a0\nperdidas\u00a0tras\u00a0la\u00a0lesi\u00f3n,\u00a0y\u00a0estas\u00a0son\u00a0perdurables \u00a0durante\u00a0toda\u00a0la\u00a0vida\u00a0del\u00a0paciente, \u00a0\nsin\u00a0posibilidad \u00a0de\u00a0mejora.\u00a0La\u00a0b\u00fasqueda \u00a0de\u00a0terapias\u00a0que\u00a0permitan\u00a0la\u00a0regeneraci\u00f3n \u00a0\ndel\u00a0sistema\u00a0nervioso\u00a0(SN)\u00a0para\u00a0la\u00a0recuperaci\u00f3n \u00a0de\u00a0la\u00a0autonom\u00eda \u00a0perdida\u00a0ha\u00a0sido\u00a0\nun\u00a0anhelo\u00a0y\u00a0un\u00a0sue\u00f1o\u00a0durante\u00a0miles\u00a0de\u00a0a\u00f1os.\u00a0\n\u00a0\nEl\u00a0tratamiento \u00a0de\u00a0los\u00a0pacientes\u00a0 con\u00a0lesi\u00f3n\u00a0medular\u00a0 espinal\u00a0comenz\u00f3\u00a0en\u00a0el\u00a0\nsiglo\u00a0XVII\u00a0a.c.\u00a0en\u00a0Egipto.\u00a0La\u00a0primera\u00a0 referencia \u00a0que\u00a0tenemos\u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0medular\u00a0\n(LM)\u00a0la\u00a0encontramos \u00a0en\u00a0el\u00a0papiro\u00a0de\u00a0Edwin\u00a0 Smith,\u00a0escrito\u00a0hace\u00a0 unos\u00a02.500\u00a0a\u00f1os\u00a0\na.c.\u00a0y\u00a0son\u00a0probablemente \u00a0copias\u00a0de\u00a0las\u00a0ense\u00f1anzas \u00a0del\u00a0sabio\u00a0 Imhotep.\u00a0\u00a0En\u00a0dicho\u00a0\npapiro\u00a0se\u00a0describen \u00a0los\u00a0s\u00edntomas\u00a0m\u00e1s\u00a0importantes\u00a0 de\u00a0la\u00a0LM\u00a0cervical,\u00a0y\u00a0as\u00ed\u00a0se\u00a0\nexpone\u00a0que\u00a0\u201cquienes\u00a0tienen\u00a0una\u00a0dislocaci\u00f3n \u00a0de\u00a0las\u00a0v\u00e9rtebras \u00a0del\u00a0cuello\u00a0presentan \u00a0\nun\u00a0cuadro\u00a0con\u00a0los\u00a0brazos\u00a0y\u00a0piernas\u00a0dormidos, \u00a0el\u00a0falo\u00a0erecto,\u00a0escap\u00e1ndose \u00a0la\u00a0orina\u00a0\nsin\u00a0que\u00a0se\u00a0d\u00e9\u00a0cuenta,\u00a0los\u00a0ojos\u00a0 rojos,\u00a0y\u00a0se\u00a0dir\u00e1\u00a0de\u00a0\u00e9l\u00a0que\u00a0sufre\u00a0una\u00a0luxaci\u00f3n\u00a0de\u00a0las\u00a0\nv\u00e9rtebras \u00a0del\u00a0cuello\u201d .\u00a0\n\u00a0Hip\u00f3crates \u00a0unos\u00a0400\u00a0a\u00f1os\u00a0a.c.\u00a0en\u00a0su\u00a0libro\u00a0\u201cSobre\u00a0las\u00a0articulaciones\u201d \u00a0\ndescribe\u00a0perfectamente \u00a0las\u00a0paraplej\u00edas\u00a0 producidas\u00a0 por\u00a0luxaciones \u00a0y\u00a0fracturas. \u00a0\nGaleno,\u00a0 en\u00a0el\u00a0a\u00f1o\u00a050\u00a0a.c.\u00a0realiz\u00f3\u00a0la\u00a0primera\u00a0laminectom\u00eda \u00a0experimental \u00a0y\u00a0\ndistingui\u00f3\u00a0\u00a0signos \u00a0correspondientes \u00a0a\u00a0diferentes \u00a0niveles\u00a0de\u00a0traumatismo \u00a0\nvertebral. \u00a0En\u00a01895,\u00a0el\u00a0descubrimiento\u00a0 de\u00a0Roentgen, \u00a0permiti\u00f3\u00a0la\u00a0correlaci\u00f3n \u00a0del\u00a0\ntraumatismo \u00a0vertebral\u00a0con\u00a0los\u00a0signos\u00a0cl\u00ednicos\u00a0de\u00a0la\u00a0funci\u00f3n\u00a0neuronal\u00a0por\u00a0el\u00a0nivel\u00a0\ndel\u00a0segmento \u00a0medular.\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0 3Desde\u00a0esa\u00a0\u00e9poca,\u00a0el\u00a0\u00edmpetu\u00a0se\u00a0pos\u00f3\u00a0 en\u00a0la\u00a0subdivisi\u00f3n \u00a0de\u00a0las\u00a0lesiones\u00a0\nmedulares \u00a0parciales\u00a0y\u00a0en\u00a0la\u00a0respuesta\u00a0 a\u00a0diferentes \u00a0reg\u00edmenes \u00a0terap\u00e9uticos. \u00a0M\u00e1s\u00a0\nadelante,\u00a0 muchos\u00a0autores\u00a0trataron\u00a0de\u00a0desarrollar \u00a0diversos\u00a0m\u00e9todos\u00a0de\u00a0\nclasificaci\u00f3n, \u00a0como\u00a0Sir\u00a0Ludwing\u00a0Guttmann\u00a0 (1),\u00a0el\u00a0cual\u00a0 utiliz\u00f3\u00a0un\u00a0sistema\u00a0de\u00a0\ngraduaci\u00f3n \u00a0de\u00a0la\u00a0funci\u00f3n\u00a0motora.\u00a0El\u00a0pron\u00f3stico \u00a0de\u00a0estos\u00a0pacientes \u00a0se\u00a0modific\u00f3\u00a0de\u00a0\nforma\u00a0sustancial \u00a0en\u00a01944\u00a0tras\u00a0la\u00a0inauguraci\u00f3n \u00a0del\u00a0Centro\u00a0Nacional\u00a0de\u00a0Lesionados \u00a0\nMedulares \u00a0del\u00a0Hospital\u00a0de\u00a0Stoke\u2010Mandeville \u00a0(Reino\u00a0Unido),\u00a0dirigido\u00a0 por\u00a0el\u00a0Dr.\u00a0\nLudwig\u00a0 Guttmann, \u00a0el\u00a0cual\u00a0 introdujo\u00a0 el\u00a0concepto \u00a0de\u00a0tratamiento \u00a0integral\u00a0pensado\u00a0\nno\u00a0s\u00f3lo\u00a0en\u00a0salvarles\u00a0la\u00a0vida\u00a0sino\u00a0 darles\u00a0sentido\u00a0a\u00a0\u00e9sta\u00a0y\u00a0reintegrarles \u00a0a\u00a0la\u00a0vida\u00a0\nfamiliar,\u00a0 social\u00a0y\u00a0profesional.\u00a0\n\u00a0\nLos\u00a0primeros\u00a0intentos\u00a0para\u00a0tratar\u00a0 a\u00a0los\u00a0lesionados \u00a0medulares \u00a0en\u00a0Espa\u00f1a\u00a0\nfueron\u00a0debidos\u00a0al\u00a0Dr.\u00a0Vallina,\u00a0de\u00a0Sama\u00a0 de\u00a0Langredo \u00a0(Asturias), \u00a0en\u00a01955.\u00a0La\u00a0\nprimera\u00a0 Unidad\u00a0 de\u00a0lesionados \u00a0medulares \u00a0encuadrada \u00a0en\u00a0un\u00a0Hospital\u00a0de\u00a0la\u00a0\nSeguridad\u00a0 Social\u00a0fue\u00a0la\u00a0de\u00a0la\u00a0Ciudad\u00a0Sanitaria\u00a0Virgen\u00a0de\u00a0Covadonga \u00a0de\u00a0Oviedo\u00a0en\u00a0\n1963,\u00a0dirigida\u00a0por\u00a0el\u00a0Dr.\u00a0\u00c1lvarez\u2010Buylla.\u00a0\n\u00a0\nDurante\u00a0las\u00a0d\u00e9cadas\u00a0de\u00a0los\u00a0a\u00f1os\u00a060\u00a0y\u00a070\u00a0se\u00a0crearon\u00a0\u201cUnidades\u00a0 de\u00a0\nParapl\u00e9jicos\u201d \u00a0en\u00a0todas\u00a0 las\u00a0Ciudades\u00a0 Sanitarias \u00a0que\u00a0se\u00a0inauguraban \u00a0a\u00a0un\u00a0ritmo\u00a0casi\u00a0\nanual.\u00a0Estas\u00a0Unidades, \u00a0se\u00a0encuadraban \u00a0dentro\u00a0del\u00a0 Departamento \u00a0de\u00a0\nRehabilitaci\u00f3n \u00a0siendo\u00a0fieles\u00a0a\u00a0las\u00a0ideas\u00a0y\u00a0directrices \u00a0de\u00a0Guttmann. \u00a0En\u00a0Septiembre \u00a0\nde\u00a01974\u00a0fue\u00a0inaugurado\u00a0 el\u00a0Centro\u00a0Nacional\u00a0de\u00a0Rehabilitaci\u00f3n \u00a0y\u00a0Tratamiento \u00a0de\u00a0\nParapl\u00e9jicos \u00a0de\u00a0Toledo\u00a0con\u00a0 226\u00a0camas\u00a0y\u00a0con\u00a0 todos\u00a0los\u00a0medios\u00a0y\u00a0personal\u00a0\napropiado \u00a0para\u00a0el\u00a0tratamiento \u00a0del\u00a0lesionado\u00a0 medular,\u00a0 desde\u00a0el\u00a0momento \u00a0del\u00a0\naccidente \u00a0hasta\u00a0su\u00a0completa \u00a0rehabilitaci\u00f3n \u00a0social\u00a0y\u00a0profesional. \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0 41.2. DEFINICI\u00d3N, \u00a0 EPIDEMIOLOG\u00cdA \u00a0 E\u00a0 IMPORTANCIA \u00a0\nSOCIOECON\u00d3MICA \u00a0\n\u00a0\nEl\u00a0traumatismo \u00a0raquimedular \u00a0incluye\u00a0todas\u00a0 las\u00a0lesiones\u00a0traum\u00e1ticas \u00a0que\u00a0\nafectan,\u00a0 conjunta\u00a0o\u00a0aisladamente, \u00a0a\u00a0las\u00a0diferentes \u00a0estructuras \u00a0de\u00a0la\u00a0CV\u00a0en\u00a0\ncualquiera \u00a0de\u00a0sus\u00a0niveles.\u00a0Se\u00a0trata\u00a0 de\u00a0cuadros\u00a0 graves,\u00a0caracterizados\u00a0 por\u00a0una\u00a0\nelevada\u00a0morbimortalidad \u00a0con\u00a0 una\u00a0creciente \u00a0incidencia, \u00a0los\u00a0cuales\u00a0requieren \u00a0de\u00a0\nuna\u00a0atenci\u00f3n\u00a0 urgente\u00a0especializada \u00a0y\u00a0de\u00a0car\u00e1cter\u00a0multidisciplinario. \u00a0\n\u00a0Es\u00a0importante \u00a0tener\u00a0en\u00a0cuenta\u00a0la\u00a0existencia \u00a0de\u00a0traumatismos \u00a0raqu\u00eddeos \u00a0\nque\u00a0no\u00a0presentan \u00a0da\u00f1o\u00a0neurol\u00f3gico \u00a0en\u00a0el\u00a0momento \u00a0inmediato \u00a0de\u00a0la\u00a0lesi\u00f3n,\u00a0y\u00a0un\u00a0\n10\u00a0%\u00a0lo\u00a0presentar\u00e1 \u00a0con\u00a0posterioridad; \u00a0por\u00a0lo\u00a0que\u00a0todos\u00a0los\u00a0traumatismos \u00a0\nraqu\u00eddeos \u00a0se\u00a0deben\u00a0considerar \u00a0como\u00a0potenciales \u00a0causas\u00a0de\u00a0da\u00f1o\u00a0neurol\u00f3gico \u00a0\nsecundario \u00a0(2).\u00a0\n\u00a0Adem\u00e1s\u00a0de\u00a0la\u00a0mortalidad, \u00a0la\u00a0morbilidad \u00a0conlleva\u00a0graves\u00a0problemas \u00a0\nindividuales, \u00a0familiares \u00a0y\u00a0socioecon\u00f3micos. \u00a0Se\u00a0asocian\u00a0frecuentemente, \u00a0entre\u00a0el\u00a0\n25%\u00a0y\u00a0el\u00a060%,\u00a0con\u00a0 traumatismos \u00a0m\u00faltiples, \u00a0principalmente \u00a0craneal,\u00a0tor\u00e1cico,\u00a0\np\u00e9lvico\u00a0y\u00a0de\u00a0huesos\u00a0 largos.\u00a0La\u00a0existencia \u00a0de\u00a0otros\u00a0 traumatismos, \u00a0la\u00a0alteraci\u00f3n \u00a0del\u00a0\nnivel\u00a0de\u00a0conciencia \u00a0y\u00a0situaciones \u00a0de\u00a0riesgo\u00a0vital,\u00a0 pueden\u00a0 hacer\u00a0dif\u00edcil\u00a0el\u00a0\ndiagn\u00f3stico\u00a0 temprano. \u00a0\n\u00a0Los\u00a0datos\u00a0 sobre\u00a0 incidencia \u00a0de\u00a0la\u00a0LM\u00a0son\u00a0distintos\u00a0seg\u00fan\u00a0pa\u00edses\u00a0y\u00a0autores.\u00a0\nEn\u00a0Estados\u00a0 Unidos\u00a0(EE.UU.),\u00a0aproximadamente \u00a0unas\u00a0 200.000\u00a0personas\u00a0han\u00a0\nsufrido\u00a0una\u00a0LM\u00a0significativa \u00a0(3,4) ;\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0estas\u00a0lesiones\u00a0 se\u00a0produjeron \u00a0por\u00a0\naccidentes \u00a0de\u00a0tr\u00e1fico,\u00a0atracos\u00a0violentos, \u00a0ca\u00eddas\u00a0y\u00a0accidentes \u00a0deportivos. \u00a0La\u00a0edad\u00a0\nmedia\u00a0 en\u00a0el\u00a0momento \u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0era\u00a0de\u00a034\u00a0a\u00f1os,\u00a0con\u00a0un\u00a0claro\u00a0predominio \u00a0en\u00a0\nvarones.\u00a0Entre\u00a0las\u00a0causas\u00a0no\u00a0traum\u00e1ticas\u00a0 se\u00a0describen \u00a0causas\u00a0tumorales, \u00a0\ninfecciosas \u00a0y\u00a0vasculares. \u00a0Se\u00a0estiman\u00a0entre\u00a0 10.000\u00a0y\u00a011.000\u00a0nuevos\u00a0casos\u00a0de\u00a0LM\u00a0al\u00a0\na\u00f1o\u00a0(5,6) .\u00a0Su\u00a0incidencia \u00a0es\u00a0entre\u00a030\u00a0y\u00a032,1\u00a0casos\u00a0 por\u00a0mill\u00f3n\u00a0de\u00a0habitantes, \u00a0y\u00a0si\u00a0se\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0 5cuentan\u00a0las\u00a0v\u00edctimas\u00a0que\u00a0mueren\u00a0antes\u00a0de\u00a0llegar\u00a0al\u00a0hospital\u00a0la\u00a0cifra\u00a0 puede\u00a0\nalcanzar\u00a0entre\u00a043\u00a0y\u00a055\u00a0casos\u00a0por\u00a0mill\u00f3n\u00a0de\u00a0habitantes. \u00a0\n\u00a0\nEn\u00a0Europa,\u00a0la\u00a0incidencia \u00a0calculada \u00a0es\u00a0entre\u00a0 10\u00a0y\u00a020\u00a0casos\u00a0por\u00a0mill\u00f3n\u00a0de\u00a0\nhabitantes \u00a0(7).\u00a0En\u00a0Espa\u00f1a,\u00a0 la\u00a0incidencia \u00a0de\u00a0lesi\u00f3n\u00a0medular\u00a0 traum\u00e1tica \u00a0(LMT)\u00a0es\u00a0de\u00a0\nunos\u00a030\u00a0nuevos\u00a0casos\u00a0por\u00a0mill\u00f3n\u00a0de\u00a0habitantes. \u00a0Aproximadamente \u00a0cada\u00a0 a\u00f1o\u00a0se\u00a0\nproducen \u00a0unos\u00a0nuevos\u00a0 1000\u00a0casos\u00a0en\u00a0toda\u00a0Espa\u00f1a\u00a0por\u00a0traumatismos; \u00a0la\u00a0mitad\u00a0\npor\u00a0accidentes \u00a0de\u00a0tr\u00e1fico,\u00a0el\u00a0resto\u00a0por\u00a0ca\u00eddas,\u00a0golpes,\u00a0accidentes \u00a0deportivos \u00a0y\u00a0\notros\u00a0 traumatismos. \u00a0Respecto\u00a0a\u00a0la\u00a0edad,\u00a0es\u00a0m\u00e1s\u00a0 frecuente \u00a0en\u00a0varones\u00a0j\u00f3venes\u00a0\nentre\u00a0 15\u00a0y\u00a020\u00a0a\u00f1os,\u00a0siendo\u00a0la\u00a0edad\u00a0media\u00a0 29,7\u00a0a\u00f1os\u00a0y\u00a0la\u00a0mediana\u00a025\u00a0a\u00f1os\u00a0(8\u201010).\u00a0\nLos\u00a0estudios\u00a0en\u00a0Estados\u00a0 Unidos\u00a0revelan\u00a0que\u00a0el\u00a080%\u00a0son\u00a0hombres\u00a0(5),\u00a0al\u00a0igual\u00a0que\u00a0\nen\u00a0nuestro\u00a0pa\u00eds.\u00a0\n\u00a0\nLa\u00a0zona\u00a0de\u00a0la\u00a0CV\u00a0m\u00e1s\u00a0frecuentemente \u00a0afectada\u00a0es\u00a0la\u00a0regi\u00f3n\u00a0cervical\u00a0baja\u00a0\n(C5\u2010C7)\u00a0seguida\u00a0en\u00a0segundo\u00a0lugar\u00a0por\u00a0la\u00a0charnela\u00a0toracolumbar \u00a0(D10\u2010 L2)\u00a0\nexistiendo\u00a0 en\u00a0ellas\u00a0mayor\u00a0frecuencia\u00a0 de\u00a0lesiones\u00a0completas \u00a0(11\u201013).\u00a0\n\u00a0\nAproximadamente, \u00a0el\u00a050%\u00a0de\u00a0los\u00a0traumatismos \u00a0raquimedulares \u00a0derivan\u00a0\nen\u00a0tetraplej\u00eda \u00a0(14).\u00a0La\u00a0mayor\u00a0parte\u00a0de\u00a0los\u00a0pacientes \u00a0padecer\u00e1n\u00a0 una\u00a0\u00f3\u00a0m\u00e1s\u00a0de\u00a0las\u00a0\nm\u00faltiples\u00a0 complicaciones \u00a0posibles.\u00a0 Entre\u00a0los\u00a0supervivientes,\u00a0 menos\u00a0del\u00a030%\u00a0\nlogran\u00a0ser\u00a0independientes, \u00a0el\u00a070%\u00a0restante\u00a0necesitar\u00e1 \u00a0aparatos\u00a0\u00f3\u00a0sillas\u00a0 de\u00a0ruedas;\u00a0\nel\u00a022%\u00a0depender\u00e1\u00a0 de\u00a0una\u00a0segunda\u00a0persona,\u00a0y\u00a0cerca\u00a0del\u00a080%\u00a0tendr\u00e1\u00a0 alg\u00fan\u00a0grado\u00a0\nde\u00a0disfunci\u00f3n \u00a0vesical\u00a0 (15,16) .\u00a0\n\u00a0\nLa\u00a0LM,\u00a0por\u00a0su\u00a0prevalencia\u00a0 y\u00a0sus\u00a0importantes \u00a0secuelas,\u00a0 presenta\u00a0una\u00a0gran\u00a0\nrepercusi\u00f3n\u00a0 socioecon\u00f3mica.\u00a0 En\u00a0EE.UU.,\u00a0se\u00a0considera \u00a0el\u00a0coste\u00a0asistencial \u00a0de\u00a0un\u00a0\npaciente\u00a0con\u00a0LM\u00a0durante\u00a0su\u00a0fase\u00a0aguda\u00a0de\u00a0aproximadamente \u00a0170.000\u00a0d\u00f3lares\u00a0y\u00a0\nla\u00a0media\u00a0 de\u00a0gastos\u00a0totales\u00a0durante\u00a0el\u00a0primer\u00a0a\u00f1o\u00a0tras\u00a0la\u00a0lesi\u00f3n\u00a0de\u00a0200.000\u00a0\nd\u00f3lares,\u00a0lo\u00a0cual\u00a0 se\u00a0traduce\u00a0en\u00a0un\u00a0gasto\u00a0estimado \u00a0anual\u00a0de\u00a04\u00a0billones\u00a0de\u00a0d\u00f3lares\u00a0\n(7).\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nEl\u00a0coste\u00a0social,\u00a0 familiar,\u00a0personal\u00a0 y\u00a0laboral\u00a0que\u00a0generan\u00a0las\u00a0lesiones\u00a0\nmedulares \u00a0agudas\u00a0es\u00a0enorme.\u00a0Todo\u00a0ello\u00a0justifica\u00a0un\u00a0enfoque\u00a0multidisciplinario \u00a0en\u00a0\nel\u00a0manejo\u00a0global\u00a0de\u00a0estos\u00a0pacientes, \u00a0comenzando \u00a0con\u00a0 medidas\u00a0preventivas \u00a0en\u00a0\ntodos\u00a0los\u00a0niveles,\u00a0continuando \u00a0con\u00a0 una\u00a0 adecuada\u00a0 asistencia \u00a0extra\u00a0e\u00a0\nintrahospitalaria, \u00a0para\u00a0posteriormente\u00a0 iniciar\u00a0un\u00a0largo\u00a0proceso\u00a0de\u00a0rehabilitaci\u00f3n \u00a0y\u00a0\nreintegraci\u00f3n \u00a0social\u00a0de\u00a0estas\u00a0v\u00edctimas.\u00a0\n\u00a0\n\u00a0\n\u00a0\n1.3. ANATOM\u00cdA \u00a0DESCRIPTIVA \u00a0DE\u00a0LA\u00a0COLUMNA \u00a0VERTEBRAL \u00a0\n\u00a0\nLa\u00a0CV\u00a0cumple\u00a0un\u00a0doble\u00a0cometido; \u00a0por\u00a0una\u00a0\nparte\u00a0sirve\u00a0de\u00a0eje\u00a0al\u00a0organismo \u00a0y\u00a0por\u00a0otra\u00a0 parte,\u00a0\nact\u00faa\u00a0 facilitando \u00a0protecci\u00f3n \u00a0al\u00a0sistema\u00a0medular,\u00a0\nalojado\u00a0en\u00a0el\u00a0conducto \u00a0raqu\u00eddeo. \u00a0La\u00a0ME\u00a0se\u00a0\nencuentra \u00a0a\u00a0continuaci\u00f3n \u00a0del\u00a0 bulbo\u00a0 cerebral,\u00a0y\u00a0\ntermina\u00a0 en\u00a0el\u00a0borde\u00a0inferior\u00a0 de\u00a0L1,\u00a0en\u00a0el\u00a0\ndenominado\u00a0 conus\u00a0 medularis; \u00a0a\u00a0continuaci\u00f3n \u00a0se\u00a0\nencuentra \u00a0el\u00a0filum\u00a0terminale \u00a0recubierta \u00a0por\u00a0la\u00a0cola\u00a0\nde\u00a0caballo.\u00a0\n\u00a0La\u00a0ME\u00a0se\u00a0encuentra \u00a0limitada\u00a0por\u00a0las\u00a0\nmeninges, \u00a0duramadre, \u00a0p\u00edamadre \u00a0\u00a0y\u00a0aracnoides. \u00a0\n\u00a0\nSu\u00a0 estructura \u00a0interna\u00a0 est\u00e1\u00a0dividida\u00a0en\u00a0\nmateria\u00a0 gris\u00a0y\u00a0materia\u00a0blanca.\u00a0La\u00a0materia\u00a0gris\u00a0\ncontiene\u00a0principalmente \u00a0cuerpos\u00a0neuronales, \u00a0tejido\u00a0\nconectivo \u00a0y\u00a0componentes\u00a0 vasculares. \u00a0\u00a0\n\u00a0\n\u00a0 6Figura\u00a01.\u2010\u00a0COLUMNA \u00a0VERTEBRAL \u00a0\nIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nLa\u00a0materia\u00a0 blanca,\u00a0de\u00a0cuya\u00a0apariencia \u00a0es\u00a0responsable \u00a0el\u00a0recubrimiento \u00a0de\u00a0\nmielina\u00a0de\u00a0los\u00a0axones\u00a0nerviosos\u00a0 contiene\u00a0\u00a0terminaciones \u00a0nerviosas \u00a0y\u00a0tejido\u00a0\nvascular.\u00a0\u00a0\n\u00a0\nEn\u00a0la\u00a0sustancia \u00a0gris\u00a0se\u00a0aprecia\u00a0un\u00a0asta\u00a0anterior\u00a0y\u00a0un\u00a0asta\u00a0posterior\u00a0por\u00a0\nlado.\u00a0En\u00a0los\u00a0segmentos \u00a0tor\u00e1cicos\u00a0se\u00a0aprecia\u00a0adem\u00e1s\u00a0un\u00a0asta\u00a0lateral.\u00a0\u00a0La\u00a0sustancia \u00a0\nblanca,\u00a0se\u00a0divide\u00a0en\u00a0tres\u00a0zonas\u00a0 denominadas\u00a0 cordones ,\u00a0que\u00a0agrupan\u00a0 tractos\u00a0o\u00a0\nfasc\u00edculos, \u00a0siendo\u00a0estos\u00a0agrupaciones \u00a0de\u00a0haces\u00a0de\u00a0fibras\u00a0que\u00a0tienen\u00a0el\u00a0mismo\u00a0\norigen,\u00a0 trayecto\u00a0y\u00a0destino.\u00a0\u00a0\n\u00a0Se\u00a0distinguen \u00a0tres\u00a0cordones: \u00a0\n\u2022 Posteriores; \u00a0\u00a0formados \u00a0por\u00a0los\u00a0fasc\u00edculos \u00a0de\u00a0Goll\u00a0y\u00a0Burdach.\u00a0\n\u2022 Laterales. \u00a0\n\u2022 Anteriores. \u00a0\n\u00a0En\u00a0un\u00a0corte\u00a0transversal\u00a0 se\u00a0observa\u00a0que\u00a0la\u00a0ME\u00a0consta\u00a0 de\u00a0una\u00a0regi\u00f3n\u00a0central\u00a0\ncon\u00a0 forma\u00a0de\u00a0H\u00a0denominada \u00a0sustancia \u00a0gris,\u00a0y\u00a0una\u00a0regi\u00f3n\u00a0perif\u00e9rica \u00a0de\u00a0aspecto\u00a0\nblanquecino \u00a0denominada \u00a0sustancia \u00a0blanca.\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0 7\nFigura\u00a02.\u2010CORTE\u00a0TRANSVERSAL \u00a0DE\u00a0LA\u00a0M\u00c9DULAIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nLas\u00a0prolongaciones\u00a0 posteriores, \u00a0relativamente \u00a0delgadas, \u00a0que\u00a0casi\u00a0\nalcanzan\u00a0 el\u00a0surco\u00a0posterior\u00a0se\u00a0denominan \u00a0astas\u00a0posteriores; \u00a0las\u00a0prolongaciones \u00a0\nanteriores, \u00a0anchas\u00a0y\u00a0redondeadas \u00a0se\u00a0denominan \u00a0astas\u00a0anteriores. \u00a0La\u00a0disposici\u00f3n \u00a0\ntridimensional \u00a0de\u00a0las\u00a0astas\u00a0anteriores \u00a0y\u00a0posteriores \u00a0conforman\u00a0 verdaderas \u00a0\ncolumnas\u00a0 que\u00a0recorren\u00a0la\u00a0ME\u00a0para\u00a0\u00a0constituir \u00a0las\u00a0columnas \u00a0grises\u00a0anterior\u00a0y\u00a0\nposterior. \u00a0Las\u00a0astas\u00a0posteriores, \u00a0funcionalmente \u00a0somatosensitivas, \u00a0est\u00e1n\u00a0\nformadas \u00a0por\u00a0neuronas \u00a0sensitivas \u00a0que\u00a0reciben\u00a0los\u00a0impulsos\u00a0que\u00a0llegan\u00a0 por\u00a0las\u00a0\nra\u00edces\u00a0posteriores. \u00a0\u00a0\nLas\u00a0astas\u00a0anteriores,\u00a0\nfuncionalmente \u00a0somatomotoras, \u00a0\nest\u00e1n\u00a0constituidas \u00a0por\u00a0neuronas \u00a0\nmotoras\u00a0cuyos\u00a0axones\u00a0salen\u00a0por\u00a0\nlas\u00a0ra\u00edces\u00a0anteriores. \u00a0La\u00a0parte\u00a0\nlateral\u00a0de\u00a0la\u00a0base\u00a0del\u00a0 asta\u00a0\nposterior\u00a0de\u00a0los\u00a0segmentos \u00a0\ncervicales \u00a0superiores \u00a0constituye \u00a0la\u00a0\nformaci\u00f3n\u00a0 reticular,\u00a0que\u00a0se\u00a0\ncontin\u00faa\u00a0superiormente \u00a0como\u00a0la\u00a0\nformaci\u00f3n\u00a0 reticular\u00a0del\u00a0tronco\u00a0\nencef\u00e1lico. \u00a0\n\u00a0\nLos\u00a0nervios\u00a0raqu\u00eddeos \u00a0(NR)\u00a0\nsalen\u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0conducto \u00a0\nraqu\u00eddeo. \u00a0En\u00a0la\u00a0columna\u00a0dorsal,\u00a0\nestos\u00a0nervios\u00a0se\u00a0encuentran \u00a0en\u00a0la\u00a0\nparte\u00a0central\u00a0de\u00a0los\u00a0agujeros\u00a0\nintervertebrales. \u00a0En\u00a0la\u00a0columna\u00a0\nlumbar,\u00a0 est\u00e1n\u00a0situados\u00a0en\u00a0la\u00a0parte\u00a0\nsuperior\u00a0de\u00a0los\u00a0agujeros.\u00a0\n\u00a0 8\nFiguras\u00a03\u00a0\u2013\u00a04.\u2010\u00a0ESQUEMA \u00a0CUERPOS \u00a0VERTEBRALES\nY\u00a0NERVIOS \u00a0RAQU\u00cdDEOS \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nFigura\u00a05.\u2010\u00a0LIGAMENTOS \u00a0VERTEBRALES\u00a0En\u00a0la\u00a0columna\u00a0lumbar,\u00a0los\u00a0NR\u00a0est\u00e1n\u00a0cerca\u00a0del\u00a0borde\u00a0medioinferior \u00a0del\u00a0\nped\u00edculo\u00a0superior.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0ganglios\u00a0 de\u00a0los\u00a0NR\u00a0dorsales\u00a0y\u00a0lumbares \u00a0se\u00a0\nencuentran \u00a0dentro\u00a0del\u00a0agujero\u00a0intervertebral \u00a0(17).\u00a0\n\u00a0\nLa\u00a0ME\u00a0est\u00e1\u00a0organizada \u00a0en\u00a0segmentos \u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0su\u00a0estructura. \u00a0En\u00a0cada\u00a0\nsegmento, \u00a0nervios\u00a0espinales\u00a0 conectan\u00a0la\u00a0m\u00e9dula\u00a0con\u00a0distintas\u00a0partes\u00a0del\u00a0cuerpo.\u00a0\u00a0\nLos\u00a0niveles\u00a0existentes \u00a0son\u00a08\u00a0cervicales, \u00a012\u00a0tor\u00e1cicos, \u00a05\u00a0lumbares, \u00a05\u00a0sacrales\u00a0y\u00a01\u00a0\ncoccigeal; \u00a0que\u00a0suman\u00a0 el\u00a0conjunto\u00a0 de\u00a0las\u00a031\u00a0o\u00a032\u00a0v\u00e9rtebras \u00a0integradoras \u00a0de\u00a0la\u00a0CV\u00a0\ncompleta. \u00a0Cada\u00a0v\u00e9rtebra\u00a0esta\u00a0constituida \u00a0por:\u00a0el\u00a0cuerpo\u00a0vertebral, \u00a0arco\u00a0neural,\u00a0\nap\u00f3fisis\u00a0articular,\u00a0espinosa\u00a0y\u00a0transversa, \u00a0l\u00e1minas\u00a0 vertebrales,\u00a0 agujero\u00a0de\u00a0\nconjunci\u00f3n, \u00a0carillas\u00a0articulares, \u00a0agujero\u00a0vertebral\u00a0y\u00a0ped\u00edculo.\u00a0\u00a0\n\u00a0\nRespecto\u00a0a\u00a0las\u00a0articulaciones \u00a0\nvertebrales, \u00a0destacan\u00a0las\u00a0superficies\u00a0\narticulares, \u00a0formadas \u00a0por\u00a0las\u00a0caras\u00a0\nsuperior\u00a0e\u00a0inferior\u00a0de\u00a0los\u00a0cuerpos\u00a0\nvertebrales. \u00a0\u00a0\n\u00a0\nTambi\u00e9n\u00a0 tienen\u00a0importancia \u00a0\nlos\u00a0medios\u00a0de\u00a0uni\u00f3n,\u00a0representados \u00a0\npor\u00a0los\u00a0discos\u00a0intervertebrales \u00a0\u00a0y\u00a0por\u00a0\nun\u00a0estuche\u00a0 fibroso\u00a0\u00a0reforzado \u00a0\u00a0\ndelante\u00a0\u00a0y\u00a0atr\u00e1s\u00a0por\u00a0los\u00a0ligamentos\u00a0\nvertebrales \u00a0comunes\u00a0anterior\u00a0y\u00a0\nposterior. \u00a0\n\u00a0La\u00a0irrigaci\u00f3n \u00a0arterial\u00a0de\u00a0la\u00a0ME\u00a0depende\u00a0fundamentalmente \u00a0de\u00a0tres\u00a0vasos\u00a0\nque\u00a0discurren\u00a0 longitudinalmente \u00a0a\u00a0su\u00a0trav\u00e9s;\u00a0una\u00a0arteria\u00a0 espinal\u00a0anterior\u00a0y\u00a0dos\u00a0\narterias\u00a0espinales\u00a0 posteriores. \u00a0La\u00a0arteria\u00a0espinal\u00a0anterior\u00a0nace\u00a0de\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0dos\u00a0\nramas\u00a0de\u00a0la\u00a0arteria\u00a0vertebral; \u00a0por\u00a0otra\u00a0 parte,\u00a0las\u00a0arterias\u00a0espinales\u00a0 posteriores \u00a0\n\u00a0 9\nIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nFigura\u00a06.\u2010\u00a0IRRIGACI\u00d3N \u00a0DE\u00a0LA\u00a0MEnacen\u00a0directamente \u00a0de\u00a0las\u00a0arterias\u00a0vertebrales \u00a0o\u00a0indirectamente \u00a0de\u00a0las\u00a0arterias\u00a0\ncerebelosas \u00a0inferiores \u00a0posteriores \u00a0para\u00a0luego\u00a0descender\u00a0 por\u00a0la\u00a0superficie \u00a0\nposterolateral \u00a0de\u00a0la\u00a0ME\u00a0cercanas\u00a0a\u00a0las\u00a0ra\u00edces\u00a0posteriores \u00a0e\u00a0irrigar\u00a0 el\u00a0tercio\u00a0\nposterior\u00a0de\u00a0la\u00a0sustancia \u00a0medular.\u00a0El\u00a0sistema\u00a0longitudinal \u00a0es\u00a0reforzado \u00a0por\u00a0una\u00a0\nserie\u00a0muy\u00a0variable\u00a0de\u00a0vasos\u00a0 tributarios \u00a0transversales \u00a0\u00a0que\u00a0penetran\u00a0al\u00a0canal\u00a0\nmedular\u00a0 por\u00a0los\u00a0agujeros\u00a0intervertebrales \u00a0junto\u00a0a\u00a0los\u00a0nervios\u00a0y\u00a0ra\u00edces\u00a0espinales.\u00a0\nLas\u00a0anastomosis\u00a0 entre\u00a0 los\u00a0vasos\u00a0longitudinales \u00a0y\u00a0los\u00a0vasos\u00a0segmentarios \u00a0se\u00a0\nproduce\u00a0en\u00a0la\u00a0superficie \u00a0de\u00a0la\u00a0ME.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n1.4. BIOMEC\u00c1NICA \u00a0Y\u00a0CLASIFICACI\u00d3N \u00a0DE\u00a0LAS\u00a0FRACTURAS \u00a0\nCERVICODORSOLUMBARES \u00a0\n\u00a0En\u00a0su\u00a0conjunto, \u00a0la\u00a0CV\u00a0se\u00a0puede\u00a0dividir\u00a0\u00a0en\u00a0tres\u00a0columnas, \u00a0anterior,\u00a0media\u00a0y\u00a0\nposterior; \u00a0limit\u00e1ndose \u00a0la\u00a0primera\u00a0 a\u00a0la\u00a0mitad\u00a0del\u00a0cuerpo\u00a0vertebral\u00a0y\u00a0la\u00a0segunda\u00a0\ndesde\u00a0la\u00a0mitad\u00a0hasta\u00a0la\u00a0columna\u00a0de\u00a0las\u00a0ap\u00f3fisis\u00a0articulares \u00a0y\u00a0desde\u00a0est\u00e1\u00a0hasta\u00a0las\u00a0\nap\u00f3fisis\u00a0espinosas \u00a0la\u00a0columna\u00a0posterior. \u00a0\n\u00a0 10IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nFigura\u00a07.\u2010\u00a0\u00a0CONCEPTO\u00a0BIOMEC\u00c1NICO \u00a0DE\u00a0LAS\u00a0TRES\u00a0 COLUMNAS \u00a0DE\u00a0DENIS\u00a0\u00a0\n\u00a0\n\u00a0\nLa\u00a0mayor\u00eda\u00a0 de\u00a0las\u00a0lesiones\u00a0medulares \u00a0son\u00a0consecuencia \u00a0de\u00a0fracturas\u00a0o\u00a0\nluxaciones \u00a0de\u00a0la\u00a0CV\u00a0o\u00a0de\u00a0ambas.\u00a0De\u00a0las\u00a0diferentes \u00a0clasificaciones\u00a0 propuestas \u00a0para\u00a0\nestas\u00a0lesiones,\u00a0la\u00a0m\u00e1s\u00a0\u00fatil\u00a0es\u00a0la\u00a0que\u00a0las\u00a0divide\u00a0seg\u00fan\u00a0el\u00a0mecanismo \u00a0causante\u00a0de\u00a0la\u00a0\nLM:\u00a0\n\u00a0a) Flexi\u00f3n\n:\u00a0cuando\u00a0el\u00a0agente\u00a0de\u00a0producci\u00f3n \u00a0viene\u00a0\nperpendicularmente \u00a0de\u00a0arriba\u00a0hacia\u00a0abajo\u00a0asociado\u00a0con\u00a0 hiperflexi\u00f3n \u00a0(por\u00a0\nejemplo,\u00a0zambullidas\u00a0 en\u00a0piscinas\u00a0 con\u00a0poca\u00a0profundidad). \u00a0\n\u00a0\nb) Flexi\u00f3n\u00a0y\u00a0rotaci\u00f3n:\u00a0cuando\u00a0el\u00a0agente\u00a0traumatizante \u00a0viene\u00a0de\u00a0\narriba\u00a0abajo\u00a0y\u00a0de\u00a0atr\u00e1s\u00a0hacia\u00a0delante,\u00a0en\u00a0sentido\u00a0oblicuo,\u00a0m\u00e1s\u00a0hiperflexi\u00f3n \u00a0(por\u00a0\nejemplo,\u00a0en\u00a0derrumbes). \u00a0\n\u00a0\nc) Compresi\u00f3n \u00a0directa:\u00a0cuando\u00a0el\u00a0agente\u00a0traumatizante \u00a0viene\u00a0en\u00a0\nsentido\u00a0horizontal\u00a0 (por\u00a0ejemplo,\u00a0en\u00a0los\u00a0atropellos). \u00a0\n\u00a0\nd) Extensi\u00f3n: \u00a0por\u00a0hiperextensi\u00f3n \u00a0como\u00a0en\u00a0las\u00a0contracturas \u00a0\nmusculares \u00a0violentas.\u00a0\n\u00a0Los\u00a0diferentes \u00a0tipos\u00a0de\u00a0fracturas\u00a0a\u00a0su\u00a0vez\u00a0se\u00a0pueden\u00a0 dividir\u00a0en:\u00a0\n\u00a0 11\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\na) Estables:\u00a0son\u00a0aquellas\u00a0que\u00a0presentan\u00a0 fracturas\u00a0con\u00a0depresi\u00f3n \u00a0del\u00a0\nborde\u00a0anterosuperior, \u00a0es\u00a0decir,\u00a0comprometen \u00a0solamente \u00a0la\u00a0columna\u00a0anterior,\u00a0\nquedando\u00a0 indemne\u00a0la\u00a0columna\u00a0media\u00a0 y\u00a0posterior.\u00a0 Estas\u00a0fracturas\u00a0son\u00a0\ndenominadas \u00a0fracturas\u00a0en\u00a0cu\u00f1a.\u00a0\n\u00a0\nb) Inestables: \u00a0este\u00a0tipo\u00a0de\u00a0fracturas\u00a0comprometen \u00a0la\u00a0columna\u00a0media\u00a0\ny\u00a0posterior\u00a0y\u00a0generalmente \u00a0se\u00a0asocian\u00a0con\u00a0 lesiones\u00a0neurol\u00f3gicas. \u00a0Este\u00a0tipo\u00a0de\u00a0\nfracturas\u00a0ocurre\u00a0 cuando\u00a0 hay\u00a0conminuci\u00f3n \u00a0de\u00a0la\u00a0parte\u00a0posterior\u00a0del\u00a0cuerpo\u00a0\nvertebral\u00a0asociado\u00a0a\u00a0subluxaciones \u00a0o\u00a0luxaciones \u00a0de\u00a0las\u00a0articulaciones \u00a0\ninterapofisiarias. \u00a0Se\u00a0denominan \u00a0a\u00a0estas\u00a0como\u00a0fracturas\u00a0conminutas.\u00a0\u00a0\n\u00a0\nTambi\u00e9n\u00a0 pueden\u00a0 dividirse\u00a0las\u00a0fracturas\u00a0en\u00a0la\u00a0columna\u00a0vertebral\u00a0con\u00a0o\u00a0sin\u00a0\nlesi\u00f3n\u00a0neurol\u00f3gica \u00a0independientemente \u00a0de\u00a0su\u00a0estabilidad\u00a0 o\u00a0inestabilidad.\u00a0\n\u00a0a) Fracturas \u00a0sin\u00a0complicaci\u00f3n \u00a0neurol\u00f3gica.\n\u00a0\n9 Fractura\u00a0 del\u00a0cuerpo\u00a0vertebral\u00a0con\u00a0alteraci\u00f3n \u00a0del\u00a0eje\u00a0vertebral:\u00a0\n\u0083 En\u00a0Flexi\u00f3n.\u00a0\n\u0083 En\u00a0Extensi\u00f3n.\u00a0\n9 Fractura\u00a0 del\u00a0cuerpo\u00a0vertebral\u00a0sin\u00a0alteraci\u00f3n \u00a0del\u00a0eje\u00a0vertebral:\u00a0\n\u0083 Fractura\u00a0 por\u00a0aplastamiento. \u00a0\n\u0083 Fracturas \u00a0marginales: \u00a0anterior,\u00a0 posterior\u00a0y\u00a0lateral.\u00a0\n\u0083 Fracturas \u00a0horizontales: \u00a0verticales, \u00a0oblicuas.\u00a0\n9 Fractura\u00a0 aislada\u00a0del\u00a0arco\u00a0posterior: \u00a0\n\u0083 Fractura\u00a0 de\u00a0la\u00a0ap\u00f3fisis\u00a0transversa. \u00a0\n\u0083 Fractura\u00a0 de\u00a0la\u00a0ap\u00f3fisis\u00a0espinosa. \u00a0\n\u0083 Fractura\u00a0 de\u00a0la\u00a0ap\u00f3fisis\u00a0articular.\u00a0\n\u0083 Fractura\u00a0 de\u00a0la\u00a0l\u00e1mina\u00a0y\u00a0ped\u00edculos. \u00a0\n\u00a0\u00a0\n\u00a0 12\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nb) Fracturas \u00a0con\u00a0complicaci\u00f3n \u00a0neurol\u00f3gica. \u00a0\nLos\u00a0s\u00edndromes \u00a0medulares \u00a0que\u00a0se\u00a0pueden\u00a0 presentarse\u00a0 tras\u00a0una\u00a0Lesi\u00f3n\u00a0\nMedular\u00a0Aguda\u00a0\u00a0(LMA)\u00a0son\u00a0diversos.\u00a0Cl\u00e1sicamente \u00a0se\u00a0distingue\u00a0entre\u00a0LM\u00a0\ncompleta \u00a0e\u00a0incompleta,\u00a0 distinci\u00f3n \u00a0que\u00a0posee\u00a0una\u00a0clara\u00a0significaci\u00f3n \u00a0en\u00a0cuanto\u00a0a\u00a0\nactitud\u00a0 terap\u00e9utica \u00a0y\u00a0pron\u00f3stica. \u00a0La\u00a0severidad \u00a0de\u00a0los\u00a0s\u00edndromes \u00a0medulares \u00a0se\u00a0\nclasifica\u00a0usando\u00a0 la\u00a0escala\u00a0ASIA\u00a0(American \u00a0Spinal\u00a0Injury\u00a0Association) \u00a0(18).\u00a0\n\u00a0\n1) Lesi\u00f3n\u00a0medular\u00a0completa. \u00a0Interrupci\u00f3n\u00a0 funcional \u00a0total\u00a0de\u00a0la\u00a0\nm\u00e9dula\u00a0con\u00a0par\u00e1lisis\u00a0 fl\u00e1ccida,\u00a0anestesia\u00a0 completa,\u00a0 alteraciones \u00a0vegetativas \u00a0y\u00a0\nabolici\u00f3n\u00a0de\u00a0reflejos\u00a0osteoendinosos \u00a0y\u00a0cut\u00e1neos\u00a0por\u00a0debajo\u00a0de\u00a0la\u00a0lesi\u00f3n.\u00a0Este\u00a0\nestado\u00a0es\u00a0conocido\u00a0 como\u00a0shock\u00a0medular,\u00a0 diferente \u00a0al\u00a0shock\u00a0neurog\u00e9nico \u00a0de\u00a0\norigen\u00a0medular,\u00a0que\u00a0se\u00a0trata\u00a0de\u00a0una\u00a0situaci\u00f3n\u00a0hemodin\u00e1mica \u00a0que\u00a0puede\u00a0\npresentarse \u00a0dentro\u00a0del\u00a0cuadro\u00a0cl\u00ednico.\u00a0La\u00a0LM\u00a0completa \u00a0presenta\u00a0un\u00a0pron\u00f3stico \u00a0\nsombr\u00edo,\u00a0con\u00a0una\u00a0alta\u00a0mortalidad\u00a0 y\u00a0escasas\u00a0posibilidades\u00a0 de\u00a0recuperaci\u00f3n \u00a0en\u00a0los\u00a0\nsupervivientes. \u00a0\n\u00a0\n2) Lesi\u00f3n\u00a0medular\u00a0incompleta. \u00a0\no S\u00edndrome \u00a0medular\u00a0anterior.\u00a0Suele\u00a0asociarse \u00a0con\u00a0 lesiones\u00a0por\u00a0\nhiperflexi\u00f3n \u00a0(19),\u00a0en\u00a0las\u00a0que\u00a0se\u00a0producen \u00a0desplazamientos\u00a0 de\u00a0la\u00a0parte\u00a0posterior\u00a0\ndel\u00a0cuerpo\u00a0vertebral\u00a0o\u00a0del\u00a0disco\u00a0hacia\u00a0atr\u00e1s,\u00a0con\u00a0 compresi\u00f3n \u00a0de\u00a0los\u00a0haces\u00a0\ncorticoespinal \u00a0y\u00a0espinotal\u00e1mico.\u00a0 Se\u00a0produce\u00a0tetra\u00a0o\u00a0paraplej\u00eda \u00a0seg\u00fan\u00a0el\u00a0nivel\u00a0\nafectado, \u00a0as\u00ed\u00a0como\u00a0hipoalgesia \u00a0e\u00a0hipoestesia; \u00a0conserv\u00e1ndose \u00a0la\u00a0sensibilidad \u00a0\npropioceptiva,\u00a0 vibratoria \u00a0y\u00a0t\u00e1ctil.\u00a0\u00a0\n\u00a0\no S\u00edndrome \u00a0medular\u00a0central.\u00a0Ocurre\u00a0 principalmente \u00a0en\u00a0la\u00a0regi\u00f3n\u00a0\ncervical,\u00a0present\u00e1ndose \u00a0compromiso\u00a0 m\u00e1s\u00a0acentuado \u00a0de\u00a0los\u00a0miembros \u00a0superiores \u00a0\nque\u00a0los\u00a0miembros \u00a0inferiores \u00a0(20).\u00a0\n\u00a0\n\u00a0 13o S\u00edndrome \u00a0de\u00a0Brown\u00a0\u2013\u00a0S\u00e9quard.\u00a0Hemisecci\u00f3n \u00a0de\u00a0la\u00a0ME\u00a0en\u00a0el\u00a0que\u00a0se\u00a0\nproduce\u00a0bloqueo\u00a0 de\u00a0todas\u00a0 las\u00a0funciones\u00a0 motoras\u00a0del\u00a0lado\u00a0de\u00a0la\u00a0secci\u00f3n\u00a0 en\u00a0todos\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nlos\u00a0segmentos \u00a0por\u00a0debajo\u00a0de\u00a0la\u00a0misma.\u00a0Las\u00a0sensaciones\u00a0 t\u00e9rmicas\u00a0y\u00a0dolorosas \u00a0se\u00a0\npierden\u00a0en\u00a0el\u00a0lado\u00a0opuesto,\u00a0y\u00a0las\u00a0sensaciones\u00a0 de\u00a0posici\u00f3n,\u00a0vibraci\u00f3n, \u00a0localizaci\u00f3n \u00a0\ny\u00a0el\u00a0tacto\u00a0fino,\u00a0se\u00a0pierden\u00a0 por\u00a0completo \u00a0en\u00a0el\u00a0lado\u00a0de\u00a0la\u00a0secci\u00f3n.\u00a0\n\u00a0\no S\u00edndrome \u00a0medular\u00a0posterior. \u00a0La\u00a0funci\u00f3n\u00a0motora\u00a0 y\u00a0sensibilidad \u00a0al\u00a0\ndolor\u00a0est\u00e1n\u00a0preservados, \u00a0pero\u00a0la\u00a0propiocepci\u00f3n \u00a0est\u00e1\u00a0alterada.\u00a0\n\u00a0\no S\u00edndrome \u00a0del\u00a0cono\u00a0medular.\u00a0La\u00a0lesi\u00f3n\u00a0de\u00a0la\u00a0ME\u00a0se\u00a0encuentra \u00a0a\u00a0nivel\u00a0\nde\u00a0T12\u2010L1,\u00a0y\u00a0resulta\u00a0 en\u00a0incontinencia \u00a0fecal,\u00a0 vesical\u00a0 y\u00a0alteraci\u00f3n \u00a0de\u00a0la\u00a0funci\u00f3n\u00a0\nsexual.\u00a0El\u00a0reflejo\u00a0bulbocavernoso \u00a0se\u00a0encuentra \u00a0ausente.\u00a0\n\u00a0\no Lesi\u00f3n\u00a0de\u00a0la\u00a0cauda\u00a0equina.\u00a0Es\u00a0una\u00a0 lesi\u00f3n\u00a0aislada\u00a0de\u00a0los\u00a0nervios\u00a0\nespinales\u00a0 de\u00a0la\u00a0cauda\u00a0equina\u00a0al\u00a0interior\u00a0del\u00a0canal\u00a0 vertebral, \u00a0generalmente, \u00a0ocurre\u00a0\npor\u00a0fracturas\u00a0distales\u00a0a\u00a0L1\u2010L2.\u00a0\n\u00a0\no Par\u00e1lisis\u00a0transitoria. \u00a0Inmediatamente \u00a0tras\u00a0una\u00a0LM\u00a0puede\u00a0existir\u00a0una\u00a0\np\u00e9rdida\u00a0fisiol\u00f3gica \u00a0de\u00a0todas\u00a0 las\u00a0funciones\u00a0 espinales \u00a0distales\u00a0a\u00a0nivel\u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0\ndurante\u00a0horas\u00a0o\u00a0semanas\u00a0y\u00a0pudiera\u00a0ser\u00a0debida\u00a0a\u00a0la\u00a0perdida\u00a0de\u00a0potasio\u00a0 medular\u00a0\n(21).\u00a0\u00a0\n\u00a0\nEn\u00a01973\u00a0Louis\u00a0 describe\u00a0el\u00a0concepto \u00a0de\u00a0las\u00a03\u00a0columnas, \u00a0una\u00a0anterior\u00a0\nformada\u00a0por\u00a0cuerpos\u00a0vertebrales \u00a0y\u00a0discos,\u00a0y\u00a0dos\u00a0columnas\u00a0 posteriores \u00a0formadas \u00a0\npor\u00a0procesos\u00a0articulares \u00a0e\u00a0istmos.\u00a0White\u00a0y\u00a0Panjabi\u00a0definen\u00a0en\u00a01978,\u00a0la\u00a0\n\u201cINESTABILIDAD\u201d \u00a0como\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0la\u00a0capacidad \u00a0de\u00a0la\u00a0columna\u00a0bajo\u00a0cargas\u00a0\nfisiol\u00f3gicas\u00a0 de\u00a0mantener \u00a0la\u00a0relaci\u00f3n\u00a0intervertebral, \u00a0preservando \u00a0el\u00a0da\u00f1o\u00a0medular\u00a0\ny/o\u00a0radicular\u00a0adem\u00e1s\u00a0de\u00a0evitar\u00a0 el\u00a0desarrollo \u00a0de\u00a0deformidad\u00a0 incapacitante \u00a0o\u00a0\ndoloroso.\u00a0\n\u00a0\n\u00a0 14La\u00a0clasificaci\u00f3n \u00a0de\u00a0Denis\u00a0se\u00a0basa\u00a0en\u00a0el\u00a0concepto \u00a0biomec\u00e1nico \u00a0de\u00a0las\u00a0tres\u00a0\ncolumnas, \u00a0y\u00a0en\u00a0ella\u00a0existen\u00a0cuatro\u00a0tipos\u00a0de\u00a0fracturas: \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\na) Tipo\u00a0I:\u00a0Fractura\u00a0compresi\u00f3n. \u00a0En\u00a0este\u00a0tipo\u00a0de\u00a0fracturas\u00a0la\u00a0columna\u00a0\nmedia\u00a0 se\u00a0encuentra \u00a0intacta\u00a0pero\u00a0una\u00a0compresi\u00f3n\u00a0 mayor\u00a0 al\u00a050%\u00a0puede\u00a0progresar \u00a0\na\u00a0una\u00a0cifosis\u00a0post\u2010traum\u00e1tica. \u00a0\n\u00a0\nb) Tipo\u00a0II:\u00a0Fracturas \u00a0por\u00a0estallido\u00a0 (BURST).\u00a0En\u00a0este\u00a0tipo\u00a0de\u00a0fracturas\u00a0el\u00a0\nestallido\u00a0es\u00a0debido\u00a0 a\u00a0una\u00a0compresi\u00f3n \u00a0perpendicular \u00a0al\u00a0platillo\u00a0 vertebral. \u00a0La\u00a0\ncolumna\u00a0media\u00a0 es\u00a0la\u00a0m\u00e1s\u00a0comprimida. \u00a0En\u00a0las\u00a0fracturas\u00a0subtipo\u00a0 A\u00a0debido\u00a0a\u00a0la\u00a0\nreducci\u00f3n \u00a0en\u00a0la\u00a0altura\u00a0del\u00a0 cuerpo\u00a0vertebral\u00a0(pared\u00a0posterior) \u00a0hay\u00a0una\u00a0\nretropulsi\u00f3n \u00a0de\u00a0casi\u00a0toda\u00a0la\u00a0pared\u00a0posterior\u00a0hacia\u00a0el\u00a0canal\u00a0vertebral. \u00a0En\u00a0las\u00a0\nsubtipo\u00a0 B\u00a0(las\u00a0m\u00e1s\u00a0frecuentes) \u00a0se\u00a0puede\u00a0observar\u00a0 un\u00a0fragmento \u00a0libre\u00a0de\u00a0la\u00a0pared\u00a0\nposterosuperior \u00a0de\u00a0la\u00a0v\u00e9rtebra,\u00a0invadi\u00e9ndo\u00a0 el\u00a0canal\u00a0 vertebral. \u00a0Con\u00a0menor\u00a0\nfrecuencia\u00a0 puede\u00a0observarse \u00a0el\u00a0fragmento \u00a0libre\u00a0intracanal \u00a0correspondiente \u00a0a\u00a0la\u00a0\npared\u00a0posteroinferior \u00a0de\u00a0la\u00a0v\u00e9rtebra;\u00a0 conformando\u00a0 la\u00a0fractura\u00a0en\u00a0subtipo\u00a0 C.\u00a0En\u00a0\nlas\u00a0subtipo\u00a0 D\u00a0se\u00a0combinan \u00a0los\u00a0mecanismos\u00a0 de\u00a0compresi\u00f3n \u00a0y\u00a0rotaci\u00f3n,\u00a0y\u00a0en\u00a0tanto\u00a0\nque\u00a0subtipo\u00a0 E\u00a0corresponden \u00a0a\u00a0un\u00a0mecanismo \u00a0de\u00a0compresi\u00f3n \u00a0y\u00a0flexi\u00f3n\u00a0 lateral.\u00a0\n\u00a0\nc) Tipo\u00a0III:\u00a0Fracturas \u00a0y\u00a0Flexi\u00f3n\u00a0\u2013\u00a0Distracci\u00f3n. \u00a0\u00a0El\u00a0mecanismo \u00a0que\u00a0produce\u00a0\nesta\u00a0lesi\u00f3n\u00a0es\u00a0una\u00a0flexi\u00f3n\u00a0forzada,\u00a0encontr\u00e1ndose \u00a0el\u00a0eje\u00a0de\u00a0flexi\u00f3n\u00a0 en\u00a0la\u00a0columna\u00a0\nanterior.\u00a0Los\u00a0subtipos\u00a0se\u00a0clasifican\u00a0de\u00a0acuerdo\u00a0a\u00a0la\u00a0localizaci\u00f3n \u00a0del\u00a0trazo\u00a0de\u00a0\nfractura,\u00a0pudiendo \u00a0atravesar\u00a0 este\u00a0la\u00a0ap\u00f3fisis\u00a0espinosa, \u00a0la\u00a0l\u00e1mina\u00a0o\u00a0el\u00a0ped\u00edculo\u00a0\nhasta\u00a0el\u00a0cuerpo\u00a0vertebral, \u00a0como\u00a0la\u00a0cl\u00e1sica\u00a0fractura\u00a0de\u00a0Chance\u00a0(50%\u00a0de\u00a0los\u00a0casos).\u00a0\nEn\u00a0este\u00a0caso\u00a0el\u00a0tratamiento \u00a0conservador \u00a0o\u00a0la\u00a0artrodesis \u00a0corta\u00a0 ofrecen\u00a0un\u00a0\nexcelente \u00a0resultado. \u00a0Sin\u00a0 embargo\u00a0si\u00a0la\u00a0lesi\u00f3n\u00a0atraviesa\u00a0los\u00a0procesos\u00a0\ndiscoligamentarios \u00a0con\u00a0 o\u00a0sin\u00a0lesi\u00f3n\u00a0\u00f3sea\u00a0parcial\u00a0(subtipo\u00a0B\u2010C\u2010D)\u00a0se\u00a0puede\u00a0\nanticipar\u00a0una\u00a0inestabilidad \u00a0que\u00a0puede\u00a0llevar\u00a0al\u00a0fracaso\u00a0del\u00a0tratamiento.\u00a0\n\u00a0\nd) Tipo\u00a0IV:\u00a0Fractura\u00a0Luxaci\u00f3n. \u00a0En\u00a0este\u00a0tipo\u00a0de\u00a0fracturas\u00a0hay\u00a0compromiso \u00a0\nde\u00a0las\u00a0tres\u00a0columnas \u00a0y\u00a0las\u00a0podemos\u00a0 dividir\u00a0en\u00a04\u00a0subtipos.\u00a0\n\u00a0\n\u00a0 15\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n1.5. EVALUACI\u00d3N \u00a0CL\u00cdNICA\u00a0Y\u00a0T\u00c9CNICAS \u00a0DE\u00a0IMAGEN\u00a0 EN\u00a0LA\u00a0LESI\u00d3N\u00a0\nMEDULAR \u00a0AGUDA\u00a0 TRAUM\u00c1TICA \u00a0\n\u00a0\nEl\u00a0Advanced \u00a0Trauma\u00a0 Life\u00a0Support\u00a0 (ATLS),\u00a0 del\u00a0 American \u00a0College\u00a0of\u00a0\nSurgeons, \u00a0define\u00a0dos\u00a0fases\u00a0en\u00a0el\u00a0manejo\u00a0inicial\u00a0del\u00a0paciente\u00a0politraumatizado; \u00a0la\u00a0\nrevisi\u00f3n\u00a0primaria,\u00a0 que\u00a0tiene\u00a0como\u00a0objetivo\u00a0 identificar \u00a0y\u00a0tratar\u00a0 las\u00a0lesiones\u00a0que\u00a0\nponen\u00a0en\u00a0peligro\u00a0la\u00a0vida\u00a0del\u00a0paciente,\u00a0 y\u00a0la\u00a0revisi\u00f3n\u00a0secundaria,\u00a0 que\u00a0intenta\u00a0\ndetectar\u00a0 todas\u00a0las\u00a0lesiones\u00a0 del\u00a0enfermo\u00a0e\u00a0instaurar\u00a0un\u00a0tratamiento \u00a0definitivo.\u00a0 Se\u00a0\ndefinen\u00a0 las\u00a0lesiones\u00a0inadvertidas \u00a0(LI)\u00a0como\u00a0aquellas\u00a0lesiones\u00a0no\u00a0identificadas \u00a0\ndurante\u00a0la\u00a0valoraci\u00f3n \u00a0primaria\u00a0y\u00a0secundaria. \u00a0La\u00a0importancia \u00a0de\u00a0las\u00a0LI\u00a0radica\u00a0en\u00a0el\u00a0\nretraso\u00a0del\u00a0inicio\u00a0del\u00a0 tratamiento \u00a0adecuado.\u00a0 Hay\u00a0 un\u00a0subgrupo \u00a0de\u00a0LI\u00a0\nespecialmente \u00a0importantes, \u00a0que\u00a0conocemos \u00a0como\u00a0LI\u00a0cl\u00ednicamente \u00a0relevantes. \u00a0\n\u00c9stas\u00a0son\u00a0las\u00a0lesiones\u00a0que\u00a0conllevan \u00a0complicaciones\u00a0 graves\u00a0o\u00a0incluso\u00a0la\u00a0muerte\u00a0\ndel\u00a0paciente. \u00a0La\u00a0incidencia \u00a0de\u00a0LI\u00a0oscila\u00a0entre\u00a0 el\u00a00,6\u00a0y\u00a0el\u00a065%,\u00a0 y\u00a0se\u00a0han\u00a0hallado\u00a0\nmenos\u00a0LI\u00a0en\u00a0los\u00a0estudios\u00a0retrospectivos. \u00a0En\u00a0los\u00a0estudios\u00a0prospectivos \u00a0se\u00a0hallan\u00a0\ndistintas\u00a0incidencias\u00a0 debido\u00a0 a\u00a0la\u00a0metodolog\u00eda \u00a0aplicada\u00a0y\u00a0a\u00a0matices\u00a0en\u00a0la\u00a0definici\u00f3n \u00a0\nde\u00a0LI.\u00a0\n\u00a0La\u00a0literatura \u00a0m\u00e9dica\u00a0indica\u00a0que\u00a0\u00a0se\u00a0reduce\u00a0dicha\u00a0incidencia \u00a0de\u00a0este\u00a0evento\u00a0\ncon\u00a0 la\u00a0atenci\u00f3n\u00a0del\u00a0paciente\u00a0politraumatizado \u00a0por\u00a0parte\u00a0de\u00a0equipos\u00a0\nmultidisciplinarios \u00a0bien\u00a0entrenados \u00a0y\u00a0con\u00a0una\u00a0asistencia \u00a0protocolizada.\u00a0\n\u00a0\u00a01.5.1.  Exploraci\u00f3n \u00a0directa\u00a0\n\u00a0 16La\u00a0evaluaci\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0la\u00a0CV\u00a0debe\u00a0seguir\u00a0un\u00a0patr\u00f3n\u00a0sistem\u00e1tico. \u00a0Cada\u00a0\nregi\u00f3n\u00a0de\u00a0la\u00a0columna\u00a0debe\u00a0palparse\u00a0directamente \u00a0y\u00a0realizarse \u00a0una\u00a0inspecci\u00f3n \u00a0\nvisual\u00a0(22).\u00a0La\u00a0tumefacci\u00f3n,\u00a0 fluctuaci\u00f3n, \u00a0desviaci\u00f3n, \u00a0crepitaci\u00f3n\u00a0 \u00f3sea,\u00a0 contusi\u00f3n \u00a0y\u00a0\nel\u00a0dolor\u00a0a\u00a0la\u00a0exploraci\u00f3n \u00a0pueden\u00a0 ser\u00a0signos\u00a0cl\u00ednicos\u00a0de\u00a0lesiones\u00a0de\u00a0la\u00a0CV,\u00a0\npotencialmente \u00a0\u00a0inestables. \u00a0Adem\u00e1s,\u00a0las\u00a0lesiones\u00a0de\u00a0las\u00a0partes\u00a0blandas\u00a0en\u00a0otras\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nzonas\u00a0 del\u00a0cuerpo\u00a0pueden\u00a0indicar\u00a0un\u00a0mecanismo \u00a0de\u00a0lesi\u00f3n\u00a0que\u00a0afecta\u00a0tambi\u00e9n\u00a0a\u00a0la\u00a0\nCV\u00a0(23).\u00a0\n\u00a0\n\u00a0\n1.5.2.  Evaluaci\u00f3n \u00a0neurol\u00f3gica \u00a0\nEn\u00a0el\u00a0paciente\u00a0despierto \u00a0y\u00a0cooperador,\u00a0 es\u00a0imprescindible \u00a0llevar\u00a0 a\u00a0cabo\u00a0una\u00a0\nexploraci\u00f3n\u00a0 neurol\u00f3gica \u00a0meticulosa \u00a0y\u00a0rigurosa;\u00a0documentando \u00a0de\u00a0forma\u00a0precisa\u00a0\nel\u00a0grado\u00a0de\u00a0conciencia, \u00a0de\u00a0dolor\u00a0y\u00a0su\u00a0capacidad\u00a0 de\u00a0demostrar\u00a0 activamente \u00a0la\u00a0\nfunci\u00f3n\u00a0motriz,\u00a0en\u00a0una\u00a0exploraci\u00f3n\u00a0 basada\u00a0en\u00a0las\u00a0ra\u00edces\u00a0nerviosas. \u00a0Los\u00a0resultados \u00a0\nde\u00a0las\u00a0pruebas\u00a0motrices,\u00a0 sensitivas \u00a0y\u00a0reflejas\u00a0deben\u00a0 registrarse \u00a0de\u00a0modo\u00a0seriado\u00a0y\u00a0\nes\u00a0necesario \u00a0evaluar\u00a0 la\u00a0sensibilidad \u00a0perianal,\u00a0 el\u00a0tono\u00a0rectal\u00a0y\u00a0el\u00a0refejo\u00a0\nbulbocavernoso. \u00a0\n\u00a0La\u00a0funci\u00f3n\u00a0neurol\u00f3gica \u00a0resulta\u00a0dif\u00edcil\u00a0de\u00a0evaluar\u00a0 en\u00a0el\u00a0paciente\u00a0\ninconsciente, \u00a0ebrio\u00a0 o\u00a0sedoanalgesiado .\u00a0Hay\u00a0que\u00a0observar\u00a0 la\u00a0movilidad \u00a0\nespont\u00e1nea \u00a0de\u00a0las\u00a0extremidades \u00a0y\u00a0la\u00a0elevaci\u00f3n \u00a0de\u00a0la\u00a0caja\u00a0tor\u00e1cica\u00a0con\u00a0 la\u00a0\nrespiraci\u00f3n\u00a0 espont\u00e1nea, \u00a0ya\u00a0que\u00a0indican\u00a0diferentes \u00a0grados\u00a0de\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0ME.\u00a0\nAs\u00edmismo, \u00a0el\u00a0paciente\u00a0que\u00a0est\u00e1\u00a0inconsciente \u00a0o\u00a0que\u00a0presenta\u00a0una\u00a0alteraci\u00f3n \u00a0del\u00a0\nestado\u00a0mental\u00a0 responder\u00e1\u00a0 a\u00a0los\u00a0est\u00edmulos\u00a0 dolorosos \u00a0con\u00a0una\u00a0funci\u00f3n\u00a0motriz\u00a0\nvoluntaria. \u00a0Los\u00a0arcos\u00a0reflejos\u00a0deben\u00a0 permanecer \u00a0intactos,\u00a0independientemente \u00a0\ndel\u00a0nivel\u00a0de\u00a0intoxicaci\u00f3n \u00a0et\u00edlica.\u00a0\n\u00a0\n\u00a0\n1.5.3.  T\u00e9cnicas\u00a0 de\u00a0imagen\u00a0\n\u00a0 17Hay\u00a0 que\u00a0mantener \u00a0las\u00a0precauciones \u00a0en\u00a0relaci\u00f3n\u00a0con\u00a0 la\u00a0CV\u00a0hasta\u00a0que\u00a0se\u00a0\nhaya\u00a0excluido\u00a0 una\u00a0lesi\u00f3n\u00a0mediante \u00a0una\u00a0exploraci\u00f3n \u00a0fiable,\u00a0que\u00a0puede\u00a0\ncomprender \u00a0una\u00a0exploraci\u00f3n \u00a0f\u00edsica\u00a0y/o\u00a0estudios\u00a0de\u00a0imagen.\u00a0Los\u00a0requerimientos \u00a0\nde\u00a0pruebas\u00a0de\u00a0imagen\u00a0avanzadas, \u00a0han\u00a0 sido\u00a0 modificados, \u00a0y\u00a0as\u00ed\u00a0en\u00a0un\u00a0paciente\u00a0\ndespierto, \u00a0colaborador,\u00a0 sin\u00a0d\u00e9ficits\u00a0 neurol\u00f3gicos, \u00a0que\u00a0est\u00e9\u00a0alerta\u00a0y\u00a0no\u00a0se\u00a0\nencuentre \u00a0bajos\u00a0 los\u00a0efectos\u00a0de\u00a0ninguna\u00a0droga;\u00a0sin\u00a0dolor\u00a0cervical\u00a0ni\u00a0en\u00a0raquis\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nvertebral\u00a0y\u00a0sin\u00a0ninguna\u00a0otra\u00a0 lesi\u00f3n\u00a0que\u00a0pudiera\u00a0hacer\u00a0pasar\u00a0desapercibida \u00a0una\u00a0\nlesi\u00f3n\u00a0de\u00a0la\u00a0CV,\u00a0no\u00a0es\u00a0necesario \u00a0la\u00a0relizaci\u00f3n \u00a0de\u00a0pruebas\u00a0de\u00a0imagen\u00a0\u00a0(24,25) .\u00a0\n\u00a0\nCualquier \u00a0paciente\u00a0con\u00a0un\u00a0traumatismo \u00a0de\u00a0alta\u00a0energ\u00eda\u00a0 requiere\u00a0la\u00a0\nobtenci\u00f3n \u00a0de\u00a0im\u00e1genes \u00a0en\u00a0la\u00a0situaci\u00f3n\u00a0inicial\u00a0independientemente \u00a0de\u00a0los\u00a0\ns\u00edntomas.\u00a0 En\u00a0este\u00a0grupo\u00a0de\u00a0pacientes \u00a0existe\u00a0una\u00a0tendencia \u00a0a\u00a0la\u00a0obtenci\u00f3n \u00a0de\u00a0\nTomograf\u00eda \u00a0Axial\u00a0Computerizada \u00a0(TAC)\u00a0de\u00a0cribado,\u00a0antes\u00a0que\u00a0radiograf\u00edas \u00a0\nconvencionales. \u00a0As\u00ed\u00a0mismo\u00a0se\u00a0prefiere\u00a0 la\u00a0TAC\u00a0a\u00a0las\u00a0radiograf\u00edas \u00a0convencionales \u00a0en\u00a0\nel\u00a0diagn\u00f3stico\u00a0 de\u00a0una\u00a0posible\u00a0lesi\u00f3n\u00a0en\u00a0pacientes \u00a0obnubilados. \u00a0Las\u00a0principales \u00a0\nt\u00e9cnicas\u00a0de\u00a0imagen\u00a0empleadas \u00a0son:\u00a0\n\u00a0\n9 Radiograf\u00eda \u00a0convencional. \u00a0Historicamente \u00a0la\u00a0norma\u00a0aceptada\u00a0\nconsiste\u00a0en\u00a0evaluar\u00a0 a\u00a0todos\u00a0 los\u00a0pacientes \u00a0traumatizados \u00a0con\u00a0 proyecciones \u00a0\nortogonales \u00a0(AP\u00a0y\u00a0lateral)\u00a0de\u00a0la\u00a0CV\u00a0completa. \u00a0En\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0anamnesis, \u00a0la\u00a0\nexploraci\u00f3n \u00a0f\u00edsica\u00a0 y\u00a0los\u00a0datos\u00a0radiol\u00f3gicos \u00a0iniciales\u00a0 del\u00a0 paciente,\u00a0 puede\u00a0\nplantearsela \u00a0realizaci\u00f3n \u00a0de\u00a0pruebas\u00a0de\u00a0imagen\u00a0m\u00e1s\u00a0avanzadas.\u00a0\n\u00a0\n\u00a0 189 Tomograf\u00eda \u00a0Axial\u00a0Computarizada \u00a0(TAC).\u00a0La\u00a0TAC\u00a0se\u00a0ha\u00a0convertido \u00a0\nen\u00a0una\u00a0t\u00e9cnica\u00a0inestimable \u00a0para\u00a0la\u00a0evaluaci\u00f3n \u00a0de\u00a0los\u00a0traumatismos \u00a0de\u00a0la\u00a0CV,\u00a0no\u00a0\nexistiendo\u00a0 ninguna\u00a0t\u00e9cnica\u00a0con\u00a0 su\u00a0capacidad \u00a0para\u00a0detectar\u00a0 las\u00a0lesiones\u00a0del\u00a0\nesqueleto \u00a0\u00f3seo\u00a0(26).\u00a0Hay\u00a0 que\u00a0obtener\u00a0cortes\u00a0finos\u00a0(2mm),\u00a0y\u00a0las\u00a0im\u00e1genes \u00a0axiales\u00a0\nsiempre\u00a0deben\u00a0 transformarse \u00a0en\u00a0reconstrucciones \u00a0sagitales\u00a0y\u00a0coronales.\u00a0 Con\u00a0\nestas\u00a0im\u00e1genes,\u00a0 es\u00a0f\u00e1cil\u00a0 realizar\u00a0una\u00a0evaluaci\u00f3n \u00a0de\u00a0la\u00a0columna\u00a0en\u00a0relaci\u00f3n\u00a0con\u00a0las\u00a0\nfracturas, \u00a0el\u00a0desplazamiento \u00a0de\u00a0fragmentos, \u00a0las\u00a0alteraciones \u00a0de\u00a0la\u00a0alineaci\u00f3n \u00a0y\u00a0el\u00a0\ngrado\u00a0de\u00a0lesi\u00f3n\u00a0\u00f3sea.\u00a0Diversos\u00a0estudios\u00a0han\u00a0 puesto\u00a0de\u00a0manifiesto \u00a0la\u00a0elevada\u00a0\nsensibilidad \u00a0de\u00a0la\u00a0TAC\u00a0respecto\u00a0a\u00a0la\u00a0radiograf\u00eda \u00a0convencional, \u00a0en\u00a0la\u00a0detecci\u00f3n \u00a0de\u00a0\nla\u00a0fractura\u00a0espinal\u00a0(27,28) ,\u00a0indicando \u00a0adem\u00e1s\u00a0la\u00a0ventaja\u00a0de\u00a0poder\u00a0mantener \u00a0la\u00a0\nposici\u00f3n\u00a0de\u00a0dec\u00fabito\u00a0supino\u00a0 del\u00a0paciente\u00a0en\u00a0el\u00a0momento \u00a0de\u00a0realizar\u00a0 la\u00a0prueba.\u00a0Si\u00a0\nadem\u00e1s\u00a0existe\u00a0Trauma\u00a0 Craneoencef\u00e1lico \u00a0(TCE)\u00a0asociado, \u00a0es\u00a0necario\u00a0realizar\u00a0 un\u00a0\nTAC\u00a0craneal\u00a0para\u00a0descartar\u00a0 la\u00a0presencia \u00a0de\u00a0lesi\u00f3n\u00a0cerebral,\u00a0es\u00a0menos\u00a0costoso\u00a0y\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nm\u00e1s\u00a0eficicaz\u00a0el\u00a0realizar\u00a0conjuntamente \u00a0un\u00a0TAC\u00a0de\u00a0CV\u00a0para\u00a0descartar\u00a0\nsimultaneamente\u00a0 la\u00a0posibilidad \u00a0de\u00a0lesi\u00f3n\u00a0a\u00a0este\u00a0nivel.\u00a0\n\u00a0\n9 Resonancia \u00a0Nuclear\u00a0Magn\u00e9tica\u00a0 (RNM).\u00a0Sus\u00a0indicaciones \u00a0en\u00a0la\u00a0\nevaluaci\u00f3n \u00a0aguda\u00a0del\u00a0trauma\u00a0 medular\u00a0a\u00fan\u00a0no\u00a0est\u00e1n\u00a0bien\u00a0definidas\u00a0(29,30) ,\u00a0si\u00a0bien\u00a0\nposee\u00a0una\u00a0capacidad \u00a0excepcional \u00a0para\u00a0evaluar\u00a0 las\u00a0estructuras \u00a0de\u00a0partes\u00a0blandas\u00a0\ny\u00a0es\u00a0claramente\u00a0 mejor\u00a0que\u00a0todas\u00a0 las\u00a0dem\u00e1s\u00a0t\u00e9cnicas\u00a0de\u00a0imagen\u00a0para\u00a0revelar\u00a0\nroturas\u00a0ligamentosas, \u00a0lesiones\u00a0discales,\u00a0 hemorragia\u00a0 o\u00a0edema\u00a0 de\u00a0la\u00a0ME\u00a0(31).\u00a0No\u00a0\nobstante, \u00a0por\u00a0lo\u00a0general\u00a0 es\u00a0menos\u00a0asequible, \u00a0lleva\u00a0m\u00e1s\u00a0tiempo\u00a0y\u00a0el\u00a0paciente\u00a0la\u00a0\ntolera\u00a0peor\u00a0que\u00a0la\u00a0TAC,\u00a0y\u00a0adem\u00e1s\u00a0la\u00a0presencia \u00a0de\u00a0ciertos\u00a0dispositivos \u00a0\nferromagn\u00e9ticos \u00a0impide\u00a0su\u00a0uso.\u00a0Las\u00a0indicaciones \u00a0m\u00e1s\u00a0frecuentes \u00a0para\u00a0la\u00a0RNM\u00a0son\u00a0\nla\u00a0evaluaci\u00f3n \u00a0del\u00a0deterioro \u00a0neurol\u00f3gico, \u00a0especialmente \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0\nobservaciones\u00a0 que\u00a0no\u00a0quedan\u00a0claramente \u00a0explicadas\u00a0 con\u00a0la\u00a0TAC\u00a0(32),\u00a0y\u00a0la\u00a0ayuda\u00a0\nen\u00a0la\u00a0evaluaci\u00f3n \u00a0del\u00a0grado\u00a0de\u00a0compresi\u00f3n \u00a0y\u00a0lesi\u00f3n\u00a0medular.\u00a0\n\u00a0\n\u00a01.5.4.  Escalas\u00a0de\u00a0valoraci\u00f3n \u00a0espec\u00edficas \u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0medular\u00a0\nInicialmente \u00a0todos\u00a0los\u00a0lesionados \u00a0medulares \u00a0que\u00a0ingresan\u00a0en\u00a0una\u00a0Unidad\u00a0\nespecializada \u00a0son\u00a0diagnosticados \u00a0de\u00a0su\u00a0lesi\u00f3n\u00a0y\u00a0valorados \u00a0seg\u00fan\u00a0la\u00a0escala\u00a0 ASIA\u00a0\n(33,34) ,\u00a0que\u00a0establece \u00a0unas\u00a0 pautas\u00a0en\u00a0la\u00a0clasificaci\u00f3n \u00a0seg\u00fan\u00a0criterios\u00a0\nneurol\u00f3gicos \u00a0y\u00a0funcionales. \u00a0Este\u00a0m\u00e9todo\u00a0nos\u00a0permite\u00a0detectar\u00a0los\u00a0cambios\u00a0en\u00a0la\u00a0\nsituaci\u00f3n\u00a0neurol\u00f3gica \u00a0del\u00a0paciente\u00a0durante\u00a0el\u00a0proceso\u00a0terap\u00e9utico, \u00a0objetivarlos \u00a0y\u00a0\ncuantificarlos. \u00a0En\u00a0cuanto\u00a0al\u00a0estado\u00a0funcional \u00a0de\u00a0estos\u00a0 pacientes, \u00a0se\u00a0han\u00a0empleado \u00a0\nnumerosas \u00a0escalas:\u00a0\u00edndice\u00a0de\u00a0Barthel,\u00a0quadriplegia \u00a0Index\u00a0of\u00a0Function\u00a0(Q.I.F.),\u00a0\nSpinal\u00a0Cord\u00a0Independence \u00a0Measure\u00a0(SCIM),\u00a0 pero\u00a0la\u00a0m\u00e1s\u00a0utilizada\u00a0actualmente \u00a0es\u00a0\nel\u00a0Functional \u00a0Independence \u00a0Measure\u00a0(FIM).\u00a0\n\u00a0\n\u00a0 19La\u00a0escala\u00a0 de\u00a0ASIA\u00a0describe\u00a0la\u00a0exploraci\u00f3n \u00a0de\u00a0la\u00a0sensibilidad \u00a0y\u00a0movilidad, \u00a0\nevaluando \u00a0el\u00a0nivel\u00a0neurol\u00f3gico, \u00a0nivel\u00a0sensitivo, \u00a0nivel\u00a0motor\u00a0y\u00a0zonas\u00a0 de\u00a0\npreservaci\u00f3n \u00a0parcial.\u00a0De\u00a0la\u00a0exploraci\u00f3n\u00a0 sensitiva\u00a0y\u00a0motora,\u00a0 se\u00a0obtiene\u00a0el\u00a0concepto \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nde\u00a0Nivel\u00a0Neurol\u00f3gico \u00a0que\u00a0es\u00a0el\u00a0segmento \u00a0medular\u00a0 m\u00e1s\u00a0distal\u00a0con\u00a0 funciones\u00a0\nsensitiva\u00a0y\u00a0motora\u00a0 normales \u00a0y\u00a0la\u00a0zona\u00a0de\u00a0preservaci\u00f3n \u00a0parcial\u00a0(sensitiva \u00a0o\u00a0\nmotora).\u00a0Se\u00a0llama\u00a0 lesi\u00f3n\u00a0medular\u00a0 completa\u00a0 (grado\u00a0A\u00a0de\u00a0ASIA)\u00a0cuando\u00a0no\u00a0existe\u00a0\nfunci\u00f3n\u00a0motora\u00a0 ni\u00a0sensitiva\u00a0por\u00a0debajo\u00a0del\u00a0 nivel\u00a0de\u00a0lesi\u00f3n.\u00a0 Si\u00a0hay\u00a0 alguna\u00a0\npreservaci\u00f3n \u00a0sensitiva\u00a0o\u00a0motora\u00a0 la\u00a0lesi\u00f3n\u00a0es\u00a0incompleta \u00a0y\u00a0se\u00a0grad\u00faa\u00a0de\u00a0la\u00a0B\u00a0a\u00a0la\u00a0E\u00a0\nseg\u00fan\u00a0la\u00a0escala\u00a0 de\u00a0ASIA\u00a0(35).\u00a0\n\u00a0\nSon\u00a0importantes \u00a0conocer\u00a0los\u00a0diferentes \u00a0dermatomas \u00a0para\u00a0evaluar\u00a0\ntopograficamente \u00a0de\u00a0\u00a0forma\u00a0aproximada \u00a0el\u00a0nivel\u00a0lesional:\u00a0\n\u00a0\nFigura\u00a08.\u2010ESQUEMA \u00a0DERMATOMAS\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0 20IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nTabla\u00a0 1.\u2010\u00a0Escala \u00a0American \u00a0Spinal\u00a0Injury\u00a0Association \u00a0(ASIA).\u00a0\nA.\u00a0\u00a0\u00a0\u00a0\u00a0COMPLETA:\u00a0 No\u00a0hay\u00a0funci\u00f3n\u00a0motora\u00a0 o\u00a0sensitiva\u00a0preservada\u00a0 en\u00a0los\u00a0\nsegmentos \u00a0sacros\u00a0S4\u2010S5.\u00a0\nB.\u00a0\u00a0\u00a0\u00a0\u00a0INCOMPLETA: \u00a0Hay\u00a0preservaci\u00f3n \u00a0de\u00a0la\u00a0funci\u00f3n\u00a0sensitiva,\u00a0 pero\u00a0no\u00a0\nmotora,\u00a0 por\u00a0debajo\u00a0del\u00a0nive\u00a0neurol\u00f3gico \u00a0hasta\u00a0los\u00a0segmentos \u00a0sacros\u00a0S4\u00a0\u2013\u00a0S5.\u00a0\nC.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0INCOMPLETA: \u00a0Hay\u00a0 funci\u00f3n\u00a0motora\u00a0preservada \u00a0por\u00a0debajo\u00a0del\u00a0nivel\u00a0\nneurol\u00f3gico \u00a0hasta\u00a0S4\u00a0\u2013\u00a0S5,\u00a0pero\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0m\u00fasculos \u00a0claves\u00a0infralesionales\u00a0\ntienen\u00a0una\u00a0valoraci\u00f3n \u00a0inferior\u00a0a\u00a03.\u00a0\nD.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 INCOMPLETA: \u00a0La\u00a0funci\u00f3n\u00a0motora\u00a0 est\u00e1\u00a0preservada\u00a0 por\u00a0debajo\u00a0del\u00a0\nnivel\u00a0neurol\u00f3gico, \u00a0y\u00a0la\u00a0mayor\u00eda\u00a0 de\u00a0los\u00a0m\u00fasculos \u00a0claves\u00a0infralesionales \u00a0tienen\u00a0una\u00a0\nvaloraci\u00f3n \u00a0superior\u00a0o\u00a0igual\u00a0a\u00a03.\u00a0\nE.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NORMAL: \u00a0Las\u00a0funciones\u00a0 sensitiva\u00a0y\u00a0motora\u00a0 son\u00a0normales. \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0 211.6. FISIOPATOLOG\u00cdA \u00a0DE\u00a0LA\u00a0LESI\u00d3N\u00a0MEDULAR\u00a0 AGUDA\u00a0\n\u00a0\nEl\u00a0tejido\u00a0medular\u00a0carece\u00a0de\u00a0capacidad \u00a0intr\u00ednseca \u00a0de\u00a0regeneraci\u00f3n, \u00a0y\u00a0por\u00a0\nello\u00a0cualquier\u00a0 lesi\u00f3n\u00a0a\u00a0este\u00a0nivel\u00a0puede\u00a0tener\u00a0una\u00a0gran\u00a0repercusi\u00f3n \u00a0neurol\u00f3gica. \u00a0\nLas\u00a0investigaciones\u00a0 m\u00e9dicas\u00a0de\u00a0las\u00a0tres\u00a0\u00faltimas\u00a0d\u00e9cadas,\u00a0han\u00a0cambiado \u00a0el\u00a0antiguo\u00a0\nconcepto \u00a0de\u00a0irreversibilidad\u00a0 total.\u00a0Los\u00a0nuevos\u00a0conocimientos \u00a0fisiopatol\u00f3gicos \u00a0\nse\u00f1alan\u00a0 que\u00a0la\u00a0LMA\u00a0es\u00a0un\u00a0proceso\u00a0din\u00e1mico, \u00a0evolutico\u00a0y\u00a0multif\u00e1sico\u00a0 a\u00a0partir\u00a0del\u00a0\nmomento \u00a0en\u00a0que\u00a0se\u00a0produce\u00a0el\u00a0traumatismo \u00a0(36,37) .\u00a0\n\u00a0\nTras\u00a0la\u00a0lesi\u00f3n\u00a0primaria\u00a0(LP)\u00a0se\u00a0inician\u00a0una\u00a0serie\u00a0de\u00a0cambios\u00a0inflamatorios, \u00a0\nvasculares, \u00a0metab\u00f3licos, \u00a0bioqu\u00edmicos \u00a0y\u00a0neuroqu\u00edmicos\u00a0 que\u00a0involucran\u00a0\nprincipalmente,de \u00a0inicio,\u00a0a\u00a0la\u00a0sustancia \u00a0gris\u00a0central,\u00a0avanzando \u00a0en\u00a0sentido\u00a0 dorsal\u00a0\ny\u00a0caudal,\u00a0afectando \u00a0tambi\u00e9n\u00a0a\u00a0la\u00a0sustancia \u00a0blanca;\u00a0siendo\u00a0este\u00a0b\u00e1sicamente \u00a0el\u00a0\nconcepto \u00a0de\u00a0lesi\u00f3n\u00a0 secundaria \u00a0(LS)\u00a0(38\u201040).\u00a0Tras\u00a0el\u00a0traumatismo \u00a0raquimedular \u00a0se\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nproducen \u00a0una\u00a0serie\u00a0de\u00a0alteraciones \u00a0metab\u00f3licas, \u00a0la\u00a0m\u00e1s\u00a0patente\u00a0y\u00a0caracter\u00edstica, \u00a0\nes\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0una\u00a0hipoxia\u00a0tisular,\u00a0asociado\u00a0a\u00a0una\u00a0disminuci\u00f3n \u00a0en\u00a0el\u00a0contenido \u00a0\nen\u00a0ATP\u00a0y\u00a0\u00a0un\u00a0cambio\u00a0en\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0NAD/NADH. \u00a0A\u00a0nivel\u00a0bioqu\u00edmico \u00a0\ntambi\u00e9n\u00a0se\u00a0pueden\u00a0 observar\u00a0\u00a0variaciones \u00a0en\u00a0el\u00a0metabolismo \u00a0de\u00a0iones\u00a0y\u00a0\nformaci\u00f3n\u00a0 de\u00a0productos \u00a0provenientes \u00a0de\u00a0la\u00a0degradaci\u00f3n\u00a0 de\u00a0membranas \u00a0\ncelulares. \u00a0\u00a0\n\u00a0\nSe\u00a0ha\u00a0determinado \u00a0que\u00a0el\u00a0intervalo\u00a0\u00f3ptimo\u00a0 para\u00a0 intentar\u00a0detener\u00a0y/o\u00a0\nrevertir\u00a0esta\u00a0cascada\u00a0 de\u00a0acontecimientos\u00a0 es\u00a0de\u00a04\u00a0horas,\u00a0e\u00a0idealmente \u00a0de\u00a02,\u00a0ya\u00a0\nque\u00a0la\u00a0inhibici\u00f3n \u00a0del\u00a0 trasporte \u00a0axopl\u00e1smico\u00a0 comienza \u00a0en\u00a0este\u00a0periodo,\u00a0es\u00a0\nmarcada\u00a0a\u00a0las\u00a04\u00a0horas\u00a0y\u00a0completa \u00a0a\u00a0las\u00a06\u00a0horas\u00a0del\u00a0traumatismo \u00a0medular\u00a0(41\u201043).\u00a0\nLa\u00a0naturaleza \u00a0progresiva \u00a0de\u00a0los\u00a0cambios\u00a0morfol\u00f3gicos \u00a0que\u00a0se\u00a0producen \u00a0tras\u00a0la\u00a0\nlesi\u00f3n\u00a0inicial\u00a0sugiere\u00a0que\u00a0tras\u00a0el\u00a0trauma\u00a0 f\u00edsico\u00a0se\u00a0produce\u00a0un\u00a0deterioro \u00a0de\u00a0las\u00a0\ncondiciones \u00a0iniciales\u00a0 como\u00a0consecuencia \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0mecanismos \u00a0\ncelulares\u00a0secundarios, \u00a0entre\u00a0 los\u00a0que\u00a0se\u00a0puede\u00a0distinguir: \u00a0\n\u00a01. P\u00e9rdida\u00a0de\u00a0la\u00a0regulaci\u00f3n \u00a0i\u00f3nica,\u00a0que\u00a0lleva\u00a0a\u00a0la\u00a0suspensi\u00f3n \u00a0del\u00a0impulso\u00a0\nnervioso\u00a0y\u00a0a\u00a0\u00a0formaci\u00f3n\u00a0 de\u00a0edema.\u00a0\n2. Liberaci\u00f3n \u00a0de\u00a0grandes\u00a0cantidades\u00a0 de\u00a0glutamato \u00a0y\u00a0aspartato, \u00a0\u00e1cidos\u00a0\ngrasos\u00a0libres,\u00a0neurop\u00e9ptidos \u00a0y\u00a0radicales\u00a0libres,\u00a0originando\u00a0 fen\u00f3menos \u00a0\nde\u00a0excitotoxicidad. \u00a0\n3. Incremento \u00a0del\u00a0 calcio\u00a0libre\u00a0intracelular, \u00a0el\u00a0cual\u00a0 activa\u00a0 diversas\u00a0\nproteasas \u00a0y\u00a0fosfolipasas \u00a0que\u00a0favorecen \u00a0el\u00a0proceso\u00a0desmielinizante. \u00a0\n4. Diversos\u00a0fen\u00f3menos \u00a0homeost\u00e1ticos\u00a0 e\u00a0hidr\u00f3lisis\u00a0de\u00a0fosfolipidos. \u00a0\n5. Estr\u00e9s\u00a0oxidante,\u00a0 estado\u00a0donde\u00a0se\u00a0pierde\u00a0el\u00a0balance\u00a0entre\u00a0 la\u00a0\ngeneraci\u00f3n \u00a0de\u00a0radicales\u00a0libres\u00a0y\u00a0la\u00a0capacidad\u00a0 de\u00a0las\u00a0defensas\u00a0\nantioxidantes \u00a0para\u00a0contrarrestarlos. \u00a0\n\u00a0 22\u00a0De\u00a0forma\u00a0resumida,\u00a0 podemos\u00a0 indicar\u00a0que\u00a0la\u00a0LS\u00a0viene\u00a0determinada \u00a0por\u00a0\nfen\u00f3menos \u00a0inflamatorios \u00a0con\u00a0 liberaci\u00f3n \u00a0de\u00a0mediadores \u00a0y\u00a0enzimas\u00a0lisosomales, \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nalteraciones \u00a0del\u00a0endotelio \u00a0vascular\u00a0con\u00a0 microtrombos \u00a0y\u00a0microhemorragias, \u00a0y\u00a0\ndesequilibrios \u00a0neuroqu\u00edmicos, \u00a0que\u00a0originan\u00a0 un\u00a0descenso \u00a0de\u00a0la\u00a0perfusi\u00f3n \u00a0medular;\u00a0\nque\u00a0a\u00fan\u00a0 empeoran \u00a0por\u00a0vasoespasmo \u00a0asociado, \u00a0resultando \u00a0en\u00a0edema\u00a0y\u00a0necrosis\u00a0\nhemorr\u00e1gica. \u00a0Las\u00a0consecuencias \u00a0inmediatas \u00a0de\u00a0la\u00a0LM\u00a0se\u00a0traducen\u00a0en\u00a0diferentes \u00a0\ngrados\u00a0y\u00a0combinaciones \u00a0de\u00a0d\u00e9ficit\u00a0 neurol\u00f3gico \u00a0motor,\u00a0sensitivo\u00a0y/o\u00a0auton\u00f3mico \u00a0\nproducido, \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0su\u00a0severidad,\u00a0 localizaci\u00f3n \u00a0y\u00a0nivel\u00a0afectado. \u00a0\u00a0\n\u00a0\nA\u00a0continuaci\u00f3n, \u00a0la\u00a0Tabla\u00a02\u00a0expone\u00a0de\u00a0forma\u00a0esquem\u00e1tica \u00a0los\u00a0distintos\u00a0\nmecanismos \u00a0implicados \u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0de\u00a0la\u00a0LS,\u00a0que\u00a0si\u00a0bien\u00a0procede\u00a0de\u00a0\nmodelos\u00a0 experimentales \u00a0en\u00a0animales\u00a0son\u00a0comunmente \u00a0aceptados. \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0 23Tabla\u00a0 2.\u2010\u00a0Mecanismos \u00a0de\u00a0progresi\u00f3n\u00a0 de\u00a0la\u00a0lesi\u00f3n\u00a0secundaria. \u00a0\nIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nActualmente \u00a0no\u00a0se\u00a0cuenta\u00a0con\u00a0 ninguna\u00a0estrategia\u00a0 terap\u00e9utica\u00a0 efectiva\u00a0\npara\u00a0restablecer \u00a0la\u00a0funci\u00f3n\u00a0neurol\u00f3gica \u00a0normal,\u00a0debido\u00a0 a\u00a0la\u00a0complejidad \u00a0para\u00a0\nregular\u00a0 los\u00a0mecanismos \u00a0de\u00a0la\u00a0LS,\u00a0as\u00ed\u00a0como\u00a0a\u00a0la\u00a0baja\u00a0capacidad \u00a0de\u00a0regeneraci\u00f3n \u00a0\nespont\u00e1nea \u00a0que\u00a0se\u00a0observa\u00a0en\u00a0el\u00a0sistema\u00a0nervioso\u00a0central\u00a0(SNC).\u00a0Existe\u00a0una\u00a0gran\u00a0\ncantidad\u00a0 de\u00a0estudios\u00a0experimentales \u00a0que\u00a0describen \u00a0los\u00a0mecanismos \u00a0\nfisiopatol\u00f3gicos \u00a0desencadenados \u00a0despu\u00e9s\u00a0de\u00a0una\u00a0 lesi\u00f3n,\u00a0y\u00a0con\u00a0 base\u00a0en\u00a0estos\u00a0\nantecedentes \u00a0se\u00a0ha\u00a0abordado\u00a0 el\u00a0problema\u00a0 proponiendo\u00a0 el\u00a0uso\u00a0de\u00a0diversos\u00a0\nf\u00e1rmacos \u00a0neuroprotectores \u00a0como\u00a0la\u00a0metilprednisolona \u00a0(MP).\u00a0\n\u00a0\n\u00a0\u00a0\n1.7. TRATAMIENTO \u00a0M\u00c9DICO\u00a0DE\u00a0LA\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\n\u00a0As\u00ed\u00a0pues,\u00a0la\u00a0LM\u00a0tendr\u00eda\u00a0dos\u00a0componentes: \u00a0\n\u00a09 Lesi\u00f3n\u00a0 medular\u00a0primaria:\u00a0producida \u00a0directamente \u00a0por\u00a0el\u00a0traumatismo \u00a0\nsobre\u00a0la\u00a0que\u00a0no\u00a0se\u00a0puede\u00a0actuar.\u00a0\n9 Lesi\u00f3n\u00a0medular\u00a0secundaria: \u00a0es\u00a0suceptible \u00a0de\u00a0tratamiento. \u00a0Las\u00a0\ncomplejas \u00a0alteraciones \u00a0bioqu\u00edmicas \u00a0y\u00a0aparici\u00f3n \u00a0de\u00a0fen\u00f3menos\u00a0 de\u00a0\napoptosis, \u00a0dar\u00edan\u00a0lugar\u00a0a\u00a0la\u00a0posterior\u00a0destrucci\u00f3n \u00a0neuronal. \u00a0\n\u00a0El\u00a0avance\u00a0 en\u00a0el\u00a0conocimiento \u00a0de\u00a0la\u00a0fisiopatolog\u00eda \u00a0de\u00a0la\u00a0LM\u00a0ha\u00a0permitido \u00a0el\u00a0\nestudio\u00a0y\u00a0propuestas \u00a0de\u00a0una\u00a0gran\u00a0variedad\u00a0de\u00a0estrategias \u00a0terap\u00e9uticas \u00a0\n(farmacol\u00f3gicas, \u00a0trasplantes\u00a0 y\u00a0administraci\u00f3n \u00a0de\u00a0diversos\u00a0 factores\u00a0tr\u00f3ficos)\u00a0\nenfocadas \u00a0a\u00a0detener\u00a0los\u00a0mecanismos \u00a0fisiopatol\u00f3gicos \u00a0desencadenados \u00a0en\u00a0la\u00a0\netapa\u00a0 aguda\u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0(44,45) .\u00a0De\u00a0las\u00a0m\u00faltiples \u00a0intervenciones \u00a0farmacol\u00f3gicas \u00a0\npara\u00a0limitar\u00a0el\u00a0agravamiento \u00a0secundario \u00a0de\u00a0las\u00a0lesiones\u00a0medulares,\u00a0 estas\u00a0se\u00a0\npueden\u00a0 clasificar\u00a0o\u00a0distinguir \u00a0entre\u00a0 las\u00a0de\u00a0certezas,\u00a0las\u00a0de\u00a0probabilidades \u00a0y\u00a0las\u00a0\nhip\u00f3tesis\u00a0de\u00a0investigaci\u00f3n.\u00a0\n\u00a0 24\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n1.7.1.  Tratamiento \u00a0Farmacol\u00f3gico\u00a0 de\u00a0certeza\u00a0\nLa\u00a0lesi\u00f3n\u00a0medular\u00a0 secundaria \u00a0se\u00a0aten\u00faa\u00a0con\u00a0 toda\u00a0probabilidad \u00a0con\u00a0 una\u00a0\nserie\u00a0de\u00a0medidas,\u00a0entre\u00a0las\u00a0que\u00a0destaca\u00a0 el\u00a0mantenimiento \u00a0de\u00a0una\u00a0presi\u00f3n\u00a0de\u00a0\nperfusi\u00f3n \u00a0medular\u00a0 adecuada, \u00a0para\u00a0esto\u00a0se\u00a0precisa\u00a0la\u00a0correcci\u00f3n\u00a0 de\u00a0la\u00a0frecuente \u00a0\nhipovolemia \u00a0relativa\u00a0por\u00a0vasodilataci\u00f3n \u00a0o\u00a0absoluta\u00a0por\u00a0fen\u00f3menos\u00a0 hemorr\u00e1gicos \u00a0\nque\u00a0se\u00a0producen \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0 trauma\u00a0 raquimedular, \u00a0mediante \u00a0una\u00a0\noptimizaci\u00f3n \u00a0del\u00a0llenado\u00a0vascular\u00a0y\u00a0drogas\u00a0vasoactivas, \u00a0siendo\u00a0de\u00a0elecci\u00f3n\u00a0la\u00a0\nnoradrenalina. \u00a0La\u00a0correcci\u00f3n \u00a0de\u00a0la\u00a0hipoxia\u00a0y\u00a0de\u00a0la\u00a0hipotermia \u00a0profunda \u00a0y\u00a0evitar\u00a0\ncualquier \u00a0hiperglucemia \u00a0tambi\u00e9n\u00a0debe\u00a0forma\u00a0parte\u00a0de\u00a0la\u00a0reanimaci\u00f3n\u00a0 medular\u00a0\nde\u00a0forma\u00a0intensiva. \u00a0\n\u00a0\n\u00a0\n1.7.2.  Tratamiento \u00a0Farmacol\u00f3gico\u00a0 Probable\u00a0\n\u00a0\n9 CORTICOIDES. \u00a0\u00a0\nExperimentalmente, \u00a0 la\u00a0\nadministraci\u00f3n \u00a0precoz\u00a0de\u00a0MP\u00a0en\u00a0\ngrandes\u00a0dosis\u00a0mejora\u00a0el\u00a0pron\u00f3stico \u00a0\nneurol\u00f3gico \u00a0de\u00a0la\u00a0compresi\u00f3n \u00a0o\u00a0de\u00a0la\u00a0\nisquemia\u00a0medular\u00a0\u00a0 inhibiendo \u00a0la\u00a0\nperoxidaci\u00f3n \u00a0lip\u00eddica\u00a0de\u00a0membrana. \u00a0\u00a0\nFigura\u00a09.\u2010METILPREDNISOLONA\u00a0\n\u00a0 25El\u00a0uso\u00a0de\u00a0corticoides \u00a0(CTC)\u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0la\u00a0LM\u00a0se\u00a0ha\u00a0estudiado \u00a0\nampliamente, \u00a0y\u00a0se\u00a0postula\u00a0que\u00a0su\u00a0empleo\u00a0resulta\u00a0ben\u00e9fico\u00a0por\u00a0sus\u00a0propiedades \u00a0\nantiinflamatorias. \u00a0La\u00a0MP\u00a0se\u00a0considera \u00a0el\u00a0f\u00e1rmaco\u00a0de\u00a0elecci\u00f3n.\u00a0Se\u00a0sabe\u00a0que\u00a0la\u00a0MP\u00a0\nejerce\u00a0un\u00a0efecto\u00a0neuroprotector \u00a0al\u00a0suprimir\u00a0la\u00a0respuesta\u00a0 inflamatoria \u00a0tisular\u00a0\nmediante \u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0inflamatorias, \u00a0incluyendo\u00a0 la\u00a0\nquimiotaxis, \u00a0fagocitosis, \u00a0s\u00edntesis\u00a0de\u00a0mediadores \u00a0inflamatorios \u00a0y\u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0\nenzimas\u00a0lisosomales.\u00a0 Adem\u00e1s,\u00a0la\u00a0MP\u00a0tiene\u00a0la\u00a0capacidad\u00a0 de\u00a0inhibir\u00a0a\u00a0la\u00a0fosfolipasa\u00a0\nA2,\u00a0enzima\u00a0que\u00a0cataliza\u00a0la\u00a0liberaci\u00f3n \u00a0del\u00a0\u00e1cido\u00a0araquid\u00f3nico \u00a0de\u00a0los\u00a0fosfol\u00edpidos \u00a0de\u00a0\nIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nla\u00a0membrana, \u00a0que\u00a0a\u00a0su\u00a0vez\u00a0dan\u00a0 inicio\u00a0a\u00a0la\u00a0formaci\u00f3n\u00a0 de\u00a0eicosanoides \u00a0que\u00a0\nexacerban \u00a0la\u00a0respuesta \u00a0inflamatoria \u00a0y,\u00a0por\u00a0lo\u00a0tanto,\u00a0la\u00a0producci\u00f3n \u00a0de\u00a0radicales\u00a0\nlibres.\u00a0\n\u00a0\nSe\u00a0han\u00a0realizado\u00a0tres\u00a0importantes\u00a0 estudios,\u00a0denominados \u00a0NASCIS\u00a0I,\u00a0II\u00a0y\u00a0III\u00a0\npor\u00a0sus\u00a0siglas\u00a0en\u00a0ingles\u00a0(National\u00a0Acute\u00a0Spinal\u00a0Cord\u00a0Injury\u00a0Study)\u00a0para\u00a0evaluar\u00a0la\u00a0\neficiencia \u00a0de\u00a0la\u00a0MP\u00a0en\u00a0pacientes \u00a0con\u00a0 LMAT .\u00a0A\u00a0continuaci\u00f3n \u00a0se\u00a0exponen\u00a0 sus\u00a0\nprincipales\u00a0 caracter\u00edsticas. \u00a0\n\u00a0\u0083 National\u00a0Acute\u00a0Spinal\u00a0Cord\u00a0Injury\u00a0Study\u00a0I\u00a0(NASCIS\u00a0I)\u00a0\nSe\u00a0trata\u00a0 de\u00a0un\u00a0estudio\u00a0cl\u00ednico\u00a0aleatorio, \u00a0prospectivo, \u00a0a\u00a0doble\u00a0ciego\u00a0y\u00a0\nmultic\u00e9ntrico \u00a0publicado\u00a0 en\u00a01984.\u00a0En\u00a0este\u00a0estudio,\u00a0se\u00a0asign\u00f3\u00a0aleatoriamente \u00a0a\u00a0los\u00a0\npacientes \u00a0en\u00a0grupos\u00a0de\u00a0tratamiento \u00a0con\u00a0MP\u00a0a\u00a0dosis\u00a0bajas\u00a0o\u00a0a\u00a0dosis\u00a0altas.\u00a0El\u00a0\ntratamiento \u00a0a\u00a0dosis\u00a0bajas\u00a0consist\u00eda\u00a0en\u00a0una\u00a0infusi\u00f3n\u00a0intravenosa \u00a0en\u00a0bolo\u00a0de\u00a0100\u00a0\nmg\u00a0seguida\u00a0de\u00a025\u00a0mg\u00a0cada\u00a06\u00a0h\u00a0durante\u00a010\u00a0d\u00edas\u00a0(46).\u00a0El\u00a0grupo\u00a0de\u00a0dosis\u00a0altas\u00a0\nrecib\u00eda\u00a0una\u00a0infusi\u00f3n\u00a0intravenosa \u00a0de\u00a0inicio\u00a0en\u00a0bolo\u00a0de\u00a01000\u00a0mg\u00a0y\u00a0250\u00a0mg\u00a0cada\u00a06\u00a0\nhoras\u00a0durante\u00a010\u00a0d\u00edas.\u00a0No\u00a0se\u00a0observ\u00f3\u00a0ninguna\u00a0mejora\u00a0en\u00a0los\u00a0pacientes \u00a0tratados\u00a0y\u00a0\nel\u00a0grupo\u00a0de\u00a0MP\u00a0a\u00a0dosis\u00a0altas\u00a0present\u00f3\u00a0\u00a0unas\u00a0 tasas\u00a0m\u00e1s\u00a0elevadas\u00a0de\u00a0infecci\u00f3n\u00a0de\u00a0\nherida,\u00a0septicemia \u00a0y\u00a0muerte,\u00a0aunque\u00a0s\u00f3lo\u00a0fue\u00a0estad\u00edsticamente \u00a0significativa \u00a0la\u00a0\ndiferencia \u00a0de\u00a0las\u00a0tasas\u00a0de\u00a0infecci\u00f3n\u00a0de\u00a0la\u00a0herida.\u00a0\n\u00a0\u0083 National\u00a0Acute\u00a0Spinal\u00a0Cord\u00a0Injury\u00a0Study\u00a0II\u00a0\u00a0(NASCIS \u00a0II).\u00a0\n\u00a0 26En\u00a01990\u00a0se\u00a0llev\u00f3\u00a0 a\u00a0cabo\u00a0el\u00a0estudio\u00a0NASCIS\u00a0II\u00a0(47)para\u00a0determinar\u00a0 la\u00a0\neficacia\u00a0de\u00a0dosis\u00a0de\u00a0CTC\u00a0 m\u00e1s\u00a0altas\u00a0que\u00a0las\u00a0utilizadas\u00a0 en\u00a0el\u00a0estudio\u00a0NASCIS\u00a0I.\u00a0Al\u00a0\nigual\u00a0que\u00a0en\u00a0el\u00a0primer\u00a0estudio,\u00a0el\u00a0NASCIS\u00a0II\u00a0se\u00a0dise\u00f1\u00f3\u00a0como\u00a0un\u00a0estudio\u00a0cl\u00ednico\u00a0\naleatorio, \u00a0prospectivo, \u00a0doble\u00a0ciego\u00a0y\u00a0multic\u00e9ntrico.\u00a0 Los\u00a0pacientes \u00a0recib\u00edan\u00a0 una\u00a0\ninfusi\u00f3n\u00a0intravenosa \u00a0en\u00a0bolo\u00a0de\u00a030\u00a0mg/kg\u00a0de\u00a0MP\u00a0seguida\u00a0de\u00a05,4\u00a0\u00a0mg/kg/h\u00a0\ndurante\u00a023\u00a0horas;\u00a0o\u00a0una\u00a0 infusi\u00f3n\u00a0intravenosa \u00a0en\u00a0bolo\u00a0de\u00a05,4\u00a0mg/kg\u00a0de\u00a0naloxona\u00a0\nseguida\u00a0de\u00a04,5\u00a0mg/kg/h\u00a0durante\u00a023\u00a0horas\u00a0o\u00a0un\u00a0placebo.\u00a0En\u00a0los\u00a0grupos\u00a0 de\u00a0estudio\u00a0\nno\u00a0se\u00a0observ\u00f3\u00a0ninguna\u00a0diferencia \u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0recuperaci\u00f3n\u00a0 neurol\u00f3gica \u00a0al\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\ncabo\u00a0de\u00a06\u00a0meses\u00a0y\u00a01\u00a0a\u00f1o\u00a0de\u00a0seguimiento. \u00a0No\u00a0obstante, \u00a0cuando\u00a0se\u00a0clasific\u00f3\u00a0a\u00a0los\u00a0\npacientes \u00a0en\u00a0funci\u00f3n\u00a0del\u00a0momento \u00a0en\u00a0que\u00a0recibieron \u00a0el\u00a0tratamiento, \u00a0se\u00a0observ\u00f3\u00a0\nque\u00a0los\u00a0pacientes \u00a0que\u00a0recibian\u00a0 MP\u00a0en\u00a0las\u00a08\u00a0horas\u00a0siguientes \u00a0a\u00a0la\u00a0lesi\u00f3n\u00a0\nexperimentaron \u00a0una\u00a0mejor\u00a0 recuperaci\u00f3n\u00a0 neurol\u00f3gica \u00a0que\u00a0los\u00a0que\u00a0recibieron \u00a0\nnaloxona\u00a0o\u00a0un\u00a0placebo.\u00a0Las\u00a0tasas\u00a0de\u00a0infecci\u00f3n\u00a0de\u00a0la\u00a0herida\u00a0y\u00a0de\u00a0embolia\u00a0pulmonar \u00a0\nse\u00a0duplicaban \u00a0en\u00a0el\u00a0grupo\u00a0tratado\u00a0con\u00a0 CTC,\u00a0aunque\u00a0sin\u00a0diferencias\u00a0\nestadisticamente \u00a0significativas. \u00a0\n\u00a0\nDebido\u00a0a\u00a0este\u00a0estudio,\u00a0la\u00a0MP\u00a0se\u00a0emplean\u00a0de\u00a0manera\u00a0generalizada \u00a0para\u00a0el\u00a0\ntratamiento \u00a0de\u00a0la\u00a0LMA,\u00a0sin\u00a0embargo, \u00a0ha\u00a0sido\u00a0 objeto\u00a0de\u00a0cr\u00edticias\u00a0 ya\u00a0que\u00a0en\u00a0dicho\u00a0\nestudio\u00a0no\u00a0particip\u00f3\u00a0ning\u00fan\u00a0paciente\u00a0con\u00a0 traumatismo \u00a0penetrante \u00a0ni\u00a0con\u00a0\nafecciones \u00a0com\u00f3rbidas \u00a0potencialmente \u00a0mortales, \u00a0la\u00a0clasificaci\u00f3n \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0\ndel\u00a0estudio\u00a0en\u00a0grupos\u00a0 tratados\u00a0antes\u00a0o\u00a0despu\u00e9s\u00a0de\u00a08\u00a0horas\u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0se\u00a0efectu\u00f3\u00a0\nuna\u00a0vez\u00a0terminado \u00a0el\u00a0estudio\u00a0 y\u00a0la\u00a0mejor\u00eda\u00a0 de\u00a0la\u00a0recuperaci\u00f3n \u00a0neuronal\u00a0observada \u00a0\ncon\u00a0los\u00a0CTC,\u00a0no\u00a0se\u00a0asoci\u00f3\u00a0a\u00a0ninguna\u00a0mejora\u00a0funcional \u00a0o\u00a0cl\u00ednicamente \u00a0importante. \u00a0\n\u00a0\n\u0083 National\u00a0Acute\u00a0Spinal\u00a0Cord\u00a0Injury\u00a0Study\u00a0III\u00a0(NASCIS\u00a0III).\u00a0\n\u00a0 27El\u00a0estudio\u00a0NASCIS\u00a0III\u00a0es\u00a0un\u00a0estudio\u00a0cl\u00ednico\u00a0aleatorio, \u00a0prospectivo, \u00a0doble\u00a0\nciego\u00a0y\u00a0multic\u00e9ntrico\u00a0 con\u00a0tres\u00a0ramas\u00a0de\u00a0tratamiento.\u00a0 Todos\u00a0los\u00a0pacientes \u00a0del\u00a0\nestudio\u00a0recibieron \u00a0una\u00a0infusi\u00f3n\u00a0intravenosa \u00a0r\u00e1pida\u00a0de\u00a030\u00a0mg/kg\u00a0de\u00a0MP\u00a0al\u00a0inicio\u00a0\ndel\u00a0tramiento. \u00a0Despu\u00e9s\u00a0de\u00a0la\u00a0infusi\u00f3n\u00a0intravenosa \u00a0del\u00a0CTC,\u00a0los\u00a0pacientes \u00a0recib\u00edan\u00a0\n5,4\u00a0mg/kg/h\u00a0de\u00a0MP\u00a0durante\u00a024\u00a0horas,\u00a0 5,4\u00a0mg/kg/h\u00a0de\u00a0MP\u00a0durante\u00a048\u00a0horas\u00a0o\u00a02,5\u00a0\nmg/kg\u00a0de\u00a0tirilazad\u00a0cada\u00a06\u00a0horas\u00a0durante\u00a048\u00a0horas\u00a0(44).\u00a0En\u00a0los\u00a0pacientes \u00a0tratados\u00a0\nen\u00a0las\u00a03\u00a0horas\u00a0siguientes \u00a0a\u00a0la\u00a0lesi\u00f3n,\u00a0 la\u00a0funci\u00f3n\u00a0neurol\u00f3gica \u00a0fue\u00a0igual\u00a0entre\u00a0 los\u00a0\ngrupos.\u00a0 En\u00a0los\u00a0pacientes \u00a0tratados\u00a0entre\u00a0 3\u00a0y\u00a08\u00a0horas\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0lesi\u00f3n,\u00a0el\u00a0\ntratamiento \u00a0con\u00a0MP\u00a0durante\u00a048\u00a0horas\u00a0se\u00a0tradujo\u00a0en\u00a0una\u00a0mejora\u00a0significativa \u00a0de\u00a0la\u00a0\nrecuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0frente\u00a0al\u00a0tratamiento \u00a0con\u00a0 MP\u00a0durante\u00a024\u00a0horas.\u00a0Los\u00a0\npacientes \u00a0del\u00a0grupo\u00a0de\u00a048\u00a0horas\u00a0presentaron \u00a0unas\u00a0 mayores\u00a0tasas\u00a0de\u00a0neumon\u00eda \u00a0\ngrave\u00a0y\u00a0septicemia \u00a0grave,\u00a0aunque\u00a0estas\u00a0diferencias\u00a0 no\u00a0se\u00a0consideraron \u00a0\nestad\u00edsticamente \u00a0significativas \u00a0(48).\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nLos\u00a0resultados \u00a0de\u00a0los\u00a0estudios\u00a0NASCIS\u00a0I\u00a0y\u00a0NASCIS\u00a0III\u00a0llevaron\u00a0 a\u00a0los\u00a0autores\u00a0\na\u00a0recomendar \u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0MP\u00a0durante\u00a024\u00a0horas\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0\nLMA\u00a0si\u00a0el\u00a0tratamiento \u00a0se\u00a0inicia\u00a0en\u00a0las\u00a03\u00a0horas\u00a0siguientes \u00a0a\u00a0la\u00a0lesi\u00f3n\u00a0o\u00a0durante\u00a048\u00a0\nhoras\u00a0si\u00a0el\u00a0tratamiento \u00a0se\u00a0inicia\u00a0entre\u00a03\u00a0y\u00a08\u00a0horas\u00a0 tras\u00a0la\u00a0lesi\u00f3n.\u00a0Los\u00a0pacientes \u00a0con\u00a0\nLMA\u00a0que\u00a0son\u00a0atendidos\u00a0 tras\u00a0m\u00e1s\u00a0de\u00a08\u00a0horas\u00a0despu\u00e9s\u00a0del\u00a0trauma\u00a0 no\u00a0deben\u00a0recibir\u00a0\ntratamiento \u00a0corticoesteroideo. \u00a0Sin\u00a0 embargo, \u00a0estos\u00a0estudios\u00a0no\u00a0han\u00a0 sido\u00a0\nconfirmados\u00a0 y\u00a0han\u00a0 recibido\u00a0m\u00faltiples\u00a0 cr\u00edticas\u00a0relativas\u00a0a\u00a0la\u00a0metodolog\u00eda \u00a0\nempleada. \u00a0Adem\u00e1s,\u00a0los\u00a0CTC\u00a0se\u00a0consideran\u00a0 causantes \u00a0de\u00a0un\u00a0aumento\u00a0significativo \u00a0\nde\u00a0complicaciones\u00a0 hemorr\u00e1gicas \u00a0digestivas, \u00a0metab\u00f3licas \u00a0e\u00a0infecciosas\u00a0 (49\u201052).\u00a0\nLas\u00a0recomendaciones \u00a0francesas, \u00a0por\u00a0ejemplo,\u00a0han\u00a0 excluido\u00a0 esta\u00a0conducta \u00a0\nterape\u00fatica. \u00a0\n\u00a0\nEn\u00a0la\u00a0Tabla\u00a03\u00a0se\u00a0exponen\u00a0a\u00a0modo\u00a0de\u00a0resumen\u00a0los\u00a0resultados \u00a0de\u00a0los\u00a0\nestudios\u00a0NASCIS.\u00a0\n\u00a0\n\u00a0 28Tabla\u00a03.\u2010\u00a0Efecto \u00a0del\u00a0tratamiento \u00a0con\u00a0metilprednisolona \u00a0administrada \u00a0sola\u00a0o\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0otros\u00a0\nf\u00e1rmacos \u00a0en\u00a0la\u00a0lesi\u00f3n\u00a0medular\u00a0aguda\u00a0traum\u00e1tica. \u00a0\nResultados \u00a0de\u00a0National\u00a0Acute\u00a0Spinal\u00a0Cord\u00a0Study\u00a0(NASCIS). \u00a0\n\u00a0\nEstudio.\u00a0\u00a0\nDosificaci\u00f3n \u00a0farmacol\u00f3gica. \u00a0\u00a0\nResultados. \u00a0\nNASCIS\u00a0I.\u00a0\nEvaluaci\u00f3n \u00a0de\u00a0330\u00a0pacientes. \u00a0\nDos\u00a0tratamientos: \u00a0\n1) Dosis\u00a0altas\u00a0MP.\u00a0\n2) Dosis\u00a0bajas\u00a0de\u00a0MP.\u00a0\u00a0\n1) Dosis\u00a0altas\u00a0MP:\u00a0Bolo\u00a0de\u00a0\u00a01\u00a0g\u00a0\ni.v.\u00a0y\u00a01\u00a0g\u00a0/d\u00eda\u00a0por\u00a010\u00a0d\u00edas.\u00a0\n2) Dosis\u00a0bajas\u00a0de\u00a0MP:\u00a0Bolo\u00a0de\u00a0\u00a0\n100\u00a0 m\u00a0g\u00a0i.v.\u00a0y\u00a0100\u00a0mg/d\u00eda\u00a0por\u00a010\u00a0\nd\u00edas.\u00a0\u00a0Requiere\u00a0dosificaci\u00f3n \u00a0intravenosa \u00a0\nprolongada. \u00a0La\u00a0MP\u00a0tiene\u00a0una\u00a0\ncurva\u00a0dosis\u00a0bif\u00e1sica.\u00a0Su\u00a0\ndosificaci\u00f3n \u00a0debe\u00a0ser\u00a0m\u00e1s\u00a0\nfrecuente. \u00a0\nNASCIS\u00a0II.\u00a0\nEvaluaci\u00f3n \u00a0de\u00a0487\u00a0pacientes. \u00a0\nDos\u00a0tratamientos. \u00a0\n1) MP/23\u00a0horas.\u00a0\n2) Naloxona \u00a0/23\u00a0horas.\u00a0\nSe\u00a0divide\u00a0en\u00a0subgrupos \u00a0de\u00a0inicio\u00a0\ntratamiento\u00a0 >\u00a0y\u00a0<\u00a08\u00a0horas.\u00a0\u00a0\u00a01) Bolo\u00a0de\u00a030\u00a0mg/kg\u00a0de\u00a0MP\u00a0\ndurante\u00a045\u00a0minutos,\u00a0e\u00a0infusi\u00f3n\u00a0\ncontinua\u00a0de\u00a0MP/23\u00a0horas\u00a023\u00a0\nhoras\u00a0a\u00a0una\u00a0dosis\u00a0de\u00a05.4\u00a0mg/kg/h. \u00a0\u00a0\n2) Bolo\u00a0de\u00a0Naloxona \u00a05,4\u00a0mg/kg\u00a0\u00a0\ne\u00a0infusi\u00f3n\u00a0continua\u00a0a\u00a0una\u00a0dosis\u00a0de\u00a0\n4\u00a0mg/kg/h\u00a0 por\u00a023\u00a0horas.\u00a0\u00a0\u00a0Tratamiento\u00a0 con\u00a0MP\u00a0dentro\u00a0de\u00a0las\u00a0\nprimeras\u00a08\u00a0horas\u00a0tras\u00a0la\u00a0\u00a0lesi\u00f3n,\u00a0\nmejor\u00a0recuperaci\u00f3n \u00a0funcional \u00a0a\u00a0\nlas\u00a06\u00a0semanas\u00a0y\u00a0a\u00a0los\u00a06\u00a0meses.\u00a0\nTratamiento\u00a0 con\u00a0MP\u00a0despu\u00e9s\u00a0de\u00a0\nlas\u00a0primeras\u00a08\u00a0horas,\u00a0no\u00a0\u00a0\nrecuperaci\u00f3n \u00a0 funcional. \u00a0\nTratamiento\u00a0 con\u00a0naloxona\u00a0no\u00a0se\u00a0\nobserva\u00a0 recuperaci\u00f3n \u00a0funcional. \u00a0\nComplicaciones \u00a0y\u00a0mortalidad \u00a0\nsimilar\u00a0 entre\u00a0grupos.\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nNASCIS\u00a0III.\u00a0\nEvaluaci\u00f3n \u00a0de\u00a0499\u00a0pacientes. \u00a0\nTres\u00a0tratamientos: \u00a0\n1) MP/23\u00a0horas.\u00a0\n2) MP\u00a0/48\u00a0horas.\u00a0\n3) MT/48\u00a0 horas.\u00a0\nDos\u00a0tiempos\u00a0de\u00a0inicio,\u00a0<\u00a03\u00a0horas\u00a0y\u00a0\nentre\u00a03\u20108\u00a0horas.\u00a0\n\u00a0\u00a0\n1) MP:\u00a01\u00a0bolo\u00a0inicial\u00a0i.v.\u00a0 30\u00a0\nmg/kg\u00a0e\u00a0infusi\u00f3n\u00a0continua\u00a0\ndurante\u00a024\u00a0o\u00a048\u00a0horas\u00a0a\u00a0una\u00a0dosis\u00a0\nde\u00a05.4\u00a0mg/kg/h\u00a0Tratamiento\u00a0 con\u00a0\nMP\u00a0por\u00a024\u00a0horas,\u00a0disminuci\u00f3n. \u00a0\n2) MT:\u00a0 Bolo\u00a0de\u00a02,5\u00a0mg/kg\u00a0cada\u00a0\n6\u00a0horas\u00a0durante\u00a048\u00a0horas.\u00a0\u00a0Infusi\u00f3n\u00a0durante\u00a0las\u00a0primeras\u00a03\u00a0\nhoras,\u00a0 mejor\u00a0 recuperaci\u00f3n \u00a0\nfuncional\u00a0 en\u00a0los\u00a0tres\u00a0grupos.\u00a0\u00a0\nMejor\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0si\u00a0\ninicio\u00a0de\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0MP\u00a0\ndentro\u00a0de\u00a0las\u00a0primeras\u00a03\u00a0horas,\u00a0\ntratamiento\u00a0 por\u00a024\u00a0horas,\u00a0pero\u00a0si\u00a0\nInicio\u00a0de\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0MP\u00a0\nentre\u00a03\u00a0hasta\u00a08\u00a0horas\u00a0tras\u00a0la\u00a0\nlesi\u00f3n,\u00a0tratamiento \u00a0durante\u00a048\u00a0\nhoras\u00a0\nLos\u00a0pacientes \u00a0tratados\u00a0con\u00a0MT\u00a0\nmostraron \u00a0una\u00a0 recuperaci\u00f3n \u00a0\nsimilar\u00a0 que\u00a0la\u00a0de\u00a0los\u00a0pacientes\u00a0\ntratados\u00a0con\u00a0MP\u00a0durante\u00a024\u00a0\nhoras.\u00a0\n\u00a0\nMP:\u00a0Metilprednisolona. \u00a0\nMT:\u00a0 Mesilato\u00a0de\u00a0tirilazad.\u00a0\n\u00a0\nOtros\u00a0 estudios\u00a0que\u00a0podemos \u00a0exponer,\u00a0relacionados \u00a0con\u00a0 esta\u00a0terapia\u00a0 se\u00a0\nexponen\u00a0 en\u00a0la\u00a0siguiente\u00a0tabla.\u00a0\n\u00a0\u00a0\nAutores,\u00a0T\u00edtulo\u00a0 Estudio,\u00a0Objetivos \u00a0 Resultados\u00a0\nBracken,\u00a0M.B.;\u00a0Shepard,\u00a0M.J.;\u00a0\nHolford,\u00a0T.R.;\u00a0et\u00a0al.\u00a0\n\u00a0\nADMINISTRATION \u00a0OF\u00a0\nMETHYLPREDNISOLONE \u00a0FOR\u00a0\n24\u00a0OR\u00a048\u00a0HOURS\u00a0OR\u00a0TIRILAZAD \u00a0\nMESYLATE \u00a0FOR\u00a048\u00a0HOURS\u00a0IN\u00a0\nTHE\u00a0TREATMENT \u00a0OF\u00a0ACUTE\u00a0\nSPINAL\u00a0CORD\u00a0INJURY:\u00a0RESULTS\u00a0\nOF\u00a0THE\u00a0THIRD\u00a0NATIONAL \u00a0\nACUTE\u00a0SPINAL\u00a0CORD\u00a0INJURY\u00a0\nRANDOMIZED \u00a0CONTROLLED \u00a0\nTRIAL.\u00a0\u00a0\nJAMA\u00a01997;277(20):1597 \u2010\n1604\u00a0\u00a0\u00a0\n\u00a0\n1) Ensayo\u00a0cl\u00ednico\u00a0\naleatorizado, \u00a0doble\u00a0ciego.\u00a0\n2) Comparar \u00a0la\u00a0eficacia\u00a0del\u00a0\ntratamiento\u00a0 con\u00a0MP\u00a0en\u00a0\npacientes \u00a0con\u00a0LMA,\u00a0\nadministrada\u00a0 durante\u00a024\u00a0\nhoras,\u00a0frente\u00a0al\u00a0tratamiento\u00a0\ncon\u00a0MT.\u00a0\u00a0\u00a0\n\u00a0\nAquellos\u00a0 pacientes \u00a0tratados\u00a0\ncon\u00a0MP\u00a0durante\u00a048\u00a0horas,\u00a0\ntuvieron\u00a0un\u00a0mayor\u00a0grado\u00a0de\u00a0\nrecuperaci\u00f3n \u00a0 funcional \u00a0\nmotora\u00a0a\u00a0las\u00a06\u00a0semanas\u00a0y\u00a0a\u00a0los\u00a0\n6\u00a0meses;\u00a0pero\u00a0tambi\u00e9n\u00a0\npresentaron \u00a0mayor\u00a0n\u00famero\u00a0\nde\u00a0episodios\u00a0 de\u00a0sepsis\u00a0y\u00a0\nneumon\u00eda \u00a0graves;\u00a0si\u00a0bien\u00a0el\u00a0\nresto\u00a0 de\u00a0complicaciones\u00a0 y\u00a0la\u00a0\nmortalidad \u00a0fue\u00a0similar.\u00a0\nGerndt,\u00a0 S.J.;\u00a0Rodr\u00edguez, \u00a0J.L.;\u00a0\nPawlik,\u00a0J.W.;\u00a0\u00a0et\u00a0al.\u00a0\n\u00a0CONSEQUENCES\u00a0 OF\u00a0HIGH\u00a0\u2013\u00a0\nDOSE\u00a0STEROID\u00a0 THERAPY\u00a0FOR\u00a0\nACUTE\u00a0SPINAL\u00a0CORD\u00a0INJURY.\u00a0\n\u00a0JOURNAL \u00a0\u00a0\u00a0OF\u00a0TRAUMA \u00a0\u00a0\u00a0\n1997;42(2):279 \u2010284\u00a0\u00a0\u00a0\n\u00a0\n1) Ensayo\u00a0cl\u00ednico.\u00a0\n2) Empleo\u00a0del\u00a0protocolo \u00a0\nNASCIS\u00a0II\u00a0en\u00a0pacientes \u00a0con\u00a0\nLMA\u00a0dentro\u00a0 de\u00a0las\u00a0primeras\u00a0\n48\u00a0horas\u00a0postlesi\u00f3n.\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nLa\u00a0aplicaci\u00f3n \u00a0del\u00a0protocolo \u00a0\nNASCIS\u00a0 II\u00a0 determina \u00a0\ncomplicaciones \u00a0infecciosas, \u00a0\npero\u00a0sin\u00a0tener\u00a0repercusi\u00f3n \u00a0\nnegativa\u00a0en\u00a0la\u00a0estancia\u00a0\nhospitalaria \u00a0 de\u00a0 estos\u00a0\npacientes. \u00a0\n\u00a0 29Tabla\u00a0 4.\u2010\u00a0Trabajos \u00a0relacionados con\u00a0los\u00a0estudios\u00a0NACIS.IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0 30Bracken,\u00a0M.B.;\u00a0Shepard,\u00a0M.J.;\u00a0\nHolford,\u00a0T.R.;\u00a0et\u00a0al.\u00a0\n\u00a0\nMETHYLPREDNISOLONE \u00a0OR\u00a0\nTIRILAZAD \u00a0MESYLATE \u00a0\nADMINISTRATION \u00a0AFTER\u00a0\nACUTE\u00a0SPINAL\u00a0CORD\u00a0INJURY:\u00a01\u00a0\n\u2013\u00a0YEAR\u00a0FOLLOW\u00a0UP.\u00a0RESULTS\u00a0\nOF\u00a0THE\u00a0THIRD\u00a0NATIONAL \u00a0\nACUTE\u00a0SPINAL\u00a0CORD\u00a0INJURY\u00a0\nRANDOMIZED \u00a0CONTROLLED \u00a0\nTRIAL.\u00a0\n\u00a0JNEUROSURG \u00a01998;89(5):699 \u2010\n70\u00a0\u00a0\u00a0\n\u00a0\n1) Ensayo\u00a0 cl\u00ednico\u00a0\naleatorizado \u00a0doble\u00a0ciego.\u00a0\n2) Comparar \u00a0la\u00a0\nrecuperaci\u00f3n \u00a0neurol\u00f3gica, \u00a0\nfuncional\u00a0 y\u00a0morbi\u00a0\u2013\u00a0\nmortalidad \u00a01\u00a0a\u00f1o\u00a0tras\u00a0la\u00a0LMA\u00a0\nen\u00a0pacientes \u00a0que\u00a0recibieron\u00a0\nMP\u00a0durante\u00a024\u00a0\u2010\u00a048\u00a0horas,\u00a0y\u00a0\nfrente\u00a0a\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0\nMT\u00a0durante\u00a048\u00a0horas.\u00a0\u00a0\u00a0\n\u00a0\nLos\u00a0 pacientes \u00a0que\u00a0recibieron \u00a0\nMT\u00a048\u00a0 horas\u00a0 tuvieron\u00a0la\u00a0\nmisma\u00a0 recuperaci\u00f3n \u00a0\nneurol\u00f3gica \u00a0que\u00a0los\u00a0 que\u00a0\nrecibieron \u00a0MP\u00a024\u00a0horas;\u00a0la\u00a0\nmorbi\u00a0\u2013\u00a0mortalidad \u00a0fue\u00a0similar\u00a0\nen\u00a0los\u00a03\u00a0grupos.\u00a0\nBracken,\u00a0Michael\u00a0 B.\u00a0\n\u00a0\nMETHYLPREDNISOLONE \u00a0AND\u00a0\nACUTE\u00a0SPINAL\u00a0CORD\u00a0INJURY:\u00a0\nAN\u00a0 UPDATE\u00a0 OF\u00a0 THE\u00a0\nRANDOMIZED \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0SPINE\u00a02001;26(24S):S47 \u2010254\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n1) Revisi\u00f3n\u00a0mediante \u00a0\nMedline,\u00a0CINAHL,\u00a0Cochrane \u00a0\nLibrary;\u00a0empleando\u00a0 como\u00a0\npalabras\u00a0claves\u00a0\u201cMP\u00a0y\u00a0LMA\u201d.\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nEl\u00a0tratamiento\u00a0 con\u00a0MP\u00a0\niniciado\u00a0 en\u00a0las\u00a0primeras\u00a08\u00a0\nhoras\u00a0postlesi\u00f3n \u00a0constituye \u00a0\nuna\u00a0terapia\u00a0 segura\u00a0y\u00a0eficaz,\u00a0\npero\u00a0son\u00a0necesario \u00a0nuevos\u00a0\u00a0\nestudios\u00a0 que\u00a0 permitan\u00a0\nconocer\u00a0nuevas\u00a0terapias.\u00a0\nHulbert,\u00a0R.\u00a0\n\u00a0THE\u00a0ROLE\u00a0OF\u00a0STEROIDS \u00a0IN\u00a0\nACUTE\u00a0SPINAL\u00a0CORD\u00a0INJURY:\u00a0\nAN\u00a0EVIDENCE \u00a0\u2013\u00a0BASED\u00a0\nANALYSIS. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0SPINE\u00a02001;26(24S):S39 \u2010S46\u00a0\u00a0\u00a0\n1) Revisi\u00f3n\u00a0de\u00a0la\u00a0literatura\u00a0\ndisponible, \u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0\nformular\u00a0recomendaciones \u00a0\nbasadas\u00a0en\u00a0la\u00a0evidencia \u00a0\nrespecto\u00a0al\u00a0tratamiento\u00a0\nfarmacol\u00f3gico \u00a0con\u00a0MP\u00a0en\u00a0\npacientes \u00a0con\u00a0lesi\u00f3n\u00a0medular\u00a0\naguda.\u00a0\u00a0\u00a0\n\u00a0El\u00a0empleo\u00a0de\u00a0MP\u00a0no\u00a0puede\u00a0ser\u00a0\nrecomendado \u00a0de\u00a0forma\u00a0\nrutinaria\u00a0en\u00a0pacientes \u00a0con\u00a0\nlesi\u00f3n\u00a0medular\u00a0aguda\u00a0 no\u00a0\npenetrante; \u00a0asimismo \u00a0la\u00a0\nadministraci\u00f3n \u00a0prolongada \u00a0de\u00a0\naltas\u00a0dos\u00a0de\u00a0MP\u00a0(48\u00a0 horas)\u00a0\npuede\u00a0ser\u00a0perjudicial\u00a0 para\u00a0el\u00a0\npaciente.\u00a0\u00a0\nMatsumoto, \u00a0Takuji\u00a0 MD;\u00a0\nTamaki,\u00a0 Tetsuya\u00a0MD;\u00a0\nKawakami, \u00a0Mamoru\u00a0MD;\u00a0 et\u00a0al.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0EARLY\u00a0COMPLICATIONS\u00a0 OF\u00a0\nHIGH\u00a0 \u2013\u00a0 DOSE\u00a0\nMETHYLPREDNISOLONE \u00a0\nSODIUM\u00a0 SUCCINATE \u00a0\nTREATMENT \u00a0IN\u00a0THE\u00a0FOLLOW\u00a0\u2013\u00a0\nUP\u00a0OF\u00a0ACUTE\u00a0CERVICAL \u00a0SPINAL\u00a0\nCORD\u00a0INJURY.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0SPINE\u00a02001;26(4):426 \u2010430\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n1) Estudio\u00a0prospectivo, \u00a0\nrabdomizado \u00a0y\u00a0doble\u00a0 ciego.\u00a0\n2) Comparar \u00a0altas\u00a0dosis\u00a0de\u00a0\nMP\u00a0con\u00a0placebo\u00a0 en\u00a0el\u00a0\ntratamiento\u00a0 de\u00a0pacientes \u00a0con\u00a0\nLMA.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nLas\u00a0 complicaciones \u00a0\npulmonares \u00a0fueron\u00a0m\u00e1s\u00a0\nfrecuentes \u00a0en\u00a0pacientes \u00a0\na\u00f1osos\u00a0 y\u00a0sometidos\u00a0 a\u00a0\ntratamiento\u00a0 con\u00a0megadosis\u00a0 de\u00a0\nMP.\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0\n\u00a0 31Mc\u00a0Cutcheon, \u00a0E.P.;\u00a0Selassie,\u00a0A.\u00a0\nW.;\u00a0Pickelsimer,\u00a0 E.E.;\u00a0et\u00a0al.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0ACUTE\u00a0TRAUMATIC \u00a0SPINAL\u00a0\nCORD\u00a0INJURY,\u00a01993\u00a0\u2013\u00a02000.\u00a0A\u00a0\nPOPULATION \u00a0 \u2013\u00a0 BASED\u00a0\nASSESSMENT \u00a0 OF\u00a0\nMETHYLPREDNISOLONE \u00a0\nADMINISTRATION \u00a0 AND\u00a0\nHOSPITALIZATION. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0JOURNAL \u00a0OF\u00a0TRAUMA \u00a0\n2004;56(5):1076 \u20101083\u00a0\u00a0\n\u00a0\n\u00a0\n1) Modelo\u00a0multivariante \u00a0de\u00a0\nregresi\u00f3n \u00a0log\u00edstica.\u00a0\n2) An\u00e1lisis\u00a0del\u00a0empleo\u00a0 de\u00a0MP\u00a0\ntras\u00a0lesi\u00f3n\u00a0medular\u00a0aguda,\u00a0en\u00a0\npacientes \u00a0del\u00a0Sur\u00a0de\u00a0Carolina,\u00a0\ndurante\u00a0el\u00a0per\u00edodo\u00a01993\u00a0\u2013\u00a0\n2000.\u00a0\u00a0\u00a0\n\u00a0\nEl\u00a0empleo\u00a0de\u00a0MP\u00a0determin\u00f3 \u00a0\nun\u00a0incremento \u00a0en\u00a0los\u00a0costes\u00a0y\u00a0\nestancia\u00a0hospitalaria. \u00a0\nEck,\u00a0J.C.;\u00a0 Nachtigall, \u00a0D.D.;\u00a0\nHumphreys, \u00a0S.C.;\u00a0 et\u00a0al.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0QUESTIONNARIE \u00a0SURVEY\u00a0OF\u00a0\nSPINE\u00a0SURGEONS \u00a0ON\u00a0THE\u00a0USE\u00a0\nOF\u00a0METHYLPREDNISOLONE \u00a0\nFOR\u00a0ACUTE\u00a0SPINAL\u00a0CORD\u00a0\nINJURY.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0SPINE\u00a02006;31(9):E250 \u2010\nE253.\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n1) Encuesta\u00a0enviada\u00a0a\u00a0los\u00a0\ncirujanos\u00a0pertenecientes \u00a0a\u00a0\n\u201cNorth\u00a0American \u00a0Spine\u00a0\nSociety\u201d.\u00a0\nDebatir\u00a0los\u00a0riesgos\u00a0\u2013\u00a0\nbeneficios, \u00a0y\u00a0posibles\u00a0\ncomplicaciones, \u00a0del\u00a0\ntratamiento\u00a0 con\u00a0MP\u00a0en\u00a0\npacientes \u00a0con\u00a0lesi\u00f3n\u00a0medular\u00a0\naguda.\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\nLa\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0cirujanos\u00a0\n(90.5%)\u00a0\u00a0 que\u00a0respondieron \u00a0la\u00a0\nencuesta, \u00a0 usaban\u00a0 este\u00a0\ntratamiento \u00a0 (seg\u00fan\u00a0\nprotocolo), \u00a0si\u00a0bien\u00a0solo\u00a0el\u00a0\n24.1%\u00a0lo\u00a0empleaban \u00a0estando\u00a0\nconvencidos\u00a0 de\u00a0la\u00a0mejor\u00eda\u00a0en\u00a0\nlos\u00a0resultados \u00a0cl\u00ednicos.\u00a0\nHulbert,\u00a0R.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0STRATEGIES \u00a0OF\u00a0MEDICAL\u00a0\nINTERVENTION \u00a0IN\u00a0THE\u00a0\nMANAGEMENT \u00a0OF\u00a0ACUTE\u00a0\nSPINAL\u00a0CORD\u00a0INJURY.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0SPINE\u00a02006;31(11S):S16 \u2010\nS21.\u00a0\n\u00a0\u00a0\u00a0\n1) Revisi\u00f3n\u00a0mediante \u00a0\nMedline\u00a0 (1996\u20102006)\u00a0 de\u00a0la\u00a0\nliteratura\u00a0 en\u00a0lengua\u00a0inglesa,\u00a0\nreferente \u00a0al\u00a0tratamiento\u00a0 con\u00a0\nMP\u00a0en\u00a0lesi\u00f3n\u00a0medular\u00a0aguda.\u00a0\u00a0\n\u00a0\nOptimismo \u00a0en\u00a0estrategias \u00a0\nfuturas.\u00a0El\u00a0tratamiento \u00a0con\u00a0\nMP\u00a0contin\u00faa\u00a0 emple\u00e1ndose \u00a0en\u00a0\nlesionados\u00a0 medulares \u00a0y\u00a0los\u00a0\nefectos\u00a0 delet\u00e9reos \u00a0\nsecundarios\u00a0 a\u00a0ello\u00a0se\u00a0siguen\u00a0\nacumulando. \u00a0\nTsutsumi, \u00a0Satoshi\u00a0MD;\u00a0 Uea,\u00a0\nTakayosi\u00a0MD;\u00a0 Shiba,\u00a0Keiichiro\u00a0\nMD,\u00a0et\u00a0al.\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0EFFECTS\u00a0OF\u00a0THE\u00a0SECOND\u00a0\nNATIONAL \u00a0ACUTE\u00a0SPINAL\u00a0\nCORD\u00a0INJURY\u00a0STUDY\u00a0OF\u00a0HIGH\u00a0\n\u2013\u00a0DOSE\u00a0\nMETHYLPREDNISOLONE \u00a0\nTHERAPY\u00a0ON\u00a0ACUTE\u00a0CERVICAL \u00a0\nSPINAL\u00a0CORD\u00a0INJURY\u00a0\u2013\u00a0\nRESULTS\u00a0IN\u00a0SPINAL\u00a0INJURIES\u00a0\nCENTER.\u00a0\n\u00a0\n\u00a0SPINE\u00a02006;31(16):2992 \u20102996.\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n1) Estudio\u00a0retrospectivo.\u00a0\n2) Evaluar\u00a0la\u00a0mejor\u00eda\u00a0en\u00a0la\u00a0\nfunci\u00f3n\u00a0motora\u00a0y\u00a0\ncomplicaciones \u00a0tempranas \u00a0en\u00a0\npacientes \u00a0con\u00a0lesi\u00f3n\u00a0medular\u00a0\naguda\u00a0 cervical\u00a0que\u00a0recibieron \u00a0\naltas\u00a0dosis\u00a0de\u00a0MP\u00a0en\u00a0las\u00a0\nprimeras\u00a08\u00a0horas\u00a0postlesi\u00f3n. \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nEl\u00a0tratamiento \u00a0con\u00a0MP\u00a0debe\u00a0\nadministrarse \u00a0seg\u00fan\u00a0protocolo \u00a0\nNASCIS,\u00a0en\u00a0aquellos\u00a0pacientes \u00a0\ncon\u00a0lesi\u00f3n\u00a0medular\u00a0cervical\u00a0\nincompleta. \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nLeypold,\u00a0Bradley\u00a0G.;\u00a0Flanders, \u00a0\nAdam\u00a0E.;\u00a0Schwartz, \u00a0Eric\u00a0D.;\u00a0et\u00a0\nal.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0THE\u00a0IMPACT\u00a0OF\u00a0\nMETHYLPREDNISOLONE \u00a0ON\u00a0\nLESION\u00a0SEVERITY \u00a0FOLLOWING\u00a0\nSPINAL\u00a0CORD\u00a0INJURY.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0SPINE\u00a02007;32(3):373 \u2010378\u00a0\u00a0\u00a0\n\u00a0\n1) Estudio\u00a0restrospectivo.\u00a0\n2) Determinar \u00a0si\u00a0la\u00a0\nadministraci\u00f3n \u00a0de\u00a0MP\u00a0tras\u00a0la\u00a0\nlesi\u00f3n\u00a0medular\u00a0aguda,\u00a0afecta\u00a0\na\u00a0la\u00a0severidad \u00a0de\u00a0las\u00a0\u00a0\nlesiones.\u00a0\u00a0\u00a0\u00a0\n\u00a0\nRMN\u00a0sugiere\u00a0 que\u00a0en\u00a0aquellos\u00a0\npacientes \u00a0tratados\u00a0con\u00a0 MP\u00a0\ndisminuye \u00a0la\u00a0extensi\u00f3n \u00a0de\u00a0la\u00a0\nhemorragia\u00a0 intramedular. \u00a0\nMP:\u00a0Metilprednisolona. \u00a0\nMT:\u00a0Mesilato\u00a0 de\u00a0tirilazad.\u00a0\u00a0\n\u00a0\n9 21\u2010AMINOESTEROIDES \u00a0(LAZAROIDES). \u00a0\nLos\u00a0lazaroides,\u00a0 derivados\u00a0 de\u00a0s\u00edntesis\u00a0 de\u00a0los\u00a0CTC,\u00a0experimentalmente \u00a0\ninhiben\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0potente\u00a0la\u00a0peroxidaci\u00f3n \u00a0lip\u00eddica\u00a0de\u00a0membrana \u00a0sin\u00a0producir\u00a0\nlos\u00a0efectos\u00a0adversos\u00a0de\u00a0los\u00a0glucocorticoides.\u00a0 Act\u00faan\u00a0mediante \u00a0un\u00a0triple\u00a0\nmecanismo \u00a0de\u00a0acci\u00f3n,\u00a0atrapadores \u00a0de\u00a0radicales\u00a0libres,\u00a0 especialmente \u00a0del\u00a0\nlipoperoxilo \u00a0e\u00a0hidroxilo, \u00a0inhibiendo \u00a0la\u00a0peroxidaci\u00f3n \u00a0de\u00a0l\u00edpidos\u00a0y\u00a0como\u00a0quelantes \u00a0\ndel\u00a0hierro,\u00a0manteniendo \u00a0los\u00a0niveles\u00a0de\u00a0vitamina\u00a0E,\u00a0actuando \u00a0sobre\u00a0el\u00a0n\u00facleo\u00a0\nhidrof\u00f3bico \u00a0de\u00a0las\u00a0membranas \u00a0celulares\u00a0con\u00a0un\u00a0efecto\u00a0estabilizador \u00a0sobre\u00a0\u00e9stas.\u00a0\nDesafortunadamente, \u00a0los\u00a0resultados \u00a0de\u00a0los\u00a0ensayos\u00a0cl\u00ednicos\u00a0de\u00a0uno\u00a0de\u00a0ellos,\u00a0el\u00a0\ntirilazad,\u00a0son\u00a0decepcionantes, \u00a0ya\u00a0que\u00a0no\u00a0han\u00a0 demostrado \u00a0su\u00a0superioridad\u00a0 con\u00a0\nrespecto\u00a0a\u00a0la\u00a0MP\u00a0(53).\u00a0\n\u00a0\n9 ANTAGONISTAS \u00a0DE\u00a0RECEPTORES\u00a0 OPIOIDES. \u00a0\nEl\u00a0incremento \u00a0de\u00a0los\u00a0niveles\u00a0end\u00f3genos\u00a0 de\u00a0opioides\u00a0tras\u00a0una\u00a0LMA\u00a0\u00a0y\u00a0\nactivaci\u00f3n \u00a0de\u00a0sus\u00a0receptores, \u00a0puede\u00a0contribuir \u00a0a\u00a0exacerbar \u00a0la\u00a0LS.\u00a0Su\u00a0mecanismo \u00a0\nde\u00a0acci\u00f3n\u00a0podr\u00eda\u00a0ser\u00a0por\u00a0una\u00a0disminuci\u00f3n \u00a0en\u00a0la\u00a0producci\u00f3n \u00a0de\u00a0ani\u00f3n\u00a0super\u00f3xido\u00a0\nen\u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0la\u00a0microglia, \u00a0evento\u00a0que\u00a0se\u00a0traduce\u00a0en\u00a0menor\u00a0producci\u00f3n \u00a0de\u00a0\nperoxinitrito \u00a0y\u00a0en\u00a0una\u00a0disminuci\u00f3n \u00a0del\u00a0estr\u00e9s\u00a0oxidante\u00a0y\u00a0del\u00a0da\u00f1o\u00a0celular.\u00a0\n\u00a0\n\u00a0\n\u00a0 32\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nLa\u00a0naloxona, \u00a0es\u00a0el\u00a0agente\u00a0\nfarmacol\u00f3gico \u00a0m\u00e1s\u00a0estudiado\u00a0 de\u00a0este\u00a0\ngrupo;\u00a0su\u00a0administraci\u00f3n \u00a0ha\u00a0demostrado \u00a0\ntener\u00a0efectos\u00a0ben\u00e9ficos\u00a0 en\u00a0modelos\u00a0\nexperimentales \u00a0de\u00a0LMA\u00a0severa,\u00a0sin\u00a0\nembargo, \u00a0no\u00a0todos\u00a0 los\u00a0estudios\u00a0han\u00a0\nconfirmado \u00a0estos\u00a0beneficios, \u00a0y\u00a0as\u00ed,\u00a0 el\u00a0\nNASCIS\u2010II\u00a0concluye\u00a0que\u00a0no\u00a0debe\u00a0ser\u00a0\nempleado \u00a0en\u00a0pacientes \u00a0con\u00a0LMA.\u00a0\n\u00a0\nNo\u00a0obstante, \u00a0tambi\u00e9n\u00a0se\u00a0ha\u00a0descrito\u00a0que\u00a0en\u00a0pacientes \u00a0con\u00a0LM\u00a0incompleta \u00a0\nla\u00a0administraci\u00f3n \u00a0precoz\u00a0de\u00a0naloxona\u00a0favorece\u00a0la\u00a0recuperaci\u00f3n \u00a0funcional.\u00a0\n\u00a09 GANGLI\u00d3SIDOS. \u00a0\nLos\u00a0gangli\u00f3sidos \u00a0son\u00a0complejos\u00a0 de\u00a0glucol\u00edpidos \u00a0\u00e1cidos\u00a0que\u00a0est\u00e1n\u00a0\npresentes \u00a0en\u00a0altas\u00a0concentraciones \u00a0en\u00a0las\u00a0membranas \u00a0del\u00a0SNC.\u00a0En\u00a0los\u00a0estudios\u00a0\nrealizados \u00a0en\u00a0animales\u00a0empleando \u00a0monosialotetrahexosilgangli\u00f3sido \u00a0(gangli\u00f3sido \u00a0\nGM\u20101)\u00a0se\u00a0observa\u00a0 un\u00a0incremento \u00a0en\u00a0la\u00a0velocidad \u00a0del\u00a0crecimiento \u00a0neur\u00edtico\u00a0y\u00a0\nest\u00edmulo\u00a0de\u00a0la\u00a0regeneraci\u00f3n\u00a0 axonal,\u00a0protecci\u00f3n \u00a0de\u00a0la\u00a0degeneraci\u00f3n \u00a0retr\u00f3grada\u00a0 y\u00a0\nanter\u00f3grada \u00a0y\u00a0una\u00a0capacidad \u00a0de\u00a0atenuar\u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0amino\u00e1cidos \u00a0\nexcitatorios. \u00a0Un\u00a0estudio\u00a0cl\u00ednico\u00a0preliminar \u00a0ha\u00a0demostrado\u00a0 el\u00a0inter\u00e9s\u00a0potencial \u00a0\ndespu\u00e9s\u00a0de\u00a0traumatismo \u00a0medular\u00a0grave\u00a0en\u00a0seres\u00a0humanos, \u00a0no\u00a0obteni\u00e9ndose \u00a0\nning\u00fan\u00a0beneficio \u00a0en\u00a0la\u00a0\u00a0LMA\u00a0poco\u00a0severas.\u00a0No\u00a0obstante, \u00a0el\u00a0peque\u00f1o\u00a0n\u00famero\u00a0de\u00a0\npacientes \u00a0incluidos\u00a0limita\u00a0considerablemente \u00a0el\u00a0alcance\u00a0de\u00a0este\u00a0estudio;\u00a0se\u00a0ha\u00a0\nachacado \u00a0a\u00a0los\u00a0gangli\u00f3sidos \u00a0la\u00a0producci\u00f3n \u00a0de\u00a0s\u00edndromes \u00a0de\u00a0Guillain\u2010Barr\u00e9.\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0 33\nFigura\u00a010.\u2010\u00a0NALOXONA \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n1.7.3.  Tratamiento \u00a0Farmacol\u00f3gico\u00a0 de\u00a0Hip\u00f3tesis\u00a0 de\u00a0investigaci\u00f3n \u00a0\n9 \u00a0REGULADORES \u00a0DE\u00a0LOS\u00a0CANALES \u00a0DE\u00a0CALCIO.\u00a0\nEl\u00a0incremento \u00a0excesivo\u00a0en\u00a0la\u00a0concentraci\u00f3n \u00a0del\u00a0calcio\u00a0intracelular \u00a0activa\u00a0\nmecanismos \u00a0de\u00a0da\u00f1o\u00a0por\u00a0fen\u00f3menos \u00a0de\u00a0apoptosis \u00a0o\u00a0necrosis.\u00a0La\u00a0regulaci\u00f3n \u00a0de\u00a0\nlos\u00a0mecanismos \u00a0del\u00a0 transporte \u00a0del\u00a0 calcio\u00a0podr\u00eda\u00a0ser\u00a0una\u00a0buena\u00a0estrategia \u00a0\nterap\u00e9utica. \u00a0Con\u00a0base\u00a0en\u00a0este\u00a0planteamiento \u00a0se\u00a0ha\u00a0probado\u00a0el\u00a0efecto\u00a0\nneuroprotector \u00a0del\u00a0\u00a0nimodipino, \u00a0f\u00e1rmaco\u00a0que\u00a0reduce\u00a0la\u00a0isquemia\u00a0postraum\u00e1tica, \u00a0\npues\u00a0se\u00a0ha\u00a0observado \u00a0que\u00a0la\u00a0acumulaci\u00f3n \u00a0de\u00a0calcio\u00a0produce\u00a0vasoespasmo \u00a0\n(54,55) .\u00a0S\u00f3lo\u00a0la\u00a0administraci\u00f3n \u00a0conjunta\u00a0de\u00a0un\u00a0vasopresor \u00a0permite\u00a0observar\u00a0 los\u00a0\nefectos\u00a0beneficiosos \u00a0del\u00a0nimodipino \u00a0sobre\u00a0el\u00a0flujo\u00a0 sangu\u00edneo \u00a0medular.\u00a0Hasta\u00a0 la\u00a0\nfecha,\u00a0ning\u00fan\u00a0estudio\u00a0cl\u00ednico\u00a0ha\u00a0demostrado\u00a0 su\u00a0inter\u00e9s\u00a0en\u00a0seres\u00a0humanos \u00a0con\u00a0\nLMAT.\u00a0\n\u00a0\n9 ANTAGONISTAS \u00a0DE\u00a0LOS\u00a0RECEPTORES \u00a0NMDA\u00a0Y\u00a0\u00a0NO\u00a0NMDA.\u00a0\nTras\u00a0una\u00a0LMA\u00a0existe\u00a0liberaci\u00f3n \u00a0de\u00a0gran\u00a0cantidad\u00a0 de\u00a0amino\u00e1cidos \u00a0\nexcitatorios, \u00a0como\u00a0el\u00a0glutamato \u00a0y\u00a0el\u00a0aspartato, \u00a0que\u00a0al\u00a0unirse\u00a0a\u00a0sus\u00a0receptores \u00a0\ndesencadenan \u00a0el\u00a0fen\u00f3meno \u00a0de\u00a0la\u00a0excitotoxicidad \u00a0y\u00a0apoptosis \u00a0(56,57) .\u00a0El\u00a0bloqueo\u00a0\nde\u00a0los\u00a0receptores \u00a0del\u00a0N\u2010metil\u2010 D\u2010aspartato \u00a0(NMDA)\u00a0 parece\u00a0disminuir \u00a0las\u00a0\nconsecuencias \u00a0de\u00a0la\u00a0isquemia\u00a0nerviosa.\u00a0Aunque\u00a0ciertos\u00a0trabajos\u00a0experimentales \u00a0\nbrinden\u00a0 esperanza, \u00a0no\u00a0se\u00a0ha\u00a0realizado\u00a0ning\u00fan\u00a0estudio\u00a0cl\u00ednico\u00a0sobre\u00a0estas\u00a0\nsustancias. \u00a0Diversos\u00a0f\u00e1rmacos \u00a0han\u00a0 sido\u00a0 probados \u00a0en\u00a0modelos\u00a0 experimentales \u00a0de\u00a0\nlesi\u00f3n\u00a0traum\u00e1tica, \u00a0entre\u00a0ellos\u00a0la\u00a0memantina, \u00a0la\u00a0dizocilpina \u00a0(MK\u2010801)\u00a0y\u00a0el\u00a0riluzol.\u00a0\nLos\u00a0resultados \u00a0experimentales \u00a0sugieren\u00a0que\u00a0su\u00a0uso\u00a0aten\u00faa\u00a0la\u00a0necrosis,\u00a0 la\u00a0\napoptosis \u00a0y\u00a0la\u00a0prote\u00f3lisis\u00a0 de\u00a0citoesqueleto \u00a0inducida\u00a0por\u00a0la\u00a0isquemia\u00a0de\u00a0manera\u00a0\ndosis\u00a0dependiente. \u00a0\n\u00a09 MODULADORES \u00a0DE\u00a0LA\u00a0RESPUESTA \u00a0INFLAMATORIA. \u00a0\n\u00a0 34Para\u00a0modular\u00a0la\u00a0respuesta \u00a0inflamatoria \u00a0despu\u00e9s\u00a0 de\u00a0la\u00a0lesi\u00f3n\u00a0 se\u00a0ha\u00a0llegado\u00a0\na\u00a0desarrollar \u00a0otras\u00a0estrategias \u00a0terap\u00e9uticas \u00a0como\u00a0la\u00a0atenuaci\u00f3n \u00a0de\u00a0la\u00a0migraci\u00f3n \u00a0\nde\u00a0los\u00a0leucocitos. \u00a0Con\u00a0base\u00a0en\u00a0estos\u00a0antecedentes \u00a0se\u00a0han\u00a0utilizado\u00a0 anticuerpos \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nmonoclonales \u00a0espec\u00edficos \u00a0dirigidos\u00a0contra\u00a0 las\u00a0mol\u00e9culas \u00a0de\u00a0adhesi\u00f3n\u00a0que\u00a0\nincluyen\u00a0la\u00a0selectina\u2010P\u00a0e\u00a0ICAM\u20101,\u00a0los\u00a0cuales\u00a0podr\u00edan\u00a0tener\u00a0efectos\u00a0\nneuroprotectores; \u00a0as\u00ed\u00a0como\u00a0el\u00a0empleo\u00a0de\u00a0anticuerpos\u00a0 monoclonales \u00a0contra\u00a0 la\u00a0\nintegrina\u00a0alfa\u2010D.\u00a0Tras\u00a0la\u00a0LMA\u00a0se\u00a0incrementa\u00a0 la\u00a0s\u00edntesis\u00a0de\u00a0prostaglandinas, \u00a0\ntromboxanos\u00a0 y\u00a0leucotrienos, \u00a0alterando \u00a0el\u00a0flujo\u00a0sangu\u00edneo \u00a0y\u00a0favoreciendo \u00a0la\u00a0\nagregaci\u00f3n \u00a0plaquetaria,\u00a0 lo\u00a0que\u00a0trae\u00a0 como\u00a0consecuencia \u00a0el\u00a0fen\u00f3meno \u00a0de\u00a0\nisquemia. \u00a0Para\u00a0tratar\u00a0de\u00a0contrarrestar \u00a0este\u00a0fen\u00f3meno \u00a0se\u00a0han\u00a0 desarrollado \u00a0\nestrategias \u00a0terap\u00e9uticas \u00a0experimentales \u00a0con\u00a0 indometacina/heparina \u00a0y\u00a0\nprostaciclina. \u00a0Los\u00a0resultados \u00a0demostraron\u00a0 que\u00a0existe\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0\nsignificativamente \u00a0mayor\u00a0cuando\u00a0se\u00a0comparan \u00a0con\u00a0el\u00a0grupo\u00a0control,\u00a0al\u00a0cual\u00a0 s\u00f3lo\u00a0\nse\u00a0le\u00a0administr\u00f3 \u00a0placebo.\u00a0\n\u00a0\n9 INMUNOSUPRESORES. \u00a0\nEn\u00a0estudios\u00a0experimentales \u00a0en\u00a0animales\u00a0se\u00a0han\u00a0utilizado\u00a0 la\u00a0ciclosporina \u00a0A,\u00a0\ntacrolimus\u00a0 (FK506),\u00a0 iloprost\u00a0y\u00a0el\u00a0mesilato\u00a0de\u00a0gabexate, \u00a0para\u00a0 disminuir \u00a0el\u00a0estr\u00e9s\u00a0\noxidante, \u00a0ya\u00a0que\u00a0las\u00a0c\u00e9lulas\u00a0inflamatorias\u00a0 son\u00a0productoras\u00a0 de\u00a0grandes\u00a0cantidades\u00a0\nde\u00a0radicales\u00a0 libres.\u00a0\u00a0 Estos\u00a0f\u00e1rmacos \u00a0pueden\u00a0poseer\u00a0la\u00a0capacidad\u00a0 de\u00a0disminuir \u00a0la\u00a0\nlipoperoxidaci\u00f3n \u00a0y\u00a0mejorar\u00a0la\u00a0funci\u00f3n\u00a0motora;\u00a0y\u00a0actuar\u00a0 como\u00a0agentes\u00a0\nneuroprotectores \u00a0y\u00a0regeneradores \u00a0sobre\u00a0axones\u00a0de\u00a0la\u00a0columna\u00a0dorsal\u00a0de\u00a0la\u00a0ME.\u00a0\n\u00a0\n9 ANTIOXIDANTES. \u00a0\n\u00a0\u00a0 Se\u00a0han\u00a0 empleado \u00a0en\u00a0diversos\u00a0modelos\u00a0 experimentales \u00a0de\u00a0\nisquemia/repercusi\u00f3n \u00a0e\u00a0hipoxia/reoxigenaci\u00f3n. \u00a0As\u00ed,\u00a0 numerosos \u00a0estudios\u00a0han\u00a0\nevaluado\u00a0el\u00a0uso\u00a0de\u00a0diversos\u00a0agentes\u00a0farmacol\u00f3gicos \u00a0para\u00a0 inhibir\u00a0el\u00a0estr\u00e9s\u00a0\noxidativo\u00a0 como\u00a0el\u00a0mexilatine \u00a0(58),\u00a0OPC\u201014117,\u00a0peroxilo,\u00a0alcoxilo\u00a0y\u00a0el\u00a0pirudoindol \u00a0\nestobadin.\u00a0\n\u00a0\n9 OTRAS\u00a0ESTRATEGIAS. \u00a0\n\u00a0 35Despu\u00e9s\u00a0de\u00a0una\u00a0LMA\u00a0se\u00a0incrementa \u00a0la\u00a0actividad\u00a0 de\u00a0las\u00a0tres\u00a0isoformas\u00a0 de\u00a0\nla\u00a0sintetasa\u00a0del\u00a0\u00f3xido\u00a0n\u00edtrico\u00a0que\u00a0se\u00a0expresan\u00a0en\u00a0el\u00a0SNC,\u00a0estas\u00a0enzimas\u00a0sintetizan\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00f3xido\u00a0n\u00edtrico\u00a0a\u00a0partir\u00a0del\u00a0amino\u00e1cido\u00a0 L\u2010arginina,\u00a0 las\u00a0altas\u00a0concentraciones\u00a0 de\u00a0este\u00a0\nmensajero \u00a0resultan\u00a0ser\u00a0citot\u00f3xicas\u00a0 y\u00a0participar \u00a0en\u00a0la\u00a0cascada\u00a0de\u00a0la\u00a0vasodilataci\u00f3n. \u00a0\nDiversos\u00a0estudios\u00a0demuestran \u00a0que\u00a0el\u00a0uso\u00a0de\u00a0inhibidores \u00a0de\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0\u00f3xido\u00a0\nn\u00edtrico\u00a0\u00a0como\u00a0\u00a0NG\u2010monometil \u2010L\u2010arginina\u00a0y\u00a0\u00a0NG\u2010nitro\u2010L\u2010arginina\u00a0metilester \u00a0\naceleran\u00a0la\u00a0recuperaci\u00f3n \u00a0motora\u00a0 despu\u00e9s\u00a0de\u00a0la\u00a0lesi\u00f3n.\u00a0\u00a0\n\u00a0\nEl\u00a0clembuterol \u00a0revierte\u00a0la\u00a0atrofia\u00a0muscular\u00a0al\u00a0facilitar\u00a0la\u00a0expresi\u00f3n\u00a0 de\u00a0\ndiversos\u00a0factores\u00a0tr\u00f3ficos,\u00a0adem\u00e1s,\u00a0se\u00a0ha\u00a0observado \u00a0que\u00a0por\u00a0medio\u00a0de\u00a0este\u00a0\nmecanismo \u00a0se\u00a0promueve \u00a0tanto\u00a0la\u00a0regeneraci\u00f3n\u00a0 como\u00a0la\u00a0neuroprotecci\u00f3n. \u00a0\n\u00a0Se\u00a0ha\u00a0probado\u00a0la\u00a0eficacia\u00a0del\u00a0sulfato\u00a0 de\u00a0magnesio \u00a0despu\u00e9s\u00a0de\u00a0una\u00a0LMA\u00a0\ncomo\u00a0agente\u00a0neuroprotector \u00a0sobre\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0los\u00a0axones\u00a0y\u00a0la\u00a0lipoperoxidaci\u00f3n \u00a0\nen\u00a0modelos\u00a0 experimentales \u00a0de\u00a0LM\u00a0en\u00a0ratas.\u00a0\u00a0\n\u00a0Otros\u00a0 autores\u00a0sugieren\u00a0como\u00a0estrategia\u00a0 terap\u00e9utica\u00a0 el\u00a0tratamiento \u00a0con\u00a0la\u00a0\n4\u2010aminopiridina, \u00a0un\u00a0f\u00e1rmaco\u00a0con\u00a0efecto\u00a0inhibitorio \u00a0sobre\u00a0los\u00a0canales\u00a0de\u00a0potasio.\u00a0\u00a0\n\u00a0\n\u00a0\n1.7.4.  Tratamiento \u00a0no\u00a0farmacol\u00f3gicos \u00a0\nDespu\u00e9s\u00a0de\u00a0producirse \u00a0una\u00a0LMA\u00a0se\u00a0observa\u00a0una\u00a0pobre\u00a0regeneraci\u00f3n \u00a0\nespont\u00e1nea. \u00a0Se\u00a0sabe\u00a0que\u00a0existen\u00a0 diversos\u00a0eventos\u00a0que\u00a0contribuyen \u00a0con\u00a0 este\u00a0\nproceso,\u00a0como\u00a0la\u00a0cicatriz\u00a0 glial,\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0remielinizaci\u00f3n, \u00a0la\u00a0propia\u00a0\nmuerte\u00a0celular\u00a0y\u00a0la\u00a0producci\u00f3n \u00a0insuficiente \u00a0de\u00a0factores\u00a0de\u00a0crecimiento \u00a0que\u00a0\npermitan\u00a0la\u00a0regeneraci\u00f3n \u00a0axonal.\u00a0\u00a0Diversos \u00a0autores\u00a0proponen \u00a0que\u00a0deben\u00a0\ndesarrollarse \u00a0estrategias \u00a0neuroprotectoras \u00a0que\u00a0intenten\u00a0restablecer \u00a0el\u00a0medio\u00a0\nambiente \u00a0favorable \u00a0para\u00a0inducir\u00a0procesos\u00a0de\u00a0crecimiento \u00a0y\u00a0regeneraci\u00f3n \u00a0axonal.\u00a0\nProbablemente \u00a0las\u00a0estrategias \u00a0futuras\u00a0 para\u00a0la\u00a0restauraci\u00f3n \u00a0de\u00a0la\u00a0ME\u00a0lesionada \u00a0\nrequieran \u00a0de\u00a0una\u00a0estrategia\u00a0 multimodal.\u00a0\u00a0\n\u00a0 36\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nActualmente \u00a0la\u00a0investigaci\u00f3n \u00a0se\u00a0centra\u00a0en\u00a0diversos\u00a0factores\u00a0de\u00a0\ncrecimiento \u00a0y\u00a0transplante, \u00a0as\u00ed\u00a0podemos\u00a0 enumerar \u00a0l\u00edneas\u00a0de\u00a0investigaci\u00f3n \u00a0como:\u00a0\n\u00a0\n1.7.4.1.\u2010\u00a0\u00a0Gliosis\u00a0y\u00a0regeneraci\u00f3n\u00a0 abortiva.\u00a0\n1.7.4.2.\u2010\u00a0\u00a0Factores\u00a0de\u00a0crecimientos\u00a0 neuronales. \u00a0\n1.7.4.3.\u2010\u00a0Factores \u00a0de\u00a0crecimientos \u00a0derivados \u00a0del\u00a0cerebro.\u00a0\n1.7.4.4.\u2010\u00a0Factores \u00a0de\u00a0crecimientos \u00a0b\u00e1sicos\u00a0 de\u00a0los\u00a0fibroblastos. \u00a0\n1.7.4.5.\u2010\u00a0Transplantes. \u00a0\n1.7.4.5.1.\u2010\u00a0\u00a0 Neuronas \u00a0derivadas \u00a0del\u00a0sistema\u00a0nervioso\u00a0central.\u00a0\n1.7.4.5.2.\u2010\u00a0 Oligodendrocitos. \u00a0\n1.7.4.5.3.\u2010\u00a0 C\u00e9lulas\u00a0de\u00a0Schwann.\u00a0\n1.7.4.5.4.\u2010\u00a0 Astrocitos. \u00a0\n1.7.4.5.5.\u2010\u00a0 C\u00e9lulas\u00a0progenitoras \u00a0multipotenciales \u00a0(Stem\u00a0 cells).\u00a0\n1.7.4.5.6.\u2010\u00a0 Fibroblastos. \u00a0\n\u00a0\n\u00a0 37Como\u00a0conclusi\u00f3n, \u00a0debemos\u00a0 incidir\u00a0que\u00a0el\u00a0mejor\u00a0tratamiento \u00a0no\u00a0quir\u00fargico \u00a0\nes\u00a0el\u00a0mantenimiento\u00a0 de\u00a0una\u00a0adecuada \u00a0ventilaci\u00f3n \u00a0(aportando\u00a0 sangre\u00a0bien\u00a0\noxigenada \u00a0al\u00a0tejido\u00a0medular\u00a0 da\u00f1ado)\u00a0y\u00a0una\u00a0hemodin\u00e1mica \u00a0estable\u00a0para\u00a0\nmantener \u00a0una\u00a0presi\u00f3n\u00a0 de\u00a0perfusi\u00f3n \u00a0en\u00a0l\u00edmites\u00a0estables.\u00a0Actualmente \u00a0la\u00a0\u00fanica\u00a0\nestrategia \u00a0farmacol\u00f3gica \u00a0utilizada\u00a0en\u00a0pacientes \u00a0con\u00a0una\u00a0LMA\u00a0es\u00a0la\u00a0administraci\u00f3n \u00a0\nde\u00a0megadosis \u00a0MP,\u00a0 sin\u00a0embargo, \u00a0su\u00a0uso\u00a0no\u00a0solamente \u00a0ofrece\u00a0efectos\u00a0ben\u00e9ficos \u00a0\nsino\u00a0 tambi\u00e9n\u00a0produce\u00a0efectos\u00a0adversos. \u00a0Levy\u00a0et\u00a0al\u00a0(118)\u00a0informaron \u00a0que\u00a0este\u00a0\ntratamiento \u00a0produce\u00a0hemorragias \u00a0digestivas, \u00a0adem\u00e1s,\u00a0puede\u00a0exacerbar \u00a0la\u00a0\nnecrosis\u00a0neuronal\u00a0 postisqu\u00e9mica, \u00a0inhibir\u00a0el\u00a0crecimiento \u00a0axonal\u00a0e\u00a0\u00a0interferir\u00a0 con\u00a0la\u00a0\nregeneraci\u00f3n \u00a0neuronal. \u00a0La\u00a0evidencia \u00a0m\u00e9dica\u00a0afirma\u00a0 que\u00a0el\u00a0uso\u00a0de\u00a0CTC\u00a0\nadministrados\u00a0 en\u00a0megadosis \u00a0y\u00a0de\u00a0forma\u00a0continua\u00a0provoca\u00a0efectos\u00a0t\u00f3xicos\u00a0que\u00a0en\u00a0\npotencia\u00a0ponen\u00a0en\u00a0peligro\u00a0la\u00a0vida\u00a0de\u00a0los\u00a0pacientes.\u00a0\u00a0La \u00a0complicaci\u00f3n \u00a0m\u00e1s\u00a0grave\u00a0es\u00a0\nla\u00a0insuficiencia \u00a0suprarrenal \u00a0aguda\u00a0por\u00a0supresi\u00f3n \u00a0del\u00a0eje\u00a0hipotal\u00e1mico \u2010hipofisario \u2010\nsuprarrenal; \u00a0existen\u00a0otras\u00a0 complicaciones\u00a0 como\u00a0anormalidades \u00a0de\u00a0l\u00edquidos\u00a0y\u00a0\nelectr\u00f3litos, \u00a0hipertensi\u00f3n \u00a0arterial\u00a0(HTA),\u00a0hiperglucemia, \u00a0incremento \u00a0de\u00a0la\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nsensibilidad \u00a0a\u00a0infecciones, \u00a0osteoporosis, \u00a0miopat\u00eda\u00a0y\u00a0alteraciones \u00a0\u00a0conductuales. \u00a0\nLa\u00a0terapia\u00a0 corticoidea \u00a0actualmente \u00a0en\u00a0la\u00a0LMA\u00a0se\u00a0esta\u00a0 reconsiderando \u00a0por\u00a0\nm\u00faltiples\u00a0 grupos\u00a0 de\u00a0estudio,\u00a0pero\u00a0al\u00a0ser\u00a0 el\u00a0\u00fanico\u00a0tratamiento \u00a0m\u00e9dico\u00a0en\u00a0\npacientes \u00a0con\u00a0LMAT\u00a0persiste\u00a0un\u00a0uso\u00a0generalizado \u00a0y\u00a0se\u00a0mantiene \u00a0en\u00a0los\u00a0diferentes \u00a0\nprotocolos \u00a0de\u00a0tratamiento \u00a0\u00a0de\u00a0los\u00a0lesionados \u00a0medulares \u00a0en\u00a0la\u00a0asistencia \u00a0\nextrahospitalaria \u00a0de\u00a0urgencia,\u00a0Unidades \u00a0de\u00a0Cuidados\u00a0Cr\u00edticos\u00a0(UC)\u00a0 y\u00a0salas\u00a0de\u00a0\nhospitalizaci\u00f3n \u00a0convencional, \u00a0lo\u00a0que\u00a0demuestra \u00a0que\u00a0nos\u00a0enfrentamos \u00a0a\u00a0un\u00a0\nproblema\u00a0 sin\u00a0buenas\u00a0 alternativas \u00a0terap\u00e9uticas. \u00a0\n\u00a0\n\u00a0\u00a0\n1.8. TRATAMIENTO \u00a0QUIRURGICO \u00a0DE\u00a0LA\u00a0LESI\u00d3N\u00a0MEDULAR\u00a0 AGUDA\u00a0\nTRAUM\u00c1TICA \u00a0\n\u00a01.8.1.  \u00a0Indicaciones \u00a0de\u00a0la\u00a0cirug\u00eda\u00a0\n\u00a0 38Como\u00a0axioma\u00a0 inicial\u00a0debe\u00a0tenerse\u00a0 presente\u00a0que\u00a0las\u00a0lesiones\u00a0asociadas\u00a0 que\u00a0\nponen\u00a0en\u00a0peligro\u00a0la\u00a0vida\u00a0tienen\u00a0prioridad\u00a0sobre\u00a0la\u00a0lesi\u00f3n\u00a0raquidea. \u00a0El\u00a0plan\u00a0 de\u00a0\ntratamiento \u00a0debe\u00a0individualizarse \u00a0para\u00a0cada\u00a0paciente\u00a0y\u00a0lesi\u00f3n\u00a0espec\u00edfica. \u00a0La\u00a0\nreducci\u00f3n \u00a0de\u00a0la\u00a0columna\u00a0y\u00a0alineaci\u00f3n \u00a0de\u00a0los\u00a0fragmentos \u00a0\u00f3seos\u00a0debe\u00a0ser\u00a0los\u00a0m\u00e1s\u00a0\nprecoz\u00a0posible,\u00a0sobre\u00a0todo\u00a0en\u00a0pacientes \u00a0con\u00a0 d\u00e9ficit\u00a0 neurol\u00f3gico. \u00a0La\u00a0tracci\u00f3n\u00a0\nesquel\u00e9tica \u00a0mediante \u00a0un\u00a0compas\u00a0o\u00a0halo\u00a0proporciona \u00a0estabilizaci\u00f3n \u00a0inicial\u00a0y\u00a0\nalineaci\u00f3n \u00a0neutral\u00a0 en\u00a0casi\u00a0todas\u00a0 las\u00a0lesiones\u00a0de\u00a0la\u00a0columna\u00a0cervical.\u00a0\u00a0\n\u00a0Debido\u00a0a\u00a0la\u00a0ausencia\u00a0de\u00a0estudios\u00a0cl\u00ednicos\u00a0prospectivos,\u00a0 aleatorizados\u00a0 y\u00a0\ncontrolados \u00a0que\u00a0hayan\u00a0evaluado\u00a0la\u00a0cirug\u00eda\u00a0vertebral\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0lesiones\u00a0\nde\u00a0la\u00a0ME,\u00a0muchos\u00a0aspectos\u00a0de\u00a0la\u00a0intervenci\u00f3n \u00a0quir\u00fargica \u00a0(IQ)\u00a0 son\u00a0pol\u00e9micos.\u00a0 Al\u00a0\ndecidir\u00a0si\u00a0est\u00e1\u00a0indicada\u00a0o\u00a0no\u00a0una\u00a0IQ,\u00a0los\u00a0cuatro\u00a0aspectos\u00a0m\u00e1s\u00a0importantes\u00a0 que\u00a0\ndeben\u00a0considerarse \u00a0son\u00a0el\u00a0estado\u00a0neurol\u00f3gico \u00a0actual\u00a0 y\u00a0su\u00a0variaci\u00f3n\u00a0 con\u00a0 el\u00a0\ntiempo,\u00a0la\u00a0presencia\u00a0 o\u00a0ausencia\u00a0de\u00a0estabilidad\u00a0 de\u00a0la\u00a0CV,\u00a0la\u00a0presencia \u00a0o\u00a0ausencia\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0 39de\u00a0compresi\u00f3n \u00a0neural\u00a0 y\u00a0otras\u00a0consideraciones\u00a0 como\u00a0son\u00a0la\u00a0edad\u00a0y\u00a0las\u00a0afecciones \u00a0\ncom\u00f3rbidas \u00a0(59).\u00a0\n\u00a0\nLas\u00a0personas\u00a0con\u00a0 afectaci\u00f3n \u00a0de\u00a0los\u00a0elementos \u00a0neurales\u00a0que\u00a0presentan\u00a0\ndeterioro \u00a0nerol\u00f3gico \u00a0deben\u00a0recibir\u00a0tratamiento \u00a0urgente\u00a0con\u00a0descompresi\u00f3n\u00a0 y\u00a0\nestabilizaci\u00f3n. \u00a0Un\u00a0paciente\u00a0con\u00a0deterioro \u00a0neurol\u00f3gico \u00a0en\u00a0el\u00a0momento \u00a0del\u00a0ingreso\u00a0\nsuele\u00a0tener\u00a0una\u00a0compresi\u00f3n \u00a0neural\u00a0y/o\u00a0una\u00a0inestabilidad \u00a0vertebral\u00a0como\u00a0para\u00a0\nindicar\u00a0que\u00a0el\u00a0tratamiento \u00a0quir\u00fargico \u00a0es\u00a0apropiado. \u00a0La\u00a0mayor\u00eda\u00a0 de\u00a0las\u00a0veces\u00a0se\u00a0\npracticar\u00e1 \u00a0eliminaci\u00f3n \u00a0de\u00a0las\u00a0esquirlas\u00a0oseas\u00a0y\u00a0descompresi\u00f3n \u00a0por\u00a0laminectomia \u00a0\nde\u00a0hematomas \u00a0en\u00a0situaciones \u00a0donde\u00a0se\u00a0adivina\u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0presi\u00f3n\u00a0\nraquimedular \u00a0con\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0presi\u00f3n\u00a0 de\u00a0perfusi\u00f3n \u00a0medular.\u00a0Los\u00a0pacientes \u00a0\ncon\u00a0fractura\u2013luxaci\u00f3n \u00a0de\u00a0la\u00a0columna\u00a0vertebral, \u00a0con\u00a0o\u00a0sin\u00a0par\u00e1lisis,\u00a0normalmente \u00a0\nse\u00a0beneficiar\u00e1n\u00a0 de\u00a0la\u00a0reducci\u00f3n, \u00a0la\u00a0instrumentaci\u00f3n \u00a0y\u00a0la\u00a0artrodesis \u00a0quir\u00fargicas. \u00a0\n\u00a0\nRespecto\u00a0a\u00a0las\u00a0artrodesis,\u00a0 el\u00a0acceso\u00a0posterior\u00a0es\u00a0el\u00a0que\u00a0m\u00e1s\u00a0se\u00a0suele\u00a0\nutilizar\u00a0para\u00a0 el\u00a0tratamiento \u00a0urgente\u00a0de\u00a0las\u00a0lesiones\u00a0de\u00a0la\u00a0columna\u00a0dorsal\u00a0y\u00a0\nlumbar.\u00a0En\u00a0las\u00a0lesiones\u00a0cervicales, \u00a0la\u00a0v\u00eda\u00a0de\u00a0acceso\u00a0 anterior\u00a0es\u00a0m\u00e1s\u00a0f\u00e1cil\u00a0que\u00a0en\u00a0los\u00a0\ndem\u00e1s\u00a0segmentos \u00a0raqu\u00eddeos. \u00a0La\u00a0utilizaci\u00f3n \u00a0de\u00a0autoinjertos \u00a0\u00f3seos\u00a0 consolida \u00a0de\u00a0\nmanera\u00a0m\u00e1s\u00a0r\u00e1pida\u00a0y\u00a0previsible \u00a0que\u00a0los\u00a0aloinjertos. \u00a0Para\u00a0estabilizar \u00a0la\u00a0reducci\u00f3n \u00a0\nse\u00a0precisa\u00a0 una\u00a0osteos\u00edntesis, \u00a0utilizando \u00a0placas\u00a0o\u00a0v\u00e1stagos\u00a0atornillados \u00a0en\u00a0los\u00a0\nped\u00edculos\u00a0 vertebrales. \u00a0\u00a0\n\u00a0\nEn\u00a0general,\u00a0cuanto\u00a0m\u00e1s\u00a0inestable\u00a0es\u00a0la\u00a0lesi\u00f3n,\u00a0m\u00e1s\u00a0 apropiado \u00a0es\u00a0el\u00a0uso\u00a0de\u00a0\nla\u00a0instrumentaci\u00f3n \u00a0y\u00a0la\u00a0artrodesis \u00a0vertebrales \u00a0posteriores, \u00a0y\u00a0menos\u00a0apropiado \u00a0es\u00a0\nplantearse \u00a0s\u00f3lo\u00a0la\u00a0instrumentaci\u00f3n\u00a0 y\u00a0la\u00a0artrodesis \u00a0anteriores. \u00a0Lo\u00a0mejor\u00a0 es\u00a0tratar\u00a0 a\u00a0\nlos\u00a0pacientes \u00a0que\u00a0sufren\u00a0una\u00a0fractura\u00a0 por\u00a0estallido\u00a0con\u00a0compresi\u00f3n \u00a0neural\u00a0 grave,\u00a0\npar\u00e1lisis\u00a0 y\u00a0alteraci\u00f3n\u00a0 posterior\u00a0m\u00ednima,\u00a0mediante \u00a0descompresi\u00f3n, \u00a0\ninstrumentaci\u00f3n \u00a0y\u00a0artrodesis \u00a0anteriores. \u00a0Si\u00a0el\u00a0paciente\u00a0es\u00a0obeso\u00a0o\u00a0si\u00a0el\u00a0cirujano\u00a0\ncree\u00a0que\u00a0la\u00a0inestabilidad \u00a0es\u00a0grave,\u00a0la\u00a0calidad\u00a0\u00f3sea\u00a0es\u00a0mala\u00a0o\u00a0las\u00a0exigencias \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\npostoperatorias \u00a0ser\u00e1n\u00a0elevadas\u00a0debido\u00a0 a\u00a0las\u00a0afecciones \u00a0com\u00f3rbidas, \u00a0todav\u00eda\u00a0es\u00a0\nm\u00e1s\u00a0apropiada \u00a0una\u00a0IQ\u00a0posterior. \u00a0\u00a0\n\u00a0\nUna\u00a0angulaci\u00f3n \u00a0de\u00a0la\u00a0columna\u00a0superior\u00a0a\u00a030\u00a0\u00ba\u00a0siempre\u00a0debe\u00a0tratarse\u00a0\nmediante \u00a0\u00a0IQ\u00a0para\u00a0evitar\u00a0 el\u00a0dolor\u00a0de\u00a0espalda\u00a0cr\u00f3nico.\u00a0Una\u00a0angulaci\u00f3n \u00a0de\u00a025\u00a0a\u00a030\u00a0\u00ba\u00a0\npuede\u00a0exigir\u00a0 tratamiento \u00a0quir\u00fargico, \u00a0aunque\u00a0este\u00a0 grado\u00a0de\u00a0deformidad \u00a0puede\u00a0\nrecibir\u00a0tratamiento \u00a0no\u00a0quir\u00fargico \u00a0si\u00a0se\u00a0somete\u00a0al\u00a0paciente\u00a0a\u00a0un\u00a0seguimiento \u00a0\nriguroso\u00a0y\u00a0se\u00a0le\u00a0informa\u00a0de\u00a0que\u00a0la\u00a0angulaci\u00f3n \u00a0puede\u00a0evolucionar \u00a0y\u00a0exigir\u00a0una\u00a0\ncorrecci\u00f3n \u00a0quir\u00fargica \u00a0m\u00e1s\u00a0adelante. \u00a0\n\u00a0\nS\u00f3lo\u00a0un\u00a0aut\u00e9ntico \u00a0estudio\u00a0prospectivo \u00a0randomizado\u00a0 permitir\u00e1 \u00a0responder \u00a0a\u00a0\nesta\u00a0cuesti\u00f3n\u00a0esencial.\u00a0Mientras\u00a0tanto,\u00a0s\u00f3lo\u00a0se\u00a0pueden\u00a0 proponer \u00a0elementos \u00a0de\u00a0\ndecisi\u00f3n\u00a0emp\u00edricos \u00a0(Tabla\u00a05).\u00a0\n\u00a0\nTabla\u00a0 5.\u2010\u00a0Elementos \u00a0principales\u00a0 en\u00a0la\u00a0decisi\u00f3n\u00a0de\u00a0una\u00a0Intervenci\u00f3n \u00a0\nQuir\u00fargica\u00a0 de\u00a0Urgencia\u00a0en\u00a0una\u00a0Lesi\u00f3n\u00a0Medular\u00a0Aguda\u00a0Traum\u00e1tica. \u00a0\nA\u00a0FAVOR.\u00a0 EN\u00a0CONTRA. \u00a0\n\u2022 \u00a0Lesi\u00f3n\u00a0incompleta. \u00a0\n\u2022 \u00a0Lesi\u00f3n\u00a0progresiva. \u00a0\n\u2022 \u00a0Retraso\u00a0inferior\u00a0a\u00a06\u00a0\nhoras.\u00a0\n\u2022 \u00a0Retraso\u00a0inferior\u00a0a\u00a024\u00a0\nhoras.\u00a0\u2022 \u00a0Lesi\u00f3n\u00a0completa. \u00a0\n\u2022 \u00a0Retraso\u00a0superior\u00a0a\u00a024\u00a0\nhoras.\u00a0\n\u2022 Contusi\u00f3n \u00a0 pulmonar \u00a0\ngrave.\u00a0\n\u2022 \u00a0Trauma\u00a0 craneal\u00a0grave.\u00a0\n\u00a0\u00a01.8.2.  Momento \u00a0adecuado \u00a0de\u00a0la\u00a0cirug\u00eda\u00a0programada \u00a0\n\u00a0 40La\u00a0evidencia \u00a0m\u00e9dica\u00a0actual\u00a0 parece\u00a0indicar\u00a0que\u00a0cuando\u00a0la\u00a0LM\u00a0es\u00a0\nincompleta \u00a0o\u00a0se\u00a0percibe\u00a0un\u00a0agravamiento \u00a0progresivo \u00a0en\u00a0las\u00a0primeras\u00a0horas,\u00a0se\u00a0\nconsidera \u00a0que\u00a0se\u00a0trata\u00a0 de\u00a0una\u00a0urgencia\u00a0 quir\u00fargica. \u00a0Por\u00a0el\u00a0contrario, \u00a0persiste\u00a0la\u00a0\npol\u00e9mica\u00a0 respecto\u00a0a\u00a0la\u00a0actitud\u00a0 quir\u00fargica \u00a0de\u00a0entrada\u00a0en\u00a0las\u00a0lesiones\u00a0medulares \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\ncompletas.\u00a0 Numerosos \u00a0estudios\u00a0(60\u201062)\u00a0han\u00a0evaluado\u00a0el\u00a0efecto\u00a0del\u00a0momento \u00a0de\u00a0\nla\u00a0descompresi\u00f3n \u00a0en\u00a0la\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0en\u00a0personas, \u00a0pero\u00a0estas\u00a0\ninvestigaciones\u00a0 no\u00a0han\u00a0proporcionado \u00a0indicios\u00a0concluyentes \u00a0que\u00a0avalen\u00a0la\u00a0\ndescompresi\u00f3n \u00a0precoz\u00a0o\u00a0tard\u00eda\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0lesiones\u00a0medulares \u00a0estables.\u00a0\nEsta\u00a0ausencia\u00a0de\u00a0unanimidad \u00a0ha\u00a0llevado\u00a0a\u00a0grandes\u00a0variaciones\u00a0 en\u00a0cuanto\u00a0a\u00a0cu\u00e1l\u00a0\nes\u00a0el\u00a0momento \u00a0adecuado \u00a0de\u00a0la\u00a0IQ\u00a0para\u00a0las\u00a0lesiones\u00a0medulares \u00a0(63\u201066).\u00a0\u00a0\n\u00a0\nHeiden\u00a0et\u00a0al\u00a0(217)\u00a0detectaron \u00a0que\u00a0las\u00a0complicaciones\u00a0 aparec\u00edan \u00a0en\u00a0el\u00a046\u00a0\n%\u00a0de\u00a0los\u00a0casos\u00a0operados \u00a0en\u00a0la\u00a0primera\u00a0 semana\u00a0despu\u00e9s\u00a0del\u00a0traumatismo \u00a0y\u00a0\nsolamente \u00a0en\u00a0el\u00a027\u00a0%\u00a0de\u00a0los\u00a0casos\u00a0operados \u00a0despu\u00e9s\u00a0de\u00a0una\u00a0semana.\u00a0Marshall\u00a0et\u00a0\nal\u00a0(218)\u00a0tambi\u00e9n\u00a0 han\u00a0 encontrado \u00a0un\u00a0agravamiento \u00a0neurol\u00f3gico \u00a0postoperatorio \u00a0\nen\u00a0el\u00a015\u00a0%\u00a0de\u00a0los\u00a0casos\u00a0operados \u00a0en\u00a0los\u00a05\u00a0primeros\u00a0d\u00edas,\u00a0mientras\u00a0que\u00a0no\u00a0se\u00a0ha\u00a0\ndetectado \u00a0ning\u00fan\u00a0deterioro \u00a0neurol\u00f3gico \u00a0en\u00a0los\u00a0pacientes \u00a0operados \u00a0m\u00e1s\u00a0tarde.\u00a0\nEstos\u00a0 estudios\u00a0han\u00a0 llevado\u00a0a\u00a0muchos\u00a0equipos\u00a0norteamericanos \u00a0a\u00a0no\u00a0practicar\u00a0ya\u00a0\nla\u00a0IQ\u00a0de\u00a0urgencia.\u00a0Por\u00a0el\u00a0contrario,\u00a0 otros\u00a0 equipos\u00a0consideran\u00a0 que\u00a0una\u00a0IQ\u00a0es\u00a0\nurgente\u00a0siempre\u00a0que\u00a0el\u00a0paciente\u00a0sea\u00a0visto\u00a0precozmente, \u00a0y\u00a0que\u00a0esta\u00a0intervenci\u00f3n \u00a0\ndebe\u00a0iniciarse,\u00a0si\u00a0es\u00a0posible,\u00a0 en\u00a0las\u00a06\u00a0horas\u00a0siguientes \u00a0al\u00a0traumatismo.\u00a0\n\u00a0Con\u00a0frecuencia, \u00a0estos\u00a0pacientes \u00a0padecen\u00a0afecciones \u00a0com\u00f3rbidas \u00a0\nimportantes \u00a0y\u00a0traumatismos\u00a0 asociados, \u00a0y\u00a0se\u00a0debe\u00a0ser\u00a0prudente \u00a0para\u00a0garantizar\u00a0\u00a0\nque\u00a0su\u00a0estado\u00a0m\u00e9dico\u00a0es\u00a0\u00f3ptimo\u00a0antes\u00a0de\u00a0la\u00a0IQ.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n1.9. COMPLICACIONES \u00a0DE\u00a0LA\u00a0LESI\u00d3N\u00a0MEDULAR\u00a0 AGUDA\u00a0\n\u00a0\n1.9.1.  Trastornos \u00a0Respiratorios \u00a0\n\u00a0 41La\u00a0insuficiencia \u00a0respiratoria \u00a0aguda\u00a0(IRA)\u00a0por\u00a0par\u00e1lisis\u00a0 de\u00a0los\u00a0m\u00fasculos \u00a0\nrespiratorios \u00a0es\u00a0la\u00a0principal\u00a0causa\u00a0de\u00a0muerte\u00a0 precoz\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0LMA,\u00a0\ncuya\u00a0rapidez\u00a0 de\u00a0instauraci\u00f3n \u00a0y\u00a0severidad \u00a0dependen\u00a0 del\u00a0nivel\u00a0medular\u00a0afectado. \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0 42En\u00a0l\u00edneas\u00a0generales,\u00a0 las\u00a0lesiones\u00a0por\u00a0encima\u00a0 de\u00a0C5\u00a0originan\u00a0 normalmente \u00a0una\u00a0\ninsuficiencia \u00a0respiratoria \u00a0severa\u00a0y\u00a0suelen\u00a0requerir\u00a0ventilaci\u00f3n \u00a0mec\u00e1nica \u00a0(VM)\u00a0de\u00a0\nforma\u00a0precoz.\u00a0Algunos\u00a0 pacientes \u00a0ventilan\u00a0espont\u00e1neamente \u00a0de\u00a0forma\u00a0aceptable \u00a0\nen\u00a0un\u00a0primer\u00a0momento, \u00a0perdiendo \u00a0esta\u00a0capacidad\u00a0 posteriormente \u00a0por\u00a0\nagotamiento \u00a0de\u00a0la\u00a0musculatura \u00a0accesoria, \u00a0hemorragia \u00a0o\u00a0edema\u00a0medular\u00a0\nascendentes,\u00a0 retenci\u00f3n \u00a0de\u00a0secreciones, \u00a0broncoaspiraci\u00f3n, \u00a0atelectasias, \u00a0\ndistensi\u00f3n \u00a0g\u00e1strica\u00a0o\u00a0traumatismos \u00a0asociados, \u00a0por\u00a0lo\u00a0que\u00a0no\u00a0se\u00a0debe\u00a0demorar\u00a0en\u00a0\nellos\u00a0la\u00a0asistencia \u00a0respiratoria. \u00a0\n\u00a0\nPuede\u00a0aparecer\u00a0edema\u00a0pulmonar \u00a0secundario \u00a0a\u00a0la\u00a0LM,\u00a0y\u00a0los\u00a0mecanismos \u00a0\nimplicados \u00a0en\u00a0su\u00a0patogenia \u00a0son\u00a0la\u00a0descarga\u00a0simp\u00e1tica \u00a0masiva\u00a0que\u00a0se\u00a0produce\u00a0tras\u00a0\nel\u00a0traumatismo \u00a0medular,\u00a0 con\u00a0 HTA\u00a0y\u00a0un\u00a0consecuente \u00a0aumento\u00a0de\u00a0la\u00a0postcarga, \u00a0\nque\u00a0unido\u00a0 a\u00a0la\u00a0bradicardia \u00a0existente, \u00a0a\u00a0las\u00a0frecuentes \u00a0arritmias\u00a0y\u00a0a\u00a0la\u00a0depresi\u00f3n\u00a0\nmioc\u00e1rdica \u00a0intr\u00ednseca\u00a0 mediada\u00a0por\u00a0beta\u2010endorfinas, \u00a0puede\u00a0desembocar\u00a0 en\u00a0\nfracaso\u00a0ventricular \u00a0izquierdo\u00a0 con\u00a0edema\u00a0pulmonar \u00a0de\u00a0origen\u00a0cardiog\u00e9nico. \u00a0Esta\u00a0\nrespuesta\u00a0 hipertensiva \u00a0puede\u00a0tambi\u00e9n\u00a0alterar\u00a0el\u00a0endotelio \u00a0capilar\u00a0pulmonar \u00a0con\u00a0\nedema\u00a0exudativo \u00a0y\u00a0hemorragias \u00a0alveolares \u00a0con\u00a0\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0un\u00a0edema\u00a0\npulmonar \u00a0no\u00a0cardiog\u00e9nico. \u00a0\n\u00a0Se\u00a0debe\u00a0tener\u00a0gran\u00a0cuidado\u00a0en\u00a0mantener \u00a0una\u00a0saturaci\u00f3n\u00a0 de\u00a0ox\u00edgeno\u00a0\nsuficiente,\u00a0 evitar\u00a0 el\u00a0ac\u00famulo\u00a0de\u00a0secreciones \u00a0y\u00a0facilitar\u00a0la\u00a0ventilaci\u00f3n \u00a0de\u00a0todos\u00a0los\u00a0\nl\u00f3bulos\u00a0pulmonares \u00a0para\u00a0 que\u00a0no\u00a0se\u00a0produzcan \u00a0atelectasias \u00a0ni\u00a0bronconeumon\u00edas. \u00a0\nA\u00a0todo\u00a0paciente\u00a0con\u00a0 la\u00a0v\u00eda\u00a0a\u00e9rea\u00a0permeable \u00a0y\u00a0respiraci\u00f3n\u00a0 espont\u00e1nea, \u00a0se\u00a0le\u00a0\nsuministrar\u00e1 \u00a0ox\u00edgeno\u00a0con\u00a0mascarilla \u00a0al\u00a040%\u00a0y\u00a0flujos\u00a0de\u00a010\u201012\u00a0litros/minuto. \u00a0\u00a0Para\u00a0\nello\u00a0es\u00a0de\u00a0gran\u00a0importancia,\u00a0 a\u00a0parte\u00a0de\u00a0los\u00a0broncodilatadores \u00a0y\u00a0los\u00a0fluidificantes\u00a0\nbronquiales, \u00a0la\u00a0fisioterapia \u00a0respiratoria \u00a0(drenaje\u00a0postural,\u00a0clapping\u00a0suave,\u00a0\nense\u00f1anza \u00a0de\u00a0la\u00a0tos\u00a0y\u00a0asistencia \u00a0de\u00a0la\u00a0espiraci\u00f3n). \u00a0\n\u00a0Durante\u00a0el\u00a0ingreso\u00a0en\u00a0las\u00a0diferentes \u00a0UC,\u00a0 debemos\u00a0 tener\u00a0presente\u00a0las\u00a0\nfrecuentes \u00a0complicaciones \u00a0respiratorias, \u00a0especialmente \u00a0la\u00a0neumon\u00eda \u00a0nosocomial \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n(NN).\u00a0Un\u00a0factor\u00a0cr\u00edtico\u00a0es\u00a0la\u00a0prevenci\u00f3n\u00a0 de\u00a0las\u00a0complicaciones\u00a0 respiratorias \u00a0y\u00a0la\u00a0\nretirada\u00a0lo\u00a0antes\u00a0posible\u00a0de\u00a0la\u00a0VM.\u00a0\u00a0\n\u00a0\n\u00a0\n1.9.2.  Alteraciones \u00a0Hemodin\u00e1micas \u00a0\n\u00a0 43Los\u00a0pacientes \u00a0con\u00a0 LMA\u00a0pueden\u00a0 presentar\u00a0\u00a0 shock\u00a0neurog\u00e9nico \u00a0y/o\u00a0\nhemorr\u00e1gico. \u00a0El\u00a0shock\u00a0neurog\u00e9nico \u00a0de\u00a0origen\u00a0medular\u00a0es\u00a0de\u00a0car\u00e1cter\u00a0distributivo, \u00a0\ny\u00a0es\u00a0el\u00a0resultado\u00a0 de\u00a0la\u00a0abolici\u00f3n\u00a0del\u00a0control\u00a0simp\u00e1tico, \u00a0con\u00a0 disminuci\u00f3n \u00a0de\u00a0las\u00a0\nresistencias \u00a0vasculares \u00a0perif\u00e9ricas \u00a0y\u00a0dilataci\u00f3n \u00a0de\u00a0los\u00a0vasos\u00a0 de\u00a0capacitancia, \u00a0\nproduci\u00e9ndose \u00a0un\u00a0secuestro \u00a0vascular\u00a0con\u00a0 ca\u00edda\u00a0de\u00a0la\u00a0precarga\u00a0e\u00a0hipotensi\u00f3n \u00a0\narterial.\u00a0Aunque\u00a0no\u00a0se\u00a0acompa\u00f1e \u00a0de\u00a0hipovolemia \u00a0real,\u00a0existe\u00a0una\u00a0disminuci\u00f3n \u00a0\nrelativa\u00a0del\u00a0volumen\u00a0circulante \u00a0por\u00a0la\u00a0expansi\u00f3n\u00a0 del\u00a0lecho\u00a0vascular.\u00a0\u00a0La\u00a0ca\u00edda\u00a0del\u00a0\ngasto\u00a0cardiaco\u00a0resultante \u00a0de\u00a0todas\u00a0 estas\u00a0alteraciones\u00a0 cardiovasculares \u00a0\ncontribuye \u00a0asimismo \u00a0a\u00a0la\u00a0hipotensi\u00f3n, \u00a0cerr\u00e1ndose \u00a0el\u00a0c\u00edrculo\u00a0vicioso.\u00a0\u00a0Pueden \u00a0\nsuperponerse \u00a0otros\u00a0 factores,\u00a0que\u00a0pueden\u00a0 contribuir \u00a0al\u00a0deterioro \u00a0hemodin\u00e1mico \u00a0\ndel\u00a0 paciente\u00a0como\u00a0son,\u00a0hipoxia,\u00a0hipovolemia \u00a0real,\u00a0aumento\u00a0de\u00a0la\u00a0presi\u00f3n\u00a0\nintrator\u00e1cica \u00a0durante\u00a0la\u00a0ventilaci\u00f3n \u00a0mec\u00e1nica\u00a0 y\u00a0f\u00e1rmacos \u00a0con\u00a0efectos\u00a0depresores \u00a0\nsobre\u00a0el\u00a0sistema\u00a0cardiovascular, \u00a0principalmente \u00a0sedantes, \u00a0opi\u00e1ceos\u00a0y\u00a0relajantes \u00a0\nmusculares. \u00a0\u00a0\u00a0\n\u00a0Tras\u00a0la\u00a0LMA,\u00a0estas\u00a0alteraciones\u00a0 hemodin\u00e1micas \u00a0anteriormente \u00a0\ncomentadas, \u00a0\u00a0\u00a0predisponen \u00a0a\u00a0la\u00a0sobrecarga \u00a0de\u00a0volumen\u00a0y\u00a0al\u00a0edema\u00a0pulmonar, \u00a0\npor\u00a0lo\u00a0que\u00a0se\u00a0debe\u00a0vigilar\u00a0estrechamente \u00a0la\u00a0respuesta \u00a0a\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0\nfluidos.\u00a0La\u00a0monitorizaci\u00f3n \u00a0est\u00e1ndar\u00a0en\u00a0nuestra\u00a0Unidad\u00a0 para\u00a0aquellas\u00a0LMA\u00a0\ntraum\u00e1ticas \u00a0severas\u00a0o\u00a0con\u00a0politraumatismos \u00a0acompa\u00f1antes \u00a0es\u00a0el\u00a0sondaje\u00a0vesical\u00a0\ncon\u00a0 sistema\u00a0cerrado\u00a0y\u00a0diuresis\u00a0 horaria,\u00a0monitorizaci\u00f3n \u00a0cardiaca\u00a0continua, \u00a0\nmonitorizaci\u00f3n \u00a0invasiva\u00a0de\u00a0la\u00a0tensi\u00f3n\u00a0arterial\u00a0y\u00a0\u00a0de\u00a0la\u00a0presi\u00f3n\u00a0venosa\u00a0central\u00a0\u00a0\nmediante \u00a0la\u00a0introducci\u00f3n \u00a0de\u00a0un\u00a0cat\u00e9ter\u00a0en\u00a0la\u00a0aur\u00edcula\u00a0derecha\u00a0 por\u00a0abordaje\u00a0\nperif\u00e9rico \u00a0o\u00a0central.\u00a0\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nCuando\u00a0 a\u00a0pesar\u00a0 de\u00a0la\u00a0sobrecarga \u00a0de\u00a0volumen\u00a0y\u00a0su\u00a0optimizaci\u00f3n, \u00a0no\u00a0se\u00a0\nconsigue\u00a0estabilizar \u00a0la\u00a0situaci\u00f3n\u00a0hemodin\u00e1mica, \u00a0es\u00a0necesario \u00a0recurrir\u00a0al\u00a0empleo\u00a0\nde\u00a0drogas\u00a0vasoactivas, \u00a0como\u00a0noradrenalina, \u00a0dopamina \u00a0o\u00a0dobutamina. \u00a0Debemos \u00a0\nincidir\u00a0en\u00a0la\u00a0vital\u00a0importancia \u00a0de\u00a0mantener \u00a0una\u00a0correcta\u00a0presi\u00f3n\u00a0 de\u00a0perfusi\u00f3n \u00a0\nmedular\u00a0 para\u00a0minimizar \u00a0la\u00a0LS\u00a0tras\u00a0la\u00a0LMAT.\u00a0La\u00a0presi\u00f3n\u00a0de\u00a0perfusi\u00f3n \u00a0medular\u00a0 esta\u00a0\ndeterminada\u00a0 por\u00a0la\u00a0presi\u00f3n\u00a0arterial\u00a0media\u00a0 y\u00a0la\u00a0presi\u00f3n\u00a0intrarraquidea. \u00a0\u00a0El\u00a0objetivo\u00a0\ndebe\u00a0ser\u00a0el\u00a0de\u00a0mantener \u00a0una\u00a0presi\u00f3n\u00a0 arterial\u00a0media\u00a0entre\u00a090\u00a0y\u00a0100\u00a0mm\u00a0 de\u00a0Hg,\u00a0\npara\u00a0garantizar\u00a0 un\u00a0adecuado \u00a0flujo\u00a0sangu\u00edneo \u00a0medular,\u00a0 partiendo \u00a0del\u00a0hecho\u00a0de\u00a0\nque\u00a0la\u00a0autorregulaci\u00f3n \u00a0medular\u00a0se\u00a0mantiene \u00a0\u00a0con\u00a0unas\u00a0 presiones\u00a0 de\u00a0perfusi\u00f3n \u00a0\nmedular\u00a0 entre\u00a050\u00a0y\u00a0130\u00a0mm\u00a0 Hg.\u00a0\n\u00a0\n\u00a0\n1.9.3.  Enfermedad \u00a0Tromboemb\u00f3lica\u00a0\n\u00a0 44La\u00a0trombosis \u00a0venosa\u00a0profunda \u00a0(TVP)\u00a0es\u00a0muy\u00a0frecuente \u00a0en\u00a0los\u00a0lesionados \u00a0\nmedulares,\u00a0 oscilando \u00a0su\u00a0incidencia \u00a0entre\u00a0 el\u00a079%\u00a0al\u00a0100%\u00a0de\u00a0los\u00a0casos\u00a0si\u00a0no\u00a0se\u00a0\ntoman\u00a0 las\u00a0medidas\u00a0de\u00a0prevenci\u00f3n. \u00a0Su\u00a0severidad\u00a0 reside\u00a0en\u00a0el\u00a0alto\u00a0riesgo\u00a0de\u00a0\nembolia\u00a0pulmonar \u00a0que\u00a0puede\u00a0provocar\u00a0la\u00a0muerte\u00a0s\u00fabita\u00a0del\u00a0paciente,\u00a0 incluso\u00a0 en\u00a0\nlos\u00a0casos\u00a0en\u00a0los\u00a0que\u00a0no\u00a0se\u00a0ha\u00a0realizado\u00a0el\u00a0diagn\u00f3stico\u00a0 cl\u00ednico\u00a0de\u00a0la\u00a0TVP.\u00a0Su\u00a0riesgo\u00a0\nes\u00a0m\u00e1ximo\u00a0entre\u00a0 los\u00a07\u00a0y\u00a010\u00a0d\u00edas\u00a0tras\u00a0la\u00a0lesi\u00f3n.\u00a0 La\u00a0prevenci\u00f3n\u00a0 debe\u00a0realizarse \u00a0con\u00a0\ntodos\u00a0los\u00a0medios\u00a0de\u00a0que\u00a0disponemos \u00a0desde\u00a0el\u00a0primer\u00a0momento \u00a0en\u00a0que\u00a0el\u00a0\npaciente\u00a0tolere\u00a0y\u00a0no\u00a0exista\u00a0contraindicaci\u00f3n. \u00a0La\u00a0administraci\u00f3n \u00a0de\u00a0\nanticoagulantes \u00a0(ACO)\u00a0es\u00a0necesaria\u00a0 y\u00a0se\u00a0han\u00a0utilizado\u00a0 con\u00a0\u00e9xito\u00a0heparinas\u00a0 de\u00a0bajo\u00a0\npeso\u00a0molecular \u00a0(HBPM).\u00a0\u00a0La\u00a0administraci\u00f3n \u00a0de\u00a0los\u00a0ACO\u00a0en\u00a0la\u00a0fase\u00a0precoz\u00a0(48\u00a0\nprimeras\u00a0horas)\u00a0probablemente \u00a0est\u00e1\u00a0contraindicada, \u00a0debido\u00a0 al\u00a0riesgo\u00a0de\u00a0\nagravamiento \u00a0de\u00a0las\u00a0lesiones\u00a0hemorr\u00e1gicas \u00a0de\u00a0la\u00a0contusi\u00f3n \u00a0medular.\u00a0\n\u00a0\nEn\u00a0la\u00a0Tabla\u00a06\u00a0se\u00a0exponen\u00a0 las\u00a0principales \u00a0medidas\u00a0de\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0TVP.\u00a0\n\u00a0\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nTabla\u00a0 6.\u2010\u00a0\u00a0Prevenci\u00f3n \u00a0\u00a0de\u00a0las\u00a0Flebotrombosis. \u00a0\n\u2022 \u00a0HBPM,\u00a0ACO.\u00a0\u00a0\n\u2022 \u00a0Movilizaci\u00f3n \u00a0pasiva\u00a0de\u00a0\u00a0miembros\u00a0 inferiores.\u00a0\n\u2022 \u00a0Colocaci\u00f3n \u00a0de\u00a0medias\u00a0especiales \u00a0en\u00a0miembros\u00a0 inferiores.\u00a0\u00a0\n\u2022 \u00a0Estimulaci\u00f3n \u00a0el\u00e9ctrica\u00a0de\u00a0flexores\u00a0 y\u00a0dorsiflexores. \u00a0\n\u2022 \u00a0Filtros\u00a0 de\u00a0vena\u00a0cava\u00a0inferior\u00a0(en\u00a0casos\u00a0de\u00a0TVP\u00a0establecida \u00a0con\u00a0 riesgo\u00a0\nimportante \u00a0de\u00a0embolia\u00a0pulmonar \u00a0y\u00a0contraindicaci\u00f3n \u00a0a\u00a0los\u00a0ACO).\u00a0\n\u00a0\n\u00a0\n\u00a01.9.4.  Complicaciones \u00a0Infecciosas \u00a0\nEn\u00a0las\u00a0Unidades \u00a0de\u00a0Reanimaci\u00f3n\u00a0 (UR),\u00a0las\u00a0infecciones\u00a0 de\u00a0las\u00a0v\u00edas\u00a0\nrespiratorias \u00a0bajas\u00a0ocupan\u00a0a\u00a0menudo\u00a0el\u00a0primer\u00a0lugar.\u00a0Las\u00a0septicemias \u00a0ocupan\u00a0el\u00a0\nsegundo\u00a0o\u00a0tercer\u00a0lugar\u00a0en\u00a0frecuencia, \u00a0alternando \u00a0con\u00a0las\u00a0infecciones \u00a0urinarias\u00a0\u00a0\n(ITU),\u00a0dependiendo \u00a0del\u00a0tipo\u00a0de\u00a0Unidad.\u00a0Las\u00a0Infecciones \u00a0quir\u00fargicas \u00a0(IQ),\u00a0salvo\u00a0en\u00a0\nUnidades \u00a0exclusivamente \u00a0Quir\u00fargicas, \u00a0son\u00a0relativamente \u00a0escasas.\u00a0\u00a0\n\u00a0Estas\u00a0complicaciones \u00a0son\u00a0frecuentes \u00a0en\u00a0el\u00a0paciente\u00a0traum\u00e1tico, \u00a0la\u00a0\nmortalidad\u00a0 tard\u00eda\u00a0en\u00a0el\u00a0hospital,\u00a0es\u00a0debido\u00a0 a\u00a0sepsis,\u00a0fracaso\u00a0multiorg\u00e1nico \u00a0(FMO)\u00a0\no\u00a0complicaciones\u00a0 evolutivas \u00a0de\u00a0las\u00a0lesiones\u00a0de\n\u00a0un\u00a0politraumatizado \u00a0muy\u00a0grave.\u00a0Se\u00a0\nproduce\u00a0 la\u00a0muerte\u00a0en\u00a0d\u00edas\u00a0o\u00a0semanas, \u00a0habitualmente \u00a0en\u00a0las\u00a0UC.\u00a0El\u00a0traumatismo \u00a0por\u00a0s\u00ed\u00a0\nmismo\u00a0incrementa \u00a0el\u00a0riesgo\u00a0de\u00a0infecciones,\u00a0 adem\u00e1s\u00a0 de\u00a0alterar\u00a0los\u00a0mecanismos \u00a0de\u00a0\ndefensa\u00a0del\u00a0hu\u00e9sped,\u00a0pero\u00a0estas\u00a0aumentan \u00a0a\u00fan\u00a0m\u00e1s\u00a0por\u00a0 la\u00a0gran\u00a0posibilidad \u00a0de\u00a0\nhospitalizaci\u00f3n, \u00a0estim\u00e1ndose, \u00a0que\u00a0alrededor \u00a0del\u00a025%\u00a0de\u00a0los\u00a0pacientes \u00a0politraumatizados \u00a0\nque\u00a0ingresen\u00a0en\u00a0un\u00a0hospital\u00a0 padecer\u00e1n \u00a0una\u00a0infecci\u00f3n\u00a0nosocomial \u00a0(IN),\u00a0que\u00a0ser\u00e1\u00a0 de\u00a0hasta\u00a0\nel\u00a060%\u00a0para\u00a0los\u00a0enfermos \u00a0que\u00a0requieran \u00a05\u00a0o\u00a0m\u00e1s\u00a0d\u00edas\u00a0de\u00a0estancia\u00a0en\u00a0una\u00a0UC\u00a0y\u00a0el\u00a0empleo\u00a0\nde\u00a0altas\u00a0dosis\u00a0de\u00a0CTC\u00a0\u00a0ha\u00a0incriminado \u00a0\u00a0la\u00a0incidencia \u00a0de\u00a0las\u00a0complicaciones \u00a0s\u00e9pticas.\u00a0\n\u00a0\n\u00a0\n1.9.5.  Alteraciones \u00a0\u00a0Digestivas \u00a0\n\u00a0 45La\u00a0Hemorragia \u00a0Digestiva\u00a0Alta\u00a0(HDA)\u00a0es\u00a0un\u00a0evento\u00a0frecuente, \u00a0incluso\u00a0 en\u00a0las\u00a0\nprimeras\u00a0horas,\u00a0en\u00a0el\u00a0paciente\u00a0politraumatizado, \u00a0pero\u00a0particularmente \u00a0en\u00a0\npresencia \u00a0de\u00a0TCE\u00a0y\u00a0en\u00a0la\u00a0LMA\u00a0por\u00a0lo\u00a0que\u00a0se\u00a0aconseja\u00a0tratamiento \u00a0antisecretor \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\nmediante \u00a0inhibidores \u00a0de\u00a0la\u00a0bomba\u00a0de\u00a0protones\u00a0o\u00a0anti\u00a0H2\u00a0de\u00a0forma\u00a0sistem\u00e1tica. \u00a0\nLos\u00a0pacientes \u00a0con\u00a0 LMA\u00a0y\u00a0tratamiento \u00a0con\u00a0 megadosis \u00a0de\u00a0MP\u00a0presentan \u00a0un\u00a0\naumento\u00a0significativo\u00a0 del\u00a0riesgo\u00a0de\u00a0este\u00a0evento.\u00a0\n\u00a0\nLos\u00a0reflejos\u00a0viscerales \u00a0de\u00a0Blumberg, \u00a0Murphy\u00a0y\u00a0diversos\u00a0datos\u00a0 de\u00a0irritaci\u00f3n\u00a0\nperitoneal\u00a0 pueden\u00a0desaparecer\u00a0 dependiendo\u00a0 del\u00a0nivel\u00a0topogr\u00e1fico \u00a0de\u00a0la\u00a0lesi\u00f3n,\u00a0\ndificultando \u00a0la\u00a0exploraci\u00f3n \u00a0cl\u00ednica\u00a0del\u00a0enfermo.\u00a0 Puede\u00a0existir\u00a0disfunci\u00f3n \u00a0sensitivo\u00a0\n\u2010\u00a0motora\u00a0 con\u00a0alteraciones \u00a0de\u00a0la\u00a0inervaci\u00f3n \u00a0espl\u00e1cnica. \u00a0Desde\u00a0las\u00a024\u00a0horas\u00a0hasta\u00a0\nlos\u00a03\u201010\u00a0d\u00edas\u00a0 se\u00a0produce\u00a0un\u00a0cuadro\u00a0de\u00a0\u00edleo\u00a0paral\u00edtico \u00a0adin\u00e1mico \u00a0gastrointestinal \u00a0\ncuya\u00a0fisiopatolog\u00eda \u00a0aun\u00a0permanece \u00a0desconocida. \u00a0\u00a0\n\u00a0\u00a0\n1.9.6.  Alteraciones \u00a0Metab\u00f3licas \u00a0\nLa\u00a0situaci\u00f3n\u00a0de\u00a0estr\u00e9s\u00a0e\u00a0inmovilidad \u00a0muscular\u00a0total\u00a0condicionan \u00a0una\u00a0\np\u00e9rdida\u00a0de\u00a0masa\u00a0muscular\u00a0que\u00a0no\u00a0puede\u00a0ser\u00a0 contrarestada \u00a0con\u00a0aportes\u00a0\nnutritivos \u00a0y\u00a0que\u00a0se\u00a0traduce\u00a0en\u00a0un\u00a0incremento \u00a0de\u00a0la\u00a0excreci\u00f3n \u00a0nitrogenada \u00a0\nproveniente \u00a0de\u00a0la\u00a0perdida\u00a0prot\u00e9ica.\u00a0Las\u00a0posibilidades \u00a0de\u00a0regulaci\u00f3n \u00a0t\u00e9rmica\u00a0 se\u00a0\nven\u00a0abolidas\u00a0 distalmente \u00a0lo\u00a0que\u00a0conduce\u00a0a\u00a0una\u00a0situaci\u00f3n\u00a0de\u00a0poiquiloitermia. \u00a0El\u00a0\ntratamiento \u00a0con\u00a0 MP\u00a0seg\u00fan\u00a0las\u00a0pautas\u00a0de\u00a0los\u00a0diferentes \u00a0estudios\u00a0NASCIS\u00a0puden\u00a0\nacarrear\u00a0hiperglucemias \u00a0de\u00a0dificil\u00a0control.\u00a0Son\u00a0frecuentes \u00a0en\u00a0periodos\u00a0posteriores \u00a0\nsituaciones \u00a0de\u00a0hipercalcemia \u00a0por\u00a0atrofia\u00a0osea\u00a0y\u00a0nefrocalcinosis. \u00a0\u00a0\n\u00a0\u00a0\n1.9.7.  Trastornos \u00a0Urinarios \u00a0\n\u00a0 46La\u00a0funci\u00f3n\u00a0del\u00a0aparato\u00a0urinario\u00a0es\u00a0la\u00a0m\u00e1s\u00a0afectada\u00a0por\u00a0la\u00a0LM;\u00a0tras\u00a0la\u00a0LM\u00a0\ncompleta \u00a0se\u00a0produce\u00a0una\u00a0par\u00e1lisis\u00a0 del\u00a0detrusor\u00a0con\u00a0retenci\u00f3n\u00a0 urinaria\u00a0hasta\u00a0que\u00a0\nla\u00a0vejiga\u00a0se\u00a0distiende \u00a0y\u00a0se\u00a0orina\u00a0por\u00a0rebosamiento. \u00a0Es\u00a0preciso\u00a0el\u00a0vaciado\u00a0de\u00a0la\u00a0\nvejiga\u00a0para\u00a0evitar\u00a0 la\u00a0infecci\u00f3n\u00a0y\u00a0la\u00a0dilataci\u00f3n \u00a0de\u00a0las\u00a0v\u00edas\u00a0urinarias\u00a0 superiores \u00a0y\u00a0ello\u00a0\nse\u00a0puede\u00a0realizar\u00a0 por\u00a0ejemplo\u00a0mediante \u00a0cateterizaci\u00f3n \u00a0intermitente \u00a0o\u00a0mediante \u00a0\nsondaje\u00a0permanente. \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n1.9.8.  Prevenci\u00f3n \u00a0de\u00a0las\u00a0\u00falceras\u00a0por\u00a0presi\u00f3n\u00a0\nLas\u00a0\u00falceras\u00a0por\u00a0presi\u00f3n\u00a0(UPP)\u00a0o\u00a0por\u00a0dec\u00fabito\u00a0se\u00a0deben\u00a0a\u00a0una\u00a0necrosis\u00a0\nisqu\u00e9mica\u00a0 de\u00a0la\u00a0piel\u00a0y\u00a0tejido\u00a0celular\u00a0 subcut\u00e1neo, \u00a0como\u00a0consecuencia \u00a0de\u00a0la\u00a0\npresi\u00f3n\u00a0 ejercida\u00a0 por\u00a0el\u00a0peso\u00a0del\u00a0cuerpo\u00a0sobre\u00a0las\u00a0zonas\u00a0 de\u00a0apoyo,\u00a0especialmente \u00a0\nlas\u00a0que\u00a0recubren\u00a0las\u00a0prominencias \u00a0\u00f3seas.\u00a0\n\u00a0\n\u00a01.9.9.  Prevenci\u00f3n \u00a0de\u00a0rigideces\u00a0y\u00a0deformidades\u00a0 articulares \u00a0\nLa\u00a0inmovilidad, \u00a0la\u00a0posici\u00f3n\u00a0inadecuada \u00a0y\u00a0el\u00a0desequilibrio\u00a0 muscular\u00a0\nconducen \u00a0a\u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0amplitud\u00a0de\u00a0movimiento \u00a0articular\u00a0y\u00a0a\u00a0las\u00a0\ndeformidades. \u00a0Estas\u00a0complicaciones \u00a0pueden\u00a0 aparecer\u00a0en\u00a0cualquier\u00a0 articulaci\u00f3n \u00a0y\u00a0\nen\u00a0cualquier \u00a0posici\u00f3n\u00a0dependiendo\u00a0 del\u00a0nivel\u00a0de\u00a0la\u00a0lesi\u00f3n,\u00a0de\u00a0la\u00a0espasticidad \u00a0y\u00a0de\u00a0\nla\u00a0postura\u00a0mantenida. \u00a0\n\u00a0En\u00a0cuanto\u00a0el\u00a0estado\u00a0del\u00a0paciente\u00a0lo\u00a0permita\u00a0se\u00a0ha\u00a0de\u00a0proceder\u00a0a\u00a0la\u00a0\npotenciaci\u00f3n \u00a0de\u00a0los\u00a0m\u00fasculos \u00a0sanos\u00a0 de\u00a0los\u00a0miembros \u00a0superiores \u00a0mediante \u00a0\ncinesiterapia \u00a0activa\u00a0resistida.\u00a0\u00a0Igualmente \u00a0importante \u00a0es\u00a0la\u00a0potenciaci\u00f3n \u00a0de\u00a0los\u00a0\nm\u00fasculos \u00a0parcialmente \u00a0paralizados \u00a0que\u00a0se\u00a0puede\u00a0realizar\u00a0 mediante \u00a0la\u00a0\ncinesiterapia \u00a0activa\u00a0o\u00a0activa\u2013asistida. \u00a0La\u00a0electroestimulaci\u00f3n, \u00a0aunque\u00a0tiene\u00a0\nescasas\u00a0indicaciones\u00a0 puede\u00a0ser\u00a0utilizada\u00a0en\u00a0par\u00e1lisis\u00a0 por\u00a0lesi\u00f3n\u00a0de\u00a0neurona\u00a0\nmotora\u00a0 inferior\u00a0o\u00a0por\u00a0lesi\u00f3n\u00a0radicular. \u00a0Su\u00a0objetivo\u00a0es\u00a0retrasar\u00a0la\u00a0atrofia\u00a0y\u00a0\nmantener \u00a0el\u00a0trofismo\u00a0muscular\u00a0aunque\u00a0para\u00a0algunos\u00a0autores\u00a0es\u00a0ineficaz,\u00a0y\u00a0los\u00a0\nefectos\u00a0son\u00a0escasos\u00a0y\u00a0no\u00a0justifican\u00a0los\u00a0requerimientos \u00a0en\u00a0tiempo,\u00a0dinero\u00a0y\u00a0\npersonal. \u00a0\n\u00a0\u00a01.9.10.  Prevenci\u00f3n \u00a0de\u00a0problemas\u00a0 psicol\u00f3gicos \u00a0y\u00a0dolor\u00a0\n\u00a0 47El\u00a0dolor\u00a0cr\u00f3nico\u00a0es\u00a0muy\u00a0frecuente \u00a0en\u00a0los\u00a0lesionados \u00a0medulares \u00a0y\u00a0puede\u00a0\ninterferir\u00a0 con\u00a0el\u00a0proceso\u00a0de\u00a0rehabilitaci\u00f3n \u00a0funcional, \u00a0adaptaci\u00f3n \u00a0sociolaboral \u00a0y\u00a0en\u00a0\nla\u00a0calidad\u00a0 de\u00a0vida\u00a0del\u00a0paciente. \u00a0La\u00a0incidencia \u00a0de\u00a0dolor\u00a0entre\u00a0 los\u00a0lesionados \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nI.\u2010\u00a0INTRODUCCI\u00d3N. \u00a0\n\u00a0 48medulares \u00a0oscila,\u00a0seg\u00fan\u00a0los\u00a0diversos\u00a0autores,\u00a0entre\u00a0 el\u00a027%\u00a0\u00a0y\u00a0el\u00a079%\u00a0.\u00a0\u00a0Entre\u00a0los\u00a0\ntrabajos\u00a0m\u00e1s\u00a0recientes, \u00a0se\u00a0estima\u00a0 que\u00a0alrededor \u00a0del\u00a065%\u00a0de\u00a0los\u00a0pacientes \u00a0\nlesionados \u00a0medulares \u00a0padecen\u00a0alg\u00fan\u00a0 tipo\u00a0de\u00a0dolor,\u00a0siendo\u00a0casi\u00a0un\u00a0tercio\u00a0los\u00a0que\u00a0\nmanifiestan\u00a0 dolor\u00a0severo.\u00a0\u00a0\n\u00a0\nUnido\u00a0al\u00a0dolor,\u00a0el\u00a0paciente\u00a0lesionado\u00a0 medular\u00a0 vive\u00a0una\u00a0situaci\u00f3n\u00a0con\u00a0\ncambios\u00a0dram\u00e1ticos \u00a0y\u00a0radicales\u00a0respecto\u00a0a\u00a0su\u00a0estilo\u00a0de\u00a0vida;\u00a0gener\u00e1ndose \u00a0tras\u00a0el\u00a0\ntrauma,\u00a0una\u00a0alta\u00a0dependencia \u00a0no\u00a0solo\u00a0f\u00edsica\u00a0 sino\u00a0tambi\u00e9n\u00a0psicol\u00f3gica \u00a0y\u00a0social\u00a0\n(67,68) .\u00a0\n\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nII.\u2010\u00a0JUSTIFICACI\u00d3N\u00a0 DEL\u00a0ESTUDIO\u00a0E\u00a0\u00a0HIP\u00d3TESIS. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\nII.\u2010\u00a0JUSTIFICACI\u00d3N\u00a0 DEL\u00a0ESTUDIO\u00a0E\u00a0HIP\u00d3TESIS \u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0 49\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nII.\u2010\u00a0JUSTIFICACI\u00d3N\u00a0 DEL\u00a0ESTUDIO\u00a0E\u00a0\u00a0HIP\u00d3TESIS. \u00a0\n\u00a0\n2.1. JUSTIFICACI\u00d3N \u00a0DEL\u00a0ESTUDIO\u00a0\n\u00a0\nEl\u00a0manejo\u00a0del\u00a0paciente\u00a0con\u00a0 trauma\u00a0 de\u00a0CV\u00a0es\u00a0complejo \u00a0debido\u00a0 a\u00a0la\u00a0\nfrecuente \u00a0presentaci\u00f3n \u00a0de\u00a0otras\u00a0lesiones\u00a0traum\u00e1ticas \u00a0acompa\u00f1antes.\u00a0 El\u00a0objetivo\u00a0\nprimario\u00a0y\u00a0\u00fanico\u00a0tratamiento \u00a0consensuado\u00a0 en\u00a0la\u00a0actualidad \u00a0debe\u00a0ser\u00a0mantener \u00a0\nuna\u00a0adecuada \u00a0presi\u00f3n\u00a0 de\u00a0perfusi\u00f3n \u00a0medular,\u00a0 evitar\u00a0 la\u00a0hiperglucemia, \u00a0mantener \u00a0\nuna\u00a0oxigenaci\u00f3n \u00a0correcta,\u00a0correcci\u00f3n \u00a0de\u00a0la\u00a0hipotermia \u00a0profunda, \u00a0mantenimiento \u00a0\nde\u00a0una\u00a0hipocapnia \u00a0moderada \u00a0y\u00a0en\u00a0los\u00a0casos\u00a0necesarios \u00a0permitir\u00a0una\u00a0\ndescompresi\u00f3n \u00a0medular\u00a0de\u00a0urgencia\u00a0(69).\u00a0Las\u00a0lesiones\u00a0medulares \u00a0traum\u00e1ticas \u00a0\npueden\u00a0 agravarse \u00a0mediante \u00a0un\u00a0mecanismo \u00a0lesional\u00a0secundario. \u00a0Los\u00a0resultados \u00a0\npara\u00a0minimizar \u00a0esta\u00a0LS\u00a0han\u00a0 sido\u00a0 decepcionantes \u00a0con\u00a0 m\u00faltiples\u00a0 f\u00e1rmacos, \u00a0como\u00a0\nlazaroides, \u00a0inhibidores \u00a0c\u00e1lcicos,\u00a0bloqueantes \u00a0de\u00a0los\u00a0receptores \u00a0NMDA,\u00a0naloxona, \u00a0\ngangliosidos, \u00a0etc.\u00a0\n\u00a0\n\u00a0 50La\u00a0administraci\u00f3n \u00a0precoz\u00a0de\u00a0MP\u00a0a\u00a0dosis\u00a0elevadas\u00a0mejora\u00a0el\u00a0pron\u00f3stico \u00a0\nneurol\u00f3gico \u00a0en\u00a0los\u00a0modelos\u00a0experimentales \u00a0de\u00a0compresi\u00f3n \u00a0y\u00a0de\u00a0\u00a0isquemia \u00a0\nmedular\u00a0 (70);\u00a0y\u00a0se\u00a0ha\u00a0se\u00f1alado\u00a0 un\u00a0mecanismo \u00a0de\u00a0acci\u00f3n\u00a0m\u00faltiple\u00a0y\u00a0complejo,\u00a0\npero\u00a0la\u00a0hip\u00f3tesis\u00a0m\u00e1s\u00a0aceptada\u00a0en\u00a0esta\u00a0posible\u00a0mejor\u00eda\u00a0neurol\u00f3gica \u00a0ser\u00eda\u00a0por\u00a0\ninhibici\u00f3n \u00a0de\u00a0la\u00a0peroxidaci\u00f3n \u00a0lip\u00eddica\u00a0de\u00a0membrana. \u00a0\u00a0Los\u00a0estudios\u00a0NASCIS\u00a0II\u00a0y\u00a0III\u00a0\nsugieren\u00a0que\u00a0la\u00a0pauta\u00a0de\u00a0MP\u00a0a\u00a0altas\u00a0dosis,\u00a0administrada \u00a0dentro\u00a0de\u00a0las\u00a08\u00a0horas\u00a0\nsiguientes \u00a0a\u00a0un\u00a0traumatismo \u00a0medular,\u00a0 durante\u00a023\u00a0o\u00a048\u00a0horas,\u00a0mejora\u00a0el\u00a0\npron\u00f3stico \u00a0neurol\u00f3gico \u00a0(47,71) .\u00a0Sin\u00a0 embargo, \u00a0estos\u00a0estudios\u00a0no\u00a0han\u00a0sido\u00a0\nconfirmados\u00a0 y\u00a0han\u00a0 recibido\u00a0m\u00faltiples\u00a0 cr\u00edticas\u00a0relativas\u00a0a\u00a0la\u00a0metodolog\u00eda \u00a0\nempleada. \u00a0Por\u00a0otra\u00a0 parte,\u00a0el\u00a0empleo\u00a0de\u00a0CTC\u00a0se\u00a0les\u00a0considera \u00a0causantes \u00a0de\u00a0un\u00a0\nimportante \u00a0aumento\u00a0de\u00a0la\u00a0incidencia \u00a0de\u00a0complicaciones \u00a0del\u00a0tipo\u00a0hemorr\u00e1gico, \u00a0\ndigestivo, \u00a0e\u00a0infecciosas.\u00a0 No\u00a0obstante,\u00a0 persiste\u00a0hoy\u00a0en\u00a0d\u00eda\u00a0un\u00a0\u00e1rea\u00a0de\u00a0\nincertidumbre \u00a0en\u00a0el\u00a0empleo\u00a0de\u00a0esta\u00a0terapia\u00a0 en\u00a0lesionados \u00a0medulares \u00a0en\u00a0su\u00a0fase\u00a0\naguda.\u00a0As\u00ed,\u00a0el\u00a0grupo\u00a0de\u00a0Bracken\u00a0et\u00a0al\u00a0(47),\u00a0postula\u00a0que\u00a0\u00a0ante\u00a0la\u00a0ausencia\u00a0de\u00a0un\u00a0\naumento\u00a0significativo\u00a0 de\u00a0la\u00a0mortalidad\u00a0 y\u00a0de\u00a0morbilidad \u00a0en\u00a0los\u00a0pacientes \u00a0tratados\u00a0\ncon\u00a0MP,\u00a0 probablemente \u00a0sea\u00a0l\u00edcito\u00a0administrar \u00a0este\u00a0 tratamiento \u00a0a\u00a0los\u00a0pacientes \u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nII.\u2010\u00a0JUSTIFICACI\u00d3N\u00a0 DEL\u00a0ESTUDIO\u00a0E\u00a0\u00a0HIP\u00d3TESIS. \u00a0\n\u00a0\ncon\u00a0traumatismos \u00a0raqu\u00eddeos \u00a0y\u00a0LM,\u00a0en\u00a0las\u00a0primeras\u00a08\u00a0horas.\u00a0Proponen \u00a0la\u00a0siguiente\u00a0\nactitud\u00a0 terap\u00e9utica: \u00a0\u201cutilizaci\u00f3n \u00a0de\u00a0la\u00a0metilprednisolona \u00a0en\u00a0los\u00a0traumatismos \u00a0\nmedulares \u00a0cervicales, \u00a0teniendo\u00a0en\u00a0cuenta\u00a0el\u00a0importante \u00a0beneficio\u00a0de\u00a0cualquier\u00a0\nmejor\u00eda\u00a0neurol\u00f3gica\u00a0 respecto\u00a0a\u00a0las\u00a0minusval\u00edas \u00a0posteriores\u00a0 y\u00a0la\u00a0existencia \u00a0de\u00a0un\u00a0\u00a0\nbajo\u00a0riesgo\u00a0 infeccioso \u00a0debido\u00a0al\u00a0car\u00e1cter\u00a0generalmente \u00a0aislado\u00a0del\u00a0traumatismo \u00a0\nmedular\u00a0cervical,\u00a0y\u00a0un\u00a0empleo\u00a0mucho\u00a0m\u00e1s\u00a0restrictivo\u00a0 en\u00a0los\u00a0traumas\u00a0medulares \u00a0\ntoracolumbares \u00a0por\u00a0el\u00a0menor\u00a0impacto\u00a0de\u00a0la\u00a0mejor\u00eda\u00a0neurol\u00f3gica \u00a0sobre\u00a0las\u00a0\nminusval\u00edas \u00a0posteriores\u00a0 y\u00a0el\u00a0alto\u00a0riesgo\u00a0 infeccioso \u00a0debido\u00a0a\u00a0las\u00a0frecuentes \u00a0lesiones\u00a0\ntraum\u00e1ticas \u00a0asociadas, \u00a0especialmente \u00a0trauma\u00a0tor\u00e1cico\u201d .\u00a0La\u00a0utilizaci\u00f3n \u00a0de\u00a0CTC\u00a0en\u00a0\npacientes \u00a0politraumatizados \u00a0puede\u00a0conllevar\u00a0en\u00a0una\u00a0serie\u00a0de\u00a0circunstancias\u00a0 un\u00a0\naumento\u00a0de\u00a0la\u00a0mortalidad. \u00a0En\u00a0contraposici\u00f3n \u00a0a\u00a0esta\u00a0actitud,\u00a0la\u00a0\u00faltima\u00a0conferencia \u00a0\nde\u00a0expertos\u00a0de\u00a0la\u00a0Sociedad\u00a0 Francesa\u00a0de\u00a0Anestesiolog\u00eda \u00a0y\u00a0Reanimaci\u00f3n, \u00a0han\u00a0\nexcluido\u00a0 el\u00a0empleo\u00a0de\u00a0MP\u00a0en\u00a0el\u00a0paciente\u00a0con\u00a0trauma\u00a0 medular\u00a0(72).\u00a0\u00a0\n\u00a0\n\u00a0 51El\u00a0tratamiento \u00a0de\u00a0las\u00a0fracturas\u00a0vertebrales \u00a0de\u00a0etiolog\u00eda\u00a0traum\u00e1tica \u00a0es\u00a0una\u00a0\nde\u00a0las\u00a0\u00e1reas\u00a0de\u00a0mayor\u00a0 controversia \u00a0en\u00a0la\u00a0cirug\u00eda\u00a0de\u00a0columna\u00a0moderna\u00a0(73).\u00a0Existe\u00a0\ncontroversia \u00a0en\u00a0cuanto\u00a0a\u00a0los\u00a0beneficios, \u00a0desventajas \u00a0e\u00a0indicaciones \u00a0claras\u00a0del\u00a0\ntratamiento \u00a0conservador \u00a0frente\u00a0a\u00a0la\u00a0IQ.\u00a0El\u00a0tratamiento \u00a0conservador \u00a0con\u00a0\nreducci\u00f3n \u00a0postural\u00a0e\u00a0inmovilizaci\u00f3n \u00a0mediante \u00a0ortesis\u00a0ha\u00a0sido\u00a0 aplicado\u00a0por\u00a0en\u00a0\nalgunos\u00a0centros\u00a0desde\u00a0hace\u00a0 varias\u00a0d\u00e9cadas\u00a0(74,75) .\u00a0La\u00a0IQ\u00a0en\u00a0las\u00a0fracturas\u00a0\nvertebrales \u00a0con\u00a0 LM\u00a0ha\u00a0tenido\u00a0como\u00a0objetivos\u00a0principales, \u00a0la\u00a0descompresi\u00f3n \u00a0\nmedular\u00a0 para\u00a0disminuir \u00a0la\u00a0lesi\u00f3n\u00a0neurol\u00f3gica; \u00a0y\u00a0la\u00a0fijaci\u00f3n\u00a0de\u00a0la\u00a0fractura\u00a0vertebral\u00a0\ncon\u00a0 el\u00a0fin\u00a0de\u00a0facilitar\u00a0el\u00a0manejo\u00a0del\u00a0 enfermo,\u00a0disminuir \u00a0el\u00a0periodo\u00a0de\u00a0\nencamamiento \u00a0y\u00a0comenzar\u00a0 precozmente \u00a0el\u00a0proceso\u00a0de\u00a0rehabilitaci\u00f3n \u00a0funcional \u00a0\n(76).\u00a0El\u00a0acceso\u00a0posterior\u00a0es\u00a0el\u00a0que\u00a0m\u00e1s\u00a0se\u00a0suele\u00a0utilizar\u00a0para\u00a0el\u00a0tratamiento \u00a0\nurgente\u00a0de\u00a0las\u00a0lesiones\u00a0de\u00a0la\u00a0columna\u00a0dorsal\u00a0y\u00a0lumbar.\u00a0La\u00a0v\u00eda\u00a0de\u00a0acceso\u00a0anterior\u00a0\nes\u00a0m\u00e1s\u00a0empleada \u00a0en\u00a0las\u00a0lesiones\u00a0a\u00a0nivel\u00a0cervical.\u00a0La\u00a0laminectom\u00eda\u00a0 para\u00a0\ndescomprimir \u00a0la\u00a0m\u00e9dula\u00a0parte\u00a0del\u00a0supuesto\u00a0de\u00a0que\u00a0si\u00a0la\u00a0LM\u00a0se\u00a0ha\u00a0producido \u00a0por\u00a0\ncompresi\u00f3n \u00a0de\u00a0la\u00a0m\u00e9dula\u00a0al\u00a0luxarse\u00a0o\u00a0fracturarse \u00a0los\u00a0distintos\u00a0elementos \u00a0del\u00a0\nestuche\u00a0que\u00a0la\u00a0envuelve, \u00a0su\u00a0liberaci\u00f3n \u00a0ser\u00e1\u00a0el\u00a0\u00fanico\u00a0medio\u00a0de\u00a0disminuir \u00a0el\u00a0da\u00f1o.\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nII.\u2010\u00a0JUSTIFICACI\u00d3N\u00a0 DEL\u00a0ESTUDIO\u00a0E\u00a0\u00a0HIP\u00d3TESIS. \u00a0\n\u00a0\nAutores\u00a0como\u00a0B\u00f6tel\u00a0 (77)\u00a0y\u00a0McAfee\u00a0(78)\u00a0recomiendan\u00a0 la\u00a0descompresi\u00f3n \u00a0\nquir\u00fargica,\u00a0 tras\u00a0hallar\u00a0mejor\u00eda\u00a0neurol\u00f3gica \u00a0en\u00a050%\u00a0de\u00a0las\u00a0lesiones\u00a0incompletas\u00a0\nintervenidas \u00a0y\u00a0un\u00a0\u00a0incremento \u00a0en\u00a0la\u00a0potencia\u00a0motora.\u00a0En\u00a0estudios\u00a0prospectivos \u00a0\nsobre\u00a0la\u00a0eficacia\u00a0de\u00a0la\u00a0cirug\u00eda\u00a0descompresiva \u00a0en\u00a0lesiones\u00a0medulares \u00a0en\u00a0humanos, \u00a0\nno\u00a0hay\u00a0datos\u00a0 concluyentes \u00a0a\u00a0favor\u00a0del\u00a0 tratamiento \u00a0quir\u00fargico \u00a0sobre\u00a0el\u00a0\nconservador, \u00a0ni\u00a0sobre\u00a0el\u00a0momento \u00a0m\u00e1s\u00a0adecuado \u00a0para\u00a0la\u00a0intervenci\u00f3n. \u00a0La\u00a0actitud\u00a0\nmayoritaria\u00a0 de\u00a0los\u00a0diferentes \u00a0grupos\u00a0 de\u00a0trabajo\u00a0es\u00a0que\u00a0si\u00a0la\u00a0LM\u00a0es\u00a0incompleta \u00a0o\u00a0\nse\u00a0percibe\u00a0un\u00a0agravamiento \u00a0progresivo\u00a0 en\u00a0las\u00a0primeras\u00a0horas,\u00a0la\u00a0mayor\u00eda\u00a0 de\u00a0los\u00a0\nequipos\u00a0consideran\u00a0 que\u00a0se\u00a0trata\u00a0de\u00a0una\u00a0urgencia\u00a0 quir\u00fargica. \u00a0Por\u00a0el\u00a0contrario, \u00a0\nexiste\u00a0pol\u00e9mica\u00a0 respecto\u00a0 a\u00a0la\u00a0actitud\u00a0quir\u00fargica \u00a0de\u00a0entrada\u00a0 en\u00a0las\u00a0lesiones\u00a0\nmedulares \u00a0completas \u00a0(69).\u00a0La\u00a0cirug\u00eda\u00a0se\u00a0asocia\u00a0a\u00a0una\u00a0mortalidad\u00a0 perioperatoria \u00a0\nbaja\u00a0\u00a0y\u00a0que\u00a0parece\u00a0l\u00f3gica\u00a0 si\u00a0se\u00a0inicia\u00a0y/o\u00a0asocia\u00a0a\u00a0un\u00a0tratamiento \u00a0farmacol\u00f3gico \u00a0\n(79,80) .\u00a0En\u00a0el\u00a0metaan\u00e1lisis \u00a0realizado\u00a0en\u00a0el\u00a02001\u00a0por\u00a0Fehlings\u00a0et\u00a0al\u00a0(121) ,\u00a0se\u00a0\nconcluye\u00a0que,\u00a0aunque\u00a0hay\u00a0evidencia \u00a0en\u00a0la\u00a0experimentaci\u00f3n \u00a0animal\u00a0de\u00a0la\u00a0eficacia\u00a0\nde\u00a0la\u00a0descompresi\u00f3n\u00a0 medular\u00a0 para\u00a0 la\u00a0mejor\u00eda\u00a0neurol\u00f3gica, \u00a0esto\u00a0no\u00a0ha\u00a0sido\u00a0\ncomprobado\u00a0 en\u00a0el\u00a0hombre.\u00a0Tampoco \u00a0se\u00a0conoce\u00a0el\u00a0momento \u00a0en\u00a0el\u00a0que\u00a0se\u00a0debe\u00a0\nhacer\u00a0la\u00a0descompresi\u00f3n, \u00a0aunque\u00a0se\u00a0suponga\u00a0que\u00a0debe\u00a0ser\u00a0precoz\u00a0si\u00a0se\u00a0tiene\u00a0en\u00a0\ncuenta\u00a0que\u00a0el\u00a0tratamiento \u00a0m\u00e9dico\u00a0con\u00a0MP\u00a0s\u00f3lo\u00a0es\u00a0eficaz\u00a0en\u00a0las\u00a0primeras\u00a08\u00a0horas\u00a0\ndespu\u00e9s\u00a0del\u00a0accidente, \u00a0antes\u00a0de\u00a0que\u00a0se\u00a0produzca\u00a0 la\u00a0cascada\u00a0de\u00a0alteraciones \u00a0\nbioqu\u00edmicas \u00a0y\u00a0vasculares \u00a0que\u00a0dan\u00a0lugar\u00a0a\u00a0la\u00a0LS.\u00a0\n\u00a0\n\u00a0 52Los\u00a0estudios\u00a0sobre\u00a0tratamiento \u00a0con\u00a0MP\u00a0y\u00a0de\u00a0descompresi\u00f3n \u00a0quir\u00fargica \u00a0\npublicados \u00a0se\u00a0limitan\u00a0 a\u00a0un\u00a0bajo\u00a0grado\u00a0de\u00a0evidencia,\u00a0 por\u00a0lo\u00a0que\u00a0se\u00a0requiere\u00a0\nestudios\u00a0aleatorizados \u00a0prospectivos \u00a0que\u00a0aporten\u00a0mayor\u00a0luz\u00a0sobre\u00a0este\u00a0tema.\u00a0Los\u00a0\nfracasos\u00a0de\u00a0la\u00a0aplicaci\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0los\u00a0resultados \u00a0de\u00a0las\u00a0investigaciones \u00a0\nexperimentales \u00a0resaltan\u00a0la\u00a0dificultad \u00a0de\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0diversos\u00a0ensayos\u00a0cl\u00ednicos\u00a0\nen\u00a0los\u00a0traumatismos \u00a0medulares. \u00a0Los\u00a0estudios\u00a0aleatorizados\u00a0 no\u00a0son\u00a0posibles\u00a0por\u00a0el\u00a0\nescaso\u00a0n\u00famero\u00a0de\u00a0pacientes \u00a0con\u00a0caracter\u00edsticas \u00a0similares\u00a0dada\u00a0la\u00a0gran\u00a0\nheterogeneidad \u00a0de\u00a0estos\u00a0pacientes \u00a0en\u00a0cada\u00a0centro;\u00a0por\u00a0motivos\u00a0\u00e9ticos,\u00a0y\u00a0por\u00a0la\u00a0\nespecializaci\u00f3n \u00a0de\u00a0cada\u00a0cirujano\u00a0en\u00a0una\u00a0t\u00e9cnica\u00a0concreta. \u00a0\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nII.\u2010\u00a0JUSTIFICACI\u00d3N\u00a0 DEL\u00a0ESTUDIO\u00a0E\u00a0\u00a0HIP\u00d3TESIS. \u00a0\n\u00a0 53\u00a0\nLos\u00a0estudios\u00a0prospectivos \u00a0no\u00a0aleatorizados\u00a0 (estudios\u00a0de\u00a0cohortes) \u00a0no\u00a0se\u00a0\npueden\u00a0 realizar\u00a0 por\u00a0la\u00a0falta\u00a0de\u00a0uniformidad \u00a0en\u00a0la\u00a0actuaci\u00f3n\u00a0 ante\u00a0el\u00a0lesionado \u00a0\nmedular\u00a0 y\u00a0la\u00a0falta\u00a0de\u00a0protocolos \u00a0tanto\u00a0a\u00a0nivel\u00a0diagn\u00f3stico\u00a0 como\u00a0terap\u00e9utico. \u00a0\u00a0\n\u00a0\nPor\u00a0ello,\u00a0 hemos\u00a0realizado\u00a0un\u00a0estudio\u00a0retrospectivo \u00a0para\u00a0describir\u00a0los\u00a0\nresultados \u00a0obtenidos \u00a0en\u00a0nuestra\u00a0Unidad\u00a0 de\u00a0Reanimaci\u00f3n \u00a0Polivalente \u00a0durante\u00a0los\u00a0\n\u00faltimos\u00a012\u00a0a\u00f1os,\u00a0para\u00a0poder\u00a0 dise\u00f1ar\u00a0protocolos \u00a0de\u00a0actuaci\u00f3n\u00a0 y\u00a0realizar\u00a0un\u00a0estudio\u00a0\nprospectivo \u00a0comparativo \u00a0entre\u00a0 los\u00a0tratamientos \u00a0con\u00a0megadosis \u00a0de\u00a0MP\u00a0seg\u00fan\u00a0los\u00a0\nestudios\u00a0NASCIS\u00a0y\u00a0del\u00a0\u00a0tratamiento \u00a0conservador \u00a0respecto\u00a0a\u00a0la\u00a0IQ.\u00a0\n\u00a0\n2.2. HIP\u00d3TESIS \u00a0Y\u00a0OBJETIVOS \u00a0\n\u00a0\nObjetivo\u00a0 principal: \u00a0\nComparar\u00a0 los\u00a0resultados \u00a0de\u00a0tratar\u00a0o\u00a0no\u00a0con\u00a0 altas\u00a0dosis\u00a0de\u00a0MP\u00a0en\u00a0el\u00a0\nperiodo\u00a0agudo\u00a0seg\u00fan\u00a0protocolo\u00a0 NASCIS\u00a0II\u00a0en\u00a0pacientes \u00a0con\u00a0 LMA\u00a0con\u00a0d\u00e9ficit\u00a0\nneurol\u00f3gico \u00a0en\u00a0t\u00e9rminos\u00a0de:\u00a0\n1) Recuperaci\u00f3n \u00a0neurol\u00f3gica. \u00a0\n2) Frecuencia \u00a0de\u00a0aparici\u00f3n \u00a0de\u00a0complicaciones\u00a0 m\u00e9dicas.\u00a0\n3) Periodo\u00a0de\u00a0hospitalizaci\u00f3n \u00a0en\u00a0la\u00a0Unidad\u00a0 Reanimaci\u00f3n.\u00a0\n\u00a0Objetivos \u00a0secundarios: \u00a0\n1) Evaluar\u00a0el\u00a0beneficio \u00a0del\u00a0 tratamiento \u00a0conservador \u00a0respecto\u00a0al\u00a0\nquir\u00fargico \u00a0en\u00a0pacientes \u00a0con\u00a0\u00a0LMAT \u00a0y\u00a0su\u00a0beneficio\u00a0 en\u00a0la\u00a0recuperaci\u00f3n \u00a0\ndel\u00a0d\u00e9ficit\u00a0 neurol\u00f3gico. \u00a0\n2) Evaluar\u00a0la\u00a0epidemiolog\u00eda \u00a0de\u00a0la\u00a0LMAT\u00a0en\u00a0nuestra\u00a0\u00e1rea\u00a0asistencial. \u00a0\n3) Evaluar\u00a0los\u00a0traumas\u00a0acompa\u00f1antes \u00a0a\u00a0la\u00a0LMAT.\u00a0\n4) Identificar \u00a0factores\u00a0cl\u00ednicos\u00a0y\u00a0epidemiol\u00f3gicos \u00a0relacionados \u00a0con\u00a0 la\u00a0\nexistencia \u00a0de\u00a0lesiones\u00a0inadvertidas \u00a0y\u00a0su\u00a0impacto\u00a0en\u00a0la\u00a0\nmorbimortalidad.\u00a0\n5) Identificar \u00a0factores\u00a0cl\u00ednicos\u00a0y\u00a0epidemiol\u00f3gicos \u00a0para\u00a0la\u00a0mortalidad.IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS \u00a0\n\u00a0 54\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n3.1. \u00c1MBITO\u00a0DE\u00a0ESTUDIO\u00a0\n\u00a0\nLa\u00a0presente\u00a0investigaci\u00f3n \u00a0se\u00a0ha\u00a0realizado\u00a0en\u00a0la\u00a0Unidad\u00a0 de\u00a0Cuidados\u00a0\nCr\u00edticos\u00a0y\u00a0Medicina \u00a0de\u00a0Emergencias \u00a0del\u00a0Servicio\u00a0de\u00a0Anestesiolog\u00eda \u00a0y\u00a0Reanimaci\u00f3n \u00a0\ndel\u00a0Hospital\u00a0General\u00a0de\u00a0Albacete\u00a0(HGA).\u00a0\n\u00a0\n\u00a0\n\u00a0\n3.2. CARACTER\u00cdSTICAS \u00a0DEL\u00a0COMPLEJO \u00a0HOSPITALARIO \u00a0DE\u00a0ALBACETE \u00a0\n\u00a0El\u00a0Complejo \u00a0Hospitalario \u00a0Universitario \u00a0de\u00a0Albacete\u00a0(CHUA)\u00a0 es\u00a0un\u00a0centro\u00a0\nasistencial \u00a0del\u00a0 Sistema\u00a0Nacional\u00a0de\u00a0Salud\u00a0de\u00a0tercer\u00a0nivel\u00a0con\u00a0 acreditaci\u00f3n \u00a0\ndocente,\u00a0constituido \u00a0por\u00a0el\u00a0Hospital\u00a0General\u00a0de\u00a0Albacete\u00a0(HGA),\u00a0 el\u00a0Hospital\u00a0\nNuestra\u00a0 Se\u00f1ora\u00a0 del\u00a0Perpetuo \u00a0Socorro\u00a0(HNPS)\u00a0y\u00a0los\u00a0Hospitales \u00a0Generales \u00a0de\u00a0\nAlmansa\u00a0y\u00a0Villarrobledo,\u00a0 perteneciente \u00a0al\u00a0Servicio\u00a0Sanitario\u00a0de\u00a0Castilla\u00a0la\u00a0Mancha\u00a0\n(SESCAM), \u00a0con\u00a0906\u00a0camas\u00a0y\u00a025\u00a0quir\u00f3fanos \u00a0seg\u00fan\u00a0 el\u00a0Contrato\u00a0Gesti\u00f3n\u00a0 del\u00a02007.\u00a0La\u00a0\npoblaci\u00f3n \u00a0asignada\u00a0a\u00a0dicho\u00a0complejo \u00a0es\u00a0de\u00a0aproximadamente \u00a0450000\u00a0\nhabitantes. \u00a0En\u00a0el\u00a0momento \u00a0actual,\u00a0el\u00a0n\u00famero\u00a0de\u00a0camas\u00a0de\u00a0Cuidados\u00a0 Cr\u00edticos\u00a0\nasignadas\u00a0 al\u00a0Servicio\u00a0de\u00a0Anestesiolog\u00eda \u2010Reanimaci\u00f3n\u00a0 en\u00a0todo\u00a0el\u00a0Complejo \u00a0\nHospitalario \u00a0es\u00a0de\u00a015,\u00a0aunque\u00a0en\u00a0el\u00a0inicio\u00a0del\u00a0periodo\u00a0de\u00a0estudio\u00a0 el\u00a0n\u00famero\u00a0de\u00a0\ncamas\u00a0era\u00a0de\u00a0siete.\u00a0\n\u00a0\nEl\u00a0CHUA\u00a0constituye \u00a0la\u00a0c\u00faspide\u00a0de\u00a0la\u00a0Atenci\u00f3n\u00a0Especializada \u00a0de\u00a0Albacete, \u00a0\nsiendo\u00a0el\u00a0centro\u00a0de\u00a0referencia \u00a0para\u00a0el\u00a0Hospital\u00a0Comarcal\u00a0 de\u00a0Hell\u00edn\u00a0y\u00a0para\u00a0las\u00a035\u00a0\nzonas\u00a0 b\u00e1sicas\u00a0de\u00a0Salud\u00a0que\u00a0conforman\u00a0 el\u00a0\u00c1rea\u00a0Sanitaria\u00a0I\u00a0de\u00a0Castilla\u00a0la\u00a0Mancha,\u00a0\nas\u00ed\u00a0como\u00a0centro\u00a0de\u00a0referencia \u00a0para\u00a0los\u00a0Servicios\u00a0 de\u00a0Neurocirug\u00eda,\u00a0 Cirug\u00eda\u00a0\nPedi\u00e1trica, \u00a0Cirug\u00eda\u00a0Tor\u00e1cica,\u00a0Cirug\u00eda\u00a0Pl\u00e1stica\u00a0 y\u00a0Maxilofacial, \u00a0Radiolog\u00eda \u00a0\nIntervencionista, \u00a0y\u00a0Litotricia.\u00a0 Tambi\u00e9n\u00a0 se\u00a0atienden\u00a0 pacientes \u00a0de\u00a0Angiolog\u00eda \u00a0y\u00a0\nCirug\u00eda\u00a0Vascular\u00a0de\u00a0Cuenca\u00a0 y\u00a0Ciudad\u00a0Real.\u00a0\u00a0\n\u00a0 55\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n3.3. SELECCI\u00d3N \u00a0DE\u00a0LA\u00a0COHORTE \u00a0Y\u00a0CARACTER\u00cdSTICAS \u00a0DE\u00a0LA\u00a0UNIDAD\u00a0\nDE\u00a0REANIMACI\u00d3N \u00a0\n\u00a0\nLa\u00a0actividad\u00a0asistencial \u00a0de\u00a0la\u00a0UR\u00a0desde\u00a01/01/1996 \u00a0al\u00a031/12/2007 \u00a0ha\u00a0sido\u00a0\nde\u00a07951\u00a0ingresos,\u00a0lo\u00a0que\u00a0origin\u00f3\u00a027380\u00a0estancias, \u00a0con\u00a0una\u00a0media\u00a0de\u00a02489\u00a0\nestancias \u00a0anuales.\u00a0 Las\u00a0camas\u00a0que\u00a0contaba\u00a0la\u00a0Unidad\u00a0 en\u00a0el\u00a0periodo\u00a0de\u00a0estudio,\u00a0\nestuvieron \u00a0destinadas \u00a0fundamentalmente \u00a0a\u00a0la\u00a0atenci\u00f3n\u00a0de\u00a0pacientes \u00a0\nposquir\u00fargicos \u00a0y\u00a0politraumatizados, \u00a0y\u00a0en\u00a0mucha\u00a0menor\u00a0medida\u00a0a\u00a0patolog\u00edas \u00a0\nm\u00e9dicas.\u00a0\u00a0\n\u00a0\nLa\u00a0estancia\u00a0media\u00a0 en\u00a0la\u00a0UR\u00a0fue\u00a0de\u00a03,44\u00a0d\u00edas,\u00a0el\u00a0porcentaje \u00a0o\u00a0\u00edndice\u00a0de\u00a0\nocupaci\u00f3n \u00a0de\u00a086,67%\u00a0con\u00a0 un\u00a0\u00edndice\u00a0de\u00a0rotaci\u00f3n\u00a0enfermo\u2010cama\u00a0de\u00a023,57,\u00a0la\u00a0\npresi\u00f3n\u00a0 de\u00a0urgencias \u00a0de\u00a023,48%,\u00a0 el\u00a0porcentaje \u00a0de\u00a0mortalidad\u00a0 de\u00a012,76%\u00a0 y\u00a0el\u00a0\nporcentaje \u00a0de\u00a0necropsias \u00a0de\u00a01,14%.\u00a0\u00a0\n\u00a0\u00a0\n3.3.1.  Dise\u00f1o\u00a0del\u00a0estudio\u00a0\n\u00a0 56Estudio\u00a0retrospectivo \u00a0con\u00a0 periodos\u00a0de\u00a0seguimiento \u00a0variables\u00a0en\u00a0funci\u00f3n\u00a0\nde\u00a0la\u00a0estancia\u00a0del\u00a0paciente. \u00a0El\u00a0objetivo\u00a0 inicial\u00a0de\u00a0la\u00a0evaluaci\u00f3n \u00a0del\u00a0paciente\u00a0\ntraumatizado \u00a0consisti\u00f3\u00a0 en\u00a0identificar \u00a0y\u00a0tratar\u00a0 cualquier\u00a0 lesi\u00f3n\u00a0potencialmente \u00a0\nmortal.\u00a0Se\u00a0realiz\u00f3\u00a0de\u00a0forma\u00a0sistem\u00e1tica \u00a0una\u00a0valoraci\u00f3n \u00a0inicial\u00a0(A,\u00a0B,\u00a0C,\u00a0D)\u00a0para\u00a0\nestablecer \u00a0un\u00a0control\u00a0de\u00a0las\u00a0v\u00edas\u00a0respiratorias, \u00a0ventilaci\u00f3n \u00a0y\u00a0circulaci\u00f3n. \u00a0\nPosteriormente, \u00a0tras\u00a0la\u00a0evaluaci\u00f3n \u00a0y\u00a0estabilizaci\u00f3n \u00a0del\u00a0paciente\u00a0se\u00a0inici\u00f3\u00a0una\u00a0\nexhaustiva \u00a0valoraci\u00f3n \u00a0secundaria \u00a0por\u00a0aparatos\u00a0y\u00a0diversas\u00a0pruebas\u00a0de\u00a0imagen\u00a0\nseg\u00fan\u00a0la\u00a0situaci\u00f3n\u00a0cl\u00ednica\u00a0del\u00a0paciente\u00a0traumatizado.\u00a0 En\u00a0el\u00a0Anexo\u00a0I\u00a0se\u00a0puede\u00a0\nconsultar \u00a0el\u00a0protocolo\u00a0 de\u00a0actuaci\u00f3n \u00a0del\u00a0paciente\u00a0politraumatizado, \u00a0as\u00ed\u00a0como\u00a0el\u00a0\nprotocolo \u00a0de\u00a0actuaci\u00f3n \u00a0para\u00a0el\u00a0estudio\u00a0radiol\u00f3gico \u00a0de\u00a0la\u00a0columna\u00a0cervical\u00a0y\u00a0\ndorsolumbar \u00a0de\u00a0la\u00a0UR\u00a0(Anexo\u00a0II).\u00a0El\u00a0seguimiento \u00a0se\u00a0realiz\u00f3\u00a0en\u00a0el\u00a0contexto\u00a0 de\u00a0un\u00a0\nsistema\u00a0de\u00a0vigilancia\u00a0epidemiol\u00f3gico,\u00a0 que\u00a0diariamente \u00a0revisaba\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0\nde\u00a0todos\u00a0los\u00a0pacientes \u00a0admitidos \u00a0en\u00a0la\u00a0Unidad\u00a0 con\u00a0estancia\u00a0superior\u00a0a\u00a0las\u00a048\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nhoras\u00a0y\u00a0hasta\u00a048\u00a0horas\u00a0tras\u00a0ser\u00a0dados\u00a0de\u00a0alta,\u00a0 junto\u00a0 a\u00a0la\u00a0hoja\u00a0de\u00a0diario\u00a0m\u00e9dico\u00a0\nrealizada\u00a0 por\u00a0los\u00a0facultativos \u00a0especialistas \u00a0de\u00a0\u00e1rea\u00a0del\u00a0Servicio\u00a0de\u00a0Anestesiolog\u00eda \u00a0\ny\u00a0Reanimaci\u00f3n. \u00a0Se\u00a0cumpliment\u00f3 \u00a0en\u00a0todos\u00a0ellos\u00a0las\u00a0hojas\u00a0de\u00a0Valoraci\u00f3n \u00a0y\u00a0\nSeguimiento \u00a0del\u00a0Paciente\u00a0Politraumatizado\u00a0 y\u00a0la\u00a0de\u00a0Vigilancia \u00a0Epidemiol\u00f3gica \u00a0\u00a0\nseg\u00fan\u00a0protocolos \u00a0aprobados\u00a0 por\u00a0\u201clas\u00a0Comisiones \u00a0de\u00a0Infecciones \u00a0y\u00a0de\u00a0Calidad\u00a0\nAsistencial \u201d\u00a0del\u00a0 Hospital\u00a0y\u00a0de\u00a0acuerdo\u00a0con\u00a0 el\u00a0Servicio\u00a0de\u00a0Anestesiolog\u00eda \u00a0y\u00a0\nReanimaci\u00f3n.\u00a0\n\u00a0Los\u00a0datos\u00a0analizados \u00a0en\u00a0este\u00a0trabajo,\u00a0fueron\u00a0recogidos \u00a0por\u00a0los\u00a0m\u00e9dicos\u00a0\nanestesi\u00f3logos \u00a0responsables \u00a0de\u00a0la\u00a0UR\u00a0y\u00a0el\u00a0Equipo\u00a0de\u00a0Vigilancia \u00a0Epidemiol\u00f3gica \u00a0de\u00a0\nla\u00a0IN\u00a0de\u00a0la\u00a0Unidad\u00a0 de\u00a0Medicina \u00a0Preventiva \u00a0del\u00a0Hospital,\u00a0teniendo\u00a0 en\u00a0cuenta\u00a0la\u00a0\ninformaci\u00f3n \u00a0proporcionada \u00a0por\u00a0los\u00a0laboratorio \u00a0de\u00a0hematolog\u00eda,\u00a0 bioqu\u00edmica \u00a0y\u00a0\nmicrobiolog\u00eda,\u00a0 con\u00a0 revisi\u00f3n\u00a0diaria\u00a0de\u00a0los\u00a0mismos\u00a0y\u00a0por\u00a0las\u00a0visitas\u00a0 a\u00a0la\u00a0UR\u00a0con\u00a0\nexamen\u00a0de\u00a0las\u00a0historias\u00a0cl\u00ednicas\u00a0 y\u00a0observaci\u00f3n\u00a0 directa\u00a0 del\u00a0paciente\u00a0(Anexo\u00a0III).\u00a0Los\u00a0\ncriterios\u00a0de\u00a0IN\u00a0utilizados \u00a0fueron\u00a0los\u00a0definidos \u00a0por\u00a0el\u00a0CDC\u00a0en\u00a01988\n\u00a0(Anexo\u00a0IV).\u00a0Si\u00a0la\u00a0\nrecogida\u00a0de\u00a0informaci\u00f3n \u00a0de\u00a0la\u00a0Historia\u00a0Cl\u00ednica\u00a0planteaba \u00a0dudas\u00a0 respecto\u00a0al\u00a0origen\u00a0\no\u00a0localizaci\u00f3n \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0se\u00a0realizaba\u00a0consulta\u00a0al\u00a0personal\u00a0facultativo\u00a0 y\u00a0de\u00a0\nenfermer\u00eda \u00a0que\u00a0atend\u00eda\u00a0al\u00a0enfermo. \u00a0\n\u00a0\u00a0\n3.3.2.  Poblaci\u00f3n \u00a0de\u00a0referencia \u00a0y\u00a0periodo\u00a0de\u00a0estudio\u00a0\nSe\u00a0considero \u00a0como\u00a0tal\u00a0la\u00a0formada\u00a0por\u00a0todos\u00a0los\u00a0pacientes \u00a0ingresados \u00a0en\u00a0la\u00a0\nUR\u00a0del\u00a0HGA\u00a0 durante\u00a0el\u00a0periodo\u00a0del\u00a01/01/1996 \u00a0a\u00a031/12/2007. \u00a0\n\u00a0\u00a0\n3.3.3.  Poblaci\u00f3n \u00a0elegible\u00a0\n\u00a0 57Constituida \u00a0por\u00a0todos\u00a0aquellos\u00a0 pacientes \u00a0ingresados \u00a0en\u00a0la\u00a0Unidad\u00a0durante\u00a0\nel\u00a0periodo\u00a0de\u00a0\u00a0estudio\u00a0que\u00a0presentaban\u00a0 como\u00a0diagn\u00f3stico\u00a0 de\u00a0ingreso\u00a0una\u00a0LMAT,\u00a0\ny\u00a0aquellos\u00a0 que\u00a0durante\u00a0su\u00a0estancia\u00a0en\u00a0la\u00a0Unidad\u00a0 se\u00a0demostr\u00f3 \u00a0la\u00a0existencia \u00a0de\u00a0\ndicha\u00a0LM.\u00a0Los\u00a0sujetos\u00a0 deb\u00edan\u00a0cumplir\u00a0el\u00a0criterio\u00a0de\u00a0inclusi\u00f3n\u00a0de\u00a0permanecer \u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\ningresados \u00a0en\u00a0la\u00a0UR\u00a0al\u00a0menos\u00a048\u00a0horas.\u00a0No\u00a0hubo\u00a0ning\u00fan\u00a0otro\u00a0criterio\u00a0para\u00a0excluir\u00a0\na\u00a0los\u00a0pacientes.\u00a0 As\u00ed,\u00a0todos\u00a0los\u00a0pacientes \u00a0con\u00a0estancia\u00a0superior\u00a0a\u00a048\u00a0horas\u00a0fueron\u00a0\nincluidos\u00a0en\u00a0\u00a0el\u00a0estudio.\u00a0\n\u00a0\n\u00a0\n3.3.4.  Poblaci\u00f3n \u00a0de\u00a0estudio\u00a0\nQuedo\u00a0configurada \u00a0por\u00a0los\u00a096\u00a0pacientes \u00a0pertenecientes \u00a0a\u00a0la\u00a0poblaci\u00f3n \u00a0\nelegible.\u00a0\n\u00a0\n\u00a0\n3.4. VARIABLES \u00a0RECOGIDAS.\u00a0 DEFINICI\u00d3N \u00a0Y\u00a0MEDIDA\u00a0\n\u00a0\n3.4.1.  Variables \u00a0con\u00a0informaci\u00f3n \u00a0demogr\u00e1fico \u2010administrativa \u00a0\n\u00a0\nEdad:\u00a0Variable\u00a0cuantitativa. \u00a0N\u00famero\u00a0de\u00a0a\u00f1os\u00a0completos \u00a0que\u00a0tiene\u00a0el\u00a0paciente\u00a0\nen\u00a0el\u00a0momento \u00a0de\u00a0su\u00a0ingreso\u00a0al\u00a0hospital.\u00a0\n\u00a0\nSexo:\u00a0Variable\u00a0cualitativa \u00a0dicot\u00f3mica, \u00a0varones\u00a0y\u00a0mujeres.\u00a0\n\u00a0Nacionalidad \u00a0espa\u00f1ola: \u00a0\u00a0\u00a0Variable \u00a0cualitativa\u00a0 dicot\u00f3mica, \u00a0si\u00a0o\u00a0no.\u00a0\n\u00a0Nacionalidad: \u00a0Variable\u00a0cualitativa\u00a0 con\u00a0cinco\u00a0categor\u00edas,\u00a0 en\u00a0funci\u00f3n\u00a0del\u00a0\ncontinente \u00a0de\u00a0procedencia. \u00a0\n\u00a0\nUrgencia: \u00a0Variable\u00a0cualitativa,\u00a0 hace\u00a0 referencia \u00a0a\u00a0si\u00a0el\u00a0ingreso\u00a0en\u00a0la\u00a0UR\u00a0es\u00a0\nurgente\u00a0o\u00a0programado. \u00a0\u00a0\n\u00a0Fecha\u00a0y\u00a0A\u00f1o\u00a0Reanimaci\u00f3n: \u00a0Fecha\u00a0 de\u00a0ingreso\u00a0en\u00a0UR.\u00a0\n\u00a0\n\u00a0 58Motivo\u00a0de\u00a0Alta:\u00a0\u00a0Variable\u00a0cualitativa\u00a0 con\u00a0 cuatro\u00a0categor\u00edas,\u00a0 alta\u00a0domiciliaria, \u00a0\ntraslado\u00a0a\u00a0otro\u00a0hospital,\u00a0alta\u00a0voluntaria \u00a0y\u00a0exitus.\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nExitus\u00a0Letal:\u00a0Variable\u00a0cualitativa\u00a0 con\u00a0dos\u00a0categor\u00edas,\u00a0 exitus\u00a0 letal\u00a0en\u00a0el\u00a0curso\u00a0de\u00a0\nla\u00a0hospitalizaci\u00f3n \u00a0o\u00a0no\u00a0exitus\u00a0letal.\u00a0\n\u00a0\nEstancia\u00a0 Hospitalaria \u00a0total:\u00a0Variable\u00a0cuantitativa. \u00a0D\u00edas\u00a0transcurridos \u00a0desde\u00a0la\u00a0\nfecha\u00a0 de\u00a0ingreso\u00a0hasta\u00a0la\u00a0fecha\u00a0 de\u00a0alta.\u00a0\n\u00a0Estancia\u00a0 Unidad\u00a0de\u00a0Reanimaci\u00f3n: \u00a0Variable\u00a0cuantitativa. \u00a0D\u00edas\u00a0transcurridos \u00a0desde\u00a0\nla\u00a0fecha\u00a0 de\u00a0ingreso\u00a0en\u00a0UR\u00a0hasta\u00a0la\u00a0fecha\u00a0 de\u00a0\nalta.\u00a0\n\u00a0Destino\u00a0al\u00a0Alta:\u00a0Variable\u00a0cualitativa. \u00a0Provincia\u00a0a\u00a0la\u00a0que\u00a0se\u00a0deriva\u00a0el\u00a0paciente\u00a0tras\u00a0\nel\u00a0alta\u00a0de\u00a0la\u00a0UR.\u00a0\n\u00a0\n\u00a0\n3.4.2.  Variables \u00a0que\u00a0aportan\u00a0informaci\u00f3n \u00a0relacionada\u00a0 con\u00a0la\u00a0lesi\u00f3n\u00a0\nmedular\u00a0aguda\u00a0traum\u00e1tica \u00a0\n\u00a0\nTipo\u00a0de\u00a0trauma:\u00a0Variable\u00a0cualitativa. \u00a0Mecanismo \u00a0de\u00a0producci\u00f3n \u00a0del\u00a0\ntrauma.\u00a0Se\u00a0clasifica\u00a0en\u00a0diez\u00a0las\u00a0causas\u00a0desencadenantes \u00a0del\u00a0trauma\u00a0 medular.\u00a0\n\u00a01. Accidente \u00a0laboral.\u00a0\n2. Accidente \u00a0de\u00a0tr\u00e1fico\u00a0por\u00a0coche.\u00a0\n3. Accidente \u00a0tr\u00e1fico\u00a0por\u00a0quad.\u00a0\n4. Accidente \u00a0tr\u00e1fico\u00a0por\u00a0cami\u00f3n.\u00a0\n5. Accidente \u00a0tr\u00e1fico\u00a0por\u00a0motocicleta. \u00a0\n6. Intento\u00a0de\u00a0Autolisis.\u00a0\n7. Accidente \u00a0dom\u00e9stico.\u00a0\n8. Aplastamiento. \u00a0\n9. Atropello. \u00a0\n10. Arma\u00a0de\u00a0fuego.\u00a0\n\u00a0\n\u00a0 59\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nTraumas\u00a0Acompa\u00f1antes: \u00a0Variable\u00a0dicot\u00f3mica\u00a0 para\u00a0la\u00a0presencia \u00a0o\u00a0\nausencia\u00a0de\u00a0diversos\u00a0traumatismos \u00a0acompa\u00f1antes. \u00a0\n\u00a01. Trauma\u00a0 Craneoencef\u00e1lico.\u00a0\n2. Trauma\u00a0 Tor\u00e1cico.\u00a0\n3. Trauma\u00a0 Abdominal. \u00a0\n4. Trauma\u00a0 Esquel\u00e9tico.\u00a0\n5. Trauma\u00a0 Vascular.\u00a0\n6. Trauma\u00a0 Maxilofacial. \u00a0\n\u00a0Diagn\u00f3stico: \u00a0Variable\u00a0cualitativa \u00a0que\u00a0nos\u00a0expresa\u00a0como\u00a0se\u00a0realiza\u00a0el\u00a0\ndiagn\u00f3stico\u00a0 de\u00a0sospecha \u00a0de\u00a0la\u00a0presencia \u00a0de\u00a0LMAT,\u00a0presentando \u00a0las\u00a0opciones\u00a0 de\u00a0\nsospecha \u00a0cl\u00ednica,\u00a0sospecha \u00a0por\u00a0radiolog\u00eda \u00a0convencional \u00a0o\u00a0por\u00a0TAC.\u00a0\n\u00a0\nFallo\u00a0en\u00a0el\u00a0diagn\u00f3stico: \u00a0Variable\u00a0dicot\u00f3mica \u00a0para\u00a0la\u00a0presencia\u00a0 o\u00a0ausencia\u00a0\nde\u00a0fallo\u00a0en\u00a0el\u00a0diagn\u00f3stico\u00a0 y\u00a0la\u00a0presencia \u00a0de\u00a0LI.\u00a0\u00a0\n\u00a0\nDiagn\u00f3stico \u00a0Definitivo: \u00a0Variable\u00a0cualitativa \u00a0con\u00a0cuatro\u00a0\u00edtems\u00a0para\u00a0valorar\u00a0\ncomo\u00a0se\u00a0realiza\u00a0el\u00a0diagn\u00f3stico \u00a0definitivo \u00a0de\u00a0la\u00a0LMAT.\u00a0\n\u00a01. Por\u00a0la\u00a0cl\u00ednica.\u00a0\n2. Por\u00a0radiolog\u00eda \u00a0convencional.\u00a0\n3. Por\u00a0Tomograf\u00eda \u00a0Axial\u00a0 Computerizada. \u00a0\n4. Por\u00a0Resonancia \u00a0Magn\u00e9tica \u00a0Nuclear.\u00a0\n\u00a0Clasificaci\u00f3n \u00a0de\u00a0Denis:\u00a0Variable\u00a0cualitativa \u00a0basada\u00a0en\u00a0el\u00a0concepto \u00a0de\u00a0las\u00a0\ntres\u00a0columnas\u00a0 de\u00a0Denis,\u00a0y\u00a0comprende \u00a0cinco\u00a0categor\u00edas \u00a0de\u00a0lesi\u00f3n\u00a0para\u00a0las\u00a0columna\u00a0\ndorsolumbar. \u00a0\n\u00a0\n\u00a0 60\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n1. Fracturas \u00a0por\u00a0aplastamiento \u00a0vertebral. \u00a0\n2. Fracturas \u00a0por\u00a0cintur\u00f3n\u00a0de\u00a0seguridad. \u00a0\n3. Fracturas \u00a0por\u00a0estallido.\u00a0\n4. Fracturas \u00a0por\u00a0fractura\u2010 luxaci\u00f3n.\u00a0\n5. Contusi\u00f3n \u00a0medular.\u00a0\n\u00a0Lesi\u00f3n:\u00a0Variable\u00a0cualitativa \u00a0que\u00a0representa \u00a0el\u00a0nivel\u00a0topogr\u00e1fico \u00a0de\u00a0la\u00a0LM.\u00a0\n\u00a0V\u00e9rtebra:\u00a0 Variable\u00a0cualitativa \u00a0que\u00a0nos\u00a0indica\u00a0la\u00a0principal\u00a0v\u00e9rtebra\u00a0que\u00a0es\u00a0\nincriminada \u00a0en\u00a0\u00a0el\u00a0cuadro\u00a0de\u00a0la\u00a0LM.\u00a0Se\u00a0inicia\u00a0en\u00a0la\u00a0primera\u00a0v\u00e9rtebra\u00a0cervical\u00a0con\u00a0el\u00a0\nn\u00famero\u00a01,\u00a0y\u00a0se\u00a0catalogan \u00a0por\u00a0orden\u00a0descendente \u00a0hasta\u00a0la\u00a0regi\u00f3n\u00a0sacra.\u00a0\n\u00a0ASIA:\u00a0Clasificaci\u00f3n \u00a0normalizada \u00a0de\u00a0la\u00a0lesiones\u00a0medulares \u00a0de\u00a0la\u00a0American \u00a0\nSpinal\u00a0Injury\u00a0Association \u00a0(ASIA).\u00a0Se\u00a0tabulan\u00a0 las\u00a0opciones\u00a0\u201cASIA\u00a01\u201d\u00a0como\u00a0el\u00a0ASIA\u00a0al\u00a0\ningreso,\u00a0\u201cASIA\u00a0 2\u201d\u00a0como\u00a0el\u00a0ASIA\u00a0al\u00a0alta\u00a0de\u00a0la\u00a0UR,\u00a0y\u00a0la\u00a0diferencia \u00a0entre\u00a0 ASIA\u00a01\u00a0y\u00a0ASIA\u00a0\n2.\u00a0Estas\u00a0variables\u00a0comprenden\u00a0 seis\u00a0grupos:\u00a0\n\u00a01. No\u00a0valorable. \u00a0\n2. ASIA\u00a0A.\u00a0No\u00a0se\u00a0conserva\u00a0la\u00a0funci\u00f3n\u00a0sensitiva\u00a0ni\u00a0motriz\u00a0en\u00a0los\u00a0segmentos \u00a0\nsacros\u00a0S\n4\u2010S5.\u00a0\n3. ASIA\u00a0B.\u00a0Se\u00a0conserva\u00a0la\u00a0funci\u00f3n\u00a0sensitiva\u00a0pero\u00a0no\u00a0la\u00a0funci\u00f3n\u00a0motriz\u00a0 por\u00a0\ndebajo\u00a0del\u00a0nivel\u00a0neurol\u00f3gico \u00a0y\u00a0comprende \u00a0los\u00a0segmentos \u00a0sacros\u00a0S4\u2010S5.\u00a0\n4. ASIA\u00a0C.\u00a0Se\u00a0conserva\u00a0la\u00a0funci\u00f3n\u00a0motriz\u00a0 por\u00a0debajo\u00a0del\u00a0nivel\u00a0neurol\u00f3gico \u00a0\ny\u00a0m\u00e1s\u00a0de\u00a0la\u00a0mitad\u00a0de\u00a0los\u00a0m\u00fasculos \u00a0clave\u00a0por\u00a0debajo\u00a0del\u00a0 nivel\u00a0\nneurol\u00f3gico \u00a0presentan \u00a0un\u00a0grado\u00a0muscular\u00a0inferior\u00a0a\u00a03.\u00a0\n5. ASIA\u00a0D.\u00a0Se\u00a0conserva\u00a0la\u00a0funci\u00f3n\u00a0motriz\u00a0 por\u00a0debajo\u00a0del\u00a0nivel\u00a0neurol\u00f3gico\u00a0\ny\u00a0m\u00e1s\u00a0de\u00a0la\u00a0mitad\u00a0de\u00a0los\u00a0m\u00fasculos \u00a0clave\u00a0por\u00a0debajo\u00a0del\u00a0 nivel\u00a0\nneurol\u00f3gico \u00a0presentan \u00a0un\u00a0grado\u00a0muscular\u00a0igual\u00a0o\u00a0superior\u00a0a\u00a03.\u00a0\n6. ASIA\u00a0E.\u00a0Las\u00a0funciones \u00a0motrices\u00a0y\u00a0sensitivas \u00a0son\u00a0normales. \u00a0\n\u00a0 61\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nPlejia:\u00a0Signos\u00a0 neurol\u00f3gicos \u00a0de\u00a0la\u00a0LM.\u00a0\n\u00a0\u00a0\n3.4.3.  Variables \u00a0que\u00a0aportan\u00a0informaci\u00f3n \u00a0relacionada\u00a0 con\u00a0la\u00a0lesi\u00f3n\u00a0\nmedular\u00a0aguda\u00a0traum\u00e1tica \u00a0y\u00a0uso\u00a0de\u00a0dispositivos \u00a0m\u00e9dicos\u00a0\n\u00a0\nNivel\u00a0de\u00a0gravedad \u00a0al\u00a0ingreso\u00a0en\u00a0la\u00a0Unidad:\u00a0Se\u00a0estim\u00f3\u00a0mediante \u00a0el\u00a0\u00edndice\u00a0\nde\u00a0Comorbilidades \u00a0de\u00a0Deyo\u2010Charlson. \u00a0Se\u00a0calcul\u00f3\u00a0al\u00a0ingreso\u00a0en\u00a0la\u00a0UR.\u00a0\u00a0\n\u00a0\nAPACHE:\u00a0 Variable\u00a0cuantitativa \u00a0basada\u00a0en\u00a0la\u00a0clasificaci\u00f3n \u00a0de\u00a0la\u00a0Acute\u00a0\nPhysiology \u00a0and\u00a0 Chronic\u00a0Health\u00a0 Evaluation, \u00a0la\u00a0cu\u00e1l\u00a0 es\u00a0uno\u00a0de\u00a0los\u00a0sistemas\u00a0m\u00e1s\u00a0\nfrecuentemente\u00a0 utilizados \u00a0para\u00a0cuantificar \u00a0la\u00a0gravedad \u00a0de\u00a0un\u00a0paciente\u00a0con\u00a0\nindependencia \u00a0del\u00a0diagn\u00f3stico. \u00a0\n\u00a0Protocolo \u00a0NASCIS\u00a0II:\u00a0Variable\u00a0dicot\u00f3mica \u00a0que\u00a0define\u00a0la\u00a0presencia \u00a0o\u00a0\u00a0\nausencia\u00a0de\u00a0tratamiento \u00a0con\u00a0 una\u00a0infusi\u00f3n\u00a0intravenosa \u00a0en\u00a0bolo\u00a0de\u00a030\u00a0mg/kg\u00a0de\u00a0\nMP\u00a0seguida\u00a0de\u00a0una\u00a0infusi\u00f3n\u00a0de\u00a05,4\u00a0mg/kg/hora \u00a0durante\u00a023\u00a0horas.\u00a0\n\u00a0Sonda\u00a0Urinaria:\u00a0Variable\u00a0cuantitativa, \u00a0define\u00a0los\u00a0d\u00edas\u00a0de\u00a0utilizaci\u00f3n \u00a0de\u00a0\nsondaje\u00a0uretral.\u00a0Se\u00a0codifica\u00a0 como\u00a0cero\u00a0la\u00a0ausencia\u00a0de\u00a0sonda\u00a0urinaria.\u00a0\n\u00a0Cat\u00e9ter\u00a0 Venoso\u00a0 Central:\u00a0 Variable\u00a0cuantitativa; \u00a0n\u00famero\u00a0de\u00a0d\u00edas\u00a0que\u00a0el\u00a0\npaciente\u00a0es\u00a0portador\u00a0de\u00a0l\u00ednea\u00a0central\u00a0(venas\u00a0subclavia,\u00a0 yugular\u00a0y\u00a0femoral).\u00a0Se\u00a0\ncodifica\u00a0 como\u00a0cero\u00a0la\u00a0ausencia\u00a0de\u00a0cat\u00e9ter\u00a0venoso\u00a0central\u00a0(CVC).\u00a0\n\u00a0Respiraci\u00f3n \u00a0asistida:\u00a0Variable\u00a0cuantitativa, \u00a0d\u00edas\u00a0que\u00a0el\u00a0paciente\u00a0ha\u00a0\nprecisado \u00a0VM.\u00a0 Se\u00a0codifica\u00a0 como\u00a0cero\u00a0la\u00a0ausencia\u00a0de\u00a0respiraci\u00f3n\u00a0 asistida.\u00a0\n\u00a0\n\u00a0 62Intervenci\u00f3n \u00a0quir\u00fargica: \u00a0Variable\u00a0cualitativa \u00a0que\u00a0tom\u00f3\u00a0los\u00a0valores\u00a0de\u00a0\npresencia, \u00a0ausencia\u00a0e\u00a0intervenci\u00f3n \u00a0demorada. \u00a0Se\u00a0consider\u00f3 \u00a0su\u00a0presencia\u00a0 incluso\u00a0\ncuando\u00a0se\u00a0practic\u00f3\u00a0previamente \u00a0al\u00a0ingreso\u00a0en\u00a0la\u00a0UR.\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nTiempo\u00a0de\u00a0Cirug\u00eda:\u00a0Variable\u00a0cuantitativa \u00a0que\u00a0indica\u00a0los\u00a0d\u00edas\u00a0transcurridos \u00a0\nentre\u00a0 el\u00a0ingreso\u00a0en\u00a0la\u00a0Unidad\u00a0 y\u00a0la\u00a0IQ\u00a0vertebral. \u00a0\n\u00a0Duraci\u00f3n \u00a0de\u00a0intervenci\u00f3n \u00a0quir\u00fargica: \u00a0Variable\u00a0cuantitativa, \u00a0refleja\u00a0el\u00a0\ntiempo\u00a0en\u00a0minutos\u00a0de\u00a0la\u00a0intervenci\u00f3n. \u00a0\n\u00a0Tipo\u00a0de\u00a0Intervenci\u00f3n \u00a0quir\u00fargica: \u00a0Variable\u00a0cualitativa. \u00a0Clasifica\u00a0las\u00a0\nintervenciones\u00a0 seg\u00fan\u00a0el\u00a0abordaje\u00a0quir\u00fargico \u00a0como.\u00a0\n\u00a0\n1. Artrodesis \u00a0Posterior. \u00a0\n2. Artrodesis \u00a0Anterior.\u00a0\n3. Artrodesis \u00a0Mixta.\u00a0\n\u00a0\nTraqueotom\u00eda: \u00a0Variable\u00a0cuantitativa, \u00a0d\u00edas\u00a0que\u00a0permanece \u00a0el\u00a0sujeto\u00a0con\u00a0\ntraqueotom\u00eda \u00a0abierta.\u00a0Se\u00a0codifica\u00a0 como\u00a0cero\u00a0la\u00a0ausencia\u00a0de\u00a0traqueotom\u00eda. \u00a0\n\u00a0Hemodi\u00e1lisis: \u00a0Variable\u00a0cuantitativa, \u00a0n\u00famero\u00a0de\u00a0d\u00edas\u00a0que\u00a0perdura\u00a0\nindicaci\u00f3n \u00a0de\u00a0apoyo\u00a0a\u00a0la\u00a0funci\u00f3n\u00a0renal.\u00a0 Se\u00a0codifica\u00a0 como\u00a0cero\u00a0la\u00a0ausencia\u00a0de\u00a0\nhemodi\u00e1lisis. \u00a0\n\u00a0Sonda\u00a0nasog\u00e1strica: \u00a0Variable\u00a0cuantitativa. \u00a0D\u00edas\u00a0de\u00a0presencia\u00a0 de\u00a0ella.\u00a0Se\u00a0\ncodifica\u00a0 como\u00a0cero\u00a0la\u00a0ausencia\u00a0de\u00a0sonda\u00a0nasog\u00e1strica.\u00a0\n\u00a0\nNutrici\u00f3n \u00a0parenteral: \u00a0Variable\u00a0cuantitativa. \u00a0D\u00edas\u00a0de\u00a0nutrici\u00f3n\u00a0parenteral \u00a0\ninsertada \u00a0por\u00a0v\u00eda\u00a0vascular.\u00a0Se\u00a0codifica\u00a0 como\u00a0cero\u00a0la\u00a0ausencia\u00a0de\u00a0nutrici\u00f3n\u00a0\nparenteral \u00a0(NP).\u00a0\n\u00a0\nNutrici\u00f3n \u00a0enteral:\u00a0 Variable\u00a0cuantitativa. \u00a0D\u00edas\u00a0de\u00a0nutrici\u00f3n\u00a0enteral.\u00a0Se\u00a0\ncodifica\u00a0 como\u00a0cero\u00a0la\u00a0ausencia\u00a0de\u00a0nutrici\u00f3n\u00a0enteral\u00a0 (NE).\u00a0\n\u00a0 63\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nDe\u00a0las\u00a0siguientes \u00a0variables,\u00a0 consideradas \u00a0dicot\u00f3micas, \u00a0se\u00a0recogi\u00f3\u00a0su\u00a0presencia \u00a0o\u00a0\nausencia\u00a0en\u00a0el\u00a0paciente\u00a0al\u00a0ingreso\u00a0en\u00a0la\u00a0UR.\u00a0\n\u00a0\nTraumatismo \u00a0craneoencef\u00e1lico \u00a0(TCE):\u00a0 Se\u00a0consider\u00f3 \u00a0cuando\u00a0as\u00ed\u00a0constaba\u00a0\nen\u00a0la\u00a0historia\u00a0cl\u00ednica.\u00a0\n\u00a0Coma:\u00a0Trastorno \u00a0de\u00a0conciencia \u00a0de\u00a0cualquier \u00a0grado\u00a0o\u00a0nivel,\u00a0 tanto\u00a0\nfarmacol\u00f3gico, \u00a0m\u00e9dico\u00a0o\u00a0postraum\u00e1tico. \u00a0\n\u00a0\nArritmias: \u00a0Cualquier \u00a0tipo\u00a0de\u00a0arritmia\u00a0 cardiaca\u00a0asociada\u00a0a\u00a0inestabilidad \u00a0\nhemodin\u00e1mica \u00a0que\u00a0precisa\u00a0durante\u00a0el\u00a0ingreso\u00a0apoyo\u00a0con\u00a0 fluidos\u00a0o\u00a0tratamiento \u00a0\nm\u00e9dico\u00a0o\u00a0el\u00e9ctrico.\u00a0\n\u00a0\nS\u00edndrome \u00a0de\u00a0Distress\u00a0 Respiratorio \u00a0del\u00a0Adulto\u00a0(SDRA):\u00a0Insuficiencia \u00a0\nrespiratoria \u00a0aguda\u00a0de\u00a0causa\u00a0no\u00a0cardiaca,\u00a0asociada\u00a0a\u00a0infiltrados \u00a0\u00a0\nalveolointersticiales \u00a0bilaterales \u00a0y\u00a0difusos\u00a0con\u00a0una\u00a0relaci\u00f3n\u00a0PaO\n2/FiO 2\u00a0<\u00a0200\u00a0\nmmHg.\u00a0\n\u00a0Atelectasia: \u00a0Confirmada \u00a0su\u00a0presencia \u00a0por\u00a0estudio\u00a0de\u00a0radioimagen. \u00a0\n\u00a0Neumot\u00f3rax: \u00a0Considerada \u00a0cuando\u00a0se\u00a0confirmaba \u00a0su\u00a0presencia \u00a0por\u00a0\nsospecha \u00a0cl\u00ednica\u00a0o\u00a0por\u00a0radiodiagn\u00f3stico. \u00a0\n\u00a0\nAspiraci\u00f3n \u00a0pulmonar: \u00a0Considerada \u00a0cuando\u00a0se\u00a0reflejaba\u00a0 en\u00a0la\u00a0historia\u00a0\ncl\u00ednica.\u00a0\n\u00a0\nShock\u00a0s\u00e9ptico:\u00a0sepsis\u00a0grave\u00a0documentada \u00a0que\u00a0precisa\u00a0de\u00a0apoyo\u00a0con\u00a0\ndrogas\u00a0vasoactivas.\u00a0\n\u00a0\n\u00a0 64\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nNeoplasia: \u00a0Enfermos \u00a0diagnosticados \u00a0de\u00a0un\u00a0proceso\u00a0neopl\u00e1sico \u00a0\ndocumentado \u00a0anatomopatol\u00f3gicamente. \u00a0\n\u00a0Insuficiencia\u00a0 Renal:\u00a0Considerado\u00a0 cuando\u00a0se\u00a0constataba \u00a0en\u00a0la\u00a0historia\u00a0\ncl\u00ednica\u00a0o\u00a0cifras\u00a0de\u00a0creatinina \u00a0superiores \u00a0a\u00a01,8\u00a0mg/dl.\u00a0\n\u00a0Rabdomiolisis: \u00a0Considerada \u00a0cuando\u00a0se\u00a0reflejaba\u00a0 en\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0o\u00a0\ncifras\u00a0de\u00a0CPK\u00a0superiores \u00a0a\u00a015000\u00a0U/L.\u00a0\n\u00a0\nCirrosis\u00a0o\u00a0insuficiencia\u00a0 Hep\u00e1tica: \u00a0Fue\u00a0recogida\u00a0cuando\u00a0se\u00a0reflejaba\u00a0en\u00a0la\u00a0\nhistoria\u00a0cl\u00ednica.\u00a0\n\u00a0\nAnemia:\u00a0Considerada \u00a0si\u00a0la\u00a0hemoglobina \u00a0era\u00a0inferior\u00a0a\u00a07\u00a0gr/dl.\u00a0\n\u00a0\nPlaquetopenia: \u00a0Considerada \u00a0si\u00a0el\u00a0recuento\u00a0de\u00a0plaquetas \u00a0era\u00a0inferior\u00a0a\u00a0\n75000/mm\n3\u00a0\n\u00a0\nNeutropenia: \u00a0Considerada \u00a0cuando\u00a0el\u00a0recuento\u00a0de\u00a0neutrofilos\u00a0 fue\u00a0inferior\u00a0\na\u00a01000/mm3\u00a0\u00a0\u00a0\n\u00a0Politransfusi\u00f3n: \u00a0Si\u00a0se\u00a0reflejaba\u00a0en\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0necesidad \u00a0\nadministraci\u00f3n \u00a0de\u00a0m\u00e1s\u00a0de\u00a08\u00a0concentrados \u00a0de\u00a0hemat\u00edes. \u00a0\n\u00a0\nDiabetes\u00a0mellitas:\u00a0Cuando\u00a0su\u00a0presencia \u00a0era\u00a0recogida\u00a0en\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0\no\u00a0se\u00a0observaban \u00a0glucemias \u00a0superiores \u00a0a\u00a0200\u00a0mg/dl\u00a0en\u00a0enfermos \u00a0sometidos \u00a0a\u00a0\nfluidoterapia \u00a0o\u00a0tratamientos \u00a0que\u00a0pudieran\u00a0 producir\u00a0aumentos \u00a0en\u00a0la\u00a0glucemia. \u00a0\n\u00a0\n\u00cdleo\u00a0paral\u00edtico: \u00a0Si\u00a0se\u00a0reflejaba\u00a0en\u00a0la\u00a0historia\u00a0cl\u00ednica.\u00a0\n\u00a0\n\u00a0 65Desnutrici\u00f3n: \u00a0Se\u00a0consider\u00f3 \u00a0con\u00a0un\u00a0nivel\u00a0de\u00a0alb\u00famina \u00a0inferior\u00a0a\u00a03\u00a0g/l.\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nDrogadicci\u00f3n: \u00a0Cuando\u00a0 se\u00a0produjo\u00a0consumo\u00a0habitual\u00a0de\u00a0drogas\u00a0por\u00a0v\u00eda\u00a0\nparenteral \u00a0o\u00a0coca\u00edna\u00a0por\u00a0cualquier\u00a0 v\u00eda\u00a0en\u00a0los\u00a0\u00faltimos\u00a0dos\u00a0a\u00f1os.\u00a0\u00a0\n\u00a0Virus\u00a0de\u00a0la\u00a0Inmunodeficiencia \u00a0Humana\u00a0(VIH):\u00a0Se\u00a0consider\u00f3 \u00a0cuando\u00a0se\u00a0\nreflejaba\u00a0en\u00a0la\u00a0historia\u00a0cl\u00ednica.\u00a0\n\u00a0Hepatitis\u00a0B\u00a0\u00f3\u00a0C:\u00a0Confirmado\u00a0 por\u00a0 serolog\u00eda\u00a0la\u00a0presencia\u00a0 de\u00a0virus\u00a0\nhepatotr\u00f3fos. \u00a0\n\u00a0\nTabaquismo: \u00a0Presencia\u00a0 de\u00a0habito\u00a0tab\u00e1quico \u00a0en\u00a0los\u00a0\u00faltimos\u00a0cinco\u00a0a\u00f1os.\u00a0\n\u00a0\nEnolismo: \u00a0Consumo\u00a0 de\u00a0alcohol\u00a0superior\u00a0a\u00a080\u00a0g/d\u00eda\u00a0durante\u00a0los\u00a0\u00faltimos\u00a0\ncinco\u00a0a\u00f1os,\u00a0o\u00a0historia\u00a0cl\u00ednica\u00a0compatible \u00a0con\u00a0hepatopat\u00eda \u00a0alcoh\u00f3lica. \u00a0\n\u00a0\nUlceras\u00a0de\u00a0dec\u00fabito: \u00a0Presencia\u00a0 de\u00a0\u00falcera(s)\u00a0de\u00a0dec\u00fabito.\u00a0\n\u00a0\nFlebitis:\u00a0Presencia\u00a0 de\u00a0flebitis.\u00a0\n\u00a0\nInmunosupresi\u00f3n: \u00a0Enfermo\u00a0sometido \u00a0a\u00a0terapia\u00a0 inmunosupresora \u00a0\n(radioterapia, \u00a0quimioterapia, \u00a0CTC)\u00a0o\u00a0cuadro\u00a0de\u00a0inmunodeficiencia \u00a0que\u00a0afecten\u00a0al\u00a0\nsujeto.\u00a0\n\u00a0\nObesidad: \u00a0Cuando\u00a0 el\u00a0\u00edndice\u00a0de\u00a0masa\u00a0corporal\u00a0 fuese\u00a0superior\u00a0al\u00a030%.\u00a0\u00a0\n\u00a0Miopat\u00eda\u00a0 del\u00a0paciente\u00a0cr\u00edtico:\u00a0Si\u00a0se\u00a0reflejaba\u00a0 en\u00a0la\u00a0historia\u00a0cl\u00ednica.\u00a0\n\u00a0Trombosis\u00a0 venosa\u00a0profunda: \u00a0Si\u00a0se\u00a0reflejaba\u00a0 en\u00a0la\u00a0historia\u00a0cl\u00ednica.\u00a0\n\u00a0\nTromboembolismo\u00a0 pulmonar \u00a0(TEP):\u00a0 Si\u00a0se\u00a0reflejaba\u00a0en\u00a0la\u00a0historia\u00a0cl\u00ednica.\u00a0\n\u00a0 66\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nHemorragia \u00a0digestiva: \u00a0Cualquier \u00a0sangrado\u00a0del\u00a0tubo\u00a0digestivo\u00a0asociado\u00a0a\u00a0\ninestabilidad \u00a0hemodin\u00e1mica \u00a0que\u00a0precisara\u00a0de\u00a0la\u00a0transfusi\u00f3n \u00a0de\u00a02\u00a0concentrados \u00a0\nde\u00a0hemat\u00edes \u00a0y/o\u00a0esclerosis \u00a0endosc\u00f3pica \u00a0o\u00a0quir\u00fargica. \u00a0\n\u00a0\nAnticoagulaci\u00f3n: \u00a0Se\u00a0recogi\u00f3\u00a0cuando\u00a0se\u00a0constataba \u00a0en\u00a0la\u00a0historia\u00a0cl\u00ednica.\u00a0\u00a0\u00a0\n\u00a0\nExistencia \u00a0de\u00a0infecci\u00f3n \u00a0previa\u00a0al\u00a0ingreso\u00a0en\u00a0la\u00a0Unidad:\u00a0Aun\u00a0cuando\u00a0la\u00a0\ninfecci\u00f3n\u00a0desarrollada \u00a0por\u00a0el\u00a0paciente\u00a0fuera\u00a0 nosocomial.\u00a0\n\u00a0\n\u00a0\n3.4.4.  Variables \u00a0referentes \u00a0a\u00a0la\u00a0infecci\u00f3n \u00a0nosocomial \u00a0\n\u00a0\nInfecci\u00f3n \u00a0Nosocomial: \u00a0Variable\u00a0dicot\u00f3mica \u00a0que\u00a0toma\u00a0 los\u00a0valores\u00a0de\u00a0\npresente\u00a0o\u00a0ausente\u00a0durante\u00a0la\u00a0estancia\u00a0del\u00a0paciente\u00a0en\u00a0la\u00a0UR,\u00a0incluyendo\u00a0 las\u00a0\nprimeras\u00a024\u00a0horas\u00a0tras\u00a0ser\u00a0dado\u00a0de\u00a0alta\u00a0de\u00a0la\u00a0Unidad.\u00a0Se\u00a0construy\u00f3, \u00a0tras\u00a0\ninformatizar \u00a0los\u00a0datos,\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0informaci\u00f3n \u00a0contenida \u00a0en\u00a0las\u00a0posibles\u00a0\nlocalizaciones \u00a0de\u00a0la\u00a0IN.\u00a0\n\u00a0Localizaci\u00f3n \u00a0de\u00a0la\u00a0Infecci\u00f3n \u00a0Nosocomial: \u00a0Variable\u00a0cualitativa,\u00a0 cuyas\u00a0\ncategor\u00edas \u00a0se\u00a0recogen\u00a0en\u00a0el\u00a0Anexo\u00a0IV.\u00a0Los\u00a0criterios\u00a0para\u00a0diagnosticar \u00a0la\u00a0IN\u00a0en\u00a0cada\u00a0\nuna\u00a0de\u00a0sus\u00a0localizaciones \u00a0fueron\u00a0los\u00a0elaborados \u00a0por\u00a0los\u00a0CDC.\u00a0\n\u00a0Microorganismos \u00a0responsables \u00a0de\u00a0la\u00a0infecci\u00f3n: \u00a0Variable\u00a0cualitativa. \u00a0Se\u00a0\nrecogieron \u00a0hasta\u00a0tres\u00a0microorganismos \u00a0distintos\u00a0para\u00a0cada\u00a0infecci\u00f3n. \u00a0\n\u00a0Infecci\u00f3n \u00a0Nosocomial \u00a0en\u00a0localizaciones\u00a0 especificas \u00a0(Neumon\u00eda, \u00a0\nBacteriemia \u00a0e\u00a0Infecci\u00f3n \u00a0de\u00a0v\u00edas\u00a0Urinarias): \u00a0Variables\u00a0dicot\u00f3micas \u00a0cada\u00a0 una\u00a0de\u00a0\nellas,\u00a0sus\u00a0categor\u00edas \u00a0son\u00a0la\u00a0presencia\u00a0 o\u00a0ausencia. \u00a0Cada\u00a0variable\u00a0se\u00a0elabor\u00f3\u00a0a\u00a0partir\u00a0\nde\u00a0la\u00a0informaci\u00f3n \u00a0contenida \u00a0en\u00a0las\u00a0cuatro\u00a0posibles\u00a0localizaciones\u00a0 de\u00a0la\u00a0IN.\u00a0\n\u00a0 67\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n\u00a0Presentaci\u00f3n \u00a0de\u00a0la\u00a0Neumon\u00eda \u00a0nosocomial:\n\u00a0Variable\u00a0dicot\u00f3mica, \u00a0clasifica\u00a0\nla\u00a0neumon\u00eda \u00a0en\u00a0precoces\u00a0\u00f3\u00a0tard\u00edas\u00a0 seg\u00fan\u00a0los\u00a0d\u00edas\u00a0desde\u00a0el\u00a0ingreso\u00a0hasta\u00a0la\u00a0\u00a0\npresentaci\u00f3n \u00a0del\u00a0cuadro.\u00a0Se\u00a0catalogan\u00a0 as\u00ed,\u00a0con\u00a0un\u00a0punto\u00a0de\u00a0corte\u00a0 estimado \u00a0en\u00a04\u00a0\nd\u00edas.\u00a0\n\u00a0Estancia\u00a0 previa\u00a0a\u00a0la\u00a0Infecci\u00f3n \u00a0Nosocomial \u00a0en\u00a0una\u00a0determinada \u00a0\nlocalizaci\u00f3n \u00a0espec\u00edfica\u00a0 Neumon\u00eda \u00a0(NN),\u00a0 Bacteriemia\u00a0 (BN)\u00a0e\u00a0infecci\u00f3n \u00a0de\u00a0v\u00edas\u00a0\nUrinarias\u00a0 (ITU):\u00a0Variable\u00a0cuantitativa. \u00a0Estancia\u00a0en\u00a0d\u00edas\u00a0en\u00a0la\u00a0UR\u00a0previa\u00a0 a\u00a0la\u00a0\naparici\u00f3n\u00a0 de\u00a0la\u00a0primera\u00a0 IN\u00a0en\u00a0una\u00a0determinada \u00a0localizaci\u00f3n \u00a0especifica. \u00a0Se\u00a0calcul\u00f3\u00a0\na\u00a0partir\u00a0de\u00a0la\u00a0fecha\u00a0 de\u00a0comienzo \u00a0de\u00a0la\u00a0primera\u00a0 en\u00a0una\u00a0determinada \u00a0localizaci\u00f3n \u00a0\ndeterminada\u00a0 y\u00a0la\u00a0fecha\u00a0 de\u00a0ingreso\u00a0en\u00a0la\u00a0Unidad.\u00a0\n\u00a0Infecci\u00f3n \u00a0de\u00a0la\u00a0Herida\u00a0Quir\u00fargica: \u00a0Variables\u00a0dicot\u00f3mica, \u00a0sus\u00a0categor\u00edas \u00a0\nson\u00a0la\u00a0presencia\u00a0 o\u00a0ausencia. \u00a0Cada\u00a0variable\u00a0se\u00a0elabor\u00f3\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0informaci\u00f3n \u00a0\ncontenida \u00a0en\u00a0las\u00a0cuatro\u00a0posibles\u00a0localizaciones \u00a0de\u00a0la\u00a0IN.\u00a0\n\u00a0Estancia\u00a0 prequir\u00fargica: \u00a0Variable\u00a0cuantitativa. \u00a0Indica\u00a0 el\u00a0tiempo\u00a0\ntranscurrido \u00a0en\u00a0d\u00edas\u00a0desde\u00a0el\u00a0ingreso\u00a0del\u00a0paciente\u00a0hasta\u00a0la\u00a0fecha\u00a0 de\u00a0la\u00a0IQ.\u00a0\n\u00a0Estancia\u00a0 posquir\u00fargica: \u00a0Variable\u00a0cuantitativa. \u00a0Indica\u00a0 el\u00a0tiempo\u00a0\ntranscurrido \u00a0en\u00a0d\u00edas\u00a0desde\u00a0el\u00a0d\u00eda\u00a0de\u00a0la\u00a0IQ\u00a0hasta\u00a0la\u00a0fecha\u00a0 de\u00a0alta.\u00a0\n\u00a0\nEstancia\u00a0 preinfecci\u00f3n \u00a0en\u00a0Unidad\u00a0de\u00a0Reanimaci\u00f3n: \u00a0Variable\u00a0cuantitativa \u00a0\nreferida\u00a0a\u00a0la\u00a0estancia\u00a0en\u00a0d\u00edas\u00a0en\u00a0UR\u00a0previa\u00a0 a\u00a0la\u00a0aparici\u00f3n\u00a0 de\u00a0la\u00a0primera\u00a0IN.\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0 68\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n3.4.5.  Variables \u00a0referentes \u00a0al\u00a0uso\u00a0de\u00a0antimicrobianos \u00a0\n\u00a0\nAntimicrobianos \u00a0utilizados: \u00a0Variable\u00a0cuantitativa. \u00a0Antimicrobianos\u00a0\ndispensados \u00a0en\u00a0el\u00a0hospital\u00a0durante\u00a0el\u00a0periodo\u00a0de\u00a0estudio.\u00a0Se\u00a0recogieron \u00a0hasta\u00a09\u00a0\nposibles\u00a0antimicrobianos \u00a0diferentes. \u00a0\n\u00a0\nProfilaxis: \u00a0Variable\u00a0cuantitativa. \u00a0Clasifica\u00a0la\u00a0adecuaci\u00f3n \u00a0de\u00a0la\u00a0profilaxis\u00a0\nantibi\u00f3tica. \u00a0\n\u00a0\n\u00a0\n3.5. METODOS \u00a0DE\u00a0AN\u00c1LISIS \u00a0\n\u00a0\n3.5.1.  Procesamiento \u00a0de\u00a0los\u00a0datos\u00a0\nEl\u00a0procesamiento \u00a0de\u00a0los\u00a0datos\u00a0 se\u00a0llev\u00f3\u00a0a\u00a0cabo\u00a0en\u00a0un\u00a0ordenador \u00a0port\u00e1til\u00a0\nACER\u00a0 Pentium\u00a0IV.\u00a0Los\u00a0datos\u00a0 recogidos \u00a0y\u00a0codificados, \u00a0fueron\u00a0introducidos \u00a0en\u00a0el\u00a0\nprograma \u00a0gestor\u00a0de\u00a0bases\u00a0de\u00a0datos\u00a0\u00a0STATA \u00a06.0\u00a0versi\u00f3n\u00a0 para\u00a0Windows, \u00a0\ndesarrollado \u00a0por\u00a0Stata\u00a0Corp\u00a0LP.\u00a0El\u00a0estudio\u00a0descriptivo, \u00a0univariante \u00a0se\u00a0realiz\u00f3\u00a0con\u00a0\nlos\u00a0programas \u00a0estad\u00edsticos \u00a0STATISTIX \u00a06\u00a0y\u00a0STATA\u00a06.0.\u00a0El\u00a0texto,\u00a0los\u00a0gr\u00e1ficos,\u00a0 figuras\u00a0\ny\u00a0tablas\u00a0se\u00a0han\u00a0dise\u00f1ado\u00a0utilizando \u00a0el\u00a0paquete\u00a0de\u00a0MICROSOFT\u00a0 \u201cOFFICE\u00a02003\u201d.\u00a0\u00a0\n\u00a0\n3.5.2.  An\u00e1lisis\u00a0descriptivo \u00a0o\u00a0univariante \u00a0de\u00a0los\u00a0casos\u00a0de\u00a0estudio\u00a0\nSe\u00a0realiz\u00f3\u00a0una\u00a0estad\u00edstica \u00a0descriptiva \u00a0inicial\u00a0con\u00a0 el\u00a0calculo\u00a0de\u00a0las\u00a0\ndistribuciones \u00a0de\u00a0frecuencia \u00a0de\u00a0las\u00a0variables\u00a0cualitativas, \u00a0y\u00a0se\u00a0calcul\u00f3\u00a0la\u00a0media,\u00a0el\u00a0\nerror\u00a0est\u00e1ndar\u00a0y\u00a0las\u00a0medidas\u00a0de\u00a0dispersi\u00f3n \u00a0para\u00a0las\u00a0variables\u00a0cuantitativas. \u00a0Para\u00a0\nconocer\u00a0la\u00a0frecuencia\u00a0 de\u00a0IN\u00a0se\u00a0calcularon \u00a0las\u00a0medidas\u00a0de\u00a0incidencia \u00a0acumulada \u00a0\n(IA)\u00a0de\u00a0NN,\u00a0BN,\u00a0ITU\u00a0e\u00a0IHQ,\u00a0 espec\u00edfica \u00a0y\u00a0seg\u00fan\u00a0grupos\u00a0 de\u00a0riesgo.\u00a0Tambi\u00e9n\u00a0 se\u00a0hall\u00f3\u00a0\nla\u00a0Tasa\u00a0o\u00a0DI\u00a0de\u00a0infecciones, \u00a0Tasas\u00a0 de\u00a0infecci\u00f3n\u00a0en\u00a0localizaciones \u00a0especificas \u00a0\nasociadas\u00a0 a\u00a0dispositivos \u00a0de\u00a0riesgo\u00a0y\u00a0la\u00a0frecuencia \u00a0de\u00a0microorganismos \u00a0aislados\u00a0en\u00a0\nlas\u00a0IN\u00a0de\u00a0la\u00a0cohorte.\u00a0Asimismo \u00a0se\u00a0calcul\u00f3\u00a0las\u00a0tasas\u00a0de\u00a0mortalidad\u00a0 global,\u00a0por\u00a0tipo\u00a0\nde\u00a0cirug\u00eda\u00a0y\u00a0UR,\u00a0por\u00a0el\u00a0\u00cdndice\u00a0ASA\u00a0 y\u00a0de\u00a0Comorbilidad. \u00a0El\u00a0denominador \u00a0de\u00a0esas\u00a0\u00a0\n\u00a0 69\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\ntasas\u00a0o\u00a0densidades \u00a0de\u00a0incidencia \u00a0(DI)\u00a0de\u00a0infecci\u00f3n\u00a0se\u00a0componen \u00a0de\u00a0la\u00a0suma\u00a0de\u00a0los\u00a0\nd\u00edas\u00a0a\u00a0riesgo\u00a0de\u00a0cada\u00a0sujeto\u00a0de\u00a0la\u00a0cohorte\u00a0hasta\u00a0la\u00a0infecci\u00f3n\u00a0o\u00a0exitus.\u00a0\n\u00a0Para\u00a0comparar\u00a0 la\u00a0diferente \u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0NN,\u00a0BN,\u00a0ITU\u00a0e\u00a0IHQ\u00a0entre\u00a0las\u00a0\nvariables\u00a0recogidas\u00a0 y\u00a0su\u00a0posible\u00a0asociaci\u00f3n \u00a0se\u00a0utiliz\u00f3\u00a0 el\u00a0test\u00a0de\u00a0la\u00a0\u201ct\u201d\u00a0de\u00a0Student\u00a0o\u00a0\nla\u00a0prueba\u00a0de\u00a0Krushall\u2010Wallis\u00a0si\u00a0no\u00a0exist\u00eda\u00a0igualdad\u00a0 de\u00a0varianzas, \u00a0para\u00a0las\u00a0variables\u00a0\ncuantitativas, \u00a0y\u00a0el\u00a0test\u00a0de\u00a0la\u00a0Chi\u2010cuadrado \u00a0(Ji\n2)\u00a0con\u00a0correcci\u00f3n \u00a0de\u00a0Yates\u00a0o\u00a0el\u00a0test\u00a0de\u00a0\nFischer\u00a0 para\u00a0 las\u00a0variables\u00a0cualitativas. \u00a0\n\u00a0\nPara\u00a0detectar\u00a0 posibles\u00a0interacciones \u00a0se\u00a0ha\u00a0realizado\u00a0un\u00a0an\u00e1lisis\u00a0\nestratificado \u00a0de\u00a0los\u00a0factores\u00a0de\u00a0riesgo\u00a0y\u00a0el\u00a0suceso\u00a0a\u00a0estudio\u00a0seg\u00fan\u00a0American \u00a0\nSociety\u00a0of\u00a0Anaesthesiology \u00a0(ASA),\u00a0como\u00a0indicador \u00a0de\u00a0gravedad \u00a0del\u00a0paciente\u00a0y\u00a0\nutilizando \u00a0la\u00a0Ji2\u00a0de\u00a0Pearson\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0estratos.\u00a0\n\u00a0Como\u00a0medida\u00a0cruda\u00a0da\u00a0la\u00a0magnitud \u00a0de\u00a0asociaci\u00f3n \u00a0en\u00a0variables\u00a0cualitativas \u00a0\nde\u00a0dos\u00a0categor\u00edas \u00a0se\u00a0utiliza\u00a0el\u00a0Riesgo\u00a0Relativo\u00a0 (RR)\u00a0 (Incidencia \u00a0en\u00a0expuestos/ \u00a0\nIncidencia \u00a0en\u00a0no\u00a0expuestos) \u00a0y\u00a0su\u00a0intervalo\u00a0de\u00a0confianza \u00a0(IC)\u00a0al\u00a095%\u00a0de\u00a0seguridad, \u00a0\npor\u00a0el\u00a0m\u00e9todo\u00a0de\u00a0Cornfield; \u00a0o\u00a0el\u00a0m\u00e9todo\u00a0de\u00a0Fisher,\u00a0si\u00a0el\u00a0n\u00famero\u00a0de\u00a0casos\u00a0 era\u00a0\npeque\u00f1o. \u00a0\n\u00a0\nSe\u00a0ha\u00a0admitido\u00a0 un\u00a0nivel\u00a0significativo\u00a0 del\u00a0 5%\u00a0para\u00a0todos\u00a0los\u00a0test\u00a0\nestad\u00edsticos \u00a0utilizados, \u00a0es\u00a0decir,\u00a0si\u00a0la\u00a0p\u00a0es\u00a0menor\u00a0de\u00a00,05\u00a0se\u00a0asume\u00a0que\u00a0hay\u00a0\ndiferencias\u00a0 estad\u00edsticamente \u00a0significativas \u00a0en\u00a0las\u00a0series\u00a0comparadas, \u00a0con\u00a0un\u00a095%\u00a0\nde\u00a0confianza. \u00a0\n\u00a0\n\u00a0\n3.5.3.  An\u00e1lisis\u00a0de\u00a0supervivencia\u00a0 de\u00a0Kaplan\u2010 Meyer\u00a0\n\u00a0 70Utilizando\u00a0 el\u00a0M\u00e9todo\u00a0de\u00a0Kaplan\u2010Meyer\u00a0y\u00a0considerando \u00a0las\u00a0diversas\u00a0\nvariables\u00a0del\u00a0estudio\u00a0como\u00a0variables\u00a0resultado \u00a0de\u00a0la\u00a0funci\u00f3n\u00a0del\u00a0tiempo\u00a0de\u00a0\nestancia\u00a0en\u00a0Unidad\u00a0 de\u00a0Reanimaci\u00f3n \u2010tiempo\u00a0de\u00a0\u201csupervivencia\u201d \u00a0hasta\u00a0la\u00a0aparici\u00f3n \u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nde\u00a0los\u00a0eventos\u00a0hemos\u00a0realizado\u00a0para\u00a0cada\u00a0una\u00a0de\u00a0estas\u00a0variables\u00a0un\u00a0an\u00e1lisis\u00a0de\u00a0\nsupervivencia. \u00a0Este\u00a0resultado, \u00a0expresado \u00a0en\u00a0tablas\u00a0de\u00a0supervivencia, \u00a0se\u00a0ha\u00a0\nresumido \u00a0presentando \u00a0la\u00a0probabilidad \u00a0de\u00a0supervivencia \u00a0para\u00a0la\u00a0media,\u00a0la\u00a0\nmediana\u00a0y\u00a0la\u00a0moda\u00a0de\u00a0la\u00a0poblaci\u00f3n. \u00a0Se\u00a0ha\u00a0considerado \u00a0la\u00a0mediana\u00a0como\u00a0medida\u00a0\nde\u00a0tendencia \u00a0central\u00a0de\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0supervivencia. \u00a0Hemos\u00a0ajustado\u00a0este\u00a0 an\u00e1lisis\u00a0\nestratificado \u00a0seg\u00fan\u00a0las\u00a0variables\u00a0categ\u00f3ricas \u00a0APACHE\u00a0II,\u00a0ASA,\u00a0Comorbilidad, \u00a0\nExitus,\u00a0etc.\u00a0Calculando \u00a0las\u00a0tasas\u00a0de\u00a0incidencia \u00a0para\u00a0cada\u00a0uno\u00a0de\u00a0los\u00a0estratos\u00a0y\u00a0\ncomparando,\u00a0 utilizando \u00a0el\u00a0m\u00e9todo\u00a0de\u00a0log\u2010rank\u00a0 de\u00a0comparaci\u00f3n\u00a0 de\u00a0curvas,\u00a0y\u00a0las\u00a0\ncurvas\u00a0de\u00a0supervivencia \u00a0estratificadas \u00a0seg\u00fan\u00a0estas\u00a0variables\u00a0aceptando \u00a0un\u00a0nivel\u00a0\nde\u00a0significaci\u00f3n \u00a0de\u00a0p<\u00a00,05.\u00a0\n\u00a0\u00a0\n3.5.4.  An\u00e1lisis\u00a0multivariante\u00a0 de\u00a0regresi\u00f3n \u00a0de\u00a0Cox\u00a0\nEl\u00a0modelo\u00a0de\u00a0regresi\u00f3n \u00a0aplicable\u00a0al\u00a0an\u00e1lisis\u00a0de\u00a0supervivencia \u00a0que\u00a0permite\u00a0\nidentificar \u00a0y\u00a0evaluar\u00a0la\u00a0relaci\u00f3n\u00a0entre\u00a0un\u00a0conjunto\u00a0 de\u00a0variables\u00a0explicativas \u00a0y\u00a0la\u00a0\ntasa\u00a0de\u00a0incidencia \u00a0de\u00a0la\u00a0variable\u00a0resultados \u00a0(empleo\u00a0de\u00a0MP,\u00a0 intervenci\u00f3n \u00a0\nquir\u00fargica \u00a0tipo\u00a0artrodesis \u00a0y\u00a0exitus),\u00a0es\u00a0el\u00a0modelo\u00a0de\u00a0riesgos\u00a0proporcionales \u00a0de\u00a0\nCox,\u00a0que\u00a0tiene\u00a0en\u00a0cuenta\u00a0el\u00a0tiempo\u00a0en\u00a0que\u00a0el\u00a0evento\u00a0a\u00a0estudio\u00a0o\u00a0variable\u00a0\ndependiente \u00a0ocurre,\u00a0 y\u00a0permite\u00a0analizar\u00a0variables\u00a0predictoras \u00a0dependientes \u00a0del\u00a0\ntiempo,\u00a0es\u00a0decir\u00a0variables\u00a0que\u00a0toman\u00a0diferentes \u00a0valores\u00a0durante\u00a0el\u00a0seguimiento \u00a0\ndel\u00a0sujeto,\u00a0y\u00a0tambi\u00e9n\u00a0variables\u00a0predictoras \u00a0no\u00a0dependientes\u00a0 del\u00a0tiempo.\u00a0\n\u00a0El\u00a0modelo\u00a0de\u00a0Cox\u00a0esta\u00a0formado\u00a0por\u00a0el\u00a0producto\u00a0de\u00a0dos\u00a0t\u00e9rminos. \u00a0El\u00a0\nprimero\u00a0h\n0(t)\u00a0depende\u00a0exclusivamente \u00a0del\u00a0tiempo,\u00a0mientras\u00a0el\u00a0segundo\u00a0depende\u00a0\nsolo\u00a0de\u00a0las\u00a0variables\u00a0predictoras \u00a0x,\u00a0expres\u00e1ndose \u00a0de\u00a0la\u00a0siguiente\u00a0manera:\u00a0\u00a0\n\u00a0\nh(t)\u00a0=\u00a0h0\u00a0(t)\u00a0(\u00a0\u03b21x1+....+\u00a0\u03b2kxk).\u00a0\n\u00a0 71Donde:\u00a0\n9 h(t;X) ,\u00a0es\u00a0la\u00a0Tasa\u00a0instant\u00e1nea \u00a0de\u00a0riesgo\u00a0de\u00a0X\u00a0y\u00a0representa\u00a0 el\u00a0riesgo\u00a0de\u00a0\n\u201cfallecer\u201d \u00a0en\u00a0el\u00a0instante\u00a0\u201ct\u201d,\u00a0de\u00a0los\u00a0sujetos\u00a0 que\u00a0tienen\u00a0un\u00a0determinado \u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\npatr\u00f3n\u00a0de\u00a0valores\u00a0x1,\u00a0x2,...x p\u00a0en\u00a0las\u00a0variables\u00a0explicativas \u00a0de\u00a0x\u00a0en\u00a0ese\u00a0\ninstante\u00a0t.\u00a0\n9 ho(t),\u00a0es\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0riesgo\u00a0de\u00a0referencia \u00a0o\u00a0riesgo\u00a0de\u00a0base\u00a0o\u00a0\n\u201cunderlying \u00a0hazard\u00a0function\u201d, \u00a0que\u00a0solo\u00a0depende\u00a0del\u00a0tiempo,\u00a0llamada\u00a0\nas\u00ed\u00a0porque\u00a0representa \u00a0las\u00a0tasas\u00a0instant\u00e1neas \u00a0de\u00a0riesgo\u00a0de\u00a0un\u00a0sujeto\u00a0\nhipot\u00e9tico \u00a0con\u00a0valor\u00a0cero\u00a0en\u00a0todas\u00a0 las\u00a0variables\u00a0explicativas. \u00a0\n\u00a0\nLa\u00a0expresi\u00f3n \u00a0anterior\u00a0se\u00a0puede\u00a0transformar \u00a0tomando\u00a0logaritmos, \u00a0en\u00a0la\u00a0\nsiguiente:\u00a0\nLn\u23d0h(t)/h 0(t)\u23d0=\u00a0(\u03b21x1+\u03b4+\u03b2kxk).\u00a0\n\u00a0Lo\u00a0que\u00a0nos\u00a0permite\u00a0interpretar\u00a0 los\u00a0coeficientes \u00a0como\u00a0estimadores \u00a0del\u00a0\nriesgo\u00a0relativo.\u00a0\n\u00a0\nHemos\u00a0analizado \u00a0por\u00a0medio\u00a0de\u00a0la\u00a0regresi\u00f3n \u00a0de\u00a0Cox\u00a0las\u00a0variables\u00a0\ndependientes \u00a0\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0los\u00a0D\u00edas\u00a0de\u00a0estancia\u00a0en\u00a0UR\u00a0\u00a0y\u00a0grado\u00a0de\u00a0recuperaci\u00f3n \u00a0\nneurol\u00f3gica, \u00a0y\u00a0construido\u00a0 un\u00a0modelo\u00a0explicativo \u00a0para\u00a0cada\u00a0una\u00a0de\u00a0ellas\u00a0con\u00a0las\u00a0\nvariables\u00a0independientes. \u00a0Los\u00a0supuestos\u00a0 de\u00a0estos\u00a0modelos\u00a0 de\u00a0regresi\u00f3n \u00a0de\u00a0\nriesgos\u00a0proporcionales, \u00a0suponen\u00a0que\u00a0el\u00a0efecto\u00a0de\u00a0las\u00a0variables\u00a0predictoras \u00a0sobre\u00a0\nla\u00a0funci\u00f3n\u00a0de\u00a0riesgos\u00a0es\u00a0log\u2010lineal\u00a0y\u00a0la\u00a0funci\u00f3n\u00a0h\n0(t)\u00a0es\u00a0proporcional.\u00a0\n\u00a0\n\u00a0 72Para\u00a0la\u00a0construcci\u00f3n \u00a0de\u00a0los\u00a0respectivos \u00a0modelos\u00a0se\u00a0ha\u00a0efectuado \u00a0una\u00a0\nprimera\u00a0 selecci\u00f3n\u00a0de\u00a0variables\u00a0independientes\u00a0 introduciendo\u00a0 una\u00a0a\u00a0una\u00a0las\u00a0\nvariables\u00a0que\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0 univariante \u00a0presentaron \u00a0un\u00a0nivel\u00a0de\u00a0significaci\u00f3n \u00a0\u2264\u00a0\n0,25\u00a0o\u00a0aquellas\u00a0que\u00a0consideramos \u00a0relevantes \u00a0seg\u00fan\u00a0la\u00a0literatura \u00a0m\u00e9dica,\u00a0o\u00a0\nposibles\u00a0variables\u00a0de\u00a0confusi\u00f3n, \u00a0independientemente \u00a0del\u00a0nivel\u00a0de\u00a0significaci\u00f3n. \u00a0\nLas\u00a0variables\u00a0cuantitativas\u00a0 se\u00a0han\u00a0 introducido\u00a0 directamente \u00a0mientras\u00a0que\u00a0las\u00a0\nvariables\u00a0categ\u00f3ricas \u00a0se\u00a0han\u00a0 transformado\u00a0 en\u00a0K\u20101\u00a0variables\u00a0o\u00a0dummy\u00a0variables\u00a0\nutilizando \u00a0el\u00a0valor\u00a00\u00a0como\u00a0valor\u00a0de\u00a0referencia. \u00a0La\u00a0variable\u00a0dependiente \u00a0ha\u00a0sido\u00a0\n\u201cD\u00edas\u00a0de\u00a0estancia\u00a0en\u00a0UR\u00a0hasta\u00a0el\u00a0suceso\u00a0a\u00a0estudio\u201d,\u00a0considerando\u00a0 como\u00a0suceso\u00a0a\u00a0\nestudio\u00a0el\u00a0empleo\u00a0de\u00a0megadosis \u00a0de\u00a0metilprednisolona, \u00a0intervenci\u00f3n \u00a0quir\u00fargica \u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\ntipo\u00a0artrodesis \u00a0y\u00a0exitus.\u00a0Este\u00a0primer\u00a0an\u00e1lisis\u00a0 permite\u00a0detectar\u00a0interacciones \u00a0\nmultiplicativas\u00a0 entre\u00a0 dos\u00a0variables\u00a0y\u00a0construir\u00a0los\u00a0correspondientes \u00a0t\u00e9rminos\u00a0de\u00a0\ninteracci\u00f3n \u00a0que\u00a0introducidos \u00a0originan\u00a0 el\u00a0cambio\u00a0significativo\u00a0 del\u00a0signo\u00a0en\u00a0el\u00a0\nlogaritmo \u00a0de\u00a0la\u00a0verosimilitud, \u00a0y\u00a0si\u00a0este\u00a0cambio\u00a0es\u00a0significativo, \u00a0lo\u00a0que\u00a0revela\u00a0 la\u00a0\nexistencia \u00a0de\u00a0interacci\u00f3n,\u00a0 el\u00a0t\u00e9rmino\u00a0se\u00a0mantiene \u00a0en\u00a0el\u00a0modelo.\u00a0A\u00a0las\u00a0variables\u00a0\ncuya\u00a0tasa\u00a0de\u00a0riesgo\u00a0no\u00a0es\u00a0proporcional \u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0tiempo\u00a0o\u00a0variables\u00a0tiempo\u00a0\ndependientes, \u00a0se\u00a0les\u00a0ha\u00a0a\u00f1adido\u00a0 un\u00a0termino\u00a0de\u00a0interacci\u00f3n \u00a0con\u00a0la\u00a0variable\u00a0\u201cD\u00edas\u00a0\nde\u00a0estancia\u00a0en\u00a0UR\u00a0hasta\u00a0el\u00a0suceso\u00a0a\u00a0estudio\u201d,\u00a0que\u00a0se\u00a0mantiene \u00a0si\u00a0este\u00a0termino\u00a0es\u00a0\nsignificativo. \u00a0\n\u00a0Se\u00a0estim\u00f3\u00a0el\u00a0modelo\u00a0inicial\u00a0de\u00a0referencia,\u00a0 o\u00a0modelo\u00a0con\u00a0 el\u00a0m\u00e1ximo\u00a0\nn\u00famero\u00a0de\u00a0variables, \u00a0como\u00a0aquel\u00a0 que\u00a0conten\u00edan \u00a0las\u00a0variables\u00a0estad\u00edsticamente \u00a0\nsignificativas, \u00a0las\u00a0variables\u00a0confusoras, \u00a0independientemente \u00a0de\u00a0su\u00a0nivel\u00a0de\u00a0\nsignificaci\u00f3n, \u00a0y\u00a0las\u00a0variables\u00a0tiempo\u00a0dependientes \u00a0con\u00a0sus\u00a0 t\u00e9rminos\u00a0de\u00a0\ninteracci\u00f3n \u00a0\u00a0si\u00a0estos\u00a0eran\u00a0significativos. \u00a0A\u00a0partir\u00a0del\u00a0modelo\u00a0de\u00a0referencia \u00a0se\u00a0\nfueron\u00a0construyendo\u00a0 todos\u00a0los\u00a0posibles\u00a0modelos\u00a0reducidos, \u00a0como\u00a0modelos\u00a0\nanidados, \u00a0excluyendo \u00a0variables\u00a0y\u00a0valorando \u00a0el\u00a0impacto\u00a0que\u00a0la\u00a0exclusi\u00f3n \u00a0de\u00a0esa\u00a0\nvariable\u00a0tenia\u00a0sobre\u00a0el\u00a0nuevo\u00a0modelo.\u00a0Esta\u00a0comparaci\u00f3n \u00a0se\u00a0efectuaba \u00a0por\u00a0medio\u00a0\ndel\u00a0likelohood \u00a0ratio\u00a0test\u00a0(estad\u00edstico \u00a0G)\u00a0que\u00a0compara\u00a0 el\u00a0modelo\u00a0de\u00a0referencia \u00a0con\u00a0\nel\u00a0nuevo\u00a0 modelo.\u00a0Si\u00a0no\u00a0se\u00a0apreciaban \u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significativas, \u00a0\nse\u00a0conclu\u00eda\u00a0que\u00a0la\u00a0variable\u00a0no\u00a0aportaba\u00a0nada\u00a0al\u00a0modelo\u00a0y\u00a0era\u00a0excluida\u00a0del\u00a0mismo.\u00a0\nEn\u00a0la\u00a0selecci\u00f3n\u00a0final,\u00a0si\u00a0dos\u00a0modelos\u00a0presentaban \u00a0un\u00a0valor\u00a0similar\u00a0se\u00a0seleccion\u00f3 \u00a0\naquel\u00a0 m\u00e1s\u00a0preciso,\u00a0cuyos\u00a0coeficientes \u00a0presentaban\u00a0 un\u00a0intervalo\u00a0de\u00a0confianza \u00a0m\u00e1s\u00a0\nestrecho. \u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0 73\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n3.6. ANEXOS\u00a0\n\u00a0\n3.6.1.  ANEXO\u00a0I.\u00a0Valoraci\u00f3n \u00a0y\u00a0seguimiento \u00a0del\u00a0paciente\u00a0\npolitraumatizado \u00a0\n3.6.2.  \u00a0\n3.6.3.  \u00a0\n\u00a0 74\nIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n3.6.4.  ANEXO\u00a0II.\u00a0Protocolo \u00a0de\u00a0actuaci\u00f3n \u00a0para\u00a0el\u00a0estudio\u00a0radiol\u00f3gico\u00a0 de\u00a0\nla\u00a0columna\u00a0 vertebral \u00a03.6.4.  ANEXO\u00a0II.\u00a0Protocolo \u00a0de\u00a0actuaci\u00f3n \u00a0para\u00a0el\u00a0estudio\u00a0radiol\u00f3gico\u00a0 de\u00a0\nla\u00a0columna\u00a0 vertebral \u00a0\n\u00a0\n\u00a0 75 \u00a0 75\nIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0 76Rx.\u00a0Cervical\u00a0lateral:\u00a0\nRx.\u00a0Pelvis:\u00a0\nRx.\u00a0Columna\u00a0dorsolumbar: \u00a0\nRx.\u00a0T\u00f3rax:\u00a0\nOtros:\u00a0EXPLORACIONES \u00a0RADIOL\u00d3GICAS\nANAL\u00cdTICA \u00a0AL\u00a0INGRESO \u00a0\n\u00b5 NEUROCIRUG\u00cdA\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fecha\u00a0y\u00a0\u00a0Firma:\n\u00a0\n\u00b5 TRAUMATOLOG\u00cdA \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fecha\u00a0y\u00a0\u00a0Firma:\u00a0\n\u00a0\n\u00b5 OTROS:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Fecha \u00a0y\u00a0\u00a0Firma:\u00a0INTERCONSULTAS\u00a0 REALIZADASIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n3.6.5.  ANEXO\u00a0III.\u00a0Examen\u00a0de\u00a0la\u00a0Historia\u00a0cl\u00ednica\u00a0y\u00a0observaci\u00f3n \u00a0directa\u00a0del\u00a0\npaciente\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0 77MOTIVO\u00a0DE\u00a0INGRESO: \u00a0\n\u00a0\nANTECEDENTES \u00a0PERSONALES: \u00a0\n\u00a0\nENFERMEDAD \u00a0ACTUAL:\u00a0INGRESO \u00a0HOSPITALARIO. \u00a0SERVICIO\nA:\u00a0\nB:\u00a0\nC:\u00a0\nD:\u00a0VALORACI\u00d3N \u00a0PRIMARIA \u00a0Y\u00a0RESUCITACI\u00d3N\nCABEZA,\u00a0 CARA\u00a0Y\u00a0CUELLO:\u00a0\nT\u00d3RAX:\u00a0\nABDOMEN: \u00a0\nPELVIS:\u00a0\nEXTREMIDADES: \u00a0\nESPALDA \u00a0Y\u00a0PERIN\u00c9:\u00a0\nS.N.C.\u00a0(reflejos\u00a0incluidos): \u00a0VALORACI\u00d3N \u00a0SECUNDARIA \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n3.6.6.  ANEXO\u00a0IV.\u00a0Vigilancia\u00a0 Epidemiol\u00f3gica. \u00a0Criterios\u00a0del\u00a0CDC\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0 78UNIDAD\u00a0DE\u00a0MEDICINA\nPREVENTIVA\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\n\u00a0\n\u00a0 79\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0\nCRITERIOS DEL \u201cCENTERS FOR DISEASE CONTROL\u201d \n(CDC) PARA DIAGN\u00d3STICO DE LAS INFECCIONES \nNOSOCOMIALES. ADAPTACI\u00d3N DE LOS CRITERIOS DEL CDC, DE \n1988 Y MODIFICADOS EN 1992. \nCRITERIOS SEGUIDOS EN LAS DEFINICIONES \n    Estas Definiciones se basa n en unos criterios generales: \nPrimero. La informaci\u00f3n usada para diagnost icar una infecci\u00f3n y clasificarla \nincluye varias combinaciones de datos cl\u00ednicos, resultados anal\u00edticos y otras \nexploraciones complementarias. La evidencia cl\u00ednica se puede obtener a partir \nde la exploraci\u00f3n directa del paciente o de la revisi\u00f3n de la Historia Cl\u00ednica u \notros documentos del enfermo, como la gr\u00e1fica de temperatura. \n    El diagn\u00f3stico de laboratorio se puede obtener a partir de los cultivos, de \npruebas para la detecci\u00f3n de ant\u00edgenos o anticuerpos, y de la visualizaci\u00f3n \ndirecta de los microorganismos. El  resultado de las exploraciones \ncomplementarias como radiograf\u00edas, ec ograf\u00edas, TAC, RNM, gammagraf\u00edas, \nendoscopias, biopsias o citolog\u00edas por aspiraci\u00f3n se utiliza para confirmar las \nsospechas cl\u00ednicas. \nSegundo. Un diagn\u00f3stico de infecci\u00f3n realizad o por un m\u00e9dico a partir de una \nobservaci\u00f3n directa durante una intervenci\u00f3n, una endoscopia o cualquier otra \nt\u00e9cnica se considera un criterio v\u00e1lido de infecci\u00f3n mientras no se demuestre \nlo contrario. En ciertas localizaciones estos criterios exigen adem\u00e1s, que el \ndiagn\u00f3stico cl\u00ednico de un m\u00e9dico se acompa\u00f1e del inicio del tratamiento \nantibi\u00f3tico adecuado. \nTercero.  Una infecci\u00f3n se considera nosocomial si no hay indicios de que el \npaciente la tuviera ni en fase cl\u00ednica ni de incubaci\u00f3n al ingresar. \n\u00a0 80Cuarto. Una infecci\u00f3n que aparece en alguna  de estas circunstancias no se \nconsidera nosocomial: 1) la asociada a una complicaci\u00f3n o diseminaci\u00f3n de una \ninfecci\u00f3n que ya estaba presente en el momento del ingreso, si no ha habido \nalg\u00fan cambio de microorganismos ni ha n aparecido s\u00edntomas muy sugestivos \nde que el paciente ha adquirido una nueva infecci\u00f3n y 2) la adquirida por v\u00eda \ntransplacentaria (herpes simple, toxoplasmosis, rub\u00e9ola, citomegalovirus, y s\u00edfilis) diagnosticada poco despu\u00e9s del nacimiento. IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n \nQuinto. E n  l a  m a y o r \u00ed a  d e  l o c a l i z a c i o n e s  n o  s e  e x i g e  u n  m \u00ed n i m o  d e  d \u00ed a s  d e  \nestancia hospitalaria para considerar que una infecci\u00f3n es nosocomial. Para establecer su tipo debe estudiarse cada caso en particular. \n    A continuaci\u00f3n se exponen los crit erios del CDC para el diagn\u00f3stico de las \ninfecciones nosocomiales m\u00e1s comunes.  \n1.- CRITERIOS PARA DIAGNOSTICAR UNA NEUMON\u00cdA \nNOSOCOMIAL  \n    La neumon\u00eda se define independient emente del resto de infecciones de las \nv\u00edas respiratorias bajas. Para diagnosticarla se han incluido diversas \ncombinaciones de signos cl\u00ednicos, radiol\u00f3gicos y de laboratorio. Normalmente, los cultivos de las secreciones respiratorias expectoradas por el paciente no \nson \u00fatiles para el diagn\u00f3stico pero s\u00ed para la identificaci\u00f3n del agente y de su \nperfil de resistencias. El diagn\u00f3stico efectuado a partir de una serie de \nradiograf\u00edas es m\u00e1s fiable que el obtenido con una \u00fanica radiograf\u00eda. \n    Una neumon\u00eda debe cumplir a lguno de los siguientes criterios: \n1. Estertores o matidez a la percusi\u00f3n en la exploraci\u00f3n f\u00edsica del t\u00f3rax y \nalguno de los siguientes: \n        -Comienzo de la expectoraci\u00f3n purulenta o cambio en las caracter\u00edsticas \ndel esputo. \n      -Aislamiento de organismos en el hemocultivo. \n      -Aislamiento de organismos en muestras obtenidas por aspiraci\u00f3n \ntranstraqueal, cepillado bronquial o biopsia. \n2. El examen radiol\u00f3gico muestra un infiltrado nuevo o progresivo, \nconsolidaci\u00f3n, cavitaci\u00f3n, o derrame pleural y alguno de los siguientes: \n      -Comienzo de la expectoraci\u00f3n purulenta o cambio en las caracter\u00edsticas \ndel esputo. \n      -Aislamiento de organismos en el esputo. \n\u00a0 81      Aislamiento de organismos en muestras obtenidas por aspiraci\u00f3n \ntranstraqueal, cepillado bronquial o biopsia. IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n \n      -Aislamiento de virus o detecci\u00f3n del ant\u00edgeno en secreciones \nrespiratorias. \n      -T\u00edtulo \u00fanico de anticuerpos diagn\u00f3sticos (Ig M) o aumento de 4 veces en \nparejas de sueros (Ig G) para el agente. \n      -Diagn\u00f3stico histopatol\u00f3gico de neumon\u00eda. \n \n2.- CRITERIOS PARA DIAGNOSTICAR UNA BACTERIEMIA  \nLas bacteriemias primarias incluyen tanto las sepsis confirmada por \nlaboratorio como las cl\u00ednicas. \n La bacteriemia confirmada por laboratorio debe cumplir uno de los \nsiguientes criterios: \n1. En el hemocultivo se ha aislado un microorganismo que no se relaciona con \nning\u00fan otro foco de infecci\u00f3n. \n2. Uno de los siguientes: fiebre (>38\u00baC), escalofr\u00edos, hipotensi\u00f3n y cualquiera \nde los siguientes: \n      -En dos hemocultivos que no se  han practicado simult\u00e1neamente se ha \naislado el mismo microorganismo, que es co ntaminante habitual de la piel y no \nse relaciona con ning\u00fan ot ro foco de infecci\u00f3n. \n      -En un hemocultivo practicado a un paciente portador de una c\u00e1nula \nintravascular se ha aislado un contaminante  habitual de la piel y el m\u00e9dico ha \nprescrito el tratamiento antibi\u00f3tico adecuado. \n      -En un test para la detecci\u00f3n de ant\u00edgenos en sangre se ha identificado un \nmicroorganismo que no se relaciona co n ning\u00fan otro foco de infecci\u00f3n. \n La sepsis cl\u00ednica debe cumplir cualquiera de los siguientes criterios: Uno de estos si no hay ninguna otra causa que los explique: fiebre (>38\u00baC), \nhipotensi\u00f3n (presi\u00f3n sist\u00f3lica < 90 mmHg) u oliguria y cualquiera de los \nsiguientes: \n\u00a0 82 IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n      -No se ha practicado ning\u00fan hemocultivo o no se ha aislado ning\u00fan \nmicroorganismo, y el resultado de los test para detecci\u00f3n de ant\u00edgenos en \nsangre son negativos. \n      -No se ha descubierto ning\u00fan otro foco de infecci\u00f3n. \n      -El m\u00e9dico ha prescrito el tr atamiento antibi\u00f3tico adecuado para una \nsepsis.  Las bacteriemias secundarias , son aquellas que el microorganismo \naislado en el hemocultivo es compatible con otra infecci\u00f3n nosocomial. Como \nexcepci\u00f3n, las bacteriemias relacionadas  con dispositivos intravasculares se \nconsideran primarias aunque en las zonas e acceso vascular haya signos de \ninfecci\u00f3n. \n \n3.- CRITERIOS PARA DIAGNOSTICAR UNA INFECCI\u00d3N DE LA \nHERIDA QUIR\u00daRGICA  \n Las infecciones del lugar de la intervenci\u00f3n se dividen en dos tipos: las \nincisionales y la de \u00f3rganos o espacios. A su vez, las incisionales se subdividen \nen superficiales y profundas. \n Las infecciones incisionales superficiales son aquellas que afectan s\u00f3lo \nla piel y el tejido celular subcut\u00e1neo, mientras que las profundas afectan los \ntejidos blandos profundos de la inci si\u00f3n. La infecci\u00f3n de los \u00f3rganos o \nespacios, abiertos o manipulados durante el acto operatorio, afecta a \ncualquier parte de la anatom\u00eda (\u00f3rganos o espacios) diferentes de la incisi\u00f3n. \n Una infecci\u00f3n superficial  debe cumplir los siguientes criterios: \nSe produce durante los 30 d\u00edas posteriores a la cirug\u00eda y afecta s\u00f3lo a la piel \ny tejido celular subcut\u00e1neo en el lugar de la incisi\u00f3n. Adem\u00e1s deben hallarse \nuno de los siguientes criterios: \n1. Drenaje purulento de la incisi\u00f3n superficial. \n2. Aislamiento de un microorganismo en el  cultivo de un l\u00edquido o de un tejido \np r o c e d e n t e  d e  l a  i n c i s i \u00f3 n  s u p e r f i c i a l  ( a  p a r t i r  d e  u n a  m u e s t r a  o b t e n i d a  d e  \nforma as\u00e9ptica). \n\u00a0 833. Al menos uno de los siguientes  signos o s\u00edntomas de infecci\u00f3n: IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n \n      -Dolor o hipersensibilidad al tacto o a la presi\u00f3n.       -Inflamaci\u00f3n (calor, tumefacci\u00f3n y eritema). \n      -La incisi\u00f3n superficial es ab ierta deliberadamente por el cirujano, a \nmenos que el cultivo sea negativo. \n      -Diagn\u00f3stico m\u00e9dico de in fecci\u00f3n superficial de la incisi\u00f3n. \n Los siguientes casos no se cons ideran infecciones superficiales: \nabsceso m\u00ednimo del punto de sutura, quemadura infectada, infecci\u00f3n incisional \nque se extiende hacia la fascia y paredes musculares. \nUna infecci\u00f3n profunda de la incisi\u00f3n  debe cumplir los siguientes criterios: \nSe produce durante los 30 d\u00edas posteriores a la cirug\u00eda si no se ha colocado \nning\u00fan implante (cualquier cuerpo extra\u00f1o de origen no humano que se implante de forma permanente), o dentro  d e l  p r i m e r  a \u00f1 o  s i  s e  h a  c o l o c a d o  \nalguno y la infecci\u00f3n est\u00e1 relacionada con el procedimiento quir\u00fargico y \nadem\u00e1s, la infecci\u00f3n afecta a los teji dos blandos profundos de la incisi\u00f3n \n(fascia y paredes musculares). Adem\u00e1s deben hallarse alguno de los \nsiguientes criterios: \n1. Drenaje purulento de la zona profunda de la incisi\u00f3n pero no de los \u00f3rganos \no espacios. La incisi\u00f3n profunda se abre espont\u00e1neamente o la abre el \ncirujano cuando el paciente tiene al menos uno de los siguientes signos o s\u00edntomas, a no ser que el cultivo sea negativo. \n      -Fiebre (>39\u00baC). \n      -Dolor localizado. \n      -Hipersensibilidad al tacto o a la presi\u00f3n. \n2. Durante una reintervenci\u00f3n o por inspecci\u00f3n directa o por estudio \nhistopatol\u00f3gico o radiol\u00f3gico, se halla un absceso u otra evidencia que afecta \na los tejidos profundos de la incisi\u00f3n. \n3. Diagn\u00f3stico m\u00e9dico de infecc i\u00f3n profunda de la incisi\u00f3n. \n\u00a0 84Una infecci\u00f3n de \u00f3rgano o de espacio af ecta a cualquier parte de la anatom\u00eda, \ndistinta de la incisi\u00f3n, abierta o manipulada durante el procedimiento \noperatorio. IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n \n La infecci\u00f3n de \u00f3rgano o de espacio  debe cumplir los siguientes \ncriterios: Se produce en los 30 d\u00edas posteriores a la  intervenci\u00f3n si no se han colocado \nimplantes, o en el curso del a\u00f1o siguiente a la intervenci\u00f3n si se han colocado, \ny la infecci\u00f3n est\u00e1 relacionada con el procedimiento quir\u00fargico, y adem\u00e1s, la infecci\u00f3n afecte cualquier parte de la anatom\u00eda, abierta o manipulada durante \nel acto operatorio, distinta de la incisi\u00f3n. Adem\u00e1s debe hallarse presente uno \nde los siguientes criterios: \n1. L\u00edquido purulento recogido mediante drenaje colocado en un \u00f3rgano o un \nespacio. Si el \u00e1rea por donde penetra el tubo de drenaje en la piel se ha \ninfectado, la infecci\u00f3n no se considerar\u00e1 quir\u00fargica, sino de la piel o de los \ntejidos blandos, seg\u00fan su profundidad. \n2. Durante una reintervenci\u00f3n, o por inspecci\u00f3n directa, o por estudio \nhistopatol\u00f3gico o radiol\u00f3gico, se halla un absceso u otra evidencia de \ninfecci\u00f3n que afecta alg\u00fan \u00f3rgano o espacio. \n3. Aislamiento de microorganismos en muestras obtenidas de forma as\u00e9ptica \na partir de fluidos o tejidos procedentes de \u00f3rganos o espacios. \n4. Diagn\u00f3stico m\u00e9dico de infecc i\u00f3n quir\u00fargica de \u00f3rgano/espacio. \n Las infecciones que afectan a m\u00e1s de un sitio espec\u00edfico. Las \ninfecciones que afectan tanto la incisi\u00f3n superficial como la profunda se \nclasificar\u00e1n como infecci\u00f3n profunda de la incisi\u00f3n. \nOcasionalmente, una infecci\u00f3n de \u00f3rga no (espacio drena a trav\u00e9s de la \nincisi\u00f3n, y generalmente estas infecciones  se consideran como complicaciones \nde la incisi\u00f3n, por lo que se clasificaran como infecciones incisionales \nprofundas. \n \n4.- CRITERIOS PARA DIAGNOSTIC AR UNA INFECCI\u00d3N DEL TRACTO \nURINARIO  \n Las infecciones de las v\u00edas urinarias incluyen las infecciones \nsintom\u00e1ticas y el resto de las infecciones urinarias. \n\u00a0 85 IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n \n La infecci\u00f3n sintom\u00e1tica del tracto urinario debe comprender uno \nde los siguientes criterios: 1. Un signo cl\u00ednico (fiebre >38\u00baC, tenesmo uretral, polaquiuria, disuria, \nsensibilidad suprap\u00fabica) y cultivo de orina de m\u00e1s de 100.000 colonias/ml de \norina con no m\u00e1s de 2 especies de organismos. \n2. Dos signos cl\u00ednicos y alguno de los siguientes: \n      -Test de tira positiva pa ra leucocito-esterasa y/o nitrato. \n      -Piuria (>10 leucocitos/ml \u00f3 > 3con campos de alta resoluci\u00f3n de orina no \ncentrifugada).  \n      -Observaci\u00f3n de organismos en una tinci\u00f3n de gram de orina no \ncentrifugada. \n       -Dos cultivos urinarios con aislamientos repetidos del mismo uropat\u00f3geno \ncon > 100 colonias/ml de orina en muestras no evacuadas. \n      -Cultivo urinario con < 100.00 0 colonias/ml de orina de un uropat\u00f3geno \n\u00fanico, en pacientes que han iniciado tratamiento antibi\u00f3tico.  La bacteriuria asintom\u00e1tica  debe comprender alguno de los siguientes \ncriterios: \n1. Presencia de cat\u00e9ter urinario en los 7 d\u00edas antes del cultivo en pacientes \ncon ausencia de signos cl\u00ednicos de infecci\u00f3n y cultivo de orina > 100.000 \norganismos/ml de orina con no m\u00e1 s de dos especies pat\u00f3genas. \n2. Ausencia de cat\u00e9ter urinario en lo s 7 d\u00edas antes del cultivo en pacientes \ncon ausencia de signos cl\u00ednicos de in fecci\u00f3n y cultivo > 100.000 organismos/ml \nde orina con no m\u00e1s de dos especies pat\u00f3genas. \n Otras infecciones del tracto urinario  (ri\u00f1\u00f3n, ur\u00e9ter, vejiga, uretra o \ntejidos circundantes de los espacios retroperitoneales o perin\u00e9fricos) deben \ncomprender uno de los siguientes criterios: \n1. Aislamiento de organismos en cultivo de  otro l\u00edquido distinto de la orina, o \ntejido de sitio afectado. \n\u00a0 862. Absceso u otra evidencia de infecci\u00f3n que aparece en el examen directo, \ndurante la cirug\u00eda o por examen histopatol\u00f3gico. IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIII.\u2010\u00a0MATERIAL \u00a0Y\u00a0M\u00c9TODOS. \u00a0\n\u00a0 87 \n3. Dos de los siguientes signos o s\u00ednt omas (fiebre > 38\u00baC, dolor localizado o \nsensibilidad dolorosa en el lugar afecto) y alguno de los siguientes:        -Drenaje purulento del sitio afectado. \n      -Aislamiento de or ganismo en el hemocultivo. \n      -Evidencia radiol\u00f3gica de infecci\u00f3n.       -Diagn\u00f3stico m\u00e9dico. \n      -El m\u00e9dico establece terapia antimicrobiana adecuada. \n  \n \n  \n \n  IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nIV.\u2010\u00a0RESULTADOS \u00a0\n\u00a0\n\u00a0\n\u00a0 88\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\n4.1. AN\u00c1LISIS \u00a0DESCRIPTIVO \u00a0\n\u00a0\n4.1.1.  Cohorte\u00a0general\u00a0y\u00a0sus\u00a0caracter\u00edsticas \u00a0\n\u00a0\nLa\u00a0actividad\u00a0asistencial \u00a0de\u00a0la\u00a0UR\u00a0desde\u00a01/01/1996 \u00a0al\u00a031/12/2007 \u00a0ha\u00a0sido\u00a0\nde\u00a07951\u00a0ingresos,\u00a0lo\u00a0que\u00a0origin\u00f3\u00a027380\u00a0estancias, \u00a0con\u00a0una\u00a0media\u00a0de\u00a02489\u00a0\nestancias \u00a0anuales.\u00a0 De\u00a0los\u00a07951\u00a0pacientes \u00a0ingresados, \u00a0se\u00a0recogieron \u00a0las\u00a0historias\u00a0\ncl\u00ednicas\u00a0 de\u00a096\u00a0pacientes \u00a0afectos\u00a0de\u00a0LMAT\u00a0que\u00a0configuran\u00a0 la\u00a0poblaci\u00f3n \u00a0de\u00a0estudio,\u00a0\ningresados \u00a0tanto\u00a0de\u00a0forma\u00a0programada \u00a0como\u00a0de\u00a0urgencia\u00a0 independientemente \u00a0\ndel\u00a0tiempo\u00a0de\u00a0ingreso\u00a0en\u00a0la\u00a0UR.\u00a0\n\u00a0\nLa\u00a0estancia\u00a0media\u00a0 en\u00a0la\u00a0UR\u00a0fue\u00a0de\u00a010,51\u00a0\u00b1\u00a011,61\u00a0d\u00edas,\u00a0con\u00a0un\u00a0rango\u00a0de\u00a02\u00a0\u2010\u00a0\n78\u00a0d\u00edas.\u00a0El\u00a0porcentaje \u00a0o\u00a0\u00edndice\u00a0de\u00a0ocupaci\u00f3n \u00a0fue\u00a0de\u00a0un\u00a086,67%.\u00a0\n\u00a0Durante\u00a0los\u00a0\u00a0a\u00f1os\u00a02007\u00a0y\u00a02005\u00a0se\u00a0produjeron \u00a0los\u00a0picos\u00a0 de\u00a0ingresos\u00a0en\u00a0la\u00a0\nUnidad\u00a0 con\u00a0un\u00a011,46%\u00a0 (11\u00a0pacientes \u00a0por\u00a0a\u00f1o),\u00a0mientras\u00a0que\u00a0en\u00a0los\u00a0a\u00f1os\u00a01996\u00a0y\u00a0\n2000\u00a0solamente \u00a0representan \u00a0un\u00a05,21%\u00a0 (5\u00a0pacientes \u00a0por\u00a0a\u00f1o)\u00a0respectivamente. \u00a0\n\u00a0\nLa\u00a0media\u00a0 de\u00a0edad\u00a0fue\u00a0de\u00a035,92\u00a0\u00b1\u00a016,13\u00a0a\u00f1os,\u00a0con\u00a0mediana\u00a0de\u00a032,5\u00a0a\u00f1os\u00a0y\u00a0\nun\u00a0rango\u00a0de\u00a03\u00a0a\u00a089,\u00a0con\u00a0 un\u00a075%\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0menor\u00a0de\u00a044\u00a0\u00a0 a\u00f1os.\u00a0La\u00a0\nestratificaci\u00f3n \u00a0de\u00a0la\u00a0cohorte\u00a0por\u00a0sexos\u00a0 fue\u00a0de\u00a076\u00a0(79,17%)\u00a0varones\u00a0 y\u00a020\u00a0(20,83%)\u00a0\nmujeres.\u00a0Su\u00a0distribuci\u00f3n \u00a0por\u00a0sexos\u00a0y\u00a0edad,\u00a0se\u00a0muestra\u00a0 en\u00a0la\u00a0siguiente\u00a0pir\u00e1mide\u00a0\npoblacional \u00a0global.\u00a0\n\u00a0\nPIRAMIDE DE POBLACION DE LA COHORTE.\n-25 -20 -15 -10 -5 0 5 1081-9071-8061-7051-6041-5031-4021-3011-200-10EDADES\nN\u00ba DE PERSONASHombres\nMujeres\n\u00a0\n\u00a0 89Figura\u00a011.\u2010\u00a0PIR\u00c1MIDE \u00a0DE\u00a0POBLACI\u00d3N \u00a0DE\u00a0LA\u00a0COHORTEIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\nObserv\u00e1ndose \u00a0que\u00a0se\u00a0trata\u00a0de\u00a0una\u00a0pir\u00e1mide\u00a0poblacional \u00a0arr\u00edtmica\u00a0 con\u00a0un\u00a0\nmarcado\u00a0desequilibrio \u00a0entre\u00a0 sexos\u00a0y\u00a0edades,\u00a0siendo\u00a0el\u00a0grupo\u00a0de\u00a0edad\u00a0m\u00e1s\u00a0\nfrecuente \u00a0el\u00a0de\u00a021\u201030\u00a0a\u00f1os.\u00a0La\u00a0raz\u00f3n\u00a0de\u00a0masculinidad \u00a0fue\u00a0de\u00a03,80\u00a0y\u00a0presenta\u00a0la\u00a0\npir\u00e1mide\u00a0poblacional \u00a0\u00a0un\u00a0perfil\u00a0t\u00edpico\u00a0de\u00a0poblaci\u00f3n \u00a0expansiva. \u00a0\n\u00a0\nDe\u00a0los\u00a0pacientes \u00a0de\u00a0la\u00a0cohorte,\u00a0los\u00a0de\u00a0nacionalidad \u00a0espa\u00f1ola\u00a0representan \u00a0\nun\u00a087,5%\u00a0 (84\u00a0pacientes) \u00a0del\u00a0total\u00a0de\u00a0los\u00a0ingresos.\u00a0El\u00a0resto\u00a0de\u00a0pacientes\u00a0 son\u00a0un\u00a0\n6,25%\u00a0 (6\u00a0pacientes) \u00a0africanos, \u00a0un\u00a04,16%\u00a0 (4\u00a0pacientes) \u00a0europeos\u00a0 y\u00a0un\u00a02,08%\u00a0 (2\u00a0\ncasos)\u00a0sudamericanos. \u00a0\u00a0\n\u00a0\nLa\u00a0distribuci\u00f3n \u00a0de\u00a0pacientes \u00a0estratificados \u00a0seg\u00fan\u00a0su\u00a0\u00edndice\u00a0de\u00a0riesgo\u00a0\nintr\u00ednseco \u00a0evaluado\u00a0por\u00a0la\u00a0clasificaci\u00f3n \u00a0del\u00a0\u00edndice\u00a0de\u00a0Comorbilidades \u00a0de\u00a0Deyo\u2010\nCharlson\u00a0y\u00a0APACHE\u00a0II\u00a0(Acuse\u00a0Physiology \u00a0and\u00a0Chronic\u00a0Health\u00a0Evaluation) \u00a0se\u00a0\nmuestran \u00a0en\u00a0la\u00a0tabla\u00a07.\u00a0\u00a0El\u00a0 71,88%\u00a0(69\u00a0pacientes) \u00a0de\u00a0la\u00a0cohorte\u00a0no\u00a0presenta\u00a0\ncomorbilidad \u00a0asociada. \u00a0\n\u00a0\n\u00a0 Tabla\u00a0 7.\u00a0\u00a0\u00cdndice\u00a0de\u00a0Comorbilidad \u00a0de\u00a0Deyo\u2010Charlson. \u00a0\n\u00a0 N\u00ba\u00a0Comorbilidades. \u00a0 N\u00ba\u00a0 %\u00a0\n\u00a0Comorbilidad \u00a00.\u00a0 69\u00a0 71,88\u00a0\n\u00a0Comorbilidad \u00a01.\u00a0 10\u00a0 10,42\u00a0\n\u00a0Comorbilidad \u00a02.\u00a0\u00a0 8\u00a0 8,33\u00a0\n\u00a0Comorbilidad \u00a03.\u00a0 4\u00a0 4,17\u00a0\n\u00a0Comorbilidad \u00a04.\u00a0 2\u00a0 2,08\u00a0\n\u00a0Comorbilidad \u00a05.\u00a0\u00a0 3\u00a0 3,12\u00a0\n\u00a0TOTAL.\u00a0 96\u00a0 100\u00a0\n\u00a0N\u00ba:\u00a0N\u00famero\u00a0de\u00a0casos.\u00a0%:\u00a0Tanto\u00a0por\u00a0ciento.\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0 90IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nRespecto\u00a0a\u00a0la\u00a0clasificaci\u00f3n \u00a0APACHE\u00a0II,\u00a0presenta\u00a0una\u00a0media\u00a0 de\u00a012,82\u00a0\u00b1\u00a07,25\u00a0\ny\u00a0un\u00a0rango\u00a0de\u00a03\u00a0\u2013\u00a042.\u00a0\u00a0\n\u00a0 Figura\u00a012.\u2010ESTRATIFICACI\u00d3N \u00a0POR\u00a0APACHE \u00a0II\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0Figura 1. APACHE II.\n624\n3 31842\n051015202530354045\n< 10 10 a 15 16 a 20 21 a 25 26 a 30 > 30\nAPACHE IIN\u00famero de casos.\n\u00a0\nLa\u00a0mortalidad\u00a0 de\u00a0la\u00a0cohorte\u00a0de\u00a0pacientes \u00a0con\u00a0LMA\u00a0durante\u00a0el\u00a0periodo\u00a0de\u00a0\nestudio\u00a0fue\u00a0de\u00a0un\u00a010,42%\u00a0 (10\u00a0casos).\u00a0Treinta\u00a0pacientes \u00a0(31,25%)\u00a0precisaron \u00a0\ndurante\u00a0el\u00a0ingreso\u00a0en\u00a0la\u00a0Unidad\u00a0 de\u00a0traqueotom\u00eda \u00a0por\u00a0diversos\u00a0motivos,\u00a0y\u00a0en\u00a06\u00a0\ncasos\u00a0fue\u00a0preciso\u00a0t\u00e9cnicas\u00a0de\u00a0depuraci\u00f3n \u00a0renal\u00a0mediante \u00a0di\u00e1lisis\u00a0y/o\u00a0\nhemofiltraci\u00f3n \u00a0veno\u2010venosa\u00a0continua\u00a0(HFVVC)\u00a0o\u00a0intermitente \u00a0(HFVVI).\u00a0\u00a0\n\u00a0\nResumiendo \u00a0las\u00a0caracter\u00edsticas \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0diremos\u00a0 que\u00a0el\u00a091,66%\u00a0 de\u00a0\nlos\u00a0pacientes \u00a0ingresaron \u00a0directamente \u00a0en\u00a0la\u00a0UR\u00a0desde\u00a0el\u00a0exterior\u00a0del\u00a0hospital,\u00a0por\u00a0\nlo\u00a0que\u00a0la\u00a0mediana\u00a0de\u00a0la\u00a0estancia\u00a0en\u00a0el\u00a0hospital\u00a0previo\u00a0al\u00a0ingreso\u00a0en\u00a0la\u00a0UR\u00a0fue\u00a0de\u00a00\u00a0\nd\u00edas,\u00a0el\u00a095,83%\u00a0de\u00a0los\u00a0ingresos\u00a0son\u00a0de\u00a0car\u00e1cter\u00a0urgente,\u00a0y\u00a0el\u00a04,17\u00a0%\u00a0programados. \u00a0\n\u00a0En\u00a0la\u00a0Tabla\u00a08\u00a0se\u00a0exponen\u00a0 las\u00a0principales \u00a0caracter\u00edsticas \u00a0demogr\u00e1ficas \u00a0de\u00a0\nforma\u00a0individualizada \u00a0de\u00a0los\u00a0pacientes \u00a0de\u00a0la\u00a0cohorte\u00a0de\u00a0LMAT\u00a0que\u00a0fueron\u00a0exitus\u00a0\nletalis\u00a0durante\u00a0el\u00a0ingreso\u00a0en\u00a0la\u00a0UR.\u00a0\u00a0\n\u00a0\n\u00a0 91\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nTabla\u00a0 8.\u2010\u00a0Caracter\u00edsticas \u00a0de\u00a0los\u00a0pacientes\u00a0 con\u00a0Exitus\u00a0Letalis\u00a0en\u00a0UR.\u00a0\nEdad/\u00a0\nSexo.\u00a0LMA.\u00a0 Etiolog\u00eda. \u00a0APACHE\u00a0\nII.\u00a0Exitus\u00a0\n(d\u00edas)\u00a0Traumas\u00a0\nasociados. \u00a0NASCIS\u00a0y\u00a0\nCirug\u00eda.\u00a0Complicaciones. \u00a0\n57\u00a0\nVar\u00f3n\u00a0Cervical\u00a0 Tr\u00e1fico.\u00a0 16\u00a0 5\u00a0 Vascular.\u00a0No.\u00a0\nSi.\u00a0Neumon\u00eda \u00a0\nCardiovascular \u00a0\nSDRA\u00a0\nPolitransfusi\u00f3n \u00a0\nCoagulopatia \u00a0\nInsuficiencia \u00a0renal\u00a0\nEmbolia\u00a0pulmonar \u00a0\n66\u00a0\nVar\u00f3n\u00a0Cervical\u00a0 Tr\u00e1fico.\u00a0 24\u00a0 26\u00a0Craneal.\u00a0\nTor\u00e1cico.\u00a0\nAbdominal. \u00a0\nEsquel\u00e9tico \u00a0Si.\u00a0\nNo.\u00a0Neumon\u00eda \u00a0\nBacteriemia \u00a0\nPolitransfusi\u00f3n \u00a0\nCoagulopatia \u00a0\nInsuficiencia \u00a0renal\u00a0\nHDA\u00a0\n56\u00a0\nVar\u00f3n\u00a0Cervical\u00a0 Laboral.\u00a0 31\u00a0 4\u00a0Craneal.\u00a0\nMaxilofacial. \u00a0\n\u00a0No.\u00a0\nNo.\u00a0Cardiovascular \u00a0\n54\u00a0\nVar\u00f3n\u00a0Cervical\u00a0y\u00a0\nDorsal\u00a0Tr\u00e1fico.\u00a0 19\u00a0 27\u00a0Craneal.\u00a0\nTor\u00e1cico.\u00a0\nAbdominal. \u00a0\nEsquel\u00e9tico. \u00a0\nVascular.\u00a0No.\u00a0\nNo.\u00a0Neumon\u00eda \u00a0\nShock\u00a0s\u00e9ptico\u00a0\nSDRA\u00a0\nPolitransfusi\u00f3n \u00a0\nCoagulopatia \u00a0\nInsuficiencia \u00a0renal\u00a0\n76\u00a0\nVar\u00f3n\u00a0Cervical\u00a0 Tr\u00e1fico.\u00a0 29\u00a0 14\u00a0 Tor\u00e1cico.\u00a0No.\u00a0\nNo.\u00a0Neumon\u00eda \u00a0\nCardiovascular \u00a0\nShock\u00a0s\u00e9ptico\u00a0\nSDRA\u00a0\nCoagulopatia \u00a0\nInsuficiencia \u00a0renal\u00a0\n25\u00a0\nVar\u00f3n\u00a0Dorsal\u00a0 Tr\u00e1fico.\u00a0 23\u00a0 24\u00a0Craneal.\u00a0\nTor\u00e1cico.\u00a0\nAbdominal. \u00a0\nEsquel\u00e9tico. \u00a0\nVascular.\u00a0No.\u00a0\nNo.\u00a0Neumon\u00eda \u00a0\nBacteriemia \u00a0\nSDRA\u00a0\nPolitransfusi\u00f3n \u00a0\nInsuficiencia \u00a0renal\u00a0\nHDA\u00a0\n27\u00a0\nVar\u00f3n\u00a0Cervical\u00a0 Domestico. \u00a0 21\u00a0 23\u00a0Craneal.\u00a0\nTor\u00e1cico.\u00a0\nAbdominal. \u00a0\nEsquel\u00e9tico. \u00a0\nVascular.\u00a0Si.\u00a0\nNo.\u00a0Neumon\u00eda \u00a0\nInfecci\u00f3n\u00a0urinaria\u00a0\nCardiovascular \u00a0\nShock\u00a0s\u00e9ptico\u00a0\nSDRA\u00a0\nCoagulopatia \u00a0\n42\u00a0\nMujer\u00a0Lumbar\u00a0 Tr\u00e1fico.\u00a0 42\u00a0 3\u00a0Craneal.\u00a0\nTor\u00e1cico.\u00a0\nAbdominal. \u00a0\nVascular.\u00a0No.\u00a0\nNo.\u00a0Neumon\u00eda \u00a0\nBacteriemia \u00a0\nCardiovacular \u00a0\nSDRA\u00a0\nPolitransfusi\u00f3n \u00a0\nCoagulopatia \u00a0\n19\u00a0\nVar\u00f3n\u00a0Cervical\u00a0 Laboral.\u00a0 22\u00a0 18\u00a0Craneal.\u00a0\nTor\u00e1cico.\u00a0\nEsquel\u00e9tico. \u00a0Si.\u00a0\nNo.\u00a0Neumon\u00eda \u00a0\nCardiovascular \u00a0\nShock\u00a0s\u00e9ptico\u00a0\nSDRA\u00a0\nCoagulopatia \u00a0\nInsuficiencia \u00a0renal\u00a0\nEmbolia\u00a0pulmonar \u00a0\n18\u00a0\nVar\u00f3n\u00a0Cervical\u00a0 Autolisis.\u00a0 28\u00a0 2\u00a0Craneal.\u00a0\nTor\u00e1cico.\u00a0\nAbdominal. \u00a0\nEsquel\u00e9tico. \u00a0Si.\u00a0\nNo.\u00a0Cardiovascular \u00a0\nPolitransfusi\u00f3n \u00a0\n\u00a0 92LMA:\u00a0Lesi\u00f3n\u00a0 medular\u00a0aguda.\u00a0Exitus\u00a0(d\u00edas):\u00a0D\u00edas\u00a0de\u00a0ingreso\u00a0en\u00a0Unidad\u00a0de\u00a0Reanimaci\u00f3n \u00a0hasta\u00a0el\u00a0exitus\u00a0letales.\u00a0NASCIS\u00a0y\u00a0Cirug\u00eda:\u00a0\nPresencia \u00a0de\u00a0utilizaci\u00f3n \u00a0de\u00a0megadosis \u00a0de\u00a0corticoides \u00a0y\u00a0cirug\u00eda\u00a0durante\u00a0el\u00a0ingreso.\u00a0Complicaciones: \u00a0Complicaciones\u00a0 acontecidas \u00a0en\u00a0la\u00a0\nUnidad\u00a0de\u00a0Reanimaci\u00f3n \u00a0durante\u00a0el\u00a0ingreso \u00a0hasta\u00a0el\u00a0exitus.\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\n4.1.2.  Caracter\u00edsticas \u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0medular\u00a0aguda\u00a0\nLa\u00a0LMA\u00a0no\u00a0penetrante \u00a0representa \u00a0un\u00a096,87%\u00a0 (93\u00a0pacientes) \u00a0en\u00a0la\u00a0cohorte.\u00a0\nEl\u00a0principal\u00a0mecanismo \u00a0de\u00a0producci\u00f3n \u00a0de\u00a0la\u00a0LMA\u00a0en\u00a0la\u00a0serie\u00a0son\u00a0los\u00a0accidentes \u00a0de\u00a0\ntr\u00e1fico,\u00a0que\u00a0representan \u00a0un\u00a073,95%\u00a0 (71\u00a0casos).\u00a0Otros\u00a0mecanismos \u00a0implicados \u00a0han\u00a0\nsido\u00a0 por\u00a0precipitaci\u00f3n \u00a0(17,70%), \u00a0intento\u00a0de\u00a0autolisis\u00a0(3,12%),\u00a0aplastamiento \u00a0\n(2,08%),\u00a0atropello\u00a0(2,08%)\u00a0 y\u00a0un\u00a0caso\u00a0por\u00a0arma\u00a0de\u00a0fuego.\u00a0\n\u00a0\nEl\u00a0diagn\u00f3stico\u00a0 de\u00a0sospecha \u00a0se\u00a0llev\u00f3\u00a0 a\u00a0cabo\u00a0por\u00a0la\u00a0cl\u00ednica\u00a0en\u00a070\u00a0pacientes \u00a0\n(72.92%)\u00a0y\u00a0tras\u00a0la\u00a0realizaci\u00f3n\u00a0 de\u00a0pruebas\u00a0de\u00a0imagen,\u00a0TAC\u00a0en\u00a026\u00a0pacientes \u00a0\n(27.08%). \u00a0Se\u00a0produjo\u00a0fallo\u00a0en\u00a0el\u00a0diagn\u00f3stico \u00a0de\u00a0sospecha \u00a0\u00fanicamente \u00a0en\u00a07\u00a0\npacientes \u00a0(7.29%),\u00a0 siendo\u00a0este\u00a0diagnostico \u00a0inicial\u00a0certero\u00a0en\u00a089\u00a0pacientes \u00a0\n(92.71%). \u00a0El\u00a0diagn\u00f3stico \u00a0definitivo \u00a0se\u00a0obtuvo\u00a0tras\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0la\u00a0TAC\u00a0en\u00a0el\u00a0\n59.38%\u00a0de\u00a0los\u00a0casos\u00a0(57\u00a0pacientes), \u00a0mediante \u00a0RNM\u00a0en\u00a0el\u00a023.96%\u00a0(23\u00a0pacientes) \u00a0y\u00a0\nmediante \u00a0radiolog\u00eda \u00a0convencional \u00a0en\u00a016\u00a0pacientes \u00a0(16.67%). \u00a0En\u00a0ning\u00fan\u00a0caso\u00a0se\u00a0\nrealizo\u00a0al\u00a0diagn\u00f3stico \u00a0definitivo \u00a0mediante \u00a0la\u00a0valoraci\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0forma\u00a0aislada.\u00a0\nLas\u00a0lesiones\u00a0acompa\u00f1antes \u00a0m\u00e1s\u00a0frecuentes \u00a0fueron\u00a0el\u00a0trauma\u00a0tor\u00e1cico\u00a0(TT)\u00a0y\u00a0el\u00a0\ntrauma\u00a0 esquel\u00e9tico \u00a0(TE).\u00a0El\u00a0n\u00famero\u00a0de\u00a0casos\u00a0de\u00a0TCE,\u00a0TT,\u00a0trauma\u00a0abdominal \u00a0(TA),\u00a0\nTE,\u00a0vascular\u00a0y\u00a0trauma\u00a0 maxilofacial \u00a0(TMx),\u00a0asociados \u00a0a\u00a0la\u00a0LMA\u00a0se\u00a0aprecian\u00a0en\u00a0la\u00a0\nfigura\u00a0 13.\u00a0\nFigura\u00a010.\u00a0TRAUMAS \u00a0ACOMPA\u00d1ANTES.\n29451236710\n0 1 02 03 04 05 0TCET.\u00a0Tor\u00e1ci coT.\u00a0AbdominalT.\u00a0Esquel \u00e9ti coT.\u00a0Vascul arT.\u00a0M axilo facial\nN\u00ba\u00a0CASOS\n\u00a0\n\u00a0 93Figura\u00a013.\u2010TRAUMAS \u00a0ACOMPA\u00d1ANTESTRAUMAS \u00a0ACOMPA\u00d1ANTESIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nLas\u00a0lesiones\u00a0medulares \u00a0inadvertidas \u00a0cl\u00ednicamente \u00a0relevantes, \u00a0definidas\u00a0\ncomo\u00a0aquellas\u00a0lesiones\u00a0no\u00a0identificadas \u00a0durante\u00a0las\u00a0revisiones \u00a0primaria\u00a0y\u00a0\nsecundaria \u00a0que\u00a0pueden\u00a0 asociarse \u00a0a\u00a0complicaciones\u00a0 graves\u00a0o\u00a0incluso\u00a0 la\u00a0muerte\u00a0del\u00a0\npaciente\u00a0durante\u00a0el\u00a0periodo\u00a0de\u00a0estudio\u00a0fueron\u00a07\u00a0(7,29%).\u00a0La\u00a0mortalidad\u00a0 de\u00a0este\u00a0\nsubgrupo \u00a0fue\u00a0elevada,\u00a0de\u00a0un\u00a028,57%,\u00a0sin\u00a0alcanzar\u00a0diferencias\u00a0 significativas \u00a0(p\u00a0=\u00a0\n0,102),\u00a0 respecto\u00a0a\u00a0aquellos\u00a0pacientes \u00a0en\u00a0los\u00a0que\u00a0no\u00a0existi\u00f3\u00a0fallo\u00a0inicial\u00a0en\u00a0el\u00a0\ndiagn\u00f3stico. \u00a0El\u00a0diagn\u00f3stico\u00a0 definitivo \u00a0en\u00a06\u00a0de\u00a0los\u00a0casos\u00a0se\u00a0realiz\u00f3\u00a0mediante \u00a0RNM,\u00a0\ny\u00a0en\u00a0el\u00a0otro\u00a0fue\u00a0por\u00a0TAC.\u00a0La\u00a0columna\u00a0cervical\u00a0fue\u00a0el\u00a0segmento \u00a0m\u00e1s\u00a0incriminado\u00a0 en\u00a0\nel\u00a0fallo\u00a0diagn\u00f3stico. \u00a0\n\u00a0Las\u00a0\u00a0variables \u00a0que\u00a0presentaron \u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significaci\u00f3n \u00a0\nfue\u00a0la\u00a0presencia \u00a0de\u00a0APACHE\u00a0II\u00a0elevados\u00a0(p\u00a0=\u00a00,014),\u00a0\u00a0empleo\u00a0drogas\u00a0vasoactivas \u00a0(p\u00a0\n=\u00a00,016),\u00a0 apoyo\u00a0respiratorio \u00a0invasivo\u00a0(p\u00a0=\u00a00,028),\u00a0 lesi\u00f3n\u00a0medular\u00a0 cervical\u00a0(p\u00a0=\u00a0\n0,029),\u00a0 TCE\u00a0(p\u00a0=\u00a00,014),\u00a0 TA\u00a0(p\u00a0=\u00a00,012)\u00a0y\u00a0la\u00a0existencia \u00a0de\u00a0traumas\u00a0acompa\u00f1antes \u00a0\n(p\u00a0=\u00a00,050).\u00a0La\u00a0existencia\u00a0 de\u00a0lesiones\u00a0medulares \u00a0inadvertidas \u00a0no\u00a0se\u00a0correlacion\u00f3 \u00a0\ncon\u00a0 un\u00a0aumento\u00a0de\u00a0la\u00a0estancia\u00a0en\u00a0la\u00a0UC,\u00a0 ni\u00a0con\u00a0 un\u00a0aumento\u00a0de\u00a0las\u00a0tasas\u00a0de\u00a0\ncomplicaciones\u00a0 m\u00e9dicas\u00a0durante\u00a0la\u00a0estancia,\u00a0 con\u00a0excepci\u00f3n\u00a0 de\u00a0la\u00a0aparici\u00f3n\u00a0 de\u00a0\nepisodios \u00a0de\u00a0fallo\u00a0renal\u00a0agudo\u00a0(FRA)\u00a0(p\u00a0=\u00a00,002).\u00a0\n\u00a0La\u00a0estratificaci\u00f3n \u00a0de\u00a0pacientes\u00a0 por\u00a0el\u00a0n\u00famero\u00a0de\u00a0traumas\u00a0acompa\u00f1antes \u00a0a\u00a0\nla\u00a0LMAT\u00a0se\u00a0expone\u00a0en\u00a0la\u00a0Figura\u00a014.\u00a0En\u00a0un\u00a035,42%\u00a0(34\u00a0casos)\u00a0el\u00a0diagn\u00f3stico\u00a0 al\u00a0\ningreso\u00a0en\u00a0la\u00a0UR\u00a0fue\u00a0de\u00a0LMAT\u00a0sin\u00a0otro\u00a0traumatismo \u00a0acompa\u00f1ante. \u00a0El\u00a052,94%\u00a0(18\u00a0\ncasos)\u00a0de\u00a0estas\u00a0LMA\u00a0puras\u00a0fueron\u00a0lesiones\u00a0a\u00a0nivel\u00a0cervical,\u00a0un\u00a017,65%\u00a0 (6\u00a0casos)\u00a0\ndorsales,\u00a0 14,71%\u00a0 (5\u00a0casos)\u00a0lumbares \u00a0y\u00a0otros\u00a0\u00a05\u00a0casos\u00a0 se\u00a0catalogaron\u00a0 como\u00a0\u00a0\n\u201cSpinal\u00a0Cord\u00a0Injury\u00a0Without\u00a0Radiographic \u00a0Abnormality\u201d \u00a0(SCIWORA). \u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0 94\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\n\u00a0\n05101520253035N\u00famero\u00a0de\u00a0pacie\n012345\nN\u00famero\u00a0traum as\u00a0asociados.Figura\u00a011.\u00a0Traumas\u00a0acompa\u00f1antes \u00a0por\u00a0paciente\u00a0durante\u00a0ingreso\u00a0\nen\u00a0Unidad\u00a0de\u00a0Reanimaci\u00f3n.\n TRAUMAS \u00a0ACOMPA\u00d1ANTES \u00a0POR\u00a0PACIENTE \u00a0DURANTE \u00a0\nINGRESO ENUNIDAD REANIMACI\u00d3NDE\n\u00a0\n\u00a0\nLas\u00a0lesiones\u00a0espec\u00edficas \u00a0cervicales \u00a0son\u00a0las\u00a0m\u00e1s\u00a0frecuentes, \u00a0representando \u00a0\nun\u00a038,54%\u00a0 (37\u00a0casos),\u00a0 seguidas\u00a0muy\u00a0de\u00a0cerca\u00a0en\u00a0frecuencia \u00a0por\u00a0las\u00a0lesiones\u00a0de\u00a0la\u00a0\nmedula\u00a0dorsal\u00a0 o\u00a0tor\u00e1cica\u00a0con\u00a0un\u00a037,50%\u00a0(36\u00a0casos).\u00a0La\u00a0LMAT\u00a0lumbar\u00a0representa \u00a0\nsolo\u00a0un\u00a08,33%\u00a0(8\u00a0casos),\u00a0 mientras\u00a0que\u00a0las\u00a0lesiones\u00a0aisladas\u00a0 del\u00a0sacro\u00a0son\u00a0\ninfrecuentes, \u00a0con\u00a0un\u00a02,08%\u00a0(2\u00a0casos).\u00a0\n\u00a0\nLos\u00a0pacientes \u00a0con\u00a0 lesiones\u00a0medulares \u00a0m\u00faltiples \u00a0son\u00a0poco\u00a0frecuentes, \u00a0\nexistiendo\u00a0 solo\u00a08\u00a0casos.\u00a0Respecto\u00a0a\u00a0estas\u00a0LMA,\u00a0las\u00a0lesiones\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0cervical\u00a0\ny\u00a0tor\u00e1cica\u00a0representan \u00a0un\u00a06,25%\u00a0 (6\u00a0pacientes), \u00a0y\u00a0solo\u00a0en\u00a0un\u00a0caso\u00a0existe\u00a0la\u00a0\nasociaci\u00f3n \u00a0de\u00a0LMA\u00a0lumbar\u2010cervical\u00a0y\u00a0en\u00a0otro\u00a0LMA\u00a0lumbar\u2010tor\u00e1cica.\u00a0\u00a0\u00a0\n\u00a0\nLas\u00a0lesiones\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0dorsal\u00a0son\u00a0las\u00a0que\u00a0m\u00e1s\u00a0frecuentemente \u00a0se\u00a0\nacompa\u00f1an\u00a0 de\u00a0otros\u00a0 traumatismos, \u00a0principalmente \u00a0tor\u00e1cicos\u00a0y\u00a0esquel\u00e9ticos. \u00a0Las\u00a0\nlesiones\u00a0espec\u00edficas\u00a0 cervicales \u00a0se\u00a0asocian\u00a0con\u00a0 una\u00a0alta\u00a0incidencia \u00a0de\u00a0TCE.\u00a0En\u00a0la\u00a0\ntabla\u00a09\u00a0se\u00a0exponen\u00a0 la\u00a0asociaci\u00f3n \u00a0entre\u00a0 los\u00a0diversos\u00a0traumatismos \u00a0acompa\u00f1antes \u00a0\ny\u00a0el\u00a0nivel\u00a0topogr\u00e1fico \u00a0de\u00a0LM.\u00a0\n\u00a0\n\u00a0 95Figura\u00a014.\u2010\u00a0TRAUMAS \u00a0ACOMPA\u00d1ANTES \u00a0POR\u00a0PACIENTE \u00a0DURANTE \u00a0INGRESO \u00a0EN\u00a0UR\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\n\u00a0\nTabla\u00a09.\u2010\u00a0Relaci\u00f3n\u00a0entre\u00a0nivel\u00a0topogr\u00e1fico \u00a0de\u00a0LMA\u00a0y\u00a0traumatismos \u00a0asociados.\u00a0\n\u00a0\nTraumatismo \u00a0\u00a0\nNivel\u00a0topogr\u00e1fico \u00a0de\u00a0LMA\u00a0\n\u00a0Cervical\u00a0 Dorsal\u00a0 Lumbar\u00a0Sacra\u00a0Cervico\u2010\nDorsal\u00a0Cervico\u2010\nLumbar\u00a0Dorso\u2010\nLumbar\u00a0\nTCE.\u00a0 14\u00a0 9\u00a0 1\u00a0 0\u00a0 4\u00a0 1\u00a0 0\u00a0\nT.\u00a0TORAC.\u00a0 13\u00a0 23\u00a0 1\u00a0 1\u00a0 6\u00a0 1\u00a0 0\u00a0\nT.\u00a0ABDOM.\u00a0 5\u00a0 4\u00a0 2\u00a0 0\u00a0 1\u00a0 0\u00a0 0\u00a0\nT.\u00a0ESQUEL.\u00a0 11\u00a0 18\u00a0 0\u00a0 2\u00a0 3\u00a0 1\u00a0 1\u00a0\nT.\u00a0VASCUL.\u00a0 1\u00a0 3\u00a0 2\u00a0 0\u00a0 1\u00a0 0\u00a0 0\u00a0\nT.\u00a0MAXILOF. \u00a0 1\u00a0 6\u00a0 1\u00a0 0\u00a0 1\u00a0 1\u00a0 0\u00a0\nTOTAL.\u00a0 45\u00a0 63\u00a0 7\u00a0 3\u00a0 16\u00a0 4\u00a0 1\u00a0\n\u00a0\nLas\u00a0v\u00e9rtebras \u00a0m\u00e1s\u00a0incriminadas \u00a0son\u00a0la\u00a0sexta\u00a0v\u00e9rtebra\u00a0cervical\u00a0(15\u00a0\npacientes) \u00a0y\u00a0la\u00a0onceava\u00a0v\u00e9rtebra\u00a0dorsal\u00a0(11\u00a0pacientes). \u00a0\u00a0Las\u00a0regiones\u00a0m\u00e1s\u00a0\nafectadas \u00a0son\u00a0la\u00a0uni\u00f3n\u00a0cervico\u2010tor\u00e1cica\u00a0y\u00a0la\u00a0charnela\u00a0toraco\u2010lumbar,\u00a0\nrepresentando \u00a0en\u00a0su\u00a0conjunto\u00a0un\u00a044,78%\u00a0de\u00a0todos\u00a0 los\u00a0casos\u00a0de\u00a0la\u00a0serie.\u00a0\u00a0\n\u00a0\nRespecto\u00a0a\u00a0las\u00a0LMA\u00a0cervicales, \u00a0las\u00a0lesiones\u00a0m\u00e1s\u00a0frecuentes \u00a0son\u00a0las\u00a0\ncervicales \u00a0bajas\u00a0o\u00a0subaxiales, \u00a0las\u00a0cuales\u00a0 representan \u00a0un\u00a072,97%\u00a0 de\u00a0todas\u00a0 las\u00a0\nfracturas\u00a0cervicales, \u00a0y\u00a0solo\u00a0existe\u00a0un\u00a0caso\u00a0de\u00a0fractura\u00a0 axial\u00a0(1,04%).\u00a0El\u00a0resto\u00a0\ncorresponden \u00a0al\u00a0s\u00edndrome \u00a0conocido\u00a0 como\u00a0SCIWORA. \u00a0\n\u00a0Los\u00a0patrones\u00a0de\u00a0las\u00a0fracturas\u00a0toraco\u2010lumbar\u00a0se\u00a0han\u00a0 dividido\u00a0por\u00a0la\u00a0cl\u00e1sica\u00a0\nclasificaci\u00f3n \u00a0de\u00a0Denis,\u00a0y\u00a0as\u00ed\u00a0las\u00a0fracturas\u00a0por\u00a0fractura\u00a0 luxaci\u00f3n\u00a0son\u00a0las\u00a0m\u00e1s\u00a0\nfrecuentes, \u00a0representando \u00a0un\u00a048,07%\u00a0 (25\u00a0casos).\u00a0El\u00a0resto\u00a0de\u00a0las\u00a0fracturas\u00a0toraco\u2010\nlumbares \u00a0son,\u00a0con\u00a0un\u00a028,84%\u00a0(15\u00a0pacientes) \u00a0fracturas\u00a0por\u00a0estallido,\u00a0un\u00a015,38%\u00a0(8\u00a0\npacientes) \u00a0de\u00a0fracturas\u00a0por\u00a0cintur\u00f3n\u00a0de\u00a0seguridad\u00a0 y\u00a0un\u00a07,69%\u00a0 (4\u00a0casos)\u00a0de\u00a0\nfracturas\u00a0por\u00a0aplastamientos \u00a0vertebrales. \u00a0\n\u00a0\n\u00a0En\u00a0nuestra\u00a0cohorte\u00a0existen\u00a0un\u00a0total\u00a0de\u00a016\u00a0pacientes \u00a0(16,67%)\u00a0con\u00a0\nSCIWORA. \u00a0\n\u00a0\n\u00a0 96\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nUn\u00a037,50%\u00a0(36\u00a0pacientes) \u00a0presentan\u00a0 durante\u00a0alg\u00fan\u00a0 momento \u00a0durante\u00a0el\u00a0\ningreso\u00a0en\u00a0nuestra\u00a0UR\u00a0\u201cshock\u00a0medular\u201d \u00a0con\u00a0 inestabilidad \u00a0hemodin\u00e1mica \u00a0\u00a0y/o\u00a0\u00a0\npar\u00e1lisis\u00a0 fl\u00e1ccida,\u00a0anestesia, \u00a0arreflexia \u00a0y\u00a0disfunci\u00f3n \u00a0vegetativa. \u00a0Los\u00a0diversos\u00a0\ns\u00edndromes \u00a0cl\u00ednicos\u00a0medulares, \u00a0excluyendo \u00a0las\u00a0fracturas\u00a0sacras\u00a0se\u00a0exponen\u00a0en\u00a0la\u00a0\nFigura\u00a015.\u00a0\n\u00a0\n22,82%\n16,30%23,91%36,95%\n0%5%10%15%20%25%30%35%40%45%50%\nTetraplejia\nincompleta.Tetraplejia\ncompleta.Paraplejia\nincompleta.Paraplejia\ncompleta.S\u00cdNDROMES \u00a0CL\u00cdNICOS \u00a0MEDULARES\n \n\u00a0\n\u00a0\n\u00a0\nLa\u00a0Clasificaci\u00f3n \u00a0ASIA\u00a0al\u00a0ingreso\u00a0en\u00a0la\u00a0UR\u00a0y\u00a0al\u00a0alta\u00a0se\u00a0expone\u00a0en\u00a0la\u00a0Tabla\u00a010.\u00a0\nDe\u00a0los\u00a096\u00a0pacientes \u00a0de\u00a0la\u00a0cohorte,\u00a0se\u00a0pudo\u00a0 valorar\u00a0la\u00a0diferencia \u00a0de\u00a0ASIA\u00a0en\u00a091\u00a0\ncasos,\u00a0hall\u00e1ndose \u00a0que\u00a0en\u00a0un\u00a058,24%\u00a0de\u00a0los\u00a0casos\u00a0no\u00a0se\u00a0observa\u00a0diferencia \u00a0en\u00a0el\u00a0\nASIA\u00a0al\u00a0alta\u00a0de\u00a0la\u00a0Unidad\u00a0 respecto\u00a0al\u00a0de\u00a0ingreso,\u00a0y\u00a0en\u00a0un\u00a030,77%\u00a0 (28\u00a0casos)\u00a0\npresentan \u00a0mejor\u00eda\u00a0 en\u00a0un\u00a0grado\u00a0de\u00a0la\u00a0escala\u00a0ASIA\u00a0y\u00a0solo\u00a0en\u00a0un\u00a010,99%\u00a0(10\u00a0casos)\u00a0\nla\u00a0mejor\u00eda\u00a0 es\u00a0de\u00a0dos\u00a0grados.\u00a0No\u00a0existe\u00a0ning\u00fan\u00a0caso\u00a0de\u00a0mejor\u00eda\u00a0superior\u00a0a\u00a0dos\u00a0\ngrados\u00a0respecto\u00a0al\u00a0ingreso.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0 97Figura\u00a015.\u2010S\u00cdNDROMES\u00a0CL\u00cdNICOS \u00a0MEDULARESIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nTabla\u00a010.\u00a0Clasificaci\u00f3n \u00a0de\u00a0la\u00a0disfunci\u00f3n \u00a0neurol\u00f3gica \u00a0mediante \u00a0\u00a0ESCALA\u00a0ASIA.\u00a0\nASIA.\u00a0ASIA\u00a0\u00a0\nal\u00a0ingreso\u00a0en\u00a0UR.\u00a0ASIA\u00a0\u00a0\nal\u00a0Alta\u00a0de\u00a0UR.\u00a0\nNo\u00a0valorable. \u00a0 6\u00a0 6\u00a0\nASIA\u00a0A.\u00a0 43\u00a0 31\u00a0\nASIA\u00a0B.\u00a0 28\u00a0 17\u00a0\nASIA\u00a0C.\u00a0 16\u00a0 28\u00a0\nASIA\u00a0D.\u00a0 3\u00a0 12\u00a0\nASIA\u00a0E.\u00a0 0\u00a0 2\u00a0\nTOTAL.\u00a0 96\u00a0 96\u00a0\nASIA:\u00a0American \u00a0Spinal\u00a0Injury\u00a0Association.\u00a0 UR:\u00a0Unidad\u00a0de\u00a0Reanimaci\u00f3n. \u00a0\n\u00a0\nLa\u00a0media\u00a0global\u00a0de\u00a0mejor\u00eda\u00a0fue\u00a0de\u00a00,53\u00a0grados\u00a0(IC\u00a095%:\u00a00,4\u20100,7).\u00a0El\u00a072,09%\u00a0\nde\u00a0las\u00a0lesiones\u00a0consideradas \u00a0como\u00a0completas \u00a0al\u00a0ingreso\u00a0siguieron\u00a0completas \u00a0al\u00a0\nalta\u00a0hospitalaria, \u00a0mientras\u00a0que\u00a0el\u00a055,31%\u00a0de\u00a0las\u00a0lesiones\u00a0incompletas \u00a0mejor\u00f3\u00a0al\u00a0\nmenos\u00a0un\u00a0grado.\u00a0 La\u00a0diferencia \u00a0media\u00a0 seg\u00fan\u00a0la\u00a0escala\u00a0ASIA\u00a0desde\u00a0el\u00a0ingreso\u00a0al\u00a0alta\u00a0\nen\u00a0la\u00a0UR\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0 tratamiento \u00a0con\u00a0MP\u00a0fue\u00a0de\u00a00,6,\u00a0mientras\u00a0que\u00a0\naquellos\u00a0 pacientes \u00a0no\u00a0tratados\u00a0fue\u00a0de\u00a00,36,\u00a0 sin\u00a0diferencias\u00a0 estad\u00edsticamente \u00a0\nsignificativas\u00a0 (p\u00a0=\u00a00,\u00a0236).\u00a0No\u00a0se\u00a0apreciaron\u00a0 diferencias\u00a0 estad\u00edsticamente \u00a0\nsignificativas\u00a0 (p\u00a0=\u00a00,095)\u00a0en\u00a0la\u00a0diferencia \u00a0de\u00a0ASIA\u00a0entre\u00a0los\u00a0pacientes \u00a0intervenidos \u00a0\nquir\u00fargicamente \u00a0de\u00a0la\u00a0LMA\u00a0de\u00a0aquellos\u00a0no\u00a0intervenidos. \u00a0En\u00a0la\u00a0Tabla\u00a011\u00a0se\u00a0expone\u00a0\nde\u00a0forma\u00a0detallada \u00a0la\u00a0evoluci\u00f3n \u00a0de\u00a0la\u00a0situaci\u00f3n\u00a0neurol\u00f3gica \u00a0de\u00a0los\u00a0pacientes \u00a0\ndesde\u00a0el\u00a0ingreso\u00a0al\u00a0alta\u00a0hospitalaria. \u00a0Se\u00a0excluyen\u00a0los\u00a06\u00a0casos\u00a0que\u00a0no\u00a0fue\u00a0posible\u00a0\nvalorar\u00a0ASIA\u00a0al\u00a0ingreso.\u00a0\n\u00a0\nTabla\u00a0 11.\u2010\u00a0Evoluci\u00f3n \u00a0de\u00a0la\u00a0Lesi\u00f3n\u00a0Neurol\u00f3gica. \u00a0\n\u00a0 Grado\u00a0de\u00a0ASIA\u00a0al\u00a0alta.\u00a0\n\u00a0 A\u00a0 B\u00a0 C\u00a0 D\u00a0 E\u00a0 Total.\u00a0\nA\u00a0 29\u00a0 7\u00a0 7\u00a0 0\u00a0 0\u00a0 43\u00a0\nB\u00a0 0\u00a0 10\u00a0 15\u00a0 3\u00a0 0\u00a0 28\u00a0\nC\u00a0 0\u00a0 0\u00a0 8\u00a0 6\u00a0 2\u00a0 16\u00a0\nD\u00a0 0\u00a0 0\u00a0 3\u00a0 0\u00a0 0\u00a0 3\u00a0Grado\u00a0de\u00a0\u00a0ASIA\u00a0al\u00a0\ningreso.\u00a0\nE\u00a0 0\u00a0 0\u00a0 0\u00a0 0\u00a0 0\u00a0 0\u00a0\n\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0 90\u00a0\n\u00a0\nASIA:\u00a0American \u00a0Spinal\u00a0Injury\u00a0Association.\u00a0\nEn\u00a0negro,\u00a0 los\u00a0casos\u00a0que\u00a0no\u00a0se\u00a0modifico\u00a0la\u00a0lesi\u00f3n\u00a0neurol\u00f3gica. \u00a0\nEn\u00a0rojo,\u00a0los\u00a0casos\u00a0que\u00a0mejoraron \u00a0el\u00a0grado\u00a0ASIA.\u00a0\n\u00a0 98En\u00a0azul,\u00a0los\u00a0casos\u00a0que\u00a0sufrieron\u00a0deterioro\u00a0neurol\u00f3gico. \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nEs\u00a0de\u00a0destacar\u00a0 la\u00a0existencia \u00a0de\u00a0dos\u00a0casos\u00a0de\u00a0empeoramiento \u00a0neurol\u00f3gico \u00a0\nen\u00a0el\u00a0grado\u00a0ASIA\u00a0que\u00a0ocurrieron \u00a0tras\u00a0tratamiento \u00a0quir\u00fargico. \u00a0En\u00a0ambos\u00a0casos\u00a0el\u00a0\ningreso\u00a0fue\u00a0en\u00a0cama\u00a0de\u00a0hospitalizaci\u00f3n \u00a0convencional \u00a0de\u00a0forma\u00a0primaria.\u00a0El\u00a0caso\u00a0\nm\u00e1s\u00a0grave\u00a0fue\u00a0un\u00a0var\u00f3n\u00a0 de\u00a029\u00a0a\u00f1os\u00a0con\u00a0una\u00a0fractura\u00a0 de\u00a0Chance\u00a0 en\u00a0L3\u00a0sin\u00a0lesi\u00f3n\u00a0\nneurol\u00f3gica \u00a0no\u00a0diagnosticada \u00a0al\u00a0ingreso\u00a0que,\u00a0tras\u00a0la\u00a0IQ\u00a0de\u00a0urgencia\u00a0 para\u00a0\nosteos\u00edntesis \u00a0de\u00a0fractura\u00a0de\u00a0f\u00e9mur,\u00a0debuto\u00a0en\u00a0el\u00a0postoperatorio \u00a0inmediato \u00a0con\u00a0\nuna\u00a0paraplejia \u00a0establecida. \u00a0Con\u00a0car\u00e1cter\u00a0de\u00a0urgencia\u00a0 se\u00a0\u00a0fijo\u00a0la\u00a0fractura\u00a0por\u00a0v\u00eda\u00a0\nposterior, \u00a0y\u00a0sufri\u00f3\u00a0una\u00a0lesi\u00f3n\u00a0de\u00a0cola\u00a0de\u00a0caballo\u00a0L3\u00a0completa \u00a0que\u00a0fue\u00a0irreversible. \u00a0\nEl\u00a0segundo\u00a0fue\u00a0el\u00a0caso\u00a0de\u00a0una\u00a0mujer\u00a0de\u00a057\u00a0a\u00f1os\u00a0que\u00a0sufri\u00f3\u00a0fractura\u00a0 por\u00a0estallido\u00a0\nen\u00a0L3\u00a0tras\u00a0accidente \u00a0de\u00a0tr\u00e1fico,\u00a0sin\u00a0lesi\u00f3n\u00a0neurol\u00f3gica \u00a0y\u00a0que\u00a0el\u00a0estudio\u00a0de\u00a0imagen\u00a0\ninicial\u00a0fue\u00a0informado \u00a0como\u00a0normal\u00a0pues\u00a0el\u00a0cintur\u00f3n\u00a0del\u00a0pantal\u00f3n\u00a0no\u00a0permiti\u00f3\u00a0\nvisualizar \u00a0la\u00a0fractura\u00a0de\u00a0la\u00a0paciente\u00a0y\u00a0tras\u00a0el\u00a0inicio\u00a0de\u00a0la\u00a0cl\u00ednica\u00a0neurol\u00f3gica,\u00a0 se\u00a0\nprocedi\u00f3\u00a0a\u00a0la\u00a0realizaci\u00f3n\u00a0 de\u00a0laminectom\u00eda \u00a0m\u00e1s\u00a0fijaci\u00f3n\u00a0posterior\u00a0conllevo\u00a0una\u00a0\nimportante \u00a0mejor\u00eda;\u00a0al\u00a0alta\u00a0hospitalaria \u00a0fue\u00a0etiquetado \u00a0con\u00a0un\u00a0grado\u00a0E\u00a0de\u00a0ASIA.\u00a0\n\u00a0\u00a0\n4.1.3.  Utilizaci\u00f3n \u00a0de\u00a0megadosis \u00a0de\u00a0corticoides \u00a0e\u00a0intervenci\u00f3n \u00a0quir\u00fargica \u00a0\nen\u00a0pacientes\u00a0 con\u00a0lesi\u00f3n\u00a0medular\u00a0aguda\u00a0\n\u00a0\nEn\u00a0todos\u00a0los\u00a0pacientes \u00a0el\u00a0objetivo\u00a0 primordial \u00a0fue\u00a0conseguir \u00a0una\u00a0adecuada\u00a0\nventilaci\u00f3n \u00a0y\u00a0una\u00a0hemodin\u00e1mica\u00a0 estable\u00a0para\u00a0mantener \u00a0una\u00a0presi\u00f3n\u00a0 medular\u00a0 en\u00a0\nl\u00edmites\u00a0normales. \u00a0Se\u00a0aplic\u00f3\u00a0 el\u00a0protocolo\u00a0 de\u00a0estudio\u00a0NASCIS\u00a0II\u00a0si\u00a0no\u00a0presentaban \u00a0\ncriterios\u00a0de\u00a0exclusi\u00f3n\u00a0 como\u00a0es\u00a0la\u00a0presencia \u00a0de\u00a0LMA\u00a0penetrante \u00a0o\u00a0si\u00a0no\u00a0se\u00a0hab\u00eda\u00a0\niniciado\u00a0por\u00a0cualquier\u00a0 causa\u00a0el\u00a0tratamiento \u00a0en\u00a0las\u00a08\u00a0horas\u00a0posteriores \u00a0al\u00a0evento.\u00a0\u00a0\nEn\u00a0la\u00a0Figura\u00a016\u00a0se\u00a0expone\u00a0la\u00a0evoluci\u00f3n \u00a0del\u00a0porcentaje \u00a0de\u00a0utilizaci\u00f3n \u00a0de\u00a0megadosis \u00a0\nde\u00a0CTC\u00a0por\u00a0a\u00f1os\u00a0de\u00a0estudio.\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0 99\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\nPorcentaje \u00a0de\u00a0empleo\u00a0de\u00a0megadosis \u00a0de\u00a0metilprednisolona \u00a0por\u00a0a\u00f1os\u00a0\nde\u00a0estudio.\n020406080100\n1994 1996 1998 2000 2002 2004 2006 2008\nA\u00f1os de estudio.Porcentaje de utilizaci\u00f3n.\n\u00a0\nFigura\u00a016.\u2010\u00a0PORCENTAJE \u00a0DE\u00a0EMPLEO \u00a0DE\u00a0MEGADOSIS \u00a0DE\u00a0MP\u00a0POR\u00a0A\u00d1OS\u00a0DE \u00a0ESTUDIO \u00a0\u00a0\n\u00a0No\u00a0hallamos\u00a0 diferencias\u00a0 estad\u00edsticamente \u00a0significativas \u00a0en\u00a0el\u00a0empleo\u00a0del\u00a0\nprotocolo\u00a0 corticoideo \u00a0NASCIS\u00a0durante\u00a0los\u00a0diferentes \u00a0a\u00f1os\u00a0del\u00a0estudio,\u00a0pero\u00a0si\u00a0se\u00a0\nobserva\u00a0una\u00a0tendencia,\u00a0 en\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os,\u00a0a\u00a0un\u00a0menor\u00a0empleo\u00a0de\u00a0esta\u00a0terapia.\u00a0\n\u00a0En\u00a0este\u00a0trabajo,\u00a0en\u00a0el\u00a070.83%\u00a0de\u00a0los\u00a0casos\u00a0(68\u00a0pacientes) \u00a0se\u00a0aplic\u00f3\u00a0el\u00a0\nprotocolo\u00a0 del\u00a0estudio\u00a0NASCIS\u00a0II,\u00a0consistente \u00a0en\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a030\u00a0mg/Kg\u00a0de\u00a0\nMP\u00a0en\u00a015\u00a0minutos,\u00a0y\u00a0tras\u00a0una\u00a0pausa\u00a0de\u00a045\u00a0minutos,\u00a0iniciar\u00a0una\u00a0perfusi\u00f3n \u00a0de\u00a05,4\u00a0\nmg/Kg/hora \u00a0durante\u00a0las\u00a023\u00a0horas\u00a0siguientes. \u00a0No\u00a0se\u00a0empleo\u00a0 en\u00a0el\u00a029.17%\u00a0 de\u00a0los\u00a0\ncasos\u00a0(28\u00a0pacientes). \u00a0Las\u00a0causas\u00a0de\u00a0exclusi\u00f3n\u00a0 para\u00a0la\u00a0administraci\u00f3n \u00a0del\u00a0protocolo\u00a0\nNASCIS\u00a0II\u00a0fueron\u00a0la\u00a0presencia\u00a0 de\u00a0LMA\u00a0penetrante \u00a0y\u00a0un\u00a0transcurso \u00a0superior\u00a0a\u00a08\u00a0\nhoras\u00a0desde\u00a0la\u00a0LMA\u00a0hasta\u00a0el\u00a0inicio\u00a0del\u00a0tratamiento \u00a0por\u00a0retraso\u00a0en\u00a0el\u00a0diagnostico \u00a0y\u00a0\nno\u00a0utilizaci\u00f3n \u00a0por\u00a0el\u00a0facultativo \u00a0responsable \u00a0por\u00a0falta\u00a0de\u00a0evidencia \u00a0m\u00e9dica\u00a0en\u00a0la\u00a0\nmejor\u00eda\u00a0 significativa \u00a0de\u00a0las\u00a0funciones\u00a0 neurol\u00f3gicas. \u00a0\n\u00a0\n\u00a0 100La\u00a0estancia\u00a0media\u00a0 en\u00a0la\u00a0UR\u00a0de\u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0 megadosis \u00a0de\u00a0\nMP\u00a0fue\u00a0de\u00a09,60\u00a0\u00b1\u00a09,88\u00a0d\u00edas,\u00a0mientras\u00a0que\u00a0el\u00a0subgrupo \u00a0de\u00a0pacientes \u00a0con\u00a0LMAT\u00a0no\u00a0\ntratados\u00a0con\u00a0la\u00a0pauta\u00a0de\u00a0CTC\u00a0seg\u00fan\u00a0protocolo\u00a0 NASCIS\u00a0II\u00a0fue\u00a0de\u00a012,71\u00a0\u00b1\u00a015\u00a0d\u00edas,\u00a0\nsin\u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significativas \u00a0(p\u00a0=\u00a00,\u00a0390).\u00a0En\u00a0la\u00a0Figura\u00a017\u00a0se\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\n\u00a0expone\u00a0las\u00a0variaciones \u00a0en\u00a0las\u00a0indicaciones \u00a0quir\u00fargicas \u00a0seg\u00fan\u00a0los\u00a0diferentes \u00a0a\u00f1os\u00a0\nde\u00a0estudio.\u00a0\nPORCENTAJE \u00a0DE\u00a0ARTRODESIS \u00a0RAQU\u00cdDEA \u00a0POR\u00a0A\u00d1OS\u00a0DE\u00a0ESTUDIO\n020406080100\n1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007\nA\u00f1os de estudio.Porcentaje de utilizaci\u00f3n.\nNo Cirug\u00eda\nFigura\u00a017.\u2010\u00a0PORCENTAJE \u00a0DE\u00a0ARTRODESIS \u00a0RAQU\u00cdDEA \u00a0POR\u00a0A\u00d1OS\u00a0DE\u00a0ESTUDIO\u00a0Cirug\u00eda demorada. Si Cirug\u00eda.\n\u00a0\n\u00a0\nEn\u00a0este\u00a0estudio,\u00a0se\u00a0demor\u00f3\u00a0el\u00a0acto\u00a0quir\u00fargico \u00a0en\u00a026\u00a0pacientes \u00a0(27.08%)\u00a0\npor\u00a0las\u00a0lesiones\u00a0asociadas\u00a0 a\u00a0la\u00a0lesi\u00f3n\u00a0 raqu\u00eddea\u00a0y\u00a0por\u00a0individualizaci\u00f3n \u00a0\u00a0del\u00a0caso,\u00a0 y\u00a0\nno\u00a0se\u00a0realiz\u00f3\u00a0en\u00a023\u00a0pacientes \u00a0(23,96%). \u00a0Durante\u00a0el\u00a0ingreso\u00a0en\u00a0la\u00a0UR\u00a0se\u00a0realizo\u00a0IQ\u00a0\nen\u00a047\u00a0pacientes \u00a0(48.96%), \u00a0consistiendo \u00a0dicha\u00a0cirug\u00eda\u00a0en\u00a0una\u00a0artrodesis \u00a0posterior\u00a0\nen\u00a0el\u00a0mayor\u00a0n\u00famero\u00a0de\u00a0casos\u00a0(26\u00a0pacientes), \u00a0seguida\u00a0en\u00a0frecuencia\u00a0 de\u00a0la\u00a0\nartrodesis \u00a0anterior\u00a0(16\u00a0pacientes) \u00a0\u00a0y\u00a0una\u00a0artrodesis \u00a0mixta\u00a0en\u00a0el\u00a010,64\u00a0%\u00a0de\u00a0los\u00a0\ncasos\u00a0(5\u00a0pacientes). \u00a0El\u00a0per\u00edodo\u00a0de\u00a0tiempo,\u00a0expresado \u00a0en\u00a0d\u00edas,\u00a0transcurrido \u00a0entre\u00a0\nel\u00a0ingreso\u00a0en\u00a0la\u00a0Unidad\u00a0 y\u00a0la\u00a0IQ\u00a0fue\u00a0de\u00a03,59\u00a0\u00b1\u00a02,42\u00a0d\u00edas.\u00a0\n\u00a0En\u00a0la\u00a0Figura\u00a018\u00a0 se\u00a0exponen\u00a0el\u00a0n\u00famero\u00a0de\u00a0casos\u00a0 intervenidos \u00a0\nquir\u00fargicamente \u00a0por\u00a0d\u00edas\u00a0de\u00a0ingreso\u00a0en\u00a0la\u00a0UR,\u00a0junto\u00a0a\u00a0su\u00a0l\u00ednea\u00a0de\u00a0tendencia. \u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0 101\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nFi\nFigura\u00a0\u00a018.\u2010\u00a0INTERVENCI\u00d3N \u00a0QUIR\u00daRGICA \u00a0TIPO\u00a0ARTRODESIS \u00a0SEG\u00daN\u00a0D\u00cdA\u00a0DE\u00a0INGRESO \u00a0EN\u00a0UR\u00a0gura\u00a015.\u00a0Intervenci\u00f3n\u00a0 quir\u00fargica \u00a0tipo\u00a0Artrodesis \u00a0seg\u00fan\u00a0d\u00eda\u00a0de\u00a0\ningreso\u00a0en\u00a0Unidad\u00a0de\u00a0Reanimaci\u00f3n.\n051015\n123456789 1 0 1 1 1 2\nD\u00edas\u00a0de\u00a0ingreso.N\u00famero\u00a0de\u00a0\nArtrodesis.INTERVE RESO\u00a0\n\u00a0\n\u00a0\nSe\u00a0observa\u00a0que\u00a0el\u00a091,30%\u00a0de\u00a0los\u00a0casos\u00a0fueron\u00a0intervenidos \u00a0\nquir\u00fargicamente \u00a0dentro\u00a0de\u00a0la\u00a0primera\u00a0semana\u00a0siguiente\u00a0al\u00a0traumatismo. \u00a0\n\u00a0La\u00a0estancia\u00a0media\u00a0 en\u00a0la\u00a0UR\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0LMAT\u00a0no\u00a0intervenidos \u00a0\nquir\u00fargicamente \u00a0del\u00a0raquis\u00a0medular\u00a0 fue\u00a0de\u00a09,63\u00a0\u00b1\u00a012,37\u00a0d\u00edas,\u00a0 mientras\u00a0que\u00a0la\u00a0\nestancia\u00a0media\u00a0de\u00a0los\u00a0pacientes \u00a0no\u00a0operados \u00a0fue\u00a0de\u00a011,16\u00a0\u00b1\u00a010,02\u00a0d\u00edas.\u00a0\n\u00a0En\u00a0las\u00a0siguientes \u00a0figuras\u00a0 se\u00a0muestran \u00a0los\u00a0grados\u00a0de\u00a0mejor\u00eda\u00a0 en\u00a0la\u00a0escala\u00a0\nASIA\u00a0(DASIA)\u00a0de\u00a0los\u00a0pacientes \u00a0tratados\u00a0o\u00a0no\u00a0con\u00a0 MP\u00a0(Figura\u00a019\u00a0y\u00a020),\u00a0 cirug\u00eda\u00a0\nraqu\u00eddea\u00a0o\u00a0tratamiento \u00a0conservador \u00a0(Figuras\u00a021\u00a0y\u00a022)\u00a0aquellos\u00a0 con\u00a0terapia\u00a0 dual\u00a0\n(Figura\u00a023).\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0 102NCI\u00d3N\u00a0QUIR\u00daRGICA \u00a0TIPO\u00a0ARTRODESIS \u00a0SEG\u00daN\u00a0D\u00cdA\u00a0DE\u00a0ING\nEN\u00a0UNIDAD\u00a0DE\u00a0REANIMACI\u00d3N\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n \n \nFigura\u00a019.\u2010\u00a0GRADOS\u00a0DE\u00a0\nRECUPERACI\u00d3N \u00a0NEUROL\u00d3GI CA \u00a0EN\u00a0\nPACIENTES \u00a0TRATADOS \u00a0CON\u00a0\u00a0\nMETI LPREDNI SOLONA\nDASI A 0 DASI A 1 DASI A2\n  \nFigura\u00a020.\u2010\u00a0GRADOS\u00a0DE\u00a0RECUPERACI\u00d3N \u00a0\nNEUROL\u00d3GICA \u00a0EN\u00a0PACIENTES \u00a0NO\u00a0\nTRTADOS \u00a0CON\u00a0METILPREDNISOLONA. \u00a0\nDASIA 0 DASIA 1 DASIA2Figura\u00a020.\u2010\u00a0GRADOS\u00a0DE\u00a0RECUPERACI\u00d3N \u00a0\nNEUROL\u00d3GICA \u00a0EN\u00a0PACIENTES\u00a0NO \u00a0\nTRATADOS \u00a0CON\u00a0MP\u00a0Figura\nRECUPERACI\u00d3N\nPA \u00a0\u00a019.\u2010\u00a0GRADOS\u00a0DE\u00a0\n\u00a0NEUROL\u00d3GICA \u00a0EN\u00a0\nCIENTES\u00a0TRATADOS \u00a0CON\u00a0MP\n \nFigura\u00a021.\u2010\u00a0GRADOS\u00a0DE\u00a0\nRECUPERACI\u00d3N \u00a0NEUROL\u00d3GICA \u00a0EN\u00a0\nPACIENTES \u00a0TRATADOS \u00a0\nQUIR\u00daRGICAMENTE. \u00a0\nDASI A 0 DASI A 1 DASI A2\n Figura\u00a022.\u2010\u00a0GRADOS\u00a0DE\u00a0RECUPERACI\u00d3N \u00a0\nNEUROL\u00d3GICA \u00a0EN\u00a0PACIENTES \u00a0\nTRATADOS \u00a0DE\u00a0FORMA\u00a0\nCONSERVADORA.\nDASIA 0 DASIA 1 DASIA2Figura\u00a021.\u2010\u00a0GRADOS\u00a0DE\u00a0\nPACIENTES\u00a0TRATADOS \u00a0\nQUIRURGICAMENTE \u00a0RECUPERACI\u00d3N \u00a0NEUROL\u00d3GICA \u00a0EN\u00a0\n \nFigura\u00a023.\u2010\u00a0GRADOS\u00a0DE\u00a0RECUPERACI\u00d3N \u00a0\nNEUROL\u00d3GICA \u00a0EN\u00a0PACIENTES \u00a0\nTRATADOS \u00a0CON\u00a0METILPREDNISOLONA \u00a0\nY\u00a0QUIRURGICAMENTE. \u00a0\nDASIA 0 DASIA 1 DASIA2\n Figura\u00a023.\u2010\u00a0GRADOS\u00a0DE\u00a0\nUPERACI\u00d3N \u00a0NEUROL\u00d3GICA \u00a0E\nPACIENTES\u00a0TRATADOS \u00a0CON\u00a0MP\u00a0Y\u00a0\nQUIRURGICAMENTE\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0 103REC N\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nNo\u00a0se\u00a0hallan\u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significativas\u00a0 en\u00a0el\u00a0grado\u00a0de\u00a0\nrecupe\n.1.4. Uso\u00a0de\u00a0dispositivos \u00a0m\u00e9dicos\u00a0 y\u00a0complicaciones\u00a0 infecciosas \u00a0\n\u00a0de\u00a0\npacien\na\u00a0ratio\u00a0de\u00a0utilizaci\u00f3n \u00a0de\u00a0la\u00a0VM\u00a0durante\u00a0el\u00a0periodo\u00a0de\u00a0estudio\u00a0fue\u00a0de\u00a00,56.\u00a0\nLa\u00a0ratioraci\u00f3n\u00a0neurol\u00f3gica \u00a0mediante \u00a0la\u00a0escala\u00a0ASIA\u00a0en\u00a0ninguno\u00a0 de\u00a0los\u00a0subgrupos \u00a0\nanalizados.\u00a0\n\u00a0\n4\n\u00a0\nn\u00a0la\u00a0tabla\u00a012\u00a0se\u00a0presenta\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0frecuencias \u00a0relativas E\ntes\u00a0seg\u00fan\u00a0su\u00a0exposici\u00f3n \u00a0a\u00a0factores\u00a0de\u00a0riesgo\u00a0extr\u00ednseco \u00a0de\u00a0la\u00a0IN;\u00a0los\u00a0\nutilizados \u00a0para\u00a0calcular\u00a0las\u00a0tasas\u00a0de\u00a0infecci\u00f3n\u00a0especificas \u00a0asociadas\u00a0 a\u00a0dispositivos \u00a0\nde\u00a0riesgo.\u00a0En\u00a0dicha\u00a0tabla\u00a0se\u00a0cuantifica \u00a0el\u00a0n\u00famero\u00a0medio\u00a0de\u00a0d\u00edas\u00a0durante\u00a0los\u00a0\ncuales\u00a0los\u00a0pacientes \u00a0sufrieron\u00a0 dicha\u00a0exposici\u00f3n.\u00a0 Ninguno\u00a0de\u00a0los\u00a0pacientes \u00a0\ninvestigados \u00a0fue\u00a0sometido \u00a0a\u00a0sondaje\u00a0urinario\u00a0abierto.\u00a0\n\u00a0L\n\u00a0de\u00a0utilizaci\u00f3n \u00a0de\u00a0CVC\u00a0fue\u00a0de\u00a00,94.\u00a0La\u00a0ratio\u00a0de\u00a0uso\u00a0de\u00a0sondaje\u00a0urinario\u00a0en\u00a0\nla\u00a0UR\u00a0fue\u00a0de\u00a01,00.\u00a0\n\u00a0\nTabla 2.\u2010\u00a0Factores\u00a0 de\u00a0Riesgo\u00a0EXTRINSECOS. \u00a0 \u00a01\n\u00a0\nFACTOR\u00a0RIESGO*\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 n\u00ba\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0(%\u00a0 \u00a0 \u00a0\n)\u00a0\u00a0\u00a0\u00a0Rango\u00a0\u00a0\u00a0Media\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0DE\u00a0\n\u00a0\nSistema\u00a0urinario\u00a0 cerrado.\u00a0\u00a0 \u00a0 95\u00a0 98,96 0\u201078\u00a0 10,47\u00a0 11,63\n\u00a0\nCat\u00e9ter\u00a0venoso\u00a0central.\u00a079\u00a0 82,29\u00a0 0\u201078\u00a0 9,93\u00a0 11,94\u00a0\nVentilaci\u00f3n \u00a0 mec\u00e1nica \u00a0\ninvasiva.\u00a052\u00a0 54,17\u00a0 0\u201056\u00a0 5,94\u00a0 9,88\u00a0\nVentilaci\u00f3n \u00a0 nica\u00a0no\u00a0\ninvasiva.\u00a0mec\u00e117\u00a0 17,71\u00a0 0\u201013\u00a0 0,66\u00a0 1,84\u00a0\n*Un\u00a0paciente puede\u00a0 pres tar \u00a0\nDuraci\u00f3n\u00a0 me\u00a0 en m\u00e1s\u00a0 d\u00a0factor\u00a0de \u00a0extr\u00edns \u00ba:\u00a0N\u00fam \u00a0casos. a:\u00a0\ndia\u00a0de\u00a0la\u00a0exposici\u00f3n\u00a0 valorado\u00a0en\u00a0d\u00edas.\u00a0Rango:\u00a0 Valor\u00a0m\u00ednimo\u00a0y\u00a0m\u00e1ximo\u00a0expresado \u00a0en\u00a0d\u00edas.\u00a0e\u00a0un \u00a0riesgo eco.\u00a0 n ero\u00a0de \u00a0Medi\nDE:\u00a0Desviaci\u00f3n\u00a0 est\u00e1ndar. \u00a0\n\u00a0\nTreinta\u00a0y\u00a0siete\u00a0pacientes \u00a0sufrieron\u00a0 al\u00a0menos\u00a0una\u00a0IN\u00a0durante\u00a0su\u00a0estancia\u00a0en\u00a0\nla\u00a0UR,\u00a0\ninfecciones \u00a0de\u00a056,24\u00a0por\u00a0cada\u00a0100\u00a0admisiones \u00a0en\u00a0UR.\u00a0El\u00a051,35\u00a0%\u00a0de\u00a0las\u00a0\u00a0\n\u00a0 104lo\u00a0que\u00a0supuso\u00a0 una\u00a0IA\u00a0anual\u00a0de\u00a038,54\u00a0infectados \u00a0por\u00a0cada\u00a0100\u00a0admisiones \u00a0\n(IC95%=\u00a028,62\u00a0\u2010\u00a048,45).\u00a0Sin\u00a0embargo, \u00a0algunos\u00a0de\u00a0estos\u00a0pacientes \u00a0presentaron\u00a0 m\u00e1s\u00a0\nde\u00a0una\u00a0infecci\u00f3n, \u00a0siendo\u00a0el\u00a0n\u00famero\u00a0total\u00a0de\u00a0infecciones \u00a0de\u00a054,\u00a0con\u00a0 una\u00a0IA\u00a0de\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\ninfecciones \u00a0fueron\u00a0IN\u00a0m\u00faltiples. \u00a0El\u00a0n\u00famero\u00a0de\u00a0pacientes \u00a0con\u00a0una\u00a0sola\u00a0IN\u00a0fue\u00a0de\u00a0\n8\u00a0(IA\u00a0de\u00a018,74\u00a0por\u00a0100\u00a0admisiones),\u00a0 12\u00a0presentaron\u00a0 dos\u00a0(IA\u00a0de\u00a012,49\u00a0por\u00a0100\u00a0\nrden\u00a0de\u00a0\nfrecuencia, \u00a0la\u00a0BN,\u00a0la\u00a0ITU\u00a0y\u00a0la\u00a0IHQ.\u00a0Los\u00a0casos\u00a0de\u00a0NN\u00a0se\u00a0presentaron \u00a0en\u00a028\u00a0pacientes \u00a0\n(29.17%\n\u00a0la\u00a0UR\u00a0hasta\u00a0\nla\u00a0aparici\u00f3n\u00a0 de\u00a0la\u00a0IN\u00a0espec\u00edfica\u00a0 se\u00a0recogen\u00a0en\u00a0las\u00a0Figuras\u00a0\u00a024,\u00a025\u00a0y\u00a026.\u00a0\u00a01admisiones) \u00a0y\u00a07\u00a0adquirieron \u00a0\u00a0tres\u00a0o\u00a0m\u00e1s\u00a0infecciones \u00a0(IA\u00a0de\u00a07,29\u00a0por\u00a0100\u00a0\nadmisiones). \u00a0Un\u00a051,35%\u00a0de\u00a0los\u00a0sujetos\u00a0 infectados \u00a0ten\u00edan\u00a0m\u00e1s\u00a0de\u00a0una\u00a0IN.\u00a0\u00a0\n\u00a0La\u00a0IN\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0la\u00a0cohorte\u00a0es\u00a0la\u00a0NN,\u00a0le\u00a0siguen\u00a0en\u00a0o\n),\u00a0clasificando \u00a0dicha\u00a0neumon\u00eda \u00a0nosocomial \u00a0en\u00a0precoz\u00a0(NNP)\u00a0si\u00a0acontec\u00eda \u00a0\nen\u00a0los\u00a0cuatro\u00a0primeros\u00a0d\u00edas\u00a0del\u00a0ingreso\u00a0y\u00a0tard\u00eda\u00a0(NNT)\u00a0si\u00a0aparec\u00eda\u00a0 tras\u00a0los\u00a0cuatro\u00a0\nd\u00edas\u00a0posteriores \u00a0al\u00a0ingreso.\u00a0 La\u00a0BN\u00a0estuvo\u00a0presente\u00a0en\u00a016\u00a0pacientes \u00a0(16.67%), \u00a0la\u00a0\nITU\u00a0en\u00a05\u00a0\u00a0pacientes\u00a0 (5.21%)\u00a0y\u00a0la\u00a0IHQ\u00a0tambi\u00e9n\u00a0en\u00a05\u00a0pacientes \u00a0(5.62%).\u00a0\n\u00a0El\u00a0n\u00famero\u00a0de\u00a0d\u00edas\u00a0con\u00a0dispositivos \u00a0de\u00a0riesgo\u00a0por\u00a0paciente\u00a0en\n\u00a0\n012345678N\u00famero\u00a0de\u00a0\nNeumon\u00edas.\n0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19\nD\u00edas\u00a0de\u00a0ventilaci\u00f3n \u00a0mec\u00e1nica.N\u00a0\nDE\u00a0NEUMON\u00cdA SOCOMIAL.Figura\u00a024.\u2010\u00a0D\u00cdAS\u00a0DE\u00a0VENTILACI\u00d3N\u00a0 MEC\u00c1NICA \u00a0HASTA\u00a0APARICI\u00d3\n\u00a0NOFigura\u00a024.\u2010\u00a0D\u00cdAS\u00a0DE\u00a0VENTILACI\u00d3N\u00a0 MEC\u00c1NICA \u00a0HASTA\u00a0APARICI\u00d3N \u00a0DE\u00a0\nNEUMON\u00cdA OSOCOMIAL \u00a0\n\u00a0\n\u00a0\nEn\u00a0cuanto\u00a0a\u00a0las\u00a0tasas\u00a0de\u00a0infecciones \u00a0en\u00a0localizaciones\u00a0 especificas \u00a0\nasociadas\u00a0 a\u00a0dispositivos \u00a0de\u00a0riesgo,\u00a0encontramos \u00a0que\u00a0la\u00a0tasa\u00a0de\u00a0neumon\u00eda \u00a0\nasociada\u00a0al\u00a0respirador \u00a0fue\u00a0de\u00a015\u00a0casos\u00a0por\u00a0cada\u00a01000\u00a0paciente\u2010d\u00eda\u00a0de\u00a0ventilaci\u00f3n \u00a0\nmec\u00e1nica. \u00a0No\u00a0se\u00a0presentaron\u00a0 casos\u00a0de\u00a0NN\u00a0en\u00a0sujetos\u00a0 no\u00a0ventilados \u00a0previamente. \u00a0\u00a0\n\u00a0 105\u00a0NIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\n01234N\u00famero\u00a0de\u00a0\nBacteriemias.\n0 1 2 4 5 6 7 8 9 1 01 11 21 31 41 52 53 03 54 04 5\nD\u00edas\u00a0de\u00a0cat\u00e9ter\u00a0venoso\u00a0central.Figura\u00a022.\u00a0D\u00edas\u00a0de\u00a0cat\u00e9ter\u00a0venoso\u00a0central\u00a0hasta\u00a0aparici\u00f3n \u00a0de\u00a0\nBacteriemia \u00a0Nosocomial.Figura\u00a025.\u2010\u00a0\u00a0D\u00cdAS\u00a0DE\u00a0CAT\u00c9TER\u00a0VENOSO\u00a0CENTRAL \u00a0HASTA\u00a0APARICI\u00d3N \u00a0\nDE\u00a0BACTERIEMIA \u00a0NOSOCOMIAL \u00a0\n\u00a0\n\u00a0\nLa\u00a0DI\u00a0de\u00a0BN\u00a0asociado\u00a0a\u00a0CVC\u00a0fue\u00a02\u00a0casos\u00a0 por\u00a0cada\u00a01000\u00a0pacientes \u2010d\u00edas\u00a0de\u00a0\ncat\u00e9ter ntral\u00a0y\u00a0no\u00a0aconteci\u00f3 \u00a0ning\u00fan\u00a0episodio\u00a0de\u00a0\u00a0BN\u00a0en\u00a0pacientes \u00a0sin\u00a0este\u00a0factor\u00a0\nde\u00a0ries\u00a0ce\ngo.\u00a0La\u00a0DI\u00a0de\u00a0ITU\u00a0asociada\u00a0a\u00a0sondaje\u00a0urinaria\u00a0fue\u00a0de\u00a05\u00a0por\u00a0cada\u00a01000\u00a0\npacientes \u2010d\u00edas\u00a0sondaje.\u00a0\n\u00a0\n0123N\u00famero\u00a0de\u00a0I\nUrinarias\n02579 1 1 1 3 1 5 3 0 4 0\nD\u00edas\u00a0de\u00a0sondaje\u00a0urinario.Figura\u00a023.\u00a0D\u00edas\u00a0de\u00a0sondaje\u00a0urinario\u00a0hasta\u00a0aparici\u00f3n\u00a0de\u00a0Infecci\u00f3n\u00a0del\u00a0\nTracto\u00a0Urinario.Figura\u00a026.\u2010\u00a0\u00a0D\u00cdAS\u00a0DE\u00a0SONDAJE \u00a0URINARIO \u00a0HASTA\u00a0APARICI\u00d3N\u00a0 DE\u00a0\nINFECCI\u00d3N \u00a0DEL\u00a0TRACTO\u00a0URINARIO \u00a0\n\u00a0\n\u00a0\u00a0\nEn\u00a0cuanto\u00a0a\u00a0las\u00a0etiolog\u00edas \u00a0m\u00e1s\u00a0frecuentes \u00a0ocurridas \u00a0en\u00a0la\u00a0UR,\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0\nlas\u00a0NN merece\u00a0la\u00a0pena\u00a0destacar\u00a0que\u00a0en\u00a0un\u00a021,42\u00a0%\u00a0(6\u00a0casos)\u00a0fueron\u00a0NN\u00a0\nmonom,\u00a0\nicrobianas. \u00a0\u00a0En\u00a0la\u00a0NNP\u00a0los\u00a0pat\u00f3genos \u00a0m\u00e1s\u00a0frecuentemente \u00a0aislados\u00a0fueron\u00a0\nStaphylococcus \u00a0aureus\u00a0y\u00a0Pseudomonas \u00a0aeruginosa ,\u00a0mientras\u00a0que\u00a0en\u00a0los\u00a0casos\u00a0de\u00a0\u00a0\nNNT\u00a0resalta\u00a0la\u00a0frecuencia \u00a0del\u00a0g\u00e9nero\u00a0 Pseudomonas \u00a0y\u00a0una\u00a0etiolog\u00eda\u00a0m\u00e1s\u00a0variada.\u00a0\nSin\u00a0embargo, \u00a0en\u00a0un\u00a075\u00a0%\u00a0de\u00a0los\u00a0aislamientos \u00a0realizados \u00a0para\u00a0la\u00a0etiolog\u00eda\u00a0de\u00a0las\u00a0BN\u00a0\u00a0\n\u00a0 106IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nse\u00a0encontraron \u00a0cocos\u00a0grampositivos, \u00a0suponiendo \u00a0los\u00a0Staphylococcus \u00a0un\u00a052,42\u00a0%\u00a0\ndel\u00a0total.\u00a0Solamente \u00a0tres\u00a0(18,75%)\u00a0de\u00a0las\u00a0BN\u00a0fueron\u00a0de\u00a0etiolog\u00eda\u00a0\u00a0polimicrobianas. \u00a0\npat\u00f3genos\u00a0 m\u00e1s\u00a0frecuentemente\u00a0 identificados \u00a0(Tabla\u00a013).\u00a0\nTabla\u00a013.\u2010\u00a0\u00a0MICROORGANISMOS \u00a0IMPLICADOS \u00a0EN\u00a0LA\u00a0NN\u00a0PRECOZ\u00a0Y\u00a0TARD\u00cdA.\u00a0\u00a0La\u00a0presencia \u00a0de\u00a0cocos\u00a0grampositivos\u00a0 y\u00a0bacilos\u00a0 gramnegativos \u00a0los\u00a0son\u00a0\n\u00a0\n\u00a0\nNN\u00a0 NN\u00a0Germen.\u00a0 NN.\u00a0Precoz.\u00a0 Tard\u00eda.\u00a0\nStreptococcus \u00a0pneumoniae. \u00a0 1\u00a0 1\u00a0 0\u00a0\nEscherichia \u00a0coli.\u00a0 3\u00a0 1\u00a0 2\u00a0\nStaphylococcus \u00a0aureus\u00a0 nsible.\u00a0 meticilin\u2010se 12\u00a0 7\u00a0 5\u00a0\nStaphylococcus \u00a0aureus\u00a0 metic ilin\u2010resistente. \u00a0 0\u00a0 0\u00a0 0\u00a0\nProteus\u00a0mirabilis. \u00a0 1\u00a0 1\u00a0 0\u00a0\nPseudomonas\u00a0 aeruginosa. \u00a0 11\u00a0 3\u00a0 8\u00a0\nAcinetobacter \u00a0baumanii.\u00a0 5\u00a0 0\u00a0 5\u00a0\nHaemophylus \u00a0influenzae. \u00a0 1\u00a0 0\u00a0 1\u00a0\nCandida\u00a0albicans.\u00a0 1\u00a0 0\u00a0 1\u00a0\nMoraxella \u00a0catharralis. \u00a0 1\u00a0 0\u00a0 1\u00a0\nKlebsiella \u00a0pneumoniae. \u00a0 1\u00a0 0\u00a0 1\u00a0\nStenotrophomona \u00a0malthophyla.\u00a0 1\u00a0 0\u00a0 1\u00a0\nTOTAL.\u00a0 38\u00a0 13\u00a0 25\u00a0\nNN:\u00a0Neumon\u00eda \u00a0nosocomial. \u00a0Las\u00a0cifras\u00a0 representan\u00a0 n\u00fameros\u00a0absolutos.\u00a0\n\u00a0En\u00a0cuanto\u00a0a\u00a0la\u00a0IHQ,\u00a0en\u00a0el\u00a080%\u00a0\u00a0de\u00a0los\u00a0pacien \u00a0se\u00a0aisl aphyloc us \u00a0\naureus (Staphylococcus \u00a0aureus\u00a0meticilin\u2010resistentes \u00a0en\u00a0un\u00a050%\u00a0de\u00a0los\u00a0\naislami\nar\u00a0ocupado\u00a0 por\u00a0Escherichia \u00a0coli\u00a0\n(80%)\u00a0y dida\u00a0albicans\u00a0(20%)\u00a0\u00a0dentro\u00a0de\u00a0los\u00a0aislamientos \u00a0efectuados. \u00a0\nincuenta\u00a0y\u00a0siete\u00a0(59,35%)\u00a0pacientes \u00a0no\u00a0recibieron \u00a0tratamiento \u00a0\nantimic los\u00a0que\u00a0\nrecibie \u00a0 \u00a0 ltes \u00f3\u00a0St occ\n\u00a0\nentos)\u00a0y\u00a0en\u00a0un\u00a0paciente\u00a0Candida\u00a0albicans.\u00a0\u00a0\n\u00a0Por\u00a0\u00faltimo,\u00a0en\u00a0la\u00a0ITU,\u00a0rese\u00f1ar\u00a0 el\u00a0primer\u00a0lug\n\u00a0C\u00e1n\n\u00a0\n4.1.5.  \u00a0Antimicrobianos \u00a0empleados \u00a0en\u00a0Unidad\u00a0de\u00a0Reanimaci\u00f3n \u00a0\nC\nrobiano\u00a0durante\u00a0su\u00a0estancia\u00a0en\u00a0la\u00a0UR,\u00a0siendo\u00a027\u00a0(28,12%)\u00a0\n\u00a0 107ron\u00a0m\u00e1s\u00a0de un antibi\u00f3tico. \u00a0La\u00a0duraci\u00f3n\u00a0media\u00a0 de\u00a0tratamiento \u00a0fue\u00a0de\u00a09,67\u00a0\nd\u00edas\u00a0y\u00a0la\u00a0raz\u00f3n\u00a0de\u00a0n\u00famero\u00a0de\u00a0antimicrobianos \u00a0por\u00a0pacientes \u00a0con\u00a0antimicrobianos \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\n\u00a0de\u00a01,29.\u00a0Los\u00a0grupos\u00a0 de\u00a0antibi\u00f3ticos \u00a0m\u00e1s\u00a0frecuentemente\u00a0 empleados \u00a0fueron,\u00a0 por\u00a0\neste\u00a0orden,\u00a0cloxacilina, \u00a0cefalosporinas\u00a0 y\u00a0diversos\u00a0carbapenem. \u00a0\u00a0Del\u00a0 total\u00a0de\u00a0la\u00a0\nlicaciones \u00a0\nLa\u00a0frecuencia\u00a0 de\u00a0complicaciones \u00a0m\u00e9dicas\u00a0generales, \u00a0tales\u00a0como\u00a0\nhiperglucemia, \u00a0respiratoria \u00a0prolongada, \u00a0trastornos \u00a0del\u00a0\nritmo\u00a0 \u00a0\nACI\u00d3N.\u00a0cohorte,\u00a047\u00a0(48,96\u00a0%)\u00a0sujetos\u00a0 fueron\u00a0intervenidos \u00a0quir\u00fargicamente, \u00a0y\u00a0de\u00a0estos,\u00a0\nun\u00a0100\u00a0%\u00a0recibieron \u00a0profilaxis\u00a0antimicrobiana. \u00a0La\u00a0duraci\u00f3n\u00a0media\u00a0 de\u00a0la\u00a0profilaxis\u00a0\nfue\u00a0de\u00a01,15\u00a0d\u00edas,\u00a0siendo\u00a0el\u00a0antibi\u00f3tico \u00a0m\u00e1s\u00a0utilizado\u00a0 las\u00a0cefalosporinas\u00a0 con\u00a0 un\u00a0\n45%\u00a0de\u00a0los\u00a0casos.\u00a0La\u00a0asociaci\u00f3n \u00a0cefazolina \u00a0y\u00a0gentamicina \u00a0fue\u00a0la\u00a0m\u00e1s\u00a0utilizada\u00a0en\u00a0la\u00a0\nprofilaxis\u00a0antimicrobiana.\u00a0\n\u00a0\n4.1.6.  Otras\u00a0comp\n\u00a0anemia,\u00a0insuficiencia\ncard\u00edaco,\u00a0 SDRA, \u00edleo\u00a0paral\u00edtico, \u00a0coagulopat\u00eda, \u00a0atelectasias, \u00a0hemorragias \u00a0\ndigestivas, \u00a0shock\u00a0s\u00e9ptico,\u00a0neumot\u00f3rax, \u00a0plaquetopenia, \u00a0insuficiencia \u00a0renal\u00a0aguda,\u00a0\nrabdomiolisis, \u00a0miopat\u00eda\u00a0del\u00a0paciene\u00a0cr\u00edtico,\u00a0s\u00edndrome \u00a0de\u00a0aspiraci\u00f3n \u00a0pulmonar\u2026 \u00a0\nacontecidas \u00a0durante\u00a0el\u00a0periodo\u00a0de\u00a0hospitalizaci\u00f3n \u00a0en\u00a0la\u00a0Unidad\u00a0 se\u00a0detalla\u00a0en\u00a0la\u00a0\nTabla\u00a014.\u00a0Posteriormente, \u00a0analizamos \u00a0la\u00a0incidencia \u00a0de\u00a0presentaci\u00f3n \u00a0de\u00a0diversas\u00a0\ncomplicaciones\u00a0 m\u00e9dicas\u00a0en\u00a0relaci\u00f3n\u00a0con\u00a0las\u00a0variables\u00a0empleo\u00a0de\u00a0CTC\u00a0e\u00a0IQ.\u00a0\n\u00a0\nTabla\u00a014.\u2010\u00a0\u00a0COMPLICACIONES \u00a0M\u00c9DICAS \u00a0DURANTE \u00a0EL\u00a0INGRESO \u00a0EN\u00a0UNIDAD\u00a0DE\u00a0REANIM\n\u00a0 \u00a0 \u00a0\nTIPO\u00a0COMPLICACI\u00d3N \u00a0M\u00c9DICA.\u00a0 n\u00ba\u00a0 %\u00a0\nHiperglucemia.\u00a0 48\u00a0 50\u00a0\nAnem \u00a0 ia.\u00a0 37\u00a0 38,54\nInsuficiencia \u00a0respiratoria \u00a0prolongada. \u00a0 30\u00a0 31,25\u00a0\nTrastornos\u00a0 del\u00a0ritmo\u00a0cardiaco. \u00a0 22\u00a0 22,91\u00a0\nS\u00edndrome \u00a0de\u00a0Distress\u00a0Respiratorio\u00a0 del\u00a0Adulto.\u00a0 21,87\u00a0 21\u00a0\n\u00cdleo\u00a0paral\u00edtico. \u00a0 19\u00a0 19,79\u00a0\nCoagulopat\u00eda. \u00a0 17\u00a0 17,70\u00a0\nAtelectasias. \u00a0 16\u00a0 16,66\u00a0\nShock\u00a0s\u00e9ptico.\u00a0 16\u00a0 16,66\u00a0\nHemorragia \u00a0digestiva.\u00a0 11\u00a0 11,45\u00a0\nNeumot\u00f3rax. \u00a0 11\u00a0 11,45\u00a0\nPlaquetopenia. \u00a0 9\u00a0 9,37\u00a0\nInsuficiencia \u00a0renal\u00a0aguda.\u00a0 9\u00a0 9,37\u00a0\nRabdomiolisis. \u00a0 8\u00a0 8,33\u00a0\nMiopatia \u00a0del\u00a0paciente\u00a0cr\u00edtico.\u00a0 8\u00a0 8,33\u00a0\nS\u00edndrome \u00a0de\u00a0aspiraci\u00f3n \u00a0pulmonar. \u00a0 7\u00a0 7,29\u00a0\nFlebitis.\u00a0 7\u00a0 7,29\u00a0\nTromboembolis mo\u00a0pulmonar. \u00a0 5\u00a0 5,20\u00a0\nn\u00ba\u00a0:\u00a0N\u00famero\u00a0de\u00a0casos.\u00a0%:\u00a0Porcen\n\u00a0 108taje\u00a0de\u00a0casos\u00a0 respecto\u00a0a\u00a0la\u00a0cohorte.\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nLa\u00a0incidencia \u00a0de\u00a0las\u00a0distintas\u00a0complicaciones \u00a0m\u00e9dicas\u00a0durante\u00a0el\u00a0ingreso\u00a0\nen\u00a0la\u00a0UR\u00a0dependiendo\u00a0 del\u00a0empleo\u00a0de\u00a0la\u00a0terapia\u00a0con\u00a0metilprednisolona \u00a0MP,\u00a0 pauta\u00a0\ndel\u00a0protocolo\u00a0 NASCIS\u00a0II,\u00a0y\u00a0la\u00a0presencia \u00a0de\u00a0la\u00a0variable\u00a0intervenci\u00f3n \u00a0quir\u00fargica \u00a0\nartrodesis \u00a0anterior,\u00a0posterior\u00a0y\u00a0mixta\u00a0se\u00a0exponen\u00a0 en\u00a0las\u00a0Tabla\u00a015.\u00a0\n\u00a0\nTabla\u00a015.\u2010\u00a0COMPLICACIONES \u00a0M\u00c9DICAS \u00a0ENTRE\u00a0GRUPOS\u00a0TRATADOS \u00a0CON\u00a0MP\u00a0E\u00a0IQ.\u00a0\nIncidencia \u00a0 Grupo\u00a0 Grupo\u00a0sin\u00a0Grupo\u00a0 Grupo\u00a0\nGlobal\u00a0 MPS.\u00a0 MPS.\u00a0 ARTM.\u00a0 CONS.\u00a0 Compli caci\u00f3n\u00a0\nN=96.\u00a0 N=68.\u00a0 N\u00a0=28.\u00a0 N=46.\u00a0 N=50.\u00a0\nHipe rglucemia. \u00a0 48\u00a0 42\u00a0 6\u00a0 24\u00a0 24\u00a0\nAnemia.\u00a0 37\u00a0 25\u00a0 12\u00a0 11\u00a0 26\u00a0\nInsuficiencia \u00a0respiratoria. \u00a0 30\u00a0 22\u00a0 8\u00a0 12\u00a0 18\u00a0\nAlterac.\u00a0Cardiovasc ular.\u00a0 22\u00a0 14\u00a0 8\u00a0 11\u00a0 11\u00a0\nSDRA.\u00a0 \u00a021 12\u00a0 9\u00a0 9\u00a0 12\u00a0\n\u00cdleo\u00a0paral\u00edtico. \u00a0 19\u00a0 12\u00a0 7\u00a0 8\u00a0 11\u00a0\nCoagulopatia. \u00a0 17\u00a0 8\u00a0 9\u00a0 7\u00a0 10\u00a0\nAtelectasia.\u00a0 16\u00a0 11\u00a0 5\u00a0 9\u00a0 7\u00a0\nNeumon\u00eda \u00a0nosocomial.\u00a0 34\u00a0 18\u00a0 16\u00a0 12\u00a0 22\u00a0\nNeumon\u00eda \u00a0precoz.\u00a0 11\u00a0 3\u00a0 8\u00a0 4\u00a0 7\u00a0\nNeumon\u00eda \u00a0tard \u00eda.\u00a0 23\u00a0 15\u00a0 8\u00a0 8\u00a0 15\u00a0\nBacteriemia. \u00a0 16\u00a0 12\u00a0 4\u00a0 7\u00a0 9\u00a0\nInfecci\u00f3n \u00a0tracto\u00a0urinario.\u00a0 5\u00a0 3\u00a0 2\u00a0 3\u00a0 2\u00a0\nInfecci\u00f3n \u00a0herida\u00a0quir\u00farg ica.\u00a0 5\u00a0 3\u00a0 2\u00a0 5\u00a0 0\u00a0\nShock\u00a0s\u00e9ptico.\u00a0 16\u00a0 10\u00a0 6\u00a0 8\u00a0 8\u00a0\nHemorragia \u00a0digestiv a.\u00a0 11\u00a0 10\u00a0 1\u00a0 5\u00a0 6\u00a0\nNeumot\u00f3rax. \u00a0 11\u00a0 7\u00a0 4\u00a0 4\u00a0 7\u00a0\nPlaquetopenia .\u00a0 9\u00a0 4\u00a0 5\u00a0 3\u00a0 6\u00a0\nInsuficiencia \u00a0renal\u00a0aguda.\u00a0 9\u00a0 4\u00a0 5\u00a0 3\u00a0 6\u00a0\nRabdomiolisis. \u00a0 8\u00a0 6\u00a0 2\u00a0 4\u00a0 4\u00a0\nMiopatia \u00a0del\u00a0cr\u00edtico.\u00a0 8\u00a0 5\u00a0 3\u00a0 3\u00a0 5\u00a0\nS\u00edndrome \u00a0aspiraci\u00f3n. \u00a0 7\u00a0 5\u00a0 2\u00a0 3\u00a0 4\u00a0\nFlebitis.\u00a0 7\u00a0 5\u00a0 2\u00a0 3\u00a0 4\u00a0\nEmbolismo \u00a0pulmonar. \u00a0 5\u00a0 4\u00a0 1\u00a0 2\u00a0 3\u00a0\nTOTAL.\u00a0 3\u00a0 2 1 1\u00a0 2 61 42\u00a0 19\u00a0 56 05\u00a0\nN:\u00a0N\u00famero\u00a0de\u00a0casos.\u00a0\nGrupo\u00a0no\u00a0tratado\u00a0conGRUPO\u00a0MPS:\u00a0Grupo\u00a0de\u00a0pa tes \u00a0tratados\u00a0cmetilpredniso a \u00a0seg\u00fan\u00a0proto o. \u00a0GRUPO\u00a0si\u00a0\nmetilprednisolona. \u00a0GRUPO M:\u00a0Grupo\u00a0dacientes\u00a0interv idos \u00a0de\u00a0artrod s \u00a0raqu\u00eddea. \u00a0 PO\u00a0\nntes\u00a0en\u00a0los\u00a0que\u00a0\u00a0trata nto \u00a0conservad MP: \u00a0Metilpre solona, \u00a0IQUIR GICA: \u00a0Interv ci\u00f3n \u00a0\n\u00a0SDRA:\u00a0S\u00edndrome \u00a0de\u00a0distress\u00a0respirato agudo\u00a0y/o\u00a0lesi\u00f3 lmonar\u00a0agucien on\u00a0 lon col n\u00a0MPS:\n\u00a0\nCONS:\u00a0Grupo\u00a0de\u00a0pacie\u00a0ART e\u00a0p en esi GRU\nmie or. dni UR en\nquir\u00fargica. rio\u00a0 n\u00a0pu da.\u00a0\n\u00a0\n4.2. AN\u00c1LISIS \u00a0UNIVARIANTE \u00a0\n4.2.1.  Mortalidad \u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0medular\u00a0aguda\u00a0traum\u00e1tica \u00a0\nLas\u00a0variables\u00a0que\u00a0se\u00a0asociaron \u00a0significativamente \u00a0(p\u00a0<\u00a00,05)\u00a0con\u00a0 la\u00a0\ne\u00a0se\u00a0muestran \u00a0\nen\u00a0las\u00a0Tablas\u00a016\u00a0y\u00a017.\u00a0\u00a0\n\u00a0 109mortalidad, \u00a0considerada \u00a0de\u00a0forma\u00a0global\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0univariantIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0 110\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nNo\u00a0se\u00a0apreciaron \u00a0diferencias\u00a0 estad\u00edsticamente\u00a0 significativas \u00a0en\u00a0la\u00a0\ndistribuci\u00f3n \u00a0del\u00a0sexo,\u00a0 en\u00a0los\u00a0diferentes \u00a0a\u00f1os\u00a0del\u00a0presente\u00a0estudio,\u00a0mecanismo \u00a0de\u00a0\nproducci\u00f3n \u00a0del\u00a0trauma,\u00a0 \u00edndice\u00a0de\u00a0comorbilidad\u00a0 de\u00a0Deyo\u2010Charlson\u00a0y\u00a0la\u00a0presencia \u00a0\nde\u00a0LI\u00a0de\u00a0la\u00a0LMAT.\u00a0Se\u00a0apreciaron \u00a0diferencias \u00a0estad\u00edsticamente \u00a0significativas\u00a0 en\u00a0el\u00a0\nriesgo\u00a0de\u00a0muerte\u00a0con\u00a0la\u00a0clasificaci\u00f3n \u00a0APACHE\u00a0II\u00a0(p\u00a0<\u00a00,0000).\u00a0\n\u00a0No\u00a0se\u00a0detectaron \u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significativas, \u00a0en\u00a0el\u00a0riesgo\u00a0\nde\u00a0exitus\u00a0 entre\u00a0los\u00a0pacientes \u00a0con\u00a0 BN,\u00a0ITU\u00a0e\u00a0IHQ\u00a0Se\u00a0apreciaron \u00a0diferencias \u00a0\nestad\u00edsticamente \u00a0significativas \u00a0en\u00a0la\u00a0mortalidad\u00a0 de\u00a0pacientes\u00a0 con\u00a0NN\u00a0respecto\u00a0a\u00a0\nlos\u00a0pacientes \u00a0que\u00a0no\u00a0desarrollaron \u00a0tal\u00a0infecci\u00f3n\u00a0nosocomial\u00a0 (p\u00a0<\u00a00,0002).\u00a0Los\u00a0\npacientes \u00a0con\u00a0NNP\u00a0multiplicaron \u00a0por\u00a024,3\u00a0veces\u00a0el\u00a0riesgo\u00a0de\u00a0exitus,\u00a0 mientras\u00a0que\u00a0\nlos\u00a0pacientes \u00a0con\u00a0NNT\u00a0presentaron \u00a0un\u00a0riesgo\u00a0de\u00a0muerte\u00a0de\u00a06,08.\u00a0\u00a0\n\u00a0La\u00a0utilizaci\u00f3n \u00a0del\u00a0protocolo \u00a0NASCIS\u00a0II\u00a0supuso\u00a0una\u00a0 disminuci\u00f3n \u00a0del\u00a0riesgo\u00a0\nde\u00a0muerte\u00a0 del\u00a0paciente\u00a0con\u00a0LMAT\u00a0(OR\u00a0=\u00a00,22,\u00a0 IC\u00a0=\u00a00,05\u00a0\u2013\u00a00,92,\u00a0p\u00a0<\u00a00,0234).\u00a0\n\u00a0Las\u00a0asociaciones \u00a0m\u00e1s\u00a0fuertes\u00a0las\u00a0mostraron\u00a0 la\u00a0presencia \u00a0de\u00a0trauma\u00a0\nvascular\u00a0(TV),\u00a0TCE\u00a0y\u00a0TA\u00a0acompa\u00f1ante \u00a0a\u00a0la\u00a0LMAT,\u00a0 as\u00ed\u00a0como\u00a0la\u00a0presencia \u00a0de\u00a0\u00a0SDRA,\u00a0\npolitransfusi\u00f3n \u00a0e\u00a0insuficiencia \u00a0renal\u00a0aguda.\u00a0\u00a0\n\u00a0TABLA\u00a017.\u2010\u00a0AN\u00c1LISIS \u00a0UNIVARIANTE \u00a0DE\u00a0LA\u00a0VARIABLE \u00a0MORTALIDAD. \u00a0\nVariables \u00a0Cuantitativas. \u00a0Cohorte\u00a0general.\u00a0\nVariable\u00a0 N\u00ba\u00a0Casos\u00a0 Media\u00a0 DE\u00a0 IC\u00a0 P\u00a0*\u00a0\nEdad (a\u00f1os) \n\u0083 Exitus. \n\u0083 No Exitus. 10\u00a0\n86\u00a044\u00a0\n39,98\u00a020,75\u00a0\n15,39\u00a029,15\u00a0\u2013\u00a058,84\u00a0\n31,68\u00a0\u2013\u00a038,28\u00a00,0474\u00a0\nAPACHE II \n\u0083 Exitus. \n\u0083 No Exitus. 10\u00a086\u00a025,3\u00a0\n11,34\u00a07,41\u00a0\n5,64\u00a020,19\u00a0\u2013\u00a030,80\u00a0\n10,13\u00a0\u2013\u00a012,55\u00a00,0000\u00a0\nD\u00edas de Ventilaci\u00f3n \nMec\u00e1nica. \n\u0083 Exitus. \n\u0083 No Exitus. 10\u00a0\n86\u00a014,4\u00a0\n4,96\u00a010,51\u00a0\n9,39\u00a06,88\u00a0\u2013\u00a021,91\u00a0\n2,95\u00a0\u2013\u00a06,97\u00a00,0019\u00a0\nAPACHE 6 \n\u2022 Exitus.        \n\u2022 No Exitus \u00a0\n10\u00a0\n86\u00a04.4\u00a0\n1.82\u00a01.07\u00a0\n1.01\u00a03,63\u00a0\u2013\u00a05,17\u00a0\n1.60\u00a0\u2013\u00a02.04\u00a00.0000\u00a0\nDE:\u00a0Desviaci\u00f3n\u00a0 t\u00edpica.\u00a0IC:\u00a0Intervalo\u00a0de\u00a0confianza. \u00a0\nP*:\u00a0Valor\u00a0de\u00a0la\u00a0p\u00a0al\u00a095%\u00a0para\u00a0la\u00a0prueba\u00a0 de\u00a0la\u00a0T\u00a0de\u00a0Student\u00a0o\u00a0la\u00a0Krushall\u2010Wallis.\u00a0\n\u00a0 111IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nNo\u00a0se\u00a0detectaron \u00a0diferencias\u00a0 estad\u00edsticamente\u00a0 significativas \u00a0en\u00a0la\u00a0\ndistribuci\u00f3n \u00a0de\u00a0la\u00a0estancia\u00a0en\u00a0UR,\u00a0as\u00ed\u00a0como\u00a0en\u00a0los\u00a0d\u00edas\u00a0de\u00a0utilizaci\u00f3n \u00a0de\u00a0CVC\u00a0y\u00a0de\u00a0\nurinario.\u00a0\ncolo\u00a0 NASCIS\u00a0II\u00a0y\u00a0lesi\u00f3n\u00a0medular\u00a0aguda\u00a0traum\u00e1tica \u00a0\ns\u00a0que\u00a0se\u00a0 ciaron\u00a0 icativ te \u00a0con\u00a0\nl nivaria \u00a0muestran \u00a0e 18\u00a0y\u00a019.\u00a0\u00a0\nSIS\u00a0UNIVARIANTE \u00a0DE\u00a0VARIABLE \u00a0NASC\nVa as.\u00a0Cohorte\u00a0g ral. \u00a0sondaje\u00a0\n\u00a0\n4.2.2.  Proto\nLas\u00a0variable aso signif amen\u00a0(p\u00a0<\u00a00,05) \u00a0el\nprotocolo\u00a0 NASCIS\u00a0II,\u00a0en\u00a0el\u00a0an\u00e1isis\u00a0u nte,\u00a0 se n\u00a0las\u00a0Tablas\u00a0\n\u00a0\nTABLA\u00a018.\u2010\u00a0ANALI IS\u00a0II.\u00a0\nriables\u00a0Cualitativ ene\nVariable\u00a0 NASCIS2\u00a0No\u00a0\nNACIS2\u00a0OR\u00a0 IC\u00a0 P\u00a0*\u00a0\nTrauma ascular.\u00a0\n\u2022 Si.\u00a0\n\u2022 \u00a0\u00a0\n2\u00a0\u00a0\n5\u00a0 0.14\u00a0 0.02\u00a0\u2013\u00a00.82\u00a0 0.0110\u00a0\u00a0V\nNo. 66\u00a0 23\u00a0\nVMI.\u00a0\n\u2022 No.\u00a0\u00a0 \u00a0\n\u2022 Si.\u00a0\n 31\u00a0\n37\u00a021\u00a0\n7\u00a00.28\u00a0 0.10\u00a0\u2013\u00a00.73\u00a0 0.0086\u00a0\nInfecci\u00f3n\u00a0nosocomial. \u00a0\n\u2022 Si.\u00a0\n\u2022 No.\u00a0\u00a0\n21\u00a0\n47\u00a0\u00a0\n16\u00a012\u00a00.33\u00a0 0.13\u00a0\u2013\u00a00.82\u00a0 0.0163\u00a0\nNN.\u00a0\n\u2022 Si.\u00a0\u00a0 \u00a0\n\u2022 No.\u00a015\u00a053\u00a013\u00a015\u00a00.32\u00a0 0.13\u00a0\u2013\u00a00.82\u00a0 0.0170\u00a0\nNN\u00a0precoz.\n\u2022 \u00a0\nSi.\u00a0\n\u2022 No.\u00a0\u00a0\n3\u00a0\n65\u00a0\u00a0\n8\u00a0\n20\u00a00.11\u00a0 0.03\u00a0\u2013\u00a00.44\u00a0 0.0007\u00a0\nCoagulopat\u00eda. \u00a0\n\u2022 Si.\u00a0\n\u2022 No.\u00a0\u00a0\n8\u00a0\u00a0\n9\u00a0 0.28\u00a0 0.09\u00a0\u2013\u00a00.81\u00a0 0.0174\u00a0\n60\u00a0 19\u00a0\nHFVVC.\u00a0\n\u2022 No.\u00a0\u00a0\u00a0\n66\u00a0\u00a0\n24\u00a0\u2022 Si.\u00a0 2\u00a0 4\u00a0 0.18\u00a0 0.029\u00a0\u2013\u00a01.11\u00a0 0.0369\u00a0\nComa.\u00a0\n\u2022 Si.\u00a0\u00a0\n29\u00a0\u00a0\n21\u00a0 0.24\u00a0 0.09\u00a0\u2013\u00a00.6\n\u2022 No.\u00a0 39\u00a0 7\u00a05\u00a0 0.0039\u00a0\nHiperglucemia. \u00a0\n\u2022 \n\u2022 \u00a0\n26\u00a0\u00a0\n22\u00a0Si.\u00a0\nNo.\u00a042\u00a0 6\u00a0 5.92\u00a0 2.16\u00a0\u2013\u00a016.08\u00a0 0.0003\u00a0\nMortalidad. \u00a0 \u00a0 \u00a0\n\u2022 Si.\u00a0\n\u2022 4 \u00a0\nNo.\u00a0\u00a0\n64\u00a06\n22\u00a00.23\u00a0 0.063\u00a0\u2013\u00a00.834\u00a0 0.0234\u00a0\nVMI:\u00a0Ventilaci\u00f3n \u00a0mec\u00e1nica \u00a0invasiva.\u00a0\nNN:\u00a0Neumon\u00eda \u00a0nosocomial. \u00a0\nHFVVC:\u00a0Hemofiltraci\u00f3n \u00a0veno\u00a0 \u2013\u00a0venosa\u00a0continua. \u00a0\nOR:\u00a0Odds\u00a0Ratio.\u00a0IC:\u00a0Intervalo\u00a0 de\u00a0confianza. \u00a0\nP*:\u00a0Valo\u00a0p\u00a0al\u00a095%\u00a0para\u00a0la\u00a0prueba\u00a0chi\u00a0cuadrado \u00a0o\u00a0el\u00a0test\u00a0de\u00a0Fisher.\u00a0\n\u00a0 112r\u00a0deIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 TABLA\u00a0 19\u00a0.\u2010\u00a0ANALISIS \u00a0UNIVARIANTE \u00a0DE\u00a0VARIABLE \u00a0NASCIS\u00a0 II\u00a0\nVariables \u00a0Cuantitativas. \u00a0Cohorte\u00a0general.\u00a0\nVariable\u00a0 N\u00ba\u00a0Casos\u00a0 Media\u00a0 DE\u00a0 IC\u00a0 P*\u00a0\nAPACHE\u00a0II.\u00a0\n\u2022 NACIS2.\u00a0\u00a0\n\u2022 No\u00a0NACIS2.\u00a0\u00a0\n68\u00a0\n28\u00a0\u00a0\n11.70\u00a015.53\u00a0\u00a0\n6.33\u00a0\n8.63\u00a0\u00a0\n10.17\u00a0 \u2013\u00a013.24\u00a0\n12.18\u00a0 \u2013\u00a018.88\u00a00.0089\u00a0\nAPACHE\u00a06.\u00a0\n\u2022 \n\u2022 NACIS2\u00a0No.\u00a0\u00a0 \u00a0 \u00a0 \u00a0\n6 3.10.0305\u00a0 NACIS2.\u00a0 68\u00a0 1.911\u00a0 1.17\u00a0 1.62\u00a0\u2013\u00a02.19\u00a0\n28\u00a0 2.535\u00a0 1.48\u00a0 1.9\u00a0\u2013\u00a01\u00a0\nDE:\u00a0Des\n*viaci\u00f3n\u00a0t\u00edpica.\u00a0IC:\u00a0Intervalo\u00a0de\u00a0confianza. \u00a0\nP :\u00a0Valor\u00a0de\u00a0p\u00a0al\u00a095%\u00a0para\u00a0la\u00a0prueba\u00a0de\u00a0la\u00a0T\u00a0de\u00a0Student\u00a0o\u00a0la\u00a0Krushall\u00a0\u2013\u00a0Wallis.\u00a0\n\u00a0\nEn\u00a0este\u00a0caso\u00a0tampoco\u00a0se\u00a0encontraron \u00a0diferencias\u00a0 estad\u00edsticamente \u00a0\ns tes\u00a0a\u00f1os\u00a0del\u00a0presente\u00a0\nestud nismo\u00a0d ci\u00f3n\u00a0d auma, ce \u00a0de\u00a0comorbilidad \u00a0de o\u2010\n\u00a0presencia de\u00a0LI\u00a0de\u00a0 \u00a0 LMAT.\u00a0Si\u00a0se\u00a0apreciaron \u00a0diferencias\u00a0\nestad\u00edsticamente \u00a0significativas \u00a0en\u00a0la\u00a0clasificaci\u00f3n \u00a0II .\u00a0\nN\u00a0detectaron iferencias stad\u00edsticamente \u00a0significativas, \u00a0entre\u00a0 los\u00a0\ncon\u00a0BN,\u00a0ITU IHQ.\u00a0Se reciar iferen d\u00edstic \u00a0\nicativas\u00a0 en\u00a0aquellos\u00a0 \u00a0 que\u00a0padecieron \u00a0NN\u00a0(p\u00a0<\u00a00,0170)\u00a0e\u00a0IN\u00a0(p\u00a0<\u00a0\n0,0163); \u00a0como\u00a0en\u00a0aquellos\u00a0 que\u00a0ron\u00a0sometidos \u00a0a n \u00a0m \u00a0\nMI).\u00a0\n\u00a0\nn\u00a0del\u00a0 tocolo\u00a0 NASCIS\u00a0II\u00a0supuso\u00a0un\u00a0r adec \u00a0\n0,11,\u00a0 IC\u00a0=\u00a00,03\u00a0\u2013\u00a0as\u00ed\u00a0 \u00a0 un\u00a0riesgo\u00a0de\u00a0muerte\u00a0del\u00a0paciente\u00a0\nmultiplicado \u00a0por\u00a00,23.\u00a0\n\u00a0L \u00a0qu bieron \u00a0protocolo\u00a0 NASCIS\u00a0II\u00a0multiplicaron \u00a0por\u00a0\u00a0\n\u00a0de\u00a0precisar VVC\u00a0y\u00a0por 28,\u00a0el\u00a0riesgo\u00a0de\u00a0p gulo\n\u00a0m\u00e1 \u00a0establecida \u00a0 NAS \u00a0\npignificativas\u00a0 en\u00a0la\u00a0distribuci\u00f3n \u00a0del\u00a0sexo,\u00a0 en\u00a0los\u00a0diferen\nio,\u00a0meca e\u00a0produc el\u00a0tr\u00a0\u00edndi \u00a0Dey\nCharlson\u00a0y\u00a0la \u00a0 la\n\u00a0APACHE \u00a0(p\u00a0<\u00a00,009)\n\u00a0\no\u00a0se \u00a0d \u00a0e\npacientes \u00a0 \u00a0e\u00a0 \u00a0ap on\u00a0d cias\u00a0 esta amente\nsignif pacientes\n\u00a0as\u00ed fue \u00a0ventilaci\u00f3 ec\u00e1nica\ninvasiva\u00a0(V\nLa\u00a0utilizaci\u00f3 pro iesgo\u00a0de\u00a0p er\u00a0NNP\n(OR\u00a0=\u00a0 \u00a00,44), como\nos\u00a0pacientes e\u00a0reci \u00a0el\n0.18\u00a0el\u00a0riesgo \u00a0HF \u00a00. resentar\u00a0 coa pat\u00eda.\u00a0\n\u00a0La\u00a0asociaci\u00f3n s\u00a0fuerte fue\u00a0entre\u00a0protocolo \u00a0 CIS\u00a0II\u00a0y\nresencia\u00a0de\u00a0hiperglucemia. \u00a0\n\u00a0\n\u00a0 113\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nNo\u00a0se\u00a0encontraron\u00a0 diferencias\u00a0 estad\u00edsticamente \u00a0significativas \u00a0respecto\u00a0a\u00a0\nla \u00a0del\u00a0 ente\u00a0cr\u00edtic \u00a0s\u00e9ptico,\u00a0ni\u00a0\n\u00a0no\u00a0se\u00a0encontraron\u00a0 \u00a0 \u00a0\nlistri \u00a0la\u00a0estancia\u00a0en\u00a0U como \u00a0pr telectasias, \u00a0\nrragia\u00a0digestiva. \u00a0\n\u00a0respecto\u00a0al\u00a0grado\u00a0de\u00a0\nrecupe\n.2.3. Intervenci\u00f3n \u00a0quir\u00fargica \u00a0y\u00a0lesi\u00f3n\u00a0medular\u00a0aguda\u00a0traum\u00e1tica \u00a0\nNALISIS\u00a0UNIVARIANTE \u00a0DE\u00a0VARIABLE \u00a0INTERVENCI\u00d3N \u00a0QUIR\u00daRGICA. \u00a0\n\u00a0Cohorte\u00a0general. \u00a0\u00a0pre \u00a0insufic al,\u00a0miopat\u00eda sencia\u00a0de iencia\u00a0ren paci o,\u00a0shock\nSDRA.\u00a0Asimi smo diferencias estad\u00edsticam ente\u00a0significativas\u00a0 en\na\u00a0d buci\u00f3n \u00a0de R,\u00a0as\u00ed\u00a0\u00a0en\u00a0la esencia\u00a0de\u00a0a\nanemia\u00a0\u00f3\u00a0hemo\n\u00a0\no\u00a0existen\u00a0diferencias\u00a0 estad\u00edsticamente\u00a0 significativas N\nraci\u00f3n\u00a0neurol\u00f3gica \u00a0mediante \u00a0la\u00a0escala\u00a0ASIA\u00a0con\u00a0 el\u00a0tratamiento \u00a0con\u00a0\nmegadosis \u00a0de\u00a0MP\u00a0y\u00a0el\u00a0nivel\u00a0topogr\u00e1fico \u00a0de\u00a0lesi\u00f3n\u00a0medular\u00a0(cervical,\u00a0dorsal\u00a0y\u00a0\nlumbar).\u00a0\n\u00a0\u00a0\n4\nLas\u00a0variables\u00a0que\u00a0se\u00a0asociaron\u00a0 significativamente \u00a0(p\u00a0<\u00a00,05)\u00a0con\u00a0la\u00a0variable\u00a0\nintervenci\u00f3n \u00a0quir\u00fargica,\u00a0 en\u00a0el\u00a0an\u00e1lisis\u00a0 univariante \u00a0se\u00a0muestran \u00a0en\u00a0las\u00a0Tablas\u00a020\u00a0y\u00a0\n21.\u00a0\n\u00a0\nTABLA\u00a020.\u2010\u00a0A\nVariables \u00a0Cualitativas.\nVariable\u00a0 IQUIR\u00daRGICA \u00a0No\u00a0\nIQUIR\u00daRGICA \u00a0OR\u00a0 IC\u00a0 P\u00a0*\u00a0\nTrauma\no.\n38\u00a0\nCraneoencef\u00e1lic \u00a0\n\u2022 Si.\u00a0\n\u2022 No.\u00a0\u00a0\n9\u00a0\n\u00a0\u00a0\n20\u00a0\n29\u00a00.34\u00a0 0.14\u00a0\u2013\u00a00.85\u00a0 0.0208\u00a0\nTraumatismo\u00a0\nTor\u00e1cico.\u00a0\n\u2022 Si.\u00a0\n\u2022 \u00a0\n16\u00a0\n31\u00a0\u00a0\n29\u00a020\u00a0\u00a0\n0,35\u00a00,15\u00a0\u2013\u00a00,81\u00a0 0,0136\u00a0\nNo.\u00a0\nTrauma\n\u2022 No.\u00a045\u00a0 39\u00a0tismo\u00a0\nAbdominal. \u00a0\n\u2022 Si.\u00a0\u00a0\n2\u00a0\u00a0\n10\u00a0 0.35\u00a0 0.15\u00a0\u2013\u00a00.81\u00a0 0.0136\u00a0\nAnemia.\n\u2022 \u2022 \u00a0 \u00a0 \u00a0\nSi.\u00a0\nNo.\u00a011\u00a0\n36\u00a026\u00a023\u00a00.27\u00a0 0.11\u00a0\u2013\u00a00.64\u00a0 0.0028\u00a0\nMortalidad. \u00a0 \u00a0\n\u2022 Si.\u00a0\n\u2022 No.\u00a01\u00a0\n46\u00a0\u00a0\n9\u00a0\n40\u00a00.09\u00a0 0.37\u00a0\u2013\u00a00.62\u00a0 0.0092\u00a0\nOR:\u00a0Odds\u00a0Ratio.\u00a0IC:\u00a0Intervalo\u00a0 de\u00a0confianza. \u00a0\nP*:\u00a0Valo\u00a0p\u00a0al\u00a095%\u00a0para\u00a0la\u00a0prueba\u00a0chi\u00a0cuadrado \u00a0o\u00a0el\u00a0test\u00a0de\u00a0Fisher\u00a0\n\u00a0 114r\u00a0deIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nTABLA\u00a021.\u2010\u00a0ANALISIS \u00a0UNIVARIANTE \u00a0DE\u00a0VARIABLE \u00a0INTERVENCI\u00d3N \u00a0QUIR\u00daRGICA. \u00a0\nVariables \u00a0Cuantitativas. \u00a0Cohorte\u00a0general\u00a0\nVariable\u00a0 N\u00ba\u00a0Casos\u00a0 Media\u00a0 DE\u00a0 IC\u00a0 P*\u00a0\nAPACHE\u00a0II.\u00a0\n\u2022 IQUIR.\u00a0\u00a0\n\u2022 No\u00a0IQUIR.\u00a0\u00a0\n47\u00a0\n49\u00a0\u00a0\n11.55\u00a014.04\u00a0\u00a0\n4.61\u00a0\n8.97\u00a0\u00a0\n10.19\u00a0 \u2013\u00a012.90\u00a0\n11.46\u00a0 \u2013\u00a016.61\u00a00.0465\u00a0\nAPACHE6. \u00a0\n\u2022 No.\u00a0\u00a0\n49\u00a0\u00a0\n1.85\u00a0\n2.32\u00a0\u00a0\n0.83\u00a0\n1.58\u00a0\u00a0\n1.60\u00a0\u2013\u00a02.09\u00a0\n1.87\u00a0\u2013\u00a02.78\u00a00.0354\u00a0 \u2022 Si.\u00a0 47\u00a0\nIQUIR: esencia\u00a0de\u00a0intervenci\u00f3n\u00a0 quir\u00fargica.\u00a0 DE:\u00a0Desviaci\u00f3n\u00a0 t\u00edpica.\u00a0IC:\u00a0Intervalo\u00a0de\u00a0confianza. \u00a0\nP*:\u00a0Val\u00a0Pr\nor\u00a0de\u00a0p\u00a0al\u00a095%\u00a0para\u00a0la\u00a0prueba\u00a0 de\u00a0la\u00a0T\u00a0de\u00a0Student\u00a0o\u00a0la\u00a0Krushall\u00a0\u2013\u00a0Wallis.\u00a0\n\u00a0\n\u00a0\nEn\u00a0el\u00a0an\u00e1lisi\u00a0univariante \u00a0de\u00a0la\u00a0variable\u00a0IQ,\u00a0no\u00a0se\u00a0encontraron \u00a0diferencias \u00a0\nestad\u00edsticams\nente\u00a0significativas \u00a0en\u00a0la\u00a0distribuci\u00f3n \u00a0del\u00a0sexo,\u00a0 en\u00a0los\u00a0diferentes \u00a0a\u00f1os\u00a0\ndel\u00a0estudio,\u00a0mecanismo \u00a0de\u00a0producci\u00f3n \u00a0del\u00a0trauma,\u00a0\u00edndice\u00a0de\u00a0comorbilidad \u00a0de\u00a0\nDeyo Charlson\u00a0y\u00a0la\u00a0presencia \u00a0de\u00a0LI\u00a0de\u00a0la\u00a0LMAT.\u00a0 Si\u00a0se\u00a0encontraron\u00a0 diferencias\u00a0\nestad\u00edsticam\n\u2010\u00a0trasfundidos, \u00a0con\u00a0presencia\u00a0 de\u00a0plaquetopenia \u00a0o\u00a0coagulopat\u00eda.\u00a0 Tampoco \u00a0se\u00a0\ndetectaron \u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significativas, \u00a0entre\u00a0los\u00a0\u00a0pacientes \u00a0con\u00a0\nB\ne\u00a0apreciaron \u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significativas\u00a0 en\u00a0aquellos\u00a0\n\u00a0presenta \u00a0TCE\u00a0(p\u00a0<\u00a00,0208),\u00a0 tra tor \u00a00,0 \u00a0\nominal\u00a0(p\u00a0<\u00a0 \u00a0 No\u00a0encontr\u00e1ndose \u00a0dicha\u00a0significaci\u00f3n \u00a0en\u00a0los\u00a0\nue\u00a0presentar traumatismo scular.\u00a0\n\u00a0an\u00e1lisis\u00a0 univariante \u00a0de\u00a0la\u00a0variable\u00a0IQ,\u00a0lo ient os \u00a0\nci\u00f3n\u00a0presentaron una\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0mortalidad\u00a0 (OR=\u00a0 0,09,\u00a0 IC\u00a0=\u00a00,37\u00a0\n\u2013,62)\u00a0y\u00a0disminuci\u00f3 n\u00a0la\u00a0presenc e\u00a0anemia \u00a0=\u00a00 1\u00a0\u2013\u00a0\nN xisten\u00a0diferencias\u00a0 estad\u00edsticamente\u00a0 significativas\u00a0 respecto\u00a0al\u00a0grado\u00a0de\u00a0\nr n\u00a0el\u00a0tratamiento \u00a0quir\u00fargico \u00a0\u00a0\u2010\nente\u00a0significativas \u00a0en\u00a0la\u00a0clasificaci\u00f3n \u00a0APACHE\u00a0II\u00a0(p\u00a0<\u00a00,0465).\u00a0\n\u00a0No\u00a0se\u00a0apreciaron \u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significativas\u00a0 en\u00a0pacientes \u00a0\npoli\nN,\u00a0ITU,\u00a0IHQ\u00a0ni\u00a0en\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0estancia\u00a0en\u00a0UR.\u00a0\n\u00a0S\npacientes \u00a0que ron uma\u00a0 \u00e1cico\u00a0(p\u00a0< 136)\u00a0y\ntrauma\u00a0 abd 0,0136).\npacientes \u00a0q on\u00a0 \u00a0va\n\u00a0En\u00a0el s\u00a0pac es\u00a0sometid \u00a0a\u00a0dicha\ninterven \u00a0\n\u00a00\u00a0una n\u00a0e ia\u00a0d \u00a0(OR ,27,\u00a0IC\u00a0=\u00a00,1\u00a00.64).\n\u00a0\no\u00a0e\n\u00a0 115ecuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0mediante \u00a0la\u00a0escala\u00a0ASIA\u00a0 coIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nresp ar\u00a0\n(\n\u00a0\n\u00a0DE\u00a0SU VIVEN \u00a0KAPLAN\u2010Mecto\u00a0al\u00a0tratamiento \u00a0conservador \u00a0y\u00a0el\u00a0nivel\u00a0topogr\u00e1fico \u00a0de\u00a0lesi\u00f3n\u00a0medul\ncervi l\u00a0y\u00a0lum cal,\u00a0dorsa bar).\u00a0\n\u00a0\n4.3. AN\u00c1LISIS PER CIA\u00a0DE EYER\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sig\n\u00a0\u00a0\u00a0\u00a0\u00a022,519\u00a0\u00a0\u00a0\u00a0\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ,000\u00a0\n\u00a0\u00a0\u00a0Figura\u00a027.\u2010\u00a0VARIABLE \u00a0APACHE\u00a06.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sig\n\u00a0\u00a0\u00a0\u00a0\u00a0,010\u00a0 Log\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a06,680\u00a0\u00a0\u00a0\u00a0\u00a01\u00a0\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a028.\u2010\u00a0VARIABLE \u00a0DIAGN\u00d3STICO. \u00a0CURVA\u00a0KAPLA\u00a0\u2013MEYER.\n\u00a0\n\u00a0 116IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sig\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a04,615\u00a0\u00a0\u00a0\u00a0\u00a0\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ,032\u00a0\n\u00a0\n\u00a0\n\u00a0Figura\u00a029.\u2010\u00a0VARIABLE \u00a0LESI\u00d3N.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\n\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sig.\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a04,197\u00a0\u00a0\u00a0\u00a0\u00a0\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 41\u00a0\u00a0\u00a0,0\n\u00a0 Figura\u00a030.\u2010\u00a0VARIABLE \u00a0PLEJIA.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a04,359\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sig.\u00a0\n\u00a0 Figura\u00a031.\u2010\u00a0VARIABLE \u00a0TRAUMATISMO \u00a0ABDOMINAL. \u00a0CURVA\u00a0KAPLAN\u00a0\u2013MEYER\u00a0\n\u00a0 117IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sig.\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a09,464\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ,002\u00a0\n\u00a0Figura\u00a032.\u2010\u00a0VARIABLE \u00a0TRAUMATISMO \u00a0VASCULAR. \u00a0CURV A\u00a0KAPLAN\u00a0\u2010MEYER\n\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sig.\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a04,976\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ,026\u00a0\n\u00a0\n\u00a0\n\u00a0Figura\u00a033.\u2010\u00a0VARIABLE \u00a0ASIA\u00a01.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYE R\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sig.\nLog\u00a0Ra 6,575\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ,010\u00a0 nk\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nFigura\u00a034.\u2010\u00a0VARIABLE \u00a0ASIA\u00a02.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\u00a0\n\u00a0 118IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nSig.\u00a0\nLogRank 11,961 1\nFigura\u00a035.\u2010\u00a0VARIABLE \u00a0NNP.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nSig.\u00a0\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a07,182\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nFigura\u00a036.\u2010\u00a0VARIABLE \u00a0TSV.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nSig.\u00a0\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a04,209\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0Figura\u00a037.\u2010\u00a0VARIABLE \u00a0SDRA.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\n\u00a0\n\u00a0 119IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\nFigura\u00a038.\u2010\u00a0V\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sig.\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a04,587\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ,032\u00a0\nARIABLE\u00a0COAGULOPAT\u00cdA. \u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sig.\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a014,562\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ,000\u00a0\n\u00a0\n\u00a0Figura\u00a039. ER \u2010\u00a0VARIABLE \u00a0POLITRASFUSI\u00d3N. \u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEY\n\u00a0\u00a0\u00a0\u00a0C\nLog\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a08,038\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ,005\u00a0hi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sig.\nRank\n\u00a0\n\u00a0\u00a0Figura\u00a0\u00a040.\u2010\u00a0VARIABLE \u00a0INSUFICIENCIA \u00a0RENAL.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\n\u00a0\n\u00a0 120IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sig.\n2\u00a0 Log\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a05,272\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ,02\n\u00a0\nFigura\u00a041.\u2010\u00a0VARIABLE \u00a0TEP.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0Chi2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 gl\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nSig.\u00a0\nLog\u00a0Rank\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a034,362\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n4.4. AN\u00c1LISIS \u00a0MULTIVARIANTE. \u00a0REGRESI\u00d3N \u00a0DE\u00a0COX\u00a0\n\u00a0\n4.4.1.  Mortalidad \u00a0y\u00a0lesi\u00f3n\u00a0medular\u00a0aguda\u00a0traum\u00e1tica \u00a0\nLa\u00a0estimaci\u00f3n\u00a0 del\u00a0Riesgo\u00a0Relativo,\u00a0 ajustados \u00a0sus\u00a0intervalos \u00a0de\u00a0confianza, \u00a0\nlos\u00a0t\u00e9rminos\u00a0de\u00a0interacci\u00f3n \u00a0y\u00a0coeficientes \u00a0de\u00a0las\u00a0variables\u00a0independientes \u00a0\nselecci a ales\u00a0de\u00a0Cox\u00a0para\u00a0la\u00a0\nMortalidad\u00a0 se\u00a0muestra\u00a0 en\u00a0la\u00a0Tabla\u00a022.\u00a0Figura\u00a042.\u2010\u00a0VARIABLE \u00a0DESTINO \u00a0AL\u00a0ALTA.\u00a0CURVA\u00a0KAPLAN\u00a0\u2010MEYER\nondos\u00a0 seg\u00fan\u00a0el\u00a0modelo\u00a0de\u00a0riesgos\u00a0proporcion\n\u00a0 121IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0\nTabla\u00a0 22.\u2010\u00a0Variables \u00a0ajustadas \u00a0seg\u00fan\u00a0an\u00e1lisis\u00a0de\u00a0riesgos\u00a0 proporcionales \u00a0de\u00a0Cox\u00a0\npara\u00a0la\u00a0variable\u00a0mortalidad. \u00a0\nIntervalo\u00a0 de\u00a0Variables \u00a0seleccionadas. \u00a0Hazard\u00a0Ratio.\u00a0 Coeficiente. \u00a0 P>\u00a0Z.\u00a0Confianza \u00a0al\u00a095%.\u00a0\n\u00a0\nAPACHE\u00a0II.\u00a0 1,388\u00a0 1,137\u00a0\u2013\u00a01,694\u00a0 0,328\u00a0 0,001\u00a0\nVM\u00a0time.\u00a0 0,852\u00a0 0,730\u00a0\u2013\u00a00,996\u00a0\u2010 0,160\u00a0 0,160\u00a0\nNivel\u00a0Lesional.\u00a0\n1. Cervical.\u00a0\n\u00a0\n2. Dorsal.\u00a0\u00a0\n63,374\u00a0\n2,502\u00a0\u00a0\n2,495\u00a0\u2013\u00a01609,399 \u00a0\n0,06\u00a0\u2013\u00a0104,544\u00a0\u00a0\n4,149\u00a0\n0,910,012\u00a0\n7\u00a0 0,630\u00a0\u00a0\nIRenal*T.Vascular.\u00a0 13,44\u00a0 1,629\u00a0\u2013\u00a0106,067\u00a0 2,576\u00a0 0,027\u00a0\nLog\u00a0Likelihood: \u00a065,044.\u00a0\nLR\u00a0chi\u00a02\u00a0(5)\u00a0=\u00a043,202.\u00a0\u00a0\u00a0\u00a0Prob\u00a0>\u00a0chi2\u00a0=\u00a00,000.\u00a0\nazard\u00a0Ratio:\u00a0Estimador \u00a0de\u00a0riesgo\u00a0relativo.\u00a0\n\u00a0Termino\u00a0d\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 VM\u00a0Time.\u00a0 Ventilaci\u00f3n \u00a0\nmec\u00e1nica. \u00a0H\n*\n\u00a0\u00a0e\u00a0interacci\u00f3n. \u00a0\n\u00a0\n\u00a0\n4.4.2.  Protocolo\u00a0 NASCIS\u00a0II\u00a0y\u00a0lesi\u00f3n\u00a0medular\u00a0aguda\u00a0traum\u00e1tica \u00a0\nLa\u00a0estimaci\u00f3n\u00a0 del\u00a0Riesgo\u00a0Relativo,\u00a0 ajustados \u00a0sus\u00a0intervalos \u00a0de\u00a0confianza, \u00a0\nlos\u00a0t\u00e9rminos\u00a0de\u00a0interacci\u00f3n \u00a0y\u00a0coeficientes \u00a0de\u00a0las\u00a0variables\u00a0independientes \u00a0\nseleccionados\u00a0 seg\u00fan\u00a0el\u00a0modelo\u00a0de\u00a0riesgos\u00a0proporcionales \u00a0de\u00a0Cox\u00a0\nprotocolo\u00a0 NASCIS\u00a0II\u00a0se\u00a0muestran \u00a0en\u00a0la\u00a0Tabla\u00a023.\u00a0\n\u00a0\nTabla\u00a0 23.\u2010\u00a0Variables \u00a0ajustadas \u00a0seg\u00fan\u00a0an\u00e1lisis\u00a0de\u00a0riesgos\u00a0 proporcionales \u00a0de\u00a0Cox\u00a0\n\u00a0para\u00a0el\u00a0\npara\u00a0la\u00a0variable\u00a0tratamiento \u00a0con\u00a0Metilprednisolona.\nIntervalo\u00a0 de\u00a0Variable seleccionadas. \u00a0 s\u00a0 Hazard\u00a0Ratio.\u00a0 Coeficiente. \u00a0 P>\u00a0Z.\u00a0Confianza \u00a0al\u00a095%.\u00a0\n\u00a0\nGL EMIA. \u00a0 5,67\u00a0 1,859\u00a0\u2013\u00a017,311\u00a0 1,736\u00a0 0,04\u00a0 UC\nMORTA AD.\u00a0 0,38\u00a0 0,066\u00a0\u2013\u00a02,216\u00a0\u2010 0,961\u00a0 0,28\u00a0 LID\nH.\u00a0Digestiva. \u00a0 19,16\u00a0 1,644\u00a0\u2013\u00a0223,308\u00a0 2,953\u00a0 0,02\u00a0\nNEUMONIA. \u00a0 0,27\u00a0 0,079\u00a0\u2013\u00a00,946\u00a0\u2010 1,296\u00a0 0,04\u00a0\nDIFASIA\u00a0 1,57\u00a0 0,697\u00a0\u2013\u00a03,514\u00a0 0,448\u00a0 0,28\u00a0\nLog\u00a0Likelihood: \u00a088,640.\u00a0\nLR\u00a0chi\u00a02\nHazard\u00a0\n*\u00a0Termino\u00a0(5)\u00a0=\u00a027,258.\u00a0\u00a0\u00a0\u00a0Prob\u00a0>\u00a0chi2\u00a0=\u00a00,000.\u00a0\n\u00a0 122Ratio:\u00a0Estimador \u00a0de\u00a0riesgo\u00a0relativo.\u00a0\n\u00a0de\u00a0interacci\u00f3n. \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 H.\u00a0Digestiva.\u00a0 Hemorragia \u00a0\ndigestiva.\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DIFASIA.\u00a0Diferencia \u00a0de\u00a0ASIA.\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nIV.\u2010\u00a0RESULTADOS. \u00a0\n\u00a0 123La\u00a0estimaci\u00f3n\u00a0 del\u00a0 \u00a0intervalos \u00a0de\u00a0confianza, \u00a0\nlos\u00a0t\u00e9rminos\u00a0de\u00a0interacci\u00f3n \u00a0y\u00a0coe \u00a0variables\u00a0independientes \u00a0\nados\u00a0 seg\u00fan\u00a0mode \u00a0riesgos ales\u00a0de \u00a0la\u00a0 \u00a0\n\u00a0intervenci\u00f3n\u00a0 quir\u00fargica \u00a0\u00a0se\u00a0muestra \u00a0la\u00a0Tabla\n\u00a0seg\u00fan\u00a0an\u00e1lisis\u00a0de\u00a0riesgos\u00a0 proporcionales \u00a0de\u00a0Cox\u00a0\nrvenci\u00f3n\u00a0quir\u00fargica. \u00a0\u00a0\n4.4.3.  Intervenci\u00f3n \u00a0quir\u00fargica \u00a0y\u00a0lesi\u00f3n\u00a0medular\u00a0aguda\u00a0traum\u00e1tica \u00a0\nRiesgo\u00a0Relativo,\u00a0 ajustados \u00a0sus\nficientes\u00a0de\u00a0las\nseleccion lo\u00a0de \u00a0proporcion \u00a0Cox\u00a0para variable\npresencia \u00a0de \u00a0en \u00a024.\u00a0\n\u00a0\n\u00a0\nTabla\u00a0 24.\u2010\u00a0Variables \u00a0ajustadas\npara\u00a0la\u00a0variable\u00a0inte\nVariables \u00a0seleccionadas. \u00a0Hazard\u00a0Ratio.\u00a0Intervalo\u00a0 de\u00a0\nConfianza \u00a0al\u00a095%.\u00a0Coeficiente. \u00a0 P>\u00a0Z.\u00a0\n\u00a0\nMORTALIDAD.\u00a0 0,11\u00a0 0,013\u00a0\u2013\u00a00,960\u00a0\u2010 2,204\u00a0 0,05\u00a0\nDIFASIA. 1,84\u00a0 0,955\u00a0\u2013\u00a03,553\u00a0 0,611\u00a0 0,07\u00a0 \u00a0\nNASCIS 0,75\u00a0 0,280\u00a0\u2013\u00a01,993\u00a0\u2010 0,291\u00a0 0,56\u00a0 \u00a0II.\u00a0\nLog\u00a0Likelihood: \u00a0125,309.\u00a0\nLR\u00a0chi\u00a02\nHazard\u00a0\n*\u00a0Termino\u00a0(3)\u00a0=\u00a07,739.\u00a0\u00a0\u00a0\u00a0Prob\u00a0>\u00a0chi2\u00a0=\u00a00,005.\u00a0\nRatio:\u00a0Estimador \u00a0de\u00a0riesgo\u00a0relativo.\u00a0\n\u00a0de\u00a0interacci\u00f3n. \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NASCIS\u00a0II.\u00a0 Protocolo \u00a0\nNASCIS\u00a0II.\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DIFASIA.\u00a0Diferencia\u00a0 de\u00a0\nASIA.\u00a0\n\u00a0\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0 124\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nLa\u00a0LMAT\u00a0se\u00a0define\u00a0como\u00a0una\u00a0alteraci\u00f3n \u00a0del\u00a0tejido\u00a0medular\u00a0 tras\u00a0un\u00a0\ntraumatismo, \u00a0que\u00a0se\u00a0caracteriza\u00a0 por\u00a0una\u00a0p\u00e9rdida\u00a0funcional \u00a0por\u00a0debajo\u00a0de\u00a0la\u00a0\nlesi\u00f3n, \u00a0que\u00a0hay\u00a0una\u00a0interrupci\u00f3n \u00a0de\u00a0las\u00a0v\u00edas\u00a0aferentes \u00a0y\u00a0eferentes \u00a0que\u00a0\ncomunican\u00a0 los\u00a0centros\u00a0neurol\u00f3gicos \u00a0superiores \u00a0con\u00a0los\u00a0efectores \u00a0perif\u00e9ricos. \u00a0En\u00a0\neste\u00a0concepto \u00a0se\u00a0incluyen\u00a0todas\u00a0 aquellas\u00a0 lesiones\u00a0de\u00a0origen\u00a0traum\u00e1tico \u00a0que\u00a0\npueden afectar,\u00a0conjunta\u00a0o\u00a0aisladamente \u00a0a\u00a0las\u00a0diferentes \u00a0estructuras \u00a0(\u00f3seas,\u00a0\nligamentosas, \u00a0cartilaginosas, \u00a0musculares, \u00a0vasculares,\u00a0 men\u00edngeas, \u00a0radiculares \u00a0y\u00a0\nmedulares) \u00a0de\u00a0la\u00a0CV\u00a0en\u00a0cualquiera \u00a0de\u00a0sus\u00a0niveles.\u00a0Los\u00a0nuevos\u00a0conocimientos \u00a0\nfisiopatol\u00f3gicos \u00a0se\u00f1alan\u00a0que\u00a0la\u00a0LMA\u00a0es\u00a0un\u00a0proceso\u00a0din\u00e1mico, \u00a0evolutivo \u00a0y\u00a0\nmultif\u00e1sico\u00a0 a\u00a0partir\u00a0del\u00a0momento \u00a0en\u00a0que\u00a0se\u00a0produce\u00a0el\u00a0traumatismo, \u00a0que\u00a0por\u00a0s\u00ed\u00a0\nsolo\u00a0puede\u00a0provocar\u00a0destrucci\u00f3n \u00a0mec\u00e1nica \u00a0de\u00a0estructuras \u00a0nerviosas, \u00a0lesi\u00f3n\u00a0\nvascula\u00a0directa\u00a0y\u00a0hemorragia, \u00a0e\u00a0incluso\u00a0secci\u00f3n\u00a0medular\u00a0completa. \u00a0La\u00a0asistencia \u00a0\ninicial\u00a0 \u00a0 los\u00a0traumatismos \u00a0raqu\u00eddeos \u00a0plantea\u00a0numerosos \u00a0problemas \u00a0al\u00a0\nanestesi\u00f3logo, \u00a0debido\u00a0 a\u00a0las\u00a0lesiones\u00a0traum\u00e1ticas \u00a0asociadas, \u00a0en\u00a0particular \u00a0a\u00a0nivel\u00a0\nmedular.\u00a0El\u00a0anestesi\u00f3logo\u00a0\u00a0puede \u00a0emplear\u00a0cualquier \u00a0agente\u00a0anest\u00e9sico \u00a0con\u00a0\nseguridad, \u00a0con\u00a0la\u00a0excepci\u00f3n \u00a0del\u00a0relajante\u00a0muscular\u00a0despolarizante, \u00a0suxametonio \u00a0\no\u00a0succinilcolina \u00a0a\u00a0partir\u00a0de\u00a0las\u00a048\u00a0horas\u00a0despu\u00e9s\u00a0de\u00a0una\u00a0lesi\u00f3n\u00a0medular\u00a0 y\u00a0durante\u00a0\nun\u00a0per\u00edodo\u00a0m\u00ednimo\u00a0de\u00a01\u00a0a\u00f1o\u00a0debido\u00a0 al\u00a0riesgo\u00a0de\u00a0hiperpotasemia \u00a0por\u00a0\nhipersensibilidad \u00a0de\u00a0denervaci\u00f3n\u00a0 de\u00a0la\u00a0membrana \u00a0muscular. \u00a0\u00a0Con\u00a0la\u00a0excepci\u00f3n\u00a0\nanteriormente \u00a0expuesta, \u00a0los\u00a0f\u00e1rmacos\u00a0anest\u00e9sicos,\u00a0 cualquiera \u00a0que\u00a0sea\u00a0el\u00a0agente\u00a0\nutilizado,\u00a0ejercen\u00a0un\u00a0efecto\u00a0protector \u00a0sobre\u00a0la\u00a0isquemia\u00a0medular.\u00a0\nl\u00a0examen\u00a0radiol\u00f3gico\u00a0 completo \u00a0del\u00a0raquis\u00a0 debe\u00a0ser\u00a0sistem\u00e1tico \u00a0en\u00a0los\u00a0\npacientes \u00a0politraumatizados, \u00a0y\u00a0el\u00a0manejo\u00a0medicoquir\u00far\ny\u00a0d\u00edas\u00a0es\u00a0de\u00a0vital\u00a0importancia \u00a0para\u00a0disminuir \u00a0la\u00a0incidencia \u00a0de\u00a0lesiones\u00a0\nsecundarias, \u00a0y\u00a0consiste\u00a0habitualmente \u00a0en\u00a0optimizar \u00a0y\u00a0mantener \u00a0una\u00a0presi\u00f3n\u00a0 de\u00a0\nperfusi\u00f3n \u00a0medular,\u00a0 evitar\u00a0 la\u00a0hiperglucemia \u00a0y\u00a0una\u00a0cirug\u00eda\u00a0urgente\u00a0si\u00a0es\u00a0necesaria \u00a0\npara\u00a0una\u00a0descompresi\u00f3n \u00a0medular.\u00a0Esta\u00a0cirug\u00eda\u00a0 est\u00e1\u00a0particularmente \u00a0indicada\u00a0en\u00a0\nlas\u00a06\u00a0primeras\u00a0horas,\u00a0en\u00a0las\u00a0lesiones\u00a0incompletas \u00a0o\u00a0en\u00a0las\u00a0que\u00a0se\u00a0agravan\u00a0\nprogresivamente. \u00a0Existe\u00a0pol\u00e9mica\u00a0 respecto\u00a0a\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0grandes\u00a0dosis\u00a0\u00a0\u00a0ya\n\u00a0\nr\nde\n\u00a0E\n\u00a0 125gico\u00a0 en\u00a0las\u00a0primeras\u00a0horas\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nde\u00a0MP.\n\u00a0 s \u00a0\nes,\u00a0familiares \u00a0y\u00a0\necon\u00f3micos. \u00a0Se\u00a0acompa\u00f1an\u00a0 de\u00a0caros\u00a0tratamientos \u00a0m\u00e9dicos\u00a0y\u00a0quir\u00fargicos, \u00a0que\u00a0\ndeman\nl \u00a0\u00a0Existen\u00a0 m\u00faltiples \u00a0trabajos\u00a0que\u00a0\u00a0cuestionan\u00a0 los\u00a0resultados \u00a0obtenidos \u00a0en\u00a0los\u00a0\nestudios\u00a0NASCIS,\u00a0 los\u00a0cuales\u00a0justifican\u00a0el\u00a0uso\u00a0de\u00a0megadosis \u00a0de\u00a0CTC\u00a0en\u00a0la\u00a0LMA.\u00a0La\u00a0\nmayor\u00a0 cr\u00edtica\u00a0 a\u00a0los\u00a0estudios\u00a0NASCIS,\u00a0se\u00a0basa\u00a0en\u00a0la\u00a0imposibilidad \u00a0de\u00a0poder\u00a0\nreproducir \u00a0sus\u00a0resultados \u00a0(49,50,71,80 \u201088).\u00a0\n\u00a0La\u00a0incidencia \u00a0anual\u00a0de\u00a0los\u00a0traumas\u00a0medulares \u00a0en\u00a0los\u00a0pa\u00edses\u00a0\nindustrializados \u00a0es\u00a0de\u00a040\u201050\u00a0casos\u00a0por\u00a0mill\u00f3n\u00a0de\u00a0habitantes. \u00a0En\u00a0nuestro\u00a0pa\u00eds\u00a0\nexisten\u00a0amplias\u00a0diferencias\u00a0 entre\u00a0los\u00a0diversos\u00a0estudios\u00a0epidemiol\u00f3gicos \u00a0\nrealizados \u00a0sobre\u00a0la\u00a0incidencia \u00a0de\u00a0LMA,\u00a0debido\u00a0 fundamentalmente \u00a0a\u00a0la\u00a0ausencia\u00a0\nde\u00a0registros\u00a0centralizados\u00a0 de\u00a0pacientes \u00a0con\u00a0esta\u00a0patolog\u00eda. \u00a0El\u00a0trabajo\u00a0de\u00a0Herruzo\u00a0\net\u00a0al\u00a0(36)\u00a0reporta\u00a0 una\u00a0incidencia \u00a0de\u00a010\u00a0casos\u00a0por\u00a0mill\u00f3n\u00a0de\u00a0habitantes \u00a0y\u00a0a\u00f1o.\u00a0En\u00a0\nEspa\u00f1a\u00a0se\u00a0producen \u00a0cada\u00a0 a\u00f1o,\u00a0como\u00a0consecuencia \u00a0de\u00a0LM\u00a0entre\u00a0800\u00a0y\u00a01000\u00a0casos.\u00a0\nEn\u00a0nuestro pa\u00eds,\u00a0los\u00a0accidente \u00a0de\u00a0tr\u00e1fico son\u00a0el\u00a0origen\u00a0de\u00a0la\u00a0LMA\u00a0de\u00a0origen\u00a0\ntraum\u00e1tico \u00a0en\u00a0un\u00a076%\u00a0de\u00a0los\u00a0casos,\u00a0las\u00a0ca\u00eddas\u00a0en\u00a0un\u00a017%,\u00a0 en\u00a0estas\u00a0se\u00a0incluye\u00a0los\u00a0\naccidentes \u00a0de\u00a0monta\u00f1a\u00a0y\u00a0de\u00a0nataci\u00f3n, \u00a0los\u00a0accidentes \u00a0de\u00a0trabajo\u00a0representan \u00a0un\u00a0\n7%,\u00a0 siendo\u00a0la\u00a0edad\u00a0media\u00a0de\u00a0los\u00a0lesionados \u00a0medulares \u00a0de\u00a035\u00a0a\u00f1os,\u00a0con\u00a0 una\u00a0\nmortalidad\u00a0 media\u00a0 del\u00a010%.\u00a0\n\u00a0\nLa\u00a0LMAT\u00a0\u00a0da\u00a0lugar\u00a0a\u00a0menudo\u00a0a\u00a0una\u00a0severa\u00a0discapacidad, \u00a0la\u00a0cual\u00a0 condiciona \u00a0\nun\u00a0acentuado \u00a0cambio\u00a0en\u00a0el\u00a0estilo\u00a0de\u00a0vida\u00a0del\u00a0paciente\u00a0y\u00a0de\u00a0su\u00a0familia.\u00a0Asimismo, \u00a0\nestas\u00a0lesiones\u00a0 ocasionan \u00a0unos\u00a0elevados\u00a0costes\u00a0individuales, \u00a0social\n\u00a0 126dan\u00a0 un\u00a0abordaje\u00a0multidisciplinar. \u00a0La\u00a0bibliograf\u00eda \u00a0referente\u00a0 al\u00a0tratamiento \u00a0\nm\u00e9dico\u00a0de\u00a0la\u00a0LMA\u00a0muestra\u00a0gran\u00a0controversia. \u00a0Se\u00a0han\u00a0 experimentado \u00a0grandes\u00a0\navances\u00a0en\u00a0a\u00a0atenci\u00f3n\u00a0urgente\u00a0y\u00a0en\u00a0los\u00a0cuidados\u00a0de\u00a0estos\u00a0pacientes. \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\natizados\u00a0de\u00a0la\u00a0zona\u00a0geogr\u00e1fica \u00a0que\u00a0\ncomprende \u00a0a\u00a0toda\u00a0la\u00a0franja\u00a0de\u00a0Castilla\u00a0La\u00a0Mancha\u00a0Oriental.\u00a0\u00a0\n\u00a0 c s\npuesta\u00a0de\u00a096\u00a0pacientes \u00a0afectos\u00a0de\u00a0LMAT,\u00a0 existe\u00a0una\u00a0\nconcordancia \u00a0con\u00a0los\u00a0datos\u00a0 reportados \u00a0por\u00a0la\u00a0literatura\u00a0 m\u00e9dica\u00a0realizados \u00a0en\u00a0el\u00a0\nextranj\n\u00a0una\u00a0media\u00a0\nde\u00a012,82\u00a0\u00b1\u00a0\u00a07,25\u00a0y\u00a0un\u00a0rango\u00a0de\u00a03\u00a0\u2013\u00a042.\u00a0\na\u00a0estancia\u00a0media\u00a0 en\u00a0la\u00a0UR\u00a0fue\u00a0de\u00a010,51\u00a0\u00b1\u00a011,61\u00a0d\u00edas,\u00a0ingresando \u00a0\ndirectamente \u00a0en\u00a0la\u00a0UR\u00a0desde\u00a0el\u00a0exterior\u00a0del\u00a0hospital\u00a0un\u00a091,66%\u00a0 de\u00a0los\u00a0pacientes, \u00a0\nsiendo l\u00a095,83%\u00a0de\u00a0los\u00a0ingresos\u00a0de\u00a0car\u00e1cter\u00a0urgente\u00a0y\u00a0el\u00a04,17%\u00a0 programados. \u00a05.1. SOBRE\u00a0 LA\u00a0COHORTE \u00a0\n\u00a0\nLa\u00a0UR\u00a0dependiente \u00a0del\u00a0Servicio\u00a0de\u00a0Anestesiolog\u00eda \u00a0\u00a0y\u00a0Reanimaci\u00f3n \u00a0es\u00a0\ncentro\u00a0de\u00a0referencia \u00a0de\u00a0pacientes \u00a0politraum\n\u00a0La\u00a0LMA\u00a0es\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0varones\u00a0j\u00f3venes,\u00a0entre\u00a025\u00a0y\u00a035\u00a0a\u00f1os,\u00a0siendo\u00a0\nla\u00a0causa m\u00e1s\u00a0frecuente \u00a0los\u00a0ac idente \u00a0de\u00a0tr\u00e1fico,\u00a0seguidos\u00a0por\u00a0los\u00a0laborales\u00a0y\u00a0\ndeportivos. \u00a0En\u00a0la\u00a0edad\u00a0infantil\u00a0e\u00a0individuos \u00a0mayores\u00a0de\u00a050\u00a0a\u00f1os,\u00a0 hay\u00a0mayor\u00a0\nporcentaje \u00a0de\u00a0LMA\u00a0sin\u00a0lesi\u00f3n\u00a0\u00f3sea,\u00a0predominando \u00a0en\u00a0ellos\u00a0los\u00a0accidentes \u00a0\ndom\u00e9sticos \u00a0(ca\u00eddas),\u00a0en\u00a0los\u00a0que\u00a0la\u00a0incidencia \u00a0de\u00a0mujeres\u00a0es\u00a0mayor,\u00a0las\u00a0cuales\u00a0\ntambi\u00e9n\u00a0est\u00e1n\u00a0m\u00e1s\u00a0frecuentemente \u00a0implicadas\u00a0 en\u00a0accidentes \u00a0por\u00a0precipitaci\u00f3n \u00a0\nvoluntaria. \u00a0En\u00a0nuestro\u00a0pa\u00eds,\u00a0al\u00a0contrario\u00a0que\u00a0en\u00a0el\u00a0continente \u00a0americano, \u00a0las\u00a0\nlesiones\u00a0penetrantes \u00a0por\u00a0armas\u00a0de\u00a0fuego\u00a0y\u00a0blanca\u00a0son\u00a0infrecuentes, \u00a0y\u00a0as\u00ed\u00a0en\u00a0\nnuestra\u00a0cohorte\u00a0la\u00a0LMA\u00a0penetrante \u00a0representa \u00a0solo\u00a0un\u00a03,13%.\u00a0\n\u00a0En\u00a0nuestra\u00a0serie,\u00a0com\nero\u00a0(4,62,89\u201096)\u00a0y\u00a0en\u00a0nuestro\u00a0pa\u00eds\u00a0(97\u201099),\u00a0y\u00a0predominan\u00a0 los\u00a0varones\u00a0\n(79,17%)\u00a0y\u00a0los\u00a0sujetos\u00a0 de\u00a0edad\u00a0joven,\u00a0con\u00a0una\u00a0media\u00a0 de\u00a035,92\u00a0a\u00f1os.\u00a0\u00a0\n\u00a0Por\u00a0lo\u00a0que\u00a0respecta\u00a0 a\u00a0la\u00a0clasificaci\u00f3n \u00a0de\u00a0los\u00a0pacientes \u00a0de\u00a0la\u00a0cohorte\u00a0seg\u00fan\u00a0\nsu\u00a0\u00edndice\u00a0de\u00a0riesgo\u00a0intr\u00ednseco \u00a0evaluado\u00a0por\u00a0la\u00a0clasificaci\u00f3n \u00a0del\u00a0 \u00edndice\u00a0de\u00a0\nComorbilidades \u00a0de\u00a0Deyo\u2010Charlson, \u00a0el\u00a071,88%\u00a0 de\u00a0los\u00a0pacientes \u00a0no\u00a0presenta\u00a0\ncomorbilidad \u00a0asociada. \u00a0Respecto\u00a0a\u00a0la\u00a0clasificaci\u00f3n \u00a0APACHE\u00a0II,\u00a0presenta\n\u00a0L\n\u00a0 127\u00a0eIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nLa\u00a0mortalidad\u00a0 de\u00a0la\u00a0coh\n\u00a0 128orte\u00a0de\u00a0pacientes \u00a0con\u00a0LMA\u00a0durante\u00a0el\u00a0periodo\u00a0de\u00a0\nestudio fue\u00a0de\u00a0del\u00a010,16%\u00a0(10\u00a0casos).\u00a0El\u00a0estudio\u00a0de\u00a0Pickett\u00a0GE\u00a0et\u00a0al\u00a0(6),\u00a0con\u00a0una\u00a0\nmetod\n\u00a0el\u00a0que\u00a0se\u00a0analiza\u00a0la\u00a0\nmortalidad\u00a0 secundaria \u00a0a\u00a0LMAT\u00a0desde\u00a01991\u20101998,\u00a0reportan\u00a0una\u00a0mortalidad\u00a0 del\u00a0\n49%\u00a0e\nn\u00a0de\u00a0dispositivos \u00a0\nm\u00e9dicos\u00a0de\u00a0riesgo\u00a0extr\u00ednseco, \u00a095\u00a0pacientes \u00a0fueron\u00a0portadores \u00a0de\u00a0sondaje\u00a0vesical\u00a0\ncerrado\ninuci\u00f3n\u00a0de\u00a0\nlas\u00a0resistencias \u00a0sist\u00e9micas, \u00a0del\u00a0retorno\u00a0venoso\u00a0y\u00a0del\u00a0flujo\u00a0cardiaco,\u00a0y\u00a0posibilidad \u00a0\nde\u00a0nec\nio\u00a0\u00a0la\u00a0colocaci\u00f3n \u00a0de\u00a0una\u00a0sonda\u00a0g\u00e1strica.\u00a0\u00a0\nolog\u00eda\u00a0similar\u00a0al\u00a0nuestro\u00a0presenta\u00a0una\u00a0mortalidad\u00a0 intrahospitalaria \u00a0de\u00a0un\u00a08\u00a0\n%,\u00a0siendo\u00a0significativamente \u00a0m\u00e1s\u00a0 alta\u00a0entre\u00a0las\u00a0edades\u00a0m\u00e1s\u00a0avanzadas.\u00a0 Los\u00a0datos\u00a0\nobtenidos \u00a0del\u00a0estudio\u00a0de\u00a0Lee\u00a0(95),\u00a0publicado\u00a0 en\u00a02009,\u00a0en\nn\u00a0un\u00a0periodo\u00a0de\u00a0un\u00a0a\u00f1o\u00a0desde\u00a0la\u00a0lesi\u00f3n.\u00a0Los\u00a0mejores\u00a0predictores \u00a0de\u00a0\nsupervivencia \u00a0para\u00a0la\u00a0mayor\u00a0 parte\u00a0de\u00a0los\u00a0autores\u00a0son\u00a0la\u00a0edad,\u00a0el\u00a0nivel\u00a0de\u00a0\nconciencia \u00a0al\u00a0ingreso,\u00a0el\u00a0nivel\u00a0medular\u00a0afectado\u00a0y\u00a0la\u00a0necesidad \u00a0de\u00a0apoyo\u00a0\nrespiratorio. \u00a0Por\u00a0tanto,\u00a0un\u00a0factor\u00a0determinante \u00a0de\u00a0la\u00a0mortalidad\u00a0 en\u00a0pacientes\u00a0 con\u00a0\nLMAT\u00a0es\u00a0la\u00a0atenci\u00f3n\u00a0inicial\u00a0del\u00a0paciente\u00a0politraumatizado. \u00a0Cada\u00a0a\u00f1o\u00a0hay\u00a011000\u00a0\nnuevos\u00a0 casos\u00a0de\u00a0LMA\u00a0en\u00a0EE.UU.,\u00a0y\u00a0en\u00a02002\u00a0se\u00a0registraron\u00a0 1648\u00a0muertes\u00a0\nsecundarias \u00a0a\u00a0LMA.\u00a0\n\u00a0\nDentro\u00a0de\u00a0la\u00a0cohorte,\u00a0destaca\u00a0la\u00a0elevada\u00a0utilizaci\u00f3\n,\u00a079\u00a0de\u00a0CVC\u00a0y\u00a069\u00a0de\u00a0VM.\u00a0La\u00a0explicaci\u00f3n \u00a0a\u00a0estos\u00a0elevados\u00a0ratios\u00a0de\u00a0\nutilizaci\u00f3n \u00a0de\u00a0dispositivos \u00a0m\u00e9dicos\u00a0son\u00a0las\u00a0caracter\u00edsticas \u00a0\u00a0de\u00a0la\u00a0LMAT,\u00a0 como\u00a0son\u00a0\nla\u00a0presencia \u00a0de\u00a0una\u00a0falta\u00a0de\u00a0autonom\u00eda \u00a0vesical,\u00a0las\u00a0consecuencias \u00a0\ncardiovasculares \u00a0por\u00a0la\u00a0desaparici\u00f3n \u00a0del\u00a0tono\u00a0simp\u00e1tico \u00a0con\u00a0una\u00a0dism\nesidad\u00a0de\u00a0asistencia \u00a0ventilatoria \u00a0por\u00a0par\u00e1lisis\u00a0 diafragm\u00e1tica, \u00a0desaparici\u00f3n \u00a0\ntotal\u00a0o\u00a0parcial\u00a0del\u00a0apoyo\u00a0de\u00a0la\u00a0musculatura \u00a0intercostal \u00a0y\u00a0ausencia\u00a0de\u00a0la\u00a0abdominal \u00a0\nque\u00a0conlleva\u00a0una\u00a0disminuci\u00f3n \u00a0m\u00e1s\u00a0o\u00a0menos\u00a0marcada\u00a0de\u00a0la\u00a0capacidad \u00a0vital\u00a0con\u00a0un\u00a0\naumento\u00a0del\u00a0volumen\u00a0residual\u00a0funcional.\u00a0\u00a0Se \u00a0asocia\u00a0a\u00a0\u00edleo\u00a0paral\u00edtico, \u00a0que\u00a0puede\u00a0\ndurar\u00a0 entre\u00a03\u00a0y\u00a010\u00a0d\u00edas,\u00a0y\u00a0hace\u00a0 necesar\n\u00a0\n\u00a0\n\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0\n5.2. LESI\u00d3N\u00a0MEDULAR\u00a0 AGUDA\u00a0TRAUM\u00c1TICA \u00a0\n\u00a0Los\u00a0accidentes \u00a0de\u00a0tr\u00e1fico\u00a0son\u00a0aproximadamente \u00a0la\u00a0causa\u00a0del\u00a060\u201070%\u00a0de\u00a0\nlos\u00a0traumatismos \u00a0de\u00a0la\u00a0CV,\u00a0esta\u00a0etiolog\u00eda\u00a0se\u00a0asocia\u00a0con\u00a0 una\u00a0alta\u00a0incidencia \u00a0de\u00a0\nlesiones\u00a0con\u00a0 tetraplej\u00eda \u00a0y\u00a0de\u00a0traumatismos \u00a0m\u00faltiples\u00a0 asociados \u00a0con\u00a0 alta\u00a0\nmorbilidad \u00a0y\u00a0mortalidad.\u00a0 En\u00a0menor\u00a0importancia, \u00a0le\u00a0siguen\u00a0las\u00a0ca\u00eddas\u00a0desde\u00a0una\u00a0\ngran\u00a0altura\u00a0por\u00a0intento\u00a0de\u00a0autolisis\u00a0o\u00a0accidentes \u00a0laborales\u00a0 y\u00a0los\u00a0accidentes \u00a0en\u00a0\nactividades \u00a0de\u00a0ocio.\u00a0Al\u00a0analizar\u00a0la\u00a0etiolog\u00eda\u00a0m\u00e1s\u00a0frecuente \u00a0de\u00a0producci\u00f3n \u00a0de\u00a0la\u00a0\nlesi\u00f3n\u00a0en\u00a0los\u00a0pacientes \u00a0de\u00a0nuestra\u00a0serie,\u00a0hallamos\u00a0que\u00a0el\u00a0mayor\u00a0 porcentaje \u00a0de\u00a0\ncasos\u00a0se\u00a0debe\u00a0a\u00a0accidentes \u00a0de\u00a0tr\u00e1fico\u00a0(73,95%)\u00a0coincidiendo\u00a0 estos\u00a0datos\u00a0 con\u00a0los\u00a0\naportados \u00a0por\u00a0otros\u00a0 estudios\u00a0(4,95,100) .\u00a0Es\u00a0de\u00a0destacar,\u00a0en\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0del\u00a0\nestudio\u00a0la\u00a0incidencia\n\u00a0 129\u00a0elevada\u00a0de\u00a0este\u00a0tipo\u00a0de\u00a0lesiones\u00a0tras\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0\naccidente \u00a0viales\u00a0con\u00a0la\u00a0pr\u00e1ctica\u00a0\u00a0de\u00a0actividades \u00a0de\u00a0ocio\u00a0con\u00a0los\u00a0quad.\u00a0La\u00a0LMA\u00a0no\u00a0\npenetr\n\u00a0n t o n \u00a0 a\nad\u00a0\nhemodin\u00e1mica \u00a0y/o\u00a0par\u00e1lisis\u00a0 fl\u00e1cida,\u00a0anestesia, \u00a0arreflexia \u00a0y\u00a0disfunci\u00f3n \u00a0vegetativa. \u00a0\nUna\u00a0posible\u00a0explicaci\u00f3n \u00a0a\u00a0esta\u00a0discordancia \u00a0con\u00a0otras\u00a0series\u00a0de\u00a0LMA\u00a0traum\u00e1ticas \u00a0\nes\u00a0la\u00a0existencia \u00a0de\u00a0un\u00a0m\u00ednimo\u00a0porcentajes \u00a0de\u00a0ingresos\u00a0de\u00a0pacientes \u00a0con\u00a0lesiones\u00a0\ncervicales \u00a0altas,\u00a0las\u00a0cuales\u00a0presentan\u00a0 una\u00a0alta\u00a0morbimortalidad, \u00a0y\u00a0probablemente \u00a0ante\u00a0representa \u00a0un\u00a096,87%\u00a0en\u00a0la\u00a0cohorte.\u00a0\n\u00a0La\u00a0literatura \u00a0indica\u00a0que\u00a0los\u00a0traumatismos \u00a0cervicales \u00a0son\u00a0m\u00e1s\u00a0frecuentes \u00a0\nque\u00a0los\u00a0dorsolumbares; \u00a0y\u00a0por\u00a0esta\u00a0raz\u00f3n\u00a0las\u00a0tetraplejias \u00a0son\u00a0m\u00e1s\u00a0comunes\u00a0que\u00a0la\u00a0\nparaplejias. \u00a0En ues ra\u00a0cohorte,\u00a0bte emos \u00a0que\u00a0ladiferenci \u00a0entre\u00a0 la\u00a0incidencia \u00a0\nde\u00a0lesiones\u00a0cervicales \u00a0y\u00a0dorsales,\u00a0 excluyendo \u00a0de\u00a0este\u00a0\u00faltimo\u00a0grupo\u00a0las\u00a0lumbares \u00a0\nson\u00a0similares, \u00a0y\u00a0por\u00a0tanto\u00a0el\u00a0s\u00edndrome \u00a0cl\u00ednico\u00a0predominante \u00a0es\u00a0la\u00a0paraplejia. \u00a0Los\u00a0\ns\u00edndromes \u00a0cl\u00ednicos\u00a0medulares,\u00a0 excluyendo \u00a0a\u00a0las\u00a0fracturas\u00a0sacras,\u00a0que\u00a0se\u00a0\nregistraron \u00a0en\u00a0este\u00a0estudio\u00a0 fueron\u00a0tetraplejia \u00a0incompleta \u00a0(22,82%), \u00a0tetraplejia \u00a0\ncompleta \u00a0(16,30%), \u00a0paraplejia \u00a0incompleta \u00a0(23,91%)\u00a0y\u00a0paraplejia \u00a0completa \u00a0\n(36,95%). \u00a0Unido\u00a0a\u00a0estos\u00a0s\u00edndromes, \u00a036\u00a0pacientes \u00a0(37,50%)\u00a0presentaron\u00a0 durante\u00a0\nalg\u00fan\u00a0 momento \u00a0de\u00a0su\u00a0ingreso\u00a0en\u00a0la\u00a0UR\u00a0shock\u00a0medular\u00a0con\u00a0 inestabilidIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0 \u00a0 plia\u00a0extensi\u00f3n \u00a0de\u00a0la\u00a0comunidad \u00a0aut\u00f3noma \u00a0\u00a0sean\u00a0exitus\u00a0 tras\u00a0el\u00a0accidente \u00a0\ny\na\u00a0m\u00e1s\u00a0vulnerable \u00a0a\u00a0la\u00a0isquemia\u00a0\npor\u00a0hallarse\u00a0alejada\u00a0de\u00a0las\u00a0colaterales \u00a0superiores \u00a0y\u00a0de\u00a0las\u00a0arterias\u00a0radiculares \u00a0\nimportpor\u00a0laam\no\u00a0durante\u00a0el\u00a0traslado\u00a0a\u00a0nuestro\u00a0centro\u00a0hospitalario.\u00a0\n\u00a0Las\u00a0lesiones\u00a0espec\u00edficas \u00a0cervicales \u00a0son\u00a0las\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0esta\u00a0cohorte,\u00a0\nseguidas\u00a0muy\u00a0de\u00a0cerca\u00a0en\u00a0frecuencia \u00a0por\u00a0lesiones\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0dorsal\u00a0o\u00a0tor\u00e1cica;\u00a0\nregistr\u00e1ndose \u00a0solo\u00a08\u00a0casos\u00a0de\u00a0LMAT\u00a0lumbar,\u00a0 \u00a0 siendo\u00a0muy\u00a0infrecuentes \u00a0las\u00a0\nlesiones\u00a0aisladas\u00a0 del\u00a0sacro\u00a0(2,08%).\u00a0Respecto\u00a0a\u00a0las\u00a0lesiones\u00a0medulares \u00a0m\u00faltiples, \u00a0\nson\u00a0poco\u00a0frecuentes,\u00a0 presentando \u00a06\u00a0pacientes \u00a0lesi\u00f3n\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0cervical\u00a0y\u00a0\ntor\u00e1cica;\u00a0\u00a0solo \u00a0un\u00a0caso\u00a0\u00a0asociaba\u00a0LMA\u00a0lumbar\u2010cervical,\u00a0y\u00a0otro\u00a0caso\u00a0\u00a0LMA\u00a0lumbar\u00a0y\u00a0\ntor\u00e1cica.\u00a0\u00a0\n\u00a0La\u00a0zona\u00a0de\u00a0la\u00a0CV\u00a0m\u00e1s\u00a0frecuentemente \u00a0afectada\u00a0es\u00a0la\u00a0regi\u00f3n\u00a0cervical\u00a0baja\u00a0\n(C5\u2010C7)\u00a0seguida\u00a0en\u00a0segundo\u00a0lugar\u00a0por\u00a0la\u00a0charnela\u00a0toracolumbar \u00a0(D10\u2010 L2),\u00a0\nexistiendo\u00a0 en\u00a0ellas\u00a0mayor\u00a0frecuencia \u00a0de\u00a0lesiones\u00a0completas.\u00a0\u00a0La \u00a0m\u00e9dula\u00a0cervical\u00a0\nbaja\u00a0(C5\u2010C8)\u00a0es\u00a0considerada\u00a0 cl\u00e1sicamente \u00a0la\u00a0zon\n\u00a0 130antes\u00a0que\u00a0se\u00a0encuentran \u00a0en\u00a0niveles\u00a0m\u00e1s\u00a0 inferiores. \u00a0As\u00ed,\u00a0 el\u00a0trabajo\u00a0de\u00a0\nGauler\u00a0et\u00a0al\u00a0(2006),\u00a0 (96)\u00a0realiza\u00a0un\u00a0an\u00e1lisis\u00a0retrospectivo \u00a0durante\u00a0un\u00a0per\u00edodo\u00a0de\u00a0\n10\u00a0a\u00f1os,\u00a0 de\u00a041\u00a0pacientes \u00a0con\u00a0 LMA\u00a0tras\u00a0accidentes \u00a0de\u00a0paracaidismo. \u00a0La\u00a0mayor\u00a0\nincidencia \u00a0de\u00a0v\u00e9rtebras \u00a0lesionadas\u00a0 incidi\u00f3\u00a0en\u00a0la\u00a0regi\u00f3n\u00a0toracolumbar,\u00a0 siendo\u00a0la\u00a0\nv\u00e9rtebra\u00a0m\u00e1s\u00a0 frecuentemente \u00a0afectada\u00a0L1.\u00a0En\u00a0este\u00a0estudio,\u00a0las\u00a0regiones\u00a0m\u00e1s\u00a0\nafectadas, \u00a0fueron\u00a0la\u00a0uni\u00f3n\u00a0cervicotor\u00e1cica \u00a0y\u00a0la\u00a0charnela\u00a0toracolumbar, \u00a0\nrepresentando \u00a0en\u00a0su\u00a0conjunto\u00a0un\u00a044,78%\u00a0de\u00a0todos\u00a0 los\u00a0casos\u00a0de\u00a0la\u00a0serie.\u00a0\u00a0\n\u00a0Las\u00a0lesiones\u00a0medulares \u00a0entre\u00a0C5\u00a0y\u00a0C7\u00a0son\u00a0las\u00a0cervicales \u00a0m\u00e1s\u00a0comunes, \u00a0y\u00a0el\u00a0\nmecanismo \u00a0principalmente \u00a0implicado\u00a0 es\u00a0la\u00a0hiperextensi\u00f3n. \u00a0En\u00a0nuestra\u00a0serie,\u00a0en\u00a0\nel\u00a0caso\u00a0de\u00a0las\u00a0LMA\u00a0cervicales, \u00a0las\u00a0m\u00e1s\u00a0frecuentes \u00a0\u00a0fueron\u00a0las\u00a0cervicales \u00a0bajas\u00a0o\u00a0\nsubaxiales, \u00a0representando \u00a0un\u00a072,97%\u00a0de\u00a0todas\u00a0 las\u00a0fracturas\u00a0cervicales, \u00a0y\u00a0solo\u00a0\nexistiendo\u00a0 un\u00a0caso\u00a0de\u00a0fractura\u00a0 axial,\u00a0en\u00a0concordancia \u00a0con\u00a0 los\u00a0datos\u00a0 reportados \u00a0\npor\u00a0los\u00a0estudios\u00a0anteriormente \u00a0referenciados. \u00a0Los\u00a0pacientes \u00a0con\u00a0LMA\u00a0sin\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nanormalidades \u00a0radiogr\u00e1ficas \u00a0constituyeron \u00a0el\u00a0resto\u00a0de\u00a0casos,\u00a0correspondiendo\u00a0 al\u00a0\ns\u00edndrome \u00a0conocido\u00a0 como\u00a0\u00a0SCIWORA. \u00a0Hendey\u00a0(101) ,\u00a0realiz\u00f3\u00a0un\u00a0estudio\u00a0con\u00a0 el\u00a0\nobjetiv\u00a0de\u00a0definir\u00a0mejor\u00a0la\u00a0incidencia \u00a0y\u00a0caracter\u00edsticas \u00a0de\u00a0pacientes \u00a0con\u00a0 este\u00a0\ns\u00edndrom\ncluyendo\u00a0 un\u00a00.08%\u00a0de\u00a0casos\u00a0con\u00a0SCIWORA; \u00a0en\u00a0nuestra\u00a0cohorte\u00a0existen\u00a0\nun\u00a0total\u00a0de\u00a016\u00a0pacientes\u00a0 con\u00a0 \u201cSpinal\u00a0Cord\u00a0Injury\u00a0Without\u00a0Radiographic \u00a0\nAbnorm\ne \u00a0\n\u00a0est\u00e1\u00a0\ndotada \u00a0menor\u00a0movilidad.\u00a0 Sin\u00a0embargo, \u00a0la\u00a0charnela\u00a0 dorsolumbar \u00a0(T10\u2010 L2)\u00a0es\u00a0\nmuchoo\ne,\u00a0para\u00a0ello\u00a0dise\u00f1\u00f3\u00a0un\u00a0estudio\u00a0prospectivo \u00a0observacional,\u00a0 analizando \u00a0los\u00a0\npacientes \u00a0con\u00a0LMA\u00a0en\u00a021\u00a0centros\u00a0m\u00e9dicos\u00a0de\u00a0Estados\u00a0 Unidos,\u00a0utilizando \u00a0la\u00a0base\u00a0\nde\u00a0datos\u00a0 del\u00a0estudio\u00a0NEXUS\u00a0 (National \u00a0Emergency \u00a0X\u2010Radiography \u00a0Utilization \u00a0\nStudy);\u00a0y\u00a0definiendo\u00a0 el\u00a0mencionado\u00a0 s\u00edndrome, \u00a0como\u00a0la\u00a0presencia \u00a0de\u00a0LMA\u00a0\nverificada \u00a0con\u00a0RNM,\u00a0en\u00a0ausencia\u00a0de\u00a0datos\u00a0 radiogr\u00e1ficos \u00a0que\u00a0la\u00a0confirmaran. \u00a0De\u00a0\nlos\u00a034.069\u00a0pacientes \u00a0incluidos\u00a0en\u00a0el\u00a0estudio,\u00a0818\u00a0pacientes \u00a0presentaron\u00a0 LMA\u00a0\ncervical,\u00a0in\nality\u201d.\u00a0Nuestra\u00a0 serie\u00a0presenta\u00a0una\u00a0mayor\u00a0 incidencia \u00a0de\u00a0SCIWORA \u00a0que\u00a0la\u00a0\nreportada\u00a0 por\u00a0Hendey\u00a0et\u00a0al.\u00a0\n\u00a0\nEn\u00a0el\u00a0manejo\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0LMAT\u00a0es\u00a0importante \u00a0el\u00a0incidir\u00a0de\u00a0nuevo\u00a0\nen\u00a0la\u00a0importancia \u00a0de\u00a0mantener \u00a0una\u00a0adecuada \u00a0perfusi\u00f3n \u00a0medular.\u00a0El\u00a0flujo\u00a0\nmedular\u00a0 se\u00a0autorregula \u00a0entre\u00a0tensiones\u00a0 arteriales \u00a0medias\u00a0de\u00a060\u00a0y\u00a0120\u00a0mm\u00a0 Hg,\u00a0\nhaci\u00e9ndose \u00a0dependiente \u00a0de\u00a0la\u00a0presi\u00f3n\u00a0por\u00a0fuera\u00a0 de\u00a0estos\u00a0l\u00edmites,\u00a0 produci\u00e9ndose \u00a0\no\u00a0agrav\u00e1ndose \u00a0las\u00a0lesiones\u00a0secundarias, \u00a0por\u00a0tanto,\u00a0se\u00a0debe\u00a0incidir\u00a0en\u00a0el\u00a0especial\u00a0\npeligro\u00a0en\u00a0la\u00a0hipotensi\u00f3n \u00a0arterial\u00a0mantenida \u00a0tras\u00a0una\u00a0LMAT.\u00a0\u00a0\n\u00a0\nEn\u00a0cuanto\u00a0al\u00a0resto\u00a0del\u00a0raquis,\u00a0hay\u00a0que\u00a0tener\u00a0n\u00a0cuenta\u00a0quela\u00a0zona\u00a0alta\u00a0de\u00a0\nla\u00a0columna\u00a0dorsal\u00a0est\u00e1\u00a0reforzada\u00a0 y\u00a0fijada\u00a0por\u00a0la\u00a0pared\u00a0tor\u00e1cica\u00a0y\u00a0por\u00a0lo\u00a0tanto,\n\u00a0de\n\u00a0 131\u00a0m\u00e1s\u00a0m\u00f3vil,\u00a0 lo\u00a0que\u00a0determina \u00a0la\u00a0mayor\u00a0 frecuencia \u00a0de\u00a0lesiones\u00a0a\u00a0este\u00a0nivel.\u00a0\nRespecto\u00a0a\u00a0las\u00a0fracturas\u00a0toracolumbares,\u00a0 se\u00a0han\u00a0 dividido\u00a0por\u00a0la\u00a0cl\u00e1sica\u00a0\nclasificaci\u00f3n \u00a0de\u00a0Denis,\u00a0si\u00a0bien\u00a0se\u00a0proponen \u00a0en\u00a0la\u00a0literatura \u00a0otras\u00a0clasificaciones \u00a0de\u00a0\nfracturas\u00a0toracolumbares, \u00a0que\u00a0facilitan\u00a0la\u00a0toma\u00a0 de\u00a0decisiones \u00a0cl\u00ednicas\u00a0 en\u00a0\nt\u00e9rminos\u00a0de\u00a0necesitar\u00a0IQ,\u00a0frente\u00a0a\u00a0tratamiento \u00a0conservador \u00a0(60,102\u2010107) .\u00a0\nUtilizando\u00a0 la\u00a0clasificaci\u00f3n \u00a0de\u00a0Denis,\u00a0las\u00a0fracturas\u00a0por\u00a0luxaci\u00f3n\u00a0son\u00a0las\u00a0m\u00e1s\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nfrecuentes \u00a0en\u00a0nuestro\u00a0estudio\u00a0(25\u00a0casos),\u00a0 las\u00a0fracturas\u00a0por\u00a0estallido\u00a0representan \u00a0\nun\u00a028,84%\u00a0de\u00a0los\u00a0casos,\u00a0un\u00a015,38%\u00a0las\u00a0fracturas\u00a0por\u00a0cintur\u00f3n\u00a0de\u00a0seguridad, \u00a0y\u00a0un\u00a0\n7,69%\u00a0 de\u00a0fracturas\u00a0por\u00a0aplastamientos \u00a0vertebrales. \u00a0\n\u00a0\nLa\u00a0clasificaci\u00f3n \u00a0normalizada \u00a0de\u00a0las\u00a0lesiones\u00a0medulares \u00a0de\u00a0la\u00a0American \u00a0\nSpinal\u00a0Injury\u00a0Association, \u00a0mostr\u00f3\u00a0una\u00a0diferencia \u00a0en\u00a091\u00a0casos,\u00a0mientras\u00a0que\u00a0en\u00a0un\u00a0\n58,24%\u00a0de\u00a0los\u00a0casos,\u00a0no\u00a0se\u00a0observa\u00a0diferencia \u00a0en\u00a0el\u00a0ASIA\u00a0al\u00a0alta\u00a0de\u00a0la\u00a0Unidad\u00a0\nrespecto\u00a0al\u00a0ingreso.\u00a0 Un\u00a030,77%\u00a0(28\u00a0casos)\u00a0presenta\u00a0mejor\u00eda\u00a0 de\u00a0un\u00a0grado\u00a0de\u00a0la\u00a0\nescala\u00a0ASIA\u00a0y\u00a0solo\u00a0en\u00a0\u00a010\u00a0casos\u00a0la\u00a0mejor\u00eda\u00a0es\u00a0de\u00a0dos\u00a0grados,\u00a0no\u00a0existiendo\u00a0 ning\u00fan\u00a0\ncaso\u00a0con\u00a0mejor\u00eda\u00a0 superior\u00a0a\u00a0dos\u00a0grados\u00a0 respecto\u00a0al\u00a0ingreso.\u00a0\u00a0\n\u00a0\nNumerosos \u00a0estudios\u00a0demuestran \u00a0que\u00a0la\u00a0incidencia \u00a0de\u00a0los\u00a0traumatismos \u00a0\nde\u00a0la\u00a0CV\u00a0se\u00a0subestima \u00a0en\u00a0la\u00a0valoraci\u00f3n \u00a0inicial\u00a0de\u00a0los\u00a0pacientes \u00a0politraumatizados. \u00a0\nLa\u00a0aparici\u00f3n \u00a0o\u00a0agravamiento \u00a0de\u00a0las\u00a0lesiones\u00a0neurol\u00f3gicas\u00a0 se\u00a0previene\u00a0\nmante\n\u00a0escrito\u00a0\u00a0un\u00a0examen\u00a0\ncl\u00ednico\u00a0etallado\u00a0 o\u00a0valoraci\u00f3n \u00a0secundaria \u00a0que\u00a0se\u00a0debe\u00a0consignar \u00a0por\u00a0escrito\u00a0y\u00a0ser\u00a0\nfirmad\nr\u00a0niendo\u00a0recto\u00a0el\u00a0eje\u00a0 cabeza\u2010cuello\u2010tronco\u00a0durante\u00a0las\u00a0maniobras \u00a0de\u00a0\nliberaci\u00f3n \u00a0y\u00a0de\u00a0traslado\u00a0en\u00a0camilla.\u00a0Siempre\u00a0debemos \u00a0mantener \u00a0el\u00a0axioma\u00a0que\u00a0\ncualquier\u00a0 paciente\u00a0traumatizado \u00a0que\u00a0est\u00e9\u00a0en\u00a0coma\u00a0\u00a0tiene\u00a0una\u00a0lesi\u00f3n\u00a0inestable\u00a0del\u00a0\nraquis\u00a0 cervical,\u00a0hasta\u00a0que\u00a0se\u00a0descarte\u00a0mediante \u00a0pruebas\u00a0de\u00a0imagen.\u00a0Tras\u00a0la\u00a0\nvaloraci\u00f3n \u00a0inicial\u00a0o\u00a0primaria\u00a0al\u00a0ingreso\u00a0en\u00a0la\u00a0UR,\u00a0y\u00a0tratadas\u00a0las\u00a0urgencias \u00a0absolutas \u00a0\nsi\u00a0existiesen, \u00a0se\u00a0efect\u00faa\u00a0mediante \u00a0la\u00a0existencia \u00a0de\u00a0\u00a0protocolo\nd\n\u00a0 132o\u00a0por\u00a0los\u00a0diferentes \u00a0facultativos \u00a0que\u00a0hallan\u00a0participado \u00a0en\u00a0esta.\u00a0Tiene\u00a0el\u00a0\nobjetivo\u00a0 de\u00a0buscar\u00a0una\u00a0afectaci\u00f3n \u00a0neurol\u00f3gica \u00a0y\u00a0precisar\u00a0 el\u00a0nivel\u00a0motor\u00a0o\u00a0\nsensitivo\u00a0de\u00a0la\u00a0lesi\u00f3n,\u00a0as\u00ed\u00a0como\u00a0su\u00a0car\u00e1cter\u00a0 completo \u00a0o\u00a0incompleto.\u00a0 Este\u00a0examen\u00a0\nha\u00a0sido\u00a0 codificado \u00a0por\u00a0la\u00a0American \u00a0Spinal\u00a0Injury\u00a0Association. \u00a0Las\u00a0pruebas\u00a0de\u00a0\nimagen\u00a0a\u00a0ealizar para\u00a0descartar\u00a0 una\u00a0LMAT\u00a0existen\u00a0por\u00a0escrito\u00a0en\u00a0la\u00a0UR,\u00a0con\u00a0un\u00a0\nalgoritmo \u00a0dependiendo \u00a0del\u00a0estado\u00a0de\u00a0conciencia \u00a0y\u00a0la\u00a0cl\u00ednica\u00a0neurol\u00f3gica \u00a0que\u00a0\npresente\u00a0el\u00a0paciente. \u00a0\n\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0nuestra\u00a0actitud\u00a0\ndepender\u00e1 \u00a0en\u00a0gran\u00a0parte\u00a0de\u00a0sus\u00a0resultados. \u00a0Los\u00a0objetivos\u00a0 generales \u00a0de\u00a0la\u00a0\nexplora\nbares\u00a0no\u00a0se\u00a0realizan\u00a0\nrutinariamente. \u00a0\ni\nntre\u00a0un\u00a00,6\u00a0\u2010 \u00a065%\u00a0de\u00a0los\u00a0pacientes \u00a0politraumatizados \u00a0\npueden presentan\u00a0 LI.\u00a0Esta\u00a0elevada\u00a0 incidencia, \u00a0disminuye \u00a0hasta\u00a0un\u00a02\u00a0\u2010\u00a022%\u00a0en\u00a0los\u00a0\nregistros\u00a0de\u00a0datos\u00a0 retrospectivos. \u00a0Este\u00a0hecho\u00a0fue\u00a0demostrado \u00a0por\u00a0Reid\u00a0et\u00a0al\u00a0\u00a0El\u00a0estudio\u00a0radiol\u00f3gico\u00a0 es\u00a0un\u00a0paso\u00a0 clave\u00a0y\u00a0determinante \u00a0en\u00a0el\u00a0proceso\u00a0\ndiagn\u00f3stico\u00a0 y\u00a0terap\u00e9utico \u00a0del\u00a0paciente\u00a0politraumatizado\u00a0 en\u00a0general\u00a0 y\u00a0en\u00a0la\u00a0LMA\u00a0\nen\u00a0particular. \u00a0Una\u00a0vez\u00a0completado \u00a0el\u00a0estudio\u00a0radiol\u00f3gico,\nci\u00f3n\u00a0radiol\u00f3gica \u00a0del\u00a0 raquis\u00a0son\u00a0detectar\u00a0lesiones\u00a0o\u00a0hallazgos\u00a0\n\"sospechosos\" \u00a0para\u00a0focalizar\u00a0sobre\u00a0ellos\u00a0posteriores \u00a0estudios\u00a0y\u00a0determinar\u00a0 el\u00a0tipo\u00a0\nde\u00a0lesi\u00f3n,\u00a0su\u00a0estabilidad \u00a0y\u00a0el\u00a0grado\u00a0de\u00a0afectaci\u00f3n \u00a0medular\u00a0si\u00a0la\u00a0hubiere,\u00a0por\u00a0lo\u00a0que\u00a0\nconstituye \u00a0una\u00a0herramienta\u00a0 fundamental \u00a0para\u00a0tomar\u00a0decisiones \u00a0terap\u00e9uticas \u00a0y\u00a0\nsentar\u00a0 la\u00a0indicaci\u00f3n \u00a0de\u00a0cirug\u00eda\u00a0 urgente.\u00a0La\u00a0valoraci\u00f3n \u00a0de\u00a0la\u00a0radiolog\u00eda \u00a0simple\u00a0debe\u00a0\nser\u00a0sistematizada \u00a0y\u00a0ordenada.\u00a0 Las\u00a0radiograf\u00edas \u00a0dorsales\u00a0y\u00a0lum\n\u00a0\nEn\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0centros\u00a0hospitalarios \u00a0se\u00a0solicitan\u00a0m\u00faltiples \u00a0pruebas\u00a0\nde\u00a0magen\u00a0para\u00a0descartar\u00a0 una\u00a0posible\u00a0LMA\u00a0en\u00a0un\u00a0paciente\u00a0politraumatizado, \u00a0si\u00a0\nbien\u00a0bas\u00e1ndonos \u00a0en\u00a0los\u00a0datos\u00a0 del\u00a0estudio\u00a0NEXUS\u00a0\u00a0(101) ,\u00a0podemos \u00a0establecer \u00a0una\u00a0\nserie\u00a0de\u00a0modificaciones \u00a0respecto\u00a0a\u00a0esta\u00a0pr\u00e1ctica\u00a0habitual.\u00a0En\u00a0un\u00a0paciente\u00a0\ndespierto, \u00a0que\u00a0no\u00a0presenta\u00a0otras\u00a0lesiones\u00a0que\u00a0desv\u00edan\u00a0la\u00a0atenci\u00f3n\u00a0y\u00a0que\u00a0tiene\u00a0un\u00a0\nbuen\u00a0 estado\u00a0de\u00a0conciencia \u00a0puede\u00a0excluirse\u00a0el\u00a0diagn\u00f3stico\u00a0 de\u00a0LMA\u00a0bas\u00e1ndose \u00a0en\u00a0\nuna\u00a0exploraci\u00f3n \u00a0f\u00edsica\u00a0 completamente \u00a0normal\u00a0 y\u00a0ausencia\u00a0de\u00a0dolor\u00a0en\u00a0CV.\u00a0Pese\u00a0a\u00a0\nestos\u00a0datos\u00a0 publicados \u00a0en\u00a0el\u00a0estudio\u00a0NEXUS,\u00a0en\u00a0nuestro\u00a0estudio\u00a0 en\u00a0ning\u00fan\u00a0caso\u00a0\nse\u00a0realiz\u00f3\u00a0el\u00a0diagn\u00f3stico\u00a0 definitivo \u00a0mediante \u00a0la\u00a0valoraci\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0forma\u00a0\naislada.\u00a0\n\u00a0\nEn\u00a0nuestra\u00a0cohorte,\u00a0el\u00a0diagn\u00f3stico\u00a0 por\u00a0sospecha \u00a0se\u00a0llev\u00f3\u00a0 a\u00a0cabo\u00a0por\u00a0la\u00a0\ncl\u00ednica\u00a0en\u00a070\u00a0pacientes, \u00a0y\u00a0tras\u00a0la\u00a0realizaci\u00f3n\u00a0 de\u00a0pruebas\u00a0de\u00a0imagen\u00a0mediante \u00a0TAC\u00a0\nen\u00a026\u00a0pacientes.\u00a0 El\u00a0fallo\u00a0en\u00a0el\u00a0diagn\u00f3stico \u00a0de\u00a0sospecha \u00a0apareci\u00f3\u00a0\u00fanicamente \u00a0en\u00a07\u00a0\npacientes, \u00a0siendo\u00a0este\u00a0diagnostico \u00a0inicial\u00a0certero\u00a0en\u00a0el\u00a092.71%\u00a0 de\u00a0los\u00a0casos.\u00a0\u00a0\nAproximadamente, \u00a0e\n\u00a0 133\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n(225) ,\u00a0que\n\u00a0\nesto\u00a0de\u00a0los\u00a0par\u00e1metros, \u00a0teniendo\u00a0 en\u00a0cuenta\u00a0 que\u00a0los\u00a0t\u00f3xicos\u00a0 no\u00a0\nson\u00a0va rables \u00a0puesto\u00a0que\u00a0s\u00f3lo\u00a0se\u00a0han\u00a0 analizado \u00a0de\u00a0forma\u00a0aislada\u00a0y\u00a0que\u00a0el\u00a0\nmecan\no\u00a0dicho\u00a0protocolo; \u00a0con\u00a0 \u00e9l\u00a0se\u00a0consigue\u00a0una\u00a0detecci\u00f3n \u00a0y\u00a0un\u00a0tratamiento \u00a0\nprecoz \u00a0mejora\u00a0la\u00a0morbimortalidad\u00a0 de\u00a0estos\u00a0pacientes.\u00a0 La\u00a0revisi\u00f3n\u00a0terciaria\u00a0\nconsist\u00a0observaron \u00a0un\u00a0cambio\u00a0del\u00a02\u00a0al\u00a09%\u00a0de\u00a0LI\u00a0seg\u00fan\u00a0se\u00a0tratase\u00a0de\u00a0un\u00a0estudio\u00a0\nretrospectivo \u00a0o\u00a0prospectivo. \u00a0Nuestra\u00a0 incidencia \u00a0del\u00a07,29%\u00a0 esta\u00a0en\u00a0concordancia \u00a0\ncon\u00a0 estos\u00a0\u00faltimos\u00a0trabajos.\u00a0Estudios\u00a0previos\u00a0han\u00a0 demostrado \u00a0una\u00a0asociaci\u00f3n \u00a0\nentre\u00a0la\u00a0aparici\u00f3n\u00a0 de\u00a0LI\u00a0y\u00a0un\u00a0\u00edndice\u00a0de\u00a0severidad\u00a0 elevado,\u00a0 un\u00a0bajo\u00a0nivel\u00a0de\u00a0\nconciencia \u00a0(por\u00a0lesi\u00f3n\u00a0cerebral,\u00a0 analgosedacci\u00f3n \u00a0o\u00a0por\u00a0t\u00f3xicos positivos\u00a0en\u00a0\nsangre),\u00a0la\u00a0intubaci\u00f3n \u00a0orotraqueal, \u00a0la\u00a0inestabilidad \u00a0hemodin\u00e1mica \u00a0y\u00a0el\u00a0\nmecanismo \u00a0de\u00a0acci\u00f3n\u00a0no\u00a0penetrante. \u00a0Nuestro\u00a0estudio\u00a0 ha\u00a0observado \u00a0una\u00a0relaci\u00f3n\u00a0\nestad\u00edsticamente \u00a0significativa \u00a0entre\u00a0las\u00a0LI\u00a0y\u00a0la\u00a0existencia \u00a0de\u00a0un\u00a0APACHE\u00a0II\u00a0elevado,\u00a0\npresencia \u00a0de\u00a0traumas\u00a0acompa\u00f1antes \u00a0tipo\u00a0TCE\u00a0y\u00a0TA\u00a0y\u00a0los\u00a0pacientes \u00a0\nhemodinamicamente \u00a0inestables \u00a0e\u00a0intubados. \u00a0No\u00a0se\u00a0ha\u00a0detectado \u00a0ninguna\u00a0\nrelaci\u00f3n\u00a0con\u00a0el\u00a0r\nlo\nismo\u00a0de\u00a0acci\u00f3n\u00a0en\u00a0un\u00a0porcentaje \u00a0muy\u00a0cercano\u00a0 al\u00a0100%\u00a0de\u00a0los\u00a0casos\u00a0es\u00a0\ncerrado\u00a0o\u00a0no\u00a0penetrante. \u00a0\n\u00a0Tras\u00a0el\u00a0an\u00e1lisis\u00a0 de\u00a0nuestros\u00a0resultados, \u00a0las\u00a0diferentes \u00a0estrategias \u00a0de\u00a0\nmejora\u00a0continua\u00a0para\u00a0la\u00a0atenci\u00f3n\u00a0del\u00a0paciente\u00a0politraumatizado \u00a0se\u00a0basan\u00a0 en\u00a0la\u00a0\nexistencia \u00a0de\u00a0equipos\u00a0multidisciplinarios \u00a0adecuadamente \u00a0formados \u00a0y\u00a0utilizando \u00a0\ndiversos\u00a0protocolos. \u00a0Puesto\u00a0que\u00a0estos\u00a0puntos\u00a0ya\u00a0los\u00a0aplicamos \u00a0en\u00a0nuestro\u00a0centro,\u00a0\nel\u00a0principal\u00a0mecanismo \u00a0adoptado \u00a0es\u00a0la\u00a0aplicaci\u00f3n \u00a0de\u00a0la\u00a0revisi\u00f3n\u00a0terciaria\u00a0\npropuesta \u00a0por\u00a0Reid\u00a0et\u00a0al\u00a0(225) ,\u00a0que\u00a0detectaron \u00a0una\u00a0disminuci\u00f3n \u00a0del\u00a035%\u00a0en\u00a0las\u00a0LI\u00a0\naplicand\n\u00a0que\n\u00a0 134e\u00a0en\u00a0un\u00a0examen\u00a0completo \u00a0del\u00a0paciente\u00a0y\u00a0de\u00a0las\u00a0pruebas\u00a0complementarias \u00a0\nrealizadas \u00a0durante\u00a0las\u00a0revisiones \u00a0primaria\u00a0y\u00a0secundaria, \u00a0y\u00a0solicitar\u00a0nuevas\u00a0\npruebas\u00a0complementarias \u00a0si\u00a0es\u00a0necesario. \u00a0Esta\u00a0revisi\u00f3n\u00a0terciaria\u00a0se\u00a0realiza\u00a0una\u00a0\nvez\u00a0finalizada \u00a0la\u00a0revisi\u00f3n\u00a0primaria\u00a0y\u00a0la\u00a0secundaria,\u00a0 y\u00a0antes\u00a0de\u00a0las\u00a0primeras\u00a024\u00a0\nhoras\u00a0del\u00a0traumatismo. \u00a0\u00a0\n\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0o\n\u00a0fractura,\u00a0el\u00a0retroceso \u00a0de\u00a0la\u00a0pared\u00a0vertebral\u00a0posterior\u00a0y\u00a0\nlos\u00a0fragmentos\u00a0 situados\u00a0en\u00a0el\u00a0canal\u00a0 vertebral\u00a0y\u00a0est\u00e1\u00a0ampliamente \u00a0indicada,\u00a0sobre\u00a0\ntodo\u00a0e\na\u00a0RNM\u00a0por\u00a0su\u00a0parte,\u00a0ofrece\u00a0una\u00a0imagen\u00a0m\u00e1s\u00a0detallada \u00a0de\u00a0la\u00a0ME,\u00a0\nligamentos\u00a0 espinales, \u00a0discos\u00a0intervertebrales \u00a0y\u00a0tejidos\u00a0paraespinales, \u00a0y\u00a0es\u00a0m\u00e1s\u00a0\u00a0Mediante \u00a0la\u00a0radiolog\u00eda \u00a0lateral\u00a0hasta\u00a0dos\u00a0terceras\u00a0partes\u00a0de\u00a0la\u00a0patolog\u00eda \u00a0\ncervical\u00a0traum\u00e1tica \u00a0puede\u00a0ser\u00a0detectada \u00a0con\u00a0esta\u00a0 proyecci\u00f3n,\u00a0 y\u00a0al\u00a0igual\u00a0que\u00a0la\u00a0de\u00a0\nt\u00f3rax,\u00a0solo\u00a0debe\u00a0demorarse \u00a0ante\u00a0la\u00a0existencia \u00a0de\u00a0lesiones\u00a0vitales.\u00a0Su\u00a0normalidad \u00a0\nno\u00a0excluye\u00a0completamente \u00a0la\u00a0existencia \u00a0de\u00a0LMA,\u00a0ya\u00a0que\u00a0el\u00a05\u201015%\u00a0de\u00a0las\u00a0lesiones\u00a0\ncervicales \u00a0no\u00a0pueden\u00a0 ser\u00a0detectadas \u00a0mediante \u00a0esta\u00a0t\u00e9cnica.\u00a0Disponer\u00a0 de\u00a0ella\u00a0\nantes\u00a0depr ceder\u00a0a\u00a0la\u00a0intubaci\u00f3n \u00a0traqueal\u00a0 nos\u00a0puede\u00a0aportar\u00a0una\u00a0valiosa\u00a0\ninformaci\u00f3n \u00a0para\u00a0el\u00a0correcto\u00a0manejo\u00a0de\u00a0la\u00a0v\u00eda\u00a0a\u00e9rea.\u00a0La\u00a0radiolog\u00eda \u00a0\nanteroposterior \u00a0debe\u00a0practicarse \u00a0tambi\u00e9n\u00a0rutinariamente. \u00a0\u00a0\n\u00a0\nLa\u00a0TAC\u00a0puede\u00a0sustituir\u00a0a\u00a0la\u00a0radiolog\u00eda \u00a0convencional \u00a0en\u00a0el\u00a0diagn\u00f3stico\u00a0 de\u00a0\nLMA,\u00a0en\u00a0aquellos\u00a0centros\u00a0en\u00a0los\u00a0que\u00a0est\u00e1\u00a0disponible \u00a0(25,108\u2010116) .\u00a0Series\u00a0\nprospectivas \u00a0de\u00a0casos\u00a0muestran \u00a0una\u00a0gran\u00a0sensibilidad \u00a0de\u00a0la\u00a0TAC\u00a0en\u00a0el\u00a0diagn\u00f3stico \u00a0\nde\u00a0fracturas\u00a0espinales, \u00a0frente\u00a0a\u00a0la\u00a0radiolog\u00eda \u00a0convencional, \u00a0ya\u00a0que\u00a0permite\u00a0\nvisualizar \u00a0bien\u00a0las\u00a0l\u00edneas\u00a0de\nn\u00a0el\u00a0nivel\u00a0dorsolumbar \u00a0(117) .\u00a0Finalmente,\u00a0 cuando\u00a0ciertas\u00a0v\u00e9rtebras \u00a0(C6,\u00a0 C7,\u00a0\nT1)\u00a0no\u00a0se\u00a0han\u00a0 podido\u00a0visualizar \u00a0correctamente \u00a0en\u00a0la\u00a0radiograf\u00eda \u00a0convencional, \u00a0la\u00a0\nTAC\u00a0se\u00a0impone\u00a0tambi\u00e9n\u00a0para\u00a0descartar\u00a0 una\u00a0lesi\u00f3n\u00a0traum\u00e1tica \u00a0a\u00a0este\u00a0nivel\u00a0\ntopogr\u00e1fico. \u00a0Sus\u00a0 indicaci\u00f3n \u00a0urgente\u00a0en\u00a0la\u00a0LMA,\u00a0son\u00a0todas\u00a0aquellas\u00a0lesiones\u00a0\ndetectadas \u00a0o\u00a0sospechadas\u00a0 en\u00a0las\u00a0radiograf\u00edas \u00a0simples,\u00a0que\u00a0puedan\u00a0suponer\u00a0\nriesgo\u00a0de\u00a0LM\u00a0por\u00a0ser\u00a0una\u00a0lesi\u00f3n\u00a0inestable, \u00a0o\u00a0que\u00a0ya\u00a0est\u00e9n\u00a0produciendo\u00a0 da\u00f1o\u00a0\nneurol\u00f3gico \u00a0susceptible \u00a0de\u00a0mejorar\u00a0o\u00a0estabilizarse \u00a0tras\u00a0descompresi\u00f3n \u00a0\nquir\u00fargica. \u00a0Por\u00a0lo\u00a0tanto\u00a0debe\u00a0realizarse \u00a0en\u00a0todos\u00a0 los\u00a0pacientes \u00a0con\u00a0 fracturas, \u00a0\nluxaciones \u00a0y\u00a0fracturas\u2010luxaciones \u00a0inestables, \u00a0y\u00a0en\u00a0aquellos\u00a0 con\u00a0d\u00e9ficit\u00a0\nneurol\u00f3gico, \u00a0preferentemente\u00a0 incompleto. \u00a0La\u00a0TAC\u00a0en\u00a0un\u00a0traumatismo \u00a0del\u00a0raquis\u00a0\ndorsal\u00a0tiene\u00a0como\u00a0ventajas\u00a0adicionales \u00a0que\u00a0nos\u00a0permite\u00a0evaluar\u00a0la\u00a0importancia \u00a0\nde\u00a0una\u00a0contusi\u00f3n \u00a0pulmonar \u00a0y\u00a0el\u00a0diagn\u00f3stico \u00a0de\u00a0un\u00a0neumot\u00f3rax \u00a0oculto.\u00a0\n\u00a0\n\u00a0 135LIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nsensibl\no \u00a0 sb\n\u00a0mediante \u00a0radiolog\u00eda \u00a0\nconvencional \u00a0en\u00a016\u00a0pacientes.\u00a0\n, u \u00e9e\u00a0en\u00a0la\u00a0detecci\u00f3n\u00a0 de\u00a0hematoma \u00a0epidural.\u00a0 La\u00a0\u00fanica\u00a0 indicaci\u00f3n \u00a0de\u00a0la\u00a0RNM\u00a0en\u00a0\nurgencias \u00a0es\u00a0la\u00a0sospecha \u00a0de\u00a0una\u00a0afectaci\u00f3n \u00a0medular\u00a0sin\u00a0lesi\u00f3n\u00a0\u00f3sea\u00a0detectable. \u00a0\nLa\u00a0RNM\u00a0no\u00a0puede\u00a0sustituir\u00a0a\u00a0la\u00a0TAC\u00a0en\u00a0el\u00a0manejo\u00a0urgente\u00a0del\u00a0paciente\u00a0con\u00a0LMA,\u00a0\nya\u00a0que\u00a0no\u00a0puede\u00a0definir\u00a0las\u00a0lesiones\u00a0\u00f3seas,\u00a0cuyo\u00a0exacto\u00a0conocimiento \u00a0es\u00a0\nfundamental.\u00a0\n\u00a0El\u00a0diagn\u00f3stic \u00a0definitivo \u00a0ennuestra\u00a0serie\u00a0e\u00a0o tuvo\u00a0 tras\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0\nla\u00a0TAC\u00a0en\u00a057\u00a0pacientes, \u00a0mediante \u00a0RNM\u00a0en\u00a023\u00a0pacientes \u00a0y\n\u00a0Los\u00a0pacientes \u00a0con\u00a0LMAT\u00a0\u00a0se\u00a0asocian\u00a0con\u00a0traumatismos \u00a0a\u00a0otros\u00a0niveles\u00a0en\u00a0\nel\u00a025\u201060%\u00a0de\u00a0los\u00a0casos,\u00a0y\u00a0en\u00a0las\u00a0lesiones\u00a0de\u00a0columna\u00a0dorsal\u00a0y\u00a0lumbar\u00a0la\u00a0presencia \u00a0\nde\u00a0lesiones\u00a0asociadas\u00a0 puede\u00a0llegar\u00a0hasta\u00a0el\u00a072%\u00a0y\u00a082%\u00a0respectivamente. \u00a0Este\u00a0\nhecho\u00a0es\u00a0relevante \u00a0porque\u00a0determina \u00a0la\u00a0indicaci\u00f3n \u00a0de\u00a0realizar\u00a0 radiograf\u00edas \u00a0de\u00a0\nestas\u00a0zonas\u00a0 en\u00a0pacientes\u00a0 con\u00a0lesiones\u00a0 traum\u00e1ticas \u00a0m\u00faltiples. \u00a0Otro\u00a0dato\u00a0que\u00a0hay\u00a0\nque\u00a0tener\u00a0en\u00a0cuenta\u00a0es\u00a0la\u00a0asociaci\u00f3n \u00a0de\u00a0lesiones\u00a0raqu\u00eddeas \u00a0a\u00a0distintos\u00a0niveles,\u00a0\nhecho\u00a0que\u00a0ocurre\u00a0 en\u00a0el\u00a04.5%\u00a0de\u00a0los\u00a0casos,\u00a0con\u00a0 riesgo\u00a0de\u00a0que\u00a0la\u00a0expresi\u00f3n \u00a0\nneurol\u00f3gica \u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0m\u00e1s\u00a0caudal\u00a0quede\u00a0enmascarada \u00a0por\u00a0la\u00a0superior\u00a0y\u00a0pase\u00a0\ninadvertida \u00a0sino\u00a0 se\u00a0realizan\u00a0diversas\u00a0t\u00e9cnicas\u00a0de\u00a0imagen\u00a0de\u00a0esas\u00a0zonas.\u00a0\u00a0 Por\u00a0\ntanto,\u00a0los\u00a0pacientes\u00a0 con\u00a0LMA\u00a0con\u00a0frecuencia \u00a0tienen\u00a0asociadas \u00a0lesiones\u00a0o\u00a0traumas\u00a0\nacompa\u00f1antes, \u00a0que\u00a0pueden\u00a0limitar\u00a0la\u00a0capacidad \u00a0del\u00a0paciente\u00a0para\u00a0localizar\u00a0el\u00a0\ndolor;\u00a0esto\u00a0complica\u00a0la\u00a0evaluaci\u00f3n \u00a0inicial,\u00a0y\u00a0el\u00a0manejo\u00a0del\u00a0paciente\u00a0con\u00a0LMA,\u00a0\nafectando \u00a0al\u00a0pron\u00f3stico.\u00a0 Las\u00a0lesiones\u00a0acompa\u00f1antes \u00a0m\u00e1s\u00a0frecuentes \u00a0de\u00a0este\u00a0\nestudio\u00a0fueron\u00a0el\u00a0trauma\u00a0 tor\u00e1cico\u00a0y\u00a0el\u00a0trauma\u00a0 esq el tico. \u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0 136\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nla\u00a0actualidad \u00a0es\u00a0aquel\u00a0 que\u00a0asegure\u00a0una\u00a0adecuada \u00a0oxigenaci\u00f3n \u00a0al\u00a0\ntejido\u00a0edular\u00a0 da\u00f1ado,\u00a0con\u00a0 una\u00a0adecuada \u00a0ventilaci\u00f3n \u00a0y\u00a0una\u00a0hemodin\u00e1mica \u00a0\nestable\niento\u00a0m\u00e9dico\u00a0que\u00a0sea\u00a0realmente \u00a0efectivo.\u00a0\nsoespasmo \u00a0asociado, \u00a0\nresultando \u00a0en\u00a0edema\u00a0y\u00a0necrosis\u00a0hemorr\u00e1gica \u00a0que\u00a0cierran\u00a0el\u00a0c\u00edrculo\u00a0vicioso.\u00a0La\u00a0\nextensi\u00f3n\u00a0 de\u00a0estas\u00a0lesiones\u00a0est\u00e1\u00a0directamente \u00a0relacionada \u00a0con\u00a0 la\u00a0severidad\u00a0 del\u00a0\ntraumatismo, \u00a0y\u00a0son\u00a0susceptibles \u00a0de\u00a0intervenci\u00f3n \u00a0terap\u00e9utica \u00a0lo\u00a0m\u00e1s\u00a0precozmente \u00a0\nposible5.3. UTILIZACI\u00d3N \u00a0DE\u00a0MEGADOSIS \u00a0DE\u00a0CORTICOIDES \u00a0\n\u00a0\nEl\u00a0manejo\u00a0de\u00a0la\u00a0LMAT\u00a0comienza \u00a0con\u00a0la\u00a0necesidad\u00a0 de\u00a0un\u00a0alto\u00a0\u00edndice\u00a0de\u00a0\nsospecha \u00a0sobre\u00a0su\u00a0propia\u00a0existencia. \u00a0El\u00a0mejor\u00a0 tratamiento \u00a0no\u00a0quir\u00fargico \u00a0\ndisponible \u00a0en\u00a0\nm\n\u00a0que\u00a0nos\u00a0permita\u00a0conseguir \u00a0y\u00a0mantener \u00a0una\u00a0presi\u00f3n\u00a0 de\u00a0perfusi\u00f3n \u00a0medular\u00a0\ndentro\u00a0de\u00a0sus\u00a0 l\u00edmites\u00a0normales. \u00a0Hasta\u00a0 el\u00a0momento \u00a0no\u00a0se\u00a0ha\u00a0demostrado \u00a0\ninequ\u00edvocamente \u00a0ning\u00fan\u00a0tratam\n\u00a0Tras\u00a0la\u00a0lesi\u00f3n\u00a0primaria,\u00a0 se\u00a0inician\u00a0una\u00a0serie\u00a0de\u00a0cambios\u00a0inflamatorios, \u00a0\nvasculares \u00a0y\u00a0neuroqu\u00edmicos \u00a0que\u00a0involucran\u00a0 principal\u00a0e\u00a0inicialmente \u00a0a\u00a0la\u00a0sustancia \u00a0\ngris\u00a0central,\u00a0avanzando \u00a0en\u00a0sentido\u00a0 dorsal\u00a0y\u00a0caudal,\u00a0afectando \u00a0tambi\u00e9n\u00a0la\u00a0\nsustancia \u00a0blanca,\u00a0pudiendo \u00a0causar\u00a0 lesi\u00f3n\u00a0medular\u00a0completa, \u00a0este\u00a0es\u00a0un\u00a0proceso\u00a0\ncomplejo \u00a0conocido\u00a0como\u00a0LS.\u00a0El\u00a0intervalo\u00a0\u00f3ptimo\u00a0para\u00a0intentar\u00a0detener\u00a0y\u00a0revertir\u00a0\nesta\u00a0cascada\u00a0 de\u00a0acontecimientos\u00a0 es\u00a0de\u00a04\u00a0horas,\u00a0e\u00a0idealmente \u00a0de\u00a02,\u00a0ya\u00a0que\u00a0la\u00a0\ninhibici\u00f3n \u00a0del\u00a0transporte \u00a0axopl\u00e1smico\u00a0 comienza \u00a0en\u00a0este\u00a0periodo,\u00a0es\u00a0marcada\u00a0a\u00a0\nlas\u00a04\u00a0horas\u00a0y\u00a0completa \u00a0a\u00a0las\u00a06\u00a0horas\u00a0del\u00a0traumatismo. \u00a0Esta\u00a0LS\u00a0viene\u00a0determinada \u00a0\npor\u00a0fen\u00f3menos \u00a0inflamatorios \u00a0con\u00a0 liberaci\u00f3n \u00a0de\u00a0mediadores \u00a0y\u00a0enzimas\u00a0\nlisosomales, \u00a0alteraciones\u00a0 del\u00a0endotelio \u00a0vascular\u00a0con\u00a0 microtrombos\u00a0 y\u00a0\nmicrohemorragias \u00a0y\u00a0desequilibrios \u00a0neuroqu\u00edmicos, \u00a0como\u00a0aumento\u00a0de\u00a0las\u00a0\nconcentraciones\u00a0 intramedulares \u00a0de\u00a0noradrenalina \u00a0y\u00a0endorfinas. \u00a0Estos\u00a0 procesos\u00a0\nen\u00a0su\u00a0conjunto\u00a0 originan\u00a0un\u00a0descenso \u00a0de\u00a0la\u00a0perfusi\u00f3n \u00a0medular\u00a0 y\u00a0de\u00a0la\u00a0presi\u00f3n\u00a0de\u00a0\noxigeno\u00a0tisular,\u00a0 que\u00a0pueden\u00a0empeorar \u00a0por\u00a0fen\u00f3menos\u00a0 de\u00a0va\n.\u00a0\u00a0\n\u00a0 137\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\nE\n\u00a0 138l\u00a0t\u00e9rmino\u00a0de\u00a0contusi\u00f3n \u00a0\u00a0medular \u00a0se\u00a0refiere\u00a0a\u00a0un\u00a0trastorno \u00a0funcional \u00a0de\u00a0\nersible\u00a0en\u00a0un\u00a0plazo\u00a0\nde\u00a0una 24\u00a0horas.\u00a0\u00a0\na\u00a0las\u00a0\nconsecuencias \u00a0del\u00a0nivel\u00a0definitivo \u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0sobre\u00a0la\u00a0minusval\u00eda \u00a0neurol\u00f3gica. \u00a0\nExiste\u00a0\n\u00a0\ns,\u00a0despu\u00e9s\u00a05,4\u00a0mg/kg/h\u00a0 durante\u00a023\u00a0horas),\u00a0 iniciada\u00a0en\u00a0las\u00a08\u00a0horas\u00a0que\u00a0\nsiguen \u00a0un\u00a0traumatismo \u00a0medular,\u00a0 mejora\u00a0el\u00a0pron\u00f3stico \u00a0neurol\u00f3gico. \u00a0Sin\u00a0\nembargo, \u00a0este\u00a0 estudio\u00a0ha\u00a0sido\u00a0 objeto\u00a0de\u00a0cr\u00edticas\u00a0metodol\u00f3gicas\u00a0 y\u00a0la\u00a0mejor\u00eda\u00a0\u00a0origen\u00a0traum\u00e1tico \u00a0con\u00a0disfunci\u00f3n \u00a0neurol\u00f3gica \u00a0transitoria \u00a0y\u00a0rev\ns\u00a0\n\u00a0\nSe\u00a0han\u00a0 estudiado\u00a0 m\u00faltiples\u00a0 intervenciones \u00a0terap\u00e9uticas \u00a0para\u00a0prevenir\u00a0\ntodo\u00a0este\u00a0evento\u00a0neuroendocrino \u00a0que\u00a0abarca\u00a0la\u00a0LS\u00a0tras\u00a0una\u00a0LMAT.\u00a0La\u00a0limitaci\u00f3n \u00a0\nde\u00a0la\u00a0extensi\u00f3n \u00a0de\u00a0las\u00a0lesiones\u00a0tiene\u00a0una\u00a0alta\u00a0importancia \u00a0en\u00a0la\u00a0\u00a0incidencia \u00a0desde\u00a0\nel\u00a0punto\u00a0de\u00a0vista\u00a0funcional, \u00a0permitiendo \u00a0una\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0en\u00a0una\u00a0o\u00a0\ndos\u00a0met\u00e1meras. \u00a0Esta\u00a0noci\u00f3n\u00a0de\u00a0limitaci\u00f3n\u00a0 de\u00a0la\u00a0progresi\u00f3n \u00a0de\u00a0las\u00a0lesiones\u00a0\nmedulares \u00a0es\u00a0crucial\u00a0para\u00a0los\u00a0traumatismos \u00a0medulares, \u00a0debido\u00a0\nuna\u00a0fuerte\u00a0evidencia \u00a0m\u00e9dica\u00a0que\u00a0la\u00a0conservaci\u00f3n \u00a0y/o\u00a0optimizaci\u00f3n \u00a0de\u00a0una\u00a0\npresi\u00f3n\u00a0 de\u00a0perfusi\u00f3n \u00a0medular\u00a0 es\u00a0importante. \u00a0Para\u00a0esto\u00a0se\u00a0precisa\u00a0la\u00a0correcci\u00f3n \u00a0\nde\u00a0la\u00a0hipovolemia \u00a0relativa\u00a0por\u00a0\u00a0vasodilataci\u00f3n \u00a0o\u00a0absoluta\u00a0por\u00a0fen\u00f3menos\u00a0\nhemorr\u00e1gicos \u00a0mediante \u00a0un\u00a0correcto\u00a0llenado\u00a0vascular\u00a0y,\u00a0a\u00a0menudo,\u00a0un\u00a0agente\u00a0\nvasoconstrictor \u00a0tipo\u00a0dopamina \u00a0o\u00a0noradrenalina. \u00a0La\u00a0noradrenalina \u00a0es\u00a0\nprobablemente \u00a0el\u00a0vasoconstrictor \u00a0m\u00e1s\u00a0adecuado \u00a0para\u00a0compensar \u00a0el\u00a0sistema\u00a0\nsimp\u00e1tico \u00a0ausente\u00a0en\u00a0el\u00a0territorio\u00a0sublesional.\u00a0\u00a0La \u00a0correcci\u00f3n \u00a0de\u00a0la\u00a0hipoxia\u00a0y\u00a0de\u00a0la\u00a0\nhipotermia \u00a0profunda \u00a0tambi\u00e9n\u00a0forma\u00a0parte\u00a0de\u00a0esta\u00a0reanimaci\u00f3n \u00a0medular.\u00a0\nAsimismo \u00a0es\u00a0preciso\u00a0evitar\u00a0 las\u00a0hiperglucemias. \u00a0\n\u00a0Experimentalmente, \u00a0la\u00a0administraci\u00f3n \u00a0precoz\u00a0de\u00a0MP en\u00a0grandes\u00a0dosis\u00a0\nmejora\u00a0el\u00a0pron\u00f3stico \u00a0neurol\u00f3gico\u00a0 de\u00a0la\u00a0compresi\u00f3n \u00a0o\u00a0de\u00a0la\u00a0isquemia\u00a0medular\u00a0\nmediante \u00a0una\u00a0mejorar\u00eda \u00a0del\u00a0edema\u00a0y\u00a0la\u00a0isquemia\u00a0medular,\u00a0bas\u00e1ndose \u00a0en\u00a0sus\u00a0\nacciones\u00a0antiinflamatoria, \u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0peroxidaci\u00f3n \u00a0lip\u00eddica\u00a0de\u00a0la\u00a0membrana, \u00a0\ninhibici\u00f3n \u00a0de\u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0enzimas\u00a0lisosomales \u00a0y\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0del\u00a0\ncomplemento \u00a0y\u00a0restauraci\u00f3n \u00a0de\u00a0la\u00a0tensi\u00f3n\u00a0arterial.\u00a0Bracken\u00a0et\u00a0al\u00a0(46\u201047)\u00a0han\u00a0\ncomunicado\u00a0 que\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0MP\u00a0en\u00a0grandes\u00a0dosis\u00a0(30\u00a0mg/kg\u00a0en\u00a0bolo\u00a0en\u00a0\n45\u00a0minuto\n\u00a0aIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nento\u00a0significativo\u00a0 de\u00a0la\u00a0mortalidad\u00a0 y\u00a0de\u00a0la\u00a0morbilidad \u00a0en\u00a0los\u00a0\npacientes \u00a0tratados\u00a0con\u00a0 MP,\u00a0 probablemente \u00a0sea\u00a0l\u00edcito\u00a0administrar \u00a0este\u00a0\ntratami\nn .\ne\u00a0 \u00a0\n118\u2010119) .\u00a0El\u00a0protocolo\u00a0 empleado \u00a0\nconsisti\u00f3\u00a0 en\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a030\u00a0mgr/kg\u00a0de\u00a0MP\u00a0en\u00a015\u00a0minutos,\u00a0y\u00a0tras\u00a0una\u00a0\npausa\u00a0neurol\u00f3gica \u00a0comunicada \u00a0es\u00a0moderada. \u00a0Este\u00a0autor,\u00a0recomienda\u00a0 que\u00a0ante\u00a0la\u00a0\nausencia\u00a0de\u00a0un\u00a0aum\nento\u00a0a\u00a0los\u00a0pacientes \u00a0con\u00a0 traumatismos \u00a0raqu\u00eddeos \u00a0y\u00a0lesiones\u00a0medulares, \u00a0\nen\u00a0las\u00a0primeras\u00a08\u00a0horas.\u00a0 Estos\u00a0 resultados \u00a0s\u00f3lo\u00a0se\u00a0aplican\u00a0a\u00a0los\u00a0traumatismos \u00a0\naislados\u00a0del\u00a0raquis\u00a0 y\u00a0conviene\u00a0ser\u00a0prudente \u00a0con\u00a0los\u00a0politraumatizados, \u00a0en\u00a0los\u00a0que\u00a0\nlos\u00a0CTC\u00a0podr\u00edan\u00a0 ser\u00a0 contraproducentes. \u00a0En\u00a0un\u00a0estudio\u00a0m\u00e1s\u00a0reciente\u00a0que\u00a0\ncomparaba\u00a0 la\u00a0administraci\u00f3n \u00a0de\u00a0MP\u00a0durante\u00a048\u00a0horas,\u00a0frente\u00a0a\u00a024\u00a0horas,\u00a0se\u00a0\nevidenci\u00f3 \u00a0u\u00a0aumento\u00a0significativo\u00a0 de\u00a0complicaciones\u00a0 infecciosas \u00a0\u00a0\n\u00a0\nSeg\u00fan\u00a0el\u00a0protocolo\u00a0 de\u00a0actuaci\u00f3n\u00a0 establecido \u00a0en\u00a0el\u00a0estudio,\u00a0la\u00a0\nadministraci\u00f3n \u00a0de\u00a0CTC\u00a0a\u00a0altas\u00a0dosis,\u00a0siguiendo \u00a0como\u00a0pauta\u00a0el\u00a0protocolo\u00a0 del\u00a0\nestudio\u00a0NASCIS\u00a0II,\u00a0se\u00a0aplic\u00f3\u00a0a\u00a0todos\u00a0aquellos\u00a0 pacientes \u00a0que\u00a0no\u00a0presentaban \u00a0\ncriterios\u00a0de\u00a0exclusi\u00f3n\u00a0 (LMA\u00a0penetrante \u00a0o\u00a0inicio\u00a0de\u00a0tratamiento \u00a0en\u00a0las\u00a08\u00a0horas\u00a0\nposteriores \u00a0al\u00a0ev nto), con\u00a0independencia \u00a0de\u00a0si\u00a0posteriormente \u00a0se\u00a0decidiera un\u00a0\ntratamiento \u00a0conservador \u00a0o\u00a0quir\u00fargico. \u00a0Existe\u00a0poca\u00a0literatura \u00a0respecto\u00a0al\u00a0uso\u00a0de\u00a0\nCTC\u00a0en\u00a0LMA\u00a0penetrante, \u00a0con\u00a0estudios\u00a0retrospectivos \u00a0posteriores \u00a0que\u00a0evidencian \u00a0\nuna\u00a0alta\u00a0tasa\u00a0de\u00a0complicaciones \u00a0y\u00a0ausencia\u00a0de\u00a0beneficios; \u00a0por\u00a0ello\u00a0no\u00a0se\u00a0emplean\u00a0\nCTC\u00a0en\u00a0LMA\u00a0penetrante \u00a0en\u00a0nuestra\u00a0Unidad\u00a0 (\n\u00a0 139de\u00a045\u00a0minutos,\u00a0inicio\u00a0de\u00a0una\u00a0perfusi\u00f3n \u00a0de\u00a05,4\u00a0mgr/Kg/hora\u00a0 durante\u00a0las\u00a023\u00a0\nhoras\u00a0siguientes. \u00a0\n\u00a0\nEn\u00a0este\u00a0trabajo,\u00a0en\u00a0el\u00a070,83%\u00a0 de\u00a0los\u00a0casos\u00a0se\u00a0aplic\u00f3\u00a0el\u00a0protocolo\u00a0 del\u00a0\nestudio\u00a0NASCIS\u00a0II,\u00a0no\u00a0emple\u00e1ndose \u00a0en\u00a028\u00a0pacientes \u00a0(29,17%). \u00a0Las\u00a0causas\u00a0de\u00a0\nexclusi\u00f3n\u00a0 a\u00a0la\u00a0hora\u00a0 de\u00a0administrar \u00a0la\u00a0pauta\u00a0de\u00a0CTC\u00a0en\u00a0nuestra\u00a0cohorte\u00a0fue\u00a0la\u00a0\npresencia \u00a0de\u00a0LMA\u00a0penetrante, \u00a0decisi\u00f3n\u00a0del\u00a0facultativo \u00a0responsable \u00a0de\u00a0la\u00a0Unidad\u00a0\nde\u00a0no\u00a0emplearlo \u00a0por\u00a0el\u00a0nivel\u00a0de\u00a0evidencia \u00a0m\u00e9dica\u00a0 disponible \u00a0o\u00a0un\u00a0ingreso\u00a0en\u00a0la\u00a0\nUR\u00a0en\u00a0las\u00a08\u00a0horas\u00a0posteriores \u00a0al\u00a0evento.\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nn II\u00a0\nen\u00a0atender\u00a0al\u00a0\npaciente,\u00a0 al\u00a085.9%\u00a0emplear\u00eda\u00a0 este\u00a0protocolo\u00a0 solo\u00a0si\u00a0han\u00a0transcurrido \u00a0menos\u00a0de\u00a08\u00a0\nhoras\u00a0d y o\na\u00a0los\u00a0estudios\u00a0NASCIS\u00a0es\u00a0muy\u00a0amplia,\u00a0justific\u00e1ndose \u00a0\nfundamentalmente \u00a0en\u00a0la\u00a0imposibilidad \u00a0a\u00a0la\u00a0hora\u00a0 de\u00a0reproducir \u00a0los\u00a0resultados \u00a0\naporta\nizados,\u00a0recibiendo \u00a025\u00a0mgr\u00a0 o\u00a0250\u00a0\nmgr\u00a0 de\u00a0cada\u00a06\u00a0horas\u00a0durante\u00a010\u00a0d\u00edas,\u00a0previa\u00a0 administraci\u00f3n \u00a0de\u00a0un\u00a0bolo\u00a0En\u00a0la\u00a0literatura \u00a0existe\u00a0un\u00a0amplio\u00a0debate\u00a0sobre\u00a0los\u00a0riesgos\u00a0y\u00a0beneficios \u00a0del\u00a0\nempleo\u00a0de\u00a0megadosis \u00a0de\u00a0CTC\u00a0en\u00a0lesionados \u00a0medulares,\u00a0 siendo\u00a0la\u00a0principal\u00a0\njustificaci\u00f3 \u00a0al\u00a0empleo\u00a0del\u00a0 protocolo\u00a0 NASCIS\u00a0 \u00a0lasrazones\u00a0medico\u2010legales\u00a0\n(119,120) .\u00a0En\u00a0el\u00a0trabajo\u00a0Jackson\u00a0 et\u00a0al\u00a0(120) ,\u00a0el\u00a0cual\u00a0 envi\u00f3\u00a0una\u00a0encuesta\u00a0 a\u00a0los\u00a0\nfacultativos \u00a0m\u00e9dicos\u00a0responsables \u00a0de\u00a0pacientes \u00a0con\u00a0 lesiones\u00a0medulares, \u00a0\npreguntando \u00a0acerca\u00a0de\u00a0su\u00a0especialidad, \u00a0centro\u00a0traumatol\u00f3gico \u00a0de\u00a0referencia, \u00a0uso\u00a0\ndel\u00a0protocolo\u00a0 de\u00a0CTC\u00a0as\u00ed\u00a0como\u00a0justificaci\u00f3n \u00a0de\u00a0tal\u00a0uso\u00a0y\u00a0n\u00famero\u00a0de\u00a0pacientes \u00a0\nlesionados \u00a0medulares \u00a0tratados.\u00a0Se\u00a0recibieron \u00a0305\u00a0cuestionarios, \u00a0obteni\u00e9ndose \u00a0\nque\u00a0un\u00a04.6%\u00a0de\u00a0ellos\u00a0empleaban \u00a0CTC\u00a0solo\u00a0si\u00a0eran\u00a0los\u00a0primeros\u00a0\nesde\u00a0el\u00a0evento,\u00a0el\u00a06.6%\u00a0\u00a0no\u00a0lo\u00a0utilizaban \u00a0nunca\u00a0CTC\u00a0 \u00a0sol\u00a0un\u00a03%\u00a0de\u00a0ellos\u00a0\nempleaban \u00a0una\u00a0protocolo\u00a0 diferente \u00a0al\u00a0del\u00a0estudio\u00a0 NASCIS.\u00a0La\u00a0justificaci\u00f3n \u00a0del\u00a0uso\u00a0\nse\u00a0bas\u00f3\u00a0 en\u00a0\u00a0mejor\u00eda\u00a0del\u00a0paciente\u00a0tras\u00a0el\u00a0tratamiento \u00a0(65\u00a0cirujanos), \u00a0protocolo \u00a0\nestablecido \u00a0en\u00a0el\u00a0centro\u00a0de\u00a0trabajo\u00a0(64\u00a0cirujanos), \u00a0razones\u00a0medicolegales \u00a0(110\u00a0\ncirujanos) \u00a0y\u00a026\u00a0cirujanos\u00a0 no\u00a0emplear\u00edan \u00a0este\u00a0tratamiento \u00a0m\u00e9dico;\u00a018\u00a0de\u00a0los\u00a0\nencuestados \u00a0justificaban \u00a0su\u00a0uso\u00a0en\u00a0la\u00a0mejor\u00eda\u00a0 cl\u00ednica\u00a0unido\u00a0 al\u00a0protocolo \u00a0\nestablecido \u00a0en\u00a0su\u00a0centro\u00a0de\u00a0trabajo\u00a0y\u00a0en\u00a022\u00a0de\u00a0las\u00a0encuestas \u00a0la\u00a0justificaci\u00f3n \u00a0de\u00a0su\u00a0\nuso\u00a0ven\u00eda\u00a0dada\u00a0por\u00a0el\u00a0protocolo\u00a0 establecido \u00a0en\u00a0el\u00a0lugar\u00a0de\u00a0trabajo\u00a0unido\u00a0 a\u00a0\nrazones\u00a0m\u00e9dicolegales. \u00a0La\u00a0mayor\u00eda\u00a0 de\u00a0los\u00a0encuestados\u00a0 (90.5%)\u00a0empleaban \u00a0el\u00a0\nprotocolo\u00a0 de\u00a0CTC.\u00a0\u00a0\n\u00a0\nLa\u00a0cr\u00edtica\u00a0\u00a0\ndos\u00a0por\u00a0estos\u00a0estudios,\u00a0la\u00a0falta\u00a0de\u00a0placebo\u00a0 en\u00a0el\u00a0estudio\u00a0NASCIS\u00a0III\u00a0y\u00a0\nposibles\u00a0errores\u00a0estad\u00edsticos \u00a0en\u00a0los\u00a0estudios\u00a0NASCIS\u00a0II\u00a0y\u00a0III.\u00a0El\u00a0tratamiento \u00a0con\u00a0\nmegadosis \u00a0de\u00a0CTC\u00a0en\u00a0LMA\u00a0se\u00a0constituyo \u00a0como\u00a0tratamiento \u00a0de\u00a0elecci\u00f3n\u00a0 tras\u00a0\npublicarse \u00a0los\u00a0resultados \u00a0preliminares \u00a0del\u00a0estudio\u00a0 NASCIS\u00a0II\u00a0en\u00a01990\u00a0(47).\u00a0Sin\u00a0\nembargo, \u00a0los\u00a0resultados \u00a0del\u00a0primer\u00a0estudio\u00a0NASCIS\u00a0fueron\u00a0publicados \u00a0en\u00a01984\u00a0\n(48).\u00a0Un\u00a0total\u00a0 de\u00a0330\u00a0pacientes \u00a0fueron\u00a0random\n\u00a0 140\u00a0MPIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0intrave\ny\u00a0as\u00ed\u00a0los\u00a0lazaroides, \u00a0derivados \u00a0de\u00a0s\u00edntesis\u00a0de\u00a0los\u00a0CTC,\u00a0\nexperimentalmente \u00a0inhiben\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0potente\u00a0la\u00a0peroxidaci\u00f3n \u00a0lip\u00eddica\u00a0de\u00a0\nmembr\n\u00a0\u00a0noso\u00a0de\u00a0100\u00a0mgr.\u00a0No\u00a0se\u00a0apreciaron \u00a0diferencias\u00a0 cl\u00ednicas\u00a0 entre\u00a0los\u00a0dos\u00a0\ngrupos,\u00a0pero\u00a0solo\u00a0en\u00a0un\u00a054%\u00a0de\u00a0los\u00a0pacientes \u00a0se\u00a0pudo\u00a0 continuar \u00a0su\u00a0evoluci\u00f3n \u00a0\ntranscurridos\u00a0 6\u00a0meses.\u00a0No\u00a0se\u00a0apreciaron \u00a0diferencias\u00a0 en\u00a0la\u00a0mejor\u00eda\u00a0 cl\u00ednica\u00a0entre\u00a0\nlos\u00a0dos\u00a0grupos,\u00a0sin\u00a0embargo\u00a0\u00a0en\u00a0el\u00a0grupo\u00a0que\u00a0recibi\u00f3\u00a0una\u00a0mayor\u00a0 dosis\u00a0de\u00a0CTC\u00a0si\u00a0\nexisti\u00f3\u00a0una\u00a0mayor\u00a0 incidencia \u00a0de\u00a0infecciones, \u00a0sepsis,\u00a0embolia\u00a0pulmonar \u00a0y\u00a0muerte,\u00a0\nsin\u00a0ser\u00a0estas\u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significativas. \u00a0Los\u00a0resultados \u00a0de\u00a0los\u00a0\nestudios\u00a0NASCIS\u00a0no\u00a0se\u00a0pueden\u00a0aplicar\u00a0a\u00a0pacientes\u00a0 LMA\u00a0y\u00a0con\u00a0m\u00faltiples \u00a0lesiones\u00a0\nsist\u00e9micas, \u00a0en\u00a0los\u00a0cuales\u00a0el\u00a0riesgo\u00a0de\u00a0complicaciones \u00a0es\u00a0notablemente \u00a0mayor\u00a0 que\u00a0\nen\u00a0aquellos\u00a0con\u00a0LMA\u00a0aislada.\u00a0Este\u00a0tipo\u00a0de\u00a0pacientes\u00a0 no\u00a0fueron\u00a0espec\u00edficamente \u00a0\nexcluidos\u00a0 de\u00a0los\u00a0estudios\u00a0NASCIS,\u00a0 pero\u00a0tuvieron\u00a0en\u00a0ellos\u00a0escasa\u00a0representaci\u00f3n. \u00a0\n\u00a0En\u00a02002,\u00a0bas\u00e1ndose \u00a0en\u00a0la\u00a0evidencia \u00a0cient\u00edfica\u00a0disponible, \u00a0la\u00a0Asociaci\u00f3n \u00a0\nAmericana \u00a0de\u00a0Neurocirujanos \u00a0concluy\u00f3\u00a0que\u00a0el\u00a0uso\u00a0de\u00a0CTC\u00a0en\u00a0LMA\u00a0es\u00a0\nrecomendado \u00a0solo\u00a0como\u00a0una\u00a0opci\u00f3n\u00a0m\u00e1s\u00a0de\u00a0tratamiento; \u00a0asimismo \u00a0otras\u00a0\nasociaciones \u00a0canadienses \u00a0y\u00a0americanas,\u00a0 indican\u00a0que\u00a0el\u00a0tratamiento \u00a0con\u00a0 CTC\u00a0es\u00a0\nuna\u00a0opci\u00f3n\u00a0m\u00e9dica\u00a0pero\u00a0no\u00a0un\u00a0tratamiento \u00a0est\u00e1ndar. \u00a0La\u00a0\u00faltima\u00a0conferencia \u00a0de\u00a0\nexpertos\u00a0franceses \u00a0ha\u00a0excluido\u00a0el\u00a0empleo\u00a0de\u00a0altas\u00a0 dosis\u00a0de\u00a0MP\u00a0en\u00a0la\u00a0LMA\u00a0(72).\u00a0\n\u00a0\nM\u00faltiples\u00a0 f\u00e1rmacos\u00a0se\u00a0han\u00a0postulado \u00a0como\u00a0tratamiento \u00a0para\u00a0minimizar \u00a0la\u00a0\nLS\u00a0tras\u00a0la\u00a0LMAT,\u00a0\n\u00a0 141ana\u00a0sin\u00a0producir\u00a0efectos\u00a0glucocorticoides.\u00a0 Desafortunadamente, \u00a0los\u00a0\nresultados \u00a0de\u00a0los\u00a0ensayos\u00a0cl\u00ednicos\u00a0de\u00a0uno\u00a0de\u00a0ellos,\u00a0el\u00a0tirilazad,\u00a0son\u00a0\ndecepcionantes, \u00a0ya\u00a0que\u00a0no\u00a0han\u00a0demostrado \u00a0su\u00a0superioridad \u00a0con\u00a0respecto\u00a0a\u00a0la\u00a0MP\u00a0\n(53,54) .\u00a0Recientemente, \u00a0los\u00a0antagonistas \u00a0del\u00a0calcio\u00a0se\u00a0han\u00a0 estudiado \u00a0por\u00a0sus\u00a0\nefectos\u00a0beneficiosos \u00a0durante\u00a0la\u00a0isquemia. \u00a0En\u00a0un\u00a0traumatismo \u00a0medular\u00a0\nexperimental,\u00a0 el\u00a0nimodipino \u00a0produce,\u00a0por\u00a0su\u00a0acci\u00f3n\u00a0sist\u00e9mica, \u00a0una\u00a0disminuci\u00f3n \u00a0\nde\u00a0la\u00a0presi\u00f3n\u00a0 arterial\u00a0y\u00a0del\u00a0flujo\u00a0sangu\u00edneo \u00a0medular,\u00a0 pero\u00a0s\u00f3lo\u00a0la\u00a0administraci\u00f3n \u00a0\nconjunta\u00a0de\u00a0un\u00a0vasopresor \u00a0permite\u00a0observar\u00a0 los\u00a0efectos\u00a0beneficiosos \u00a0de\u00a0este\u00a0\nf\u00e1rmaco.\u00a0 Hasta\u00a0la\u00a0fecha,\u00a0ning\u00fan\u00a0estudio\u00a0cl\u00ednico\u00a0ha\u00a0demostrado \u00a0su\u00a0inter\u00e9s\u00a0enIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nseres\u00a0humanos \u00a0con\u00a0 traumatismo \u00a0medular.\u00a0El\u00a0bloqueo\u00a0 de\u00a0los\u00a0receptores \u00a0del\u00a0N\u2010\nmetil\u2010 D\u2010aspartato \u00a0(NMDA)\u00a0 parece\u00a0disminuir \u00a0las\u00a0consecuencias \u00a0de\u00a0la\u00a0isquemia\u00a0\nnerviosa.\u00a0Entre\u00a0los\u00a0f\u00e1rmacos\u00a0antagonistas \u00a0de\u00a0estos\u00a0receptores \u00a0NMDA\u00a0est\u00e1n\u00a0el\u00a0\ndextrorfano, \u00a0el\u00a0MK\u2010801,\u00a0magnesio \u00a0y\u00a0ketamina. \u00a0Aunque\u00a0ciertos\u00a0trabajos\u00a0\nexperimentales \u00a0brinden\u00a0esperanza, \u00a0no\u00a0se\u00a0ha\u00a0realizado\u00a0ning\u00fan\u00a0estudio\u00a0cl\u00ednico\u00a0\nsobre\u00a0estas\u00a0sustancias \u00a0(55\u201058).\u00a0La\u00a0naloxona, \u00a0que\u00a0fue\u00a0objeto\u00a0de\u00a0muchos\u00a0trabajos\u00a0\nexperimentales, \u00a0se\u00a0ha\u00a0mostrado \u00a0ineficaz\u00a0 en\u00a0la\u00a0cl\u00ednica.\u00a0Un\u00a0estudio\u00a0cl\u00ednico\u00a0\npreliminar \u00a0ha\u00a0demostrado \u00a0el\u00a0inter\u00e9s\u00a0potencial \u00a0de\u00a0un\u00a0gangli\u00f3sido \u00a0(GM\u20101)\u00a0despu\u00e9s\u00a0\nde\u00a0traumatismo \u00a0medular\u00a0 en\u00a0seres\u00a0humanos, \u00a0no\u00a0obstante, \u00a0el\u00a0peque\u00f1o\u00a0n\u00famero\u00a0de\u00a0\npacientes \u00a0incluidos\u00a0limita\u00a0considerablemente \u00a0el\u00a0alcance\u00a0de\u00a0este\u00a0estudio,\u00a0con\u00a0 la\u00a0\ndesventaja\u00a0 de\u00a0estar\u00a0 incriminados \u00a0en\u00a0la\u00a0producci\u00f3n \u00a0de\u00a0s\u00edndromes \u00a0de\u00a0Guillain\u2010\nBarr\u00e9.\u00a0\ns \u00a0\nia\u00a0\nhiperb\u00e1rica. \u00a0\nlar\u00a0\u00a0La\u00a0eritropoyetina \u00a0ha\u00a0producido\u00a0 efectos\u00a0interesantes \u00a0en\u00a0modelos\u00a0\nexperimentales, \u00a0tal\u00a0 vez\u00a0en\u00a0relaci\u00f3n\u00a0a\u00a0us\u00a0 efectos antiapopt\u00f3sicos, \u00a0\nantiinflamatorios \u00a0y\u00a0antirradicales\u00a0 libres.\u00a0 Otras\u00a0terap\u00e9uticas \u00a0investigadas \u00a0han\u00a0sido\u00a0\nla\u00a0hormona\u00a0liberadora \u00a0de\u00a0tirotrofina, \u00a0dimetil\u00a0sulf\u00f3xido, \u00a0diur\u00e9ticos, \u00a0\nsimpaticol\u00edticos, \u00a0lidoca\u00edna\u00a0y\u00a0otros\u00a0muchos\u00a0m\u00e1s.\u00a0Entre\u00a0los\u00a0tratamientos \u00a0no\u00a0\nfarmacol\u00f3gicos \u00a0podemos\u00a0 citar\u00a0 la\u00a0hipotermia \u00a0local\u00a0profunda \u00a0y\u00a0la\u00a0oxigenoterap\n\u00a0 142\u00a0\u00a0\u00a0\n5.4. INTERVENCI\u00d3N \u00a0QUIR\u00daRGICA\u00a0\n\u00a0\nLas\u00a0indicaciones \u00a0quir\u00fargicas \u00a0dependen \u00a0de\u00a0la\u00a0existencia \u00a0de\u00a0signos\u00a0de\u00a0d\u00e9ficit\u00a0\nneurol\u00f3gicos \u00a0y\u00a0de\u00a0la\u00a0presencia \u00a0de\u00a0las\u00a0lesiones\u00a0osteoligamentarias \u00a0que\u00a0\u00a0conllevan \u00a0\nun\u00a0grado\u00a0de\u00a0desplazamiento \u00a0y\u00a0estabilidad \u00a0variable\u00a0en\u00a0cada\u00a0caso\u00a0de\u00a0forma\u00a0\nindividual. \u00a0\n\u00a0Existe\u00a0una\u00a0cierta\u00a0concordancia \u00a0entre\u00a0los\u00a0diferentes \u00a0grupos\u00a0 de\u00a0trabajo\u00a0en\u00a0\nla\u00a0consideraci\u00f3n \u00a0de\u00a0una\u00a0urgencia\u00a0 quir\u00fargica \u00a0en\u00a0el\u00a0supuesto\u00a0que\u00a0la\u00a0lesi\u00f3n\u00a0meduIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nes\u00a0incompleta \u00a0o\u00a0se\u00a0percibe\u00a0un\u00a0agravamiento \u00a0progresivo \u00a0en\u00a0las\u00a0primeras\u00a0horas.\u00a0\nPor\u00a0el\u00a0contrario, \u00a0existe\u00a0una\u00a0importante \u00a0\u00e1rea\u00a0de\u00a0incertidumbre, \u00a0y\u00a0hasta\u00a0cierta\u00a0\npol\u00e9mica\u00a0 respecto\u00a0a\u00a0la\u00a0actitud\u00a0 quir\u00fargica \u00a0de\u00a0entrada\u00a0en\u00a0las\u00a0lesiones\u00a0medulares \u00a0\ncompletas.\u00a0 Elestudio\u00a0de\u00a0Heiden\u00a0et\u00a0al\u00a0(217)\u00a0detectaron \u00a0que\u00a0las\u00a0compl caciones \u00a0\naparec\u00edan \u00a0con\u00a0mayor\u00a0 frecuencia \u00a0en\u00a0aquellos\u00a0 pacientes \u00a0intervenidos \u00a0en\u00a0la\u00a0primera\u00a0\nsemana\u00a0tras\u00a0el\u00a0traumatismo \u00a0medular\u00a0que\u00a0respecto\u00a0de\u00a0aquellos\u00a0donde\u00a0la\u00a0\nintervenci\u00f3n \u00a0quir\u00fargica \u00a0se\u00a0realiz\u00f3\u00a0\u00a0tras\u00a0transcurridos \u00a0siete\u00a0d\u00edas\u00a0o\u00a0m\u00e1s\u00a0(47%\u00a0versus\u00a0\n27%).\u00a0El\u00a0grupo\u00a0de\u00a0Marshall\u00a0 et\u00a0al\u00a0(218)\u00a0reporta\u00a0 un\u00a0empeoramiento \u00a0neurol\u00f3gico \u00a0\npostoperatorio \u00a0en\u00a0el\u00a015\u00a0%\u00a0de\u00a0los\u00a0casos\u00a0operados \u00a0en\u00a0los\u00a05\u00a0primeros\u00a0d\u00edas,\u00a0mientras\u00a0\nque\u00a0no\u00a0se\u00a0ha\u00a0detectado \u00a0ning\u00fan\u00a0deterioro \u00a0neurol\u00f3gico \u00a0en\u00a0los\u00a0pacientes \u00a0operados \u00a0\nm\u00e1s\u00a0tarde.\u00a0Estos\u00a0 estudios\u00a0han\u00a0 llevado\u00a0a\u00a0muchos\u00a0equipos\u00a0norteamericanos \u00a0a\u00a0no\u00a0\npracticar\u00a0y\u00a0la\u00a0IQ\u00a0con\u00a0car\u00e1cter\u00a0de\u00a0urgencia.\u00a0Por\u00a0el\u00a0contrario, \u00a0 \u00a0 grupos,\u00a0\nconsideran\u00a0 que\u00a0la\u00a0IQ\u00a0ebe\u00a0 rse\u00a0si\u00a0es\u00a0 le,\u00a0e\u00a0las\u00a06\u00a0horas\u00a0siguientes \u00a0al\u00a0\ntraumatismo. \u00a0El\u00a0trabajo\u00a0de\u00a0Wilberger\u00a0 (79)\u00a0compara\u00a0 las\u00a0intervenciones \u00a0precoces\u00a0\n(menos\u00a0de\u00a024\u00a0 oras)\u00a0y\u00a0tard\u00edas\u00a0despu\u00e9s\u00a0de\u00a0untraumatismo \u00a0medula\u00a0cervical,\u00a0y\u00a0\nhalla\u00a0una\u00a0disminuci\u00f3n \u00a0significativa \u00a0del\u00a0porcentaje \u00a0de\u00a0\u00a0neuropat\u00edas\u00a0 (21%\u00a0frente\u00a0al\u00a0\n10\u00a0%),\u00a0tromboflebitis \u00a0(11%\u00a0frente\u00a0al\u00a00\u00a0%),\u00a0embolias\u00a0 pulmonares\u00a0 (5%\u00a0frente\u00a0 al\u00a00\u00a0%)\u00a0\ny\u00a0de\u00a0diversas\u00a0 i\na otros\nd realiza posib n\nh \u00a0 r\n\u00a0complicaciones\u00a0 asociadas\u00a0 al\u00a0dec\u00fabito\u00a0(16%\u00a0frente\u00a0al\u00a010\u00a0%)\u00a0en\u00a0los\u00a0\npacientes \u00a0operados \u00a0precozmente. \u00a0Este\u00a0trabajo\u00a0destaca\u00a0 que\u00a0la\u00a0cirug\u00eda\u00a0se\u00a0asocia\u00a0a\u00a0\nuna\u00a0mortalidad\u00a0 perioperatoria\u00a0 baja,\u00a0con\u00a0 una\u00a0incidencia \u00a0inferior\u00a0al\u00a02%.\u00a0No\u00a0\nobstante, \u00a0a\u00a0veces\u00a0es\u00a0necesario \u00a0contraindicar \u00a0una\u00a0IQ\u00a0precoz\u00a0debido\u00a0 al\u00a0riesgo\u00a0vital\u00a0\ns\u00a0asociadas.\u00a0 Esencialmente \u00a0se\u00a0trata\u00a0 de\u00a0\ntraumatismos \u00a0graves\u00a0del\u00a0raquis\u00a0 dorsal\u00a0que\u00a0se\u00a0asocian\u00a0a\u00a0contusi\u00f3n \u00a0pulmonar \u00a0\ngrave.\u00a0\u00a0\n\u00a0beneficio \u00a0de\u00a0la\u00a0cirug\u00eda\u00a0iniciada\u00a0en\u00a0las\u00a06\u00a0primeras\u00a0horas.\u00a0Por\u00a0el\u00a0\ncontrario, \u00a0es\u00a0posible\u00a0que\u00a0una\u00a0cirug\u00eda\u00a0 efectuada \u00a0despu\u00e9s\u00a0de\u00a024\u00a0horas\u00a0 pueda\u00a0\nagravapreoperatorio \u00a0o\u00a0a\u00a0las\u00a0lesiones\u00a0traum\u00e1tica\n\u00a0\nLos\u00a0argumentos \u00a0experimentales \u00a0permiten \u00a0pensar\u00a0 que\u00a0no\u00a0es\u00a0razonable \u00a0\nesperar\u00a0un\n\u00a0 143r\u00a0las\u00a0lesiones\u00a0medulares. \u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0neurol\u00f3gica \u00a0sin\u00a0realizar\u00a0 descompresi\u00f3n/estabilizaci\u00f3n, \u00a0lo\u00a0que\u00a0lleva\u00a0a\u00a0\npensar que\u00a0la\u00a0demora\u00a0en\u00a0la\u00a0cirug\u00eda\u00a0o\u00a0la\u00a0no\u00a0realizaci\u00f3n\u00a0 de\u00a0la\u00a0misma,\u00a0en\u00a0\ncombin\nultic\u00e9ntricos, \u00a0que\u00a0proporcionaran\u00a0 un\u00a0buen\u00a0 nivel\u00a0\u00a0\nde\u00a0evidencia. \u00a0Pero\u00a0el\u00a0mayor\u00a0 problema \u00a0a\u00a0este\u00a0respecto\u00a0es\u00a0que\u00a0muchos\u00a0cirujanos\u00a0\u00a0El\u00a0primer\u00a0tiempo\u00a0de\u00a0la\u00a0descompresi\u00f3n \u00a0es\u00a0la\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0deformaci\u00f3n \u00a0\nraqu\u00eddea\u00a0que\u00a0devuelve\u00a0al\u00a0canal\u00a0 raqu\u00eddeo\u00a0su\u00a0forma\u00a0normal\u00a0 y\u00a0libera\u00a0as\u00ed\u00a0la\u00a0m\u00e9dula.\u00a0\nEl\u00a0acceso\u00a0posterior\u00a0es\u00a0el\u00a0que\u00a0m\u00e1s\u00a0se\u00a0suele\u00a0utilizar\u00a0para\u00a0el\u00a0tratamiento \u00a0urgente\u00a0de\u00a0\nlas\u00a0lesiones\u00a0de\u00a0la\u00a0columna\u00a0dorsal\u00a0y\u00a0lumbar.\u00a0En\u00a0las\u00a0lesiones\u00a0cervicales, \u00a0la\u00a0v\u00eda\u00a0de\u00a0\nacceso\u00a0anterior\u00a0es\u00a0m\u00e1s\u00a0f\u00e1cil\u00a0 que\u00a0en\u00a0los\u00a0dem\u00e1s\u00a0segmentos \u00a0raqu\u00eddeos. \u00a0Para\u00a0\nestabilizar \u00a0la\u00a0reducci\u00f3n \u00a0se\u00a0precisa\u00a0de\u00a0una\u00a0osteos\u00edntesis, \u00a0la\u00a0mayor\u00eda\u00a0de\u00a0las\u00a0veces\u00a0\nposterior, \u00a0utilizando \u00a0placas\u00a0o\u00a0v\u00e1stagos\u00a0atornillados \u00a0en\u00a0los\u00a0ped\u00edculos \u00a0vertebrales. \u00a0\n\u00a0\nDe\u00a0los\u00a096\u00a0pacientes\u00a0 de\u00a0nuestro\u00a0estudio,\u00a0se\u00a0realiz\u00f3\u00a0intervenci\u00f3n \u00a0quir\u00fargica \u00a0\nen\u00a047\u00a0pacientes, \u00a0consistiendo \u00a0dicha\u00a0cirug\u00eda\u00a0en\u00a0una\u00a0artrodesis \u00a0posterior\u00a0en\u00a026\u00a0\npacientes, \u00a0una\u00a0artrodesis \u00a0anterior\u00a0en\u00a016\u00a0pacientes \u00a0y\u00a0una\u00a0artrodesis \u00a0mixta\u00a0 en\u00a05\u00a0\npacientes.\u00a0 El\u00a0per\u00edodo\u00a0de\u00a0tiempo,\u00a0expresado \u00a0en\u00a0d\u00edas,\u00a0transcurrido \u00a0entre\u00a0el\u00a0ingreso\u00a0\nen\u00a0la\u00a0Unidad\u00a0 y\u00a0la\u00a0IQ\u00a0fue\u00a0de\u00a03,59\u00a0\u00b1\u00a02,42\u00a0d\u00edas.\u00a0Respecto\u00a0al\u00a0tratamiento \u00a0quir\u00fargico, \u00a0\nse\u00a0demor\u00f3\u00a0en\u00a026\u00a0pacientes \u00a0(27,08%)\u00a0por\u00a0las\u00a0lesiones\u00a0asociadas \u00a0a\u00a0la\u00a0lesi\u00f3n\u00a0\nraqu\u00eddea\u00a0y\u00a0por\u00a0individualizaci\u00f3n \u00a0del\u00a0caso,\u00a0 y\u00a0no\u00a0se\u00a0realiz\u00f3\u00a0en\u00a023\u00a0pacientes \u00a0\n(23,96%). \u00a0\u00a0\n\u00a0El\u00a0tiempo\u00a0de\u00a0realizar\u00a0 una\u00a0descompresi\u00f3n\u00a0 tras\u00a0LMA\u00a0es\u00a0uno\u00a0de\u00a0los\u00a0puntos\u00a0\nm\u00e1s\u00a0controvertidos \u00a0en\u00a0el\u00a0tratamiento \u00a0quir\u00fargico \u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0 LMA.\u00a0\nBas\u00e1ndose \u00a0en\u00a0un\u00a0meta\u2010an\u00e1lisis\u00a0de\u00a0la\u00a0literatura, \u00a0Fehlings\u00a0et\u00a0al,\u00a0mostraron\u00a0 que\u00a0\nexiste\u00a0beneficio\u00a0 tras\u00a0la\u00a0descompresi\u00f3n \u00a0precoz,\u00a0tras\u00a0objetivarse \u00a0compresi\u00f3n \u00a0\nmedular;\u00a0pero\u00a0esos\u00a0\u00a0datos\u00a0 no\u00a0se\u00a0han\u00a0reproducido \u00a0en\u00a0humanos \u00a0(121) .\u00a0Tambi\u00e9n\u00a0 es\u00a0\ncierto,\u00a0que\u00a0estudios\u00a0con\u00a0tratamiento \u00a0conservador \u00a0ante\u00a0LMA\u00a0han\u00a0 mostrado \u00a0\nmejor\u00eda\n\u00a0\n\u00a0 144aci\u00f3n\u00a0con\u00a0 varias\u00a0terapias\u00a0farmacol\u00f3gicas, \u00a0puede\u00a0ser\u00a0el\u00a0camino\u00a0a\u00a0seguir\u00a0\nante\u00a0una\u00a0LMA.\u00a0Ser\u00eda\u00a0 necesario \u00a0definir\u00a0cu\u00e1l\u00a0 es\u00a0el\u00a0momento \u00a0id\u00f3neo\u00a0en\u00a0el\u00a0que\u00a0se\u00a0\ndebe\u00a0proceder\u00a0a\u00a0la\u00a0cirug\u00eda\u00a0 tras\u00a0LMA,\u00a0mediante \u00a0estudios\u00a0bien\u00a0dise\u00f1ados, \u00a0\nprospectivos, \u00a0randomizados \u00a0y\u00a0mIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\npresen\n5.5. U\n\u00a0Los\u00a0datos\u00a0de\u00a0los\u00a0\u00faltimos\u00a0estudios\u00a0ENVIN\u2010UCI\u00a0parecen\u00a0mostrar\u00a0una\u00a0\ntendencia \u00a0a\u00a0un\u00a0aumento\u00a0en\u00a0la\u00a0IN\u00a0y\u00a0de\u00a0la\u00a0resistencia \u00a0a\u00a0antibi\u00f3ticos \u00a0de\u00a0algunos\u00a0\nmicroorganismos \u00a0(124) .\u00a0Este\u00a0estudio\u00a0espa\u00f1ol\u00a0incluye\u00a0a\u00a0pacientes\u00a0 con\u00a0estancia\u00a0en\u00a0\nUC\u00a0superior\u00a0a\u00a024\u00a0horas,\u00a0y\u00a0presenta\u00a0unas\u00a0ratio\u00a0de\u00a0empleo\u00a0de\u00a0dispositivos \u00a0m\u00e9dicos\u00a0\nen\u00a0los\u00a0pacientes \u00a0traum\u00e1ticos\u00a0 de,\u00a0respecto\u00a0a\u00a0la\u00a0utilizaci\u00f3n \u00a0de\u00a0VM,\u00a050\u00a0al\u00a055%;\u00a0de\u00a0\nsonda\u00a0vesical\u00a0 con\u00a0sistema\u00a0urinario\u00a0cerrado\u00a0del\u00a079,6\u00a0al\u00a084,8%\u00a0y\u00a0una\u00a0proporci\u00f3n \u00a0de\u00a0\nuso\u00a0de\u00a0cat\u00e9teres \u00a0vasculares \u00a0del\u00a0113\u00a0al\u00a0126%.\u00a0Respecto\u00a0a\u00a0este\u00a0trabajo,\u00a0destaca\u00a0 la\u00a0\nmayor\u00a0 proporci\u00f3n \u00a0de\u00a0empleo\u00a0de\u00a0sondaje\u00a0urinario\u00a0en\u00a0nuestra\u00a0cohorte\u00a0y\u00a0una\u00a0\nmenor\u00a0tasa\u00a0de\u00a0uso\u00a0de\u00a0cat\u00e9teres \u00a0venosos\u00a0centrales\u00a0y/o\u00a0arteriales, \u00a0este\u00a0hecho\u00a0es\u00a0\nexplicado \u00a0por\u00a0la\u00a0alta\u00a0necesidad\u00a0 de\u00a0cateterizaci\u00f3n \u00a0urinaria\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0LM\u00a0\npor\u00a0la\u00a0falta\u00a0de\u00a0autonom\u00eda \u00a0vesical,\u00a0y\u00a0la\u00a0ausencia\u00a0de\u00a0manifestaciones \u00a0\ncardiovasculares \u00a0en\u00a0las\u00a0lesiones\u00a0medulares \u00a0con\u00a0bajo\u00a0nivel\u00a0topogr\u00e1fico. \u00a0El\u00a0empleo\u00a0\nde\u00a0VMI\u00a0 en\u00a0el\u00a0periodo\u00a0de\u00a0estudio\u00a0fue\u00a0del\u00a054,17%,\u00a0 mientras\u00a0que\u00a0un\u00a017,71%\u00a0\nrecibieron \u00a0apoyo\u00a0ventilatorio \u00a0bajo\u00a0la\u00a0modalidad \u00a0de\u00a0ventilaci\u00f3n \u00a0no\u00a0invasiva\u00a0tipo\u00a0\nCPAP\u00a0o\u00a0BiPAP,\u00a0datos\u00a0 en\u00a0concordancia \u00a0con\u00a0 los\u00a0aportados \u00a0por\u00a0el\u00a0estudio\u00a0ENVIN\u2010\nUCI.\u00a0\n\u00a0La\u00a0IA\u00a0de\u00a0IN\u00a0fue\u00a0de\u00a056,24\u00a0por\u00a0\u00a0cada\u00a0100\u00a0admisiones \u00a0en\u00a0UR,\u00a0cifra\u00a0 elevada\u00a0en\u00a0\nrelaci\u00f3n\u00a0con\u00a0otros\u00a0 estudios,\u00a0con\u00a0rangos\u00a0que\u00a0suelen\u00a0oscilar\u00a0entre\u00a0\u00a0el\u00a05\u201033%\u00a0de\u00a0\u00a0tan\u00a0problemas \u00a0\u00e9ticos\u00a0a\u00a0la\u00a0hora\u00a0 de\u00a0no\u00a0descomprimir \u00a0o\u00a0reducir\u00a0elementos \u00a0\nneuronales \u00a0obviamente \u00a0descompresibles, \u00a0especialmente \u00a0en\u00a0pacientes \u00a0con\u00a0lesi\u00f3n\u00a0\nmedular\u00a0 incompleta \u00a0(122\u2010123) .\u00a0Pese\u00a0a\u00a0todo,\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0\ndescompresiones \u00a0o\u00a0reducciones \u00a0tempranas,\u00a0 realizadas \u00a0por\u00a0cirujanos\u00a0 expertos\u00a0\ndan\u00a0lugar\u00a0a\u00a0mejor\u00edas\u00a0evidentes. \u00a0\n\u00a0\u00a0\u00a0\n\u00a0 145SO\u00a0DE\u00a0DISPOSITIVOS \u00a0M\u00c9DICOS \u00a0Y\u00a0COMPLICACIONES \u00a0\nINFECCIOSAS \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\ntodos\u00a0los\u00a0pacientes \u00a0ingresados \u00a0en\u00a0UC\u00a0(125\u2010129) .\u00a0Un\u00a051,35%\u00a0 de\u00a0las\u00a0infecciones \u00a0\nfueron\u00a0catalogadas\u00a0 como\u00a0IN\u00a0m\u00faltiples. \u00a0El\u00a0n\u00famero\u00a0de\u00a0pacientes\u00a0 con\u00a0una\u00a0sola\u00a0IN\u00a0\nfue\u00a0de\u00a018(IA\u00a0de\u00a018,74\u00a0por\u00a0100\u00a0admisiones), \u00a012\u00a0presenta on \u00a02\u00a0infecciones\u00a0 (IA\u00a0de\u00a0\n12,49\u00a0por\u00a0100\u00a0admisiones) \u00a0y\u00a07\u00a0adquirieron \u00a03\u00a0\u00f3\u00a0m\u00e1s\u00a0infecciones\u00a0 (IA\u00a0de\u00a07,29\u00a0por\u00a0\n100\u00a0admisiones). \u00a0Estos\u00a0 datos\u00a0son\u00a0 r\n\u00a0similares\u00a0a\u00a0los\u00a0hallados\u00a0por\u00a0otros\u00a0 autores\u00a0en\u00a0UC\u00a0\nde\u00a0nuestro\u00a0entorno\u00a0(130) ,\u00a0con\u00a0valores\u00a0cercanos\u00a0al\u00a045%,\u00a0 pudiendo \u00a0justificar\u00a0esta\u00a0\ndiferencia \u00a0de\u00a0porcentajes \u00a0a\u00a0la\u00a0presumible \u00a0menor\u00a0gravedad \u00a0de\u00a0los\u00a0pacientes \u00a0\natendidos\u00a0 en\u00a0la\u00a0UR\u00a0de\u00a0nuestro\u00a0hospital\u00a0de\u00a0tercer\u00a0nivel,\u00a0 y\u00a0principalmente \u00a0\u00a0que\u00a0la\u00a0\nle\u00a0 a t i\nunida \u00a024\u00a0horas,\u00a0por\u00a0lo\u00a0que\u00a0los\u00a0resultados \u00a0no\u00a0son\u00a0\ncomparables.\u00a0 Los\u00a0pacientes \u00a0ingresados \u00a0con\u00a0 estancia\u00a0inferior\u00a0a\u00a024\u00a0horas\u00a0tienen\u00a0\nmenos\u00a0riesgo\u00a0de\u00a0IN\u00a0y\u00a0su\u00a0inclusi\u00f3n\u00a0en\u00a0el\u00a0denominador \u00a0dar\u00eda\u00a0como\u00a0resultado \u00a0una\u00a0\nmenor\u00a0frecuencia \u00a0de\u00a0IN,\u00a0en\u00a0comparaci\u00f3n,\u00a0 con\u00a0pacientes \u00a0de\u00a0estancia\u00a0superior\u00a0a\u00a048\u00a0\nhoras.\u00a0La\u00a0elecci\u00f3n,\u00a0en\u00a0nuestro\u00a0estudio,\u00a0de\u00a0un\u00a0periodo\u00a0de\u00a0estancia\u00a0superior\u00a0a\u00a048\u00a0\nhoras\u00a0se\u00a0realiz\u00f3\u00a0en\u00a0consonancia \u00a0con\u00a0 los\u00a0criterios\u00a0del\u00a0CDC\u00a0que\u00a0fijan\u00a0 48\u00a0horas\u00a0el\u00a0\nperiodo\u00a0de\u00a0tiempo\u00a0m\u00ednimo\u00a0para\u00a0desarrollar \u00a0una\u00a0IN.\u00a0\n\u00a0\nLa\u00a0IN\u00a0m\u00e1s\u00a0frecuente \u00a0de\u00a0la\u00a0cohorte\u00a0fue\u00a0la\u00a0NN\u00a0con\u00a0una\u00a0frecuencia \u00a0relativa\u00a0\ndel\u00a029,17%;\u00a0sigui\u00e9ndole \u00a0en\u00a0orden\u00a0de\u00a0frecuencia \u00a0la\u00a0BN\u00a0(16,67%), \u00a0ITU\u00a0(5,62%)\u00a0y\u00a0la\u00a0\nIHQ\u00a0(5,21%).\u00a0\u00a0\n\u00a0Al\u00a0igual\u00a0que\u00a0en\u00a0nuestro\u00a0estudio,\u00a0otros\u00a0 trabajos\u00a0revisados \u00a0en\u00a0la\u00a0literatura, \u00a0\nmuestran \u00a0la\u00a0NN\u00a0como\u00a0la\u00a0IN\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0las\u00a0UC\u00a0(131\u2010132) ;\u00a0estando\u00a0asociado\u00a0\nesto\u00a0a\u00a0una\u00a0mayor\u00a0 estancia\u00a0hospitalaria, \u00a0mayores\u00a0costes\u00a0y\u00a0un\u00a0incremento \u00a0en\u00a0las\u00a0\ncifras\u00a0de\u00a0mortalidad. \u00a0La\u00a0NN\u00a0es\u00a0muy\u00a0prevalente \u00a0en\u00a0pacientes \u00a0\u00a0lesionados \u00a0\nmedulares,\u00a0 constituyendo \u00a0estos\u00a0un\u00a0importante \u00a0grupo\u00a0de\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0\ninfecciones \u00a0con\u00a0 microorganismos \u00a0multiresistentes. \u00a0Los\u00a0microorganismos \u00a0gram\u00a0\nnegativos\u00a0 son\u00a0los\u00a0principales\u00a0 responsables \u00a0de\u00a0la\u00a0neumon\u00eda \u00a0intrahospitalaria, \u00a0\ndestacando \u00a0Pseudomonas\u00a0 aeruginosa, \u00a0aunque\u00a0la\u00a0incidencia \u00a0de\u00a0microorganismos \u00a0\ngram\u00a0positivos\u00a0se\u00a0ha\u00a0incrementado \u00a0en\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os,\u00a0as\u00ed\u00a0diversos\u00a0estudios\u00a0\u00a0\n\u00a0 146poblaci\u00f3n \u00a0e gible estaba\u00a0constituid \u00a0por\u00a0pacien es \u00a0ngresados \u00a0en\u00a0dichas\u00a0\ndes\u00a0al\u00a0menos\u00a0duranteIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nmuestran \u00a0al\u00a0Staphylococcus \u00a0aureus\u00a0como\u00a0el\u00a0primer\u00a0agente\u00a0pat\u00f3geno \u00a0responsable \u00a0\nde\u00a0las\u00a0NN\u00a0(134\u2010142) .\u00a0En\u00a0nuestro\u00a0estudio,\u00a0la\u00a0etiolog\u00eda\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0la\u00a0NP\u00a0\nfueron\u00a0los\u00a0g\u00e9neros\u00a0Staphylococcus\u00a0 y\u00a0Pseudomonas, \u00a0mientras\u00a0que\u00a0en\u00a0los\u00a0casos\u00a0de\u00a0\nNT\u00a0resalta\u00a0 la\u00a0frecuencia \u00a0del\u00a0g\u00e9nero\u00a0Pseudomonas.\u00a0 En\u00a0el\u00a0per\u00edodo\u00a0postlesi\u00f3n \u00a0\ninmediato, \u00a0la\u00a0neumon\u00eda \u00a0es\u00a0una\u00a0de\u00a0las\u00a0complicaciones \u00a0pulmonares\u00a0 m\u00e1s\u00a0\nfrecuentes, \u00a0siendo\u00a0una\u00a0importante \u00a0causa\u00a0de\u00a0muerte.\u00a0El\u00a0riesgo\u00a0de\u00a0desarrollar \u00a0\nneumon\u00eda \u00a0est\u00e1\u00a0influenciado \u00a0por\u00a0m\u00faltiples \u00a0factores\u00a0como\u00a0insuficiencia \u00a0\nrespiratoria \u00a0aguda\u00a0que\u00a0precisa\u00a0apoyo\u00a0ventilatorio \u00a0invasivo,\u00a0tos\u00a0improductiva, \u00a0\natelectasias, \u00a0aspiraci\u00f3n \u00a0pulmonar, \u00a0lesi\u00f3n\u00a0pulmonar \u00a0aguda,\u00a0\u00edleo\u00a0paral\u00edtico, \u00a0\ncirug\u00eda/anestesia \u00a0tras\u00a0la\u00a0lesi\u00f3n\u00a0medular,\u00a0 ineficacia \u00a0de\u00a0tratamiento \u00a0para\u00a0eliminar\u00a0\nsecreciones, \u00a0etc.\u00a0(143,144) .\u00a0\u00a0\n\u00a0La\u00a0inserci\u00f3n\u00a0de\u00a0cat\u00e9teres \u00a0venosos\u00a0 centrales\u00a0y\u00a0sondaje\u00a0urinario\u00a0constituye \u00a0\nuna\u00a0pr\u00e1ctica\u00a0habitual\u00a0en\u00a0el\u00a0cuidado\u00a0del\u00a0 paciente\u00a0cr\u00edtico,\u00a0si\u00a0bien\u00a0\ndesafortunadamente \u00a0suponen\u00a0un\u00a0incremento \u00a0del\u00a0riesgo\u00a0de\u00a0padecer\u00a0infecci\u00f3n\u00a0\niatrog\u00e9nica. \u00a0\u00a0Un\u00a0\u00a0estudio\u00a0de\u00a0cuidados\u00a0cr\u00edticos\u00a0intensivos \u00a0en\u00a0EE.UU.\u00a0revel\u00f3\u00a0que\u00a0el\u00a0\n7%\u00a0de\u00a0las\u00a0bacteriemias \u00a0primarias \u00a0estaban\u00a0asociadas \u00a0con\u00a0 cat\u00e9teres \u00a0venosos\u00a0\ncentral\nestos\u00a0cat\u00e9teres \u00a0pueden\u00a0disminuir \u00a0significativamente \u00a0la\u00a0morbi\u2010\nmortalidad\u00a0 y\u00a0los\u00a0costes\u00a0m\u00e9dicos.\u00a0En\u00a0un\u00a075%\u00a0de\u00a0los\u00a0aislamientos \u00a0realizados \u00a0para\u00a0la\u00a0\netiolog\n\u00a08\nes,\u00a0y\u00a0el\u00a095%\u00a0de\u00a0las\u00a0infecciones\u00a0 urinarias\u00a0 eran\u00a0debidas\u00a0al\u00a0sondaje\u00a0urinario\u00a0\n(133,145\u2010150) .\u00a0Las\u00a0estrategias \u00a0destinadas\u00a0 a\u00a0prevenir\u00a0la\u00a0infecci\u00f3n\u00a0asociada\u00a0a\u00a0la\u00a0\ninserci\u00f3n\u00a0 de\u00a0\n\u00a0 147\u00eda\u00a0de\u00a0BN\u00a0se\u00a0encontraron \u00a0cocos\u00a0gram\u00a0positivos, \u00a0suponiendo \u00a0los\u00a0\nSthaphylococcus \u00a0un\u00a052,42%\u00a0 del\u00a0total;\u00a0solamente \u00a0el\u00a018,75%\u00a0 de\u00a0los\u00a0BN\u00a0fueron\u00a0de\u00a0\netiolog\u00eda\u00a0polimicrobianas. \u00a0En\u00a0nuestra\u00a0cohorte\u00a0el\u00a0germen\u00a0aislado\u00a0con\u00a0m\u00e1s\u00a0\nfrecuencia\u00a0 fue\u00a0Staphylococcus\u00a0 Aureus.\u00a0\n\u00a0Respecto\u00a0a\u00a0las\u00a0infecciones \u00a0urinarias, \u00a0es\u00a0la\u00a0Escherichia \u00a0coli\u00a0 el\u00a0principal\u00a0\npat\u00f3geno \u00a0responsable \u00a0seguido\u00a0a\u00a0distancia\u00a0por\u00a0la\u00a0C\u00e1ndida\u00a0albicans\u00a0(151\u2010156) .\u00a0En\u00a0\u00a0\nnuestra\u00a0serie\u00a0estos\u00a0dos\u00a0pat\u00f3genos\u00a0 son\u00a0los\u00a0m\u00e1s\u00a0habituales, \u00a0representando \u00a0un\u00a080%\u00a0\ny\u00a020%\u00a0respectivamente \u00a0dentro\u00a0de\u00a0los\u00a0aislamientos \u00a0efectuados. \u00a0En\u00a0la\u00a0encuesta\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\npublicada \u00a0por\u00a0el\u00a0NNIS\u00a0(157)\u00a0la\u00a0especie\u00a0 C\u00e1ndida\u00a0representa\u00a0 el\u00a0microorganismo \u00a0\naislado\u00a0con\u00a0 mayor\u00a0 frecuencia \u00a0en\u00a0las\u00a0ITU\u00a0asociadas \u00a0a\u00a0sondaje\u00a0urinario.\u00a0Este\u00a0\nhallazgo\u00a0se\u00a0puede\u00a0justificar\u00a0parcialmente \u00a0por\u00a0la\u00a0creciente\u00a0 gravedad \u00a0de\u00a0los\u00a0\nenfermos \u00a0de\u00a0nuestras\u00a0unidades, \u00a0el\u00a0empleo\u00a0generalizado \u00a0de\u00a0sondas\u00a0urinarias\u00a0y\u00a0de\u00a0\nantibi\u00f3ticos de\u00a0mplio\u00a0espectro. \u00a0\n\u00a0El\u00a0grupo\u00a0de\u00a0Duh\u00a0(158) ,\u00a0 \u00a0 los\u00a0resultados \u00a0neur l\u00f3gicos medidos\u00a0 en\u00a0\npuntuaci\u00f3n \u00a0motota\u00a0y\u00a0sensitiva\u00a0de\u00a0487\u00a0pacientes \u00a0lesionados \u00a0medulares \u00a0en\u00a0el\u00a0\nsubgrupo \u00a0de\u00a0pacientes \u00a0del\u00a0 estudi\u00a0NASCIS\u00a0II,\u00a0y\u00a0aunque\u00a0ugiere\u00a0que\u00a0la\u00a0\nrecuperaci\u00f3n \u00a0motora\u00a0 fue\u00a0mayor\u00a0 en\u00a0aquellos\u00a0 pacientes \u00a0operados, \u00a0no\u00a0encuentra \u00a0\ndiferencias\u00a0 entre\u00a0 el\u00a0tratamie\u00a0a\nanaliza o\u00a0\no s\nnto\u00a0quir\u00fargico \u00a0y\u00a0conservador \u00a0en\u00a0lo\u00a0que\u00a0se\u00a0refiere\u00a0 a\u00a0\nrecupe ci\u00f3n \u00a0neurol\u00f3gica \u00a0evaluada\u00a0al\u00a0a\u00f1o\u00a0de\u00a0la\u00a0lesi\u00f3n.\u00a0 Los\u00a0pacientes \u00a0con\u00a0 LMA\u00a0\nque\u00a0re\n\u00a0 e s \u00a0 o\ns C m\n\u00a0256\u00a0pacientes \u00a0con\u00a0 LMA\u00a0tratados\u00a0\nquir\u00fargicamente \u00a0mediante \u00a0descompresi\u00f3n \u00a0\u00f3\u00a0estabilizaci\u00f3n, \u00a0reporta\u00a0 unas\u00a0tasas\u00a0de\u00a0\nIHQ\u00a0dra\nquieren\u00a0cirug\u00eda\u00a0 presentan \u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0infecci\u00f3n\u00a0de\u00a0la\u00a0herida\u00a0\nquir\u00fargica \u00a0que aquellos\u00a0paci nte \u00a0sometidos \u00a0acirug\u00eda\u00a0medular\u00a0 de\u00a0f rma\u00a0\nprogramada \u00a0(159,163) .\u00a0Dado\u00a0el\u00a0incrementado \u00a0riesgo\u00a0de\u00a0IQ\u00a0en\u00a0este\u00a0tipo\u00a0de\u00a0\npacientes, \u00a0todos\u00a0los\u00a0posibles\u00a0factores\u00a0de\u00a0riesgo\u00a0ex\u00f3genos \u00a0deben\u00a0ser\u00a0tenidos\u00a0en\u00a0\ncuenta,\u00a0tratando\u00a0de\u00a0disminuirlos \u00a0en\u00a0la\u00a0medida\u00a0de\u00a0lo\u00a0posible\u00a0durante\u00a0el\u00a0periodo\u00a0\nperioperatorio. \u00a0\n\u00a0La\u00a0incidencia \u00a0de\u00a0IHQ\u00a0en\u00a0nuestra\u00a0serie\u00a0es\u00a0de\u00a0un\u00a05,21%,\u00a0y\u00a0este\u00a0dato\u00a0esta\u00a0en\u00a0\nconcordancia \u00a0con\u00a0m\u00faltiples\u00a0 estudios\u00a0epidemiol\u00f3gicos \u00a0realizados \u00a0en\u00a0pacientes \u00a0con\u00a0\nLMA\u00a0y\u00a0siguiendo\u00a0 la\u00a0definiciones \u00a0del\u00a0 DC\u00a0(160)\u00a0para\u00a0la\u00a0IHQ,\u00a0la\u00a0enor\u00a0incidencia \u00a0\nen\u00a0nuestro\u00a0estudio\u00a0pudiera\u00a0deberse\u00a0a\u00a0que\u00a0parte\u00a0de\u00a0las\u00a0intervenciones \u00a0quir\u00fargicas \u00a0\nse\u00a0han\u00a0 realizado\u00a0de\u00a0forma\u00a0programada,\u00a0 sin\u00a0car\u00e1cter\u00a0de\u00a0urgencia.\u00a0As\u00ed,\u00a0Blam\u00a0et\u00a0al\u00a0\n(161)\u00a0tras\u00a0un\u00a0estudio\u00a0retrospectivo \u00a0sobre\n\u00a0 148el\u00a09,4%.\u00a0Rechtine\u00a0et\u00a0al\u00a0(162)\u00a0estudian\u00a0 a\u00a0117\u00a0pacientes \u00a0tratados\u00a0\nquir\u00fargicamente \u00a0con\u00a0instrumentaci\u00f3n \u00a0tras\u00a0fractura\u00a0 tor\u00e1cica\u00a0o\u00a0lumbar,\u00a0\nencontrando \u00a0una\u00a0tasa\u00a0de\u00a0infecci\u00f3n\u00a0similar\u00a0del\u00a010,5%.\u00a0Mc\u00a0Afee\u00a0y\u00a0Bohlam\u00a0(78)\u00a0\nrevisaron \u00a0una\u00a0serie\u00a0de\u00a040\u00a0pacientes \u00a0con\u00a0instrumentaci\u00f3n \u00a0de\u00a0fracturas\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\ntoracolumbares,\u00a0 registrando \u00a0una\u00a0tasa\u00a0de\u00a0infecci\u00f3n\u00a0del\u00a015%.\u00a0Del\u00a0mismo\u00a0modo,\u00a0\nKornberg \u00a0et\u00a0al\u00a0(164)\u00a0retrospectivamente \u00a0revisaron\u00a0 22\u00a0pacientes \u00a0que\u00a0presentaron \u00a0\nigualmente \u00a0\u00a0instrumentaci\u00f3n \u00a0(descompresi\u00f3n \u00a0\u00f3\u00a0instrumentaci\u00f3n \u00a0Harrington) \u00a0de\u00a0\nfracturas\u00a0tor\u00e1cicas\u00a0y\u00a0lumbares \u00a0encontrando\u00a0 una\u00a0 tasa\u00a0de\u00a0infecci\u00f3n\u00a0del\u00a014%.\u00a0\nAutores\u00a0de\u00a0otros\u00a0 estudios\u00a0han\u00a0 aportado\u00a0datos\u00a0 similares\u00a0a\u00a0estos.\u00a0Los\u00a0autores\u00a0de\u00a0\nestos\u00a0 \u00a0 hallaron\u00a0tasa\u00a0de\u00a0infecciones \u00a0superiores \u00a0a\u00a0las\u00a0registradas \u00a0en\u00a0\npacien\naraci\u00f3n\u00a0 de\u00a0los\u00a0valores\u00a0de\u00a0IN\u00a0encontrados, \u00a0con\u00a0 los\u00a0de\u00a0otros\u00a0\nestudios,\u00a0ha\u00a0de\u00a0realizarse \u00a0con\u00a0 cautela,\u00a0 por\u00a0la\u00a0limitaci\u00f3n \u00a0que\u00a0supone\u00a0la\u00a0\ncompaestudios\ntes\u00a0tras\u00a0cirug\u00eda\u00a0medular\u00a0electiva;\u00a0siendo\u00a0las\u00a0tasas\u00a0de\u00a0infecci\u00f3n\u00a0\u00a0mostradas\u00a0\nen\u00a0estos\u00a0casos\u00a0seg\u00fan\u00a0la\u00a0literatura \u00a0del\u00a03\u20106%\u00a0(165) .\u00a0\n\u00a0\nTras\u00a0diagnosticar \u00a0la\u00a0infecci\u00f3n, \u00a0debe\u00a0iniciarse\u00a0un\u00a0tratamiento \u00a0en\u00e9rgico\u00a0\ncomplementado \u00a0con\u00a0revisi\u00f3n\u00a0quir\u00fargica \u00a0de\u00a0la\u00a0herida,\u00a0porque\u00a0la\u00a0IHQ\u00a0en\u00a0pacientes \u00a0\nlesionados \u00a0medulares,\u00a0 puede\u00a0determinar \u00a0la\u00a0colonizaci\u00f3n \u00a0por\u00a0m\u00faltiples \u00a0\nmicroorganismos; \u00a0si\u00a0bien\u00a0el\u00a0tratamiento \u00a0antibi\u00f3tico\u00a0 no\u00a0debe\u00a0realizarse \u00a0hasta\u00a0\nobtener\u00a0los\u00a0cultivos\u00a0necesarios \u00a0que\u00a0permitan\u00a0identificar \u00a0los\u00a0microorganismos \u00a0\nresponsables; \u00a0empleando\u00a0 antibi\u00f3ticos \u00a0de\u00a0amplio\u00a0espectro\u00a0hasta\u00a0la\u00a0identificaci\u00f3n\u00a0\nde\u00a0los\u00a0mismos.\u00a0\n\u00a0\nLa\u00a0comp\n\u00a0 149raci\u00f3n\u00a0 de\u00a0tasas\u00a0crudas\u00a0de\u00a0IN\u00a0debido\u00a0 a\u00a0la\u00a0diversidad\u00a0 de\u00a0factores\u00a0de\u00a0riesgo\u00a0\nde\u00a0la\u00a0IN\u00a0presentes \u00a0en\u00a0las\u00a0UC,\u00a0 por\u00a0la\u00a0gran\u00a0variedad\u00a0de\u00a0riesgos\u00a0individuales \u00a0de\u00a0\ninfecci\u00f3n\u00a0entre\u00a0los\u00a0pacientes, \u00a0derivados\u00a0 de\u00a0su\u00a0diferente \u00a0enfermedad \u00a0de\u00a0base\u00a0y\u00a0su\u00a0\ndesigual\u00a0exposici\u00f3n \u00a0a\u00a0factores\u00a0de\u00a0riesgo.\u00a0Siendo\u00a0 tambi\u00e9n\u00a0el\u00a0tipo\u00a0de\u00a0hospital\u00a0\u00a0\nimportante \u00a0paran\u00a0poder\u00a0comparar\u00a0 tasa\u00a0de\u00a0infecci\u00f3n.\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0 de\nde\u00a0calidad\u00a0en\u00a0las\u00a0UC\u00a0(166\u2010168) .\u00a0El\u00a059,35%\u00a0 de\u00a0los\u00a0pacientes \u00a0no\u00a0recibieron \u00a0\ntratamiento \u00a0antibi\u00f3tico\u00a0 y\u00a0fueron\u00a027\u00a0los\u00a0que\u00a0recibieron \u00a0m\u00e1s\u00a0de\u00a0un\u00a0antibi\u00f3tico. \u00a0\u00a0La\u00a0\nduraci\u00f3n\u00a0media\u00a0de\u00a0este\u00a0tratamiento \u00a0fue\u00a0de\u00a09,67\u00a0d\u00edas\u00a0y\u00a0la\u00a0raz\u00f3n\u00a0 de\u00a0n\u00famero\u00a0de\u00a0\nantimicrobianos \u00a0por\u00a0pacientes \u00a0con\u00a0 antimicrobianos \u00a0fue\u00a0de\u00a01,29.\u00a0Los\u00a0grupos\u00a0de\u00a0\nantibi\u00f3ticos \u00a0m\u00e1s\u00a0frecuentemente\u00a0 empleados \u00a0fueron,\u00a0 por\u00a0este\u00a0orden,\u00a0 cloxacilina, \u00a0\ncefalosporinas\u00a0 y\u00a0diversos\u00a0carbapenem. \u00a0\n\u00a0\nEn\u00a0los\u00a0casos\u00a0de\u00a0LMAT\u00a0abiertos\u00a0 (habitualmente \u00a0heridas\u00a0por\u00a0arma\u00a0blanca\u00a0o\u00a0\nde\u00a0fuego)\u00a0y\u00a0cerrados, \u00a0que\u00a0requieran \u00a0cirug\u00eda\u00a0urgente,\u00a0debe\u00a0realizarse \u00a0profilaxis\u00a0\nantibi\u00f3tica \u00a0preoperatoria \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0las\u00a0IN\u00a0y\u00a0resistencias \u00a0bacterianas \u00a0del\u00a0\nhospital.\u00a0La\u00a0profilaxis\u00a0antibi\u00f3tica \u00a0de\u00a0la\u00a0IHQ\u00a0se\u00a0reserva\u00a0para\u00a0cirug\u00eda\u00a0limpia,\u00a0limpia\u2010\ncontaminada \u00a0y\u00a0contaminada,\u00a0 aunque\u00a0su\u00a0uso\u00a0en\u00a0cirug\u00eda\u00a0limpia\u00a0es\u00a0controvertido \u00a0\n(169,170) .\u00a0Su\u00a0objetivo\u00a0primario\u00a0es\u00a0conseguir \u00a0niveles\u00a0de\u00a0antimicrobianos \u00a0\nsuficientes \u00a0para\u00a0neutralizar \u00a0a\u00a0los\u00a0microorganismos \u00a0que\u00a0pudieran\u00a0 colonizar\u00a0 el\u00a0\ncampo\u00a0operatorio \u00a0en\u00a0el\u00a0momento \u00a0de\u00a0la\u00a0incisi\u00f3n\u00a0quir\u00fargica \u00a0y\u00a0durante\u00a0el\u00a0tiempo\u00a0\nquir\u00fargico. \u00a0En\u00a0la\u00a0actualidad, \u00a0se\u00a0aconseja\u00a0la\u00a0dosis\u00a0\u00fanica\u00a0 preoperatorio, \u00a0que\u00a0se\u00a0\nrepite\u00a0intraoperatoriamente \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0intervenci\u00f3n \u00a0y\u00a0de\u00a0la\u00a0\nvida\u00a0media\u00a0 del\u00a0antibi\u00f3tico, \u00a0no\u00a0administr\u00e1ndose \u00a0dosis\u00a0postoperatoria. \u00a0Del\u00a0total\u00a0de\u00a0\nla\u00a0cohorte\u00a047\u00a0sujetos\u00a0 fueron\u00a0intervenidos \u00a0quir\u00fargicamente, \u00a0recibiendo \u00a0el\u00a0100%\u00a0\nprofilaxis\u00a0antibi\u00f3tica. \u00a0La\u00a0duraci\u00f3n\u00a0media\u00a0de\u00a0la\u00a0profilaxis\u00a0fue\u00a0de\u00a01,15\u00a0d\u00edas,\u00a0siendo\u00a0 el\u00a0\nantibi\u00f3tico\u00a0 m\u00e1s\u00a0utilizado\u00a0las\u00a0cefalosporinas\u00a0 con\u00a0 un\u00a045%\u00a0de\u00a0los\u00a0casos.\u00a0La\u00a0\nasociaci\u00f3n \u00a0cefazolina \u00a0y\u00a0gentamicina \u00a0fue\u00a0la\u00a0m\u00e1s\u00a0utilizada\u00a0en\u00a0la\u00a0profilaxis\u00a0\nantibi\u00f3tica. \u00a0Los\u00a0f\u00e1rmacos \u00a0utilizados \u00a0con\u00a0mayor\u00a0 frecuencia \u00a0en\u00a0la\u00a0literatura \u00a0son\u00a0las\u00a0\ncefalosporinas, \u00a0en\u00a0particular \u00a0las\u00a0de\u00a03\u00aa\u00a0generaci\u00f3n. \u00a0En\u00a0nuestra\u00a0serie,\u00a0los\u00a0datos\u00a0 son\u00a0\ncoincidentes \u00a0con\u00a0estos\u00a0resultados \u00a0(171,172) .\u00a0\n\u00a0 1505.6. ANTIMICROBIANOS \u00a0EMPLEADOS \u00a0EN\u00a0UNIDAD\u00a0DE\u00a0\nREANIMACI\u00d3N \u00a0\n\u00a0\nLaproporci\u00f3n \u00a0 \u00a0pacientes \u00a0que\u00a0recibi\u00f3\u00a0alg\u00fan\u00a0 antimicrobiano \u00a0durante\u00a0su\u00a0\nestancia\u00a0en\u00a0la\u00a0Unidad\u00a0 (40,65%)\u00a0es\u00a0inferior\u00a0al\u00a050%\u00a0recomendado \u00a0como\u00a0par\u00e1metro \u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0 i\n\u00a0tasa\u00a0m\u00e1s\u00a0frecuente \u00a0fue\u00a0la\u00a0hiperglucemia, \u00a0que\u00a0afect\u00f3\u00a0al\u00a0menos\u00a0una\u00a0vez\u00a0\nal\u00a050%\n\u00a0\n\u00a0\nla nsecundarias.\n\u00a0\n\u00a0 \u00a0 \u00a0\na \u00a0 todo\n\u00a0pulmonar \u00a0secundario \u00a0a\u00a0la\u00a0LM\u00a0\npor\u00a0la\u00a0descarga\u00a0simp\u00e1tica \u00a0masiva\u00a0con\u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0postcarga,\u00a0 que\u00a0en\u00a0\u00a05.7. OTRAS\u00a0 COMPLICACIONES \u00a0\n\u00a0\nA\u00f1adido\u00a0a\u00a0las\u00a0complicaciones\u00a0 anteriormente \u00a0mencionadas, \u00a0acontecieron \u00a0\notras\u00a0complicaciones \u00a0m\u00e9dicas\u00a0durante\u00a0la\u00a0fase\u00a0de\u00a0hospitalizaci\u00f3n, \u00a0entre\u00a0las\u00a0que\u00a0\ndestacamos la\u00a0presenc a \u00a0de\u00a0hiperglucemia,\u00a0 anemia,\u00a0insuficiencia \u00a0respiratoria \u00a0\nprolongada, \u00a0trastornos \u00a0del\u00a0ritmo\u00a0card\u00edaco,\u00a0 SDRA,\u00a0\u00edleo\u00a0paral\u00edtico, \u00a0coagulopat\u00eda, \u00a0\natelectasias, \u00a0shock\u00a0s\u00e9ptico,\u00a0hemorragia\u00a0 digestiva, \u00a0neumot\u00f3rax,\u00a0 plaquetopenia, \u00a0\ninsuficiencia \u00a0renal\u00a0aguda,\u00a0 rabdomiolisis, \u00a0miopat\u00eda\u00a0del\u00a0paciente\u00a0cr\u00edtico,\u00a0\u00a0s\u00edndrome \u00a0\nde\u00a0aspiraci\u00f3n \u00a0pulmonar,\u00a0 flebitis\u00a0 y\u00a0TEP.\u00a0\n\u00a0La\n\u00a0 151\u00a0de\u00a0los\u00a0pacientes \u00a0durante\u00a0la\u00a0fase\u00a0aguda\u00a0de\u00a0hospitalizaci\u00f3n \u00a0en\u00a0nuestra\u00a0\nUnidad;\u00a0la\u00a0causa\u00a0de\u00a0esta\u00a0hiperglucemia \u00a0es\u00a0multifactorial, \u00a0entre\u00a0los\u00a0factores\u00a0m\u00e1s\u00a0\ndestacados puede\u00a0considerarse \u00a0al\u00a0empleo\u00a0de\u00a0megadosis\u00a0 de\u00a0MP,\u00a0 y\u00a0las\u00a0\nalteraciones \u00a0endocrinometab\u00f3licas \u00a0desencadenadas \u00a0tras\u00a0el\u00a0trauma\u00a0inicial.\nDebemos \u00a0enfatizar\u00a0la\u00a0importancia \u00a0del\u00a0tratamiento \u00a0agresivo\u00a0de\u00a0la\u00a0hiperglucemia \u00a0\npara\u00a0disminuir \u00a0 \u00a0incidencia \u00a0de\u00a0lesio es\u00a0 \u00a0\n\u00a0\nFue\u00a0frecuente \u00a0la\u00a0presencia \u00a0de\u00a0anemia\u00a0 (38,54%), \u00a0insuficiencia\u00a0 respiratoria \u00a0\nprolongada (31,25%)\u00a0y\u00a0trastornos \u00a0del\u00a0ritmo\u00a0card\u00edaco\u00a0(22,91%). \u00a0La\u00a0insuficiencia \u00a0\nrespiratoria \u00a0y\u00a0necesidad \u00a0de\u00a0apoyo\u00a0ventilatorio \u00a0es\u00a0\u00a0frecuente \u00a0\u00a0en\u00a0los\u00a0pacientes \u00a0\npolitraumatizados, \u00a0y\u00a0especialmente \u00a0en\u00a0aquellos\u00a0 con\u00a0 LMA.\u00a0La\u00a0par\u00e1lisis\u00a0de\u00a0los\u00a0\nm\u00fasculos \u00a0respiratorios \u00a0origina\u00a0alteraciones \u00a0de\u00a0los\u00a0diversos\u00a0par\u00e1metros \u00a0\nfuncionales \u00a0(especialmente \u00a0de\u00a0la\u00a0capacidad \u00a0vital\u00a0forzada\u00a0y\u00a0de\u00a0la\u00a0distensibilidad \u00a0\npulmonar \u00a0est\u00e1tica)\u00a0e\u00a0\u00a0incapacidad \u00a0para\u00a0toser, con retenci\u00f3n\u00a0 desecreciones \u00a0y\u00a0\ntendencia \u00a0 \u00a0la\u00a0aparici\u00f3n de\u00a0broncoaspiraciones \u00a0y\u00a0atelectasias, \u00a0 \u00a0 lo\u00a0cual\u00a0\ndetermina\u00a0 un\u00a0desequilibrio\u00a0 en\u00a0la\u00a0relaci\u00f3n\u00a0ventilaci\u00f3n/perfusi\u00f3n \u00a0e\u00a0hipoventilaci\u00f3n \u00a0\nalveolar,\u00a0con\u00a0 la\u00a0posible\u00a0aparici\u00f3n\u00a0 de\u00a0una\u00a0insuficiencia \u00a0respiratoria \u00a0global.\u00a0Otras\u00a0\ncausas\u00a0de\u00a0insuficiencia \u00a0respiratoria \u00a0son\u00a0el\u00a0edemaIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nconjunci\u00f3n \u00a0a\u00a0las\u00a0frecuentes \u00a0arritmias\u00a0y\u00a0a\u00a0la\u00a0depresi\u00f3n\u00a0 mioc\u00e1rdica \u00a0intr\u00ednseca\u00a0\nmediada\u00a0por\u00a0beta\u2010endorfinas\u00a0 puede\u00a0desembocar \u00a0en\u00a0fracaso\u00a0ventricular \u00a0izquierdo \u00a0\ncon\u00a0 ed\n\u00a0respiratoria, \u00a0\u00e9sta\u00a0ser\u00e1\u00a0mayor\u00a0 cuanto\u00a0m\u00e1s\u00a0\nalto\u00a0seel\u00a0nivel\u00a0neurol\u00f3gico. \u00a0Las\u00a0lesiones\u00a0completas \u00a0C3\u00a0o\u00a0superiores \u00a0necesitar\u00e1n \u00a0\nVM\u00a0a\u00a0\ne\nica\u00a0\u00a0 aconseja\u00a0tratamiento \u00a0\nantisecretor \u00a0(ranitidina \u00a0u\u00a0omeprazol) \u00a0de\u00a0forma\u00a0sistem\u00e1tica. \u00a0El\u00a0tratamiento \u00a0con\u00a0\nf\u00e1rmacema\u00a0pulmonar \u00a0de\u00a0origen\u00a0cardiog\u00e9nico.\u00a0 Tambi\u00e9n\u00a0 se\u00a0puede\u00a0alterar\u00a0el\u00a0\nendotelio \u00a0capilar\u00a0pulmonar \u00a0con\u00a0 edema\u00a0exudativo \u00a0y\u00a0hemorragias \u00a0alveolares \u00a0y\u00a0\nconducir\u00a0a\u00a0un\u00a0edema\u00a0pulmonar \u00a0no\u00a0cardiog\u00e9nico \u00a0tipo\u00a0lesi\u00f3n\u00a0pulmonar \u00a0aguda\u00a0y/o\u00a0\ns\u00edndrome \u00a0de\u00a0distress\u00a0 respiratorio \u00a0agudo.\u00a0La\u00a0sobrecarga \u00a0de\u00a0volumen\u00a0durante\u00a0las\u00a0\nprimeras\u00a0horas\u00a0tras\u00a0el\u00a0ingreso\u00a0es\u00a0una\u00a0causa\u00a0frecuente \u00a0de\u00a0edema\u00a0pulmonar. \u00a0A\u00a0\nmodo\u00a0de\u00a0resumen,\u00a0 podemos \u00a0indicar\u00a0que\u00a0Los\u00a0pacientes \u00a0con\u00a0niveles\u00a0por\u00a0encima\u00a0de\u00a0\nT12\u00a0tienen\u00a0riesgo\u00a0de\u00a0alguna\u00a0disfunci\u00f3n\na\u00a0\nlargo\u00a0plazo,\u00a0niveles\u00a0C4\u00a0o\u00a0inferiores \u00a0podr\u00e1n\u00a0destetarse \u00a0de\u00a0la\u00a0ventilaci\u00f3n \u00a0\naunque\u00a0inicialmente \u00a0la\u00a0requieran. \u00a0\n\u00a0La\u00a0HDA\u00a0 pued\u00a0plantear\u00a0importantes \u00a0problemas \u00a0en\u00a0la\u00a0UR\u00a0y\u00a0durante\u00a0todo\u00a0el\u00a0\ningreso\u00a0hospitalario.\u00a0 La\u00a0HDA\u00a0 es\u00a0un\u00a0evento\u00a0frecuente, \u00a0incluso\u00a0 en\u00a0las\u00a0primeras\u00a0\nhoras,\u00a0en\u00a0el\u00a0paciente\u00a0politraumatizado, \u00a0pero\u00a0particularmente \u00a0en\u00a0presencia \u00a0de\u00a0\nTCE\u00a0y\u00a0en\u00a0la\u00a0LMA,\u00a0por\u00a0lo\u00a0que\u00a0la\u00a0literatura \u00a0m\u00e9d\n\u00a0 152os\u00a0ulcerog\u00e9nicos\u00a0 tipo\u00a0CTC\u00a0y\u00a0AINE\u00b4s\u00a0pueden\u00a0 incrementar \u00a0hasta\u00a0en\u00a0un\u00a05\u201025%\u00a0\nlas\u00a0ulceras\u00a0g\u00e1stricas\u00a0y\u00a0en\u00a0m\u00e1s\u00a0de\u00a0dos\u00a0veces\u00a0el\u00a0riesgo\u00a0de\u00a0sangrado. \u00a0Aquellos\u00a0\npacientes \u00a0con\u00a0antecedentes \u00a0de\u00a0tabaquismo, \u00a0historia\u00a0de\u00a0abuso\u00a0 de\u00a0alcohol,\u00a0HTA\u00a0y\u00a0\nde\u00a0enfermedad \u00a0renal\u00a0tienen\u00a0una\u00a0predisposici\u00f3n \u00a0a\u00a0presentar \u00a0episodios \u00a0de\u00a0HDA.\u00a0En\u00a0\nnuestra\u00a0cohorte,\u00a0este\u00a0incidente \u00a0aconteci\u00f3 \u00a0en\u00a0un\u00a011,45%.\u00a0\n\u00a0La\u00a0incidencia \u00a0de\u00a0enfermedad \u00a0tromboemb\u00f3lica \u00a0en\u00a0la\u00a0LMA\u00a0es\u00a0alta,\u00a0\ndependiendo \u00a0de\u00a0la\u00a0severidad \u00a0de\u00a0la\u00a0lesi\u00f3n,\u00a0la\u00a0edad\u00a0y\u00a0los\u00a0m\u00e9todos\u00a0de\u00a0diagn\u00f3stico \u00a0\nutilizados \u00a0las\u00a0cifras\u00a0pueden\u00a0variar\u00a0 del\u00a07%\u00a0al\u00a0100%.\u00a0Esta\u00a0incidencia \u00a0alta\u00a0de\u00a0TVP\u00a0y\u00a0\nTEP\u00a0se\u00a0relaciona\u00a0con\u00a0 la\u00a0estasis\u00a0venosa\u00a0y\u00a0la\u00a0hipercoagulabilidad, \u00a0ambas\u00a0\nrelacionadas\u00a0 con\u00a0la\u00a0lesi\u00f3n\u00a0neurol\u00f3gica \u00a0aguda.\u00a0Los\u00a0fen\u00f3menos \u00a0tromboemb\u00f3licos, \u00a0\nprincipalmente \u00a0TVP\u00a0y\u00a0TEP\u00a0son\u00a0habitualmente \u00a0fen\u00f3menos \u00a0tard\u00edos.\u00a0 Para\u00a0la\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nsospecha \u00a0diagn\u00f3stica \u00a0es\u00a0importante \u00a0el\u00a0examen\u00a0f\u00edsico\u00a0regular\u00a0 de\u00a0los\u00a0miembros \u00a0\ninferiores; \u00a0el\u00a0diagn\u00f3stico\u00a0 de\u00a0confirmaci\u00f3n \u00a0se\u00a0realiza\u00a0por\u00a0flebograf\u00eda; \u00a0tambi\u00e9n\u00a0son\u00a0\n\u00fatiles\u00a0el\u00a0ultrasonido\u00a0 Doppler\u00a0 y\u00a0la\u00a0pletismograf\u00eda.\u00a0 La\u00a0profilaxis\u00a0con\u00a0 HBPM\u00a0en\u00a0las\u00a0\nprimeras\u00a0horas\u00a0tras\u00a0el\u00a0traumatismo \u00a0puede\u00a0suponer\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0hemorragias \u00a0a\u00a0\notros\u00a0 niveles,\u00a0especialmente \u00a0graves\u00a0en\u00a0pacientes\u00a0 con\u00a0 TCE,\u00a0por\u00a0lo\u00a0que\u00a0parece\u00a0\nrazonable \u00a0demorar\u00a0 su\u00a0inicio.\u00a0 La\u00a0tasa\u00a0de\u00a0TEP\u00a0(5,20%)\u00a0es\u00a0inferior\u00a0al\u00a0resultado \u00a0\npropuesto \u00a0por\u00a0Wilberger\u00a0 (79)\u00a0y\u00a0hay\u00a0que\u00a0tener\u00a0en\u00a0cuenta\u00a0 que\u00a0las\u00a0medidas\u00a0\nprofil\u00e1cticas \u00a0han\u00a0ido\u00a0evolucionando \u00a0\u00a0con\u00a0 el\u00a0tiempo,\u00a0 reduci\u00e9ndose \u00a0la\u00a0incidencia \u00a0de\u00a0\nenfermedad \u00a0\u00a0tromboemb\u00f3lica \u00a0desde\u00a0el\u00a0uso\u00a0sistem\u00e1tico \u00a0de\u00a0las\u00a0HBPM.\u00a0\n\u00a0La\u00a0Insuficiencia \u00a0renal\u00a0aguda\u00a0es\u00a0un\u00a0s\u00edndrome \u00a0relativamente \u00a0com\u00fan\u00a0 en\u00a0el\u00a0\npaciente\u00a0cr\u00edtico,\u00a0y\u00a0especialmente \u00a0en\u00a0el\u00a0paciente\u00a0traum\u00e1tico. \u00a0La\u00a0\u00a0incidencia \u00a0var\u00eda\u00a0\nentre\u00a0 \u00a0 7%\u00a0y\u00a0un\u00a030%.\u00a0En\u00a0nuestra\u00a0 serie\u00a0presenta\u00a0una\u00a0tasa\u00a0del\u00a09,37%.\u00a0La\u00a0\ninsufici\ncr\u00edticos\u00a0que\u00a0precisan\u00a0\nresucit \u00a0volum\u00e9trica \u00a0aguda,\u00a0 y\u00a0se\u00a0comprueba \u00a0una\u00a0tendencia\u00a0 a\u00a0una\u00a0mayor\u00a0\nmortalun\nencia\u00a0renal\u00a0aguda\u00a0prerrenal \u00a0es\u00a0la\u00a0causa\u00a0m\u00e1s\u00a0frecuente \u00a0de\u00a0insuficiencia\u00a0\nrenal\u00a0aguda,\u00a0representando \u00a0una\u00a0respuesta\u00a0 fisiol\u00f3gica \u00a0a\u00a0la\u00a0hipoperfusi\u00f3n \u00a0renal\u00a0por\u00a0\nhipovolemia, \u00a0bajo\u00a0gasto\u00a0cardiaco,\u00a0vasodilataci\u00f3n \u00a0sist\u00e9mica \u00a0o\u00a0vasoconstricci\u00f3n \u00a0\nintrarrenal. \u00a0El\u00a0empleo\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0AINE\u00b4s,\u00a0 los\u00a0cuales\u00a0inhiben\u00a0la\u00a0bios\u00edntesis \u00a0de\u00a0\nprostaglandinas \u00a0\u00a0que\u00a0poseen\u00a0un\u00a0efecto\u00a0vasodilatador \u00a0sobre\u00a0la\u00a0arteriola\u00a0aferente\u00a0\nglomerular\u00a0 puede\u00a0precipitar \u00a0insuficiencia \u00a0renal\u00a0aguda\u00a0prerrenal \u00a0especialmente \u00a0\nen\u00a0pacientes\u00a0 con\u00a0 disminuci\u00f3n \u00a0del\u00a0 volumen\u00a0circulante \u00a0eficaz.\u00a0La\u00a0evidencia \u00a0\nexistente\u00a0muestra\u00a0que\u00a0el\u00a0uso\u00a0de\u00a0hidroxi\u2010etil\u2010almid\u00f3n\u00a0 se\u00a0asocia\u00a0a\u00a0un\u00a0mayor\u00a0riesgo\u00a0\nde\u00a0insuficiencia \u00a0renal\u00a0aguda\u00a0grave\u00a0y\u00a0necesidad \u00a0de\u00a0depuraci\u00f3n \u00a0extrarrenal \u00a0\ncomparado \u00a0con\u00a0 el\u00a0uso\u00a0de\u00a0cristaloides \u00a0en\u00a0pacientes \u00a0\naci\u00f3n\n\u00a0 153idad.\u00a0El\u00a0protocolo \u00a0analg\u00e9sico \u00a0de\u00a0la\u00a0Unidad\u00a0 excluye\u00a0 el\u00a0empleo\u00a0de\u00a0AINE\u00b4s\u00a0en\u00a0\nel\u00a0paciente\u00a0cr\u00edtico,\u00a0y\u00a0de\u00a0forma\u00a0predominante \u00a0la\u00a0reposici\u00f3n \u00a0de\u00a0volumen\u00a0se\u00a0realiza\u00a0\ncon\u00a0cristaloides, \u00a0y\u00a0estas\u00a0dos\u00a0pautas\u00a0pudieran\u00a0 explicar\u00a0la\u00a0baja\u00a0presentaci\u00f3n \u00a0de\u00a0los\u00a0\nepisodios \u00a0de\u00a0insuficiencia \u00a0renal\u00a0aguda.\u00a0\n\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0\n;\u00a0p\u00a0=\u00a00,0002,\u00a0 OR=\u00a05.29;\u00a0p\u00a0=\u00a00,026)\u00a0\nrespect ente. \u00a0\u00a05.8. MORTALIDAD \u00a0Y\u00a0LESI\u00d3N\u00a0MEDULAR\u00a0 AGUDA\u00a0TRAUM\u00c1TICA \u00a0\n\u00a0\n5.8.1.  An\u00e1lisis\u00a0univariante \u00a0\nDe\u00a0forma\u00a0cl\u00e1sica,\u00a0la\u00a0mortalidad\u00a0 tras\u00a0traumas\u00a0 graves\u00a0se\u00a0ha\u00a0dividido\u00a0en\u00a0tres\u00a0\npicos\u00a0de\u00a0incidencia \u00a0en\u00a0relaci\u00f3n\u00a0con\u00a0el\u00a0tiempo,\u00a0y\u00a0as\u00ed\u00a0podemos\u00a0considerar: \u00a0\n\u00a0\n1) Un\u00a0primer\u00a0pico\u00a0o\u00a0de\u00a0mortalidad\u00a0 inmediata,\u00a0 generalmente \u00a0ocasionada \u00a0\npor\u00a0TCE\u00a0severos,\u00a0lesiones\u00a0medulares \u00a0por\u00a0encima\u00a0 de\u00a0C4,\u00a0lesiones\u00a0card\u00edacas\u00a0y\u00a0de\u00a0los\u00a0\ngrandes\u00a0 vasos.\u00a0Pueden\u00a0llegar\u00a0a\u00a0suponer\u00a0hasta\u00a0un\u00a015%\u00a0de\u00a0la\u00a0mortalidad. \u00a0\u00a0\n2) Un\u00a0segundo\u00a0pico\u00a0de\u00a0mortalidad,\u00a0 que\u00a0acontece\u00a0en\u00a0las\u00a0primeras\u00a0horas;\u00a0\ntiene\u00a0 su\u00a0origen\u00a0generalmente \u00a0por\u00a0hemorragias \u00a0intracraneales, \u00a0neumot\u00f3rax, \u00a0\nhemot\u00f3rax \u00a0masivo,\u00a0rotura\u00a0espl\u00e9nica\u00a0o\u00a0hep\u00e1tica\u00a0y/o\u00a0hemorragias \u00a0masivas\u00a0 en\u00a0general.\u00a0\nAbarca\u00a0un\u00a055\u201060%\u00a0de\u00a0la\u00a0mortalidad. \u00a0\n\u00a0\n3) Un\u00a0tercer\u00a0pico\u00a0o\u00a0de\u00a0mortalidad \u00a0tard\u00eda,\u00a0ocurre\u00a0a\u00a0los\u00a0d\u00edas\u00a0o\u00a0semanas\u00a0tras\u00a0el\u00a0\ntrauma\u00a0y\u00a0est\u00e1\u00a0 originado\u00a0por\u00a0sepsis\u00a0o\u00a0FMO,\u00a0abarcando \u00a0un\u00a015\u201020%\u00a0de\u00a0la\u00a0mortalidad. \u00a0\u00a0\n\u00a0\nLos\u00a0mejores\u00a0predictores \u00a0de\u00a0supervivencia \u00a0para\u00a0la\u00a0mayor\u00a0parte\u00a0de\u00a0los\u00a0\nautores\u00a0son\u00a0la\u00a0edad,\u00a0el\u00a0nivel\u00a0de\u00a0conciencia \u00a0al\u00a0ingreso,\u00a0el\u00a0nivel\u00a0medular\u00a0 afectado\u00a0y\u00a0\nla\u00a0necesidad\u00a0 de\u00a0apoyo\u00a0respiratorio \u00a0(173,174) .\u00a0La\u00a0mortalidad\u00a0 tras\u00a0la\u00a0LMAT\u00a0est\u00e1\u00a0\ninfluenciada \u00a0por\u00a0varios\u00a0factores\u00a0como\u00a0anteriormente \u00a0hemos\u00a0enumerado, \u00a0pero\u00a0\nquiz\u00e1s\u00a0 el\u00a0m\u00e1s\u00a0importante \u00a0de\u00a0\u00e9stos\u00a0es\u00a0la\u00a0severidad\u00a0 de\u00a0las\u00a0lesiones\u00a0asociadas, \u00a0ya\u00a0\nque\u00a0muchas\u00a0de\u00a0estas\u00a0lesiones\u00a0\u00a0son\u00a0fatales.\u00a0 Para\u00a0las\u00a0lesiones\u00a0espinales\u00a0 \u00fanicas,\u00a0la\u00a0\nmortalidad\u00a0 despu\u00e9s\u00a0de\u00a0un\u00a0a\u00f1o\u00a0es\u00a0solo\u00a0del\u00a05\u20107\u00a0%.\u00a0Tras\u00a0el\u00a0an\u00e1lisis\u00a0univariante, \u00a0\nhallamos\u00a0 que\u00a0la\u00a0presencia \u00a0de\u00a0traumas\u00a0asociados, \u00a0como\u00a0TV,\u00a0TCE,\u00a0TA\u00a0y\u00a0TT;\u00a0poseen\u00a0\nuna\u00a0fuerte\u00a0asociaci\u00f3n \u00a0con\u00a0la\u00a0mortalidad\u00a0 en\u00a0nuestra\u00a0serie\u00a0(OR\u00a0=\u00a018,44;\u00a0p\u00a0=\u00a00,0000,\u00a0\nOR=\u00a012.38;\u00a0p=\u00a00,0003,\u00a0OR\u00a0=\u00a011,28\nivam\n\u00a0 154\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nEl\u00a0grupo\u00a0de\u00a0trabajo\u00a0de\u00a0Neumann \u00a0et\u00a0al\u00a0(173)\u00a0identifica \u00a0mediante \u00a0un\u00a0\nn\u00e1lisis\u00a0bivariante \u00a0que\u00a0la\u00a0mortalidad \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0LMA\u00a0durante\u00a0su\u00a0fase\u00a0\naguda\u00a0 encia\u00a0de\u00a0un\u00a0alto\u00a0score\u00a0de\u00a0severidad\u00a0 de\u00a0las\u00a0\nlesione\n\u00a0fallo\u00a0renal\u00a0\nagudo. esultados \u00a0similares\u00a0hallamos\u00a0en\u00a0nuestra\u00a0serie,\u00a0donde\u00a0la\u00a0presencia \u00a0de\u00a0un\u00a0\nAPACH\ndurante\u00a0el\u00a0\ngreso,\u00a0se\u00a0correlacionan\u00a0 de\u00a0un\u00a0modo\u00a0consistente \u00a0con\u00a0la\u00a0mortalidad\u00a0 en\u00a0nuestra\u00a0\nserie,\u00a0 c\nnes\u00a0durante\u00a0el\u00a0ingreso\u00a0en\u00a0la\u00a0UR\u00a0se\u00a0relacionan\u00a0\nn\u00a0diferente \u00a0grado\u00a0con\u00a0 la\u00a0mortalidad, \u00a0con\u00a0 diferencias\u00a0 estad\u00edsticamente \u00a0\nsignific a\n,\u00a0\nomplicaciones\u00a0 hematol\u00f3gicas \u00a0(coagulopat\u00eda, \u00a0plaquetopenia), \u00a0estados\u00a0\ninfeccio\nna\u00a0alta\u00a0capacidad \u00a0predictiva \u00a0respecto\u00a0a\u00a0la\u00a0variable\u00a0mortalidad.\u00a0\nResultados \u00a0concordantes \u00a0hallamos\u00a0 en\u00a0nuestra\u00a0serie,\u00a0donde\u00a0la\u00a0edad,\u00a0presencia \u00a0de\u00a0\u00a0a\nse\u00a0correlacionan \u00a0con\u00a0 la\u00a0pres\ns,\u00a0escala\u00a0 de\u00a0Glasgow\u00a0menores\u00a0de\u00a09,\u00a0existencia \u00a0de\u00a0severos\u00a0d\u00e9ficits\u00a0\nneurol\u00f3gicos, \u00a0estados\u00a0 de\u00a0shock\u00a0al\u00a0ingreso,\u00a0uso\u00a0de\u00a0vasopresores, \u00a0VM\u00a0y\n\u00a0R\nE\u00a0II\u00a0elevado\u00a0con\u00a0 traumas\u00a0asociados, \u00a0principalmente \u00a0TV\u00a0y\u00a0\u00a0TCE\u00a0\n(correlacionados \u00a0cl\u00e1sicamente \u00a0con\u00a0escalas\u00a0de\u00a0Glasgow\u00a0bajas),\u00a0 presencia \u00a0de\u00a0coma\u00a0\nfarmacol\u00f3gico \u00a0o\u00a0estructural,\u00a0 necesidad \u00a0de\u00a0apoyo\u00a0vasoactivo \u00a0y\u00a0de\u00a0VM\u00a0\u00a0\nin\nas\u00ed\u00a0omo\u00a0la\u00a0aparici\u00f3n\u00a0 durante\u00a0el\u00a0ingreso\u00a0en\u00a0la\u00a0UR\u00a0de\u00a0una\u00a0serie\u00a0de\u00a0\ncomplicaciones\u00a0 m\u00e9dicas.\u00a0\u00a0\n\u00a0La\u00a0presencia \u00a0de\u00a0complicacio\ne\nativ s,\u00a0as\u00ed\u00a0como\u00a0son\u00a0las\u00a0complicaciones \u00a0de\u00a0tipo\u00a0respiratorio \u00a0(neumon\u00edas \u00a0\nnosocomiales, \u00a0s\u00edndrome \u00a0de\u00a0Mendelson, \u00a0SDRA),\u00a0complicaciones\u00a0 cardiovasculares\nc\n\u00a0 155sos\u00a0consistentes \u00a0en\u00a0shock\u00a0s\u00e9ptico\u00a0y\u00a0neumopat\u00edas\u00a0 nosocomiales \u00a0precoces\u00a0\ny\u00a0tard\u00edas,\u00a0alteraciones \u00a0renales\u00a0y\u00a0la\u00a0necesidad \u00a0de\u00a0soporte\u00a0de\u00a0reemplazamiento \u00a0\nrenal.\u00a0La\u00a0necesidad\u00a0 de\u00a0politransfusi\u00f3n \u00a0durante\u00a0la\u00a0reanimaci\u00f3n \u00a0(OR\u00a0=\u00a063;\u00a0p\u00a0=\u00a0\n0,0000),\u00a0presencia\u00a0 o\u00a0aparici\u00f3n \u00a0de\u00a0fallo\u00a0renal\u00a0agudo\u00a0(OR\u00a0=\u00a041,5;\u00a0p\u00a0=\u00a00,0000),\u00a0\nepisodio\u00a0neum\u00f3nico\u00a0 (OR\u00a0=\u00a013,2;\u00a0p\u00a0=\u00a00,0002),\u00a0empleo\u00a0de\u00a0drogas\u00a0vasoactivas \u00a0(OR\u00a0=\u00a0\n11,04;\u00a0p\u00a0=\u00a00,0002),\u00a0\u00a0son\u00a0 las\u00a0complicaciones \u00a0m\u00e1s\u00a0 relacionadas \u00a0con\u00a0 la\u00a0variable\u00a0\nmortalidad. \u00a0\u00a0\n\u00a0Numerosos \u00a0estudios\u00a0afirman\u00a0que\u00a0los\u00a0pacientes \u00a0m\u00e1s\u00a0j\u00f3venes\u00a0y\u00a0con\u00a0mejor\u00a0\nnivel\u00a0de\u00a0conciencia \u00a0al\u00a0ingreso\u00a0tienen\u00a0mayor\u00a0 supervivencia,\u00a0 y\u00a0la\u00a0asistencia \u00a0\nrespiratoria \u00a0tiene\u00a0uIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nVM\u00a0y\u00a0\nd\n\u00a0de\u00a0\u00a0mortalidad\u00a0 de\u00a0dichas\u00a0pacientes \u00a0infectados \u00a0(130) .\u00a0\nDel\u00a0 mismo\u00a0modo\u00a0esta\u00a0asociaci\u00f3n \u00a0es\u00a0establecida \u00a0claramente \u00a0para\u00a0algunas\u00a0\nlocaliza\nte\u00a0a\u00a0otros\u00a0 autores\u00a0que\u00a0si\u00a0encuentran \u00a0que\u00a0un\u00a0porcentaje \u00a0de\u00a0la\u00a0\nmortalidad\u00a0 en\u00a0sus\u00a0trabajos,\u00a0podr\u00eda\u00a0ser\u00a0atribuible\u00a0 a\u00a0la\u00a0BN\u00a0(187\u2010190) .\u00a0La\u00a0presencia \u00a0\nde\u00a0ITUel\u00a0tiempo\u00a0necesario \u00a0de\u00a0esta\u00a0\u00a0son\u00a0factores\u00a0predictores \u00a0del\u00a0exitus.\u00a0En\u00a0el\u00a0\nestudio\u00a0anteriormente \u00a0mencionado\u00a0 (173)\u00a0reporta\u00a0una\u00a0mortalidad\u00a0 de\u00a0los\u00a0\npacientes \u00a0con\u00a0LMA\u00a0sin\u00a0traumas\u00a0acompa\u00f1antes \u00a0de\u00a0un\u00a05,2%,\u00a0mientras\u00a0que\u00a0en\u00a0\nnuestra\u00a0serie,\u00a0no\u00a0se\u00a0produce\u00a0ning\u00fan\u00a0caso\u00a0en\u00a0pacientes \u00a0con\u00a0LMAT\u00a0pura.\u00a0\n\u00a0La\u00a0aplicaci\u00f3n \u00a0de\u00a0un\u00a0sistema\u00a0de\u00a0vigilancia\u00a0de\u00a0IN\u00a0tiene\u00a0como\u00a0objetivo\u00a0\nprioritario \u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0las\u00a0tasas\u00a0 e\u00a0IN,\u00a0mediante \u00a0la\u00a0introducci\u00f3n \u00a0de\u00a0medidas\u00a0\nde\u00a0intervenci\u00f3n \u00a0destinadas \u00a0a\u00a0prevenir\u00a0 la\u00a0infecci\u00f3n\u00a0y\u00a0a\u00a0optimizar \u00a0los\u00a0tratamientos \u00a0\nemp\u00edricos. \u00a0Los\u00a0cambios\u00a0introducidos \u00a0para\u00a0la\u00a0reducci\u00f3n \u00a0de\u00a0las\u00a0IN\u00a0deber\u00edan\u00a0tener\u00a0\nimpacto\u00a0en\u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0mortalidad, \u00a0de\u00a0las\u00a0estancias\u00a0hospitalarias\u00a0 \u00f3\u00a0de\u00a0\nlos\u00a0costes\u00a0del\u00a0proceso.\u00a0 Diversos\u00a0estudios\u00a0han\u00a0encontrado \u00a0una\u00a0asociaci\u00f3n \u00a0positiva\u00a0\nentre\u00a0la\u00a0IN\u00a0y\u00a0el\u00a0incremento\nciones\u00a0espec\u00edficas\u00a0 de\u00a0la\u00a0infecci\u00f3n, \u00a0como\u00a0la\u00a0NN\u00a0(175\u2010183)\u00a0como\u00a0ocurre\u00a0 en\u00a0\nnuestro\u00a0estudio\u00a0 en\u00a0el\u00a0cual\u00a0 podemos \u00a0apreciar\u00a0una\u00a0asociaci\u00f3n \u00a0estad\u00edsticamente \u00a0\nsignificativa \u00a0entre\u00a0la\u00a0mortalidad\u00a0 y\u00a0la\u00a0NN\u00a0tanto\u00a0precoz\u00a0como\u00a0tard\u00eda.\u00a0As\u00ed\u00a0la\u00a0\npresencia \u00a0de\u00a0un\u00a0episodio\u00a0de\u00a0IN\u00a0conlleva\u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0probabilidad \u00a0de\u00a0exitus\u00a0\nde\u00a07,8\u00a0veces,\u00a0 mientras\u00a0que\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0NN\u00a0precoz\u00a0y\u00a0tard\u00eda\u00a0incrementa \u00a0de\u00a0\nmanera\u00a0muy\u00a0sustancial \u00a0la\u00a0mortalidad \u00a0(0R\u00a0=\u00a024,03;\u00a0p\u00a0=\u00a00,000,\u00a00R\u00a0=\u00a06,08;\u00a0p\u00a0=\u00a0\n0,0048)\u00a0de\u00a0forma\u00a0respectiva. \u00a0\n\u00a0En\u00a0cuanto\u00a0a\u00a0la\u00a0BN\u00a0encontramos \u00a0discordancias \u00a0en\u00a0la\u00a0mortalidad\u00a0 atribuible, \u00a0\nas\u00ed\u00a0los\u00a0grupos\u00a0 de\u00a0DiGiovine, \u00a0Sanfir\u00a0y\u00a0Warren;\u00a0no\u00a0hallan\u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0\nmortalidad\u00a0 por\u00a0esta\u00a0IN\u00a0(184\u2010186) ,\u00a0lo\u00a0que\u00a0coincide\u00a0con\u00a0los\u00a0resultados \u00a0de\u00a0nuestro\u00a0\nestudio;\u00a0fren\n\u00a0 156\u00a0e\u00a0IHQ\u00a0no\u00a0podemos \u00a0atribuirla\u00a0como\u00a0causa\u00a0de\u00a0mortalidad\u00a0 en\u00a0nuestra\u00a0\ncohorte.\u00a0\n\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0\ntica,\u00a0no\u00a0se\u00a0estableci\u00f3 \u00a0para\u00a0determinar \u00a0pron\u00f3sticos \u00a0\nindividuales \u00a0de\u00a0mortalidad, \u00a0sino\u00a0 de\u00a0grupos.\u00a0La\u00a0clasificaci\u00f3n \u00a0APACHE\u00a0 II\u00a0constituye \u00a0\nun\u00a0bue\nla\u00a0naturaleza \u00a0del\u00a0traumatismo \u00a0(cerrado\u00a0o\u00a0penetrante), \u00a0del\u00a0Revised\u00a0\nTraum Score \u00a0(RTS)\u00a0que\u00a0comprende \u00a0la\u00a0presi\u00f3n\u00a0arterial\u00a0sist\u00f3lica,\u00a0la\u00a0escala\u00a0de\u00a0\nGlasgow\u00a0y\u00a0la\u00a0frecuencia\u00a0 respiratoria,\u00a0 y\u00a0de\u00a0las\u00a0lesiones\u00a0anat\u00f3micas \u00a0evaluadas \u00a0por\u00a0\u00a0Existe\u00a0ausencia\u00a0de\u00a0asociaci\u00f3n \u00a0entre\u00a0la\u00a0presencia \u00a0de\u00a0LI\u00a0y\u00a0mortalidad. \u00a0\nJim\u00e9nez\u00a0et\u00a0al\u00a0(191)\u00a0muestra\u00a0 en\u00a0su\u00a0estudio\u00a0 que\u00a0el\u00a0n\u00famero\u00a0de LI\u00a0no\u00a0era\u00a0elevado,\u00a0si\u00a0\nbien,\u00a0 llamaba\u00a0la\u00a0atenci\u00f3n\u00a0 que\u00a0en\u00a0el\u00a073%\u00a0de\u00a0los\u00a0casos\u00a0se\u00a0tratar\u00e1\u00a0de\u00a0lesiones\u00a0\ncl\u00ednicamente \u00a0relevantes. \u00a0\n\u00a0\n\u00a0\n5.8.2.  An\u00e1lisis\u00a0multivariante. \u00a0Regresi\u00f3n \u00a0de\u00a0Cox\u00a0univariante \u00a0\nLas\u00a0variables\u00a0ajustadas\u00a0 que\u00a0presentaron \u00a0diferencias \u00a0estad\u00edsticamente \u00a0\nsignificativas\u00a0 en\u00a0el\u00a0an\u00e1lisis\u00a0 multivariante \u00a0de\u00a0Cox\u00a0para\u00a0la\u00a0variable\u00a0mortalidad \u00a0\nfueron\u00a0tres.\u00a0El\u00a0APACHE\u00a0II\u00a0al\u00a0ingreso\u00a0en\u00a0la\u00a0Unidad,\u00a0la\u00a0presencia \u00a0de\u00a0traumas\u00a0\nmedulares \u00a0cervicales \u00a0y\u00a0la\u00a0coexistencia \u00a0de\u00a0lesi\u00f3n\u00a0vascular\u00a0y\u00a0fallo\u00a0renal.\u00a0\n\u00a0El\u00a0APACHE\u00a0II,\u00a0es\u00a0un\u00a0sistema\u00a0de\u00a0valoraci\u00f3n \u00a0pronostica\u00a0 de\u00a0mortalidad, \u00a0que\u00a0\npunt\u00faa\u00a0los\u00a0trastornos\u00a0 fisiol\u00f3gicos \u00a0agudos\u00a0 que\u00a0atentan\u00a0contra\u00a0 la\u00a0vida\u00a0del\u00a0paciente\u00a0\ny\u00a0se\u00a0fundamenta \u00a0en\u00a0la\u00a0determinaci\u00f3n\u00a0 de\u00a0las\u00a0alteraciones \u00a0de\u00a0variables\u00a0fisiol\u00f3gicas \u00a0\ny\u00a0de\u00a0par\u00e1metros \u00a0de\u00a0laboratorio, \u00a0cuya\u00a0puntuaci\u00f3n \u00a0es\u00a0un\u00a0factor\u00a0predictivo\u00a0 de\u00a0\nmortalidad, \u00a0siendo\u00a0este\u00a0\u00edndice\u00a0v\u00e1lido\u00a0para\u00a0un\u00a0amplio\u00a0rango\u00a0de\u00a0diagn\u00f3sticos, \u00a0f\u00e1cil\u00a0\nde\u00a0usar\u00a0y\u00a0que\u00a0puede\u00a0sustentarse \u00a0en\u00a0datos\u00a0 disponibles \u00a0en\u00a0la\u00a0mayor\u00a0 parte\u00a0de\u00a0las\u00a0\nUC.\u00a0Es\u00a0importante \u00a0destacar\u00a0que\u00a0el\u00a0uso\u00a0de\u00a0esta\u00a0escala,\u00a0as\u00ed\u00a0como\u00a0cualquier\u00a0 otro\u00a0\nsistema\u00a0de\u00a0valoraci\u00f3n \u00a0pron\u00f3s\nn\u00a0predictor \u00a0de\u00a0mortalidad\u00a0 en\u00a0nuestra\u00a0UR\u00a0para\u00a0la\u00a0poblaci\u00f3n \u00a0de\u00a0pacientes \u00a0\npolitraumatizados \u00a0con\u00a0 LMA,\u00a0con\u00a0 una\u00a0ampliaci\u00f3n \u00a0progresiva \u00a0del\u00a0 riesgo\u00a0de\u00a0\nmortalidad\u00a0 seg\u00fan\u00a0aumenta\u00a0 el\u00a0valor\u00a0en\u00a0la\u00a0clasificaci\u00f3n \u00a0APACHE\u00a0II.\u00a0\u00a0\n\u00a0En\u00a0la\u00a0actualidad, \u00a0el\u00a0score\u00a0m\u00e1s\u00a0utilizado\u00a0y\u00a0de\u00a0mayor\u00a0 rendimiento \u00a0es\u00a0el\u00a0\nTrauma\u00a0 Related\u00a0Injury\u00a0Severity\u00a0Score\u00a0(TRISS).\u00a0 El\u00a0TRISS\u00a0se\u00a0formula\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0\nedad,\u00a0de\u00a0\n\u00a0 157a\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nel\u00a0Inju\nn\u00a0elevado\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0con\u00a0 LMA\u00a0cervical\u00a0precisar\u00e1\u00a0 VM\u00a0e\u00a0\nintubaci\u00f3n \u00a0traqueal\u00a0 dentro\u00a0de\u00a0las\u00a0primeras\u00a024\u00a0horas\u00a0tras\u00a0la\u00a0lesi\u00f3n,\u00a0y\u00a0en\u00a0un\u00a0alto\u00a0\nporcen del\u00a0nivel\u00a0de\u00a0\nconcien\nplicaciones \u00a0\nrespiratorias. \u00a0Berney\u00a0et\u00a0al\u00a0(212)\u00a0describen \u00a0en\u00a0su\u00a0estudio\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0\nmorbil\n\u00a0transfusi\u00f3n \u00a0de\u00a0\nhemoderivados\u00a0 pudiendo\u00a0 contribuir \u00a0esto\u00a0tambi\u00e9n\u00a0a\u00a0la\u00a0creaci\u00f3n\u00a0de\u00a0CID\u00a0y\u00a0fallo\u00a0\nmultiory\u00a0Severity\u00a0Score\u00a0(ISS).\u00a0Por\u00a0tanto,\u00a0en\u00a0un\u00a0futuro\u00a0podr\u00eda\u00a0y\u00a0deber\u00eda\u00a0 ser\u00a0\nconveniente \u00a0la\u00a0sustituci\u00f3n \u00a0del\u00a0 APACHE\u00a0II\u00a0por\u00a0 el\u00a0TRISS\u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0diagn\u00f3stico\u00a0 de\u00a0ingreso\u00a0de\u00a0politraumatismo. \u00a0\n\u00a0\nU\ntaje\u00a0en\u00a0nuestra\u00a0cohorte\u00a0se\u00a0asocian\u00a0con\u00a0 TCE\u00a0con\u00a0 alteraci\u00f3n \u00a0\ncia.\u00a0En\u00a0nuestra\u00a0serie,\u00a0los\u00a0pacientes \u00a0con\u00a0LMA\u00a0tor\u00e1cica\u00a0\u00f3\u00a0lumbar\u00a0respecto\u00a0a\u00a0\nlos\u00a0pacientes\u00a0 con\u00a0 LMA\u00a0cervical\u00a0tienen\u00a0un\u00a0riesgo\u00a0menor\u00a0de\u00a0NN\u00a0y\u00a0de\u00a0mortalidad\u00a0\n(OR=63,374) \u00a0pudiendo\u00a0 atribuirlo \u00a0al\u00a0hecho\u00a0de\u00a0que\u00a0estos\u00a0pacientes \u00a0precisar\u00e1n \u00a0con\u00a0\nm\u00e1s\u00a0frecuencia \u00a0VM,\u00a0acompa\u00f1\u00e1ndose \u00a0dicha\u00a0ventilaci\u00f3n \u00a0de\u00a0com\nidad\u00a0en\u00a0los\u00a0pacientes \u00a0lesionados \u00a0medulares \u00a0con\u00a0 la\u00a0realizaci\u00f3n\u00a0 de\u00a0una\u00a0\ntraqueostom\u00eda \u00a0precoz,\u00a0 en\u00a0aquellos\u00a0 que\u00a0pudieran\u00a0 precisar\u00a0 VM\u00a0prolongada \u00a0y\u00a0\nfijaci\u00f3n\u00a0de\u00a0la\u00a0columna\u00a0cervical;\u00a0pero\u00a0esto\u00a0podr\u00eda\u00a0favorecer\u00a0 el\u00a0desarrollo \u00a0de\u00a0\ninfecci\u00f3n\u00a0de\u00a0la\u00a0cirug\u00eda\u00a0de\u00a0fijaci\u00f3n\u00a0cervical.\u00a0\n\u00a0\nEn\u00a0este\u00a0an\u00e1lisis\u00a0 de\u00a0regresi\u00f3n \u00a0m\u00faltiple\u00a0encontramos \u00a0que\u00a0la\u00a0presencia \u00a0de\u00a0TV\u00a0\ne\u00a0insuficiencia \u00a0renal\u00a0conllevan \u00a0un\u00a0incremento \u00a0en\u00a0la\u00a0mortalidad.\u00a0 Los\u00a0pacientes \u00a0con\u00a0\nLMA\u00a0y\u00a0TV\u00a0acompa\u00f1antes \u00a0serian\u00a0m\u00e1s\u00a0propensos \u00a0a\u00a0precisar\u00a0un\u00a0aporte\u00a0\nsuplementario \u00a0de\u00a0volumen\u00a0 y\u00a0en\u00a0ocasiones \u00a0f\u00e1rmacos\u00a0vasopresores, \u00a0tratando\u00a0con\u00a0\ntodo\u00a0ello\u00a0de\u00a0restaurar\u00a0 la\u00a0p\u00e9rdida\u00a0de\u00a0volumen\u00a0circulante,\u00a0 la\u00a0cual\u00a0 puede\u00a0dar\u00a0lugar\u00a0a\u00a0\nuna\u00a0hipoperfusi\u00f3n \u00a0renal\u00a0determinando\u00a0 episodios \u00a0de\u00a0insuficiencia \u00a0renal.\u00a0 Adem\u00e1s\u00a0\npara\u00a0restaurar \u00a0dicho\u00a0volumen\u00a0circulante \u00a0puede\u00a0ser\u00a0necesaria \u00a0la\n\u00a0 158rg\u00e1nico\u00a0cuando\u00a0esta\u00a0transfusi\u00f3n \u00a0es\u00a0masiva\u00a0(213\u2010214) .\u00a0\n\u00a0M\u00faltiples\u00a0 estudios\u00a0relacionan \u00a0la\u00a0edad\u00a0con\u00a0la\u00a0mortalidad\u00a0 en\u00a0pacientes \u00a0con\u00a0\nLMAT.\u00a0No\u00a0hallamos\u00a0 una\u00a0correlaci\u00f3n \u00a0con\u00a0significaci\u00f3n \u00a0entre\u00a0 la\u00a0edad\u00a0y\u00a0mortalidad, \u00a0\ndatos\u00a0 en\u00a0concordancia \u00a0con\u00a0el\u00a0estudio\u00a0de\u00a0Krassioukov \u00a0et\u00a0al\u00a0(23).\u00a0\u00a0El\u00a0trabajo\u00a0de\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nFurlan\u00a0 et\u00a0al\u00a0(215)\u00a0concluye\u00a0a\u00a0pensar\u00a0que\u00a0la\u00a0edad\u00a0es\u00a0un\u00a0importante \u00a0factor\u00a0de\u00a0\nmortalidad\u00a0 en\u00a0el\u00a0an\u00e1lisis\u00a0 univariante \u00a0inicial;\u00a0al\u00a0realizar\u00a0la\u00a0regresi\u00f3n \u00a0de\u00a0Cox,\u00a0\u00a0la\u00a0\nmortalidad\u00a0 de\u00a0su\u00a0serie\u00a0se\u00a0relaciona\u00a0con\u00a0 la\u00a0presencia\u00a0 de\u00a0una\u00a0alta\u00a0comorbilidad \u00a0\nbasal\u00a0 ante\u00a0el\u00a0\u00edndice\u00a0de\u00a0Deyo\u2010Charlson\u00a0m\u00e1s\u00a0que\u00a0la\u00a0edad\u00a0del\u00a0paciente. \u00a0\nNosotr\n\u00a0\n5.9.1. An\u00e1lisis\u00a0univariante \u00a0\nEl\u00a0uso\u00a0de\u00a0CTC\u00a0para\u00a0minimizar \u00a0la\u00a0LMA\u00a0mantiene \u00a0una\u00a0vigencia\u00a0de\u00a030\u00a0a\u00f1os.\u00a0\nActualmente \u00a0persiste\u00a0la\u00a0controversia \u00a0sobre\u00a0su\u00a0uso\u00a0rutinario, \u00a0aunque\u00a0en\u00a0la\u00a0\nmayor\u00eda\u00a0 de\u00a0los\u00a0centros\u00a0poseen\u00a0protocolos \u00a0de\u00a0actuaci\u00f3n \u00a0que\u00a0incluyen\u00a0las\u00a0\ndirectrices \u00a0de\u00a0los\u00a0estudios\u00a0NASCIS\u00a0II\u00a0y\u00a0III\u00a0para\u00a0el\u00a0manejo\u00a0del\u00a0paciente\u00a0con\u00a0LMA.\u00a0\nEsta\u00a0medida\u00a0farmacol\u00f3gica \u00a0ha\u00a0conseguido\u00a0 disminuir \u00a0el\u00a0grado\u00a0de\u00a0lesi\u00f3n\u00a0medular\u00a0\nsecundaria \u00a0tras\u00a0el\u00a0traumatismo, \u00a0probablemente \u00a0debido\u00a0a\u00a0sus\u00a0 propiedades \u00a0\nantiinflamatorias \u00a0y\u00a0neuroprotectoras \u00a0mediante \u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0peroxidaci\u00f3n \u00a0\nlip\u00eddica,\u00a0modulaci\u00f3n \u00a0de\u00a0diversas\u00a0citoquinas, \u00a0mejora\u00a0de\u00a0la\u00a0perfusi\u00f3n \u00a0vascular\u00a0y\u00a0la\u00a0\ndisminuci\u00f3n \u00a0de\u00a0la\u00a0apoptosis \u00a0celular\u00a0al\u00a0impedir\u00a0el\u00a0acumulo\u00a0del\u00a0calcio\u00a0intracelular. \u00a0\u00a0\n\u00a0La\u00a0hiperglucemia \u00a0posee\u00a0una\u00a0fuerte\u00a0asociaci\u00f3n \u00a0con\u00a0 el\u00a0empleo\u00a0de\u00a0MP\u00a0en\u00a0\nnuestra\u00a0serie\u00a0(OR=5,92). \u00a0Resultados \u00a0semejantes \u00a0han\u00a0 sido\u00a0publicados \u00a0por\u00a0\nnumerosos \u00a0autores.\u00a0La\u00a0causa\u00a0es\u00a0atribuida\u00a0a\u00a0que\u00a0su\u00a0empleo\u00a0tiene\u00a0una\u00a0poderosa \u00a0\ninfluencia \u00a0en\u00a0el\u00a0metabolismo \u00a0de\u00a0la\u00a0glucosa,\u00a0 resultando \u00a0en\u00a0un\u00a0deficitario \u00a0control\u00a0\nde\u00a0esta\u00a0y\u00a0una\u00a0resistencia \u00a0a\u00a0la\u00a0insulina\u00a0en\u00a0el\u00a0paciente\u00a0cr\u00edtico.\u00a0Se\u00a0recomienda \u00a0un\u00a0\u00a0medi\n\u00a0 159os\u00a0no\u00a0encontramos \u00a0asociaci\u00f3n \u00a0entre\u00a0mortalidad\u00a0\u00a0 e\u00a0\u00edndice\u00a0de\u00a0Deyo\u00a0\nCharlson, \u00a0una\u00a0posible\u00a0explicaci\u00f3n \u00a0pudiera\u00a0ser\u00a0el\u00a0peque\u00f1o\u00a0tama\u00f1o\u00a0muestral, \u00a0pues\u00a0\nhasta\u00a0un\u00a071,88%\u00a0 de\u00a0nuestra\u00a0 cohorte\u00a0no\u00a0presenta\u00a0comorbilidad \u00a0asociada, \u00a0y\u00a0un\u00a0\n75%\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0de\u00a0este\u00a0estudio\u00a0tienen\u00a0una\u00a0edad\u00a0inferior\u00a0a\u00a044\u00a0a\u00f1os.\u00a0\n\u00a0\n\u00a0\n\u00a0\n5.9. PROTOCOLO \u00a0NASCIS\u00a0II\u00a0Y\u00a0LESI\u00d3N\u00a0MEDULAR\u00a0 AGUDA\u00a0\nTRAUM\u00c1TICA \u00a0\n IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\ncontrol\u00a0de\u00a0la\u00a0glucemia\u00a0en\u00a0el\u00a0paciente\u00a0gravemente \u00a0enfermo\u00a0para\u00a0disminuir \u00a0su\u00a0\nmorbi\u2010mortalidad. \u00a0Un\u00a0pobre\u00a0control\u00a0gluc\u00e9mico \u00a0y\u00a0un\u00a0excesivo\u00a0uso\u00a0de\u00a0insulina\u00a0se\u00a0\nrelacionan\u00a0 con\u00a0 un\u00a0incremento \u00a0de\u00a0la\u00a0mortalidad\u00a0 en\u00a0pacientes \u00a0m\u00e9dicos,\u00a0\nposquir\u00fargicos \u00a0y\u00a0politraumatizados \u00a0(193\u2010197) .\u00a0\n\u00a0Se\u00a0observa\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0 de\u00a0resultados \u00a0un\u00a0sesgo\u00a0en\u00a0la\u00a0gravedad \u00a0de\u00a0los\u00a0\npacientes, \u00a0reflejado\u00a0en\u00a0un\u00a0mayor\u00a0 APACHE\u00a0II,\u00a0presencia\u00a0 de\u00a0pacientes \u00a0con\u00a0TCE,\u00a0TV,\u00a0\ncoagulopat\u00eda, \u00a0necesidad \u00a0VMI,\u00a0empleo\u00a0de\u00a0t\u00e9cnicas\u00a0de\u00a0depuraci\u00f3n \u00a0rena l\u00a0y\u00a0en\u00a0la\u00a0\npresencia \u00a0de\u00a0neumopat\u00edas\u00a0 nosocomiales. \u00a0\u00a0As\u00ed,\u00a0 la\u00a0IA\u00a0anual\u00a0de\u00a0exitus\u00a0por\u00a0100\u00a0\npacientes \u00a0ingresados \u00a0en\u00a0la\u00a0UR\u00a0con\u00a0 diagnostico\u00a0 de\u00a0LMA\u00a0fue\u00a0en\u00a0el\u00a0periodo\u00a0 de\u00a0\nestudio de\u00a0un\u00a010,42%,\u00a0cifra\u00a0en\u00a0consonancia \u00a0con\u00a0 el\u00a0estudio\u00a0retrospectivo \u00a0\nal 5\u00a0\nperio a\u00a0mortalidad\u00a0 de\u00a0la\u00a0LMAT\u00a0en\u00a0EE.UU.\u00a0de\u00a0un\u00a08%.\u00a0En\u00a0nuestra\u00a0\ncohorte\u00a0de\u00a0pacientes \u00a0tratados\u00a0con\u00a0megadosis \u00a0de\u00a0MP\u00a0la\u00a0mortalidad\u00a0 global\u00a0es\u00a0de\u00a0\nun\u00a05,88%,\u00a0 ntras\u00a0que\u00a0la\u00a0mortalidad\u00a0 del\u00a0grupo\u00a0de\u00a0pacientes\u00a0 no\u00a0tratados\u00a0con\u00a0\nesteroides \u00a0alcanza\u00a0un\u00a021,43%.\u00a0La\u00a0explicaci\u00f3n \u00a0a\u00a0esta\u00a0causa\u00a0es\u00a0multifactorial, \u00a0pero\u00a0\nentre\u00a0 las\u00a0causas\u00a0m\u00e1s\u00a0destacadas \u00a0esta\u00a0la\u00a0frecuente \u00a0asociaci\u00f3n \u00a0entre\u00a0 las\u00a0lesiones\u00a0\nraquimedulares \u00a0y\u00a0el\u00a0TCE,\u00a0que\u00a0ensombrecen \u00a0el\u00a0pron\u00f3stico \u00a0y\u00a0aumenta\u00a0la\u00a0gravedad \u00a0\ndel\u00a0paciente\u00a0cr\u00edtico\u00a0en\u00a0las\u00a0diversas\u00a0escalas\u00a0de\u00a0valoraci\u00f3n. \u00a0El\u00a0estudio\u00a0 CRASH\u00a0\nestablece\u00a0 de\u00a0forma\u00a0categ\u00f3rica \u00a0que\u00a0los\u00a0CTC\u00a0no\u00a0poseen\u00a0ninguna\u00a0indicaci\u00f3n \u00a0en\u00a0el\u00a0\ncontexto\u00a0de\u00a0la\u00a0lesi\u00f3n\u00a0cerebral\u00a0postraum\u00e1tica. \u00a0Es\u00a0m\u00e1s,\u00a0este\u00a0ensayo\u00a0cl\u00ednico\u00a0\ndemuestra \u00a0una\u00a0asociaci\u00f3n \u00a0entre\u00a0el\u00a0uso\u00a0de\u00a0CTC\u00a0y\u00a0el\u00a0aumento\u00a0de\u00a0mortalidad\u00a0 en\u00a0\u00a0los\u00a0\n14\u00a0d\u00edas\u00a0siguientes \u00a0al\u00a0trauma\u00a0 craneal,\u00a0estim\u00e1ndose \u00a0que\u00a0el\u00a0incremento \u00a0bruto\u00a0de\u00a0\nmortalidad\u00a0 en\u00a0pacientes\u00a0 tratados\u00a0con\u00a0MP\u00a0de\u00a0un\u00a03,4%\u00a0(IC\u00a0al\u00a095%:\u00a01,7\u20105,1),\u00a0por\u00a0lo\u00a0\nque\u00a0est\u00e1n\u00a0formalmente\u00a0 contraindicados. \u00a0Por\u00a0tanto,\u00a0en\u00a0nuestra\u00a0cohorte\u00a0al\u00a0no\u00a0\ntratar\u00a0 con\u00a0 el\u00a0protocolo\u00a0 NASCIS\u00a0II,\u00a0desde\u00a0que\u00a0existe\u00a0evidencia \u00a0cient\u00edfica, \u00a0a\u00a0estos\u00a0\npacientes \u00a0produce\u00a0un\u00a0desequilibrio \u00a0en\u00a0la\u00a0gravedad \u00a0entre\u00a0 grupos.\u00a0Este\u00a0\ndesequilibrio \u00a0puede\u00a0ser\u00a0 influenciado \u00a0por\u00a0otras\u00a0causas\u00a0subjetivas, \u00a0como\u00a0la\u00a0\ndecisi\u00f3n\u00a0del\u00a0anestesi\u00f3logo \u00a0de\u00a0no\u00a0tratar\u00a0con\u00a0altas\u00a0dosis\u00a0de\u00a0CTC\u00a0a\u00a0aquellos\u00a0\u00a0\n\u00a0\u00a0\nnorteamericano \u00a0de\u00a0Saunders\u00a0et\u00a0\u00a0(9 ),\u00a0elcual\u00a0 reporta\u00a0 tras\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0un\u00a0\ndo\u00a0de\u00a018\u00a0a\u00f1os,\u00a0 un\n\u00a0 160mieIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\npacientes \u00a0m\u00e1s\u00a0cr\u00edticamente \u00a0enfermos\u00a0 por\u00a0la\u00a0posibilidad \u00a0de\u00a0aparici\u00f3n\u00a0 de\u00a0efectos\u00a0\nadversos\u00a0potencialmente \u00a0graves.\u00a0\u00a0\n\u00a0Probablemente \u00a0por\u00a0una\u00a0sumatoria \u00a0de\u00a0causas\u00a0anteriormente \u00a0expuestas, \u00a0\nobservamos \u00a0que\u00a0el\u00a075%\u00a0de\u00a0los\u00a0pacientes \u00a0no\u00a0tratados\u00a0mediante \u00a0protocolo\u00a0 NASCIS\u00a0\nII\u00a0preci\ne a l\n\u00a0\n\u00a0 161san\u00a0VM\u00a0frente\u00a0a\u00a0un\u00a045%\u00a0de\u00a0la\u00a0cohorte\u00a0tratada\u00a0con\u00a0MP.\u00a0Las\u00a0diferencias \u00a0en\u00a0\nla\u00a0incidencia \u00a0de\u00a0neumon\u00eda \u00a0asociada\u00a0a\u00a0VM\u00a0(NAV)\u00a0en\u00a0los\u00a0an\u00e1lisis\u00a0estad\u00edsticos \u00a0\nrealizados \u00a0en\u00a0nuestra\u00a0serie\u00a0podr\u00edan\u00a0explicarse \u00a0por\u00a0estos\u00a0dos\u00a0factores\u00a0expuestos, \u00a0\ncomo\u00a0son\u00a0la\u00a0diferente \u00a0gravedad \u00a0y\u00a0el\u00a0empleo\u00a0de\u00a0la\u00a0VM\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0el\u00a0grupo\u00a0\nno\u00a0tratado\u00a0con\u00a0 esteroides. \u00a0La\u00a0intubaci\u00f3n \u00a0traqueal\u00a0 en\u00a0numerosos\u00a0 estudios\u00a0se\u00a0\nconsidera \u00a0el\u00a0factor\u00a0m\u00e1s\u00a0importante \u00a0en\u00a0el\u00a0desarrollo\u00a0 de\u00a0complicaciones \u00a0\ninfecciosas \u00a0pulmonares.\u00a0 La\u00a0NAV\u00a0posee\u00a0una\u00a0mortalidad\u00a0 bruta\u00a0de\u00a020\u201040%\u00a0en\u00a0las\u00a0\nUC.\u00a0En\u00a0varios\u00a0estudios\u00a0(183,189,198) \u00a0la\u00a0mortalidad\u00a0 atribuible \u00a0oscil\u00f3\u00a0entre\u00a0un\u00a027\u2010\n33%,\u00a0 demostrando \u00a0que\u00a0aquellos\u00a0 que\u00a0requieren \u00a0VMI\u00a0 y\u00a0desarrollan \u00a0NAV\u00a0tienen\u00a0un\u00a0\nriesgo\u00a0de\u00a0morir\u00a0de\u00a02\u00a0a\u00a02,5\u00a0veces\u00a0mayor\u00a0 que\u00a0los\u00a0controles.\u00a0 Sin\u00a0embargo, \u00a0un\u00a0\nestudio\u00a0caso\u2010control\u00a0reciente\u00a0 (216)\u00a0no\u00a0evidenci\u00f3 \u00a0una\u00a0mayor\u00a0 mortalidad\u00a0 en\u00a0\npacientes \u00a0con\u00a0NAV\u00a0respecto\u00a0de\u00a0aquellos\u00a0libres\u00a0de\u00a0esta\u00a0complicaci\u00f3n \u00a0(30,5%\u00a0\nfrente\u00a0a\u00a030,4%),\u00a0pues\u00a0la\u00a0evoluci\u00f3n \u00a0final\u00a0de\u00a0un\u00a0paciente\u00a0con\u00a0NN\u00a0es\u00a0altamente \u00a0\ndependiente \u00a0de\u00a0la\u00a0virulencia \u00a0del\u00a0germen\u00a0en\u00a0cuesti\u00f3n,\u00a0las\u00a0defensas\u00a0 del\u00a0hu\u00e9sped\u00a0y\u00a0\ndel\u00a0empleo\u00a0de\u00a0una\u00a0apropiada \u00a0terapia\u00a0antibi\u00f3tica \u00a0emp\u00edrica\u00a0 de\u00a0inicio.\u00a0\n\u00a0Como\u00a0sugieren\u00a0Girou\u00a0 (130) ,\u00a0para\u00a0establecer \u00a0la\u00a0verdadera\u00a0 relaci\u00f3n\u00a0entre\u00a0 la\u00a0\ngravedad \u00a0de\u00a0la\u00a0enfermedad, \u00a0una\u00a0actividad\u00a0terap\u00e9utica\u00a0 determinada, \u00a0la\u00a0\nocurrencia\u00a0 de\u00a0IN\u00a0y\u00a0su\u00a0evoluci\u00f3n \u00a0final,\u00a0se\u00a0requiere\u00a0por\u00a0una\u00a0parte\u00a0el\u00a0an\u00e1lisis\u00a0aislado\u00a0\nde\u00a0la\u00a0gravedad \u00a0y\u00a0la\u00a0actividad\u00a0terap\u00e9utica\u00a0 asociada\u00a0como\u00a0causa\u00a0de\u00a0IN.\u00a0Pero,\u00a0por\u00a0\notra\u00a0 parte,\u00a0es\u00a0necesario \u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0la\u00a0IN\u00a0como\u00a0causa\u00a0de\u00a0exceso\u00a0de\u00a0gravedad \u00a0y\u00a0\nde\u00a0actividad\u00a0terap\u00e9utica \u00a0xtra.\u00a0Este\u00a0tipo\u00a0de\u00a0n\u00e1 isis\u00a0es\u00a0muy\u00a0complejo \u00a0y\u00a0dif\u00edcil\u00a0de\u00a0\nrealizar\u00a0en\u00a0la\u00a0pr\u00e1ctica,\u00a0 permaneciendo \u00a0en\u00a0el\u00a0plano\u00a0de\u00a0la\u00a0teor\u00eda.\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n\u00a0en\u00a0la\u00a0supervivencia \u00a0en\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0con\u00a0la\u00a0\naplicaci\u00f3n \u00a0de\u00a0la\u00a0VMI\u00a0 \u201cprotectora\u201d. \u00a0El\u00a0SDRA\u00a0 se\u00a0caracteriza \u00a0en\u00a0su\u00a0\u00a0fase\u00a0subaguda \u00a0\npor\u00a0un\ne d\nariables\u00a0ajustadas\u00a0\npara\u00a0nuestro\u00a0modelo\u00a0fueron\u00a0cinco,\u00a0aunque\u00a0las\u00a0que\u00a0presentaron\u00a0 diferencias\u00a0\nestad\u00edsticamente \u00a0significativas \u00a0fueron\u00a0tres.\u00a0La\u00a0hiperglucemia, \u00a0la\u00a0presencia \u00a0de\u00a0\u00a0El\u00a0SDRA\u00a0 presenta\u00a0 una\u00a0elevada\u00a0 incidencia \u00a0y\u00a0sigue\u00a0teniendo\u00a0 una\u00a0alta\u00a0\nmortalidad, \u00a0a\u00a0pesar\u00a0de\u00a0una\u00a0mejor\u00eda\n\u00a0estado\u00a0inflamatorio \u00a0mantenido \u00a0y\u00a0la\u00a0evoluci\u00f3n \u00a0r\u00e1pida\u00a0a\u00a0fibrosis\u00a0 pulmonar. \u00a0\nVarios\u00a0estudios\u00a0multic\u00e9ntricos \u00a0han\u00a0ensayado \u00a0el\u00a0tratamiento \u00a0con\u00a0MP\u00a0a\u00a0bajas\u00a0 dosis\u00a0\n(1\u00a0mg/kg/d\u00eda) \u00a0\u00a0de\u00a0forma\u00a0precoz\u00a0y\u00a0prolongada \u00a0durante\u00a0esta\u00a0fase\u00a0fibroproliferativa, \u00a0\ncon\u00a0 resultados \u00a0prometedores, \u00a0pero\u00a0no\u00a0concluyentes \u00a0(199\u2010202) .\u00a0En\u00a0nuestro\u00a0\ntrabajo,\u00a0limitado\u00a0 por\u00a0un\u00a0tama\u00f1o\u00a0muestral\u00a0peque\u00f1o, \u00a0as\u00ed\u00a0como\u00a0por\u00a0un\u00a0mayor\u00a0\nn\u00famero\u00a0de\u00a0pacientes \u00a0en\u00a0situaci\u00f3n\u00a0de\u00a0shock\u00a0en\u00a0el\u00a0grupo\u00a0no\u00a0tratado\u00a0no\u00a0\napreciamos\u00a0 diferencias\u00a0 en\u00a0la\u00a0incidencia \u00a0y\u00a0evoluci\u00f3n \u00a0del\u00a0SDRA\u00a0 en\u00a0pacientes\u00a0 con\u00a0\naltas\u00a0dosis\u00a0de\u00a0CTC\u00a0durante\u00a024\u00a0horas.\u00a0\n\u00a0\nLa\u00a0enfermedad \u00a0neuromuscular \u00a0adquirida \u00a0(miopat\u00eda \u00a0del\u00a0paciente\u00a0cr\u00edtico)\u00a0\ncl\u00e1sicamente \u00a0se\u00a0ha\u00a0relacionado \u00a0con\u00a0 el\u00a0empleo\u00a0de\u00a0esteroides \u00a0y\u00a0de\u00a0bloqueantes \u00a0\nneuromusculares.\u00a0 En\u00a0nuestra\u00a0serie\u00a0el\u00a0empleo\u00a0de\u00a0altas\u00a0dosis\u00a0de\u00a0CTC\u00a0 no\u00a0se\u00a0\nrelaciona\u00a0con\u00a0esta\u00a0entidad\u00a0 (p=0,58).\u00a0Recientes \u00a0estudios\u00a0 relacionan \u00a0la\u00a0enfermedad \u00a0\nneuromuscular \u00a0con\u00a0la\u00a0gravedad \u00a0del\u00a0cuadro\u00a0de\u00a0base,\u00a0factores\u00a0relacionados \u00a0con\u00a0la\u00a0\nsedorrelajaci\u00f3n \u00a0y\u00a0al\u00a0tiempo\u00a0de\u00a0VM\u00a0y\u00a0descartan\u00a0 la\u00a0importancia \u00a0de\u00a0la\u00a0asociaci\u00f3n \u00a0\ncon\u00a0el\u00a0empleo\u00a0de\u00a0esteroides. \u00a0\n\u00a0\u00a0\n\u00a0 1625.9.2.  An\u00e1lisis\u00a0multivariante. \u00a0Regresi\u00f3n \u00a0de\u00a0Cox\u00a0\nEn\u00a0l\u00a0caso\u00a0e\u00a0la\u00a0utilizaci\u00f3n \u00a0de\u00a0megadosis \u00a0de\u00a0MP,\u00a0la\u00a0regresi\u00f3n \u00a0de\u00a0Cox\u00a0nos\u00a0\nha\u00a0permitido \u00a0tener\u00a0en\u00a0cuenta\u00a0los\u00a0diferentes \u00a0periodos\u00a0de\u00a0seguimiento \u00a0para\u00a0cada\u00a0\npaciente\u00a0y\u00a0sus\u00a0variables\u00a0asociadas, \u00a0y\u00a0por\u00a0tanto\u00a0conocer\u00a0el\u00a0riesgo\u00a0de\u00a0la\u00a0utilizaci\u00f3n \u00a0\nde\u00a0CTC\u00a0seg\u00fan\u00a0pautas\u00a0del\u00a0protocolo \u00a0NASCIS\u00a0II\u00a0en\u00a0el\u00a0paciente\u00a0con\u00a0 LMAT\u00a0de\u00a0una\u00a0\nforma\u00a0din\u00e1mica. \u00a0El\u00a0m\u00e9todo\u00a0requiere\u00a0identificar \u00a0las\u00a0covariables\u00a0 tiempo\u00a0\ndependiente \u00a0e\u00a0introducirlas \u00a0como\u00a0tales\u00a0en\u00a0el\u00a0modelo,\u00a0y\u00a0as\u00ed\u00a0las\u00a0vIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nhemor\nantener\u00a0el\u00a0tratamiento \u00a0esteroideo\u00a0 con\u00a0MP\u00a0\ndurant 48\u00a0horas\u00a0\u00a0si\u00a0el\u00a0tratamiento \u00a0se\u00a0inicia\u00a0entre\u00a0las\u00a03\u20108\u00a0primeras\u00a0horas\u00a0tras\u00a0el\u00a0\nevento\nspitalaria\u00a0global.\u00a0En\u00a0nuestra\u00a0serie\u00a0hallamos\u00a0una\u00a0\nsignificativa \u00a0disminuci\u00f3n \u00a0del\u00a0n\u00famero\u00a0de\u00a0episodios \u00a0de\u00a0NN\u00a0de\u00a0aparici\u00f3n \u00a0precoz\u00a0\n(OR= \u00a0p\u00a0=\u00a00,04),\u00a0 este\u00a0dato\u00a0contradictorio \u00a0puede\u00a0explicarse \u00a0por\u00a0el\u00a0estudio\u00a0de\u00a0\nRello\u00a0e s\u00a0en\u00a0UC\u00a0con\u00a0una\u00a0menor\u00a0\ngravedragia\u00a0digestiva, \u00a0la\u00a0diferencia \u00a0de\u00a0ASIA\u00a0del\u00a0ingreso\u00a0respecto\u00a0 al\u00a0alta\u00a0de\u00a0la\u00a0\nUnidad,\u00a0la\u00a0NN\u00a0y\u00a0la\u00a0mortalidad. \u00a0\n\u00a0La\u00a0administraci\u00f3n \u00a0de\u00a0MP\u00a0en\u00a0perfusi\u00f3n \u00a0continua\u00a0durante\u00a024\u00a0horas\u00a0se\u00a0\nasocia\u00a0con\u00a0un\u00a0importante \u00a0incremento \u00a0de\u00a0complicaciones \u00a0m\u00e9dicas,\u00a0as\u00ed\u00a0en\u00a0nuestra\u00a0\ncohorte\u00a0su\u00a0empleo\u00a0multiplica \u00a0por\u00a019\u00a0el\u00a0riesgo\u00a0de\u00a0la\u00a0presencia \u00a0de\u00a0al\u00a0menos\u00a0un\u00a0\nepisodio\u00a0de\u00a0hemorragia\u00a0 digestiva\u00a0y\u00a0por\u00a05,67\u00a0en\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0hiperglucemia, \u00a0la\u00a0\nliteratura \u00a0m\u00e9dica\u00a0refleja\u00a0similares\u00a0complicaciones \u00a0m\u00e9dicas\u00a0en\u00a0m\u00faltiples\u00a0 estudios.\u00a0\nMatsumoto \u00a0et\u00a0al\u00a0(81)\u00a0en\u00a0un\u00a0estudio\u00a0 prospectivo, \u00a0randomizado\u00a0 y\u00a0a\u00a0doble\u00a0ciego\u00a0\nrelata\u00a0resultados \u00a0similares, \u00a0pero\u00a0especialmente \u00a0en\u00a0pacientes\u00a0 con\u00a0edad\u00a0avanzada. \u00a0\nEl\u00a0estudio\u00a0NASCIS\u00a0III,\u00a0que\u00a0propone\u00a0m\ne\u00a0\n,\u00a0reporta\u00a0una\u00a0incidencia \u00a0de\u00a0complicaciones \u00a0m\u00e1s\u00a0elevada\u00a0tras\u00a0el\u00a0empleo\u00a0de\u00a0\nMP\u00a0durante\u00a048\u00a0horas.\u00a0\u00a0\n\u00a0Las\u00a0complicaciones\u00a0 infecciosas, \u00a0especialmente \u00a0la\u00a0NN\u00a0se\u00a0han\u00a0relacionado \u00a0\ncon\u00a0el\u00a0uso\u00a0del\u00a0protocolo \u00a0NASCIS\u00a0II,\u00a0as\u00ed\u00a0el\u00a0estudio\u00a0de\u00a0Gerndt\u00a0 et\u00a0al\u00a0(203)\u00a0describe\u00a0\nun\u00a0riesgo\u00a0de\u00a02,6\u00a0en\u00a0la\u00a0aparici\u00f3n\u00a0 de\u00a0NAV,\u00a0acompa\u00f1ado\u00a0 de\u00a0un\u00a0aumento\u00a0de\u00a0los\u00a0d\u00edas\u00a0\nde\u00a0VM\u00a0y\u00a0de\u00a0la\u00a0estancia\u00a0ho\n\u00a00,27,\nt\u00a0al\u00a0(216)\u00a0que\u00a0evidencia\u00a0 que\u00a0pacientes \u00a0ingresado\n\u00a0 163ad,\u00a0la\u00a0exposici\u00f3n \u00a0al\u00a0factor\u00a0de\u00a0riesgo\u00a0de\u00a0\u00a0intubaci\u00f3n \u00a0orotraqueal\u00a0 podr\u00eda\u00a0no\u00a0\nser\u00a0suficiente \u00a0para\u00a0desarrollar \u00a0NAV,\u00a0y\u00a0por\u00a0el\u00a0contrario\u00a0pacientes \u00a0con\u00a0niveles\u00a0\nelevados\u00a0de\u00a0gravedad \u00a0podr\u00edan\u00a0morir\u00a0antes\u00a0de\u00a0desarrollar \u00a0un\u00a0episodio\u00a0neum\u00f3nico. \u00a0\nLa\u00a0literatura \u00a0refleja\u00a0que\u00a0la\u00a0administraci\u00f3n \u00a0precoz\u00a0de\u00a0antibi\u00f3ticos \u00a0en\u00a0pacientes \u00a0\nparece\u00a0tener\u00a0un\u00a0efecto\u00a0protector \u00a0para\u00a0 el\u00a0desarrollo \u00a0de\u00a0esta\u00a0entidad,\u00a0estim\u00e1ndose \u00a0\nen\u00a0el\u00a0estudio\u00a0de\u00a0Rello\u00a0anteriormente \u00a0referenciado \u00a0de\u00a0una\u00a0OR\u00a0de\u00a00,29.\u00a0La\u00a0\nexposici\u00f3n \u00a0previa\u00a0 a\u00a0la\u00a0antibi\u00f3ticoterapia \u00a0produce\u00a0un\u00a0incremento \u00a0del\u00a0riesgo\u00a0\n(OR=1,4)\u00a0de\u00a0NNT.\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nn\u00a02,6\u00a0en\u00a0la\u00a0variable\u00a0mortalidad, \u00a0y\u00a0por\u00a0tanto\u00a0ser\u00eda\u00a0\nuna\u00a0variable\u00a0protectora. \u00a0La\u00a0posible\u00a0explicaci\u00f3n \u00a0respecto\u00a0a\u00a0la\u00a0asociaci\u00f3n \u00a0de\u00a0\nempleo\na\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0mediante \u00a0la\u00a0diferencia \u00a0de\u00a0la\u00a0escala\u00a0ASIA\u00a0al\u00a0\ningreso\nP.\u00a0\u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0 de\u00a0regresi\u00f3n \u00a0m\u00faltiple,\u00a0hallamos\u00a0 que\u00a0el\u00a0empleo\u00a0de\u00a0esteroides \u00a0\nconlleva\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0u\n\u00a0de\u00a0esteroides \u00a0y\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0mortalidad\u00a0 en\u00a0nuestro\u00a0estudio\u00a0es\u00a0la\u00a0\nexistencia \u00a0de\u00a0diferencias\u00a0 estad\u00edsticamente \u00a0significativas\u00a0 en\u00a0la\u00a0gravedad \u00a0de\u00a0los\u00a0\npacientes \u00a0como\u00a0hemos\u00a0comentado \u00a0anteriormente, \u00a0con\u00a0 un\u00a0menor\u00a0APACHE\u00a0II\u00a0\nentre\u00a0 los\u00a0pacientes \u00a0incluidos\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0terapia\u00a0protectora \u00a0con\u00a0CTC\u00a0(p=\u00a00,02),\u00a0\ncon\u00a0un\u00a0APACHE\u00a0II\u00a0respectivo \u00a0de\u00a011,7\u00a0vs\u00a015,6.\u00a0As\u00ed,\u00a0a\u00a0modo\u00a0de\u00a0resumen,\u00a0 podemos \u00a0\nindicar\u00a0que\u00a0el\u00a0posible\u00a0efecto\u00a0protector \u00a0del\u00a0empleo\u00a0de\u00a0megadosis\u00a0 de\u00a0CTC\u00a0 en\u00a0las\u00a0\nvariables\u00a0mortalidad\u00a0 y\u00a0NAV\u00a0precoz\u00a0se\u00a0explican\u00a0por\u00a0la\u00a0menor\u00a0gravedad \u00a0de\u00a0estos\u00a0\npacientes, \u00a0menor\u00a0necesidad \u00a0de\u00a0VMI\u00a0 y\u00a0el\u00a0empleo\u00a0precoz\u00a0de\u00a0antibi\u00f3ticos \u00a0de\u00a0los\u00a0\nfacultativos \u00a0responsables \u00a0del\u00a0enfermo\u00a0por\u00a0la\u00a0situaci\u00f3n\u00a0de\u00a0inmunodepresi\u00f3n \u00a0que\u00a0\nocasiona\u00a0esta\u00a0terapia.\u00a0\u00a0\n\u00a0\nL\n\u00a0 164\u00a0respecto\u00a0al\u00a0alta\u00a0de\u00a0la\u00a0UR\u00a0nos\u00a0muestra\u00a0 que\u00a0el\u00a0tratamiento \u00a0en\u00a0las\u00a0primeras\u00a0\n8\u00a0horas\u00a0tras\u00a0la\u00a0LM,\u00a0mediante \u00a0un\u00a0bolo\u00a0de\u00a030\u00a0mg/kg\u00a0en\u00a015\u00a0minutos\u00a0y\u00a0una\u00a0infusi\u00f3n\u00a0\nintravenosa \u00a0de\u00a05,4\u00a0mg/kg\u00a0por\u00a0hora\u00a0 durante\u00a023\u00a0horas\u00a0no\u00a0conlleva\u00a0una\u00a0mejor\u00eda\u00a0en\u00a0\nla\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0(OR=1,57, \u00a0IC\u00a095%\u00a0de\u00a00,697\u00a0\u2013\u00a03,514,\u00a0 p=\u00a00,27).\u00a0La\u00a0\nLiteratura \u00a0refleja\u00a0 en\u00a0m\u00faltiples \u00a0trabajos\u00a0resultados \u00a0contradictorios, \u00a0habitualmente \u00a0\ncon\u00a0 peque\u00f1os\u00a0 tama\u00f1os\u00a0muestrales \u00a0y\u00a0con\u00a0 importantes \u00a0cr\u00edticas\u00a0a\u00a0la\u00a0diferente \u00a0\nmetodolog\u00eda \u00a0empleada \u00a0en\u00a0ellos\u00a0respecto\u00a0a\u00a0la\u00a0eficacia\u00a0de\u00a0los\u00a0diferentes \u00a0protocolos \u00a0\nNASCIS\u00a0para\u00a0el\u00a0tratamiento \u00a0precoz\u00a0de\u00a0LMA.\u00a0Tres\u00a0grandes\u00a0estudios\u00a0randomizados, \u00a0\ncontrolados \u00a0y\u00a0multic\u00e9ntricos \u00a0han\u00a0 sido\u00a0 realizados, \u00a0as\u00ed\u00a0en\u00a0el\u00a0estudio\u00a0\nnorteamericano \u00a0y\u00a0japon\u00e9s\u00a0 se\u00a0evidencia \u00a0\u00a0una\u00a0mejor\u00eda\u00a0en\u00a0la\u00a0recuperaci\u00f3n \u00a0motora\u00a0\ntras\u00a0emplear\u00a0 la\u00a0terapia\u00a0con\u00a0 MP,\u00a0 resultados \u00a0en\u00a0consonancia \u00a0con\u00a0 los\u00a0hallados\u00a0en\u00a0\nnuestra\u00a0cohorte.\u00a0El\u00a0estudio\u00a0del\u00a0grupo\u00a0franc\u00e9s\u00a0no\u00a0encuentra \u00a0mejor\u00eda\u00a0 alguna\u00a0con\u00a0\nesta\u00a0terapia.\u00a0Los\u00a0trabajos\u00a0de\u00a0Michael\u00a0et\u00a0al\u00a0(204) ,\u00a0\u00a0George \u00a0et\u00a0al\u00a0(205)\u00a0y\u00a0diversos\u00a0\nestudios,\u00a0nos\u00a0muestran \u00a0una\u00a0ausencia\u00a0de\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0tras\u00a0la\u00a0infusi\u00f3n\u00a0\nde\u00a0altas\u00a0dosis\u00a0de\u00a0MIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nNuestros\u00a0resultados \u00a0indican\u00a0 que\u00a0el\u00a0empleo\u00a0de\u00a0megadosis \u00a0de\u00a0MP\u00a0durante\u00a0\nun\u00a0periodo\u00a0de\u00a024\u00a0horas\u00a0no\u00a0se\u00a0asocia\u00a0con\u00a0un\u00a0\u00a0beneficio \u00a0cl\u00ednico\u00a0en\u00a0la\u00a0recuperaci\u00f3n \u00a0\nneurol\u00f3gica \u00a0en\u00a0pacientes\u00a0 con\u00a0LMA\u00a0pero\u00a0si\u00a0con\u00a0un\u00a0importante \u00a0incremento \u00a0de\u00a0los\u00a0\nefectos\u00a0adversos\u00a0m\u00e9dicos.\u00a0 La\u00a0evidencia \u00a0m\u00e9dica\u00a0actual\u00a0refleja\u00a0un\u00a0\u00e1rea\u00a0de\u00a0\nincertidumbre \u00a0en\u00a0este\u00a0tema.\u00a0Tres\u00a0estudios\u00a0multic\u00e9ntricos, \u00a0concluyen \u00a0que\u00a0el\u00a0\ntratamiento \u00a0con\u00a0 MP\u00a0de\u00a0la\u00a0LMAT\u00a0no\u00a0puede\u00a0ser\u00a0considerado \u00a0un\u00a0tratamiento \u00a0\nest\u00e1ndar, \u00a0y\u00a0se\u00a0debe\u00a0considerar \u00a0solo\u00a0como\u00a0una\u00a0opci\u00f3n\u00a0terap\u00e9utica, \u00a0conociendo \u00a0\nque\u00a0la\u00a0evidencia \u00a0m\u00e9dica\u00a0resalta\u00a0 m\u00e1s\u00a0 sus\u00a0efectos\u00a0adversos\u00a0que\u00a0sus\u00a0hipot\u00e9ticos \u00a0\nbeneficios \u00a0cl\u00ednicos.\u00a0\u00a0\n\u00a0Son\u00a0necesarios \u00a0nuevos\u00a0estudios,\u00a0amplios\u00a0 con\u00a0 un\u00a0potente\u00a0poder\u00a0\nestad\u00edstico \u00a0y\u00a0estandarizados, \u00a0sobre\u00a0el\u00a0uso\u00a0de\u00a0las\u00a0diferentes \u00a0sustancias \u00a0\ninvolucradas\u00a0 en\u00a0la\u00a0neuroprotecci\u00f3n\u00a0 medular\u00a0 conocidos\u00a0 hoy\u00a0en\u00a0d\u00eda\u00a0(MP,\u00a0\nnaloxona, \u00a0mesilato\u00a0de\u00a0tirilazad\u00a0y\u00a0gangli\u00f3sido\u00a0 GM\u20101)\u00a0para\u00a0intentar\u00a0aclarar\u00a0esta\u00a0\nzona\u00a0d\n\u00a0\n5.10.1. An\u00e1lisis\u00a0univariante \u00a0\nRespecto\u00a0al\u00a0tratamiento \u00a0quir\u00fargico, \u00a0no\u00a0existe\u00a0consenso\u00a0 en\u00a0el\u00a0tiempo\u00a0\napropiado \u00a0para\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0una\u00a0IQ,\u00a0ni\u00a0hay\u00a0evidencia \u00a0que\u00a0la\u00a0cirug\u00eda\u00a0\ndescompresiva \u00a0influya\u00a0sobre\u00a0el\u00a0resultado\u00a0 neurol\u00f3gico \u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0LM.\u00a0\nLos\u00a0estudios\u00a0cl\u00ednicos\u00a0son\u00a0s\u00f3lo\u00a0de\u00a0clase\u00a0II\u00a0y\u00a0III\u00a0de\u00a0evidencia \u00a0m\u00e9dica.\u00a0Por\u00a0tanto,\u00a0el\u00a0\nmomento \u00a0\u00f3ptimo\u00a0para\u00a0realizar\u00a0una\u00a0descompresi\u00f3n \u00a0\u00f3\u00a0fijaci\u00f3n\u00a0quir\u00fargica \u00a0en\u00a0un\u00a0\npaciente\u00a0con\u00a0LMAT\u00a0es\u00a0una\u00a0de\u00a0las\u00a0decisiones \u00a0m\u00e1s\u00a0controvertidas. \u00a0Es\u00a0evidente\u00a0la\u00a0\u00a0\n\u00a0 165e\u00a0incertidumbre \u00a0existente\u00a0en\u00a0medicina\u00a0desde\u00a0hace\u00a0varias\u00a0d\u00e9cadas,\u00a0as\u00ed\u00a0\ncomo\u00a0otras\u00a0v\u00edas\u00a0de\u00a0investigaci\u00f3n \u00a0con\u00a0otros\u00a0f\u00e1rmacos \u00a0y\u00a0las\u00a0novedosas\u00a0 terapias\u00a0con\u00a0\nfactores\u00a0regeneradores \u00a0neuronales \u00a0y\u00a0con\u00a0c\u00e9lulas\u00a0 embrionarias. \u00a0\n\u00a0\n\u00a0\n\u00a0\n5.10. INTERVENCI\u00d3N \u00a0QUIR\u00daRGICA \u00a0Y\u00a0LESI\u00d3N\u00a0MEDULAR\u00a0 AGUDA\u00a0\nTRAUM\u00c1TICA \u00a0\n IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\nnecesid\nica\u00a0objetiva\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0espinal;\u00a0otros\u00a0 autores\u00a0sin\u00a0embargo, \u00a0\nmuestran \u00a0en\u00a0sus\u00a0estudios\u00a0una\u00a0mejor\u00eda\u00a0 neurol\u00f3gica \u00a0sin\u00a0descompresi\u00f3n\u00a0 y/o\u00a0fijaci\u00f3n\u00a0\nquir\u00farg a\n\u00a0\nn\u00a0comprimiendo \u00a0\nelementos \u00a0neurales\u00a0especialmente \u00a0en\u00a0pacientes \u00a0con\u00a0LMA\u00a0incompleta. \u00a0\u00a0\nn\u00a0nuestra\u00a0serie,\u00a0todas\u00a0 las\u00a0intervenciones \u00a0quir\u00fargicas \u00a0se\u00a0realizaron \u00a0como\u00a0\ncomp s\u00a0aparec\u00edan \u00a0en\u00a0el\u00a046\u00a0%\u00a0de\u00a0los\u00a0casos\u00a0 operados \u00a0en\u00a0la\u00a0\nprimera\u00a0 semana\u00a0despu\u00e9s\u00a0 del\u00a0traumatismo \u00a0y\u00a0solamente \u00a0en\u00a0el\u00a027\u00a0%\u00a0de\u00a0los\u00a0casos\u00a0\noperados \u00a0e p \u00e9s\u00a0de\u00a0una\u00a0semana.\u00a0Marshall\u00a0et\u00a0al\u00a0(218)\u00a0tambi\u00e9n\u00a0han\u00a0encontrado \u00a0\nun\u00a0agravamiento \u00a0neurol\u00f3gico \u00a0postoperatorio \u00a0en\u00a0el\u00a015\u00a0%\u00a0de\u00a0los\u00a0casos\u00a0operados \u00a0en\u00a0\nlos\u00a05\u00a0primeros\u00a0 d\u00edas,\u00a0mientras\u00a0que\u00a0no\u00a0se\u00a0ha\u00a0detectado \u00a0ning\u00fan\u00a0deterioro \u00a0\nneurol\u00f3gico \u00a0en\u00a0los\u00a0intervenidos \u00a0de\u00a0forma\u00a0tard\u00eda.\u00a0En\u00a0contraposici\u00f3n, \u00a0el\u00a0grupo\u00a0de\u00a0\nWilberger\u00a0 et\u00a0al\u00a0(79),\u00a0al\u00a0comparar\u00a0 las\u00a0intervenciones \u00a0precoces\u00a0y\u00a0tard\u00edas\u00a0despu\u00e9s\u00a0\nde\u00a0un\u00a0traumatismo \u00a0medular\u00a0cervical,\u00a0\u00a0ha\u00a0constatado\u00a0 una\u00a0disminuci\u00f3n \u00a0\nsignificativa \u00a0de\u00a0neuropat\u00edas, \u00a0tromboflebitis, \u00a0embolias\u00a0pulmonares \u00a0\u00a0y\u00a0de\u00a0\u00a0ad\u00a0de\u00a0una\u00a0correcta\u00a0monitorizaci\u00f3n \u00a0y\u00a0un\u00a0tratamiento \u00a0hemodin\u00e1mico \u00a0\nintensivo\u00a0durante\u00a0la\u00a0fase\u00a0aguda\u00a0postlesi\u00f3n \u00a0para\u00a0mantener \u00a0una\u00a0presi\u00f3n\u00a0de\u00a0\nperfusi\u00f3n \u00a0medular\u00a0 optima,\u00a0pero\u00a0el\u00a0papel\u00a0 de\u00a0la\u00a0cirug\u00eda\u00a0a\u00a0este\u00a0respecto\u00a0no\u00a0est\u00e1\u00a0\nbien\u00a0definido\u00a0(206,207) .\u00a0\n\u00a0Bas\u00e1ndose \u00a0en\u00a0un\u00a0metaan\u00e1lisis\u00a0 de\u00a0la\u00a0literatura, \u00a0Fehlings\u00a0et\u00a0al\u00a0(121)\u00a0\npublicaron \u00a0que\u00a0existen\u00a0numerosos \u00a0estudios\u00a0en\u00a0animales\u00a0que\u00a0demuestran \u00a0los\u00a0\nbeneficios \u00a0significativos \u00a0de\u00a0una\u00a0descompresi\u00f3n \u00a0quir\u00fargica \u00a0precoz\u00a0tras\u00a0una\u00a0\ncompresi\u00f3n \u00a0traum\u00e1t\nica\u00a0(208\u2010211) ,\u00a0lo\u00a0que\u00a0ha\u00a0llevado\u00a0 \u00a0pensar\u00a0que\u00a0el\u00a0retraso\u00a0\u00f3\u00a0la\u00a0no\u00a0\nintervenci\u00f3n \u00a0quir\u00fargica \u00a0combinado \u00a0con\u00a0 medidas\u00a0 de\u00a0tratamiento \u00a0farmacol\u00f3gico, \u00a0\npodr\u00eda\u00a0ser\u00a0el\u00a0camino\u00a0a\u00a0\u00a0seguir\u00a0en\u00a0pacientes \u00a0con\u00a0LMA.\u00a0Para poder\u00a0aclarar\u00a0esta\u00a0\ndisparidad \u00a0de\u00a0criterios\u00a0ser\u00edan\u00a0necesarios \u00a0nuevos\u00a0 estudios\u00a0bien\u00a0dise\u00f1ados, \u00a0\nrabdomizados \u00a0y\u00a0multic\u00e9ntricos; \u00a0siendo\u00a0el\u00a0principal\u00a0problema \u00a0para\u00a0su\u00a0realizaci\u00f3n, \u00a0\nel\u00a0hecho\u00a0de\u00a0que\u00a0muchos\u00a0m\u00e9dicos\u00a0tienen\u00a0un\u00a0claro\u00a0problema\u00a0 \u00e9tico\u00a0a\u00a0la\u00a0hora\u00a0 de\u00a0\nrealizar\u00a0una\u00a0descompresi\u00f3n \u00a0tard\u00eda\u00a0cuando\u00a0claramente \u00a0se\u00a0est\u00e1\n\u00a0E\nm\u00e1ximo\u00a0a\u00a0los\u00a07\u00a0d\u00edas\u00a0tras\u00a0el\u00a0ingreso.\u00a0\u00a0Heiden\u00a0et\u00a0al\u00a0(217)\u00a0observan\u00a0que\u00a0las\u00a0\nlicaciones\u00a0 m\u00e9dica\n\u00a0 166d s uIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\ncomplicaciones\u00a0 de\u00a0dec\u00fabito\u00a0en\u00a0los\u00a0pacientes \u00a0operados \u00a0de\u00a0forma\u00a0precoz.\u00a0La\u00a0\nausencia\u00a0de\u00a0significaci\u00f3n \u00a0estad\u00edstica \u00a0en\u00a0la\u00a0presencia \u00a0de\u00a0complicaciones\u00a0 m\u00e9dicas\u00a0\ncon\u00a0respecto\u00a0a\u00a0la\u00a0presencia \u00a0y/o\u00a0ausencia\u00a0de\u00a0la\u00a0\u00a0variable \u00a0IQ\u00a0de\u00a0raquis\u00a0pudiera\u00a0ser\u00a0\ndebido\u00a0 a\u00a0la\u00a0no\u00a0diferenciaci\u00f3n \u00a0entre\u00a0 intervenciones\u00a0 durante\u00a0las\u00a0primeras\u00a024\u00a0horas,\u00a0\nrespecto\u00a0a\u00a0las\u00a0otras.\u00a0\n\u00a0lesi\u00f3n;\u00a0la\u00a0\n\u00fanica\u00a0 variable\u00a0independiente \u00a0predictora\u00a0 de\u00a0resultados \u00a0neurol\u00f3gicos \u00a0fue\u00a0la\u00a0escala\u00a0\nASIA.\u00a0R\ne\nd,\u00a0\u00a0\u00a0Los\u00a0pacientes \u00a0con\u00a0 traumatismos \u00a0asociados \u00a0(TT,\u00a0TCE\u00a0y\u00a0TA),\u00a0as\u00ed\u00a0como\u00a0\naquellos\u00a0 con\u00a0 importantes\u00a0 p\u00e9rdidas\u00a0sangu\u00edneas \u00a0se\u00a0intervinieron\u00a0 con\u00a0 una\u00a0 menor\u00a0\nfrecuencia, \u00a0dado\u00a0que\u00a0a\u00a0veces\u00a0es\u00a0necesario \u00a0contraindicar \u00a0una\u00a0IQ\u00a0precoz\u00a0debido\u00a0 al\u00a0\nalto\u00a0riesgo\u00a0vital\u00a0preoperatorio, \u00a0y\u00a0esencialmente \u00a0se\u00a0trata\u00a0 de\u00a0traumatismos \u00a0graves\u00a0\ndel\u00a0raquis\u00a0 dorsal\u00a0que\u00a0se\u00a0asocian\u00a0a\u00a0una\u00a0contusi\u00f3n \u00a0pulmonar \u00a0grave.\u00a0\n\u00a0Papadopoulos \u00a0et\u00a0al\u00a0(61)\u00a0realizaron \u00a0un\u00a0estudio\u00a0prospectivo \u00a0constituido\u00a0 por\u00a0\n91\u00a0pacientes \u00a0con\u00a0LMA\u00a0cervical,\u00a0a\u00a0los\u00a0que\u00a0se\u00a0les\u00a0hab\u00eda\u00a0realizado\u00a0RNM\u00a0para\u00a0verificar\u00a0\nla\u00a0compresi\u00f3n \u00a0medular,\u00a0 seguido\u00a0si\u00a0estaba\u00a0indicado,\u00a0de\u00a0una\u00a0cirug\u00eda\u00a0descompresiva \u00a0\n\u00f3\u00a0fijaci\u00f3n\u00a0inmediata. \u00a0Al\u00a0igual\u00a0que\u00a0en\u00a0nuestro\u00a0estudio\u00a0no\u00a0se\u00a0encontraron\u00a0\ndiferencias\u00a0 estad\u00edsticamente \u00a0significativas \u00a0respecto\u00a0a\u00a0la\u00a0distribuci\u00f3n \u00a0por\u00a0sexos,\u00a0\npromedio \u00a0de\u00a0d\u00edas\u00a0de\u00a0estancia\u00a0en\u00a0UCI\u00a0y\u00a0mecanismo \u00a0de\u00a0producci\u00f3n \u00a0de\u00a0la\n\u00a0 167especto\u00a0a\u00a0nuestro\u00a0estudio,\u00a0existe\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0mortalidad\u00a0 en\u00a0\naquellos\u00a0 pacientes \u00a0sometidos \u00a0a\u00a0intervenci\u00f3n, \u00a0pudiendo\u00a0 justificar\u00a0estos\u00a0resultados \u00a0\nel\u00a0hecho\u00a0de\u00a0que\u00a0este\u00a0grupo\u00a0de\u00a0pacientes \u00a0est\u00e9\u00a0constituido \u00a0por\u00a0los\u00a0pacientes \u00a0\nmenos\u00a0graves.\u00a0\n\u00a0\u00a0\n5.10.2.  An\u00e1lisis\u00a0multivariante. \u00a0Regresi\u00f3n \u00a0de\u00a0Cox\u00a0\nNo\u00a0encontramos\u00a0 ning\u00fan\u00a0modelo\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0 multivariante \u00a0que\u00a0\npudi\u00e9semos \u00a0considerar \u00a0\u00f3ptimo.\u00a0 En\u00a0el\u00a0modelo\u00a0escogido, \u00a0las\u00a0variables\u00a0ajustadas \u00a0\nque\u00a0presentaron\u00a0 diferencias \u00a0stad\u00edsticamente \u00a0significativas \u00a0fueron\u00a02;\u00a0la\u00a0\nmortalidad\u00a0 y\u00a0la\u00a0diferencia \u00a0de\u00a0ASIA\u00a0del\u00a0ingreso\u00a0respecto\u00a0al\u00a0alta\u00a0de\u00a0la\u00a0UnidaIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\naunque\u00a0tambi\u00e9n\u00a0se\u00a0introdujo\u00a0 la\u00a0variable\u00a0utilizaci\u00f3n \u00a0de\u00a0megadosis\u00a0 de\u00a0MP\u00a0seg\u00fan\u00a0\npautas\u00a0del\u00a0protocolo\u00a0 NASCIS\u00a0II\u00a0para\u00a0mejorar\u00a0 la\u00a0potencia\u00a0del\u00a0mencionado\u00a0 modelo.\u00a0\n\u00a0Debido\u00a0a\u00a0la\u00a0ausencia\u00a0de\u00a0estudios\u00a0cl\u00ednicos\u00a0prospectivos, \u00a0aleatorizados, \u00a0\ncontrolados \u00a0y\u00a0con\u00a0elevado\u00a0poder\u00a0estad\u00edstico, \u00a0que\u00a0hayan\u00a0evaluado\u00a0la\u00a0cirug\u00eda\u00a0en\u00a0los\u00a0\npacientes \u00a0con\u00a0lesiones\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0espinal,\u00a0muchos\u00a0aspectos\u00a0de\u00a0la\u00a0IQ\u00a0todav\u00eda\u00a0\nson\u00a0po\nom\u00f3rbidas. \u00a0La\u00a0\nevidencia \u00a0m\u00e9dica\u00a0actual,\u00a0parece\u00a0indicar\u00a0que\u00a0aquellos\u00a0 casos\u00a0de\u00a0LMAT\u00a0con\u00a0\ncompre\n\u00a0ese\u00a0intervalo. \u00a0No\u00a0se\u00a0pudo\u00a0 demostrar\u00a0 que\u00a0los\u00a0efectos\u00a0positivos\u00a0de\u00a0\nla\u00a0cirug\u00a0se\u00a0relacionaban \u00a0con\u00a0el\u00a0intervalo\u00a0de\u00a0tiempo\u00a0hasta\u00a0el\u00a0tratamiento, \u00a0pero\u00a0\neste\u00a0 ortante\u00a0trabajo\u00a0posee\u00a0el\u00a0sesgo\u00a0de\u00a0una\u00a0muestra\u00a0 poblacional \u00a0insuficiente, \u00a0\nya\u00a0que adamente \u00a0los\u00a0efectos\u00a0de\u00a0\nla\u00a0cirug\nq p\nca\u00a0\u00a0l\u00e9micos.\u00a0 Al\u00a0decidir\u00a0si\u00a0est\u00e1\u00a0indicada\u00a0\u00f3\u00a0no\u00a0una\u00a0IQ\u00a0precoz\u00a0se\u00a0deben\u00a0considerar \u00a0\nseg\u00fan\u00a0indica\u00a0la\u00a0literatura \u00a0m\u00e9dica\u00a0una\u00a0serie\u00a0de\u00a0aspectos\u00a0fundamentales \u00a0como\u00a0son\u00a0\nel\u00a0estado\u00a0neurol\u00f3gico \u00a0del\u00a0paciente\u00a0y\u00a0su\u00a0variaci\u00f3n\u00a0en\u00a0el\u00a0tiempo,\u00a0la\u00a0presencia\u00a0 \u00f3\u00a0\nausencia\u00a0de\u00a0compresi\u00f3n\u00a0 neural\u00a0y\u00a0otras\u00a0consideraciones \u00a0tales\u00a0como\u00a0la\u00a0edad\u00a0del\u00a0\npaciente,\u00a0 traumas\u00a0asociados \u00a0y\u00a0la\u00a0presencia \u00a0de\u00a0afecciones \u00a0c\nsi\u00f3n\u00a0de\u00a0los\u00a0elementos \u00a0neurales\u00a0que\u00a0presentan \u00a0deterioro \u00a0neurol\u00f3gico \u00a0\ndebe\u00a0realizarse \u00a0de\u00a0la\u00a0forma\u00a0m\u00e1s\u00a0precoz\u00a0posible\u00a0\u00a0un\u00a0tratamiento \u00a0quir\u00fargico, \u00a0con\u00a0\nuna\u00a0demora\u00a0m\u00e1xima\u00a0 de\u00a024\u00a0horas.\u00a0\n\u00a0La\u00a0presencia\u00a0 de\u00a0una\u00a0IQ\u00a0tras\u00a0una\u00a0LMAT\u00a0en\u00a0nuestro\u00a0modelo\u00a0final\u00a0no\u00a0\nencuentra \u00a0diferencias\u00a0 estad\u00edsticamente\u00a0 significativas \u00a0en\u00a0el\u00a0grado\u00a0de\u00a0recuperaci\u00f3n \u00a0\nneurol\u00f3gica \u00a0mediante \u00a0la\u00a0escala\u00a0ASIA.\u00a0El\u00a0cl\u00e1sico\u00a0estudio\u00a0prospectivo \u00a0de\u00a0Waters\u00a0et\u00a0\nal\u00a0(219) ,\u00a0que\u00a0eval\u00faa\u00a0los\u00a0resultados \u00a0de\u00a0la\u00a0cirug\u00eda\u00a0en\u00a0LMA\u00a0usando\u00a0 la\u00a0escala\u00a0 de\u00a0ASIA,\u00a0\nconcluye\u00a0con\u00a0la\u00a0afirmaci\u00f3n \u00a0que\u00a0la\u00a0mayor\u00a0 parte\u00a0de\u00a0la\u00a0recuperaci\u00f3n \u00a0motora\u00a0 ocurre\u00a0\nentre\u00a0el\u00a01\u00ba\u00a0mes\u00a0y\u00a0el\u00a01\u00ba\u00a0a\u00f1o\u00a0y\u00a0cualquier\u00a0 efecto\u00a0positivo\u00a0de\u00a0la\u00a0cirug\u00eda\u00a0debe\u00a0ser\u00a0\ndemostrado \u00a0en\n\u00eda\nimp\n\u00a0\u00a0no\u00a0hay\u00a0suficientes \u00a0pacientes\u00a0 para\u00a0analizar\u00a0separ\n\u00a0 168\u00eda\u00a0en\u00a0los\u00a0distintos\u00a0tipos\u00a0de\u00a0fractura.\u00a0\u00a0\n\u00a0\nProbablemente, \u00a0al\u00a0igual\u00a0ue\u00a0sucede\u00a0en\u00a0nuestra\u00a0serie,\u00a0que\u00a0resenta\u00a0como\u00a0\nresultados \u00a0de\u00a0una\u00a0cuasi\u00a0significaci\u00f3n \u00a0para\u00a0el\u00a0grado\u00a0de\u00a0recuperaci\u00f3n \u00a0neurol\u00f3giIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0\n(Hazard\u00a0ratio\u00a0=\u00a01,85;\u00a0IC95%\u00a0=\u00a00,95\u20103,55,\u00a0p\u00a0=\u00a00,07),\u00a0 el\u00a0peque\u00f1o\u00a0n\u00famero\u00a0de\u00a0\npacientes, \u00a0el\u00a0seguimiento \u00a0realizado\u00a0solamente \u00a0durante\u00a0el\u00a0periodo\u00a0agudo\u00a0de\u00a0\nhospitalizaci\u00f3n \u00a0y\u00a0la\u00a0imposibilidad \u00a0de\u00a0realizar\u00a0un\u00a0estudio\u00a0de\u00a0subgrupos, \u00a0hace\u00a0\u00a0\nposible\n\u00a0conservador \u00a0esta\u00a0en\u00a0discordancia \u00a0\ncon\u00a0 el\u00a0abajo\u00a0de\u00a0Gertzbein \u00a0(220) ,\u00a0en\u00a0el\u00a0cual\u00a0 con\u00a0una\u00a0amplia\u00a0muestra\u00a0de\u00a01019\u00a0\npacien\nrefiere\u00a0a\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0\nevaluada\u00a0al\u00a0a\u00f1o\u00a0de\u00a0la\u00a0lesi\u00f3n.\u00a0\u00a0plantear\u00a0la\u00a0hip\u00f3tesis\u00a0de\u00a0trabajo\u00a0que\u00a0la\u00a0descompresi\u00f3n \u00a0sea\u00a0efectiva\u00a0en\u00a0\u00a0\nciertos\u00a0tipos\u00a0de\u00a0fractura.\u00a0\u00a0\u00a0\n\u00a0Un\u00a0importante \u00a0sesgo\u00a0de\u00a0nuestra\u00a0cohorte,\u00a0es\u00a0que\u00a0todos\u00a0los\u00a0pacientes \u00a0\nfueron\u00a0intervenidos \u00a0en\u00a0un\u00a0periodo\u00a0de\u00a07\u00a0d\u00edas,\u00a0considerado \u00a0por\u00a0diversos\u00a0autores\u00a0\ncomo\u00a0intervenciones \u00a0quir\u00fargicas\u00a0 precoces, \u00a0y\u00a0los\u00a0argumentos \u00a0experimentales \u00a0\npermiten \u00a0pensar\u00a0 que\u00a0no\u00a0es\u00a0razonable \u00a0esperar\u00a0 un\u00a0beneficio \u00a0de\u00a0la\u00a0cirug\u00eda\u00a0iniciada\u00a0\nen\u00a0las\u00a06\u00a0primeras\u00a0horas,\u00a0y\u00a0por\u00a0el\u00a0contrario, \u00a0es\u00a0posible\u00a0que\u00a0una\u00a0cirug\u00eda\u00a0efectuada \u00a0\ndespu\u00e9s\u00a0de\u00a024\u00a0horas\u00a0pueda\u00a0 agravar\u00a0 las\u00a0lesiones\u00a0medulares. \u00a0\u00a0\n\u00a0Esta\u00a0ausencia\u00a0de\u00a0mejor\u00eda\u00a0 en\u00a0el\u00a0grado\u00a0de\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0de\u00a0la\u00a0\nintervenci\u00f3n \u00a0quir\u00fargica \u00a0frente\u00a0al\u00a0tratamiento\ntr\ntes\u00a0con\u00a0fractura\u00a0vertebral, \u00a0mostr\u00f3\u00a0que\u00a0la\u00a0IQ\u00a0se\u00a0acompa\u00f1aba \u00a0de\u00a0un\u00a0\nporcentaje \u00a0mayor\u00a0 de\u00a0mejor\u00eda\u00a0 neurol\u00f3gica \u00a0y\u00a0funcional \u00a0que\u00a0el\u00a0tratamiento \u00a0\nconservador. \u00a0Sin\u00a0 embargo\u00a0otros\u00a0autores\u00a0(221\u2010224) ,\u00a0presentan \u00a0datos\u00a0 en\u00a0\nconcordancia \u00a0con\u00a0 los\u00a0nuestros, \u00a0y\u00a0afirman\u00a0que\u00a0no\u00a0existe\u00a0relaci\u00f3n\u00a0entre\u00a0 las\u00a0\ndimensiones \u00a0del\u00a0canal\u00a0 y\u00a0la\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica, \u00a0y\u00a0por\u00a0tanto\u00a0que\u00a0la\u00a0cirug\u00eda\u00a0\nno\u00a0influye\u00a0sobre\u00a0la\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0medida\u00a0en\u00a0nivel\u00a0lesional\u00a0y\u00a0\nseveridad. \u00a0\u00a0Utilizando\u00a0 los\u00a0datos\u00a0 del\u00a0estudio\u00a0NASCIS\u00a0II,\u00a0Duh\u00a0(158)\u00a0analiza\u00a0los\u00a0\nresultados \u00a0neurol\u00f3gicos \u00a0medidos\u00a0 en\u00a0puntuaci\u00f3n \u00a0motora\u00a0y\u00a0sensitiva\u00a0de\u00a0487\u00a0\nlesionado\u00a0 medulares, \u00a0y\u00a0aunque\u00a0sugiere\u00a0que\u00a0la\u00a0recuperaci\u00f3n \u00a0motora\u00a0 fue\u00a0mayor\u00a0 en\u00a0\naquellos\u00a0 pacientes \u00a0operados, \u00a0no\u00a0encuentra \u00a0diferencias\u00a0 entre\u00a0 el\u00a0tratamiento \u00a0\nquir\u00fargico \u00a0y\u00a0conservador \u00a0en\u00a0lo\u00a0que\u00a0se\u00a0\n\u00a0 169\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nV.\u2010\u00a0DISCUSI\u00d3N.\u00a0\n\u00a0 170\u00a0\ngresi\u00f3n\u00a0m\u00faltiple,\u00a0hallamos\u00a0 que\u00a0una\u00a0IQ\u00a0se\u00a0asocia\u00a0con\u00a0\nuna\u00a0marcada\u00a0 disminuci\u00f3n \u00a0de\u00a0la\u00a0mortalidad, \u00a0y\u00a0por\u00a0tanto\u00a0podr\u00eda\u00a0ser\u00a0considerada \u00a0\u00a0\nuna\u00a0va\ns\u00a0grupos\u00a0 de\u00a0estudio\u00a0\nhan\u00a0 publicado \u00a0resultados \u00a0de\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0estancia\u00a0en\u00a0unidades\u00a0de\u00a0\ncr\u00edticos\u00a0Por\u00a0desgracia, \u00a0los\u00a0estudios\u00a0aleatorizados \u00a0no\u00a0son\u00a0factibles\u00a0 por\u00a0el\u00a0gran\u00a0\nespectro\u00a0de\u00a0diferentes \u00a0lesiones\u00a0que\u00a0no\u00a0estar\u00edan\u00a0presentes \u00a0en\u00a0un\u00a0mismo\u00a0centro\u00a0\nen\u00a0un\u00a0n\u00famero\u00a0suficiente \u00a0de\u00a0casos.\u00a0\n\u00a0\nEn\u00a0el\u00a0an\u00e1lisis\u00a0 de\u00a0re\nriable\u00a0protectora. \u00a0La\u00a0explicaci\u00f3n \u00a0respecto\u00a0a\u00a0la\u00a0asociaci\u00f3n \u00a0tratamiento \u00a0\nquir\u00fargico \u00a0y\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0mortalidad \u00a0es\u00a0la\u00a0menor\u00a0gravedad \u00a0de\u00a0los\u00a0pacientes \u00a0\nincluidos\u00a0en\u00a0el\u00a0grupo\u00a0IQ,\u00a0respecto\u00a0al\u00a0grupo\u00a0conservador \u00a0(APACHE\u00a0 II\u00a0respectivo \u00a0de\u00a0\n11.55\u00a0vs\u00a014.04).\u00a0Los\u00a0pacientes \u00a0intervenidos \u00a0quir\u00fargicamente \u00a0presentaban \u00a0menos\u00a0\ntraumas\u00a0acompa\u00f1antes.\u00a0 Otra\u00a0explicaci\u00f3n \u00a0pudiera\u00a0ser\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0\nmortalidad\u00a0 atribuida\u00a0a\u00a0la\u00a0intervenci\u00f3n \u00a0per\u00a0se,\u00a0y\u00a0as\u00ed,\u00a0diferente\n,\u00a0menor\u00a0apoyo\u00a0ventilatorio, \u00a0menor\u00a0estancia\u00a0hospitalaria \u00a0y\u00a0mortalidad\u00a0\nsignificativamente \u00a0m\u00e1s\u00a0reducida\u00a0con\u00a0un\u00a0tratamiento \u00a0quir\u00fargico \u00a0precoz.\u00a0\n\u00a0\nLa\u00a0falta\u00a0de\u00a0unanimidad \u00a0respecto\u00a0 al\u00a0momento \u00a0id\u00f3neo\u00a0para\u00a0llevar\u00a0a\u00a0cabo\u00a0el\u00a0\ntratamiento \u00a0quir\u00fargico \u00a0en\u00a0pacientes \u00a0con\u00a0 LMA\u00a0precisa\u00a0 el\u00a0dise\u00f1o\u00a0de\u00a0nuevos\u00a0\nestudios,\u00a0amplios,\u00a0rabdomizados \u00a0y\u00a0con\u00a0un\u00a0elevado\u00a0poder\u00a0estad\u00edstico, \u00a0que\u00a0ayuden\u00a0\na\u00a0establecer \u00a0algoritmos \u00a0de\u00a0actuaci\u00f3n \u00a0en\u00a0estos\u00a0pacientes. \u00a0\n\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVI.\u2010\u00a0CONCLUSIONES. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0 171\u00a0\n\u00a0\nVI.\u2010\u00a0CONCLUSIONES \u00a0\n\u00a0\n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVI.\u2010\u00a0CONCLUSIONES. \u00a0\n\u00a0\n1) La raci\u00f3n\u00a0de\u00a0corticoides, \u00a0mediante \u00a0protocolo\u00a0 con\u00a0altas\u00a0dosis\u00a0de\u00a0\nmetilprednisolona \u00a0seg\u00fan\u00a0la\u00a0pauta\u00a0NASCIS\u00a0II,\u00a0no\u00a0se\u00a0correlacion\u00f3 \u00a0con\u00a0 una\u00a0\nrecuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0mediante \u00a0escala\u00a0ASIA,\u00a0ni\u00a0con\u00a0un\u00a0incremento \u00a0de\u00a0la\u00a0\nestancia\u00a0hospitalaria, \u00a0pero\u00a0si\u00a0con\u00a0 la\u00a0aparici\u00f3n \u00a0de\u00a0complicaciones \u00a0m\u00e9dicas\u00a0\ntipo\u00a0hemorragia\u00a0 digestiva\u00a0e\u00a0hiperglucemia. \u00a0\u00a0\n2) No existen\u00a0diferencias\u00a0 en\u00a0la\u00a0recuperaci\u00f3n \u00a0neurol\u00f3gica \u00a0global\u00a0en\u00a0los\u00a0\npacientes \u00a0sometidos \u00a0a\u00a0tratamiento \u00a0quir\u00fargico \u00a0respecto\u00a0a\u00a0tratamiento \u00a0\nconservador \u00a0en\u00a0severidad\u00a0 de\u00a0la\u00a0lesi\u00f3n\u00a0medida\u00a0en\u00a0grados\u00a0de\u00a0ASIA,\u00a0\u00a0sin\u00a0\nasociarse \u00a0este\u00a0a\u00a0un\u00a0aumento\u00a0o\u00a0disminuci\u00f3n \u00a0del\u00a0 riesgo\u00a0complicaciones \u00a0\nm\u00e9dicas.\u00a0La\u00a0cuasi\u00a0significaci\u00f3n \u00a0del\u00a0modelo\u00a0podr\u00eda\u00a0ser\u00a0debido\u00a0 a\u00a0un\u00a0tama\u00f1o\u00a0\nmuestral\u00a0insuficiente, \u00a0y\u00a0no\u00a0es\u00a0descartable \u00a0que\u00a0un\u00a0tratamiento \u00a0quir\u00fargico \u00a0\nprecoz\u00a0podr\u00eda\u00a0determinar \u00a0una\u00a0mejor\u00eda\u00a0 neurol\u00f3gica. \u00a0\n3) En \u00a0estudio,\u00a0la\u00a0causa\u00a0m\u00e1s\u00a0frecuente \u00a0de\u00a0lesi\u00f3n\u00a0medular\u00a0 traum\u00e1tica \u00a0\nfueron\u00a0los\u00a0accidentes \u00a0de\u00a0tr\u00e1fico,\u00a0con\u00a0 un\u00a0claro\u00a0predominio \u00a0en\u00a0varones\u00a0\nj\u00f3venes\u00a0sin\u00a0comorbilidad \u00a0asociada. \u00a0La\u00a0lesi\u00f3n\u00a0neurol\u00f3gica, \u00a0en\u00a0grados\u00a0de\u00a0ASIA,\u00a0\ndesde\u00a0el\u00a0ingreso\u00a0hasta\u00a0el\u00a0alta\u00a0hospitalaria \u00a0no\u00a0se\u00a0modific\u00f3\u00a0en\u00a0el\u00a058,24%\u00a0 de\u00a0los\u00a0\npacientes, \u00a0mejor\u00f3\u00a0en\u00a0el\u00a030,77%\u00a0 en\u00a0un\u00a0grado\u00a0en\u00a0la\u00a0escala\u00a0ASIA\u00a0y\u00a0solo\u00a0en\u00a0un\u00a0\n10,99%\u00a0la\u00a0mejor\u00eda\u00a0fue\u00a0de\u00a0dos\u00a0grados.\u00a0La\u00a0paraplejia \u00a0completa \u00a0(36,95%)\u00a0es\u00a0la\u00a0\nlesi\u00f3n\u00a0m\u00e1s\u00a0preponderante. \u00a0\n4) Lo traumatismos \u00a0asociados \u00a0m\u00e1s\u00a0frecuentes \u00a0fueron\u00a0el\u00a0trauma\u00a0 tor\u00e1cico,\u00a0\nesquel\u00e9tico \u00a0y\u00a0el\u00a0craneal.\u00a0Los\u00a0pacientes\u00a0 con\u00a0trauma\u00a0 medular\u00a0 cervical\u00a0\npresentaron \u00a0una\u00a0elevada\u00a0 incidencia \u00a0de\u00a0tr\n(35,13%)\u00a0y\u00a0esquel\u00e9tico \u00a0(29,72%)\u00a0acompa\u00f1antes, \u00a0mientras\u00a0aquellos\u00a0 con\u00a0\nlesiones\u00a0medulares \u00a0dorsales\u00a0presentan \u00a0una\u00a0elevada\u00a0 frecuencia, \u00a0estimada\u00a0 en\u00a0\nun63,88%\u00a0 de\u00a0trauma\u00a0tor\u00e1cico.\u00a0Las\u00a0lesiones\u00a0medulares \u00a0lumbares \u00a0poseen\u00a0una\u00a0\nbaja\u00a0incidencia \u00a0de\u00a0traumas\u00a0acompa\u00f1antes. \u00a0\n\u00a0\u00a0administ\n\u00a0\n\u00a0\n\u00a0\n\u00a0nuestro\n\u00a0\ns\u00a0\nauma\u00a0craneal\u00a0(37,83%), \u00a0tor\u00e1cico\u00a0\n\u00a0 172\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVI.\u2010\u00a0CONCLUSIONES. \u00a0\n\u00a0 173les\u00a0hemodin\u00e1micamente \u00a0y\u00a0la\u00a0\nencia\u00a0de\u00a0traumas\u00a0m\u00faltiples\u00a0 acompa\u00f1antes.\u00a0 La\u00a0columna\u00a0cervical\u00a0fue\u00a0la\u00a0\n6) \n\u00a0\n\u00a0\u00a0\n5) La\u00a0incidencia \u00a0de\u00a0lesiones\u00a0medulares \u00a0inadvertidas \u00a0cl\u00ednicamente \u00a0relevantes\u00a0 es\u00a0\nde\u00a0un\u00a07,79%,\u00a0con\u00a0 una\u00a0mortalidad \u00a0elevada.\u00a0Se\u00a0ha\u00a0observado \u00a0una\u00a0relaci\u00f3n\u00a0\nentre\u00a0 la\u00a0aparici\u00f3n\u00a0 de\u00a0lesiones\u00a0inadvertidas \u00a0y\u00a0pacientes \u00a0con\u00a0 \u00edndice\u00a0de\u00a0\nseveridad \u00a0(APACHE\u00a0II)\u00a0elevado,\u00a0bajo\u00a0nivel\u00a0de\u00a0conciencia \u00a0farmacol\u00f3gico\u00a0 o\u00a0\nestructural, \u00a0pacientes \u00a0intubados, \u00a0inestab\npresregi\u00f3n\u00a0m\u00e1s\u00a0incriminada. \u00a0\n\u00a0\nLa\u00a0mortalidad\u00a0 fue\u00a0del\u00a010,42%,\u00a0 asoci\u00e1ndose \u00a0a\u00a0elevados\u00a0APACHE\u00a0II\u00a0al\u00a0ingreso\u00a0\nen\u00a0la\u00a0Unidad,\u00a0presencia \u00a0de\u00a0trauma\u00a0medular\u00a0cervical\u00a0y\u00a0la\u00a0coexistencia \u00a0de\u00a0\ntrauma\u00a0 vascular\u00a0 y\u00a0fallo\u00a0renal\u00a0agudo.\u00a0\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA \u00a0\u00a0\n\u00a0\n\u00a0 174\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n1.-Guttmann L. Spinal Cord Injuri es: Comprehensive Management and \nResearch. 2nd ed. Oxford: Blackwe ll Scientific Publications; 1976. \n2.-Ebraheim, Nabil;  Jabaly, Georges;  Xu, Rongming; et al. Anatomic \nRelations of the Thoracic Pedicle to the Adjacent Neural Structures. Spine\n1997;22(14):1553-1556. \n3.-Surkin, Joseph BS.; Gilbert, Brenda J.; Harkey, Louis H.; et al. Spinal Cord\nInjury in Mississippi: Findings  and Evaluation, 1992-1994. Spine \n2000;25(6):716-721. \n4.-Sekhon, Lali HS.; Fehlings, Michael G. Epidemiology, Demographics, and \nPathophysiology of Acute Spinal Co rd Injury. Spine 2001;26(24S):S2-S12. \n\u00a0\n5.-Vitale, Michael G.; Goss, Jordan M.; Matsumoto, Hiroko MA.; et al. \nEpidemiology of Pediatric Spinal Cord Injury in the United States: Years 1997\nand 2000. Journal of Pediatric  Orthopaedics 2006;26(6):745-749. \n\u00a0\n6.-Pickett, Gwynedd E.; Campos-Benitez, Mauricio; Keller, Jana L.; et al\nEpidemiology of Traumatic Spinal Cord Injury in Canada. Spine 2006;31(7):799-805. \n\u00a0\n7.-Tator CH. Epidemiology and Genera l Characteristics of the Spinal-Cord\nInjured patient. In: Tator, CH.; Benzel, EC. Contemporary Management ofSpinal Cord Injury: From Impact to Rehabilitation. 2\nnded. Park Ridge, IL: \nAmerican Association of Neurological Surgeons;2000:15-20. \n\u00a0\n8.-Ackey, A.; Tator, C.; Krassioukov, A .; et al. A global perspective on Spinal \nCord Injury Epidemiology . J Neurotrauma 2004;21:1355. \n\u00a0\n9.-Paker, Nurdan A.; Soy, Derya A.; Kesiktas, Nur B.; et al. Reasons forRehospitalization in patients with Spin al cord Injury: 5 years\u00b4experience. \nInternational Journal of Rehabilitation Research 2006;29(1):71-76. \n\u00a0\n10.-Beekhuizen, Kristina S. New Perspectives on Improving Upper Extremityafter Spinal Cord Injury. Journal of Neurologic Physical Therapy \n2005;29(3):157-162. \n \n11.-\n Kattail,  Deepa MD.; Furlan, Julio C.; Feh\nand Clinical Outcomes of Acute Spine  Trauma and Spinal Cord Injury: \nExperience From a Specialized  Spine Trauma Center in Canada in Comparison \nwith a Large National Registry. Journal of Trauma-Injury Infection & Critical Care 2009;67(5):936-943. \n    \n \n \n.  \n \n \n \n \n\u00a0 175lings, Michael G. Epidemiology IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n45. \n\u00a0\nl Clearance Protocol for Unconscious Pediatric Trauma \nPatients. Journal of Trauma-Injury Infection & Critical Care 2009;67(4):681-\ns: Inter \u2013 M\u00e9dica \n988;3:1-14. \nla M\u00e9dula Espinal. \nEnfoque global: Prevenci\u00f3n, Atenci\u00f3n M\u00e9di ca de Urgencia y Manejo en la Sala \niones de la \nM\u00e9dula Espinal. En: Lesiones agudas de la M\u00e9dula Espinal. Cl\u00ednicas de Terapia \nMD.; Tominaga, Toshikatsu MD. Predictors of Neurologic \nRecovery in Acute Central Cervical Co rd Injury with Only Upper Extremity \n4-1582. \n\u00a0\n\u00a012.-Fisher, Charles G.; Noonan, Vanessa K.; Dvorak, Marcel F. Changing Face \nof Spine Trauma Care in North  America. Spine 2006;31(11S):S2-S8. \n\u00a0\n13.-Huang, Yu-Hua; Yang, Tzu-Ming; Li, Wei-Che; et al. The Prognosis of \nAcute Blunt Cervical Spinal Cord Injury. Journal of Trauma-Injury & Critical \nCare 2009;66(5):1441-14\n14.-Hutchings, Lynn; Atijosan, Oluwar antimi; Burgess, Chris; et al. \nDeveloping a Spina\n686. \n\u00a0\n15.-Rintala, Diana H.; Young, Mary E.; Hart, Karen A.; et al. Social Support \nand the Well-Being of Persons with Spinal Cord Injury Living in the \nCommunity. Rehabilitation Psychology 2002;37(3):155-163. \n \n16.-Duchnnick, Jennifer J.; Letsch, Elisabeth A.; Curtiss, Glenn. Coping \nEffectiveness Training During Acute Rehabilitation of Spinal Cord \nInjury/Dysfunction: A Randomized Clinical Trial. Rehabilitation Psychology \n009;54(2):123-132. 2 17.-Albin, MS.; White, RJ. Epidemiol og\u00eda, Fisiopatolog\u00eda y Tratamiento \nexperimental de las Lesiones Agudas de la M\u00e9dula. En: Lesiones agudas de la M\u00e9dula Espinal. Cl\u00ednicas de Terapia Inte nsiva. Buenos Aire\n1 18.-Green, BA.; Eismont, FJ.; O\u00b4Heir, JT. Lesiones de \nde Emergencias. En: Lesiones Agudas de la M\u00e9dula Espinal. Cl\u00ednicas de \nTerapia Intensiva. Buenos ai res: Inter-M\u00e9dica 1988;3:37-62. \n \n19.-Bunegin, L.; Hung, TK.; Chang, GL. Biomec\u00e1nica de las Les\nIntensiva. Buenos Aires: Inter \u2013 M\u00e9dica 1988;3:15-36. \n \n20.-Ishida, Yoichiro \n\u00a0 176Impairment. Spine 2002;27(15):1652-1657. \n\u00a0\n21.-Hiersemenzel, Lutz-Peter MD.; Curt, Armin MD.; Dietz, Volker MD. From Spinal Shock to Spasticity: Neuronal adaptations to a Spinal Cord Injury. \nNeurology 2000;54(8):157IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n22.-Samuels, LE.; Kerstein, MD. \u201cRouti ne\u201d Radiological Evaluation of the \nThoracolumbar Spine in Blunt Trauma patients: a Repraisal. J Trauma \n993;34:85-89. \n \ndam, R. Brooks; Willet, Keith M. Ev aluation of the Oxford Protocol for \notal Spinal Clearance in the Uncons cious Trauma Patient. Journal of \nark L. Efficient \nethod of Cervical Spine Clearance in the Obtunded Trauma Patient. Journal \ning for the Evaluati on of the Cervical Spine in the \nnconscious, Intubated Trauma Patient. Journal of Trauma-Injury Infection \n. The Adult Spinal Co rd Injury Without Radiographic \nbnormalities Syndrome: Magnetic Reso nance Imaging and Clinical Findings \n9.-Bondurant, Fonda J.; Cotler, Howard B.; Kulkarni, Madan V.; et al. Acute \n0.-Kalfas, Iain MD.; Wilberger, Jack MD.; Goldberg, Andrew MD.; et al. \n1.-Selden, Nathan R.; Quint, Douglas J.; Patel, Nayna BA.; et al. Emergency \njury Without Radiographic Abnormality. \nNeurosurgery 2002;50(3):S100-S104. 1\n 23.-Krassioukov, AV.; Furlan, JC.; Fehlings, MG. Medical Comorbidities, secondary Complications, and Mortality in elderly with Acute Spinal Cord \nnjury. J Neurotrauma 2003;20:391-399. I\n24.-Keenen, TL.; Anthony, J.; Benson, DR. Non \u2013 Contiguous Spinal \nFractures. J Trauma 1990;30:489-491.  25.-A\nT\nTrauma-Injury Infection & Crit ical Care 2001;50(5):862-867. \n 26.-Stassen, Nicole A.; Williams, Valerie A.; Gestring, MMof Trauma-Injury Infection & Critical Care 2006;60(1):171-177.  \n27.-Brohi, Karim; Healy, Marie; Fotheringham, Tim; et al. Helical Computed \nTomographic ScannU& Critical Care 2005;58(5):897-901.  28.-Kasimatis, Georgios B.; Panagiotopoulos, Elias MD.; Megas, Panagiotis \nMD.; et al\nAin Adults With Spinal Cord Injuries Having Normal Radiographs and Computed Tomography Studies. Jour nal of Trauma-Injury Infection & \nCritical Care 2008;65(1):86-93.  2\nSpinal Cord Injury: A Study Using Ph ysical Examination and Magnetic \nResonance Imaging. Spine 1990;15(3):161-168. \n\u00a0 \n3\nMagnetic Resonance Imaging in Acute Spinal Cord Trauma. Neurosurgery \n1998;23(3):295-299. \n\u00a0 \n3Magnetic Resonance Imaging of Cervic al Spinal Cord Injuries: Clinical \nCorrelation and Prognosis. Ne urosurgery 1999;44(4):785-792. \n\u00a0 \n32.-Stevens RD. Spinal Cord In\n\u00a0 177\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n33.-Kirshblum, Steven C.; Memmon, Pietro MD.; Kim, Nancy MD.; et al. \nComparison of the Revised 2000 American Spinal Injury Association Classification Standards with the 1996 Guidelines. American Journal of \nhysical Medicine & Rehabilitation 2002;81(7):502-505. \nAssociation (ASIA) Motor  Score and \ne National Acute Spinal Cord Injury  Study (NASCIS) Motor Score. Spine \n5.-\u00c1lvarez JA. Dec\u00e1logo operativo en la asistencia prehospitalaria al \n6.-Herruzo, R.; Garc\u00eda, J.; Vizca\u00edno, MJ.; et al. Epidemiolog\u00eda descriptiva y \n7.-Ayensa A. Traumatismos Espino \u2013 Medulares. En: Ginestal, RJ.; Blanco, \noor Experiences. International Journal of \nehabilitation Research 2004;27(1):7-15. \n, Elizabeth M.; Nair, Preeti M.; et al. Beyond \nait Speed: A Case Report of a Mult idimensional Approach to Locomotor \n41.-Mirovsky, Yigal MD.; Shalmon, Ehud MD.; Blankstein, Alexander MD.; et \n42.-Li, Xuejun; Huang, Chunhai; Liu, Sh angming; et al. Establishment and \n43.-Fisher, Charles G.; Noonan, Vanessa K.; Smith, Donna E.; et al. Motor \npine 2005;30(19):2200-2207. P\n 34.-El Masry, Wagih S.; Tsubo, Masahiko MD.; Katoh, Shinsuke MD.; et al. \nValidation of the American Spinal Injury \nth1996;21(5):614-619.  3traumatizado grave. En: Perales N, editor. Avances en Emergencias y \nResucitaci\u00f3n I. Barcelona: Edikamed; 1996:49-63.  \n 3anal\u00edtica de la Lesi\u00f3n Medular Espinal Traum\u00e1tica ocurrida en Espa\u00f1a durante \n1984 y 1985. Rev Clin Espa\u00f1ola 1993;192:217-222.  3\nJL.; Borasteros, C.; et al. Libro de text o de Cuidados Intensivos II. Madrid: \nELA; 1991:1269-1278. \n 38.-Beringer, A. Spinal Cord OutdR \n39.-Dumont, Randall J.; Okonkwo, David O.; Verma, Subod H.; et al. Acute \nSpinal Cord Injury, Part I: Patho pysiologic Mechanisms. Clinical \nNeuropharmacology 2001;24(5):254-264.  40.-Bowden, Mark G.; HannoldGRehabilitation Outcomes in Incomplete Spinal Cord Injury. Journal of \nNeurologic Therapy 2008;32(3):129-138. \n \nal. Complete Paraplegia Following Guns hot Injury without Direct Trauma to \nthe Cord. Spine 2005;30(21):2436-2438. \n \nEvaluation of a rat model of complete transected Spinal Cord Injury. Neural \nRegeneration Research 2008;3(4):367-371.  \nRecovery, Functional Status, and Health -Related Quality of Life in Patients \nwith Complete Spinal Cord Injuries. S\n\u00a0 178\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n44.-Tator, CH.; Fehlings, MG. Review of  the Secondary Injury Theory of \nAcute Spinal Cord Trauma with emphasis on Vascular Mechanisms. J \nNeurosurg 1991;75:15-26.  45.-Amar, AP.; Levy, ML. Pathogenesis and Pharmacological Strategies for \nl B.; Shepard, Mary  J.; Holford, Theo dore R.; et al. \ndministration of Methylprednisolone fo r 24 or 48 Hours or Tirilazad Mesylate \nthe Second National Acute \npinal Cord Injury Study.  N Engl J Med 1990;322:1405-1411. \nute Spinal Cord In jury: 1 \u2013 year follow up. Results of \ne Third National Acute Spinal Cord Injury randomized controlled trial. \n9.-Hugenholtz, Herman L. Methylprednisolone for Acute Spinal Cord Injury: \n0.-Hulbert, John R. Strategies of Medi cal Intervention in the Management of \n Spinal Cord 2005;43:199-203. \n3.-Coates, JR.; Sorjonen, DC.; Simpson, ST.; et al. Clinicopathology effect of mitigating Secondary Damage in Acute Spinal Cord Injury. J Neurosurg \n1990;44:1027-1039. \n 46.-Bracken, MichaeAfor 48 Hours in the Treatment of Acute Spinal Cord Injury: Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. JAMA \n1997;277(20):1597-1604. \n 47.-Bracken, Michael B.; Shepard, Mary  J.; Collins, Willians F.; et al. A \nrandomized controlled trial of Meth ylprednisolone or Naloxone in the \nTreatment of Acute Spinal Cord Injury: results of \nS\n \n48.-Yancey, Lynne M. Methylprednisolone or Tirilazad Mesylate administration after ActhAnnals of Emergency Medicine 1999;33(4):483. \n \n4\nnot a standard of care. CMAJ Canadian Medical Association Journal \n2003;168(9):1145-1146.  5Acute Spinal Cord Injury. Spine 2006;31(11S):S16-S21. \n \n51.-Qian, T.; Guo, X.; Levi, AD. High-dose Methylprednisolone may cause \nMyopathy in Acute Spinal Cord patients.\n \n52.-Qian, T.; Campagnolo, D.; Kirshblum  S. High-dose Methylprednisolone \nmay do more harm for Spinal Cord Injury. Med Hypotheses 2000;55:452-453. \n 5\na 21-aminoesteroid compound (U7 4389G) on High dose Methylprednisolone \non Spinal Cord Function after stim ulated Spinal Cord Trauma. Vet Surg \n1995;24(2):128-139. \n 54.-Geisler, FH.; Coleman, WP.; Grieco, G .; et al. The Sygen Study Group. The \nSygen Multicenter Acute Spinal Cord Injury Study. Spine 2001;15(24S):S87-\nS98. \n\u00a0 179\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n55.-Fehlings, MG.; Tator, CH. The effect of Nimodipine and Dextran on \naxonal function and blood flow following  experimental Spin al Cord injury. J \nNeurosurg 1989;71(3):403-416. \n7.-VonEuler, M.; Li-Li, M.; Whirtemore, S.; et al. No protective effect on the \nrly Ultrastructural Findings in Experimental Spinal \nord Injury. J Neurosurg 1999;(2):200-204.  \nniversitaria de \nFisioterapia 2002;(5)7-30. \ne. Journal of Tr auma-Injury Infection & Critical Care \n002;52(2):323-332. \nGiacinto  M.; et al. \nRecruitment and Early Treatment in a Multicenter Study of Acute Spinal \n3.-Mirza, Sohail K.; Krengel, Walter F.; Chapman, Jens R.; et al. Early \n5.-Schinkel, Chistian S.; Anastasiadis , Alexander P. The Timing of Spinal \n\u00a0 56.-Choi, DW. Ion dependence of Glut amate Neurotoxicity. J Neurosci \n1987;7(2):369-379. \n \n5NMDA antagonist memantine on expe rimental Spinal Cord Injuries. J \nNeurotrauma 1997;14(1):53-61.  58.-Kaptanoglu, E.; Canner, HH.; Surucu,  HS.; et al. Effect of Mexilate on \nlipid peroxidation and eaC 59.-Forner-Valero, JV.; Forner-Cordero , I. Rehabilitaci\u00f3n del Lesionado \nMedular. En: I Jornadas Universitarias de Fisioterapia y Salud. Papel de la Fisioterapia en los procesos de Salud.  A Coru\u00f1a: Escuela U\n 60.-Vaccaro, Alexander R.; Daugherty, Re za J.; Sheehan, Terrence P.; et al. \nNeurologic Outcome of Early Versus Late  Surgery for Cervical Spinal Cord \nInjury. Spine 1997;22 (22):2609-2613.  61.-Papadopoulos, Stephen M.; Selden, Na than R.; Quint, Douglas J.; et al. \nImmediate Spinal Cord Decompression for Cervical Spinal Cord Injury: Feasibility and Outcom2 62.-Geisler, Fred H.; Coleman, Willian P.; Grieco, \nCord Injury. Spine 2001;26(24S):S58-S67. \n \n6Versus Delayed Surgery for Acute Cerv ical Spinal Cord Injury. Clinical \nOrthopaedics & Related Research 1999;359:104-114.  64.-Fehlings, Michael G.; Perrin, Richard G. The Timing of Surgical \nIntervention in the Treatment of Spina l Cord Injury: A Systematic Review of \nRecent Clinical Evidence. Spine 2006;31(S11):S28-S35. \n 6Stabilization in Polytrauma and in pa tients with Spinal Cord Injury. Current \nOpinion in Critical Care 2008;14(6):685-689. \n\u00a0 180\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n66.-Schegel, John; Bayley, James; Yuan, Hansen; et al. Timing of Surgical \nDecompression and Fixation of Acute Spinal Fractures. Journal of Orthopaedic Trauma 1996;10(5):323-330. \ns concerning experi ences with an Acute and Dramatic \npinal Cord Injury. Scandi navian Journal of Caring  Sciences 2009;23(1):67-75. \nof Health Care Professionals Involved in the \nare of People With Spinal Cord In jury: The Consumer \u2013 Professional \n9.-Langeron, O.; Riou, B. Prise en Charge du Rachis Traumatique. EMC \n Succinate on posttraumatic Spinal Cord Ischemia: \nose-response and time-reaction analysis. J Neurosurg 1984;61:124-130. \nal Cord Injury Studies (II and III) of \nethylprednisolone in Acute Spinal Cord Injury. J Spinal Disord 2000;13:185-\no-m\u00e9dullaire. Conf\u00e9r ence d\u00b4expert de la Soci\u00e9t\u00e9 Francaise \n\u00b4Anesth\u00e9sie et de R\u00e9animation. www.sfar.org/t/spip.php.article246 67.-Lohne, Vibeke RNT. The incomprehen sible Injury \u2013 Interpretations of \npatients\u00b4 narrative\nS\n 68.-Kroll, Thilo PHD.; Groah, Suzanne MD .; Gilmore, Brenda BFA.; et al. \nConsumer \u2013 Directed Teaching CPartnership Program. Journal of Continuing Education in Nursing \n2008;39(5):228-234. \n \n6\n(Elsevier Masson SAS; Paris), Anes th\u00e9sie-R\u00e9animation 2009;36-605-A-20. \n 70.-Hall, ED.; Wolf, DL.; Braughler, JM.; et al. Effects of a single large dose of \nMethylprednisolone Sodium\nd\n 71.-Coleman, WP.; Benzel, D.; Cahill, DW .; et al. A Critical Appraisal of the \nReporting of the National Acute SpinM199. \n \n72.-Edouard A. Coordonnateur. Prise en Charge d\u00b4un less\u00e9 adulte pr\u00e9sentant in traumatisme vert\u00e9brd\n. \n Surg 2003;85(12)2456-2470. \n5.-Brooks, ME.; Ohry, A. Conservative Versus Surgical Treatment of the \n6.-Dons, K. Thoraco-lumbar Spinal Fr actures. In: Neurosurgery, Churchill \nurgical treatment of Acute Spinal \nParalysed patients. Spinal Cord 1997;35:420-428.  \n73.-Vaccaro, AR.; Kim, DH.; Brodke, DS.; et al. Diagnosis and Management of Thoracolumbar Spine Fracture s. J Boint\n 74.-Bedbrook, GM. Spinal injuries with  Tetraplegia and Paraplegia. J Bone \nJoint Surg Br 1979;61(3):267-284. \n \n7Cervical and Thoracolumbar Spine in Spinal Trauma. Paraplegia 1992;30:46-\n49.  7Livingstone, 1996:736-739.  77.-B\u00f6tel, U.; Gl\u00e4ser, E.; Niedeggen, A. T he s\n\u00a0 181\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n78.-McAfee, PC.; Bohlman, HH.; Yuan, HA. Anterior decompression of \ntraumatic Thoracolumbar Fractures with incomplete neurological deficit using a Retroperitoneal Approach. J bo ne and Joint Surg 1985;67:89-103. \n0.-Nesathurai, Shanker MD. Steroids and Spinal Cord Injury: Revisiting the \nmplications of High \u2013 Dose Methylprednisolone Sodium \nSuccinate Treatment in the Follow-Up of Acute Cervical Spinal Cord Injury. \n2.-Frampton, A.E.1; Eynon, C.A.2. High Dose Methylprednisolone in the \n \ny. Spine 2001;26(24):E562-E564. \n \n \n):140-\n42. \ndnisolone in Acute Spinal Cord Injury: Is \nThere Any Other Ethical Choice?. Journal of Neurosurgical Anesthesiology \nomino, Karen B. Should High \u2013 Dose Methylprednisolone be \ndministered in the Treatment of Acute Spinal Cord Injury?. Journal of \n8.-Hulbert, RJ. Methylprednisolone for Acute Spinal Cord Injury: an  79.-Wilberger, JE. Diagnosis and Man agement of Spinal Cord Trauma. J \nNeurotrauma 1991;8:S21-S30. \n \n8NASCIS 2 and NASCIS 3 Trials. Journal or Trauma-Injury Infection & Critical Care 1998;45(6):1088-1093.  81.-Matsumoto, Takuji MD.; Tamaki, Tetsuya MD.; Kawakami, Mamoru \nMD.; et al. Early Co\nSpine 2001;26(4):426-430. \n \n8\nImmediate Management of Acute, blunt Spinal Cord Injury: What is the Current Practice in Emergency Departm ents, Spinal Units, and Neurosurgical \nUnits in the UK?. Emergency Me dicine Journal 2006;23(7):550-553. \n83.-Molloy, S.; Price, M.; Casey, A. Questionnaire Survey of the Views of the Delegates at the European Cervical Spine Research Society Meeting on the Administration of Methylprednisolone  for Acute Traumatic Spinal Cord \nInjur\n84.-Walker, Jeffrey RN.; Criddle, Laura M. Methylprednisolone in Acute \nSpinal Cord Injury: Fact or Fantas y?. Journal of Emergency Nursing \n2001;27(4)401-403. \n85.-Miller, Sanford M. Methylprednisolo ne in Acute Spinal Cord Injury: A \nTarnished Standard. Journal of Neur osurgical Anesthesiology 2008;20(2\n1\n 86.-Rozert, Irene MD. Methylpre\n2000;20(2):137-139. \n \n87.-D\nANeurosurgical Anesthesiology 2008;20(2):136.  8inappropriate Standard of Care. J Neurosurg 2000;93:1. \n\u00a0\n\u00a0 182\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n89.-Hulbert, RJ.; Moulton, R. Why do you prescribe Methylprednisolone for \nAcute Spinal Cord Injury?. Can Neurol Sci 2000;29:236-239. \n \n90.-Short, DJ.; El Masry, WS.; Jones, PW. High \u2013 Dose Methylprednisolone in \nd 2000;38:273-286. \n \ns, Allison P.; Lammertse, Daniel P. Administration \nof Corticosteroids for Acute Spinal Co rd Injury: The Curre nt Practice of \nSurvey of \nTraumatic Spinal Cord Injury. The grupo  Italiano Studio Epidemiol\u00f3gico \nof Trauma-Injury Infection & Critical \nare 2009;66(1):184-190. \njury: 10 Years\u00b4Experience at a Single Institution. Spine \n2006;31(10):1125-1130. \nn parapl\u00e9jicos. Acta Fisio ter\u00e1pica Ib\u00e9rica 1961;6(3):3-13. \n \n \n the Management of Acute Spinal Cord Injury: A Systematic Review from a Clinical Perspective. Spinal Cor\n \n91.-De Vivo, MJ.; Black, KJ.; Coo, BK.; et al. Trends in Spinal Cord Injury Demographics and Treatment Outcomes Between 1973 and 1986. Arch Phys Med Rehabil 1992;73:424-430. \n92.-Short, Deborah. Is the role of Steroids in Acute Spinal Cord Injury Now \nResolved?. Current Opinion in Neurology 2001;14(6):759-763.  \n \n93.-Peter, Vellman; Hawke\nTrauma Medical Directors and Emergency Medical System Physician \nAdvisors. Spine 2003;28(9):941-947. \n \n94.-Pagliacci, MC.; Celani, MG.; Zampolin i, M.; et al. An Italian \nMielolesiono Stydy. Arch Phys  Med Rehabil 2003;84:1266-1275. \n 95.-Saunders, Lee; Selassie, Anbesaw; Elizabeth, G.; et al. Traumatic Spinal Cord Mortality, 1981-1988.  Journal \nC\n \n96.-Gauler, Rolf; Moulin, Patrick; Koch, Hans; et al. Paragliding Accidents \nwith Spinal Cord In\n \n97.-Blanco, Arg\u00fcelles M.; Moret, Branyas A. Experiencias sobre el tratamiento \nde cie\n98.-Garc\u00eda \u2013 Reneses, J.; Herrunzo \u2013 Cabr era, R. Epidemiolog\u00eda Descriptiva de \nla prevalencia de la Lesi\u00f3n Medular Espinal en Espa\u00f1a. M\u00e9dula Espinal \n1995;1:111-115. \n99.-Mazaira \u2013 \u00c1lvarez, J.; Labarta, MC.; Rujo, J.; et al. Epidemiolog\u00eda de la \nLesi\u00f3n Medular de 8 Comunidades Aut\u00f3nomas. 1974-1993. M\u00e9dula Espinal \n1997;3:28-57. \n100.-Stover, Sl.; Fine, PR . The Epidemiology and Economics of Spinal Cord \nInjury. Paraplegia 1987;25:225-228. \n\u00a0\n\u00a0 183\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n101.-Hendey, Gregory W.; Wolfson, Allan B.; William, R.; et al. Spinal Cord \nInjury Without Radiographic Abnorm ality: Results of The National \nEmergency X-Radiography Utilization Study in Blunt Cervical Trauma. \n of Thoracolumbar Injuries: \nThe importance of Injury, Morphology , the Integrity of  the posterior \ntasiadis , Alexander. The Timing of Spinal \nStabilization in Polytrauma and in pa tients with Spinal Cord Injury. Current \n104.-Donovan, Willian H.; Dwyer, Anthony P. An Update on the Early \n, Paul A.; Henley, Bradford M. Early \nStabilization and Decompression for Inco mplete Paraplegia Due to a Thoracic-\ns L. The Role \nf Surgery in Traumatic Central Cord Syndrome. Neurosurgery Quarterly \nley, James; Yuan , Hansen; et al. Timing of Surgical \nDecompression and Fixation of Acute Spinal Fractures. Journal of \nnatser, Paige RN .; Lancaster, Penny RN.; et al. \nPrevalence of Incidental Findings in Trauma patients detected by Computed \ning in the Identification of Occult Injuries to the Cervical \npine: A Meta-Analysis. Journal of Trauma-Injury Infection & Critical Care \nJames F.; Mirvis, Stuart E.; Panacek, Edward A.; et al. \nVariability in Computed Tomography and Magnetic Resonance Imaging in Journal of Trauma-Injury Infectio n & Critical Care 2002;53(1):1-4. \n \n102.-Vaccaro, A.; Lehman, R. A new classi fication\nligamentous complex, and neurol ogic status. Sp ine 2005;30:2325-2333. \n \n103.-Schinkel, Chistian; Anas\nOpnion in Critical Care 2008;14(6):685-689. \n \nManagement of Traumatic Parapleg ia (Nonoperative and Operative \nManagement). Clinical Orthopaedics  & Related Research 1984;189:12-21. \n \n105.-Krengel, Walter F.; Anderson\nLevel Spinal Cord Injury. Spine 1993;18(14):2080-2087. \n \n106.-Stevens, E. Andrew; Powers, Alexan der K.; Branch, Charle\no\n2009;19(4):222-227.  \n \n107.-Schelegel, John; Bay\nOrthopaedic Trauma 1996;10(5):323-330. \n \n108.-Stephan, MD.; CoTomography Imaging. American Journal of Emergency Medicine \n2009;(84):428-435. \n \n109.-Schoenfeld, Andrew J.; Bono, Christo pher M.; McGuire, Kevin J.; et al. \nComputed Tomography Alone Versus Co mputed Tomography and Magnetic \nResonance Imag\nS\n2010;68(1):109-114. \n \n110.-Holmes, \nPatients with Cervical Spine Injuries. Journal of Ttrauma-Injury & Critical \nCare 2002;53(3):524-530. \n\u00a0\n\u00a0 184\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n111.-Gale, Stephen C.; Gracias, Vicente  H.; Reilly, Patrick M.; et al. The \nInefficiency of Plain Radiography to Ev aluate the Cervical Spine after Blunt \nTrauma. Journal of Trauma-Injury In fection & Critical Care 2005;59(5):1121-\n1125. \n \n112.-Como, John J.; Thompson, Marsha A.; Anderson, Jame s S.; et al. Is \nMagnetic Resonance Imaging Essential in Clearing the Cervical Spine \nObtunded Patients with Blunt Trauma?. Journal of Trauma-Injury Infection & Critical Care 2007;63(3):544-549. \nin the Polytraumatized Patient. \nCurrent Orthopaedic Practice 2008;19(4):411-415. \niable \nPatient-Are We There Yet?. Journal of Trauma-Injury Infection & Critical \n Alexander R.; et al. \nInitial Radiographic Evaluation of the Spine After Trauma: When, What, \n116.-Widder, Sandy MD.; Doig, Christopher MD.; Burrowes, Paul MD.; et al. \n004;56(6):1179-1184.  \n119.-Prendergast, Michael R.; Saxo, Jonathan M.; Ledgerwood, Anna M.; et al.  \n113.-France, John C. Update on the Appropriate Radiographic Studies for \nCervical Spine: Evaluation and Cleara nce \n \n114.-Menaker, Jay MD.; Phil, Allan MD.; Boswell, Sharon ACNP.; et al. Computed Tomography Alone for Cervic al Spine Clearance in the Unrel\nCare 2008;(84):898-904. \n \n115.-France, John C.; Bono, Christopher  M.; Vaccaro,\nWhere, and How to Image the Acutel y Traumatized Spine. Journal of \nOrthopaedic Trauma 2005;19(9):640-649. \n \nProspective Evaluation of Computed Tomographic Scanning for the Spinal Clearance of Obtunded Trauma Patien ts: Preliminary Results. Journal of \nTrauma-Injury Infection & Critical Care 2\n \n117.-Antevil, Jared l.; Sise, Michael J.; Sa ck, Daniel.; et al. Spiral Computed \nTomography for the Initial Evaluation of Spine Trauma: A New Standard of \nCare?. Journal of Trauma-Injury In fection & Critical Care 2006;61(29):382-\n387. \n \n118.-Levy, Michael L.; Gans, Willian B.; Wijesinghe, Hiran S.; et al. Use of \nMethylprednisolone as an Adjunct in  the Management of Patients with \nPenetrating spinal Cord Injury: Outcome Analysis. Neurosurgery 1996;39(6):1141-1149. \n \nMassive Steroids do not Reduce the zone of injury After Penetrating Spinal Cord Injury. Journal of Trauma-Injury Infection & Critical Care 1994;37(4):576-580. \n\u00a0\n\u00a0 185\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n120.-Eck, Jason C.; Nachtigall, Dean Do.; Humphreys, Craig S.; et al. \nQuestionnaire Survey of Spine Surgeons on the Use of Methylprednisolone for Acute Spinal Cord Injury. Spine 2006; 31(9):250-253. \n \n121.-Fehlings, Michael G.; Sekhon, Lali HS.; Tator, Charles MD.; et al. The \ner R.  Summary Statement: The Role and \nTiming of Decompression in Acute Spinal Cord injury: Evidence \u2013 based \nTimothy R. Penetrating \nThoracolumbar Spine Injuries. Cu rrent Opinion in Orthopaedics \nNVIN. Revista electr\u00f3nica de Medicina Intensiva. \nArt\u00edculo n\u00ba 1079, Vol 7 n\u00ba3, Marzo 2007. \nntensive Care Unit. Infect Control \nHosp. Epidemiol 2003;24:207-213. \n127.-Bass, Sylvia; Hawkey, Peter M.; Fraise, Adam P.; et al. A Long-term \n \n128.-Weber, David J.; Raasch, Ralph; Rutala, Willian A. Nosocomial \n; Rossi, Carlotta; Bertolini, Guido; et al. Antibiotic \nUsage in Intensive Care Units: a Pharmaco-Epidemiological Multicentre \nns: Results of a Matched case \u2013 control Study of ICU \nPatients. Am J Respir Crit Care Med 1998;46:1151-1158. \n\u00a0Role and Timing of Decompression in Ac ute Spinal Cord Injury: What Do We \nKnow? What Should We Do?. Spine 2001;26(24S):S101-S110. \n \n122.-Silber, Jeff; Vaccaro, Alexand\nGuidelines. Spine 2001;26(24S):S111. \n \n123.-Potter, Benjamin K.; Adam, T.; Kuklo, \n2005;16(3):163-168. \n \n124.-\u00c1lvarez - Lerma F. Vigilancia de la  Infecci\u00f3n Nosocomial en pacientes \ncr\u00edticos: el programa E\n \n125.-Olaechea. PM.; Ulibarrena, MA.; Alva rez-Lerma, F.; et al. ENVIN-UCI \nStudy Group. Factors Related to Ho spital Stay Among Patients with \nNosocomial Infection Acquired in the I\n \n126.-Singh, Nina MD.; Yu, Victor L. Rational Empiric Antibiotic Prescription \nin the ICU: Clinical Research in Ma ndatory. Chest 2000;117(5):1496-1499.  \n \nEcological Study of Two Defined Empi rical Antibiotic regimens in the \nintensive Care Units. Infectious Diseases in Clinical Practice 2006;14(5):273-280.   \nInfections in the ICU: The Growing Importance of Antibiotic-Resistant \nPathogens. Chest 1999;115(3):S34-S41. \n \n129.-Malacarne, Paolo\nStudy. Journal of Antimicrobial Chemotherapy 2004;54(1):221-224. \n \n130.- Girou, E.; Stephan, F.; Novara, A.; et al. Risk Factors and Outcome of \nNosocomial Infectio\n\u00a0 186\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n131.-Beyersmann, Jan; Gastmeier, Petra; Grundmann, Hajo; et al. \nTransmission-associated Nosocomial Infections: Prolongation of Intensive Care Unit Stay and Risk Factor Analysis  Using Multistate Models. American \nJournal of Infection Control 2008;36(2):98-103.  \nnas Aeruginosa \nProducing Metallo \u2013 (beta) \u2013 lactam ase in two Tertiary-Care teaching \navid A.; Davies, H.; et al. Population-\nbased assessment of Intensive Care Unit-Acquired Bloodstream Infections in \n134.-Chen, Yin-Yin; Wang, Fu-Der; Liu, C heng-Yi; et al. Incidence Rate and \n35. Orsi, GB.; Raponi, M.; St icca, G.; et al. Hospital Infections Surveillance in \nections in 55 Intensive Care Units of 8 \neveloping Countries. Annals of In ternal Medicine 2006;145(8):582-591. \n al. \nDevice-Associated Nosocomial Infection Ra tes in Intensive Care Units in tour \nastemeier, Petra MD.; Sohr, Dorit;  Just, Heinz-Michael MD.; et al. How \nto Survey Nosocomial Infection. Infection Control & Hospital Epidemiology \n; Buising, Kirsty; et al. Epidemiology, \nPrevalence, and Sites of Infections in Intensive Care Units. Seminars in 140.-Inweregbu, Ken; Dave, Jasyhree; Pi ttard, Alison. Nosocomial Infections.  \n132.-Zavascki, Alexandre P.; Barth, Afonso L.; Gaspareto, Patrick B.; et al. \nRisk Factors for Nosocomial Infections due to Pseudomo\nHospitals. Journal of Antimicrobial Chemotherapy 2006;58(4):882-885. \n \n133.-Laupland, Kevin B.; Zygun, D\nAdults: Incidence, Risk Factors, and associated Mortality Rate. Critical care \nMedicine 2002;30(11):2462-2467. \n \nVariable Cost of Nosocomial Infections in Different Types of Intensive Care \nUnits. Infection Control & Hospital Epidemiology 2009;30(1):39-46. \n \n15 Roman Intensive Care Units. Ann Ig 2003;15 (2):23-34. \n \n136.-Rosenthal, Victor D.; Maki, Dennis G.; Salomao, Reinaldo MD.; et al. \nDevice-Associated Nosocomial InfD\n \n137.-Barba, Ector J.; Rosenthal, Victor  D.; Higuera, Francisco C.; et\nMexican Public Hospitals. American Journal of Infection Control 2006;34(4):244-247.  \n \n138.-G\n2000;21(6):366-370. \n \n139.-Richards, Michael; Thursky, Karin\nRespiratory & Critical Care Medicine. Em erging Infections in Intensive Care \nUnits 2003;24(1):3-22. \n \nContinuing Education in Anaesthesia, Critical Care & Pain 2005;5(1):14-17. \n\u00a0\n\u00a0\n\u00a0 187\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n141.-Roshental, Victor D. Device \u2013 associated Nosocomial Infections in \nlimited-Resources Countries: Findings of the International Nosocomial Infection Control Consortium (INICC). American Journal of Infection Control 2008;36(10):S171. \n \n142.-Fridkin, Scott. Increasing Preval ence of Antimicrobial Resistance in \nIntensive Care Units. Critical Care Medicine 2001;29(4):64-68. \n \n143.-Weaver, Frances M.; Smith, Bridget; Evans, Charlesnika T.; et al. Outcomes of Outpatient Visits for Acute Respiratory Illness in Veterans with \nMike, P.; et al. Long-Term Outcomes from \nary Tract \nippe. Prev ention of Intravascular Catheter Infection. \nns: Many Aspects, Many Populations. Journal of Infusion \nn Intens ive Care. Lancet 2000;35(92):1864-1868. \nd, \nEtiology and Antimicrobial Suscepti bility (ESGNI-003 Study). Clinical \nMicrobiology & Infection 2001;7(10):523-531. Spinal Cord Injuries and Disorders. American Journal of Physical Medicine & \nRehabilitation 2006;85(9):718-726. \n\u00a0\n144.-LaVela, SL.; Miskevics, S.; Nosocomial Infections in Persons with  Spinal Cord Injuries and Disorders. \nAmerican Journal of Infection Control 2006;34(5):E21-E22. \n \n145.-Hull, Richard; Rudy, Delbert; Donovan, Willian; et al. Urin\ninfection prophylaxis Usin g Escherichia Coli 83972  in Spinal Cord Injuried \nPatients. Journal of Ur ology 2000;163(3):872-874.  \n \n146.-Esclarin de Ruz, A.; Garcia Leoni, E.; Herruzo Cabrera, R. Epidemiology \nand Risk Factors for Urinary Tract In fection in Patients with Spinal Cord \nInjury. Journal of Urol ogy 2000;164(4):1285-1289. \n \n147.-O\u00b4Grady, Naomi P.; Alexander, Mary BS.; Dellinger, E.; et  al. Guidelines \nfor the Prevention of intravascular catheter-related Infections. American Journal of Infection Control 2002;30(8):476-489. \n \n148.-Eggimann, PhilCurrent Opinion in Infectious Diseases 2007;20(4):360-369. \n \n149.-Meyer, Jeannette. A Broad-Spectrum Look at Catheter-Related Bloodstream InfectioNursing 2009;32(2):80-86.  \n \n150.-Eggimann, Philippe; Harbarth, Stepha n; Constantin, Marie-Noelle; et al. \nImpact of a Prevention Strategy Targeted at Vacular-Acces Care on Incidence of Infections Acquired i\n \n151.-Bouza, E.; San Juan, R.; Mu\u00f1oz, P. ; et al. A European Perspective on \nNosocomial Urinary Tract Infections I. Report on the Microbiology Workloa\n\u00a0 188\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n152.-Nicolle, Lindsay E. Resistant Pathogens in Urinary Tract Infections. \nJournal of The American Geriatrics Society 2002;50:S30-S35.  153.-Oden, H.; Kahlmeter, G. ECO-SENS II: Antimicrobial Susceptibility in Escherichia Coli from Community Acquired Urinary Tract Infections in \n155.-Bagshaw, Sean m.; Laupland, Kevin B. Epidemiology of Intensive Care \n156.-Clec\u00b4h, Chistopher; Schwebel, Caro le; Francais, Adrien; et al. Does \n157.-National Nosocomial Infections Surveillance (NNIS) System Report, \ngery 1994;35(2):240-249. \nRelated Research \n006;444:114-119. \nurgical Wound Infections. Infect Control Hosp. \nEpidemiol 1992;13:606-608. \nSpine \n2003;28(13):1475-1480. Austria, Greece, Portugal, Sweden and Unit ed Kingdom. Clinical Microbiology \n& Infection 2009;15(4):S162-164. \n \n154.-Laupland, Kevin B.; Zygun, David A.; Davies, H.; et al. Incidence and \nRisk Factors for Acquiring Nosocomial Urinary Tract Infection in the \nCritically Ill. Journal of Critical Care 2002;17(1):50-57. \n\u00a0\nUnit-Acquired Tract Infections. Current  Opinion in Infectious Diseases \n2006;19(1):67-71.  \n \nCatheter-Associated Urinary Tract Infectio n Increase Mortality in Critically Ill \nPatients?. Infection Control & Hospit al Epidemiology 2007;28(12):1367-1373.  \n \nData Summary from January 1992 through June 2004, issued October 2004. A Report from the NNIS System. American Journal of Infection Control 2004;32(8):470-485. \n \n158.-Duh, Mei-Sheng M.; Shepard, Ma ry J.; Wilberger, Jack E. The \nEffectiveness of Surgery on the Treatment of Acute Spinal Cord Injury and Its \nrelation to Pharmacological Treatm ent. Neurosur\n \n159.-Lim, Moe R.; Lee, Joon Y.; Vaccaro, Alexander R. Surgical Infections in \nthe Traumatized Spine. Clinical Orthopaedics & \n2\n \n160.-Horant. CDC Definitions of Nosocomial Surgical Site Infections, 1992: A \nModification of CDC of S\n \n161.-Blam, Oren G.; Vaccaro, Alexander R .; Vanichkachorn, Jed S.; et al. Risk \nFactors for Surgical Site Infection in the Patient UIT Spinal Injury. \n \n162.-Rechtine, GR. The Metabolic Response  to Spinal Cord Injury. Spinal \nCord 1997;35:599-684. \n\u00a0\n\u00a0 189\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n \n163.-Kim, Daniel; Jaikumar, Sivakumar; Kam, Andrew; et al. Minimally \nInvansive Spine Instrumentation. Neurosurgery 2002;51(5S):S15-S25. \n \niago de Compostela, 22-25 septiembre 1993;293-312. \nsideraciones sobre la cirug\u00eda limpia. Cir Esp 1995;57:7-10. \n34. \ne Literature. Canadian Journal of Surgery \natic Cervical Spinal Cord Injury: Brazilian Data. \nArthur, Melanie; Mullins, Richard J.; et al. Variations \nin Injury Patterns, Treatment, and Ou tcome for Spinal Fracture and Paralysis \nin Adult Versus Geriatric Pati ents. Spine 2004;29(7):796-802. 164.-Kornberg, Markus L.; Rechtine, Glenn R.; Herndon, Willian A. Surgical Stabilization of Thoracic and Lumbar Spine Fractures: A Retrospective Study in a Military Population. Journal of Tr auma-Injury Infection & Critical Care \n1984;24(2):140-146. \n \n165.-Brown, Erwin M.; Pople, Ian K.; de Louvois, John F.; et al. Spine \nUpdate: Prevention of Postoperative In fection in Patients Undergoing Spinal \nSurvey. Spine 2004;29(8):938-945. \n \n166.-Garc\u00eda Caballero J. Vigilancia Epidemiol\u00f3gica de la Infecci\u00f3n Nosocomial. Proyecto y programa EPIHOS. En: Libro de ponencias y comunicaciones. I \nCongreso Internacional y VI Nacional  de Higiene y Medicina Preventiva \nHospit larias. Sant a\n \n167.-Sing, Nina MD.; Yu, Victor L. Ration al Empiric Antibiotic Prescription \nin the ICU: Clinical Research is Mandatory. Chest 2000;117(5):1496-1499. \n \n168.-Geissler, A.; Gerbeaux, P.; Granier, I.; et al. Rational use of Antibiotics in  \nthe Intensive Care Unit: Impact on microbial Resistance and cost. Intensive Care Med 2003;29:49-54. \n \n169.-Lozano, SF. Con\n \n170.-Bad\u00eda, JM.; Gubem, JM. Profilaxis anti bi\u00f3tica: el tiempo es oro. Cir Esp \n1996;60:377-378. \n \n171.-de Beer, Justin; Petruccelli, Dani elle; Rotstein, Coleman. Antibiotic \nProphylaxis for total Joint Replacemen t Surgery: results of a Survey of \nCanadian Orthopaedic Surgeons. Canadian Journal of Surgery \n2009;52(6):E229-E2\n \n172.-Gagliardi, Anna; Fenech, Darlene; Es kicioglu, Cagla. Factors Influencing \nAntibiotic Prophylaxis for Surgical Site Infection Prevention in General \nSurgery: a review of th2009;52(6):481-489. \n \n173.-Neumann, Cristina R.; Brasil, Albert V.; Albers, Felix MD. Risk Factors \nfor Mo tality in Traum r\nJournal of Trauma-Injury Infectio n & Critical Care 2009;67(1):67-70. \n \n174.-Ir in, Zareth N.; \n\u00a0 190wIMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n\u00a0\n \n175.-Ewig, Santiago; Torres, Antoni. Prevention and Management of \nidence-Based Approac h of Modifiable Risk Factors. \nyear-Br unch, Caryl. Ventilator-Associated \ntients. \ns to \nhierry. Mortality Rate Attributable to Ventilator-\nuences of Ventilator-Associated Pneumonia: A Systematic \n in European Intensive Care Units. Critical Care \nedicine 1997;25(11):1862-1867. Ventilator-Associated Pneumonia. Current Opinion in Critical Care \n2002;8(1):58-69. \n \n176.-Isakow, Warren; Kollef, Marin. Preventing Ventilator-Associated Pneumonia: An EvSeminars in Respiratory & Critical Ca re Medicine. Ventilator-Associated \nPneumonia 2006;27(1):5-17. \n \n177.-Murray, Theresa MSN.; Good\nPneumonia Improvement Program. Adva nced Critical Care 2007;18(2):190-\n199. \n 178.-Cook, Deborah J.; Walter, Stephen D.; Cook, Richard J. Incidence of and Risk Factors for Ventilator-Associated Pneumonia in Critically Ill Pa\nAnnals of Internal Medicine 1998;129(6):433-440. \n \n179.-McCrory, R.; Jones, DS.; Gorman , SP. Pharmaceutical Strategie\nPrevent Ventilator-Associated Pneumonia. J Pharm Pharmacol 2003;55:411-428. \n \n180.-Bercault, Nicolas; TAssociated Pneumonia in an adult Inte nsive Care Unit: A Prospective Case-\nControl Study. Critical Care Medicine 2001;29(12):2303-2309. \n \n181.-Safdar, Nasia; Dezfulian, Cameron; Collard, Harold; et al. Clinical and \nEconomic ConseqReview. Critical Care Medicine 2005;33(10):2184-2193. \n \n182.-Koulenti, Despoina; Lisboa, Thago; Brun-Buisson; et al. Spectrum of \nPractice in the Diagnosis of Nosoco mial Pneumonia in Patients Requiring \nMechanical VentilationMedicine 2009;37(8):2360-2369. \n \n183.-Rello, Jordi; Rue, Montse; Jubert, Paola; et al. Survival in Patients with Nosocomial Pneumonia: Impact of the Severity of Illness and the Etiologic \nAgent. Critical Care M\n \n184.-DiGiovani, B.; Chenoweth, C.; Watts, C.; et al. The Attributable \nMortality and Costs of Primary Nosocomial Bloodstream Infections in the Intensive Care Unit. Am J Respir Crit Care Med 1999;160:976-981. \n \n\u00a0 191185.-Sanfir, L.; Timsit, JF.; Mahe, C.; et al. Attributable Morbidity and Mortality of Catheter-Related Septicaemia in Critically Ill Patients: a IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\nMatched, Risk-adjusted, Cohort Study. Infect Control Hosp Epidemiol \n1999;20:396-401. \nMonth Prospective Study.  Clin Infect Dis 2001;15:1329-\n Surgery 2002;137(12):1353-1359.  \nstream Infections in the Intensive Care Unit. Journal of Patient Safety \nients with \n \nlly Ill Patients with Bacteraemia \n al. Lesiones \nCervical Cord Injury and Critical \n  \n186.-Warren, DK.; Zack, JE.; Edward, Am.; et al. Nosocomial Primary \nBloodstream Infections in Intensive Care Unit in a Nonteaching Community \nMedical Center: a 21-1335. \n \n187.-Harbarth, Stephan MD.; Ferriere, Karin MD.; Hugonnet, Stephane MD.; \net al. Epidemiology and Prognostic Dete rminants of Bloodstream Infections in \nSurgical Intensive Care. Archives of\n \n188.-Patel, Bhavesh M.; Dauenhauer, Co rinna J.; Rady, Mohamed Y.; et al. \nImpact of Peripherally Inserted Ce ntral Catheters on Catheter-Related \nloodB2007;3(3):142-148.  \n \n189.-Combes, Alain MD.; Luyt, Charles-Edouard MD.; Trouillet, Jean-Louis MD.; et al. Gender Impact on the Outcomes of Critically Ill PatNosocomial Infections. Critical  Care Medicine 2009;37(9):2506-2511. \n \n190.-Blot, Stijn I.; Vandewoude, Koenraad H.; Hoste, Eric A.; et al. Outcomeand Attributable Mortality in CriticaInvolving Methicillin-Susceptible and Meticillin-Resistant Staphylococcus \nAureus. Archives of Internal  Medicine 2002;162(19):2229-2235. \n \n191.-Jim\u00e9nez-G\u00f3mez, LM.; Amunategui, L.;  S\u00e1nchez, M.; et\nInadvertidas en el politraumatizado: an\u00e1 lisis de un registro de trauma. Cir Esp \n2005;78:303-307. \n \n192.-Furlan, Julio C.; Fehlings, Michael G. Hyponatremia in the Acute Stage \nAfter Acute  Traumatic Cervical Spinal Cord Injury: Clinical and Neuroanatomic Evidence for Autonomic Dysfunction. Spine 2009;34(5):501-\n511. \n \n193.-Denton, Michelle; McKinlay, Justin. \nCare. Continuing Education in Anesthesia , Critical Care & Pain 209;9(3):82-86. \n \n194.-Sala, Francesco; Menna, Gaetano; Bricolo, Albino; et al. Role of Glycemia \nin Acute Spinal Cord Injury: Data From a Rat Experimental Model and \nClinical Experience. Anals of the New York Academy of Sciences \n1999;890:133-154. \n \n195.-Reeds, Dominic. Near-Normal Glyc emia for Critically Ill Patients\n\u00a0 192Receving Nutrition Support: Fact or Folly. Current Opinion in \nGastroenterology 2010;26(2):152-155.  \n\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n\u00a0\n \n196.-Bilotta, Federico; Giovannini, Federi co; Caramia, Remo; et al. Glycemia \nManagement in Neurocritical Care Patients: A Review.  Journal of \nNeurosurgical Anesthesiology 2009:21(1):29.  \n \n197.-Krinsley, James; Jones, Richard. Cost Analysis of Intensive Glycemic \nill; Burns, Karen;  Meade, Maureen. Pharmacologic \natory Distress \nfor Acute Spinal Cord Injury. Journal f Trauma-Injury \n68. \n-689.   Control in Crinically Ill Adult Patient. Chest 2006;129(3):644-650. \n \n198.-Lynch, Joseph. Hospital-Acqui red Pneumonia: Risk Factors, \nMicrobiology, and Treatment. Chest 2001;119(2S):373S-384S. \n \n199.-Thompson, B.; Taylor, MD. Glucocorticoids and Acute Lung Injury. Critical Care Medicine 2003;31(4):S253-S257. \n \n200.-Adhikari, NeTreatments for Acute Respiratory Distre ss Syndrome and Acute Lung Injury: \nSystematic Review and Meta-Analysis. Treatments in Respiratory Medicine \n2004;3(5):307-328.  \n \n201.-Spiegler, Peter. Steroids in Acute Respiratory Distress Syndrome Revisited. Clinical Pulmonar y Medicine 2007;14(5):307-308.  \n \n202.-Meduri, G.; Headley, A.; Golden, E.; et al. Effect of Prolonged Methylprednisolone Therapy in Unresolving Acute Respir\nSyndrome: A Randomized Controlle d Trial. JAMA  1998;280(2):159-165.  \n \n203.-Gerndt, S.; Rodriguez, J.; Pawlik, J.; et al. Consequences of High-Dose \nSteroid Therapy \nInfection & Critical Care 1997;42(2):279-284.  \n \n204.-Stackpool, Michael. Failure of Methylprednisolone to improve Outcome \nSpinal Cord Injuries. Annals of Emergency Medicine 1996;27(1):108-109.  \n \n205.-George, ER.; Scholten, DJ.; Buech ler, CM.; et al. Failure of  \nmethylprednisolone to Improve Outcom e of Spincal Cord Injuries. AM Surg \n1995;61:659-663. \n \n206.-Rabinowitz, Richard S.; Eck, Jason C.; Harper, C.; et al. Urgent Surgical \nDecompression Compared to Methylpred nisolone for the Treatment of Acute \nSpinal Cord Injury: A Randomized Prospective Study in Beagle Dogs. Spine 2008;33(21):2260-22\n \n207.-Schinkel, Christian; Anastasiadis, Alexander. The Timing of Spinal \nStabilization in Polytrauma and in Pati ents with Spinal Cord Injury. Current \nOpinion in Critical Care 2008;14(6):685\n\u00a0 193\u00a0IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n\u00a0\n \n208.-Kerwin, Andrew J.; Fryberg, Eric R.; Schinco, Miren A .; et al. The Effect \nof Early Spine Fixation on Non-Neurologic Outcome. Journal of Trauma-\nInjury Infection & Critical Care 2005;58(1):15-21.  \nafter Acute \nSpinal Cord Injury. Arch Phys Med Rehabil 2004;85:1818-1825. \n e al. Timing of \nThoracic Spine Stabilization in Trauma Patients: Impact on Clinical Course \n212.-Berney, S.; Stockton, K.; Berlowitz,D.; et al. Can Early Extubation and \ntudy. Physiother \nRes Int 2002;7(1):14-22. \n:685-\n693. \n):117-134. \new of \nthe Literature. J Neurotrauma 2009;23:6-7. \nraphy at the Hospital  and Mortality in Patients with Severe \nCommunity-Acquired Pneumonia. In tensive Care Med 2002;28:1030-1035. \n218.-Marshall, LF.; Knowlton, S.; Garfin, SR.; et al. Deterioration following \n  \n209.-McKinley, W.; Meade, MA.; Kirshbl um, S.; et al. Outcomes of Early \nSurgical Management Versus Late or no  Surgical Intervention \n \n210.-Schinkel, Christian; Frangen, Thom as; Kmetic, Andrej;\nand Outcome. Journal of Trauma-Injury Infection & Critical Care \n2006;61(1):156-160.  \n \n211.-Rutges, JP.; Oner, FC.; Leenen, LP . Timing of Thoracic and Lumbar \nFracture Fixation in Spinal Injuries: A Systematic Review of Neurological and \nClinical Outcome. Eur Spine 2007;16:579-587. \n \nIntensive Physiotherapy decrease Leng th of Stay of Acute Quadriplegic \nPatients in Intensive Care?. A retrospect ive Case Control S\n \n213.-Knaus, Willian A.; draper, Elizabet h A.; Wagner, Douglas P.; et al. \nPrognosis in Acute Organ-System Failure. Annals of Surgery  1985;202(6)\n \n214.-Deitch, Edwina. Multiple Organ Fa ilure Pathophysiology and Potential  \nFuture Therapy. Annals of Surgery 1992;216(2\n \n215.-Furlan, JC.; Noonan, V.; Sing, A. et al. Assessment of Impairment in \nPatients with Acute Traumatic Spinal Cord Injury: A Systematic Revi\n 216.-Rello, J.; Catal\u00e1n, M.; D\u00edaz, E.; et al. Association Between Empirical \nAntimicrobial The\n \n217.-Heiden, JS.; Weiss, MH.; Rosenberg, AW.; et al. Management of Cervical \nSpinal Cord Trauma in Southern Ca lifornia. J Neurosurg 1975;43:732-736. \n \n\u00a0 194Spinal Cord injury: A Multicenter Study. J Neurosurg 1987;66:400-404. \n \n IMPACTO \u00a0DEL\u00a0TRATAMIENTO \u00a0CON\u00a0MEGADOSIS\u00a0 DE\u00a0CORTICOIDES \u00a0EN\u00a0\u00a0LESI\u00d3N\u00a0MEDULAR \u00a0AGUDA\u00a0\nTRAUM\u00c1TICA\u00a0 EN\u00a0UNA\u00a0 UNIDAD\u00a0DE\u00a0CR\u00cdTICOS\u00a0POLIVALENTE. \u00a0\nVII.\u2010\u00a0BIBLIOGRAFIA. \u00a0\n\u00a0\n\u00a0 195 \n219.-Waters, RL.; Adkins, RH.; Yakura, JS.; et al. Effect of Surgery on Motor \n P. Management of Fractures of \n Recovery Following Traumatic Spinal Cord Injury. Spinal Cord 1996;34:188-\n192. \n 220.-Gertzbein, SD. Scoliosis Research So ciety. Multicenter Spine Fracture \nStudy. Spine 1992;17:528-540. \n \n221.-Bedbrook, GM. Treatment of Thorac olumbar dislocation and Fractures \nwith paraplegia. Clin Orthop 1975;112:27-43. \n \n222.-Osebold, WR.; Weinstein, SL.; Spr ague, BL.; Thoracolumbar Spine \nFractures. Results of Treatm ent. Spine 1981;6(1):13-34. \n \n223.-Durward, QJ.; Schweigel, JF.; Harrison,the Thoracolumbar and Lumbar Spin e. Neurosurgery 1981;8(5):555-561. \n \n224.-Herdon, WA.; Galloway, D. Neurol ogic Return Versus Cross-Sectional \nCanal Area in Incomplete Thoracolumbar Spinal Cord Injuries. J Trauma1988;28(5):680-683. \n \n225.-Reid, D.; Henderson, R.; Saboe, L.; et  al. Etiology and Cl inical Course of \nMissed Spine Fractures. The Journal of Trauma Injury, Infection, and Critical Care 1987;(27):9-10. \n\u00a0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}